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Purinergic signalling: past, present and future
Professor Geoffrey Burnstock PhD DSc FAA FRCS(Hon) FRCP(Hon) FMedSci FRS
President, Autonomic Neuroscience Centre
Following a brief account of the early history of the discovery of purinergic signalling, a personal view of some of
the exciting cutting-edge directions being taken by research in the ﬁeld will be considered. In particular, emphasis
will be placed on the pathophysiology of purinergic signalling and its therapeutic potential.
A Fuller Quiver Adenosine Receptors as Therapeutic Targets
Bruce N. Cronstein, MD
NYU School of Medicine, 50 First Ave., New York, NY 10016
Cronsb01@med.nyu.edu
Recent advances in understanding the role of adenosine and its receptors in physiology and pathophysiology as
well as new developments in medicinal chemistry of these receptors have made it possible to begin to realize the
therapeutic potential of adenosine and its receptors. Currently adenosine itself is targeted at the heart; a bolus of
adenosine intravenously is commonly used to treat supraventricular tachycardia whereas an infusion of adenosine
is used as a coronary vasodilator during pharmacologic stress testing. Non-selective adenosine receptor
antagonists are used to maintain wakefulness (caffeine), as an analgesic (caffeine) and, less commonly at present,
to treat bronchospasm (theophylline, aminophylline, enprofylline). Currently a number of new selective
adenosine receptor agonists and antagonists are in testing for a variety of new indications and one adenosine-
targeted indication. The older indication is pharmacologic stress testing and new selective A2A receptor agonists,
ATL146e (Apadenoson, Adenosine Therapeutics) and Regadenoson (CV Therapeutics), are currently under
study (Phase II–III) for this indication. In addition, a selective A1 receptor agonist is in trials for supraventricular
tachycardia (tecadenoson, CV Therapeutics), Currently a number of companies are testing selective adenosine
receptor agonists for newer indications including Rheumatoid Arthritis, cancer and wound healing, Adenosine A3
receptor agonists are in trials for the treatment of Rheumatoid Arthritis and Cancer (CF101, CF102, Can-Fite
Biopharmaceuticals) and preliminary promising results in patients with RA have been reported. Topical
application of an adenosine A2A receptor agonist to promote healing of diabetic foot ulcers is currently in Phase II
trials after the successful completion of a Phase I safety/early efﬁcacy trial (MRE94, King Pharmaceuticals). An
allosteric enhancer at the adenosine A1 receptor is in trials for neuropathic pain (T-62, King Pharmaceuticals).
Because adenosine receptor stimulation may also be involved in disease pathogenesis selective adenosine receptor
antagonists are being studied for select indications as well. Istradefylline (KW-6002, Kyowa Pharmaceuticals), a
selective adenosine A2A receptor antagonist, is now in late stage clinical trials for the treatment of Parkinson"s
Disease. Another approach to targeting adenosine receptors is to increase extracellular adenosine concentrations,
mechanisms shown to mediate the anti-inﬂammatory effects of two drugs commonly used in the treatment of
Rheumatoid Arthritis, methotrexate and sulfasalazine. Dipyridamole inhibits adenosine uptake and this clearly
underlies its effect as a coronary vasodilator during pharmacologic cardiac stressing. New methotrexate analogues
are in therapeutic trials in Rheumatoid Arthritis and recent pre-clinical studies of an adenosine uptake inhibitor
for the treatment of inﬂammatory arthritis have been reported (KF24345, Kyowa Hakka Kogyo). In the future
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Activation of Adenosine A2A Receptors on CD4
+ T Cells Reduces Reperfusion
Injury
Joel Linden
Department of Medicine, Cardiovascular Research Center, University of Virginia, Charlottesville, VA, 22908 USA
Agonists of adenosine A2A receptors (A2AR) such as ATL146e can substantially reduce necrosis of liver, heart
and other tissues when added at the time of reperfusion following ischemia. Protection is attenuated by A2AR
antagonists and is absent in A2AR KO mice. We prepared bone marrow chimera mice by transplanting bone
marrow from A2AR KO mice to previously irradiated WT syngenic recipients (KO/WT chimera) or vice versa.
Experiments with these mouse chimera revealed that A2AR-mediated protection from liver or heart reperfusion
injury is entirely dependent on A2ARs on bone marrow-derived cells. A mouse line with a ﬂoxed adora2a gene
was constructed to enable speciﬁc deletion of receptors in tissues expressing Cre recombinase. The lysM promoter
was used to express Cre selectively in macrophages and neutrophils. LysMCre-A2AR
f/f mice effectively delete the
A2AR gene, adora2a, in macrophages and neutrophils but not T cells based both on functional assays and PCR
based assays to quantify the ﬂoxed and recombined genes in puriﬁed cell populations. ATL146e was able to
inhibit reperfusion injury in LysMCre-A2AR
f/f mice, indicating that bone marrow derived cells other than
neutrophils and macrophages contribute to protection. Macrophages participate in liver reperfusion injury
because injury is reduced by depletion of macrophages with liposomal clodronate. Lymphocytes also appear to
participate in reperfusion injury because Rag1 KO mice that lack lymphocytes and B cells are protected.
Reperfusion injury is restored in Rag1 KO mice by adoptive transfer of CD4
+, but not CD8
+ T cells, and injury is
not restored by CD4
+ cells derived from INF+ KO mice. Assays of CD4
+ T cells in vitro indicates that activation
of the TCR causes rapid induction of A2AR mRNA, and that ATL146e binding to the A2AR can reduce TCR-
stimulated INF+ production by 98%. ATL146e reduces reperfusion injury in Rag1 KO mice following adoptive
transfer of WT, but not A2AR KO CD4
+ cells puriﬁed from donor spleens. As conﬁrmation that CD4
+ cells are
important in reperfusion injury we found that depletion of these cells with anti-CD4
+ antibodies also reduced liver
or hear reperfusion injury but anti-CD8
+ antibodies that effectively deplete CD8
+ cells from blood are ineffective.
Immunohistochemistry was used to measure the time course of accumulation of T cells into the heart and liver
after initiating reperfusion following ischemia. In both tissues there is a small but signiﬁcant accumulation of T
cells within minutes that is largely attenuated by ATL146e. These data suggest that an important means by which
A2AR activation reduces reperfusion injury is by activating receptors on CD4
+ T lymphocytes. This reduces
macrophage-dependent T cell activation and INF+ release required for further rapid recruitment of additional
lymphocytes and/or subsequent recruitment of neutrophils into the tissue. In ongoing work we are attempting to
determine what factors are responsible for activating CD4
+ T cells during reperfusion injury and if a particular
subpopulation of CD4
+ T cells are selectively activated. A2A agonists may be clinically useful for the treatment of
ischemia-reperfusion injury, e.g. during coronary reperfusion following myocardial infarction, or tissue
transplantation.
Berne Award Lecture: Targeting Adenosine Receptors
Bertil B. Fredholm
Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden
Bertil.fredholm@ki.se
My work in the adenosine area started, inspired by the professors Berne, Gerlach and Fain, with attempts to
examine the physiological roles of adenosine in circulation and metabolism. It was realised early—especially by
Rall and Daly—that methylxanthines including theophylline and caffeine were very useful tools to examine roles
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actions of adenosine also prompted several investigators, not least Westermann, to initiate development of
adenosine analogues with some level of selectivity. Using these as tools we discovered that adenosine and ATP
reduced neurotransmitter release, something that was independently discovered by Ribeiro.
The work of Van Calker, Hamprecht and Londos had clariﬁed that there are at least two receptor subtypes,
which we now call A1 and A2. With many collaborators, especially the late Tom Dunwiddie, we explored the roles
of A1 and A2 receptors in brain tissue and related these actions to studies of adenosine formation. To the latter
end, we used and modiﬁed techniques pioneered by McIlwain and Daly, and found with Ungerstedt ( in the ﬁrst
ever study using microdialysis) that there are resting levels of adenosine that are substantial (20–300 nM). The
effects of adenosine on transmitter release and neurotransmission were mediated by A1 receptors, whereas the
marked effect on lymphocytes and blood vessels were mediated by A2 receptors. Radioligands were developed by
several different groups and this enabled careful studies of receptor distribution. Autoradiographic techniques
were especially important. When adenosine receptors were cloned this allowed even more precise localization
studies and it was found that adenosine A2A receptors are co-localized with dopamine D2 receptors in one cell
type of the basal ganglia and related structures. The A2A receptors were found to be of tremendous importance in
the basic physiology of the basal ganglia and to be involved in many drug actions and physiological responses.
Cloning of the adenosine receptors also allowed the generation of knock-out mice to pinpoint the roles of the
different receptors. These mice have shown that adenosine is not critically important for development or basic
physiology, and that adenosine has, as suspected from the earlier investigations, a predominantly modulatory role.
Therefore modulatory adaptations are limited and adenosine receptors are interesting drug targets. Using
A2Areceptor knock-out mice it has been shown that these receptors are of fundamental importance for the
stimulatory actions of caffeine and for its effects on arousal. It is also shown that A2A receptors can be a target for
drugs to combat Parkinson ´s disease, as well as ischemia. Mice with targeted deletions of A1receptors have shown
that these receptors are critically important in kidney physiology. A1 receptors are important in limiting epileptic
seizures and resulting neuronal death. They are very important in regulating transmitter release, but apparently
play little role in ischemic cell death. This suggests that excitatory amino acid release may be overemphasized as a
mechanism of neuronal cell death after ischemia. By contrast, A1 receptors are very important in mediating
protective effects in the heart, cause analgesia, and they play a role in metabolic adaptations.
Thus, many years of research targeting adenosine receptors have shown that they are important in some, but
not many, physiological process. Adenosine receptors, do, however play several important pathophysiological
roles. Therefore drugs that target adenosine receptors have a future.
P2X and P2Y receptor-involvement in pain sensation; possible targets for new
analgesics
Peter Illes
1, Wolfgang Schro ¨der
2 and Zoltan Gerevich
1
1Rudolf-Boehm-Institute for Pharmacology and Toxicology, University of Leipzig, D-04107 Leipzig and
2Department of Pharmacology, Gru ¨nenthal GmbH, D-52099 Aachen, Germany
illp@medizin.uni-leipzig.de
Cultured dorsal root ganglion (DRG) neurons of rats are known to be endowed at their cell bodies as well as at
their peripheral and central processes with P2X3 receptors mediating rapidly desensitizing inward current
responses to ATP or its structure analogue !,"-methylene ATP (!,"-meATP). In addition, we described the
presence of P2Y1 receptors at these neurons, negatively coupled to N-type voltage-sensitive Ca
2+ channels.
Whereas P2X3 receptor-activation is supposed to induce propagated action potentials and thereby pain sensation,
P2Y receptor-activation may cause an opposite effect, by decreasing the Ca
2+ dependent release of sensory
transmitters from the central terminals of DRG neurons. According to the known transduction mechanisms of
P2X3 and P2Y1 receptors an early and rapidly declining pronociceptive action of ATP is expected to be followed
by a more protracted antinociceptive action of the same compound. In support of this assumption, we found a
negative interaction between P2Y1 and P2X3 receptors at rat DRG neurons, which was due to G protein
activation, but did not utilize any of the hitherto known second-messenger mechanisms including phospholipase
C, phosphatidylinositol 3 kinase, protein kinase C, inositoltriphosphate or Ca
2+/calmodulin kinase II. In
accordance with our in vitro data the intrathecal application of P2Y receptor agonists exhibited analgesic activity
Invited Lectures 3in an acute pain model (tail-ﬂick test). In conclusion, the endogenous P2X/P2Y receptor agonist ATP either by
itself or via its degradation product ADP may on the one hand induce pain and on the other hand may limit an
overt pain reaction. These two opposing mechanisms may operate with a considerable time-lag between each
other.
Structure and function in P2X receptors
R. Alan North
Faculty of Life Sciences, University of Manchester, Manchester, M13 9PT, UK
P2X receptors belong to a superfamily of membrane proteins that are characterised by two membrane-spanning
domains and a cysteine-rich ectodomain. Other members of this superfamily include (a) the nucleoside
triphosphate diphosphohydrolase enzymes (NTPDase 1–8) which catalyse the extracellular degradation of ATP
and ADP, and (b) the family of ion channels that includes the acid-sensing ion channels (ASIC 1–4), epithelial
sodium channels (ENaC !-%) and degenerins of C. elegans (e.g. MEC-4, MEC-10, DEG-1, DEL-1, UNC-8, UNC-
105). The three families of proteins are unrelated in primary structure. In terms of quaternary structure, P2X
receptors are considered to be trimers, whereas the body of evidence suggest that ENaC/ASIC channels are
tetramers. This lecture will summarise and review experiments in which site-directed mutagenesis and functional
expression have been used to deduce those parts of the P2X receptor involved in (a) ATP binding, (b) ion
permeation, and (c) interactions with other proteins. The principal focus will be on P2X1, P2X2, P2X2/3 and P2X4
subunits, with comparisons from studies on other family members where appropriate.
This work was supported by Wellcome Trust.
North, RA Physiol. Rev 2002 82, 1013–1067
The ecto-nucleotidase CD39/NTPDase1 is a key modulator of vascular
inﬂammation and immunity
Simon C. Robson
Liver and Transplant Centers, Beth Israel Deaconess Medical Center,Harvard Medical School, Boston. MA, USA
srobson@bidmc.harvard.edu
Extracellular nucleotides (e.g. ATP, ADP, UTP) activate type-2 purinergic/pyrimidinergic (P2Y and P2X)
receptors on platelets, endothelium and leukocytes. Ecto-nucleotidases hydrolyze these mediators, ultimately to
the respective nucleosides, to regulate P2-signaling. Ecto-nucleotidases of the CD39/E-NTPDase family are
expressed at high levels in the vasculature and immune systems. In addition to catalytic functions of the ecto-
domain of CD39, the palmitoylated intracytoplasmic N-terminus has been shown to structurally and functionally
associate with a Ran binding protein, termed RanBPM. This multi-adaptor, scaffolding membrane protein
regulates small GTPases and inﬂuences integrin signaling.
We have proposed that spatial and temporal expression of CD39/NTPDase1 within the vasculature, by immune
cells and/or derived microparticles (viz. membrane vesicles) could regulate inﬂammatory processes, immune
reactions and also impact development of cancers.
Expression of vascular CD39 appears crucial in regulating innate immunity, platelet thrombotic reactions,
acute ischemic insults, altered vascular permeability, angiogenesis and tumor growth. For example, as visualized
by in vivo video-microscopy, laser-induced arteriolar thrombus is characterized by rapid accumulation of platelets
and microparticles. This process is then stabilized by platelet disaggregation with decreases in thrombus mass. The
accumulation of NTPDase1 within thrombi blocks further ADP-mediated platelet activation. Mutant mice null
for Cd39 and transgenic over-expressors of CD39 show the predicted abnormalities with marked differences in
clot formation in vivo.
Dendritic cell expression of CD39 inﬂuences antigen presentation and T cellular responses that are crucial in
the evolution of adaptive immunity e.g. alloimmune reactions. CD39 is both an important surface marker of T
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Treg and the adenosine A2A receptor on activated effector T cells (Teff) generates a paracrine, immunosup-
pressive loop. Adoptive transfer of Cd39 null Treg fails to inhibit allograft rejection in vivo. Furthermore, Cd39
null mice develop autoimmune manifestations with deviated Th1 responses.
In addition to major recognized thromboregulatory roles, CD39 expression also has functional relevance for
cellular immunoregulation, in both allo- and autoimmune reactions. These ﬁndings suggest integration of vascular
inﬂammatory and immunologic purinergic mechanisms. Pharmacologic modalities to modulate or boost
NTPDase1 expression may suppress unwanted, deleterious vascular or immune reactions, as seen in autoimmune
disease and transplant graft rejection. In turn, related approaches could be employed to augment host protective
responses promoting tissue regeneration and normal repair processes.
Grant support from the National Institutes of Health (HL57307, HL63972 and HL076540).
1. Mizumoto N et al. Nature Medicine 2002. 8: 358–365.
2. Robson SC et al. Semin Thromb Hemost. 2005;31(2):217–233.
3. Wu, Y et al. RanBPM associates with CD39. Biochem. J. 2006. In press.
4. Deaglio S and Dwyer K. et al. 2006. The ecto-nucleotidase CD39 is a surface marker of regulatory T cells and a catalyst for
immunoregulation (submitted).
Giuliana Fassina Award: Therapeutic Potential of Partial A1Agonists in Insulin
Resistance and Diabetes.
Luiz Belardinelli, John Shryock, Arvinder Dhalla
Department of Pharmacological Sciences, CV Therapeutics Inc. Palo Alto, CA. USA 94304
luiz.belardinelli@cvt.com
A1 adenosine receptor (A1AdoR) agonists are potent anti-lipolytic agents that inhibit adipose tissue lipolysis and
lower circulating free fatty acids (FFA) levels. A reduction of lipolysis in adipocytes is of potential beneﬁt in
treatments of dyslipidemia, type II diabetes, and metabolic syndrome. Therefore, an A1AdoR agonist that
reduces lipolysis in adipocytes may be useful in the therapy of insulin-resistant states. However, A1AdoR agonists
have potential unintended side effects as a result of the presence of A1AdoR in many tissues in addition to the
adipose tissue. Functional selectivity of drug action (maximal or near-maximal anti-lipolytic effect with minimal
or no cardiovascular effects) can be achieved by exploiting the differential receptor-effector coupling between
adipose tissue and cardiac tissue. The undesired effects of A1AdoR in non-adipose tissues can be further
minimized by use of low-efﬁcacy agonists or partial agonists. We have discovered a novel partial agonist (CVT-
3619) of the A1AdoR that inhibits adipose tissue lipolysis and lowers circulating FFA levels. CVT-3619 is more
than 10–30-fold selective for A1 vs other AdoRs as determined by binding assays. CVT-3619 reduces cyclic AMP
content and release of FFA from rat epididymal adipocytes with IC50 values (potency) of 6 and 44 nM,
respectively. CVT-3619 is a partial agonist relative to CPA (a full agonist) to reduce lipolysis in rat isolated
adipocytes. CVT-3619 (at concentrations of 10 nM–30 2M) does not change atrial rate in rat isolated heart and
causes a small (6-msec) prolongation of the AV nodal conduction time without causing atrioventricular block in
guinea pig isolated heart. In in-vivo studies, CVT-3619 (1–10 mg/kg) decreases both FFA and triglyceride (TG)
levels (15–57%) in a dose-dependent manner in awake rats. CVT-3619 does not have any signiﬁcant effect on
heart rate and blood pressure at the doses that have maximal anti-lipolytic effects. At higher doses of CVT-3619
there is a signiﬁcant but small decrease in heart rate. CVT-3619 also increases the potency of insulin to decrease
lipolysis by 3-fold, suggesting that CVT-3619 increases insulin sensitivity. The potential anti-diabetic effect of
CVT-3619 (10 mg/kg sc given twice daily for 5 consecutive days) was studied in ZDF rats, an animal model of type
II diabetes. CVT-3619 treatment signiﬁcantly lowers fasting plasma glucose, insulin, FFA and triglycerides as
compared to vehicle treated rats. An oral glucose tolerance test performed on the 5th day of treatment with CVT-
3619 shows an improvement in insulin sensitivity as determined by the area under the curve of the time-
dependent changes in plasma glucose and insulin levels (AUCg x AUCi). In conclusion, CVT-3619 is a partial,
orally bioavailable A1AdoR agonist that lowers circulating FFA and TG levels resulting in improved insulin
sensitivity, with minimal cardiovascular effects.
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signalling and hydrolysis
H. Zimmermann
Institute of Cell Biology and Neuroscience, Biocenter, J.W .Goethe-University, 60439 Frankfurt am Main Germany
h.zimmermann@cns.uni.frankfurt.de
ATP was ﬁrst identiﬁed in muscle extracts in 1929. Proof for its role as an extracellular signaling molecule became
apparent considerably later and was not without controversy in the beginning. Some of the strongest support for a
potential extracellular function of ATP came from the demonstration of its storage inside granules of a variety of
secretory cells such as in blood platelets and in chromafﬁn granules in the 1950ies, and later in adrenergic (1958/
1963) and cholinergic (1974) synaptic vesicles. ATP was found to be costored with the noradrenaline or
acetylcholine. On nerve stimulation, ATP is depleted from cholinergic synaptic vesicles in parallel with
acetylcholine and is replenished together with acetylcholine during a subsequent period of rest. Adenosine taken
up into cholinergic nerve terminals via a high afﬁnity transporter becomes immediately phosphorylated, ends up
in synaptic vesicles in the form of ATP and becomes coreleased with acetylcholine (Zimmermann, 1982) [1]. The
costrorage of ATP with neurotransmitter substances as well as the coexistence of neuropeptides with classical
neurotransmitters raised the question whether neurons may be able to employ more than one signaling substance,
a new principle borne out by Geoffrey Burnstock in 1976 [2].
Also the notion of cell surface-located ATPases reaches far back into the 1950ies, based on both biochemical
and enzyme histochemical evidence. Yet the functional role of extracellular ATP hydrolysis remained a matter of
speculation. The evidence for an involvement of extracellular nucleotides in a variety of physiological functions
increased dramatically form the 1970ies onwards. But the general acceptance of nucleotide signaling by the
scientiﬁc community began only with the molecular cloning, heterologous expression and functional character-
ization of the molecular players involved. The ﬁrst one was ecto-50-nucleotidase (1990) followed by P2 receptors
(1993), and NTPDase1 (CD39) (1996).
By now, nucleotides have been demonstrated to control major functions in the nervous system. These include
synaptic transmission and its modulation, reciprocal signaling between neurons and glia, propagation of glial
calcium waves, induction of gliosis or also activation, modulation and transmission in sensory systems. A major
role of ecto-nucleotidases in these settings is in the modulation of ligand availability at nucleotide and nucleoside
receptors. A novel and interesting function of nucleotides uncovered more recently concerns their role in adult
and embryonic neurogenesis where ATP and UTP cooperate with growth factor receptors in activating
progenitors (Mishra et al., 2006) [3]. This and other recent examples highlight the functional importance of
interactive pathways between signaling via nucleotides and other cellular messengers.
(1) Zimmermann, H. 1982, In: Co-transmission, Cuello, A.C. (ed) London: The MacMillan Pess, p. 243–259.
(2) Burnstock, G. Neuroscience 1976, 1, 239–248
(3) Mishra, S.K., Braun, N., Shukla, V., Fu ¨llgrabe, M., Schomerus, C., Korf, H.-W., Gachet, C., Ikehara, Y., Se ´vigny, J.,
Robson, S.C., and Zimmermann, H. Development 2006, 133, 675–684
Basic Pharmacology
Molecular Physiology and Pharmacology of P2X1 Receptors
Jonathan Roberts, Catherine Vial, Helen Digby, Kelvin Agboh, Hairuo Wen & Richard J. Evans
Department of Cell Physiology and Pharmacology, Medical Sciences Building, University of Leicester, Leicester,
U.K. LE1 9HN
ATP binds to the large extracellular loop of P2X receptors and results in channel activation. It seems likely that
residues important for ATP action at the receptor would be conserved in the family and in the extracellular loop
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Alanine replacement mutagenesis of the majority of conserved amino acids in the extracellular loop of the P2X1
receptor has little or no effect on the response to ATP indicating that they do not play an essential role. The
results from systematic alanine scanning of conserved residues in the extracellular loop give rise to a model of the
site of ATP action at the P2X1 receptor with K68 and K309 binding to the phosphate tail and the motifs F185T186
and N290F291R292 co-ordinating the binding of the adenine ring. A similar binding environment has been
described for the crystal structure of rat synapsin II. To test and reﬁne the model we have used cysteine scanning
mutagenesis of the region S286-I329 to investigate the environment adjacent to important conserved amino acids
N290F291R292 and K309 and the residues close to the second transmembrane domain. Methanthiosulphonate
(MTS) compounds can be used to modify any accessible free cysteine residues. For the majority of cysteine
mutants there was little or no effect on ATP evoked responses or modiﬁcation by either positively charged
MTSEA or negatively charged MTSES. At mutants D316C, G321C, A323C and I328C responses were sensitive to
MTS compounds, e.g. an ~50% reduction in response to ATP on application of MTSEA for G321C. However at
these mutants there was no shift in ATP potency of the point mutants from WT either before or after MTS
reagent application. These results indicate that the modiﬁcation of ATP response results from an effect on ionic
permeation and not on agonist binding. At mutants N290C, F291C, R292C and K309C responses were sensitive to
MTS reagent application, however in these cases ATP potency was signiﬁcantly reduced compared to WT
channels and MTS reagents resulted in a change in ATP potency, for example at K309C the EC50 was decreased
~40 fold on addition of positively charged MTSEA showing that charge at this position is important. These
support previous ﬁndings and suggest that these residues mediate part of the ATP binding pocket.
Supported by the Wellcome Trust.
New insights into P2X7 receptor signaling
Annmarie Surprenant
Institute of Molecular Physiology, Department of Biomedical Science, University of Shefﬁeld, Shefﬁeld, UK
a.supprenant@shefﬁeld.ac.uk
Abstract not received
Novel Signal Transduction Pathways Regulated by P2Y2 Nucleotide Receptors
Mediate Inﬂammatory Responses in Mammalian Cells
Weisman, G.A., Seye, C.I., Liao, Z., Yu, N., Wang, M., Liu, J., Chorna, N.,
1 Baker, O., Camden, J., Sun,
G.Y., Gonzalez, F.A.,
1 and Erb, L.
University of Missouri-Columbia, Columbia, MO 65212 USA and *University of Puerto Rico, San Juan, PR 00931
USA
weismang@missouri.edu
The Gq/11-coupled P2Y2 nucleotide receptor (P2Y2R) for ATP and UTP activates phospholipase C leading to an
increase in IP3-dependent calcium mobilization and diacylglycerol-dependent activation of protein kinase C,
responses that regulate the activity of phospholipases A2 in primary murine astrocytes. Recent studies indicate
that P2Y2Rs possess novel molecular determinants that enable them to activate other signaling pathways
independent of Gq proteins. For example, data indicate that proline rich Src-homology-3 (SH3) binding domains
in the intracellular C-terminus of the P2Y2R can mediate the transactivation of growth factor receptors (e.g.,
vascular endothelial growth factor receptor-2) to promote the up-regulation of cell adhesion molecules (e.g.,
vascular cell adhesion molecule-1) in endothelium that promote the binding and vascular inﬁltration of monocytes
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(RGD) motif in the extracellular domain of the P2Y2R mediates interactions with !v"3/"5 integrins that are
required for Go protein activation and nucleotide-induced increases in the motility of primary astrocytes, and G12-
mediated stress ﬁber formation that regulates cytoskeletal rearrangements required for cell chemotaxis. The
P2Y2R is also capable of activating matrix metalloproteases including the adamalysins ADAM 10 and ADAM 17
that increase the degradation of amyloid precursor protein in astrocytoma cells to generate the non-
amyloidogenic peptide s-APP!, suggesting that P2Y2R function may be neuroprotective in Alzheimer"s disease.
Other data indicate that P2Y2R-mediated activation of metalloproteases in salivary gland epithelial cells plays a
role in the up-regulation of cell adhesion molecules that facilitate lymphocyte binding, a response associated with
the auto-immune disease Sjo ¨gren"s syndrome. Taken together, our results indicate that P2Y2R expression in a
variety of mammalian cell types can promote inﬂammatory responses due to the ability of the P2Y2R to activate
diverse signaling pathways in addition to the well-established activation of Gq proteins. This study was supported
by the National Institutes of Health Grants 1 P01-AG-018357 and 1 R01-DE-07389.
Nucleotide presynaptic ionotropic receptors are accurately tuned by other
neurotransmitters
Miguel Dı ´az-Herna ´ndez, Rosa Gomez-Villafuertes, Javier Gualix, Maria Diez-Zaera, Miriam Leo ´n-Otegui and
M. Teresa Miras-Portugal
Presynaptic functional P2X receptors and dinucleotide receptors are widely present in the CNS. Calcium
responses induced by purinergic agonists evoke neurotramitter stores release of synaptic vesicles from
Cholinergic, GABAergic and Glutamatergic nerve terminals. However, when a single cholinergic terminal was
stimulated with nucleotide and nicotinic agonists altogether results in a signiﬁcant decrease of the [Ca
2+]i
signalling compared to responses of each independent agonist. Inhibitory interaction between both receptors is
reverted when one of them is blocked by speciﬁc antagonists. The receptor"s inhibitory cross-talk conﬁrms the
involvement of calcium/calmoduline-dependent protein kinase II, CaMKII, as the inhibitory effects are reverted
in the presence of the speciﬁc inhibitors KN-62 and KN-93.
In GABAergic nerve endings it has been described that activation of GABA-B autoreceptors positively
modulated the ATP and dinucleotide responses, inducing a signiﬁcantly increase on the afﬁnity of purinergic
receptors.
Finally preliminary results obtained on Glutamatergic synaptic terminals appear indicate the existence of an
inhibitory interaction between P2X and glutamatergic autoreceptors.
All these results demonstrate the existence of an efﬁcient interaction between purinergic and other
autoreceptors populations, opening a new understanding on the functional regulation of terminals releasing the
most abundant neurotransmitters in the CNS.
Quantiﬁcation and agonist-promoted regulation of the P2Y1 receptor
T. K. Harden, D. Houston, D.M. Bourdon, G.L. Waldo, M. Ohno, and K.A. Jacobson
Dept. Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA and NIDDKD,
NIH, Bethesda, MD, USA
tkh@med.unc.edu
The P2Y1 receptor (P2Y1-R) is expressed broadly in mammalian tissues, for example on the surface of platelets
where it is essential for ADP-promoted aggregation. Our laboratories have focused on the development of P2Y1-
R-selective antagonists, agonists, and radioligands as reagents for delineating the physiological and molecular
properties of this important cell signaling protein. Synthesis of a series of selective, high afﬁnity, non-nucleotide
competitive antagonists for the P2Y1-R led to development of [
3H]MRS2279 as a radioligand for reliable
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homogeneity taking advantage of this radioligand and high level expression of recombinant receptor from a
baculovirus in insect cells. We recently developed methodology for radiolabelling with
32P the highest afﬁnity (Kd
~0 . 5n M )P 2 Y 1-R antagonist, 2-iodo-N
6-methyl-(N)-methanocarba-20-deoxyadenosine-30,50-bisphosphate
(MRS2500). This high speciﬁc radioactivity, high afﬁnity radioligand has proved very useful for quantiﬁcation
of natively expressed P2Y1-R across mammalian tissues. Moreover, we have applied this radioligand to quantify
native P2Y1-R during agonist-induced trafﬁcking in human platelets and in cell lines. Structure activity studies of
P2Y1-R antagonists also were instrumental in development of (N)-methanocarba-2MeSADP (MRS2365), which
is a high afﬁnity full agonist at the ADP-activated P2Y1-R but does not bind to the ADP-activated P2Y12-R or
P2Y13-R. This molecule provides a reagent for speciﬁc activation of the P2Y1 receptor in tissues, e.g. platelets,
where multiple ADP-activated receptors exist.
Release of nucleotides and UDP-sugars from Airway Epithelia
Eduardo R. Lazarowski
Cystic Fibrosis Center. University of North Carolina School of Medicine
Eduardo_Lazarowski@med.unc.edu
Extracellular nucleotides modulate multiple components of the innate lung defense by activating epithelial airway
surface purinergic receptors. ATP, UTP, UDP, and adenosine control the production of airway surface liquid
(ASL) by regulating ion transport. ASL nucleotides also promote cilia beating and mucin secretion, and thereby
activate the mucociliary clearance (MCC) process that removes noxious materials from the airways. In addition, a
recent study illustrated that the P2Y14 receptor (the cognate receptor for UDP-glucose, UDP-Glc) is expressed in
alveolar epithelial type II and other lung epithelial cells and promotes the secretion of the potent neutrophil
chemoattractant IL-8 (1). Thus, UDP-Glc may be an inﬂammatory mediator in the airways. Noteworthy, P2Y14
receptor transcripts are most abundantly expressed in circulating neutrophils, relative to other peripheral tissues
(2). Quantitative PCR analysis on human neutrophils illustrated the presence of P2Y14 receptor transcripts in
copy number comparable to that of the abundantly expressed chemotactic peptide (fMLP) receptor FPR-1.
Despite the physiological and pathophysiological relevance of the responses triggered by extracellular
nucleotides and UDP-sugars in the airways, the mechanisms and pathways for nucleotide release from airway
epithelia are unknown. UDP-sugars are donor substrates for glycosylation reactions in the lumen of the secretory
pathway. UDP is a byproduct of this process, which in turn is hydrolyzed to UMP by a Golgi resident UDPase.
UDP-sugar/UMP antiporters translocate luminal UMP to the cytosol and cytosolic UDP-sugars to the lumen of
the Golgi. We have discovered that in addition to ATP, airway epithelial cells release UDP-Glc constitutively and
that release of UDP-Glc from resting epithelial cells is markedly affected by genetic manipulation of Golgi UDP-
sugar translocators. These observations suggest that UDP-Glc is released to the extracellular milieu from the
secretory pathway, i.e., following translocation to the Golgi via UDP-sugar/UMP antiporters.
Impaired MCC, mucus hypersecretion, and neutrophil inﬂammation are characteristics of chronically diseased
airways, e.g., cystic ﬁbrosis (CF), chronic obstructive lung disease (COPD), and asthma. UDP-Glc levels in
sputum samples from CF patients are markedly elevated, reaching concentrations (~500 nM) capable of
promoting robust activation of P2Y14 receptors. Unlike ATP, UDP-Glc added either onto the mucosal surface of
airway epithelial cells or to CF sputum was poorly hydrolyzed. In addition, enhanced ATP and UDP-Glc release
occurs during Ca
2+-promoted vesicle exocytosis and mucin granule secretion from airway epithelial goblet cells
(3). Therefore, nucleotide release from goblet cells may be mechanistically associated with mucin secretion, e.g.,
as co-cargo molecules within mucin granules.
Together, our observations suggest that (i) airway epithelial cell nucleotide release has an exocytotic
component, and (ii) sustained UDP-Glc accumulation in ASL during conditions associated with mucin
hypersecretion e.g., CF, COPD, and asthma, provides long lasting pro-inﬂammatory signaling in the airways.
1. Muller T, Bayer H, Myrtek D et al. Am J Respir Cell Mol Biol 2005.
2. Moore DJ, Murdock PR, Watson JM et al. Brain Res Mol Brain Res 2003; 118(1–2): 10–23.
3. Kreda S, Okada S, van Heusden C et al. Abstract to the 8th International Symposium on Adenosine and
Adenine Nucleotides (Ferrara, 2006).
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As the epithelium is the most external layer of the cornea, it is often damaged by several factors causing corneal
wounds. These wounds are repaired in a three-step process called corneal wound healing. Diadenosine
polyphosphates, ApnA, are present in rabbit and human tears. This fact invites to think that these dinucleotides
may participate in ocular surface processes such as corneal wound healing. Therefore, we have investigated the
possible role of diadenosine polyphosphates on corneal wound healing by studying the changes in the rate of
corneal epithelial cell migration after dinucleotide applications.
Primary corneal epithelial cell cultures were obtained from New Zealand white rabbits. Immunocytochemical
experiments were carried out by ﬁxing the cells with 4% PFA and incubated with citokeratine 3 primary antibody
which was subsequently incubated with a secondary Ig-G mouse labelled with FITC an cells were observed under
confocal microscopy. Migration studies were carried out by taking conﬂuent monolayers which were wounded
with a pipette tip and challenged with different di- and mononucleotides (Ap3A, Ap4A, Ap5A, Up4U, ATP, UTP,
ADP and UDP). For concentration-response analysis compounds were tested in doses ranging from 10
j8 to 10
j3
M. When the P2 antagonists, PPADS, suramin and reactive blue 2, were used, they were assayed at 100 2M, and
from 10
j7 to 10
j3 M in concentration-response studies. In order to study the intracellular pathways involved in
cell migration, several MAPK and citoskeleton inhibitors (U0126 100 2M, Y27632 100 2M, AG1478 100 2M,
PAO (phenylarsine oxide) 5 2M, (j)-Blebblistatin 10 2M and ML7 25 2M) were assayed in the presence or
absence of Ap4A and Ap3A both 100 2M. Stability of the dinucleotides was assayed by HPLC using an isocratic
method.
Cells under study were identiﬁed as corneal epithelial cells due to this positive labelling to cytokeratine-3 in the
immunocytochemicalanalysis.CellmigrationexperimentsshowedthatAp4A, UTP and ATP accelerate the rate of
healing, while Ap3A, Ap5A and UDP delay it. ADP and Up4U did not modify the rate of migration. For further
experiments we took Ap4A (which accelerates the rate of wound) and Ap3A which delays it. P2Y antagonists
presented small differences between Ap4A and Ap3A. The assays with MAPK and citoskeleton inhibitors,
revealed that both, MAPK pathway and cdc-42/RAC/RhoA/ROCK pathways are involved in the epithelial
migration. In this sense, Ap4A activating cdc-42 cascade increase the rate of corneal epithelial cell migration,
while the delay caused by Ap3A is mainly due to the MAPK pathway Finally, concerning the possible degradation
of the dinucleotides it was almost impossible to detect any product as a consequence of their cleavage.
Degradation of 1–3% of the dinucleotides in 2 min perfusion indicates that the active molecules are the
diadenosine polyphosphates and not the generated mononucleotides.
In summary, analysing the pharmacological proﬁle of all the compounds tested we can conclude that
diadenosine polyphosphates activate two main P2Y receptors: a P2Y2 receptor accelerating the rate of healing
a n daP 2 Y 6 receptor which delays this process.
Medicinal Chemistry
Adenine nucleosides as reversible P2Y12 antagonists
James G. Douglass, Adam Samuelson, J. Bryan deCamp, Emilee Glaub, Dima Smirnov, Sanjoy
Mahanty, Anna Morgan, Chris Crean, Jose L. Boyer, Stephanie Anderson, and Paul S. Watson
Inspire Pharmaceuticals Inc., 4222 Emperor Boulevard, Suite 200, Durham, North Carolina, USA 27703-8466
pwatson@inspirepharm.com
ADP serves as an endogenous agonist for both P2Y1 and P2Y12 on platelets, and antagonism of its action at either
receptor has been shown to inhibit platelet aggregation. Inhibition of platelet aggregation using irreversible P2Y12
antagonists has proven to be a useful therapy to treat Acute Coronary Syndrome (ACS). Previously we had
10 Invited Lecturesidentiﬁed several lipophilic modiﬁcations to adenine nucleotides that enable them to reversibly block aggregation
mediated by P2Y12. This presentation will brieﬂy discuss human clinical trial results of one of these reversible
P2Y12 adenine nucleotide antagonists, INS50589, and the discovery of reversible P2Y12 adenine nucleoside
antagonists stemming from observations gained from our original nucleotide research.
Development of pharmacological tools for studying P2Y receptors
C.E. Mu ¨ller
Pharmaceutical Sciences Bonn (PSB), Pharmaceutical Chemistry, Pharmaceutical Institute Poppelsdorf, University
of Bonn, Kreuzbergweg 26, 53115 Bonn, Germany
christa.mueller@uni-bonn.de
P2Y receptors are G protein-coupled receptors (GPCRs) activated by nucleotides, such as ATP, ADP, UTP,
UDP, or UDPglucose, depending on the receptor subtype. Currently, 8 subtypes are known (physiological agonist
in brackets): P2Y1 (ADP), P2Y2 (UTP, ATP), P2Y4 (UTP), P2Y6 (UDP), P2Y11 (ATP), P2Y12 (ADP), P2Y13
(ADP), and P2Y14 (UDPglucose) [1].
Our project focussed on the synthesis of base-modiﬁed uracil nucleotides and metabolically stable nucleotide
mimetics as ligands for the uracil nucleotide-sensitive P2Y receptor subtypes. A series of nucleotides and analogs
was synthesized, investigated at recombinant human P2Y2, P2Y4, and P2Y6 receptors, and structure-activity
relationships were analyzed. Alkyl substituents in the 6-position of UTP and UDP were not tolerated by the three
receptor subtypes. Large, aromatic substituents at N3 of UDP were well tolerated by the P2Y6 receptor leading to
potent, P2Y6-selective agonists. Modiﬁcation of the triphosphate chain by introduction of a ",+-dichloromethylene
bridge in UTP derivatives, resulting in compounds with enhanced metabolic stability, was well tolerated by all
three receptor subtypes.
Radioligands are valuable tools for studying GPCRs, however, selective radioligands have only been available
for the P2Y1 receptor subtype so far. We have recently developed the ﬁrst selective radioligand for the P2Y12
receptor subtype [2], an ADP receptor predominantly expressed on platelets, and in lower density in the brain.
The P2Y12 antagonist radioligand [
3H]PSB-0413 (2-propylthioadenosine-50-adenylic acid (1,1-dichloro-1-phos-
phonomethyl-1-phosphonyl) anhydride, AR-C67085MX) has been successfully used for characterizing P2Y12
receptors on the protein level in various tissues and cells. The radioligand allowed to set up a fast and efﬁcient
screening assay for identifying novel lead structures for the development of P2Y12 antagonists, which are potent
antithrombotic agents.
Extracellular nucleotides are quickly hydrolyzed by ectonucleotidases to limit their action. Inhibitors of such
enzymes would act as indirect P2Y receptor agonists by prolonging the effects of endogenously released
nucleotides. We have developed a fast and convenient nanoscale capillary electrophoresis assay to screen and
characterize inhibitors of ectonucleotidases [3]. The enzymatic reaction is performed within the capillary followed
by electrophoretic separation and quantiﬁcation (by UV) of the reaction products. A novel class of
ectonucleotidase inhibitors has been discovered by this approach.
1. Brunschweiger A, Mu ¨ller CE. Curr Med Chem 2006; 12: 763–71.
2. El-Tayeb A, Griessmeier KJ, Mu ¨ller CE. Bioorg Med Chem Lett 2005; 15: 5450–2
3. Iqbal J, Vollmayer P, Braun N, Zimmermann H, Mu ¨ller CE. Purinergic Signalling 2005; 1: 349–58
Molecular Recognition in P2Y Nucleotide Receptors
Kenneth A. Jacobson
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
kajacobs@helix.nih.gov
Invited Lectures 11Agonists selective for P2Y1, P2Y2, and P2Y6 receptors and nucleotide antagonists selective for P2Y1 and P2Y12
receptors have been identiﬁed. Selective non-nucleotide antagonists have been reported for P2Y1,P 2 Y 2, P2Y6,
P2Y11, P2Y12, and P2Y13 receptors. Three-dimensional structural models of P2Y receptors, deduced mainly from
rhodopsin-based homology modeling and mutagenesis studies, have aided in the development of selective ligands
[1]. We have synthesized, as ligands for P2Y receptors, nucleotide analogues in which the ribose moiety is
substituted by a variety of novel ring systems, including conformationally-locked moieties. The focus on
conformational factors of the ribose-like moiety allows the inclusion of general modiﬁcations that lead to
enhanced potency and selectivity. In solution, the ribose ring of an unbound nucleotide may exist in a dynamic
equilibrium between (N) (North; 20-exo/30-endo) and (S) (South; 20-endo/30-exo) conformations, and X-ray
crystallographic structures of diverse nucleotide complexes through nature indicate a clustering around these
conformations. It is possible to stabilize each of these conformational clusters by chemical bridging within a ring.
Replacement of the ribose moiety of ATP with a bicyclo[3.1.0]hexane ring (methanocarba, mc) ring system, i.e.
fused cyclopropane and cyclopentane rings, locks the analogue in either a (N) or (S) conformation, depending on
the position of the CH2-bridge. These two isomeric variants produce agonist analogues having widely differing
activities at P2 receptors (collaboration w/T.K. Harden). At P2Y1,2,4,11 receptors, there is a preference for the (N)
conformation as indicated with (N)-methanocarba analogues, such as the potent, competitive P2Y1 antagonist
MRS2500. MRS2500 was sufﬁciently stable in vivo to inhibit ADP-induced platelet aggregation in mice [2].
[
33P]MRS2500 was synthesized enzymatically and studied as a radioligand having a Kd value of 0.3 nM at the rat
brain P2Y1 receptor [3]. MRS2365, an (N)-methanocarba analogue of 2-MeSADP, displayed potency (EC50)o f
0.4 nM at the P2Y1 receptor with >10,000-fold selectivity in comparison to P2Y12 and P2Y13 receptors [3]. Basic
structure activity relationships were explored at P2Y2 and P2Y4 receptors. However, there is a fundamental
conformational difference between the binding sites of P2Y6 and various other P2Y receptors. A uridine 50-
diphosphate analogue locked in the (N) envelope conformation was inactive [4]. Based on a prediction from
docking of nucleotide derivatives to a P2Y6 receptor model, (S)-mc-20-deoxy-UDP was synthesized and found to
be more potent than the corresponding riboside, dUDP, indicating a preference for the (S) conformation. At the
recombinant human P2Y13 nucleotide receptor, MRS2211 (6-[(2-chloro-5-nitrophenyl)-azo]-pyridoxal-50-phos-
phate) an analogue of the known P2 receptor antagonist PPADS was found to competitively and selectively
inhibit functional activity with a pIC50 value of 5.97, being 45-fold more potent than PPADS [5].
1. Costanzi S et al. J Med Chem 2005; 48: 8108–11.
2. Hechler B et al. J Pharm Exp Therap 2006; 316; 556–63.
3. Houston H et al. Br J Pharmacol 2006; in press.
4. Chhatriwala M et al. J Pharm Exp Therap 2004; 311: 1038–43.
5. Kim YC et al. Bioorg Med Chem Lett 2006; 16: 596–601.
New Nucleotides and Nucleotides Analogs and their Activity on P2 Receptors
Gloria Cristalli and Rosaria Volpini
Dipartimento di Scienze Chimiche, Universita ` di Camerino, via S. Agostino, 1, 62032 Camerino, Italy
Presenting author: gloria.cristalli@unicam.it
P2 receptors, activated by nucleotides like ATP, ADP, UTP, and UDP, belong to two families: the ionotropic
P2X receptors (P2X1–7), which represent a class of ligand-gated ion channels and the metabotropic P2Y receptors
(P2Y1,2,4,6,11–14), which are ubiquitously expressed in the human body. All these receptors play important
pathophysiological roles, hence, the availability of new ligands can provide novel drugs for the treatment of a
number of currently-incurable diseases including tumors and neurodegenerative disorders. However, a limited
number of reports described the identiﬁcation of potent and selective P2X/P2Y ligands. Hence, the present work
will be focused on the design and characterization of novel P2 receptor ligands obtained through the
phosphorylation of substituted purine and pyrimidine nucleosides [1]. Furthermore, the design of Bmini
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Studies on different pharmacological models such as: a) effects on the human platelet aggregation, b) neuronal
differentiation and commitment to death in the human neuroblastoma SH-SY5Y cells, and c) activity on HEK 293
cells transfected by ionotropic P2X3 receptors, will be discussed. Preliminary results demonstrated that the above
mentioned nucleotides interact with the P2 receptors; in particular, some 2-alkynyladenosine nucleotides behave
as agonists or antagonists at platelet P2Y1 and P2Y12 subtypes, depending on the nature of the substituent in 2-
position [2], while the 5-iodouridine triphosphate interacts with the metabotropic P2Y4 receptor subtype leading
to neuroblastoma SH-SY5Y cell death. Furthermore, some mininucleotides demonstrated agonist activity on
P2X3 receptors.
1. Cristalli G, Dal Ben D, Lambertucci C et al. Synthesis of new P2 receptor ligands. Collection Symposium Ser 2005; 7: 87–93.
2. Cristalli G, Podda GM, Costanzi S et al. Effects of 50-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl
adenosine on responses of human platelets mediated by P2Y receptors. J Med Chem 2005; 48: 2763–6.
Novel orthosteric and allosteric ligands for adenosine receptors.
Ad P. IJzerman
Leiden/Amsterdam Center for Drug Research, PO Box 9502, 2300RA Leiden, The Netherlands
(email: ijzerman@lacdr.leidenuniv.nl)
Adenosine receptor antagonists usually possess a bi- or tricyclic heteroaromatic structure at their core with
varying substitution patterns to achieve selectivity and/or greater afﬁnity. Taking into account molecular
modelling results from a series of potent A1 adenosine receptor antagonists, we derived a pharmacophore
suggesting that a monocyclic core can be equally effective. As a further design criterion we imposed a restriction
on the polar surface area (PSA) of the molecules that would allow them to penetrate into the CNS. In
consequence, we have synthesised two novel series of pyrimidines and a related series of purines with
unanticipated substitution pattern, possessing good antagonistic potency at the A1 adenosine receptor and
desirable PSA values. In particular, pyrimidine LUF5735 and purine LUF5962 display excellent, even



















Invited Lectures 13As a next challenge, a series of 1H-imidazo-[4,5-c]quinolin-4-amine derivatives was synthesized as allosteric
modulators of the human A3 adenosine receptor. Structural modiﬁcations were made at the 4-amino and 2-
positions. The compounds were tested in both binding and functional assays, and many were found to be allosteric
enhancers of the action of A3AR agonists by several different criteria. First, a potentiation of the maximum
efﬁcacy of the agonist Cl-IB-MECA was observed for numerous derivatives, with the greatest increase of 45–50%
observed for LUF6000. Also, a number of these compounds, including LUF6000, decreased the rate of
dissociation of the agonist [
125I]I-AB-MECA from the A3 receptor. It was found that the capability of these
compounds to increase agonist efﬁcacy correlated with their ability to decrease the dissociation rate, but not their
inhibition of equilibrium binding.
In conclusion we have prepared and evaluated novel series of compounds that display remarkable
characteristics at either human adenosine A1 or A3 receptors.
Recent developments in the ﬁeld of A2B and A3 adenosine receptors antagonists
Pier Giovanni Baraldi
1, Delia Preti
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Adenosine, an endogenous modulator of a wide range of biological functions in the nervous, cardiovascular, renal,
and immune systems, interacts with at least four cell surface receptor subtypes classiﬁed as A1,A 2A,A 2B and A3
[1]. Clariﬁcation of the role of adenosine and its receptors in cancer development may hold great promise for the
chemotherapeutic treatment of patients affected by malignancies [2].
Different classes of compounds with non-xanthine structures have been reported to be A3 adenosine receptor
antagonists [3]. The pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine nucleus has been largely investigated by our
group. Our interests were focused on the effects of substitution of the phenyl ring of the arylcarbamoyl moiety at
N
5 position and of substituents at C
9 and/or at N
7–N
8 pyrazole nitrogens. These studies allowed us to obtain a
large variety of compounds which showed afﬁnities in the nanomolar range to human A2A or A3 adenosine
receptors with high degree of selectivity [3].
Compounds presenting an additional fused ring on the xanthine nucleus have been reported to exhibit
antagonistic activity with various levels of afﬁnity and selectivity towards the four adenosine receptors subtypes
[4]. We evaluated the effect of the introduction of a benzyl and a propyl at the 1 and 3 positions, respectively, in a
new series of 7-aryl/alkyl-1H,6H-pyrrolo[2,1-f]purine-2,4-diones and 7-aryl/alkyl-1H,8H-imidazo[2,1-f]purine-2,4-
diones [5], among which, very potent and selective A3 receptors antagonists have been identiﬁed. In particular 1-
benzyl-7-methyl-3-propyl-1H,8H-imidazo[2,1-f]purine-2,4-dione, shows a subnanomolar afﬁnity with a notewor-
thy selectivity versus the other adenosine receptors subtypes (Ki (hA3) = 0.8 nM, Ki (hA1/hA3) = 3163, Ki (hA2A/
hA3) > 6250, IC50 (hA2B)/Ki (hA3) = 2570).
Colotta et al. directed much effort toward the study of adenosine receptor antagonists investigating the 2-
arylpyrazolo[3,4-c]-quinoline nucleus [6]. In light of the reported activity proﬁle, we decided to synthesize the
structural isomers, 2-arylpyrazolo[4,3-c]quinolines [7], some of which showed high A3 receptor afﬁnity and
complete selectivity (2-p-tolyl-2,5-dihydro-pyrazolo[4,3-c]quinolin-4-one; KihA1,K ihA2A,E C 50hA2B>1000 nM,
KihA3= 9 nM).
In the search for improved selective A2B antagonists for the treatment of asthma [8], we synthesized a variety
of new 1,3-dipropyl-8-heterocyclic-substituted xanthines [9]. We introduced several heterocycles, such as pyrazole,
isoxazole, pyridine and pyridazine at the 8-position of the xanthine nucleus. We have also investigated different
spacers (substituted acetamide, oxyacetamide and urea moieties) on the heterocycle introduced. Some of the
synthesized C8-substituted xanthines showed high afﬁnity at A2B receptor subtype and very good selectivity (N-
benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-
yloxy]-acetamide; hA2B = 5.5 nM, hA1,h A 2A,h A 3 > 1000).
14 Invited Lectures(1). Fredholm et al. Pharmacol Rev 2001; 53: 527–52.
(2). Merighi et al. Pharmacol Ther 2003; 100(1): 31–48.
(3). Baraldi et al. Drug Dev Res 2003; 58: 315–29.
(4). Drabczyn ˜ska et al. Eur J Med Chem 2003; 38: 397–402.
(5). Baraldi et al. J Med Chem 2005; 48: 4697–701.
(6). Calotta et al. J Med Chem 2000; 43: 3118–24.
(7). Baraldi et al. J Med Chem 2005; 48: 5001–8.
(8). Auchampach et al. Mol Pharmacol 1997; 52: 846–60.
(9). Baraldi et al. J Med Chem 2004; 47: 1434–47.
Synthesis and molecular modeling studies of new pyrazolo[3,4-b]pyridines,
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Adenosine is an endogenous neuromodulator, which mediates its biological effects by interacting with four
receptor subtypes named A1,A 2A,A 2B, and A3. The physiological signiﬁcance and functions of adenosine have
been extensively studied and in the last twenty years a large number of adenosine ligands, agonists and
antagonists, have been developed. Particularly, many efforts have been invested in the synthesis of A1ARs
antagonists, that can stimulate cerebral activity by blocking the adenosine central inhibitory activity. In this
context, a number of new 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridines 5-carboxylic acid
esters have been synthesized by our research group and their binding afﬁnity at the A1,A 2A and A3 adenosine
receptors (AR) have been evaluated. The new compounds were characterized by a high afﬁnity and selectivity
toward the bovine A1 receptor subtype (bA1AR). In addition, to rationalize the relationships between structure
and afﬁnity of such compounds together with A1AR antagonists taken from the literature, molecular modeling
studies were carried out. As a ﬁrst approach, a pseudoreceptor model [1] was built to derive a hypothesis of the
interaction pathway between the set of A1AR antagonists and a model of the putative A1 receptor. Nevertheless,
biological evaluation of several compounds suggested by the model did not give the expected results,
demonstrating that the model itself was scarcely able to predict the activity of inhibitors subjected to
modiﬁcations at the position 5. As a consequence, a new and more accurate model was required to better
predict the activity of A1AR inhibitors. To reach this goal, a highly predictive 3D QSAR model for antagonists of
A1AR was generated [2]. Such model demonstrated to have the knowledge for estimating the afﬁnity of a very
large number of inhibitors belonging to different structural classes. The generated 3D QSAR has been also used
to reﬁne a model of the A1AR receptor built by homology and then molecular modeling study of the interaction
of the compounds under investigation with the bovine A1 adenosine receptor was carried out. On the other hand,
the ADME (absorption, distribution, metabolism, excretion) properties of the synthesized pyrazolo-[3,4-
b]pyridines were evaluated by means of the Volsurf software with the aim to have a prediction of the aqueous
solubility and cell permeability of such molecules. All computational studies together with the synthesis of new
pyrazolo-[3,4-b]pyridines will be reported during the oral presentation and the biological evaluation of the
inhibitors on both the bovine and human A1 receptors (bA1AR and hA1AR respectively) will be also discussed.
(1). Bondavalli F, Botta M, Bruno O et al. J Med Chem 2002; 45: 4875–87.
(2). Manetti F, Schenone S, Bondavalli F et al. J Med Chem 2005; 48: 7172–85.
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The P1 family of adenosine receptors consists of two Gi couple receptors, A1 and A3, and two Gs coupled
receptors, A2A and A2B. The A2B adenosine receptor (AdoR) is found in multiple tissues including the lung where
it is found in bronchial smooth muscle cells [1] and mast cells [2]. In vitro experiments, demonstrate the release of
inﬂammatory cytokines from both bronchial smooth muscle cells and mast cells, effects that can be blocked by an
A2B AdoR antagonist [1,2]. Thus, we hypothesize that the A2B AdoR may play a role in asthma. We will disclose
an overview of our A2B AdoR antagonist structure activity relationships starting with MRS-1754 [3] as a lead
molecule to the discovery of 8-(1H-pyrazol-4-yl)xanthine 1, a compound with a 1 nM Ki for the A2B AdoR and
excellent selectivity (Figure 1). The complete SAR leading up to the discovery of 1 involved a systematic
optimization of the heterocycle at the 8 position, followed by varying the chain length of the N-1 aralkyl
(phenpropyl, phenethyl, and benzyl), optimizing substituents on the phenyl ring for afﬁnity and selectivity for the
A2B AdoR, and ﬁnally varying the N-1 and N-3 alkyl substituents. Unfortunately, 1 did not possess high oral
bioavailability (rats), and this was attributed to low water solubility. Therefore, an effort to add charge to the
molecule to enhance water solubility was explored. Initially, adding a carboxylate to the phenyl ring or benzylic
methylene was explored, and the latter approach afforded a compound 2 of modest A2B AdoR afﬁnity and
selectivity (Figure 1). However, upon oral administration of 2 to rats it was rapidly converted to the unsubstituted
pyrazole, a non-selective A2B antagonist. Fortunately, replacement of the phenyl group with pyridyl as in 4
resulted in high afﬁnity for the A2B AdoR and modest selectivity. Furthermore, 4 demonstrated improved oral
bioavailability following dosing in rats. A homology model of the A2B AdoR receptor was built using MODELER
based on the X-Ray of bovine rhodopsin. Various docking techniques (Ligand-Fit and Afﬁnity), were used to
develop a hypothetical binding pose for 1 and 4 consistent with the above SAR and published site-directed
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1. Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I, Zeng D. Am J Respir Cell Mol Biol 2004; 30: 118–25.
2. Ryzhov S, Goldstein AE, Matafonov A et al. J Immunol 2004; 172: 7726–33.
3. Kim YC, Ji X, Melman N et al. J Med Chem 2000; 43: 1165–72.
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Adenosine and Vasomotor Regulation in the Coronary Microcirculation
Lih Kuo
1 and Travis W. Hein
2
1Department of Systems Biology and Translational Medicine, and
2Department of Surgery, Scott & White Memorial
Hospital, College of Medicine, Texas A&M University System Health Science Center, Temple, TX 76504, USA.
LKUO@tamu.edu
The nucleoside adenosine has been suggested to play a major role in the regulation of coronary blood ﬂow during
metabolic stress (i.e., hypoxia and ischemia) by the preferential dilation of small coronary arterioles primarily
through the activation of adenosine A2A receptors. However, the signaling pathways leading to this dilation are
incompletely understood. Since tissue acidosis and alteration in local hemodynamics are associated with metabolic
stress, it is important to examine whether the adenosine-induced vasodilatory response can be inﬂuenced by these
factors. Using an isolated vessel approach and videomicroscopic techniques, these issues were addressed recently
in our laboratory. It was found that disruption of endothelium, blockade of endothelial ATP-sensitive potassium
(KATP) channels by glibenclamide, inhibition of nitric oxide (NO) synthase by L-NAME and of soluble guanylyl
cyclase by ODQ produced identical attenuation of vasodilation to adenosine. Combined administration of these
inhibitors did not further attenuate the vasodilatory response. Pertussis toxin (PTX), but not cholera toxin,
signiﬁcantly inhibited vasodilation to adenosine, and this inhibitory effect was only evident in vessels with an
intact endothelium. Both glibenclamide and a high concentration of extraluminal KCl abolished vasodilation of
denuded vessels to adenosine; however, inhibition of calcium-activated potassium channels had no effect on this
dilation. Rp-8-Br-cAMPS, a cAMP antagonist, inhibited vasodilation to cAMP analog 8-Br-cAMP but failed to
block adenosine-induced dilation. These results suggest that adenosine activates both endothelial and smooth
muscle pathways to exert its vasomotor activity. On one hand, adenosine opens endothelial KATP channels
through activation of PTX-sensitive G-proteins. This signaling leads to the inﬂux of Ca
2+ for NO synthesis, which
subsequently increases smooth muscle cGMP for vasodilation. On the other hand, adenosine activates smooth
muscle KATP channels and leads to vasodilation through hyperpolarization. The latter pathway is independent of
G-proteins and cAMP/cGMP signaling. In the presence of a threshold concentration of adenosine (0.1 nM), the
vasodilation in response to increased lumenal ﬂow was signiﬁcantly enhanced. Inhibiting endothelial KATP
channels (by lumenal glibenclamide) or depolarizing endothelial cells (by lumenal KCl, 40 mM) abolished the
effect of adenosine. Reducing intraluminal pressure from 80 to 40 cmH2O signiﬁcantly enhanced vasodilations to
adenosine and pinacidil (KATP channel activator). These enhanced responses were not affected by endothelial
removal but were abolished by a subthreshold concentration of glibenclamide. In contrast to adenosine, sodium
nitroprusside (SNP)-induced dilation was not affected by pressure changes. In the acidic solution (pH = 7.3), the
dilations to both adenosine and pinacidil, but not to SNP and KCl (10 to 20 mM), were enhanced in a
glibenclamide-sensitive manner. In summary, these ﬁndings suggest that adenosine elicits coronary arteriolar
dilation by activating KATP channels for membrane hyperpolarization in the endothelial (i.e., NO release) and
smooth muscle cells. Adenosine, by activating endothelial KATP channels, can potentiate coronary arteriolar
dilation in response to increased ﬂow. In addition, activation of smooth muscle KATP channels, by a mild acidosis
or lowering intraluminal pressure, increases coronary arteriolar dilation to adenosine. It appears that adenosine
can interact with local hemodynamics and chemical factors for integrative vasomotor regulation by selectively
modulating resting KATP channel activity in either endothelial or smooth muscle cells.
An Emerging Role for Adenosine in Angiogenesis
Thomas H. Adair
Department of Physiology & Biophysics, University of Mississippi Medical Center, 2500 North State Street,
Jackson, MS 39216, USA
tadair@physiology.umsmed.edu
It is well-established that metabolic factors have a critical role in the regulation of angiogenesis [1]. An increase in
metabolic activity leads to a decrease in tissue oxygenation causing tissues to become hypoxic. The hypoxia
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oxygen delivery to the tissues. When the tissues receive adequate amounts of oxygen even during peak levels of
activity, the intermediate effectors return to normal levels, and angiogenesis ceases.
An emerging concept is that adenosine released from hypoxic tissues has an important role in driving the
angiogenesis [2, 3]. The following feedback control hypothesis is proposed: AMP is dephosphorylated by ecto-50-
nucleotidase, producing adenosine under hypoxic conditions in the extracellular space adjacent to a parenchymal
cell (eg, cardiomyocyte, skeletal muscle ﬁber, hepatocyte, etc.). Extracellular adenosine activates A2 receptors,
which stimulates release of vascular endothelial growth factor (VEGF) from the parenchymal cells. VEGF binds
to its receptor (VEGFR-2) on endothelial cells, stimulating their proliferation and migration. Adenosine can also
stimulate endothelial cell proliferation independently of VEGF, which probably involves modulation of other
proangiogenic and antiangiogenic growth factors, and perhaps an intracellular mechanism. In addition,
hemodynamic factors associated with adenosine-induced vasodilation may have a role in development and
remodelling of the vasculature. Once a new capillary network has been established, and the diffusion/perfusion
capabilities of the vasculature are sufﬁcient to supply the parenchymal cells with adequate amounts of oxygen,
adenosine and VEGF as well as other proangiogenic and antiangiogenic growth factors return to near normal
levels, thus closing the negative feedback loop. The available data indicate that adenosine might be an essential
mediator for up to 50–70% of the hypoxia-induced angiogenesis in some situations; however, additional studies in
intact animals will be required to understand fully the quantitative importance of adenosine.
Adenosine stimulation of angiogenesis is a natural phenomenon that occurs in the microenvironment of tissues
in accordance with local metabolic needs. Ampliﬁcation of this natural process through modulation of the
enzymes of adenosine metabolism, or genetic or pharmacological induction of A2A or A2B receptors could,
theoretically, lead to stimulation of angiogenesis in those areas of a tissue where hypoxia is most severe and
adenosine levels are highest. This type of physiological therapy can be viewed as a departure from classical
attempts to stimulate angiogenesis in a global manner, in which many or most cells of an organ or tissue are made
to produce greater amounts of VEGF. In contrast to adenosine-based therapies, global induction of VEGF may
not be an effective means to build capillary networks in the microenvironment of a tissue where hypoxia is most
severe. (Supported by National Heart, Lung, and Blood Institute, HL51971.)
1. Adair TH, Gay WJ. Montani JP. Growth regulation of the vascular system: evidence for a metabolic hypothesis. Am J
Physiol 1990; 259: R393–404.
2. Adair TH. Growth regulation of the vascular system: an emerging role for adenosine. Am J Physiol 2005; 289: R283–296.
3. Adair TH. An emerging role for adenosine in angiogenesis. Hypertension 2004; 44: 618–620.
Control of extracellular adenosine concentration by ecto-50-nucleotidase
A. Deussen, A. Pexa, J. Weichsel, S. Sternberger
Department for Physiology, Medical Faculty Carl Gustav Carus, TU Dresden
Adenosine is produced inside the cell by action of 50-nucleotidase(s) and S-adenosylhomocysteine hydrolase. In
addition, there is compelling evidence for extracellular adenosine production by ecto-50-nucleotidase. A previous
analysis of complex data sets of cardiac adenosine production has provided strong evidence that the prevailing
path of adenosine production in the heart is intracellular (Deussen et al., Circulation 1999; 99: 2041–47). However,
it was also found that intracellular removal of adenosine via adenosine kinase and adenosine deaminase was very
rapid, and for physiological baseline conditions a transmembraneous adenosine concentration gradient was
predicted, which was directed from extra- to intracellular. This scenario opens the possibility that extracellular
adenosine production by ecto-50-nucleotidase (CD73) is an important source of adenosine, which may signiﬁcantly
modulate the extracellular adenosine concentration.
This hypothesis was tested in isolated endothelial cells and isolated perfused mouse hearts with respect to an
activation of CD73, pharmacological block of the enzyme and a genetic knock out approach. Baseline activity of
CD73 was assessed by measurement of the conversion of 1,N
6-etheno-AMP to 1,N
6-etheno-adenosine in intact
cells or hearts (HPLC assay with ﬂuorescence detection). While conversion of the etheno-labeled AMP provided
a read out of CD73 activity of intact cells or tissues, additional measurement of native adenosine release (HPLC-
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Application of lyso-phospholipids (lysophosphatidyl-choline,10 2M or platelet activation factor, 5 2M) enhanced
catalytic activity of CD73 of micro- and macrovascular endothelial cells. Moreover, in presence of blockers of
membrane transport inhibitors (nitrobenzylthioinosine 1 2M, dipyridamole 1 2M) the native extracellular
adenosine concentration was doubled within 2 min after application of lyso-phospholipids. In contrast, block of
CD73 by !,"-methylene-ADP (50 2M) signiﬁcantly decreased the extracellular adenosine concentration and
completely blocked the effect of lyso-phospholipids on CD73 activity. In isolated hearts from CD73 j/j mice the
adenosine concentration in the venous efﬂuent perfusate was only 1/3 of the concentration measured in hearts of
WT mice under identical conditions (pO2 > 600 mm Hg, perfusion pressure 85 mm Hg).
We conclude that ecto-50-nucleotidase (CD73) represents a key enzyme for modulation of extracellular
adenosine concentration in the cardiovascular system. This extracellular adenosine production may be of
particular importance for conditions when total adenosine production is low. Lyso-phospholipids are of potential
physiological or pathophysiological importance, because they can almost instantly enhance the activity of ecto-50-
nucleotidase resulting in increased extracellular adenosine concentrations.
The forearm model as a tool to study the clinical pharmacology of adenosine
in humans
Gerard A. Rongen, M.D., Ph.D.
Departments of Pharmacology-Toxicology and Internal Medicine, Radboud University Nijmegen Medical Center,
Nijmegen, the Netherlands
G.Rongen@pharmtox.umcn.nl
Preclinical evidence identiﬁes adenosine as a Fretaliatory metabolite_, protecting cells against the deleterious
consequences of ischemia and limited nutrient supply. Translation of this knowledge to humans in-vivo is needed
because of inter-species differences in the pharmacology of adenosine. Various challenges are encountered in this
translational effort including (1) extremely short plasma half-life of adenosine due to rapid cellular uptake and
metabolism, preventing circulating adenosine from reaching its target cells, (2) adenosine-induced autonomic
reﬂexes that mask the local actions of adenosine at autonomic nerve endings, vascular smooth muscle cells and
cardiomyocytes [1] and (3) the lack of tools to study ischemic injury in an experimental setting in humans. Various
strate-gies have successfully been applied to meet these challenges. The forearm model has proven its value in this
regard. In this model, the brachial artery is cannulated for drug infusion and blood sampling. Intra-arterial
delivery of drugs provides a concentration gradient between infused forearm and systemic circulation, allowing
exploration of local effects of adenosine with minimal interference by autonomic reﬂexes or systemic actions [1,
2]. Using forearm strain gauge plethys-mography, the inﬂuence of adenosine on forearm blood ﬂow can be
studied. In this model, we have successfully demonstrated that the vasodilator property of adenosine is mediated
by adenosine re-ceptors, and involves nitric oxide [3]. Using dipyridamole to inhibit cellular uptake of adenosine,
we provided support in humans in-vivo for the hypothesis that KATP-channels are involved in adeno-sine-induced
vasodilation [4] and that extracellular adenosine levels are reduced in patients with hyperhomocysteinemia but
increased during oral treatment with methotrexate [5, 6]. When the model is further reﬁned by cannulation of an
antecubital vein, effects on local and systemic release of endogenous substances such as norepinephrine can be
explored. In this way, we have demonstrated that adenosine reduces norepinephrine release from sympathetic
nerve endings [2, 7]. Recently, we have developed forearm annexin A5 scintigraphy to quantify forearm ischemia-
reperfusion (I/R) injury. With this technique, we detected protection against I/R injury by ischemic
preconditioning, local infusion of adenosine and oral treatment with dipyridamole [8, 9]. Future research will
charac-terize environmental and genetic factors that determine protection against I/R injury by adenosine.
1. Rongen GA, Smits P, Ver Donck K, Willemsen JJ, de Abreu RA, Van Belle H, Thien T. Hemodynamic and neurohumoral
effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in
cardioprotection. J Clin Invest 1995; 95: 658–68.
2. Rongen GA, Brooks SC, Ando S, Abramson BL, Floras JS. Angiotensin AT1 receptor blockade abolishes the reﬂex
sympatho-excitatory response to adenosine. J Clin Invest 1998; 101: 769–76.
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vasodilator effect of adenosine in humans. Circulation 1995; 92: 2135–41.
4. Bijlstra P, van Ginneken EEM, Huls M, van Dijk R, Smits P, Rongen GA. Glyburide inhibits dipyridamole-induced forearm
vasodilation but not adenosine-induced forearm vasodilation. Clin Pharmacol Ther 2004; 75: 147–56.
5. Riksen NP, Rongen GA, Boers GH, Blom HJ, van den Broek PH, Smits P. Enhanced cellular adenosine uptake limits
adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler. Thromb Vasc Biol 2005; 25(1): 109–14.
6. Riksen NP, Barrera P, van den Broek PH, van RP, Smits P, Ron-gen G. Methotrexate modulates the kinetics of adenosine
in humans in vivo. Ann Rheum Dis 2006, in press.
7. Rongen GA, Lenders JWM, Lambrou G, Willemsen JJ, Van Belle H, Thien T, Smits P. Presynaptic inhibition of
norepinephrine release from sympathetic nerve endings by endogenous adenosine. Hypertension 1996; 27: 933–8.
8. Riksen NP, Oyen WJ, Ramakers BP, van den Broek PH, Engbersen R, Boerman OC, Smits P, Rongen GA. Oral therapy
with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther 2005; 78 (1): 52–9.
9. Rongen GA, Oyen WJG, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of
forearm as a novel in-vivo model of skeletal muscle preconditioning in man. Circulation 2005; 111: 182–7.
Molecular mechanisms of coronary ﬂow regulation by adenosine
S. Jamal Mustafa
Department of Physiology & Pharmacology and Center for Interdisciplinary Research in Cardiovascular Sciences,
West Virginia University, Morgantown, West Virginia, 26505, USA
E-mail address: smustafa@hsc.wvu.edu
Adenosine, a purine nucleoside acts through its cell surface receptors (A1,A 2A,A 2B,a n dA 3) via its coupling to
G-proteins. Adenosine causes an increase in coronary ﬂow mostly through A2A adenosine receptors. However,
the involvement of other adenosine receptors in the modulation of coronary ﬂow regulation is not well
understood. Using adenosine receptor knockout mice, we have investigated the roles of each adenosine receptor
subtype in the regulation of coronary ﬂow. Recently, using the isolated mouse heart preparation from A3
adenosine receptor knockout mice, we reported an increased A2A receptor-mediated coronary ﬂow [1]. Similarly,
we found an increase in coronary ﬂow in A1 adenosine receptor knockout mice [2]. These data support inhibitory
roles for A3 and A1 adenosine receptors in the regulation of coronary ﬂow. Additionally, in A2A adenosine
receptor knockout mice, the response to A2A selective agonist (CGS-21680) was totally abolished [3]. On the
other hand, adenosine A2A receptor knockout mice showed a decrease in blood ﬂow to NECA (non-selective
agonist). Currently, we are investigating the coronary ﬂow responses to both NECA and CGS-21680 in A2B
adenosine receptor knockout mice. Further, real time-PCR for all four adenosine receptor knockout mice showed
no signiﬁcant change in all four adenosine receptors. These data support stimulatory roles for A2A and A2B
adenosine receptors in the regulation of coronary ﬂow. These observations provide new evidence for the presence
and possible roles of all four adenosine receptor subtypes in coronary ﬂow regulation. (Supported by National
Heart Lung and Blood Institute grant # HL-027339).
1. Morrison, RR, Talukder MAH, Ledent C, Mustafa SJ. Am J Physiol 2002; 282: H-437–H-444.
2. Tawﬁk HE., Teng B, Morrison RR, Schnermann J, Mustafa SJ. Am J Physiol Heart and Circulation-In Review.
3. Talukder MAH, Morrison RR, Jacobson MA, Jacobson KA, Ledent C, Mustafa SJ. Am J Physiol 2002; 282: H-
2183–H-2189.
Subcellular Aspects of Adenosine Receptor-Mediated Signaling in Ventricular
Myocardium
Robert D. Lasley
Department of Surgery, University of Kentucky College of Medicine, Lexington, KY, USA
rlasley@uky.edu
For years the effects of adenosine in ventricular myocardium (intact hearts and myocytes) were attributed solely
to A1 receptor subtypes. However evidence generated by numerous laboratories over the past several years
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pathways. Although the adenosine A3 receptor subtype has received much interest in adenosine_s effects in
ischemic myocardium, there is additional evidence for the involvement of the A2a receptor subtype. We have
previously reported that: 1) intracoronary infusion of the A2a agonist CGS21680 increased load-insensitive
contractility in stunned, but not normal, in vivo porcine myocardium, independent of changes in coronary blood
ﬂow, [1] and 2) the preconditioning (PC) effect of the adenosine agonist AMP579 in in vivo rat myocardium is
blocked by both the A1 antagonist DPCPX and the A2a antagonist ZM241385 [2]. Studies from other investigators
using isolated hearts and cardiomyocytes suggesting a role for A2a receptor effects are consistent with our report
that rat ventricular myocytes express A2a receptors [3]. Additional observations from our laboratory indicate that
although A2a receptor activation does not induce PC, ZM241385 blocks the cardioprotective effects of the A1
agonist CCPA and the non-selective agonist NECA to a similar degree as DPCPX. Additional preliminary
observations from our laboratory suggest that A2b receptors are expressed in ventricular myocardium and
myocytes. However based on Western blot analysis and immunocytochemistry the majority of A2a and A2b
immunoreactivity is expressed in cytosolic, not membrane, fractions. In addition to adenosine receptor subtype
interactions, adenosine receptors have been reported to interact with other G protein coupled receptors (GPCR),
such as opioid receptors, in various tissues via signaling cross-talk and/or receptor hetero-dimerization. Although
there have been few such studies in the heart, it has been reported that in vivo A1 agonist PC is blocked by a delta
opioid receptor antagonist and morphine-induced PC is blocked by DPCPX [4]. We have observed similar
ﬁndings that indicate that this interaction is selective for delta, but not kappa, opioid receptors. Adenosine
receptors have been shown to couple to the activation of mitogen activated protein kinases (MAPKs) in various
tissues. Studies in our laboratory indicate that adenosine receptors activate MAPKs in both intact myocardium
and ventricular myocytes; however this activation occurs in distinct subcellular compartments. Our observations
also indicate that the acute and delayed PC effects of adenosine receptor activation are dependent on MAPK
signaling. Thus there is increasing evidence that the effects of adenosine in ventricular myocardium are mediated
by multiple receptor subtypes and their interactions as well as via the modulation of cardiomyocyte subcellular
signaling.
1. Lasley RD, Jahania MSA, Mentzer RM Jr. Am J Physiol (Heart Circ Physiol) 2001; 280: H1660–6.
2. Reid EA, Kristo G, Yoshimura Y, Ballard-Croft C, Keith BJ, Mentzer RM Jr, Lasley RD Am J Physiol (Heart Circ Physiol)
2005; 288: H2253–9.
3. Kilpatrick EL, Narayan P, Mentzer RM Jr, Lasley RD. Am J Physiol (Heart Circ Physiol) 2002; 282: H1035–40.
4. Peart JN, Gross GJ. Am J Physiol (Heart Circ Physiol) 2003; 285: H81–9.
Use of Adenosine Compounds for Identifying Patients Prone to Suffer from
Tachyarrhythmias
Raphael Rosso, M.D.
Department of Cardiology, Tel Aviv – Sourasky Medical Center and Sackler School of Medicine, Tel Aviv
University
In our presentation we review our experience in the use of adenosine-compounds for diagnostic purposes in
cardiac arrhythmias. Adenosine-compounds are the treatment of choice for common supraventricular tachyar-
rhythmias involving the atrio-ventricular node. Moreover, adenosine-compounds can also be used for diagnostic
purposes.
Injection of adenosine compounds during sinus rhythm leads to short lasting bradycardia (sinus arrest or block
of conduction along the AV-node). This effect is short lasting and invariably resolves within seconds. The induced
bradyarrhythmia is always followed by sinus tachycardia. This unique effects of adenosine compounds may be
used for the following diagnostic purposes: 1) to reveal the presence of Wolff-Parkinson-White in patients with
minor preexcitation due to a left sided location of the accessory pathway and fast AV nodal conduction, 2) to
reveal the presence of dual AV node physiology in patients with AV-node reentry tachycardia, 3) to reveal the
presence of concealed accessory pathways in patients with AV reentry tachycardia. The last two effects can be
useful when evaluating patients who have a history of palpitations but no documented arrhythmias. Finally, since
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or sudden acceleration (tachycardia dependent torsade) of the heart rate, we have used adenosine-compounds for
diagnosing long QT syndrome in patients with borderline QT intervals.
Bone and Cartilage
Integrating Local and Systemic Regulation of Bone Turnover Through P2
Receptor Signalling
J.A. Gallagher
Human Bone Cell Research Group, Department of Human Anatomy and Cell Biology, The University of
Liverpool, Liverpool, L69 3GE U.K.
jag1@liv.ac.uk
Bone is continually remodelled throughout life by bone-resorbing osteoclasts and bone-forming osteoblasts. This
remodelling is regulated by a complex interaction of systemic hormones, including parathyroid hormone (PTH),
and local factors, including mechanical loading, which together ensure that the skeleton adapts to physiological
requirements. Extracellular nucleotides acting through multiple P2 receptors play a major role in integrating the
local and systemic signalling. Since the early descriptions of P2 receptor expression in bone
1, functional and
molecular evidence has accumulated for the presence of multiple P2X and P2Y receptors on osteoblasts and
osteoclasts. In addition to expressing P2 receptors, bone cells release ATP constitutively
2 and this release is
enhanced by mechanical stimulation. The exact mechanism for the constitutive release of ATP by osteoblasts
remains to be identiﬁed, although exocytosis probably plays some part.
Some of the the functional consequences of ATP release in bone and subsequent activation of P2 receptors on
bone cells have been identiﬁed. For example, activation of osteoblastic P2Y1 receptors leads to an up regulation
of receptor activator of nuclear factor-kB ligand (RANKL), which stimulates the formation and activity of
osteoclasts and thereby stimulates bone resorption
3, and P2X7 receptors are expressed on osteoblasts and
osteoclast and may play important roles in mechanotransduction and osteoclast formation
4. One observation that
we regard as particularly signiﬁcant is the effect of activation of osteoblastic P2Y receptors on the induction of c-
fos, an immediate early gene that plays a key role in the proliferation and differentiation of bone cells. Activation
of osteoblastic P2Y receptors alone results in a only a moderate induction of c-fos, whereas dual activation of P2
receptors and PTH receptors leads, through multiple levels of interaction in downstream signalling, to a massive
synergy in c-fos expression
5. This synergy provides a molecular mechanism whereby locally released extracellular
nucleotides can sensitise cells to systemic PTH and thereby activate remodelling at discrete sites in bone. This
may represent a common mechanism to integrate systemic and local signals in the regulation of turnover in other
tissues.
1. Scho ¨ﬂ C, Cuthbertson KS, Walsh CA, Mayne C, Cobbold P, von zur Mu ¨hlen A, Hesch RD, Gallagher JA. Evidence for P2-
purinoceptors on human osteoblast-like cells. J Bone Miner Res 1992; 7: 485–91.
2. Buckley KA, Golding SL, Rice JM, Dillon JP, Gallagher JA. Release and interconversion of P2 receptor agonists by human
osteoblast-like cells. FASEB J 2003; 17: 1401–10.
3. Buckley KA, Hipskind RA, Gartland A, Bowler WB, Gallagher JA. Adenosine triphosphate stimulates human osteoclast
activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kB ligand. Bone 2002; 31: 582–90.
4. Gartland A, Buckley KA, Hipskind RA, Bowler WB, Gallagher JA. P2 receptors in bone–modulation of osteoclast
formation and activity via P2X7 activation. Crit Rev Eukaryot Gene Expr 2003; 13(2–4): 237–42.
5. Buckley KA, Wagstaff SC, McKay G, Gaw A, Hipskind RA, Bilbe G, Gallagher JA, Bowler WB. Parathyroid hormone
potentiates nucleotide-induced [Ca
2+]i release in rat osteoblasts independently of Gq activation or cyclic monophosphate
accumulation: A mechanism for localizing systemic responses in bone. J Biol Chem 2001; 276: 9565–71.
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Nattapon Panupinthu, Jasminka Korcok, Joseph T. Rogers, Stephen M. Sims and S. Jeffrey Dixon
CIHR Group in Skeletal Development and Remodeling, Schulich School of Medicine & Dentistry, The University
of Western Ontario, London, Canada, N6A 5C1
E-mail: jeff.dixon@schulich.uwo.ca
Since ATP is released from cells in response to mechanical stimulation, it has been proposed that P2 nucleotide
receptors mediate mechanotransduction in bone.
1 Mice with targeted disruption of the P2X7 receptor gene
exhibit diminished periosteal bone formation together with excessive trabecular bone resorption
2 and impaired
response to mechanical loading.
3 Our goal was to understand the roles of P2X7 receptors in osteoblasts (bone
forming cells) and osteoclasts (bone resorbing cells). Whereas the expression of functional P2X7 receptors has
been established in osteoclasts,
4 their existence in osteoblasts has been controversial. Osteoblast-enriched cultures
were obtained from calvariae of newborn rats, and wild-type (WT) and P2X7 receptor knockout (KO) mice.
Osteoblast-enriched cultures were supplemented with ascorbic acid and "-glycerophosphate to induce formation
of mineralized nodules. Cells expressing functional P2X7 receptors were associated with bone nodules.
Benzoylbenzoyl-ATP (BzATP, P2X7 agonist), but not UTP, promoted mineralization in rat calvarial cell
cultures. Moreover, mineralization in KO cultures was markedly reduced compared to WT, consistent with a role
for P2X7 receptors. Expression of osteoblast marker genes (encoding Runx2, Osterix, osteocalcin and bone
sialoprotein) was assessed by real-time PCR. Transcript levels were signiﬁcantly enhanced by BzATP in rat
calvarial cell cultures and suppressed in cultures from KO mice compared to WT (except Runx2). Cyclooxygenase
inhibitors abolished the stimulatory effect of BzATP on bone formation without affecting mineralization in
untreated cultures. Thus, P2X7 receptors stimulate osteoblast differentiation through a cell-autonomous,
cyclooxygenase-dependent mechanism. The lifespan of osteoclasts is an important regulator of bone resorption.
Osteoclasts were isolated from long bones of newborn WT and KO mice and cell survival was assessed. In the
absence of exogenous nucleotides, higher numbers of WT than KO osteoclasts were apoptotic at 6 h. Consistent
with this observation, fewer WT osteoclasts survived at 12 h. Interestingly, BzATP had no additional effect on
either apoptosis or survival. Control experiments revealed that WT and KO osteoclasts were equally susceptible
to apoptosis induced by the proapoptotic agent staurosporine. Brilliant blue G (P2X7 antagonist) decreased
apoptosis and increased survival of WT osteoclasts, providing additional evidence for involvement of the P2X7
receptor. Treatment of WT osteoclasts with alkaline phosphatase (to hydrolyze endogenous nucleotides)
increased their survival to levels comparable to KO osteoclasts, consistent with activation of P2X7 receptors by
constitutively released nucleotides. In summary, P2X7 receptors stimulate osteoblast differentiation and induce
osteoclast apoptosis. Since the P2X7 receptor both enhances bone formation and suppresses bone resorption, it
represents a potential target for the development of drugs with combined anabolic and antiresorptive effects.
Supported by the Canadian Institutes of Health Research (CIHR).
(1) Dixon SJ, Sims SM. Drug Dev Res 2000; 49: 187–200.
(2) Ke HZ, Qi H, Weidema AF, Zhang Q, Panupinthu N, Crawford DT, Grasser WA, Paralkar VM, Li M, Audoly LP, Gabel
CA, Jee WS, Dixon SJ, Sims SM, Thompson DD. Mol. Endocrinol. 2003; 17: 1356–67.
(3) Li J, Liu D, Ke HZ, Duncan RL, Turner CH. J Biol Chem 2005; 280: 42952–9.
(4) Naemsch LN, Dixon SJ, Sims SM. J Biol Chem 2001; 276: 39107–14.
P2Y nucleotide receptor function in osteoblasts
Isabel Orriss, Geoffrey Burnstock and Timothy R. Arnett
Department of Anatomy and Developmental Biology, University College London, London WC1E 6BT, UK.
e-mail: t.arnett@ucl.ac.uk
Accumulating evidence suggests that extracellular nucleotides, signalling through P2 receptors, play a role in
modulating bone cell function. ATP and ADP stimulate osteoclastic resorption, whilst ATP and UTP are
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1. We investigated changes in the expression of P2 receptors
with cell differentiation in primary osteoblast cultures. Rat calvarial osteoblast, derived by trysin/collagenase
digestion and cultured for up to 10 days, were loaded with the intracellular Ca
2+-sensing ﬂuorophore, Fluo-4 AM,
and a ﬂuorescence imaging plate reader (FLIPR) was used to measure responses to nucleotide agonists. Peak
responses occurred within 20 sec, and were evoked by ATP or UTP at concentrations as low as 2 2M. Numbers of
osteoblasts doubled between days 4 and 10 of culture but the peak intracellular Ca
2+ response to ATP or UTP
increased up to 6-fold over the same period, indicating that osteoblast responsiveness to nucleotides increased as
cell differentiation proceeds. The approximate order of potency for the most active nucleotide agonists at day 8 of
culture was ATP > UTP & ATP+S > ADP > UDP, consistent with the expression of functional P2Y2, P2X2,P 2 Y 4,
P2Y1 and P2Y6 receptors. Smaller responses were elicited by 2-MeSATP, Bz-ATP and !,"-meATP, additionally
suggesting the presence of functional P2X1, P2X3, P2X5 and P2X7 receptors. Expression of mRNA for the ATP
and UTP-selective P2Y2 receptor increased strongly between days 6 and 15 in primary osteoblasts, whereas
mRNAs for the P2Y4 (also ATP/UTP selective) and P2Y6 (UDP/UTP selective) receptors were highly expressed
at intermediate time points. In contrast, mRNA for the cell-proliferation-associated P2X5 receptor decreased to
undetectable as osteoblasts matured, but mRNA for the cell death-associated P2X7 receptor was detected at all
time points. Similar trends were evident using immunostaining and Western blotting for P2 receptors. Exposure to
1–10 2M ATP or UTP during days 10–14 of culture was sufﬁcient to cause near-total blockade of alizarin red-
stained bone nodules formed by osteoblasts; however, UDP and ADP were without effect. Microscopy revealed
that ATP and UTP-treated osteoblasts deposited abundant collagenous material with the characteristic
morphology of bone nodules, but that mineralisation failed to occur. In osteoblast cultures treated with 10 2M
ATP or UTP, the activity of alkaline phosphatase (thought to participate in bone mineralisation) was reduced by
>50%. Our results show that there is a shift from P2X to P2Y expression during osteoblast differentiation in
culture, with mature osteoblasts preferentially expressing the P2Y2 receptor and, to a lesser extent, P2Y4 and
P2Y6 receptors. Taken together, these data suggest that the P2Y2 receptor and, possibly, the P2Y4 receptor could
function as Foff-switches_ for mineralised bone formation. It should be noted, however, that since several ecto-
nucleotidases can generate pyrophosphate (PPi) from nucleotide triphosphates, and that PPi is a potent inhibitor
of bone mineralisation (at Q1 2M in our in vitro system), the possibility remains that a component of the effect of
extracellular nucleotides on mineralisation could also occur independently of P2 receptors. We are grateful for the
support of the Arthritis Research Campaign.
1. Hoebertz A, Arnett TR, Burnstock G. Regulation of bone resorption and formation by purines and pyrimidines. Trends
Pharmacol Sci 2003; 24: 290–7.
The role of nucleotides and P2 receptors in intercellular signaling in bone
Niklas Rye Jørgensen
Dep. of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
Email: niklas@dadlnet.dk
The regulation of bone turnover is a complex and ﬁnely tuned process. Many factors regulate bone remodelling,
including hormones, growth factors, cytokines etc. However, little is known about the signals coupling bone
formation to bone resorption, and how mechanical forces are translated into biological effects in bone.
Intercellular calcium waves are increases in intracellular calcium concentration in single cells, subsequently
propagating to adjacent cells, and can be a possible mechanism for the coupling of bone formation to bone
resorption and for the translation of mechanical forces on bone into biological signals.
Intercellular calcium waves have been demonstrated to occur not only among osteoblasts in vitro, but also
between osteoblasts and osteoclasts, in response to mechanical stimuli. Calcium signaling among osteoblasts can
be propagated by the secretion of a nucleotide, possibly ATP, acting in an autocrine action to purinergic P2Y2
receptors on the neighboring cells, leading to IP3 generation and subsequent release of calcium from intracellular
stores. In the signaling from osteoblasts to osteoclasts, paracrine action of ATP seems to be responsible, with the
involvement of purinergic P2X7 pore forming receptor.
24 Invited LecturesActivation of P2 receptors in bone cells not only involves the propagation of intercellular calcium waves but
also the proliferation and activity of the cells. Further, alterations in receptor expression and function have effects
on bone development and turnover as well as on bone quality and fracture risk in vivo.
Thus, nucleotide-mediated intercellular calcium signalling is taking place in vitro among osteoblasts and
between osteoblast and osteoclasts, and might be a mechanism by which mechanical forces regulate bone turnover
in vivo. The mechanisms involved in the calcium signaling are deﬁnitely important in normal bone development
and turnover, and might be future targets for pharmacological manipulation of bone metabolism.
Immunology and Inﬂammation
Activation of P2X7 by ADP-Ribosylation
Friedrich Koch-Nolte
Institute of Immunology, University Hospital, Martinistr. 52, Hamburg, 20246 Germany
nolte@uke.uni-hamburg.de
The cytolytic P2X7 purinoceptor is widely expressed by inﬂammatory cells. P2X7 has attracted attention because
of its unique capacity to induce the formation of a large pore and cell death. Activation of P2X7 requires much
higher concentrations of ATP than activation of other P2X family members. P2X7 on murine T cells can also be
activated by ADP-riboslyation of cell surface proteins catalyzed by the toxin like ecto-ADP-ribosyltransferase
ART2 following release of the ART substrate, NAD, from cells [1]. Much lower concentrations of NAD than
ATP sufﬁce to activate P2X7. However, at saturating doses, ATP induces stronger activation signals than ADP-
ribosylation. Moreover, activation of P2X7 is readily reversed after short exposures to ATP followed by washing
away of the soluble ligand, wheras short exposures to NAD followed by washing chronically activate P2X7 by
providing covalently bound ligands. Using site directed mutagenesis we have identiﬁed the sites of ADP-
ribosylation on P2X7. The results shed light on the issue whether P2X7 is activated by ADP-ribose moieties
attached to neighboring proteins or to P2X7 itself.
Supported by DFG grant No310/6-1 to FH and FKN
(1) Seman M, Adriouch S, Scheuplein F, Krebs C, Freese D, Glowacki G, Deterre P, Haag F, Koch-Nolte F. NAD-induced T
cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 2003;
19 (4): 571–82.
Adenosine 2A Receptor (A2AR) Agonists Regulate Renal Nitric Oxide
Production in Diabetic Nephropathy
Alaa S. Awad, Elizabeth Duong, Liping Huang, Joel Linden and Mark D. Okusa
Departments of Medicine, University of Virginia, Charlottesville, VA 22908
awad@virginia.edu
Background Nitric oxide (NO) regulates renal hemodynamics, endothelial function and inﬂammation. However,
the role of NO in the pathophysiology of diabetic nephropathy (DN) remains controversial. We have shown
previously that A2A receptor agonists prevent renal tissue injury and inﬂammation in DN [Am J Physiol Renal
Physiol 2006, in press]. Whether the protective effect of A2A receptor agonists is mediated by regulation of renal
NO production is not known. We hypothesized that A2A agonists ameliorate renal endothelial dysfunction and
inﬂammation associated with DN through an effect on NO production.
Methods Diabetes was induced with single iv injection of streptozotocin (STZ) in Sprague Dawley rats (50 mg/
kg). Urinary NO end products (NOX) and nitric oxide synthases (NOS) mRNA were evaluated in control,
Invited Lectures 25diabetes with vehicle and diabetes with ATL146e, a selective A2A agonist (10 ng/kg/min) via osmotic pump over 6
weeks.
Results Blood glucose increased in the diabetes and treatment groups 48 hours after STZ-induction of diabetes.
Renal medullary blood ﬂow and urinary NOX excretion were reduced signiﬁcantly in diabetes group (67%; p <
0.001 and 60%; p < 0.01 from control) and restored to normal levels by ATL146e (86% and 100% from control),
respectively. There was a signiﬁcant correlation between urinary albumin excretion rate and urinary NOX (r =
0.84; p < 0.0001). We next sought to determine renal NO synthase (NOS) isoforms altered in DN. By using real-
time PCR, diabetes led to a decrease in renal eNOS mRNA expression (67% from control) that was reversed by
ATL146e (137% from control; p < 0.05 from diabetes). iNOS mRNA expression was not detectable in control but
was induced in diabetes, an effect that was reversed by ATL146e. Immunohistochemistry with iNOS antibody of
the kidney tissue conﬁrmed the result of mRNA expression and was corelated with increased macrophages
inﬁltration, a major source of iNOS, in diabetic kidneys. In contrast, there was no signiﬁcant change in nNOS gene
expression between groups.
Summary These results demonstrate that DN is associated with decreased renal production of NO mainly through
decreased expression of eNOS an effect reversed by A2A agonists. Furthermore an increase iNOS due in part to
macrophage inﬁltration in DN is reversed with ATL146e.
Conclusion The effects of A2A agonists on ameliorating the previously described functional and morphological
changes associated with DN may in part be due to effects on NO.
Adenosine in Dermal and Hepatic Fibrosis
Edwin SL Chan
New York University School of Medicine, New York, NY 10016, USA
Chane01@nyu.edu
Adenosine promotes the healing of wounds and matrix deposition in the skin, actions known to be mediated
through the A2A receptor. The release of adenosine also accounts for the anti-inﬂammatory activity of
methotrexate, one of the most widely used anti-rheumatic agents. We hypothesized that ligation of the A2A
receptor is responsible for the development of hepatic ﬁbrosis, one of the most serious complications of chronic
methotrexate therapy, as well as cirrhosis arising from other causes such as ethanol consumption. Epidemiological
studies have demonstrated a protective effect of caffeine in hepatic cirrhosis and we speculate that this protective
effect is also related to the antagonistic activity of caffeine at the adenosine receptor. The capacity of adenosine
for modulating ﬁbrous tissue development in the skin is also relevant to the pathogenesis of another rheumatic
disease, scleroderma, where skin ﬁbrosis is a prominent feature. Using in vitro and in vivo models, we have
demonstrated a role for the A2A receptor in the pathogenesis of these disorders. These ﬁndings provide a strong
rationale for the exploitation of adenosine receptor antagonist therapies in future treatment of ﬁbrotic diseases.
Adenosine receptors and the regulation of chronic lung disease
Michael R. Blackburn
Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School
michael.r.blackburn@uth.tmc.edu
Chronic lung diseases are associated with persistent lung inﬂammation and damage that lead to the progressive
loss of lung function. In contrast to most injury and repair responses, the inﬂammation seen in these disorders is
chronic and may last throughout the life of the afﬂicted individual. The mechanisms that are responsible for the
intensity and chronicity of these disorders have not been elucidated. Adenosine is a signaling nucleoside that can
elicit a variety of cellular functions by engaging cell surface adenosine receptors. Adenosine levels are elevated in
the lungs of patients with chronic lung disease suggesting this signaling pathway may be involved in these
disorders. My laboratory makes use of genetically modiﬁed mice to examine the importance of adenosine
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deaminase (ADA) that controls the levels of adenosine in tissues and cells. Adenosine levels accumulate in the
lungs of these mice and are associated with increased lung inﬂammation and histopathologies seen in asthma and
chronic obstructive pulmonary disease including ﬁbrosis and alveolar airway enlargement. We have used both
genetic and pharmacologic approaches to examine the contributions of the different adenosine receptors to the
inﬂammation and damage seen in the lungs of ADA-deﬁcient mice. In addition, we have examined the
contribution of adenosine and its receptors in other models of chronic lung disease. My presentation will use data
gathered in the above model systems to highlight the various pro-inﬂammatory/tissue destructive effects of
adenosine receptors as well as anti-inﬂammatory/tissue protective effects, as they pertain to aspects of chronic
lung disease.
ADP-ribosylation by ARTs introduces diacritic modiﬁcations in the cytokine
network
Michel Seman
EA1556 University Denis Diderot-Paris7 and INSERM U519, Faculty of Medicine and Pharmacy, 22 Boulevard
Gambetta, 76000, Rouen, France
michel.seman@univ-rouen.fr
Mammalian mono ADP-ribosyl transferases (ARTs) constitute a family of ectoenzymes catalyzing the transfer of
ADP-ribose from NAD
+ onto arginine residues of target proteins. They are thus responsible for unusual post-
translational modiﬁcations of proteins in the extracellular compartment. NAD
+ is released during inﬂammation
and can be detected in inﬂammatory liquids. This provides enough substrate to ARTs and renders possible ADP-
ribosylation of neighboring membrane targets on the surface of ART expressing cells such as integrins or P2X7,
and free soluble proteins present in surrounding extracellular ﬂuids including cytokines and growth factors.
Several cytokines can thus be ADP-ribosylated by ART1 but others are not although they all contain arginine
residues in their primary sequence. This provides evidence for selective ADP-ribosylation sites. Cytokine ADP-
ribosylation can either block their functions and/or modulate their bioavailability. ART-mediated ADP-
ribosylation of cytokines represents a new mechanism of regulation in the immune system which may contribute
to the control of inﬂammation and host-tumor interactions. It may also participate in the resistance of patients to
cytokine-based therapies.
Supported by grants from the Ministe `re de la Recherche, Ligue Nationale contre le cancer, Association pour la
recherche sur le cancer.
Nicolo ` Copernico Award: From BHellstrom Paradox’’ to Redox-Adenosinergic
Rule of Immune Response
Michail V. Sitkovsky
New England Inﬂammation and Tissue Protection Institute, Consortium at Northeastern University, Boston,
MA,USA
M.Sitkovsky@neu.edu
We will describe the redox-adenosinergic mechanism of protection of normal tissues from excessive immune
damage. These studies were motivated by the long-standing BHellstrom Paradox’’ of the peaceful co-existence of
tumors and anti-tumor immune cells in the same cancer patient. We summarize the more than 25 years of
research that was focused ﬁrst on mechanisms of cell-cell interactions during T-cell mediated lethal hit delivery to
tumor target cells, then on mechanisms that propagate or may inhibit the T cell receptor-triggered signaling. We
provide evidence, which suggests that down-regulation of overactive immune cells in inﬂamed areas may be
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interruption of normal blood and oxygen supply leads to low tissue oxygen tension. This is associated with an
accumulation of extracellular adenosine and signaling through A2A and A2B adenosine receptors on the surface
of surrounding cells, including activated myeloid and T cells. This chain of events culminates in inhibition of
activated immune cells in a delayed, negative feedback manner due to the well-established immunosuppressive
effects of cAMP-elevating A2 adenosine receptors. We also describe the rationale behind the model that the
tissue protecting effects of hypoxia involve both hypoxia-stabilized Hypoxia Inducible Factor-1! and A2
adenosine receptors. Similar mechanism mat explain Hellstrom paradox. An example of the predictive power of
the redox-adenosinergic rule is provided by the conﬁrmed exacerbation of acute lung injury by hypoxia-
eliminating supplemental oxygen therapy.
Target genes of extracellular ATP in human dendritic cells
Didier Communi





1Institute of Interdisciplinary Research, IRIBHM, Universite ´ Libre de Bruxelles, Belgium; communid@ulb.ac.be
2 Department of Medical Chemistry, Erasme Hospital, Universite ´ Libre de Bruxelles, Belgium
Extracellular ATP affects the maturation of human monocyte-derived dendritic cells (MoDCs), mainly by
inhibiting Th1 cytokines, promoting Th2 cytokines, and modulating the expression of costimulatory molecules.
Comparison of ATP and PGE2 expression proﬁles in human moDCs revealed an extensive number of target
genes involved in immunosuppression, maturation and chemotaxis.
More particularly, ATP elicited a drastic up-regulation of two mediators involved in immunosuppression:
thrombospondin-1 and indoleamine 2,3-dioxygenase. Extracellular ATP released from damaged cells and
previously considered as danger signal is thus a potent regulator of mediators playing key roles in immune
tolerance.
We also observed that ATP is able to regulate several chemokines and chemokine receptors. More particularly,
adenine nucleotides induced down-regulation of major monocyte recruiters such as MCP-1 and MIP-1!
chemokines and reduced the capacity of MoDCs to attract monocytes and immature DCs.
Pharmacological data support the involvement of the P2Y11 receptor in the regulation of these ATP target
genes in human MoDCs. Consequently nucleotides derivatives may be considered as useful tools for DC-based
immunotherapies. Several other promising genes regulated by ATP have been identiﬁed in human DCs and their
study is ongoing.
P2 Receptors: Role in host defence against intracellular microorganisms
Robson Coutinho-Silva
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A growing number of studies have demonstrated the importance of ATPe-signalling via P2 receptors as an
important component of the inﬂammatory response to infection. More recent studies have shown that ATPe can
also have a direct effect on infection by intracellular pathogens, by modulating membrane trafﬁcking in cells that
contain vacuoles that harbor intracellular pathogens, such as mycobacteria and chlamydiae. A conserved
mechanism appears to be involved in controlling infection by both of these pathogens, as a role for phospholipase
D in inducing fusion between lysosomes and the vacuoles has been demonstrated. P2X7 receptors is involved in
clearance of intracellular bacteria, but in mycobacteria, infection seems to controlled by an additional P2 receptor.
28 Invited LecturesOther P2-dependent mechanisms are most likely operative in the cases of pathogens such as Leishmania, which
survive in an acidic phagolysosomal-like compartment. We explored the possibility that P2 receptors could be
used as a therapeutic drug against Leishmania infection. BALB/c mice infected with L. amazonensis were treated
for three weeks, twice a week, with PBS, ATP (50 mM), or UTP (5 mM) in 20 2l injections in foot lesions. We
observed that ATP and UTP reduced the parasitic load by two-log units compared to control mice treated with
PBS.. In vitro, peritoneal macrophages were infected for 48 h at 37-C, and then treated with ATP (500 2M), ADP
(100 2M), adenosine (100 2M), UTP (100 2M), UDP (100 2M) or oATP (300 2M) in PBS for 30 min. Only ATP
showed signiﬁcant anti-amastigotic activity (36% inhibition), with no signiﬁcant cytotoxicity observed for any of
the nucleotides, and UTP and UDP inducing production of nitric oxide. Measurements of calcium ﬂux and
apoptosis induced by the nucleotides data suggest possible modulation of at least two P2 receptor during in vitro
infection with L. amazonensis, one being sensitive to ATP and the other, to UTP. These results suggest that P2
receptors are potential targets for anti-leishmanial therapy, that the immunological environment is probably
important for this activity, and that there are several P2 receptors involved in the anti-microbial effect of the
nucleotides.
Acknowledgment FAPERJ and CNPq.












1 and Warwick Britton
2
1Department of Medicine, University of Sydney, Nepean Hospital, Penrith NSW 2750, and
2Centenary Institute of
Cancer Medicine and Cell Biology, Camperdown, 2042, Australia
Email: wileyj@medicine.usyd.edu.au
The search for the function of the P2X7 receptor has drawn on results from two models; the gene-deleted mouse
and rare genetic variants within the human population. Studies of the knock-out mouse by both the Pﬁzer and
Glaxo groups have pointed to P2X7 as a pro-inﬂammatory gene which may have a role in bone structure. Parallel
clinical studies by our group and others have suggested that P2X7 may also have a role in innate immunity and
resistance to certain infections.
The innate immune system is vital for the control of infection by intracellular pathogens such as mycobacteria,
chlamydia and toxoplasma. These organisms evade the adaptive immune response by entering and replicating
inside host cells and tissues. Recent studies have shown that activation of the P2X7 receptor on cells of the
monocyte – macrophage series is needed for killing of intracellular mycobacteria and that the same activation
signal leads to subsequent apoptotic death of the infected macrophage. Wide variations in P2X7 function have
been observed between individuals and genetic factors play a major role in this variability. Much of the variability
is due to the polymorphic structure of the gene with an average of one single nucleotide polymorphism (SNP)
every 160 bp of coding DNA and we have described at least 5 SNPs causing loss of function and a further one has
been reported giving gain of function.
In around 30% of the Caucasian population, a Glu-496 to Ala polymorphism in P2X7 receptors (1513 AYC),
of the carboxyl terminus leads to loss of function. Homozygosity for this polymorphism abolishes ATP-induced
channel dilatation (pore formation) while the heterozygous state gives cells with half the pore function of cells
with wild type P2X7 protein. A second polymorphism, Ile-568 to Asn (1729 T YA) lies in a trafﬁcking motif of
the carboxyl terminus and prevents normal trafﬁcking and surface expression of the receptor. A third
polymorphism, Arg-307 to uncharged glutamine (946 GYA) lies within the ATP binding pocket of the
extracellular domain and abolishes the binding of ATP to the receptor with severe functional loss. A fourth
polymorphism occurs as a splice site mutation at position +1 of the ﬁrst intron of the gene (151+1 gYt) and gives
rise to a null allele in 1-2% of the Caucasian population. While each of the latter three polymorphisms (1729A,
946A and 151+1t) occurs at an allele frequency of 1-2% in Caucasians, none have been found in a large cohort of
S.E. Asian immigrants to Australia.
The effect of loss-of-function SNPs appears to be additive such that macrophages from compound
heterozygous subjects have total ablation of P2X7 function. Thus we have observed severe illness due to
Toxoplasma gondii in two compound heterozygotes with total absence of P2X7 function. In two large case control
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Australia. The 1513 AYC polymorphism was strongly associated with extrapulmonary but not pulmonary
tuberculosis in both the ﬁrst (OR 3.99, P< 0.001) and second cohorts (OR 2.99, P < 0.01). These data conﬁrm the
major effects of P2X7 polymorphisms on macrophage function and innate immunity of man.
Tissue-Derived Adenosine promotes Peripheral T cell Tolerance by Stimulating
the A2A Receptor
Jonathan D. Powell*
+Paul E. Zarek*, Charles Drake
+, Drew M. Pardoll
+
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A2a receptor (A2aR) engagement by endogenous adenosine has been implicated as an important negative
regulator of inﬂammation. Using microarray analysis, we determined that the A2aR is differentially upregulated
on T cells under conditions that induce T cell tolerance. In vitro,A 2aR WT, but not A2aR null T cells that were
initially activated in the presence of CGS-21680 (CGS) were hyporesponsive upon rechallenge; they were anergic.
In vivo, the adoptive transfer of A2aR null HA-speciﬁc 6.5 T cells into mice expressing HA as a self-antigen led to
rapid autoimmune-induced death when compared with the transfer of T cells from WT mice. Furthermore,
treating mice with just 4 days of CGS inhibited autoimmune-induced death and promoted the induction of T cell
anergy. In this model, mice that survive the initial adoptive transfer develop inducible LAG-3+ regulatory T cells
that protect the mice from a subsequent rechallenge with clonotypic T cells. LAG-3 expression levels and kinetics
are enhanced in A2aR WT cells from CGS-treated mice, but decreased in A2aR null T cells, regardless of CGS-
treatement. CGS-treated mice that survived the initial adoptive transfer were protected against a subsequent
rechallenge with lethal numbers of clonotypic cells. Conversely, CGS failed to protect mice from the adoptive
transfer of LAG-3 null T cells. It is notable that the concentration of adenosine in the tumor mciroenvironment is
in the mM range. This suggests that one mechanism by which tumors evade immune destruction is via A2aR-
induced tumor-antigen-induced tolerance. To test this hypothesis we examined the efﬁcacy of tumor vaccines in
A2aR null mice or when given in conjunction with A2aR antagonists. We found that in the A2aR null mice or in
mice which received A2aR antagonists, the efﬁcacy of immunotherapy was greatly enhanced. Overall, our data
implicate tissue derived adenosine as a novel mechanism for promoting peripheral T cell tolerance.
Round table on Caffeine and Health
Caffeine and Headache: An Update
Astrid Nehlig
INSERM U 666, Strasbourg, France
e-mail: nehlig@neurochem.u-strasbg.fr
The use of caffeine as an adjunctive constituent of analgesic medications dates back to 1875 while the ﬁrst clinical
trials were performed after 1950. The combination of caffeine with current prescription and nonprescription drugs
in alleviating migraine and tension-type headache-related symptoms and pain has been the subject of a number of
studies.
Caffeine has intrinsic antinociceptive actions in animal models. These are linked to its antagonism at the level
of adenosine receptors. Adenosine A1 receptor activation is antinociceptive by decreasing and A2 receptor
activation is pronociceptive by increasing cAMP levels in the sensory nerve terminals. Adenosine A3 receptor
activation produces pain behaviors due to the release of histamine and serotonin from mast cells and subsequent
actions on nerve cell terminals. The intrinsic antinociceptive actions of caffeine have been proposed to result from
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terminals. In addition, during headaches, adenosine receptor-mediated vasodilation and/or irregular vascular tone
contribute to pain.
Based on a pooled analysis of 30 clinical studies including about 10,000 patients suffering from various types of
pain including headaches, the combination of caffeine with current analgesics was reported to increase the
analgesic effect of aspirin or acetaminophen by 41%. Caffeine is well known to alleviate withdrawal-induced
headache which occurs after the abrupt cessation of caffeine intake. This effect is strongly linked to the
psychological satisfaction related to the ingestion of caffeine; this is especially true for the ﬁrst cup of coffee in the
morning. In tension-type headaches, the efﬁcacy of the combination of caffeine with acetaminophen, aspirin or
ibuprofen has been repeatedly reported both for pain intensity and total pain relief. In this type of headache,
caffeine displays also analgesic properties when given alone. In migraine, the combination of acetaminophen,
aspirin and caffeine is more effective than the placebo in alleviating pain and associated symptoms even in
severely disabled migraineurs. However, in the latter type of headache, the studies do not allow to outline the
speciﬁc role of caffeine in the drug combination tested since no comparison was performed with combinations
containing or not caffeine or with caffeine alone. A recent work on migraine suggested to use a combination of
products that would act on a whole subset of physiological regulations that are impaired during migraine attacks.
The role of cerebral blood ﬂow changes in headaches is unclear, except in caffeine withdrawal-induced
headaches. In the latter ones, cerebral blood ﬂow velocities are increased and they are signiﬁcantly decreased
within 30 min after caffeine intake, suggesting that increased blood volume may be involved in caffeine
withdrawal headache. In tension-type headache, there does not seem to be vascular changes related to the attack
and for migraine attacks, the literature is rather in favor of a decrease in cerebral blood ﬂow during the attacks.
Thus, in these two latter headache types, caffeine does not seem to exert analgesia via its vasoconstrictive
properties.
Caffeine effects on blood pressure and stress responses in persons at risk for
developing hypertension
William R. Lovallo
University of Oklahoma and Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA
bill@mindbody1.org
Caffeine is the worlds most widely consumed pharmacologically active substance. A constituent in coffee, tea, and
soft drinks, caffeine acts to block adenosine receptors, and it is capable of interacting with all levels of the stress
axis [1]. This action has implications for a range of systemic functions. Our work has concentrated on the effect of
caffeine on blood pressure regulation and cortisol secretion, with an emphasis on these responses in hypertension.
At the blood vessel wall, caffeine blocks A2a receptors on the prejunctional sympathetic nerve ending, reducing
the ability of adenosine to regulate release of norepinephrine onto alpha adrenoreceptors on the smooth muscle
cell. This increases contractile state of vascular smooth muscle and causes a rise in peripheral vascular resistance,
providing a physiological basis for caffeine"s ability to elevate blood pressure. This receptor blockade causes a
greater and longer lasting rise in vascular resistance and blood pressures in persons with above-normal pressures
[2,3]. Caffeine also increases the secretion of the stress hormone cortisol, and this effect is also greater in persons
at high risk of developing hypertension. The effect of caffeine on blood pressure and cortisol secretion is not
affected by the amount of caffeine the person normally consumes in their diet, raising the question of the extent of
tolerance development in regular consumers. Our study of tolerance to caffeine shows that most persons do not
develop a complete tolerance to caffeine"s effect on blood pressure or cortisol output. Examination of individual
differences in tolerance shows that half of the persons tested did not show tolerance to a morning dose of 250 mg
of caffeine given in even when given a structured diet of 600 mg of caffeine per day (equivalent to 6 cups of
brewed coffee) for the previous ﬁve days. These effects call into question the long-term effects of caffeine on
blood pressure regulation in the development and progression of hypertension.
1. al"Absi M, Lovallo WR. Caffeine effects on the human stress axis. In Nehlig A (ed): Coffee, Tea, Chocolate and The Brain.
Boca Raton, FL: CRC Press LLC 2004; 113–31.
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3. Shepard JD, al"Absi M, Whitsett TL et al. Additive pressor effects of caffeine and stress in male medical students at risk for
hypertension. Am J Hypertens 2000; 13(5 Pt 1): 475–81.
The effects of caffeine on anxiety- and mood-related behaviors in mice
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FRE 2735 CNRS, IFRMP 23, U.F.R. de Medecine & Pharmacie, 22 Boulevard Gambetta, 76183 Rouen Cedex,
France
malika.el-yacoubi@univ-rouen.fr; jean-marie.vaugeois@univ-rouen.fr
It is now well established that the effects exerted in the brain by caffeine depend on its ability to act as an
antagonist at A1 and A2A receptors of the ubiquitous neuromodulator adenosine. Caffeine can cause anxiety
symptoms, especially in individuals with pre-existing anxiety disorders. It has been claimed too that caffeine use
may be also associated with symptoms of depression, supporting a self-medication theory. However the precise
mechanism of action of the drug is unclear. The elevated plus-maze (EPM) and the light/dark box are established
behavioral tests useful to screen putative anxiogenic/anxiolytic effects of drugs. We have previously [1]
investigated whether the anxiogenic effects of caffeine observed in mice depend on the blockade of A2A
receptor. Caffeine acutely administered (50 or 100 mg/kg IP) induced anxiety-like effects in both procedures. Its
chronic administration (50 mg/kg IP twice daily) for 1 week or consumption in the drinking water (0.3 g/l) for
8 days or 2 months were also anxiogenic in the EPM. The A2A receptor antagonists ZM241385 (up to 60 mg/kg
IP) and SCH58261 (up to 10 mg/kg IP) were devoid of acute effects in both tests. One week administration of
ZM241385 (30 mg/kg IP) or SCH58261 (3 mg/kg IP) had no effects in the EPM. An antagonist (DPCPX) and an
agonist (CPA) at A1 receptors had no acute effects on anxiety-related indices in our hands but anxiolytic effects of
adenosine acting through A1 receptors or of other A1 receptor agonists were found in other experimental
conditions. An A2A receptor agonist (CGS 21680) displayed non-speciﬁc motor effects in the EPM. Acute
administration of caffeine (50 mg/kg IP) induced no clear-cut anxiety-like effects in the EPM in A2A receptor
knockout mice that exhibited higher basal anxiety levels than wild-type mice. Chronic administration (50 mg/kg
IP twice daily) for 1 week elicited less anxiety-like behavior in A2A receptor knockout than in wild-type mice.
Thus, adaptive mechanisms following mutation in A2A receptors or their long-term blockade after chronic
ingestion of caffeine may be responsible for increased proneness to anxiety. However, the short-term anxiety-like
effect of caffeine in mice may not be related solely to the blockade of adenosine A2A receptors, since A2A
selective antagonists do not share it. It may likely be dependent on blockade of A1 receptors, in accordance with
the increased anxiety-like behavior seen in A1 receptor knockout mice [2]. Adenosine and its analogues have
been shown to induce Bbehavioral despair’’ in animal models believed to be relevant to depression. Selective
adenosine A2A receptor antagonists (e.g., SCH 58261, ZM241385, and KW6002) or genetic inactivation of the
receptor were effective in reversing signs of behavioral despair in the tail suspension test (TST) and forced swim
test (FST) [3]. A2A antagonists were active in the TST using either mice previously screened for having high
immobility scores or mice that were selectively bred for their spontaneous Bhelplessness’’ in this test. We
hypothesized that the antidepressant-like effect of selective A2A antagonists is linked to an interaction with
dopaminergic transmission, possibly in the frontal cortex. However this view of antidepressant-like effects
induced by an antagonism at A2A receptors has been recently challenged. Caffeine was effective in the FST at
stimulant doses but a clear-cut antidepressant-like effect could not be ascribed to it. In conclusion, data from mice
show that caffeine i) can induce anxiety at high doses through A1 and possibly A2A receptors and ii) cannot be
viewed as a typical antidepressant.
1. El Yacoubi M, Ledent C, Parmentier M et al. Psychopharmacology (Berl) 2000; 148: 153–63.
2. Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM et al. Eur J Neurosci 2002; 16: 547–50.
3. El Yacoubi M, Costentin J, Vaugeois JM. Neurology 2003; 61(11 Suppl 6): S82–7.
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Adenosine: A promising clinical indicator of inﬂammation in asthma
Riccardo Polosa
Dipartimento di Medicina Interna e Specialistica Ascoli-Tomaselli Hospitals, University of Catania, Italy
polosa@unict.it
Interest in the role of adenosine in asthma has escalated considerably since the early observation of its powerful
bronchoconstrictor effects in asthmatic but not normal airways. A growing body of evidence has emerged in
support of a pro-inﬂammatory and immunomodulatory role for the purine nucleoside adenosine in the pathogenic
mechanisms of chronic inﬂammatory disorders of the airways such as asthma. The fact that adenosine enhances
mast cell allergen-dependent activation, that elevated levels of adenosine are present in chronically inﬂamed
airways, and that adenosine given by inhalation cause dose-dependent bronchoconstriction in subjects with
asthmaemphasizes the importance of adenosine in the initiation, persistence and progression of these common
inﬂammatory disorders of the airways. These distinctive features of adenosine have been recently exploited in the
clinical and research setting to identify innovative diagnostic applications for asthma. In addition, because
adenosine exerts its multiple biological activities by interacting with four adenosine receptor subtypes, selective
activation or blockade of these receptors may lead to the development of novel therapies for asthma.
Coordinated Nucleotide Metabolism and Vascular Leak
Sean P. Colgan
1, Linda F. Thompson
2, and Holger K. Eltzschig
3
1Center for Experimental Therapeutics, Brigham and Women"s Hospital and Harvard Medical School, Boston,
Massachusetts, USA
2ImmunobiologyandCancerResearchProgramOklahomaMedicalResearchFoundation,OklahomaCity,Oklahoma
3Department of Anesthesiology and Intensive Care Medicine, Tu ¨bingen University Hospital, D-72076 Tu ¨bingen,
Germany
colgan@zeus.bwh.harvard.edu
At sites of ongoing inﬂammation, polymorphonuclear leukocytes (PMN, neutrophils) migrate across barrier cell
types including vascular endothelia and mucosal epithelia. Such transmigration has the potential to disturb barrier
properties and can result in organ dysfunction. It is recently appreciated that endogenous pathways exist to
dampen barrier disruption during transmigration and may provide an important anti-inﬂammatory link. For
example, during transmigration, PMN-derived adenine nucleotides activate endothelial and epithelial cells and
induce a cyclic AMP-dependent re-sealing of barrier cell types. In recent work, we have sought to understand the
link between extracellular nucleotide metabolism and vascular barrier function. In particular, these studies have
revealed that activated PMN release ATP, which through the action of extracellular nucleotidases is
enzymatically cleaved to adenosine. Once liberated, adenosine binds surface A2 receptors to coordinate barrier
protection. As part of this analysis, we have recently addressed inﬂammatory microenvironmental inﬂuences, such
as hypoxia, on adenine nucleotide metabolism. These studies have identiﬁed an hypoxia-dependent, transcrip-
tionally-mediated program which coordinates the elevation of extracellular adenosine. Target molecules in this
program include hypoxia-inducible factor (HIF)-dependent induction of ecto-50-nucleotidase (CD73) and
adenosine A2b receptor (A2bR), as well as HIF-dependent repression of the dipyridamole-sensitive equilibrative
nucleoside transporters (ENT1 and ENT2)1–3. These studies provide new insight and potential therapeutic
targets for diseases in which tissue permeability may be abnormal.
1. Eltzschig HK, Abdulla P, Hoffman E et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in
hypoxia. J Exp Med 2005; 202: 1493–505.
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3. Synnestvedt K, Furuta GT, Comerford KM et al. Ecto-50-nucleotidase (CD73) regulation by hypoxia-inducible factor-1
(HIF-1) mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110: 993–1002.
Inﬂammatory role of adenosine in human lung cells
Dewan Zeng, Hongyan Zhong, and Luiz Belardinelli
Department of Pharmacological Sciences, CV Therapeutics, Inc., Palo Alto, California 94304
dewan.zeng@cvt.com
It has been suggested that adenosine might have both pro- and anti-inﬂammatory actions depending on the
pathophysiology of the diseases. In the lungs of asthmatics, inhaled adenosine or adenosine monophosphate
(AMP) increases the release of histamine, tryptase and leukotrienes, suggesting a pro-inﬂammatory role of
adenosine presumably due to the activation of adenosine receptors present in mast cells. The objective of our
study was to determine the potential role of adenosine and its receptors in the human lung cells such as bronchial
epithelial cells, airway smooth muscle cells and lung ﬁbroblasts. Among the four subtypes of adenosine receptors
(A1,A 2A,A 2B and A3), the A2B receptor is expressed at the highest level in all three types of lung cells. In airway
smooth muscle cells, activation of A2B receptors leads to the release of IL-6 and MCP-1. Similarly, in lung
ﬁbroblasts, activation of A2B receptors increases the release of IL-6, which in turn promotes the differentiations of
ﬁbroblasts into myoﬁbroblasts. In bronchial epithelial cells, activation of A2B receptors increases the release of IL-
19, which leads to the release of TNF-! from a monocytic cell line. Altogether, these results suggest that activation
of A2B receptors in the human lung cells increases the release of several pro-inﬂammatory cytokines and
chemokines, which could lead to deleterious inﬂammatory responses in the lung.
Role of adenosine receptors in regulation of pro-inﬂammatory and pro-
angiogenic cytokines in mast cells
Igor Feoktistov and Italo Biaggioni
Vanderbilt University, Nashville, Tennessee 37232, USA
igor.feoktistov@vanderbilt.edu
Asthma is a chronic inﬂammatory disorder often accompanied by airway and vascular remodeling. Many of the
pathologic features of asthma are attributed to the effects of mast cell-derived mediators. Adenosine is a powerful
bronchoconstrictor of asthmatic, but not normal, airways. Growing lines of evidence, from early studies in isolated
mast cells to more recent investigations in mice models, support a role of adenosine in Th2 and airway remodeling
responses. Our own studies in this area suggested that the asthmatic response to adenosine is primarily mediated
via the A2B receptors, which is selectively antagonized by enprofylline1. This work also provided evidence that
adenosine is capable to regulate cytokine release from human mast cells. In recent studies, we showed that
adenosine stimulates mast-dependent angiogenesis via cooperative interaction between A2B and A3 adenosine
receptors. Activation of mast cell A2B adenosine receptors stimulates the synthesis of the pro-angiogenic factors
VEGF and IL-8, whereas activation of A3 receptor induces the expression of angiopoietin-2.2 Thus, adenosine
can contribute to the vascular remodeling associated with asthma. In addition, adenosine can contribute to Th2
response through A2B-mediated release of IL-4 and IL-13 from mast cells. The induction of IgE synthesis by the
interaction between adenosine-stimulated mast cells and B-lymphocytes suggests that this mechanism is involved
in the ampliﬁcation of the allergic inﬂammatory responses associated with asthma3. The molecular mechanisms
underlying this unique role of A2B adenosine receptors in promoting Th2 inﬂammation were explored in HMC-1
human mast cells. A2B receptors are coupled to Gs proteins linked to increase in cAMP, and are coupled to Gq to
stimulate phospholipase C". We found that A2B receptors upregulate IL-4 through Gq signaling that is
potentiated via crosstalk with Gs-coupled pathways. These data explain the presence and underscore the
importance of dual coupling of A2B receptors to Gs/Gq proteins with concurrent stimulation of diverse
34 Invited Lecturesintracellular pathways for adenosine-dependent regulation of Th2 cytokines in human mast cells. These studies
provide new insight and identify A2B receptors as a potential therapeutic target for asthma.
1. Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-
sensitive mechanism with implications for asthma. J Clin Invest 1995; 96: 1979–86.
2. Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I. Mast cell-mediated stimulation of angiogenesis: cooperative interaction
between A2B and A3 adenosine receptors. Circ Res 2003; 92: 485–92.
3. Ryzhov S, Goldstein AE, Matafonov A et al. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an
A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 2004; 172: 7726–33.
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Increased intraocular pressure (IOP) may lead to retinal ganglion cell (RGC) injury, and consequent visual
deﬁcits, as it is observed in glaucoma, a leading cause of blindness. Decades of studies have shown that chronic
IOP alterations cause a number of detrimental effects, including mechanical damage of RGC axons, reduced
blood supply, microglia activation and release of cytotoxic factors. Much less is known of the acute effects of
pressure increments, mostly for the lack of adequate tools for this investigation.
Using a novel pressure incubator we have addressed this issue in isolated rat retinas, then extended our
observations in vivo.
Imaging individual RGCs before and after pressure application we found that increasing pressure to 50 mmHg
for 1 min affects almost 30% of the RGCs within 1 hour. The percentage of damaged RGCs and the extent of cell
injury increase when multiple pressure spikes are applied and pressure peaks are increased. However, even in the
worst conditions, RGC damage is prevented by degrading extracellular ATP (eATP) with apyrase, or by blocking
the P2X receptors with either oxidized ATP (300 uM), or Brilliant Blue G (0.5 uM).
In vivo, short IOP transients increase the levels of eATP in the eye ﬂuids, damage RGCs within 1 hour, and
impair RGC light-responses. Reducing eATP levels in the eye prevents RGC damage and shortens the
impairment of light responses due to pressure.
These data show that pressure transients can injure RGCs within hours and demonstrates a causal link between
eATP and such pressure-induced RGC damage. These ﬁndings may open the way to novel neuroprotective
strategies in pathologies associated to high-pressure transients in the eye.
P2 receptors in glial cells
Maria P. Abbracchio
Laboratory of Molecular and Cellular Pharmacology of Purinergic Transmission, Department of Pharmacological
Sciences, University of Milan, Italy
mariapia.abbracchio@unimi.it
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and pathological conditions. In the CNS, ATP has been proposed as a main signaling molecule involved in short-
term, calcium-dependent cell-to-cell signaling [1, 2]. ATP released from astrocytes activates P2 receptors on both
astrocytes and other brain cells and generates a propagating wave of intracellular calcium increases allowing a
homotypic and heterotypic signalling which also involves microglia, neurons and oligodendrocytes. Multiple P2X
and P2Y receptors are expressed by both astrocytes and microglia [3–5]: however, these receptors are
differentially recruited by nucleotides under speciﬁc patho-physiological conditions. P2Y1,2,4 and, maybe, P2X7
receptors, seem to be speciﬁcally recruited during calcium-dependent short-term signaling. Multiple P2 receptor
subtypes (i.e., P2Y1,2,6,12,13 and P2X7) seem instead to cooperate to the long-term changes of astrocytes during
inﬂammatory reactive gliosis. In these cells, P2 receptor-mediated gliosis occurs via activation of the ERK and
protein kinase B/Akt pathways, and involves induction of both inﬂammatory and anti-inﬂammatory genes, cyclins,
growth factors, adhesion and anti-apoptotic molecules. Conversely, genes involved in apoptotic cell death are
down-regulated (for review, see: 6). Such a pattern of gene induction is consistent with the activation of
neuroprotective mechanisms. Functional studies indeed suggest that, globally, the net effect of nucleotide-induced
astrogliosis may be beneﬁcial [6]. In microglial cells, exposure to inﬂammatory and immunological stimuli results
in differential functional changes of distinct P2 receptor subtypes, suggesting that these receptors may play highly
speciﬁc roles in the acquisition of the activated microglial phenotype [5, 6]. On this basis, it is currently believed
that nucleotide-induced activation of both astrocytes and microglia may originally start as an acute defense
mechanism aimed at protecting neurons from cytotoxic and ischemic insults. Dysregulation of this process in
chronic inﬂammatory diseases [7] eventually results in neuronal cell damage and loss. On this basis, the full
elucidation of the speciﬁc roles of P2 receptors in these effects may help exploiting the beneﬁcial neuroprotective
features of activated glial cells while attenuating their harmful properties, and thus provide the basis for novel
neuroprotective strategies which speciﬁcally target the purinergic system.
Partially supported by The Italian Ministry of University and Research, progetti FIRB2001 and FIRB2003,
COFIN-MIUR2004 to MPA.
1. Haydon PG. Nat Rev Neurosci 2001; 2: 185–93.
2. Fields RD, Stevens B. Trends Neurosci 2000; 23: 625–33.
3. Fumagalli M, Brambilla R, D"Ambrosi N, Volonte C, Matteoli M, Verderio C, Abbracchio MP. Glia 2003; 43: 218–03.
4. Fumagalli M, Trincavelli L, Lecca D, Martini C, Ciana P, Abbracchio MP. Biochem Pharmacol 2004; 68: 113–24.
5. Bianco F, Fumagalli M, Pravettoni E, D"Ambrosi N, Volonte C, Matteoli M, Abbracchio MP, Verderio C. Brain Res Brain
Res Rev 2005; 48: 144–56.
6. Abbracchio MP, Ceruti S. Purinergic Signalling 2006, submitted for publication.
7. Marchetti B, Abbracchio MP. Trends Pharmacol Sci 2005; 26: 517–25.
Presynaptic P2 receptors - interaction with other receptors and role in
neuroprotection
Lisiane O Porciu ´ncula, Ricardo J Rodrigues, Paula M Canas, Teresa Almeida, Carla G. Silva, Jean P.
Oses, A. Patrı ´cia Simo ˜es, Catarina R Oliveira, Rodrigo A Cunha
Ctr. Neuroscience Coimbra, Fac.Medicine, Univ.Coimbra, Portugal
racunha@ci.uc.pt
In the brain, ATP can either act as a neurotransmitter or neuromodulator or be involved in the communication
with astrocytes or microglia. In hippocampal preparations, ATP is released in a calcium- and frequency-
dependent manner but its intensity-dependent release differs from that of classical transmitters (glutamate or
acetylcholine, ACh). Also, ATP release was sensitive to L-type calcium channel blockers, in contrast to glutamate
or ACh release. Thus, the pattern of ATP release seems to differ from that of classical neurotransmitters.
The investigation of the sub-synaptic localization of P2 receptors (P2Rs) revealed a robust immunoreactivity
for P2X1,2,3Rs and P2Y1,2,4Rs in the presynaptic active zone of hippocampal terminals. Combined immunocy-
tochemical and pharmacological characterization of glutamatergic terminals indicated a biphasic control of
glutamate release by facilitatory P2X1–3Rs and inhibitory P2Y1,2,4Rs in hippocampal terminals.
Not only P2Rs but also nicotinic ACh receptors (nAChRs), namely !3*, but not !4*, were enriched in
hippocampal terminals. P2X ligands displaced binding to nAChRs and nAChR ligands displaced binding to P2Rs.
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!-conotonin MII-sensitive) or ",+-imido ATP (3–60 2M, prevented by NF-023 but not reactive blue-2) and, again,
P2R antagonists prevented nAChR responses and, conversely, nAChR antagonists prevented P2XR responses.
Also, P2X2Rs co-immunoprecipitated with !3, but not !4 subunits, showing that P2X1-3 and !3"2 nAChRs are
physically linked and interact to control transmitter release.
Finally, we tested the role of P2Rs in the control of synaptotoxicity that is thought to predates neurotoxicity in
neurodegenerative disorders. We tested if P2Rs controlled damage in cultured hippocampal neurons using two
different noxious stimuli: 1) glutamate (100 2M for 25 min), mimicking a general feature of excitotoxicity, causing
26 T 4% neuronal death 24 h after, and 2) A"1–42 (500 nM, 48 h), a causative factor of Alzheimer_s disease, causing
22 T 3% neuronal death, which displayed apoptotic features (nuclear condensation, cytochrome c release, caspase
3 activation). This neurotoxicity was preceded by a synaptotoxicity (decreased synaptophysin immunoreactivity
after 12 h, when no neuronal death was observed) and dendritic atrophy (MAP-2 staining). Blockade of P2Rs (10
2M PPADS) or P2YRs (10 2M reactive blue 2), but not P2X1–3Rs (10 2M NF023 or TNP-ATP), prevented these
neurotoxicity features. Notably, the selective P2Y1R antagonist MRS2179 (10 2M) was also neuroprotective.
Furthermore, P2Y1R immunoreactivity was enhanced in hippocampal terminals 15 days after A"1–42 (2 nmol, icv)
administration, at a time where mice became amnesic (passive avoidance and Y maze tests) and displayed a loss
of nerve terminals (loss of synaptophysin or SNAP-25 immunoreactivities) without neuronal loss (FluoroJade C
staining). This indicates that extracellular ATP may be involved in the development of the synaptotoxicity and
prompts the hypothesis that P2Y1R antagonists may be potential novel neuroprotective drugs. (Supported by
Portuguese Society of Neuroscience, Pﬁzer and FCT).
Purinergic coordination of synaptic cross-talk mediated by astrocytes
Philip G. Haydon
Department of Neuroscience, Conte Center for Integration at the Tripartite Synapse, University of Pennsylvania
School of Medicine, Philadelphia, PA 19104, USA
pghaydon@mail.med.upenn.edu
Though it is well known that there is a tonic accumulation of adenosine in the hippocampus which results in a
suppression of synaptic transmission, there is little information regarding its source and control. Using inducible
transgenic animals in which we used the tetracycline-regulated gene expression system to control the expression
of transgenes selectively in astrocytes, we demonstrate that astrocytes control extracellular adenosine levels
through the release of ATP(Pascual et al., 2005).
During the past decade it has become appreciated that astrocytes, the predominant glial cell type of the central
nervous system, respond to neuronal activity with Ca
2+ oscillations which induce the release of gliotransmitters
that include glutamate, ATP and D-serine (Volterra and Meldolesi, 2005;Haydon, 2001). Our recent work has
focused on the roles of these glial feedback pathways in the regulation of integration in the nervous system. Using
a combination of imaging, electrophysiology and molecular genetics our studies indicate that astrocytes provide
balanced excitation and inhibition to neurons through immediate actions of glutamate followed by delayed
actions of accumulating adenosine. These gliotransmitters serve several functions that include the synchroniza-
tion of neuronal activity, the suppression of synaptic transmission, as well as in mediating adenosine-dependent
heterosynaptic depression (Pascual et al., 2005).
We generated inducible astrocyte speciﬁc transgenic animals which perturbed the release of ATP from these
glial cells (Pascual et al., 2005). As a consequence we were able to identify critical roles for glial-derived purines
in the regulation of synaptic transmission. We demonstrate that after releasing ATP this purine is hydrolysed to
adenosine where it tonically suppresses excitatory synaptic transmission. As a consequence the dynamic range for
synaptic plasticity (LTP) is enhanced. Additionally, in response to high frequency activity of presynaptic
afferents, we have demonstrated that astrocytes releases ATP and cause a heterosynaptic suppression of
neighboring unstimulated synapses that is also mediated through the actions of adenosine. Together these results
allow us to conclude that astrocyte-derived purines coordinate synaptic networks by tonically regulate the
strength of synaptic transmission, the range available for synaptic plasticity and heterosynaptic depression.
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Purinergic signaling in regulating myelination by action potentials
R. Douglas Fields
Nervous System Development and Plasticity Section, National Institutes of Health, NICHD, Bethesda, MD, USA
ﬁeldsd@mail.nih.gov
Myelin is the membrane wrapping around axons that provides electrical insulation essential for rapid impulse
conduction. Impulse activity can affect the formation of myelin, and this may be important in regulating nervous
system structure and function according to environmental experience. Our studies performed on mouse dorsal
root ganglion (DRG) neurons in cell culture show that impulse activity releases ATP from DRG axons, and that
this is detected by different purinergic receptors on the two types of glia forming myelin in the PNS (Schwann
cells) and CNS (oligodendrocytes). Both P1 and P2 receptors are involved in axon signaling to both types of
myelinating glia, but ATP is of primary importance in regulating early development and myelination by Schwann
cells, where it inhibits myelination; whereas adenosine is of primary importance in regulating early development
of oligodendrocyte progenitor cells (OPCs), where it stimulates myelination. After OPCs mature, activity-
dependent release of ATP stimulates myelin formation through a different mechanism involving release of the
cytokine LIF from astrocytes, which are non-myelin forming glia of the CNS. The activity-dependent release of
ATP from axons provides a mechanism for regulating myelination in the central and peripheral nervous system,
through both P1 and P2 signaling at different stages of development and in different types of glia.
Cell Proliferation and Cancer
ATP: A new treatment modality in cancer?
P.C. Dagnelie
Department of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
Email: Dagnelie@epid.unimaas.nl
Cancer is a devastating disease. Despite decades of research, the prognosis of many cancer types is still
disappointingly poor. Adenosine 50-triphosphate (ATP), given as intravenous infusions, may have several
potential applications in cancer:
1. Inhibition of the cancer cachexia (weight loss) syndrome, improving fatigue and quality-of-life;
2. Attenuation of side effects of curative anti-cancer treatment;
3. Anti-tumour efﬁcacy, either alone or in combination with current cancer treatments.
In this presentation, these three effects will be outlined and their prospects brieﬂy discussed.
(1): So far, clinical experience with ATP treatment in cancer patients is limited. In 1995, following an
uncontrolled phase I study in the US, we initiated a randomised clinical trial (RCT) with ATP infusions in
cancer.
1 A total of 58 patients with advanced non-small-cell lung cancer in the palliative treatment stage were
randomised to ATP (continuous infusion for 30 h, max. rate 75 ug/kg.min, frequency 1 /2–4 wks) or control
(palliative care only). Over a period of 6 months, ATP completely inhibited the loss in weight, fat mass, body cell
mass, muscle strength and functional status (walking stairs, household activities, etc.) which were seen in the
control group; also, ATP improved quality-of-life and fatigue.
The most intriguing ﬁnding was that ATP increased life expectancy from 3.5 to 9.2 months in a subgroup of
cachectic lung cancer patients at a relatively early tumour stage (IIIB), Based on these results, further RCTs in
38 Invited Lecturescancer patients have been intiated. One such RCT (S. Beijer et al., presented at this meeting) is targeted at
patients with mixed tumour types in the late palliative treatment stage cancer, and aims to improve weight,
appetite, fatigue, physical disability and quality of life. ATP infusions in this protocol are applied in the home
situation, which is feasible and safe provided a strict protocol is followed.
To (2/3) The strong favourable effect of ATP on life expectancy in lung cancer patients has triggered
therapeutic studies, combining ATP with curative cancer treatment modalities such as radiotherapy and
chemotherapy. At the same time, laboratory studies focus upon unravelling underlying mechanistic of the effects
of ATP in cancer, especially the ATP-effects on therapy-induced inﬂammation and oxidative stress (Swennen et
al., presented at this meeting).
We conclude that ATP holds promise for cancer treatment, not only for alleviating some of the devastating side
effects of cancer, such as weight loss and fatigue, but also for increaing survival in selected patient groups.
Moreover, ATP has potential to enhance the anti-tumour effects of current anti-tumour agents, while at the same
time attenuating their side effects.
1. Dagnelie PC, Agteresch HJ. Drug Devel Res 2003; 59: 146–51 (7th Adenosine Meeting, Gold Coast, Australia).
2. Agteresch HJ, Burgers SA, van der Gaast A et al. Anti-Cancer Drugs 2003; 14: 639–44.
Design, synthesis and antitumor activity of 40-Thionucleosides as highly potent
and selective A3 adenosine receptor agonists
Lak Shin Jeong
Laboratory of Medicinal Chemistry, College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea
A number of ligands have been synthesized and tested for binding afﬁnity at the rat, sheep, and human A3 versus
A1 and A2A receptors. Among these ligands, IB-MECA (1) was found to be a highly potent human A3 agonist
(Ki = 1.8 nM), which is 900- and 1620-fold selective for human A3 versus either human A1 or A2A receptors,
respectively. Introduction of chlorine at the 2-position of IB-MECA, resulting in the formation of Cl-IB-MECA
(2) also increased binding afﬁnity and selectivity. Compound 2 has been reported to display a Ki value of 1.4 nM
and showed 900- and 3800-fold human A3 receptor selectivity versus human A1 and A2A receptors, respectively.
Compounds 1 and 2 are in phase II clinical trials and preclinical trials as anticancer agents, respectively.




























1, IB-MECA 2, Cl-IB-MECA
3
Ki = 1.8 nM for human A3 Ki = 1.4  nM for human A3
R1 = hydrogen, alkyl, or arylalkyl
R2 = CH2OH or amide
X = H or Cl
On the basis of high binding afﬁnity and selectivity of 1 and 2 on human A3 adenosine receptors, we designed
and synthesized the 40-thio analogues 3, since a sulfur atom may serve as a bioisostere of an oxygen atom. The
synthesized 40-thionucleoside derivatives exhibited dramatic increases in afﬁnity and selectivity for human A3
receptors versus human A1 and A2A receptors. Among compounds tested, 2-chloro-N
6-(3-iodobenzyl)-40-
thioadenosine-50-methyluronamide (Thio-Cl-IB-MECA) inhibited the growth of human promyelocytic leukemia
HL-60 cells by arresting cell cycle and induction of apoptosis. The growth inhibitory activity of thio-Cl-IB-MECA
Invited Lectures 39was also found to be related with the modulation of Wnt signaling pathway by measuring the levels of "-catenin,
phosphorylated forms of GSK-" and Akt. Oral administration of Thio-Cl-IB-MECA exhibited highly potent
antitumor activity in in vivo tumor xenograft model, indicating that it may be developed as a clinically useful
anticancer agent.
Design, synthesis, and antitumor activity of the 40-thionucleosides 3 as ultrapotent and selective agonists at the
human A3 adenosine receptor will be presented in detail.
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Hypoxia appears to induce a program which shifts the cellular phenotype toward an increase in intracellular
adenosine. Hypoxia-inducible factor-1 (HIF-1) is a key regulator of genes crucial to many aspects of cancer
biology. Since the levels of both HIF-1 and adenosine are elevated within the hypoxic environment of solid
tumors, we investigated whether adenosine may regulate HIF-1. In particular, we investigated the effect of A3
receptor antagonists on HIF-1, vascular endothelial growth factor and Angiopoietin-2 expression. Furthermore,
this presentation will discuss new signaling pathways induced by A3 receptors in hypoxia and provide results of
how human melanoma and glioblastoma tumor growth may be inﬂuenced through the adenosinergic system.
Inhibition of hepatocellular carcinoma growth by an A3 adenosine receptor
agonist: De-regulation of PKB/Akt-NF-kB signaling pathway
Sara Bar-Yehuda, Avivit Ochaion, Shira Cohen, Faina Barer, Pnina Fishman
Can-Fite BioPharma, Petach Tikva, Israel
The A3 adenosine receptor (A3AR) belongs to the family of the Gi-protein associated cell surface receptors and is
highly expressed in various tumor cell types in comparison to the normal adjacent tissue. Lately it has been
demonstrated that peripheral blood mononuclear cells (PBMNC) derived from colorectal patients also highly
express A3AR in comparison to PBMNC derived from healthy volunteers. A3AR activation by the synthetic
agonist suppress the development of melanoma, colon and prostate carcinoma in vitro and in vivo. The molecular
mechanism is mediated via down-regulation of PKB/Akt which induces down-stream deregulation of the Wnt and
the NF-kB signal transduction pathways.
In this study we followed A3AR expression in hepatocellular carcinoma (HCC) as well as in PBMNC both in
human and in an animal model. The effect of an A3AR agonist administration on A3AR expression level, tumor
development and signal transduction pathways involved were studied.
Utilizing parafﬁn embedded slides derived from human HCC samples, it was demonstrated that A3AR is
highly expressed in HCC tumor tissues, in comparison to the normal adjacent tissue. The high expression of the
A3AR in the tumor tissue was reﬂected in PBMNC derived from HCC patients. In addition, in tumor tissues as
well as in PBMNC derived from N1S1 hepatoma bearing rats high A3AR expression level was noted in
comparison to normal liver tissues. The expression level of the receptor was down-regulation upon oral treatment
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PKB/Akt, IKK, NF-.B and TNF-!, all members of the NF-.B signaling pathway. Moreover, GSK-3" was up-
regulated while "-catenin, Lef/Tcf and c-Myc expression level was down-regulated, demonstrating that de-
regulation of the Wnt signaling pathway took place. As a result, a marked inhibiting in the growth of the N1S1
tumors was observed in the CF102 treated animals.
Taken together we conclude that the A3AR may be developed as a new surrogate marker. In addition the
receptor may be suggested as target to be activated by synthetic small and orally bioavailable agonists which
inhibits HCC growth.
P2X7: A growth-promoting receptor
Francesco Di Virgilio
Department of Experimental and Diagnostic Medicine, Section of General Pathology, University of Ferrara
fdv@unife.it
P2X7 is a receptor for extracellular nucleotides expressed by different normal cell types. Activation of P2X7 may
result in stimulation of cell proliferation or induction of apoptosis, depending on the level of activation. We have
previously correlated the level of P2X7 expression to disease severity in lymphocytes from patients affected by
chronic lymphocytic leukemia (1). Furthermore, we have recently shown that expression of this receptor allows
growth in the absence of serum (2). This growth-promoting effect appears to be mediated by three main factors:
a) increased cytoplasmic Ca
2+ levels; b) increased mitochondrial potential; c) enhanced ATP synthesis. P2X7-
expressing cells also release larger amounts of ATP into the pericellular space. We have found that tumours,
among which human neuroblastoma, express a higher level of P2X7 compared to non-tumour cells (3). Growth-
promotion by P2X7 may be mediated via additional mechanisms involving release of growth stimulatory factors
among which substance P and ATP itself.
This novel ﬁndings suggest that overstressing the well known cytotoxic activity of this receptor may be
limitative and in certain conditions even misleading.
1. Adinolﬁ E, Melchiorri M, Falzoni S et al. P2X7 receptor expression in evolutive and indolent forms of B lymphocytic
leukemia. Blood 2002; 99: 706–8.
2. Adinolﬁ E, Callegari MG, Ferrari D et al. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and
potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 2005; 16: 3260–72.
3. Raffaghello L, Chiozzi P, Falzoni S et al. The P2X7 receptor sustains the growth of human neuroblastoma cells through a
substance P-dependent mechanism. Cancer Res 2006; 66; 907–14.
Regulation of astrocyte proliferation by P2Y and P2X purinergic receptors
Joseph T. Neary, Yuan Kang, and You-Fang Shi
Research Service, Miami VA Healthcare System, Departments of Pathology, Biochemistry & Molecular Biology,
and Neuroscience Program, University of Miami Miller School of Medicine, Miami, Florida 33125, USA
jneary@med.miami.edu
Extracellular ATP enhances the mitogenic activity of ﬁbroblast growth factor-2 (FGF2) in astrocytes
1, but the
molecular mechanism(s) and the P2 purinergic receptor type(s) involved are not well understood. As one
approach to determine whether the potentiating effect of extracellular ATP involves cell cycle control
mechanisms, we measured the expression of cyclins that are induced in different phases of the cell cycle in
primary cultures of rat cortical astrocytes
2. ATP potentiated the ability of FGF2 to stimulate expression of cyclin
D1, a regulator of cell cycle entry, as well as cyclin A, a regulator of DNA replication. The potentiating effect of
ATP on cyclin expression was attenuated by inhibiting activation of extracellular signal regulated protein kinase
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cyclin expression and mitogenesis whereas 2-methylthio ADP was ineffective, thereby suggesting a role for P2Y2
or P2Y4 receptors in the potentiation of astrocyte proliferation induced by FGF2. In contrast to the effect of
UTP, we found that an agonist of P2X receptors, 20,30-O-(4-benzoyl)benzoyl-ATP (BzATP), inhibited FGF2-
induced mitogenesis by 90%. This effect was not explained by a cytotoxic response to BzATP because at least
95% of astrocytes treated with BzATP remained viable. BzATP is an agonist of P2X7 as well as P2X1 and P2X3
receptors, but !,"-methylene ATP (in the media free of phenol red, an antagonist of P2X1 and P2X3 receptors
3)
did not inhibit FGF2-induced mitogenesis. In addition, dose-response studies demonstrated that 300 to 1000
micromolar ATP reduced the ability of FGF2 to stimulate DNA synthesis. These results indicate that P2X7
receptors mediate growth arrest in astrocytes. Consistent with opposing effects of P2Y and P2X receptors on
mitogenesis, UTP stimulated a transient activation of ERK whereas BzATP stimulated a more sustained ERK
signal. In addition, phospho-histone 3, a marker of mitosis during M phase of the cell cycle, was decreased by
BzATP whereas UTP increased levels of phospho-histone 3 induced by FGF2. Collectively, these ﬁndings suggest
that signaling by P2Y2/4 receptors enhance the ability of FGF2 to stimulate entry into a new cell cycle, DNA
replication and mitosis by an ERK-dependent mechanism, whereas signaling by P2X7 receptors inhibits FGF2-
induced mitogenesis in astrocytes and leads to growth arrest. Interactions between P2Y, P2X and polypeptide
growth factor signaling pathways may have important implications for CNS development as well as injury and
repair. [This work was supported by the National Institutes of Health (NS046651) and the Department of
Veterans Affairs.]
1. Neary JT, Whittemore SR, Zhu Q, Norenberg MD. Synergistic activation of DNA synthesis in astrocytes by ﬁbroblast
growth factors and extracellular ATP. J Neurochem 1994; 63: 490–4.
2. Neary JT, Kang Y, Shi YF. Cell cycle regulation of astrocytes by extracellular nucleotides and ﬁbroblast growth factor-2.
Purinergic Signaling 2005; 1: 329–36.
3. King BF, Liu M, Townsend-Nicholson A et al. Antagonism of ATP responses at P2X receptor subtypes by the pH indicator
dye, Phenol red. Br J Pharmacol 145: 313–22, 2005.
Targeting the A3 adenosine receptor to combat cancer and autoimmune
inﬂammatory diseases
Pnina Fishman, Avivit Ochaion, Shira Cohen, Faina Barer, and Sara Bar-Yehuda
Can-Fite BioPharma, Petach Tikva, Israel
CF101 is a small molecule adenosine derivative which binds speciﬁcally to the A3 adenosine receptor (A3AR).
The latter is abundantly expressed on the surface of cancer and inﬂammatory cells whereas only low expression
was found in normal cells. Activation of this receptor de-regulates key intracellular signaling pathways and
inhibits the proliferation of cancer and inﬂammatory cells. We have built a drug development platform around
this novel target and utilized synthetic A3AR agonists, with high afﬁnity to the receptor, to treat cancer and
inﬂammatory diseases.
CF101 inhibited the growth of melanoma, colon prostate and pancreatic carcinoma tumors in experimental
mice models when given daily orally. The molecular mechanism involves de-regulation of the Wnt and the NF-kB
signal transduction pathway, i.e., downregulation of PKA and PKB/Akt and up-regulation of GSK-3" which
subsequently phosphorylates "-catenin leading to its ubiquitination. As a result, a decrease in the level of the 2
cell cycle progression genes, cyclin D1 and c-Myc takes place.
CF101 inhibits the clinical and pathological manifestations of adjuvant induced arthritis in rats and collagen
induced arthritis in DBA mice. On the molecular level, CF101 deregulates the PI3K-PKB/Akt-NF-kB pathway
thus leading to the inhibition of TNF-! and the induction of apoptosis of inﬂammatory cells. CF101 also showed
efﬁcacy as a disease modiﬁer in additional experimental inﬂammatory models including colitis and multiple
sclerosis.
CF101 is an orally administered molecule with excellent safety proﬁle and speciﬁc activity against targeted
pathological cells. This molecule is being tested in several clinical trials, including an early PhII study in patients
42 Invited Lectureswith active rheumatoid arthritis. A recent interim analysis of this trial demonstrated provocative evidence of
therapeutic activity and an excellent safety proﬁle.
Pain and Nerve Transmission
Adenosine receptors in astrocytes, cytokines and neuroprotection
Knut Biber
Department of Medical Physiology, University Medical Center Groningen, University of Groningen, The
Netherlands
K.Biber@med.umcg.nl
High concentrations of adenosine are released in the brain under neuropathological conditions. Recent evidence
suggest that stimulation of adenosine (A1,A 2B or A3) receptors in glial cells induces the release of
neuroprotective substances, indicating that also adenosine receptors in glia cells contribute to adenosine-
dependent neuroprotection. The release of NGF in astrocytes for example is regulated by adenosine A1 receptor
activation, whereas other adenosine receptors are involved in astrocytic release of neuroprotective cytokines. We
have recently provided evidence that stimulation of adenosine A3 receptors in cultured astrocytes stimulates the
release of the neuroprotective chemokine CCL2 (formerly known as MCP-1). This is based on pharmacological
evidence since the selective adenosine A3 receptor agonist 2-chloro-N6-(3-iodobenzyl)-N-methyl-50-carbamoyla-
denosine (CL-IB-MECA) induced the release of CCL2, whereas speciﬁc ligands for adenosine A1 or A2 receptors
did not affect CCL2 release. Furthermore, CL-IB-MECA-induced CCL2 synthesis was inhibited by adenosine A3
receptor antagonists [4]. Earlier studies of our group have shown that stimulation of astrocytic adenosine A2B
receptor is instrumental for the release of IL-6, a cytokine with well-known neuroprotective properties [1, 2]. Thus
these data demonstrate that various adenosine receptor subtypes in astrocytes are responsible for the synthesis of
different neuroprotective agents. Since these receptor subtypes display different afﬁnities for adenosine it is
suggested that depending on the concentration of extracellular adenosine speciﬁc patterns of neuroprotective
substances are synthesized by astrocytes [3].
How cytokines like CCL2 or IL-6 protect neurons is not understood yet. We have recently obtained evidence
that might explain the neuroprotective properties of IL-6. It is presented here that IL-6 enhances expression and
function of neuronal adenosine A1 receptors in vitro and in vivo. It is therefore suggested that IL-6 increases
neuronal survival in vitro and in vivo by enhancing the function of neuronal adenosine A1 receptors, the brains
major protective system. The data presented here thus indicate a tight interplay between cytokines and the
adenosinergic system in astrocytes and neurons with major impact in neuroprotection.
1. Fiebich BL, Biber K, Gyufko K et al. J Neurochem 1996; 66: 1426–31.
2. Fiebich BL, Akundi RS, Biber K et al. Neurochem 2005; 46: 501–12.
3. Van Calker D, Biber K. Neurochem Res 2005; 30: 1205–17.
4. Wittendorp MC, Boddeke HWGM, Biber K. GLIA 2004; 46: 410–8.
Adenosine regulation of neurotrophin synaptic actions
Ana M. Sebastia ˜o, M. Jose ´ Dio ´genes, Paula I. Pousinha, Catarina C. Fernandes, Anto ´nio Pinto-Duarte,
Catarina A. Gomes, Sandra H. Vaz and J. Alexandre Ribeiro
Institute of Pharmacology and Neurosciences, Faculty of Medicine and Institute of Molecular Medicine, University
of Lisboa, Portugal
ATP and neurotrophins, in particular Brain Derived Neurotrophic factor (BDNF) have been implicated in
generation and modulation of pain (e.g. Coull et al., 2005 – Nature 438: 1017–21). In contrast, adenosine has
signiﬁcant potential for alleviating various types of pain (see e.g. Hayashida et al., 2005 – J Anesth 19: 225–35).
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out as one of the causes for BDNF-related development of persistent pain (Guo et al., 2006 – J Neurosci 26: 126–
37). BDNF-induced changes in synaptic activity and efﬁcacy also occur in other areas of the central nervous
system, including hippocampus (e.g. Braham and Messaoudi, 2005 – Prog Neurobiol 76: 99–125). Synaptic actions
of BDNF are facilitated by enhanced neuronal activity (see Nagappan and Lu, 2005 – Trends Neurosci 28: 464–
71), depolarization (Boulanger and Poo, 1996 – Nature Neurosci 2: 346–51) and cyclic AMP (Boulanger and Poo,
1996 – Science 284: 1982–4). Depolarization induces the release of adenosine (e.g. Latini and Pedata, 2001 – J.
Neurochem 79: 463–84) and enhanced neuronal activity facilitates adenosine A2A receptor mediated actions
(Correia-de-Sa ´ et al., 2000 – J. Neurochem 74: 2462–9). Since adenosine A2A receptors are coupled to cyclic AMP
and since activation of these receptors can induce transactivation of BDNF TrkB receptors (Lee and Chao, 2001 –
Proc Natl Acad Sci 98: 3555–60) we evaluated how activation of adenosine A2A receptors could inﬂuence synaptic
actions of BDNF.
We observed that A2A receptor activation by released adenosine is an essential pre-requisite to observe an
effect of BDNF upon excitatory synaptic transmission in the CA1 area of the hippocampus (Dio ´genes et al. 2004 –
J Neurosci 24: 2905–13). The BDNF-induced enhancement of the release of acetylcholine at the hippocampus
(Fernandes et al., Program No. 157.17. Abstract Viewer. SfN, 2005) and the BDNF-induced enhancement of
neuromuscular transmission at the innervated phrenic-diaphragm (Pousinha et al., 2006 – Br. J. Pharmacol, proc
sup, in the press) also require tonic activation of adenosine A2A receptors. Triggering BDNF actions by A2A
receptor activation involves cyclic AMP and protein kinase A (Dio ´genes et al., 2004). BDNF inhibits GABA
uptake from hippocampal nerve terminals but this action is independent of A2A receptor activation (Vaz et al., Br
J. Pharmacol, Proc suppl, in the press). In the striatum, another neurotrophin, glial cell line-derived neurotrophic
factor (GDNF) enhances the release of dopamine and this action is also modulated by A2A receptor activation
(Gomes et al. 2005, J. Neurochem., 94, Supl 2, 264).
The above results clearly show that A2A receptors trigger synaptic actions of neurotrophins. Whether A2A
receptors also facilitate BDNF-induced enhancement of pain mechanisms and whether A2A receptor mediated
inhibition of adenosine A1 receptor functioning (Cunha et al., 1994 – Brain Res 649: 208–16) and of A1 tonic
inhibitory actions (Pinto-Duarte et al., 2005 – J. Neurochem 93: 595–604) may inﬂuence adenosine actions on
pain, deserves further investigation.
Work supported by Fundac ¸a ˜o para a Cie ˆncia e Tecnologia, Portugal. BDNF was a gift by Regeneron.
Expression, function and modulation of P2X3 receptors on trigeminal ganglion
nociceptors
A. Nistri, E. Fabbretti, A. Fabbro, M. D_Arco, M. Simonetti and R. Giniatullin
Neurobiology Sector, International School for Advanced Studies (SISSA), Trieste, Italy
nistri@sissa.it.
Painful stimuli from head tissues are transmitted to the brainstem via certain populations of trigeminal ganglion
(TG) neuron. Such neurons can be activated by a wide range of signals which comprise locally released substances
like ATP, or acid pH, mechanical stimulation etc. In chronic pain states including migraine, it is suggested that
there is a process of sensitization of trigeminal neurons which become hyper-responsive to stimuli. In the attempt
to understand the molecular mechanisms responsible for chronic pain sensitization, we developed a primary
culture of rat or mouse TG neurons to test the role of various pain mediators over an extended time period.
Cultures were prepared from TGs of 2 week old animals and grown for 1–4 days in vitro without adding
exogenous NGF. The ﬁrst issue was to characterize the neuronal population in culture and to compare it with the
one normally found in ganglia in situ. The focus of this study was on ATP-sensitive P2X receptors and capsaicin-
sensitive TRPV1 receptors: both classes are important transducers of nociception on sensory neurons.
Rat or mouse "-tubulinIII positive neurons demonstrated good viability in vitro with <10% of them labeled
against the early markers of apoptosis JNK or activated caspase3. Neurons were predominantly of small and
medium diameter like those found in ganglia. Real time RT-PCR and Western blot analysis showed upregulation
of P2X3 and TRPV1 receptors in culture versus ganglia, while P2X2 ones were unchanged. The number of
neurons immunoreactive to P2X3 and TRPV1 receptors grew with more frequent co-localization. TRPV1
immunoreactivity was, however, comparatively low in mouse ganglia and cultures. Ca
2+ imaging and whole-cell
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response mediated by P2X3 receptor activity and antagonized by the selective blocker A-317491. More rat than
mouse neurons generated mixed responses indicative of more efﬁcient heteromerization of P2X3 and P2X2
subunits. We next tested if algogenic substances could modify P2X3 or TRPV1 receptors in culture. Twentyfour
h application of NGF (50 ng/ml) selectively upregulated P2X3 receptors without affecting TRPV1 receptors, while
10 2M serotonin application (24 h) largely potentiated TRPV1 function without changing P2X3 receptor activity.
These data show that TG cultures allow studying early adaptive changes of nociception-transducing receptors
including their selective modulation by algogenic substances. This work is supported by grants from Telethon
Foundation (GGP 04037) and MIUR (FIRB).
Functional consequences of P2X7 activation in astrocytes and microglial cells
F. Bianco, A. Colombo, R. Mele, M. Matteoli and C. Verderio
CNR-Institute of Neuroscience, University of Milano Department of Medical Pharmacology, Center of Excellence
on Neurodegenerative Diseases, Milano, Italy
c.verderio@in.cnr.it
Formation and shedding of vesicles from the plasmamembrane commonly occur in haematopoietic and immune
cells and represents a process whereby signal molecules are released into the microenvironment. We have recently
shown, in microglial cells, that ATP stimulation controls vesicle shedding through the activation of P2X7 receptors
and that shed vesicles represent a pathway for the release of the pro-inﬂammatory cytokine IL1-beta. Isolation of
shed vesicles, followed by IL-1 beta evaluation by a speciﬁc ELISA revealed the presence of the cytokine inside
the vesicular organelles and its subsequent efﬂux into the extracellular medium. Western blot analysis revealed
the presence of P2X7 receptors, pro- IL-1 beta and pro-caspase-1 in isolated vesicles, solubilized immediately after
isolation. Processed bands of both IL-1 beta and caspase-1 were detected in vesicles exposed 30 min to ATP
before lysis, suggesting that shed vesicles are the site of IL1-beta processing. ATP-binding cassette (ABC)
transporters, a large family of proteins whose role is to translocate various substances across biological
membranes, mediate the efﬂux of IL1-beta from shed vesicles, as cytokine release was suppressed by the general
ABC transporter inhibitor glibenclamide. Since shedding also occurs in resting microglia not expressing IL1-beta,
it may represent a cargo system for the release of other signalling molecules from these cells. For these reasons,
we are carrying out a biochemical characterization of isolated vesicles, to further characterize the protein
composition of shed vesicles and investigate the role and function of these organelles.
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Resident microglia exhibit ramiﬁed shapes in the normal brain, however, in response to pathological stimuli, they
transform rapidly themselves into more motile amoeboid form called activated microglia and migrate toward the
lesioned sites, where the accumulating microglia secret a variety of substances [1] to repair the tissues. Thus,
microglial cell migration is an important initial step of amelioration of the damaged nervous system.
Extracellular ATP is known to regulate physiological functions of microglia [2]. Microglia possesses both
ionotropic P2X receptors (P2X4R and P2X7R) and G-protein-coupled P2Y receptors (P2Y2R, P2Y6R and
P2Y12R). We previously showed that ATP induced membrane rufﬂing and chemotaxis of microglia and suggested
that the membrane rufﬂing is mediated by Gi/o-protein-coupled P2Y12R [3, 4]. We showed here that the ATP-
induced chemotaxis of microglia is also regulated by the ionotropic receptor, P2X4R in addition to the P2Y12R.
Stimulation of G-protein-coupled receptor lead to activation of phospholipase C (PLC) and phosphoinositide
3-kinase (PI3K). We examined the effect of PLC and PI3K inhibitors on the formation of membrane rufﬂing and
the chemotaxis of microglia following the stimulation by ATP. A PLC inhibitor inhibited both membrane rufﬂing
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These observations indicate that PLC activation is essential for both of the membrane rufﬂing and the chemotaxis,
while the activation of PI3K is necessary only for the chemotaxis. Phosphorylation of Akt, which is known to be a
downstream target of PI3K pathway, was enhanced by ATP stimulation. The increase in Akt phosphorylation was
suppressed by chelating extracellular calcium. These results indicate that activation of PI3K pathway is modulated
by the extracellular calcium inﬂux suggesting a possibility that ionotropic P2XRs are involved in the PI3K
activation. Therefore, we examined the effect of various P2XRs antagonists on the ATP-induced chemotaxis of
microglia. TNP-ATP signiﬁcantly inhibited the chemotaxis, but neither PPADS nor BBG were effective.
Furthermore, we constructed the lentivirus vector expressing short hairpin RNAi against P2X4R and introduced
the vector into microglia and showed that suppression of P2X4R reduced the ATP-induced chemotaxis of the
cells. These results clearly indicate that P2X4R in addition to P2Y12R are involved in the ATP-induced
chemotaxis of microglia.
1. Kreutzberg GW. Trends Neurosci 1996; 19: 312–8.
2. Inoue K. Glia 2002; 40; 156–63.
3. Honda S, Sasaki Y, Ohsawa K et al. J Neurosci 2001; 21: 1975–82.
4. Sasaki Y, Hoshi M, Akazawa C et al. Glia 2003; 44: 242–50.
P2X4-dependent neuropathic pain: A mechanism of the facilitation in pain
transmission via microglia
Kazuhide Inoue and Makoto Tsuda
Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu
University, 3-1-1 Maidashi, Higashi, Fukuoka 812-8582, Japan
inoue@phar.kyushu-u.ac.jp
There is abundant evidence that extracellular ATP and other nucleotides have an important role in pain signaling
at both the periphery and in the CNS. The focus of attention now is on the possibility that endogenous ATP and
its receptor system might be involved in neuropathic pain. Neuropathic pain is often a consequence of nerve
injury through surgery, bone compression, diabetes or infection. This type of pain can be so severe that even light
touching can be intensely painful; unfortunately, this state is generally resistant to currently available treatments.
We recently reported that the expression of P2X4 receptors in the spinal cord is enhanced in spinal microglia after
peripheral nerve injury, and blocking pharmacologically and suppressing molecularly P2X4 receptors produce a
reduction of the neuropathic pain behaviour (Nature 2003; 424: 778–83). More recently, we have reported that
brain-derived neurotrophic factor (BDNF) released from microglia by the stimulation of P2X4 causes the
depolarizing shift in reversal potential of anion in LI neurons of rats with nerve injury (Nature 438, 1017–21,
2005), resulting in causing neuropathic pain. Understanding the key roles of these ATP receptors may lead to new
strategies for the management of intractable chronic pain.
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The P2X7 receptor is unique in its ability to regulate the release of mature, biologically active interleukin-1" (IL-
1") [1]. We have demonstrated that in mice lacking this receptor, inﬂammatory and neuropathic hypersensitivity is
completely absent to both mechanical and thermal stimuli, but that normal nociceptive responses are preserved [2].
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spinal cord in microglial cells following nerve injury [3]. Whilst inhibition of P2X4 receptor expression by
antisense oligonucleotides has been shown to inhibit nerve-injury pain behaviour [3], the role of this receptor in
inﬂammatory pain, and its role in regulating inﬂammatory mediators has not been explored.
In this study, we describe the phenotypic characterization of P2X4 knockout animals (j/j) in inﬂammatory
pain, and preliminary characterization of inﬂammatory mediator regulation in these animals, and compare these
with phenotypic and cytokine characterization in P2X7 j/j animals to aid elucidation of the role these P2X
receptor subtypes play in pain.
A fully backcrossed colony of P2X4 j/j mice (n = 15 per group) was examined in the Freund_s complete
adjuvant (FCA) model of inﬂammatory hypersensitivity and compared with responses in P2X4 +/+ littermate
controls (n = 15 per group). 24 hrs following intraplantar injection of FCA, signiﬁcant mechanical hyperalgesia
was observed in the P2X4 +/+ animals, but no signiﬁcant hyperalgesia was observed in the P2X4 j/j cohort.
These data are similar to those observed in the P2X7 j/j animals [2], so a preliminary analysis of cytokine
expression proﬁle was performed in the P2X4 j/j animals to provide initial insight into commonality of
mechanisms between the two transgenic lines.
Following intraplantar FCA injection, analysis of paw samples from the P2X7 j/j animals revealed signiﬁcant
attenuation of FCA-induced increases in IL-1" and IL-10, but a signiﬁcant increase in IL-6 (see [2]). Conversely,
in the P2X4 j/j animals, there was no reduction in FCA-induced increases in IL-1", and an increase in
concentrations of IL-10.
Taken together, these data indicate the P2X4 j/j and P2X7 j/j animals share a common pain phenotype, but
this phenotype appears to be conferred via different mechanisms. Further studies are required to conﬁrm and
elucidate the mechanistic differences, and also to explore cross-talk between P2X4 and P2X7 in both transgenic
lines.
1. Perregaux DG, Gabel CA. J Biol Chem 1994; 269: 15195–203.
2. Chessell IP, Hatcher JP, Bountra C et al. Pain 2005; 114: 386–96.
3. Tsuda M, Shigemoto-Mogami Y, Koizumi S et al. Nature 2003; 424: 778–83
Round table on non-Adenine-Based Purines
Evidence for a patho-physiological and pharmacological role of guanine-based
purines as a new extracellular signalling system
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In addition to the adenine-based purinergic intercellular signaling systems, involving adenine, adenosine and
adenosine phosphates, over the last 15 years analogous guanine-based systems have been discovered. Most of
these are involved in Btrophic’’ effects, affecting the growth, differentiation and survival of various cells. Indeed,
guanine-based purines act synergistically with certain growth factors such as NGF, and also stimulate the
production and release from cells of several growth factors and cytokines. Guanine-based purinergic signaling has
been particularly investigated in cells of the nervous system and muscle. However, in addition other tissues,
including skin, respond to these compounds, indicating that, like adenine based purinergic signaling, guanine
based signaling may be widespread throughout many cell types and organs.
Guanine-based purines are released from cells, and when cells are damaged the release increases substantially.
Indeed, under conditions simulating ischemia, cells release more guanine-based purines than adenine based
purines. Moreover, the extracellular concentration of the guanine-based purines is higher than that of the
adenine-based counterparts.
There is evidence that in some cases guanosine produces its effects through entering cells and interacting with
an NGF-inducible protein kinase. But there is also evidence that guanosine may interact with unique receptors on
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of its effects. Moreover, guanosine is metabolized to guanine by the enzyme purine nucleoside phosphorylase
(PNP). Experimental studies have indicated that exogenous extracellular guanosine is relatively persistent
compared to adenosine, but a large proportion of guanosine is metabolized to guanine. Emerging evidence
indicates that guanine may also have its own extracellular signaling system that is distinct from guanosine.
Certainly, this would be of particular interest, since the enzyme that metabolizes guanine, guanine deaminase,
shows 50 fold regional variations in brain. This degree of regional variation is characteristically associated with
enzymes that degrade neurotransmitters.
It appears that the concept of intercellular signaling by guanine-based purines is now well substantiated. Since
GTP, guanosine and guanine have different biological effects, different receptive mechanisms and likely different
signal transduction mechanisms, it could be suggested the intriguing possibility that the extracellular
interconversion of these guanine derivatives provides an extra layer of signal regulation by cells.
Guanosine stimulates remyelination in injured spinal cord through promotion of
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The commonest type of spinal cord injury is a crush, which causes a central area of damage within the spinal cord,
disrupting long tract nerve ﬁbers passing up and down the spinal cord. Commonly, in the penumbra around the
injury some nerve ﬁbers survive, but the oligodendroglia that myelinate them die. Therefore these ﬁbers do not
conduct impulses, or do not conduct them well. However, the spinal cord contains endogenous precursors of the
myelin-forming oligodendroglia, which, under certain circumstances, can differentiate into mature oligodendrog-
lia and myelinate axons. This raises the possibility that after injury there is insufﬁcient signal to trigger the
differentiation of the oligodendroglial precursor cells into mature oligodendroglia that are capable of
remyelinating axons. Guanosine (GUO) stimulates proliferation and differentiation of many types of cells in
vitro and exerts neuroprotective effects in the central nervous system. Thirty ﬁve days after a standard moderate
crush injury rats have a chronic, stable, permanent neurological motor deﬁcit. We treated these rats with
intraperitoneal (i.p.) GUO, 8 mg/kg body weight/day for up to 14 days. Their motor function began to improve
after three days and continued to improve throughout the duration of the treatment. The improvement in motor
function correlated with the increase in myelination in the penumbra of the injury. The myelin was characteristic
of central nervous system myelin. The myelin arose from NG2-positive oligodendroglial precursor cells that
matured into myelin-forming oligodendroglia. These may contribute to the myelin-forming cells. We hypothesize
that the injury may Fprime_ the intrinsic adult pregenitor cells in the penumbra of the lesion to respond to
guanosine. Since GUO was administered systemically we questioned whether it acted directly on the nervous
system as GUO, or as a metabolic product, or whether it did not even enter the central nervous system but instead
exerted its effects by stimulating production of some peripheral hormone or cytokine. We used capillary
electrophoresis combined with the radioactivity measurement to evaluate the distribution and metabolism of
GUO (8 mg/Kg body weight), containing an aliquot (about 0.005% of the total GUO) of [3H]-GUO (7.3 Ci/
mmol) administered by i.p. injection. GUO entered lesioned areas of spinal cord to the same extent as the
remainder of the central nervous system. Over-basal exogenous GUO (eGUO) rapidly increased in plasma,
reaching 80% maximum after 7.5 minutes and peaked after 30 minutes, thereafter remaining constant for the next
hour. The amount of eGUO and its metabolite guanine (GUA) increased in the central nervous system and
adipose tissue. Fifteen minutes after injection the amount of cerebral GUO was nearly doubled in comparison
with basal value and the ratio of eGUO:eGUA was about 2:1, but after 60 minutes the eGUO:eGUA ratio was
<1. Meanwhile the total eGUO + eGUA continued to increase in brain, spinal cord and adipose tissue, but not in
other tissues, where it remained stable. These data indicate that systemically-administered GUO may certainly
stimulate oligodendroglial precursor cells. But as well, it raises the possibility that GUA may also play a role.
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Extracellular nucleotides and nucleosides trigger diverse immunomodulatory, prothrombotic and vasoactive
signaling events in the vasculature. The duration and magnitude of purinergic signaling are thought to be mainly
governed by ecto-nucleotidases expressed on endothelial and hematopoietic cells. In contrast to traditional
paradigms that focus on cell-associated inactivating mechanisms, the existence of alternative pathways has
received little attention. By using human vascular endothelial cells, normal and leukaemic lymphocytes, and cell-
free serum as enzyme sources, we identiﬁed the following three groups of cell surface-associated and soluble
activities: (1) nucleotide-inactivating enzymes, NTP diphosphohydrolase/CD39, nucleotide pyrophosphatase and
ecto-50-nucleotidase/CD73; (2) nucleotide-phosphorylating enzymes, adenylate kinase and nucleoside diphos-
phate kinase; (3) nucleoside-inactivating enzymes, adenosine deaminase and purine nucleoside phosphorylase.
Evidence for this was obtained by using independent assays, including bioluminescent measurement of ATP
metabolism, radio-TLC and reverse-phase HPLC analyses. The comparative measurements of enzymatic
activities indicated the predominance of the nucleotide-inactivating pathway on the endothelial cells, whereas
the lymphocytes are generally characterised by counteracting ATP-regenerating/nucleoside-eliminating pheno-
type. Next, given that ecto-adenylate kinase represents the only AMP-converting pathway on ecto-5-nucleotidase
negative leukaemic T- and B-lymphocytes, we employed this ectoenzyme as an intrinsic probe for accurate
’’sensing’’ ATP in the pericellular space. This novel enzyme-coupled approach, together with confocal imaging of
putative ATP stores, suggests that, along with predominant ATP accumulation within cytoplasmic granules,
micromolar concentrations of ATP are constitutively retained on lymphoid cell surface without signiﬁcant
convection into bulk milieu. In conclusion, identiﬁcation of the extensive network of enzymes directionally
regulating active cycling between ATP and other nucleotides and nucleosides provides a novel insight into the
purinergic homeostasis in the vasculature. Furthermore, the ability of lymphocytes to maintain micromolar ATP
halo may represent an important route initiating signaling cascades within immunological synapses and facilitating
leukocyte trafﬁcking between the blood and tissues.
The guanine-based purinergic system as a new target for neuroprotection against
glutamatergic excitotoxicity
Diogo O. Souza
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Glutamate is the main excitatory neurotransmitter in mammalian CNS, essential for brain activities, as those
involved in development, aging, memory, and adaptation to the environment. However, hyper-activation of the
glutamatergic system may be potentially neurotoxic, involved in the pathogenesis of various acute and chronic
brain injuries.
Our group has given strong evidence that the guanine-based purinergic system is effectively neuroprotective
against glutamate toxicity, in acute and chronic animal models, both in vitro and in vivo studies. Although the
administration of guanine derivatives (GD) exerts neuroprotection, our results strongly indicate that the active
compound is the nucleoside guanosine (GUO).
In in vivo studies carried out in rat and mouse, GD protect against brain damage caused by hyper-activation of
the glutamatergic system. Indeed: i) chronically, GMP administration in rat striatum protects cells against death
Invited Lectures 49caused by quinolinic acid (QA); ii) acutely, GMP or GUO i.c.v., i.p. or orally administered protect against
seizures induced by QA (or !-dendrotoxin). In in vitro studies carried out in brain slices, GUO protects cell
against death caused by in vitro ischemia.
Searching for mechanisms implicated in this neuroprotection, we demonstrated that: i) GUO stimulates the
astrocytic glutamate uptake (in astrocyte cultures and brain slices), the main process involved in endogenous
neuronal protection; ii) QA induced-seizures decrease glutamate uptake by cortical brain slices and this decrease
is reversed by GUO when it acts as anticonvulsant; iii) Brain ischemia decreases glutamate uptake by
hippocampal slices and i.p. GUO administration prevents this decrease. Thus we propose that the stimulatory
effect on glutamate uptake is involved in the neuroprotective actions of GUO.
These results encourage further studies aiming at the therapeutic use in humans of GUO in acute (hypoxia,
ischemia, brain traumatism) and chronic (neurodegenerative diseases) brain injuries involving glutamate
excitotoxicity.
The role of uridine kinase and uridine phosphorylase in the cross regulation of
uracil and adenine nucleotides salvage synthesis in rat and human brain
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A wealth of experimental data support the idea that uridine and its nucleotides (NT) have critical functions that
help regulating a variety of biological systems [1, 2]. In cultured cells the concentration of uridine (~3–8 2M) is
sufﬁcient to meet the pyrimidine requirement. At 12 2M the UTP pool doubles, and the de novo pyrimidine
synthesis is almost 100% inhibited, pointing for the importance of the nucleoside as a precursor in the pyrimidine
salvage pathway. In contrast, purines are salvaged from their bases. Both in bacteria and in mammals the
pathways for de novo pyrimidine and purine synthesis from simple precursors are cross regulated, i.e.
accumulation of a purine NT (ATP) activates pyrimidine synthesis and inhibits that of purines, and vice versa.
However, it is well established that several tissues and organs, including brain, rely more heavily in the salvage
synthesis of NT from preformed purine and pyrimidine rings, rather than on de novo synthesis. This raises the
following question: how do these districts maintain the right balance between their purine and pyrimidine pools?
Recent in vitro evidence suggests that in rat and human brain cytosol the two processes of purine and pyrimidine
NT salvage respond in an opposite manner to the ﬂuctuation of intracellular [purine nucleoside triphosphates]/
[pyrimidine nucleoside triphosphates] ratio (PUR/PYR ratio). The metabolic sensor is a two enzyme system,
composed of uridine kinase (Uk) and uridine phosphorylase (UPase), which contributes in maintaining uridine
homeostasis. When the activity of Uk becomes inhibited by relatively high UTP and CTP concentrations (low
PUR/PYR ratio), uridine accumulates and the equilibrium of the UPase reaction is shifted towards uridine
phosphorolysis [3]. The ribose1-P produced forms PRPP [4], an obligate substrate of purine salvage. At a high ratio
these effects are reversed. Uk is fully active, and pyrimidine salvage is favoured over purine salvage. Uridine might
therefore be considered as a signal of pyrimidine abundance and a ribose carrier for purine nucleotides salvage.
An additional factor which might contribute in balancing the purine and pyrimidine salvage processes is the
Boxypurine cycle,’’ in which hypoxanthine (or guanine) is converted to IMP (or GMP) by HPRT, at the expense
of PRPP. IMP (or GMP) is then dephosphorylated to inosine (or guanosine) by cN-II, and inosine (or guanosine)
is converted back to hypoxanthine (or guanine) and Rib 1-P by PNP [5]. We notice that both PRPP, the Bfuel’’ of
the cycle, and Rib 1-P, its main product, are essential in NT salvage synthesis. PRPP is an obligate precursor of
purine salvage, while the only known pathway for salvaging uracil is its Rib 1-P mediated ribosylation to give
uridine, followed by multiple phosphorylation steps. The observation that in vitro uracil is readily converted into
uridine in the presence of PRPP, provided hypoxanthine is present in the reaction mixture, led to the proposal that
Rib 1-P needed to ribosylate uracil might well arise from PRPP breakdown occurring in the oxypurine cycle [5].
1. Lo ¨fﬂer M, Fairbanks LD, Zameitat E, Marinaki AM, Simmonds HA. Trends Mol Med 2005; 11: 430–7.
2. Cao D, Leffert JJ, McCabe J, Kim B, Pizzorno G. J Biol Chem 2005; 280: 21169–75.
3. Tozzi MG, Camici M, Mascia L, Sgarrella F, Ipata PL. FEBS J 2006; in press.
4. Barsotti C, Tozzi MG, Ipata PL. J Biol Chem 2002; 277: 9865–9.
5. Barsotti C, Pesi R, Felice F, Ipata PL. Cell Mol Life Sci 2003; 60: 786–93.
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A growing evidence indicates that guanosine (GUO) exerts multiple neuroprotective activities. Indeed, it controls
glutamate-induced excitotoxicity; causes astrogliosis and activates oligodendroglial cell precursors; modulates
expression and function of some glial K
+,C l
j and water channels; stimulates ApoE production and cholesterol
efﬂux from astrocytes; enhances trophin production and exerts anti-apoptotic activity. These effects are not
substantially affected by cell pre-treatment with nucleoside and nucleobase transporter inhibitors, thus indicating
that they are due to the extracellular activity of GUO, likely mediated by speciﬁc plasma membrane receptor(s).
To correctly evaluate the effects caused by the extracellular GUO (eGUO) and to individuate receptor(s)
mediating these effects, it is crucial to know whether and how eGUO is metabolized and affects the breakdown
and the effects of the extracellular adenine-based purines.
We found that eGUO stimulates the efﬂux of purine and pyrimidine nucleotides from cultured glial cells and it
is well known that the purine/pyrimidine nucleotide ratio as well as the concentrations of ATP and Pi control the
activity of nucleotidases which play a pivotal role in the purine metabolism, especially in the nucleoside
formation. On the other hand, the receptor-mediated activity of released nucleotides as well as that of the de novo
formed nucleosides (especially adenosine) affect, in synergistic or, sometimes, in antagonistic manner, the effects
caused by eGUO. Indeed, eGUO up-regulates the expression of P2Y2 receptors thus amplifying the ATP and
UTP effects mediated by these receptors and extracellular adenosine, like eGUO, contributes, via A1 receptors,
to the production of trophic factors whereas it affects, in opposite manner, the apoptotic death of glial cells via A1
and A3 receptors, respectively.
Moreover, we individuated the presence of a purine nucleoside phosphorylase (PNP) on the external surface of
the plasma membranes of glial cells (ecto-PNP) which, in nature and in presence of Pi, catalyzes the
phosphorolysis of non adenine-based nucleosides (GUO and Inosine) thus producing the corresponding
nucleobases (guanine and hypoxanthine). In this context, we recently addressed our attention to establish
whether the ecto-PNP-mediated formation of purine nucleobases could also interfere with the effects caused by
the respective nucleosides, by especially evaluating (in cells provided or not provided with PNP) the possible
effects caused by extracellular guanine (eGUA) and by comparing them with those caused by eGUO, in the same
cells. We found that eGUO and eGUA, by different molecular mechanisms, affect cell proliferation/death/
apoptosis and learning/memory processes. In particular, eGUA (8 mg/kg orally administered) almost completely
counteracted the L-NAME-induced loss of memory in a passive avoidance task carried out in rats. Accordingly,
an exonic polymorphism in PNP gene (transition G/A at +3052 position), compatible with changes in GUA
formation, resulted to be coupled with a rapid and severe decay of cognitive activity (MMSE test) in patients with
clinical diagnosis of Alzheimer_s disease.
Ectonucleotidases Structure and Function
Contibution of NPP-type ectophosphodiesterases to extracellular nucleotide
metabolism
Mathieu Bollen
Division of Biochemistry, Faculty of Medicine, Catholic University of Leuven, B-3000 Leuven, Belgium
Invited Lectures 51The extracellular level of nucleotides is dynamically controlled by the action of ecto-nucleoside diphosphokinases,
ectoadenylate kinases and ectonucleotidases [1, 2]. There exist four structurally unrelated families of
ectonucleotidases, namely E-NTPDases, alkaline phosphatases, NPP-type ectophosphodiesterases and 5-
nucleotidase. The family of NPPs belongs to the superfamily of phospho-/sulfo-coordinating metalloenzymes
that all have a similar catalytic fold and action mechanism. The NPP-family consists of seven members but only
three of these, NPP1-3, are known to hydrolyse nucleotides. They are expressed as secreted (NPP2) or
transmembrane proteins (NPP1, NPP3). In addition to the catalytic domain, they contain one nuclease-like
domain and two somatomedin-B like domains, which are essential for the expression of catalytic activity.
The enzymatic action of NPP1-3 (in)directly results in the termination of nucleotide signaling, the salvage of
nucleotides and/or the generation of new messengers like ADP, adenosine or pyrophosphate [2]. NPP1 and NPP3
are only known to hydrolyze nucleotides but NPP2 also acts as an extracellylar lysophospholipase-D. The
simultaneous hydrolysis of lysophospholipids and nucleotides generates products that have the potential to
synergistically promote cell motility.
1. Stefan C, Jansen S, Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 2005; 30: 542–50.
2. Stefan C, Jansen S, Bollen M. Modulation of purinergic signalling by NPP-type ectophosphodiesterases. PUSI 2006; in press.
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My laboratory has studied aspects of several ecto-nucleotidases for more than a decade. Recently, we have
focused on three such proteins—two members of the human Nucleoside TriPhosphate Diphosphohydrolase
(NTPDase) family of nucleotidases, and one human Calcium Activated Nucleotidase (CAN) with homology to
the soluble nucleotidases used by insects to enable blood feeding by hydrolyzing host ADP.
The two NTPDases are NTPDase3, a cell surface, integral membrane protein, whose likely function is
modulation of purinergic signaling, and NTPDase6, which exists as a membrane-bound form in internal
membranes, but can also be secreted as a soluble form by cleavage of its N-terminal signal peptide. Studies on the
soluble NTPDase6 have included methods of expression and refolding, as well as disulﬁde bond determination,
and attempts to develop speciﬁc peptide inhibitors for the NTPDases using phage-display technology. Studies on
NTPDase3 have centered on mutagenic approaches to delineate residues and regions important for nucleotidase
activities and for oligomer formation and stability. We developed computational models for the 3-D structure of
the extracellular portions of the NTPDases, and have re-interpreted previous site-directed mutagenesis results
using these models. We also propose a speculative cartoon model for how movements in the transmembrane
domains of cell-surface NTPDases (demonstrated by Dr. Guidotti_s group) might be linked to movements in the
active site lobes of the 3-D model, mediated via several conserved proline residues near the juncture of the
extracellular and transmembrane domains. The extracellular active site lobes predicted by the 3-D models are
postulated to undergo hinge-like movements based on the homology of NTPDases with the actin superfamily of
proteins, which exhibit butterﬂy-like domain movements.
Brain is one of the few tissues where NTPDase3 is relatively abundantly expressed. Therefore, we
immunolocalized NTPDase3 in adult rat brain, and found it to be associated with neurons and mostly limited
to midline regions of the forebrain and midbrain. Based on co-localization with hypocretin-1/orexin-A cells and
ﬁbers in the hypothalamus, we hypothesize that NTPDase3 may modulate feeding and sleep-wake behaviors
under purinergic control in this brain region.
A crystal structure of soluble human Calcium Activated Nucleotidase (CAN) has been published. However, we
are investigating the possibility of multiple structural and functional roles for Ca
2+ in this calcium-binding
nucleotidase, as well as studying the newly discovered Ca
2+-dependent dimerization that occurs in this human
CAN.
This work was supported by NIH grants HL59915 and HL72882.
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CD39 is anchored to the plasma membrane by two transmembrane domains, one at each end of the protein.
Removal of either or both transmembrane domains or disruption of their native state by detergent solubilization
reduces activity by 90%, indicating that native function requires both transmembrane domains to be present and
in the membrane. The transmembrane domains are also involved in dimerization of CD39. Here we report the
results of experiments on the oligomeric state of CD39 in the plasma membrane of COS7 cells. We also
investigate the interactions between the transmembrane domains of CD39 by mutation of selected residues
analyzed by yeast selection, by disulﬁde crosslinking of cysteines introduced within the transmembrane helices
and by manipulation of the lipid bilayer. The results indicate that the principal interactions between the
transmembrane domains are intramolecular, that the helices are highly mobile, and that these dynamic motions
are required for enzymatic activity and regulated by the status of the lipid bilayer.
Ecto-ATPases and Metabolism
Co-ordinated regulation of P2-receptor signaling by membrane bound
NTPDases
J. Se ´vigny, F. Ben Yebdri, M. Fausther, G. Kauffenstein, F. Kukulski, E.G. Lavoie, J. Lecka, S.A. Le ´vesque,
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Through the activation of different and speciﬁc P2-receptors, extracellular nucleotides (ATP, ADP, UTP, UDP)
regulate a variety of biological functions. The concentrations of these molecules are tightly regulated at the cell
surface by ectonucleotidases. The most important family of enzymes that dephosphorylate ATP and other
extracellular nucleotides are the members 1, 2 ,3 and 8 of the ecto-nucleoside triphosphate diphosphohydrolase
(E-NTPDase) family. These enzymes sequentially hydrolyze the terminal phosphate residue of triphospho- and
diphosphonucleosides, and, in conjunction with ecto-50-nucleotidase, facilitates the formation of adenosine,
another important biological messenger. NTPDases 1,2,3 and 8 differ in their catalytic abilities to dephosphorylate
nucleotides, as for example ATP. Using this substrate, NTPDase1 gives a rapid accumulation of AMP with little
formation of ADP. In contrast, NTPDase2 hydrolyzes poorly the diphosphonucleoside derivative and
accumulates it in its immediate environment. To give further options to the cells to tightly regulate nucleotide
levels, NTPDases 3 and 8 generate a transient accumulation of ADP (a potent ecto-50-nucleotidase inhibitor) with
a late formation of AMP (the substrate of ecto-50-nucleotidase).
These enzymatic properties are certainly of importance in the deﬁnition of functions of NTPDases. Another
important parameter in the identiﬁcation of functions is the cellular localization. With a set of antibodies that we
have developed, we observed that NTPDase1 is mainly located on vascular endothelium, smooth muscles, as well
as on macrophages. A number of experiments clearly demonstrated the function of NTPDase1 in platelet
aggregation and thromboregulation. With mice deﬁcient in NTPDase1 expression, preliminary data suggest a
function of the enzyme in vascular smooth muscle cell contraction. Other recent data suggest that monocytic
NTPDase1 may be involved in inﬂammation and cytokine secretion such as IL-8. NTPDase2 is localized to the
adventitia of large blood vessels and on the external surface of some capillaries, in nerve structures, and in portal
ﬁbroblasts where a function in the control of cell proliferation has been proposed. NTPDase3 have been recently
localized to neurons by Dr. T.L. Kirley and co-workers. We have also observed high expression of the enzyme in
Invited Lectures 53few epithelia of the digestive system as well as in Langerhans islet cells of the pancreas. Finally, we have
demonstrated that NTPDase8 is the long known liver canalicular ecto-ATPase.
Localization of these ectonucleotidases in different cells and tissue compartments suggests distinct roles of
these enzymes. In this presentation, I will discuss about the characterization and function of plasma membrane
bound NTPDases, namely NTPDase1,2,3 and 8.
Ecto-50-nucleotidase (CD73) and mucosal inﬂammation
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Sites of inﬂammation are characterized by signiﬁcant shifts in metabolic activity1. Shifts in energy supply and
demand can result in diminished delivery and/or availability of oxygen, leading to inﬂammation-associated tissue
hypoxia and metabolic acidosis. These shifts in tissue metabolism, as indicated by previous studies, are frequently
associated with vasculitis and profound recruitment of inﬂammatory cell types, particularly myeloid cells such as
neutrophils (PMN) and monocytes. Under such conditions, we and others have observed activation of the global
hypoxia regulatory transcription factor hypoxia-inducible factor (HIF). A signiﬁcant HIF target gene during
mucosal inﬂammatory disease (e.g. inﬂammatory bowel disease, colitis) is CD732. Previous studies have
determined that CD73 is regulated by HIF at the gene promoter level3. Since tissue proﬁling studies revealed
highest expression of CD73 in mucosal tissues, particularly the intestine4, we have addressed the role of CD73 in
model inﬂammatory disease in vitro and in vivo. Studies using intestinal epithelial cells have revealed that high
expression of CD73 is protective for a number of epithelial properties (e.g. barrier function, ion transport), likely
through generation of adenosine at the epithelial apical surface. Inﬂammatory studies in mice conditionally
lacking the alpha subunit of HIF-1 in intestinal epithelial cells have shown that the loss of functional HIF-1
correlates with decreased expression of CD73 and enhanced inﬂammatory disease in these mice. More recent
studies have addressed the role of CD73 colitic disease progression. These ongoing studies have revealed that the
induction of colitis increases epithelial expression of CD73 mRNA and activity during the acute phase colitic
disease. Studies utilizing Cd73-null mice4 have revealed that relative that the loss of CD73 correlated with more
severe clinical symptoms of colitis (weight loss, colon length), and increased levels of inﬂammatory markers
(neutrophil numbers). Mechanisms of increased susceptibility with decreased CD73 will be discussed. Taken
together, these studies provide unique insight into tissue microenvironmental changes during model inﬂammatory
disease and identify CD73 as a critical control point during mucosal insult.
1. Karhausen J, Haase VH, Colgan SP. Inﬂammatory Hypoxia: Role of Hypoxia-Inducible Factor. Cell Cycle 2005; 4: 256–8.
2. Karhausen JO, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is
protective in murine experimental colitis. J Clin Invest 2004; 114: 1098–106.
3. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP.
Ecto-50-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 (HIF-1) mediates permeability changes in intestinal
epithelia. J Clin Invest 2002; 110: 993–1002.
4. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP. Crucial role for ecto-50-
nucleotidase (CD73) in vascular leak during hypoxia. J Exp Med 2004; 200: 1395–405.
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On the basis of primary sequence alignments it is clear that the bacterial 50-nucleotidases (50-NT) are related to
the vertebrate ecto-50-nucleotidases. The bacterial enzymes are present as monomers, whereas the ecto-enzymes
form homodimers. A crystal structure is available for E. coli 50-NT [1]. The enzyme consists of two domains: The
N-terminal domain (residues 25–342) binds two metal ions and contains an Asp-His dyad, which are important for
the catalytic activity. This domain is related to other known enzyme structures of the calcineurin superfamily of
dimetal phosphoesterases. The C-terminal domain (residues 362–550) has a unique structure, which has so far not
been found in other protein structures. This domain provides the binding site for the adenosine moiety of the
substrate. Thus, the active site is located between the two domains.
In the crystal structures, the protein has been characterised in two conformations, which differ in the relative
orientation of the two domains [2]. The domain movement can be described as a rotation of the C-terminal domain
around an axis, which passes through the center of the C-terminal domain. A rotation of up to 96- is necessary for
the change between the inactive open and the active closed conformation. The domain rotation is necessary for the
catalytic action of the enzyme, presumably to allow for substrate binding and product release [3, 4].
A sequence alignment of E. coli 50-NT and the mammalian ecto-enzymes shows that both domains are
conserved and a homology model can be built for ecto-50-NT [5]. The ligands for the two catalytic metal ions are
all conserved in ecto-50-NT with the exception of M1-ligand Gln254 which corresponds to Asn245 in ecto-50-NT. It
appears unlikely that the shorter side chain supports metal coordination of Asn245, but the Asn245 carboxamide
group may bind a water molecule which is coordinated to M1. Structures of E. coli 50-NT in complex with the
substrate analogue inhibitor !,"-methylene-ADP revealed the characteristics of the substrate binding pocket of
the C-terminal domain. A central feature is the hydrophobic stacking interaction of the adenine moiety, which is
sandwiched between two phenylalanine side chains. The N1 nitrogen of the adenine ring is recognized by the
carboxamide group of Asn431. The ribose group of the nucleotide is bound by Asp504, the backbone oxygen of
Gly458 and Arg410.
Of these residues, the two phenylalanines are conserved in the ecto-enzymes or in electric ray 50-NT are
replaced by a tyrosine, which should also support the stacking interaction. Asn431 is replaced by a glycine residue.
There is no other side chain nearby in the model which could replace the asparagine. Most likely, a water
molecule interacts with N1 of the adenine ring. The aspartate residue bound to the hydroxyl groups of the ribose
is conserved, as well as two of the three arginines. Arg375 of the E. coli enzyme is replaced by a serine. Thus, from
the differences in the substrate binding site it is not obvious how the stronger substrate speciﬁcity of the
mammalian enzymes towards AMP (vs. ADP and ATP) is achieved.
1. Kno ¨fel T, Stra ¨ter N. Nat Struct Biol 1999; 6: 448–51.
2. Kno ¨fel T, Stra ¨ter N. J Mol Biol 2001; 309: 255–66.
3. Schultz-Heienbrok R, Maier T, Stra ¨ter N. Biochemistry 2005; 44: 2244–52.
4. Schultz-Heienbrok R, Maier T, Stra ¨ter N. Protein Science 2004; 13: 1811–22.
5. Stra ¨ter N. Purinergic Signalling 2006, in press.
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The mechanisms that regulate tissue calciﬁcation are of fundamental importance, as they ensure that ossiﬁcation
proceeds normally in the skeleton while pathological or ectopic calciﬁcation is prevented elsewhere in the body.
Alterations in these regulatory mechanisms, either due to genetic defects or as a result of aging, lead to disease,
such as the development of vascular calciﬁcation and osteoarthritis. Vascular calciﬁcation is a common occurrence
in aging, atherosclerosis, diabetes, renal failure, aortic stenosis and prosthetic valve replacement. Osteoarthritis
refers collectively to a number of disease states that affect the properties and functionality of the joints. Our work
has shown that mice deﬁcient in the nucleoside triphosphate pyrophosphohydrolase-1 (NPP1) isozyme (Enpp1
j/j
mice) or in the Ankylosis protein (ank/ank mutant mice) both have a deﬁcit in inorganic pyrophosphate (PPi)
production. PPi is a potent mineralization inhibitor and both these mutant mice share phenotypic features of soft-
tissue ossiﬁcation, corrected by simultaneous deletion of the tissue-nonspeciﬁc alkaline phosphatase (TNAP) gene
(Akp2
j/j)
1. Simultaneous inactivation of the Akp2 gene in Enpp1
j/j and ank/ank mutant mice led to
normalization of inorganic pyrophosphate (PPi) levels, which in turn led to the normalization of depressed
osteopontin (OPN) levels and importantly, correction of their calciﬁcation abnormalities [2, 3]. Enpp1
j/j and
ank/ank mice also display arterial calciﬁcation similar to that seen in human patients with mutations in the NPP1
gene. Mice deﬁcient in matrix Gla protein (Mgp
j/j) mice are also characterized by ectopic calciﬁcation of all
arteries in addition to bone abnormalities. When crossed to the Hyp Bhypophosphatemic’’ mice, Mgp
j/j mice
never developed arterial calciﬁcation and had a normal life span [4]. Similarly, [ank/ank; Hyp] double mutant
mice had a normal life span, as opposed to ank/ank mice that usually die around 6 months of age. Also, injection
of PPi into Mgp
j/j mice corrected their arterial calciﬁcation and normalized their life span. These results indicate
that lowering the extracellular Pi/PPi ratio is sufﬁcient to prevent the appearance of an osteoarthritis-like




j/j] mice has suggested that OPN may in fact be a more important mineralization inhibitor
than PPi, and that the effects of modulating PPi levels are carried out by the changes in OPN levels [5]. Our work
currently focuses on developing therapeutic drugs to target the function of TNAP and NPP1 as a strategy to
normalize the extracellular Pi/PPi levels and prevent/correct ectopic calciﬁcation. Funded by grants DE 12880 and
AR 47908 from the National Institutes of Health, USA.
1. Hessle L, Johnsson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Milla ´n JL. Proc Natl Acad Sci USA
2002; 99: 9445–9.
2. Johnson K, Goding J, Van Etten D, Sali A, Hu S-I, Farley D, Krug H, Hessle L, Milla ´n JL, Terkeltaub R. J Bone Miner Res
2003; 18: 994–1004.
3. Harmey D, Hessle L, Narisawa S, Johnson K, Terkeltaub R, Milla ´n JL. Am J Pathol 2004; 164: 1199–209.
4. Murshed M, Harmey D, Milla ´n JL, McKee MD, Karsenty G. Broadly expressed genes accounts for the special restriction of
ECM mineralization to bone. Genes Dev 2005; 19: 1093–104.
5. Harmey D, Johnson K, Hoylaerts MF, Noda M, Terkeltaub R, Milla ´n JL. Elevated osteopontin levels contribute to the
hypophosphatasia phenotype in Akp2
j/j mice. J Bone Miner Res submitted 2005.
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A2a adenosine receptors regulate CNS responses to ethanol and addicting
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Very high levels of Gs(olf)-coupled A2a adenosine receptors (A2a) are found in the nucleus accumbens (NAcb),
a mesolimbic brain reward region involved in alcoholism and addiction. Ethanol inhibits adenosine re-uptake and
increases extracellular adenosine levels, thereby activating A2a receptors. Activation of A2a receptors promotes
stimulation of adenylyl cyclase (AC) and cAMP/PKA signaling. In the NAcb, A2a receptor expression occurs
postsynaptically on the same neurons expressing Gi-coupled D2 dopamine (D2), mu opioid (MOR) and
cannabinoid (CB1) receptors. All of these receptors are involved in addiction. Activation Gi-coupled receptors
for 30 min. ordinarily inhibits cAMP production. By contrast, we show that a 10 min. activation of Gi-receptors
involved in addictive behaviors acts synergistically with A2a adenosine receptors to stimulate cAMP/PKA
signaling and induction of CRE-mediated gene expression. In all instances, synergy is mediated by free
Gi_betagamma subunit stimulation of AC II and IV. Synergistic stimulation of cAMP production requires A2a
adenosine receptors. Importantly, knockdown or inhibition of the betagamma/cAMP signaling pathway prevents
synergy in primary NAcb neurons and eliminates addictive behaviors. Relapse is the most serious complication of
addiction that prevents effective medical treatment of human addicts. In rats, A2a receptor antagonists
administered directly into the NAcb or indirectly by i.p. injection reduces voluntary ethanol drinking and
eliminates reinstatement of heroin-seeking behavior in rats. These ﬁndings in a rodent model of human relapse
suggest that A2a adenosine receptor antagonists may be useful therapeutic agents in the treatment of alcoholism
and addiction. (Supported by grants from NIAAA and the Department of the Army).
Adenosine A2A receptors and Parkinson_s disease – Effects of Istradefylline on
functional models of Parkinson_s disease
Tomoyuki Kanda, PhD.
Department of CNS Research, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd.
Currently, dopamine replacement therapy is most effective treatment for the motor symptoms of Parkinson_s
disease(PD) [1]. However, its association with the development of motor complications such as dyskinesia and
wearing-off phenomenon, limits its usefulness in late stages of the PD [2]. Adenosine A2A receptors are
abundantly localized to the indirect striato-pallidal output pathway, which is one of two major striatal output
pathwayscontroling motor behavior via basalganglia network. Istradefylline is a novel selective adenosine A2A
receptor antagonist currently in Phase III clinical trials in PD. The results from Phase II clinical trials has
demonstrated that the coumpaund provided a clinically meaningful reduction in OFF time and an increased ON
time with non-troublesome dyskinesia in the L-dopa treated patients with motor complications [3].
In PD, loss of dopaminergic neurons in substantia nigra causes imbalance in neuronal activity between the
indirect strato-pallidal and direct striato-nigral pathways by loss of dopaminergic inﬂuences onto striatal medium
spiny neurons gerenrating each pathway. This imbalance induces entire abnormality of basal ganglia network,
resulting in abnormal movements (i.e., hypokinetic motor control). It has been demonstrated that the adenosine
A2A receptor activation causesinduces excessive activation of the indirect striato-pallidal pathway via the dual
modulation in the striatum and globus palidus [4]. Therefore, blockade of the A2A receptors should decrease such
an excessive excitability of the indirect pathway and alleviated the motor symptoms of PD. The results from
studies in animal models of PD have demonstrated that istradefylline increases locomotor activity and decreases
motor disabilities without inducing involuntary movements in animals rendered dyskinetic by previous exposure
Invited Lectures 57to L-dopa [5]. In MPTP treated non-human primate(marmoset) models of PD, istradefylline was administered
with a low dose of L-dopa for 21 days to animals primed to exhibit dyskinesia. The amplitude of involuntary
movements observed was not greater than that produced by L-dopa alone in MPTP treated marmosets. In
addtion, istradefylline shows signiﬁcant reduction of L-dopa induced dyskinesias compared with L-dopa alone [6].
Results of studies on animal models of PD indicate that istradefylline did not exacerbate L-dopa-induced
dyskinesia, and suggested that chronic coadministration of istradefylline with L-dopa may decrease dyskinesias
caused by L-dopa. The results from functional models, providing relevance to clinical study outcomes in PD
patients, described that adenosine A2A antagonists appear to be most promising as the ﬁrst major non-
dopaminergic therapy for PD.
1. Bonuccelli U. Curr Opin Neurol 2003; 16(Suppl. 1): S13–9.
2. (a) Olanow CW Ann Rev Med 2004; 55: 41–60. (b) Rascul O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc
JL. Ann Neurol 2003; 53(Suppl. 3): S3–S12.
3. (a) Chase TN, Bibbiani F, Bara_Jimenez W, Dimitrova T, Oh-Lee JD. Neurology 2003; 61(Suppl. 6): S107–S111. (b) LeWitt
PA, Parkinson Relat Disord 2005; 11(Supple. 2): 266.
4. (a) Mori A, Shindou T. Neurology 2003; 61 (Suppl. 6): S44–S48. (b) Agnati LF, Ferre S, Lluis C, Franco R, Fuxe K.
Pharmacol Rev 2003; 55: 509–50.
5. Kase H, Neurology 2003; 61 (Suppl. 6): S97–S100.
6. Kanda T, Tashiro T, Shiozaki S. manuscript in preparation.
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The adenosine A2A receptor (A2AR) has recently emerged as a leading non-dopaminergic therapeutic target for
Parkinson_s disease for its ability to regulate motor activity. Furthermore, A2ARs inﬂuence brain injury outcome
in variety of neurological disease models, presumably through modulation of glutamate release. Using forebrain
neuronal-speciﬁc A2AR knockout (KO) mice, we here provide the ﬁrst direct evidence that A2AR-mediated
control of motor function and neuroprotection involve distinct cellular mechanisms. By crossing the ﬂoxed A2AR
mice with the CaMKII-Cre transgenic line, we selectively depleted A2AR mRNA and protein in forebrain
neurons to the background level of the global A2AR KO mice, as demonstrated by in situ hybridization,
immunochemistry and receptor binding assays. This genetic deletion of A2ARs in forebrain neurons abolished the
psychomotor effect of the A2AR selective agonist CGS21680 and antagonist KW-6002 and of the non-selective
antagonist caffeine, and largely attenuated the pyschostimulant effect of cocaine. This demonstrates the key role
of forebrain neuronal A2ARs in the modulation of psychomotor activity. In contrast, genetic deletion of the A2AR
in forebrain neurons did not confer protection against ischemic brain injury by middle cerebral arterial occlusion
or against MPTP-induced dopaminergic neurotoxicity, despite abolishing CGS21680-mediated presynaptic
facilitation of glutamate release in forebrain A2AR KO mice. Furthermore, intracerebral ventricular
administration of KW-6002 into forebrain A2AR KO mice reinstated neuroprotection against MPTP
neurotoxicity. These results provide the clearest data yet that A2AR activity in forebrain neurons is critical to
control psychomotor activity, but not for neuroprotection against brain injury, indicating that A2ARs modulate
motor activity and brain damage by distinct cellular mechanisms. This opens up the new possibility of selectively
manipulating A2AR_s motor and neuroprotective effects by targeting different cellular elements.
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Huntington_s disease (HD) is an autosomal dominant neurodegenerative disease characterized by chorea,
dementia, and psychiatric symptoms. The causative mutation is a CAG trinucleotide expansion in exon 1 of the
Huntingtin (Htt) gene. The normal Htt gene has 35 or fewer repeats in the N-terminal region, whereas the
appearance of neurological symptoms is associated with 36 or more CAG repeats in the Htt gene. Among all
brain areas, neurons within the striatum and cortex are most susceptible to HD. Besides the well-characterized
neurological deﬁcits, metabolic abnormalities have also been reported in HD. In addition to the brain, formation
of Htt aggregates has also been documented in peripheral tissues including the liver. Several rodent models based
on chemical lesions of the striatum or genetic manipulations of the Htt gene have been established and
extensively used to develop beneﬁcial treatments for HD. Among the four adenosine receptors, the A1 and A2A
adenosine receptors have been suggested as potential drug targets in HD. Using an HD transgenic mouse model
(R6/2), we found that daily administration of an A2A adenosine receptor-selective agonist (CGS21680, CGS)
delayed the progressive deterioration of motor performance and prevented a reduction in brain weight. 3D-2MRI
analysis revealed that CGS reversed the enlarged ventricle-to-brain ratio of R6/2 mice, with particular
improvements in the left and right ventricles.
1H-MRS showed that CGS signiﬁcantly reduced the increased
choline levels in the striatum. Immunohistochemical analyses further demonstrated that CGS reduced the size of
ubiquitin-positive neuronal intranuclear inclusions (NIIs) in the striatum of R6/2 mice and amended mutant Htt
aggregation in a striatal progenitor cell line overexpressing mutant Htt with expanded polyQ. Moreover, chronic
CGS treatment also ameliorated the formation of Htt aggregates and the decrease in two protein chaperones in
the liver. Collectively, the above ﬁndings support the potential use of adenosine-related agents for treating HD.
Adenosine receptor-receptor interactions: Relevance for ischemia and caffeine
tolerance
Rafael Franco, Sergi Ferre ´, Rodrigo Cunha, Vicent Casado ´, Carmen Lluis, Francisco Ciruela
Molecular Neurobiology Unit. Institut d"Investigacions Biome `diques August Pi i Sunyer (IDIBAPS). University of
Barcelona. Diagonal 645. 08028 Barcelona
rfranco@ub.edu
Of the four known adenosine receptors (A1,A 2A,A 2B and A3), adenosine A1 receptors (A1Rs) and adenosine
A2A receptors (A2ARs) are primarily responsible for the central effects of adenosine. In addition to their
postsynaptic location in different brain regions, A1R and A2AR can be found presynaptically, where they
modulate neurotransmitter release. A1Ra n dA 2AR are coupled to Gi/o and Gs/olf proteins, respectively.
Presynaptic A1Rs are the prototype of G protein-coupled receptors whose stimulation decreases the probability
of neurotransmitter release. On the other hand, presynaptic A2ARs are mostly excitatory and their stimulation
induces neurotransmitter release. In this presentation evidence for heteromerization of A1 and A2A receptors is
provided. This heteromerization have physiological consequences as described below.
Previous studies have provided evidence for colocalization and functional antagonistic interactions between
A1Rs and A2ARs that modulate glutamate release in the striatum and hippocampus. A similar kind of interaction
has been suggested to exist in the terminals of striatal cholinergic interneurons, although the localization and
functional signiﬁcance of A2AR in striatal cholinergic neurons is controversial. The coexistence of both
stimulatory A2ARs and inhibitory A1Rs in the same terminal is intriguing particularly in view of their opposite
functional effects.
Invited Lectures 59A1R and A2AR form A1R-A2AR heteromers in transfected cells and in striatal glutamatergic nerve terminals.
A1R-A2AR heteromerization plays a role in controlling the afﬁnity of A1Ra n dA 2AR for agonists and
antagonists, like caffeine. Functional studies show that A1R-A2AR heteromers are responsible for a strong A1R-
A2AR antagonistic cross_talk. The strength of this cross-talk would depend on the concentration of extracellular
adenosine, which is enhanced in ischemia. Tolerance to caffeine can be explained by the occurrence of A1R-A2AR
heteromers. Heteromerization of receptors for a given neurotransmitter or neuromodulator constitutes a novel
way to regulate presynaptic neurotransmission.
Part of the results in this presentation will be published in 2006: Ciruela et al., J Neurosc. In the press.
Ectonucleotidases Physiological Implication
Biphasic regulation of airway E-NTPDases by Pseudomonas Aeruginosa
lipopolysaccharide
Maryse Picher
1 and Lauranell H. Burch
2
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Chronic obstructive lung diseases are characterized by the inability to prevent bacterial infection causing
recurrent inﬂammatory responses, epithelial damage and loss of lung function. In the past decade, numerous
studies have demonstrated the importance of extracellular nucleotides for bacterial clearance. Their binding to P2
receptors on airway epithelia stimulates mucus secretion, cilia beating activity and hydration of the airway surface
liquid layer. On the other hand, abnormally-high ATP levels resulting from damaged epithelia and bacterial lysis
may cause lung edema and exacerbate inﬂammation-related epithelial damage. This study demonstrates the
importance of ecto nucleoside triphosphate diphosphohydrolases (E-NTPDases; ATP Y ADP Y AMP) for the
regulation of P2 receptor-mediated airway functions and identiﬁes the mechanisms regulating their activities in
lung diseases. All experiments were conducted on polarized primary cultures of human bronchial epithelial cells
maintained at air-liquid interface. The E-NTPDase inhibitor, azide, reduced the metabolism of UTP and UDP by
45% and 55%, respectively. Chronic lung diseases, including cystic ﬁbrosis (CF) and primary ciliary dyskinesia
(PCD), exhibited 4–6 fold higher rates of nucleotide elimination and azide-sensitive E-NTPDase activities. The
mechanisms regulating these ectonucleotidases (NTPDase 1 and NTPDase 3) under pathological conditions were
ﬁrst studied using the common lung pathogen, Pseudomonas aeruginosa lipopolysaccharide (LPS). Bronchial
cultures exposed to an optimum (30 ng/ml) endotoxin concentration displayed a biphasic response characterized
by an acute reduction in total activity (<8 h) followed by chronic (24 h) increases in activity, NTPDase 1 and 3
expression. P. aeruginosa LPS induces several acute responses from airway epithelia, including oxidative stress,
lipid peroxidation and inﬂammation. Bronchial cultures were exposed (2 h) on the mucosal surface to LPS (30 ng/
ml) or TNF! (10 ng/ml) in the absence/presence of bilateral scavengers of peroxide (catalase) or superoxide
radicals (superoxide dismutase; SOD). Although total azide-sensitive NTPDase activity was reduced by acute
exposures to LPS or TNF!, ebselen-sensitive NTPDase 3 activity was increased 3-fold while NTPDase 1 activity
was completely inhibited. Normal activity levels were partially restored by the scavengers (catalase > SOD). The
contribution of inﬂammatory pathways was demonstrated by the protective effect of the anti-inﬂammatory
cytokine, IFN+, and by SN50, cell permeable peptide preventing the translocation of the pro-inﬂammatory
transcription factor, NFkB, to the nucleus. Altogether, these results suggest that NTPDase 1 and NTPDase 3 are
co-expressed on human airway epithelia. Their opposite regulation by acute insults supports different roles in
airway homeostasis. In contrast, elevated E-NTPDase activities in chronic lung diseases may represent an attempt
to prevent P2 receptor desensitization and nucleotide-mediated lung damage.
This study was supported by the Cystic Fibrosis Foundation (Picher 05G0)
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The plasma membrane of human cells hosts a relatively large number (~5%) of molecules acting as enzymes
apparently operating in an anti-economical manner. Nucleotide-metabolizing ectoenzymes constitute a family
within this larger family and are represented by a set of molecules involved in the catabolism and scavenging of
extracellular nucleotides. This process results in the synthesis of compounds that play a critical role in cell
homeostasis and metabolism, suggesting that the physiological role of this complex family goes beyond the simple
recycling of nucleotides.
In this context, the story behind the CD38 gene family (CD38 and CD157) is representative of a more general
trend involving several nucleotide-metabolizing ectoenzymes, such as CD39 and CD26. Indeed, human CD38 is
the mammalian prototype of a family of phylogenetically conserved proteins which share structural similarities
and enzymatic activities involved in the production of an intracellular second messenger with calcium mobilizing
effects. Engagement of CD38 by agonistic monoclonal antibodies and the CD31 ligand initiates a cytoplasmic
signaling cascade involving tyrosine phosphorylation of the proto-oncogene c-cbl and of the extracellular
regulated kinase 1/2 complex. Further requirements for signal transduction include a privileged localization within
the cholesterol-rich areas of the plasma membrane and physical association with specialized surface receptors.
CD38-mediated signals are crucial in heterotypic cell adhesion and migration as well as in the activation of
proliferation / survival programs by normal and neoplastic cells. A direct role in the pathogenesis of diseases is
also suggested by the involvement of CD38 in directing the prognosis of chronic lymphocytic leukemia. Further
studies concerning the association between the CD38 gene family and human diseases will provide a better insight
into the biological functions of the complex family of receptors and enzymes.
Ectoenzymes of CD38 and CD39 gene families catalyze immunomodulation
Silvia Deaglio
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CD39 [ENTPD1 (ecto nucleoside triphosphate diphosphohydrolase-1), EC 3.6.1.5] is a member of a family of
ecto-nucleotidases, surface molecules with extracellular catalytic sites that hydrolyze nucleotides. CD39 is the rate
limiting enzyme that hydrolyses ATP/UTP and ADP/UDP to AMP; AMP is then rapidly degraded to adenosine
by soluble or membrane-bound 50-nucleotidase such as the ubiquitous CD73 (EC 3.1.3.5). This family of
nucleotide-metabolizing ectoenzymes also includes molecules for which a clear-cut role in lymphocyte activation
has been extensively proven, such as CD26 and CD38. Speciﬁcally, experience gathered with the CD38 gene
family has clearly shown a non-redundant role in leukocyte trafﬁcking and migration to inﬂammatory sites.
Further, human disease models such as chronic lymphocytic leukemia, have highlighted a crucial receptor-like
role for CD38 in controlling proliferation and survival signals to normal and neoplastic lymphocytes.
Little is known on the role of CD39 in lymphocyte activation. Preliminary data indicates that the enzymatic
functions controlled by CD39 are involved in the recruitment, activation and polarization of naı ¨ve T cells by
Langherhan_s dendritic cells. We have now expanded these observations by exploring CD39 expression and the
functional role within quiescent and activated T cell subsets. Our data indicate that CD39 efﬁciently distinguishes
Treg from other resting or activated T cells in humans and mice. Furthermore, CD39 serves as an integral
component of the suppressive machinery of Treg, acting, at least in part, through the modulation of extracellular
levels of adenosine. We show that the coordinated regulation of CD39 expression and of the adenosine receptor
A2A activates an immuno-inhibitory network that regulates Th1 responses. The in vivo relevance of this network
Invited Lectures 61is manifest in the phenotype of Cd39 null mice. These mice spontaneously develop autoimmune diseases
associated with heightened Th1 responses. These data conﬁrm the potential of CD39 as a phylogenetically
conserved marker of Treg that has immunomodulatory functions.
Finally, these results may also be read in the wider context of a network of ectoenzymes acting in synergy to
scavenge nucleotides and to generate powerful mediators of immune responses. Further work will be needed to
determine the functional interactions between this complex family of cell surface enzymes.
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We have recently reported that mice with targeted deletion of ecto-50-nucleotidase/CD73 are characterized by
reduced coronary ﬂow, enhanced platelet activation and increased adherence of monocytes to the endothelium. In
the present study we have investigated the molecular mechanisms by which this proinﬂammatory response is
mediated and explored whether CD73-derived adenosine modulates neointima formation in an acute injury
model and inhibits development of arteriosclerosis in ApoE/CD73j/j double mutants.
CD73
-/- mice exibit increased luminal staining for vascular adhesion molecule (VCAM)-1 in carotid arteries
and increased expression of VCAM-1 transcripts and protein in whole carotid lysates. Endothelial cells cultured
from CD73
-/- show an up-regulation of mRNA and protein expression of VCAM-1, which was associated with in
creased nuclear factor (NF)-kB activity. Measurement of expression of the A1,A 2a,A 2b and A3 receptor by
RTPCR in the aorta and freshly harvested aortic endothelial cells revealed substantial downregulation the A1
receptor (20% of control) while the other adenosine receptors remained unchanged. Ex-vivo perfusion of carotid
arteries show that the incresed monocyte arrest in carotid arteries of CD73
-/- is mediated by !4"1 integrin. After
wire-induced injury of the carotid artery, CD73 expression was upregulated in WT mice, while neointima
formation and macrophage content was increased in CD73
-/- mice, concomitant with elevated NF-kB activation,
luminal VCAM-1 expression and soluble VCAM-1 concentration. Treatment of mice with the speciﬁc A2a recetor
agonist ATL-146e reversed the increased VCAM-1 transcript and protein expression in CD73
-/-derived
endothelial cells. Most importantly, ATL-145e fully prevented wire-induced neointima formation in CD73
-/- mice.
To explore whether CD73-derived adenosine also modulates chronic inﬂammation we have generated ApoE/
CD73-/- double mutants and found in 6 month old animals kept on normal diet, that the development of
arteriosclerotic lesions in the aorta was 2.5 fold higher compared with ApoE controls. Measurement of various
cytokines in plasma substantiate the increased inﬂammatory state in the double knockout.
Our data demonstrate that CD73-derived adenosine through activation of A2a recetors protects against
vascular inﬂammation, monocyte recruitment and neointima formation. This adenosine is also important in
limiting the progression of arteriosclerosis.
Platelets
Congenital and drug-induced P2Y12 defects in the clinical setting
Marco Cattaneo
Unita ` di Ematologia e Trombosi, Ospedale San Paolo, Dipartimento di Medicina, Chirurgia e Odontoiatria,
Universita ` di Milano, Milano, Italy
marco.cattaneo@unimi.it
P2Y12 plays an important role in platelet function. It mediates ADP-induced platelet aggregation and ampliﬁes
platelet secretion induced by release-inducing platelet agonists. Congenital defects of the platelet P2Y12 receptor
is characterized by mild/moderate bleeding tendency. Six patients with congenital P2Y12 defect, belonging to ﬁve
62 Invited Lectureskindred, have been described so far. Five patients had severe deﬁciency of the protein, while one expressed
normal number of dysfunctional P2Y12 receptors on his platelets. P2Y12 is important in the pathogenesis of
arterial thrombosis, since substances inhibiting its function are potent antithrombotic drugs. The thienopyridines
ticlopidone and clopidogrel, which irreversibly inactivate the receptor, dramatically decrease the incidence of
arterial thrombosis in patients at risk. The extent of inhibition by clopidogrel (and ticlopidine) of ADP-mediated
platelet responses varies widely among individuals, and insufﬁcient inhibition has been called Bclopidogrel
resistance’’. Both ticlopidine and clopidogrel are a pro-drugs, which need to be metabolized by the liver to their
active metabolites with anti-aggregating activity. Therefore, their pharmacological effects can be detected only
some time after their ﬁrst administration and, more importantly, the plasma levels of the active metabolites, and,
consequently, the degree of inhibition of platelet aggregation induced by ADP, vary widely among subjects. In
published studies, about 50% of the patients were either clopidogrel non responders or low responders. Inter-
individual variability in platelet inhibition by clopidogrel correlated well with the metabolic activity of the hepatic
cytochrome P450, which activates the pro-drug to its active metabolite. Interference with clopidogrel metabolism
by other drugs that are frequently given to patients with atherosclerosis, such as atorvastatin, can increase the
number of patients who are resistant to clopidogrel, although this is still a controversial issue. A more recent
thienopyridine, prasugrel, is currently under study. Preliminary data suggest that it may accomplish a greater
inhibition of platelet aggregation than ticlopidine and clopidogrel and that the interindividual variability in
response may be less marked. Cangrelor and AZD6140 are direct antagoinists of the platelet P2Y12 receptor.
Both are currently under further clinical investigation.
P2Y1 and P2X1 as targets for new antiplatelet agents
C. Gachet
INSERM U311, EFS-Alsace, University Louis Pasteur, Strasbourg, France
christian.gachet@efs-alsace.fr
ADP and ATP play a key role in normal haemostasis as well as in arterial thrombosis where platelet activation is
pivotal. Upon activation, the nucleotides are released from the so-called dense granules, and stimulate three
separate P2 receptors, the ATP-gated P2X1 cation channel and the two ADP receptors P2Y1 and P2Y12. The
P2X1 receptor is involved in platelet shape change, activation by collagen and thrombus formation under high
shear. The P2Y1 receptor initiates platelet aggregation through mobilisation of intracellular calcium stores while
the P2Y12 receptor ampliﬁes the responses to all agonists and stabilizes the aggregates. Among the platelet P2
receptors, the P2Y12 receptor is the molecular target of the efﬁcient antiplatelet drug clopidogrel and several
competitive antagonists which are under clinical evaluation. Its expression seems to be limited to the
megakaryocytic lineage although several other cell types have been shown to express P2Y12 transcripts. It is
thus a well established target for antiplatelet drugs. Less is known concerning the P2X1 and the P2Y1 receptors
which are broadly expressed in many tissues. However, studies in knock-out mice and experimental thrombosis
models using selective antagonists have shown that both the P2X1 and the P2Y1 receptors are potential targets for
new antithrombotic drugs.
P2Y1 deﬁcient mice display increased resistance to thromboembolism induced either by a mixture of collagen and
adrenaline or by tissue factor. Moreover, IV administration to mice of the P2Y1 antagonists MRS2179 or
MRS2500 similarly results in prolongation of the bleeding time, inhibition of ex vivo platelet aggregation to ADP
and resistance to thromboembolism. Models of localized arterial thrombosis have also been used to further
evaluate the P2Y1 receptor as a target for antiplatelet therapy. In a model of superfusion of ferric chloride to
induce injury of mesenteric arterioles and intravital microscopy examination it could be shown that P2Y1
inhibition was as efﬁcient as P2Y12 inhibition. Interestingly, the treatment of P2Y1 deﬁcient mice by clopidogrel
resulted in additive inhibition of thrombosis, suggesting that a combination of drugs targeting both P2Y1 and
P2Y12 could be of beneﬁt. A second model of localized arterial thrombosis consists in laser injury of mesenteric
arterioles. In this case, P2Y1 deﬁcient mice or MRS2500 treated mice again displayed reduced thrombosis as
compared to the wild type but to a lesser extend as compared to mice treated with maximal doses of clopidogrel.
Again, the combination of MRS2500 with clopidogrel resulted in additive inhibition of thrombosis. P2X1 deﬁcient
mice similarly display resistance to all these experimental thrombosis models, including systemic thromboembo-
Invited Lectures 63lism and localized thrombosis. Moreover, the suramin analog NF449 which displays some selectivity for P2X1 as
been shown to reduce thrombosis in vivo.
Altogether, these results indicate that both P2Y1 and P2X1 are potential targets for new antiplatelet compounds,
which should be evaluated now in experimental thrombosis in higher animals.
1. Gachet C. Annu Rev Pharmacol Toxicol 2006
2. Le ´on et al., J Clin Invest 1999
3. Le ´on et al., Circulation 2001
4. Hechler et al., J Exp Med 2003
5. Lenain et al., J Thromb Haemost 2003
6. Hechler et al., JPET 2005
7. Hechler et al., JPET 2006
Purinoceptor-evoked signalling via P2X1 and other ion channels in the platelet
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The role of ion channels in platelet function has proven difﬁcult to investigate due to the challenge of conducting
direct electrophysiological recordings from these small and fragile cell fragments. As the megakaryocyte must
generate most, if not all proteins of the anuclear platelet, the giant precursor cell provides a useful means to study
the regulation and identity of platelet ion channels. Indeed, using confocal ﬂuorescence imaging of ﬁbrinogen
binding to murine megakaryocytes, we show that ADP-evoked activation of !IIb"3 requires co-stimulation of P2Y1
and P2Y12 receptors as is well established in platelets. Under whole-cell patch clamp, hexokinase-puriﬁed ADP
stimulated multiple phases of inward currents, which conduct both Na
+ and Ca
2+ into the cell. All currents were
dependent upon the presence of P2Y1 receptors, although P2Y12 receptors played a synergistic role through a PI
3-kinase-dependent pathway. The main conductance showed both early transient and delayed sustained phases,
which mirrored the intracellular Ca
2+ increase. In addition, P2X1 receptor currents appeared as multiple transient
currents, indicating that ATP secretion stimulates this non-selective cation channel in a repetitive, focal manner.
Transient receptor potential (TRP) ion channels represent candidates for the direct P2Y receptor-dependent
current and screening by RT-PCR from individually selected megakaryocytes indicates that TRPC6 is the
dominant message amongst the TRPs known to be stimulated by phospholipase-C activity. To examine the
relative role of P2X1 receptors as an autocrine pathway for Ca
2+ inﬂux in human platelets, we established
pharmacological conditions that selectively block this pathway (NF449 or !,"meATP predesensitisation). Multiple
platelet agonists utilised the P2X1 receptor as a major pathway by which they increase [Ca
2+]i. The maximal
reduction of peak [Ca
2+]i increases following P2X1 inhibition was 48.3 T 1.3%, 75.5 T 8.8%, 65.3 T 3.1% and 30.9 T
6.6% for thrombin (0.03 Uml
j1), collagen (0.5 2gm l
j1), U46619 (thromboxane A2 analogue, 1.0 2M) and ADP
(30 2M), respectively. We conclude that P2X1 receptors represent an important and widespread means of
elevating Ca
2+ in the platelet but that P2Y1/12 receptors stimulate another non-selective cation channel, most
likely TRPC6, with a role in ADP-evoked Ca
2+ inﬂux.
Supported by the British Heart Foundation, Wellcome Trust and Medical Research Council
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Cardiovascular ATP release: Focus on the red blood cell
David Erlinge
Department of Cardiology, Lund University, Sweden
Previous studies have demonstrated that nucleotides can be released from various sources in the cardiovascular
system such as platelets, sympathetic nerves, endothelial cells and cardiomyocytes. We have focused on the
regulation of nucleotide release in man, and the possible clinical implications.
ATP is released from red blood cells (RBC) when intracellular cAMP levels are increased in response to
reductions in oxygen tension and pH. The released ATP then binds to P2Y receptors on the endothelium and
stimulates vasodilatation. Because blood consists of approximately 40% RBCs, containing a 1000-fold higher ATP
concentration than plasma (mM vs. 2M), even a minor release of ATP from the high intracellular concentrations
could have major circulatory effects and may need to be regulated. We found that the ATP degradation product
ADP inhibits ATP release by acting on P2Y13 receptors that inhibit cAMP in the RBC [1]. This negative feedback
system could be important in the control of plasma ATP levels and tissue circulation. The ﬁrst selective P2Y13
antagonist MRS2211, blocked the ADP induced inhibition of ATP release in micromolar concentrations, giving us
a tool to evaluate the importance of P2Y13 negative feedback pathway for circulatory control.
Nucleotide release in the heart comes from both cardiac myocytes and endothelial cells, but the RBC may also
be an important source. In patients with acute myocardial infarction, we found that both ATP and UTP are
released and may have effect on cardiac function and coronary ﬂow [2]. The ATP receptor P2Y11, the UTP
receptor P2Y2 and the UDP receptor P2Y6 are expressed in human myocardium and mediate inotropic effects [2,
3]. The prominent increase in blood ﬂow following ischemia (reactive hyperemia) is to a major part mediated by
ADP acting on endothelial P2Y1 receptors [4].
In the peripheral vasculature we found that purines and pyrimidines may provide a link between glucose and
diabetic microvascular disease [5]. High glucose induced NFAT activation in cerebral microvessels by a
mechanism totally blocked by apyrase and by 50% by the P2Y6 receptor blocker MRS2578, indicating that the
vascular growth factors ATP, UTP and UDP are released in response to high glucose and may stimulate
intracellular reactions associated with microvascular disease.Inﬂammation in the atherosclerotic plaque is
important for destabilisation and plaque rupture that is the major cause of myocardial infarction. We have
indirect evidence that ATP is released in the plaque. The common Ala-87-Thr polymorphism of the ATP receptor
P2Y11 that is present in one ﬁfth of the population was examined in 1200 patients with myocardial infarction and
2400 controls and markedly increased the risk of myocardial infarction, especially for early myocardial infarction
and patients with family history. Interestingly, the inﬂammatory marker C-reactive protein was signiﬁcantly
increased in carriers of the Ala-87-Thr polymorphism, indicating an inﬂammatory mechanism.
In conclusion, purines and pyrimidines seem to be released and involved in most aspects of human
cardiovascular pathophysiology.
1. Wang et al. Circ Res 2005.
2. Wihlborg et al. Circ Res 2006.
3. Balogh et al. J Mol Cell Card 2005.
4. Olivecrona et al. Purinergic Sign 2005.
5. Nilsson et al. ATVB 2005.
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endothelium- derived vasoconstrictive factor’’
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Beyond serving as a mechanical barrier, the endothelium shows important regulatory functions. The discovery of
nitric oxide (NO) revolutionized our understanding of vasoregulation. In contrast, the identity of endothelial-
derived vasoconstrictive factors (EDCFs) remains unclear. The supernatant obtained from mechanically
stimulated human endothelial cells obtained from dermal vessels elicited a vasoconstrictive response in an
isolated perfused rat kidney. Endothelial-derived vasoconstriction in the isolated perfused rat kidney was
decreased by a purinoceptor blocker more than by an endothelin receptor blocker. The nucleotide, uridine
adenosine tetraphosphate (Up4A) was isolated from the supernatant of stimulated human endothelium and
identiﬁed by mass spectrometry. Up4A most likely exerts vasoconstriction predominantly via P2X1 receptors, and
probably also via P2Y2 and P2Y4 receptors. In healthy subjects Up4A plasma concentrations are found which
cause vasoconstriction. Stimulation with adenosine 50-triphosphate (ATP), uridine 50-triphosphate (UTP),
acetylcholine, endothelin, A23187 and mechanical stress release Up4A from endothelium, suggesting that Up4A
contributes to vascular autoregulation. Up4A is the ﬁrst dinucleotide containing both purine and pyrimidine
moieties isolated from living organisms. We conclude that Up4A is a novel potent non-peptidic EDCF. Its
vasoactive effects, plasma concentrations and its release upon endothelial stimulation strongly suggest that Up4A
has a functional vasoregulatory role.
P2Y and P2X receptors and their role in exocrine pancreas
Ivana Novak
August Krogh Building, Institute of Molecular Biology and Physiology, University of Copenhagen, Copenhagen,
Denmark
inovak@aki.ku.ak
The exocrine pancreas secretes digestive enzymes and ﬂuid rich in HCO3
- and poor in Ca
2+. These secretions
originate from acini and ducts in response to classical secretagogues cholecystokinin and secretin. The function of
these epithelia needs to be coordinated, such that digestive enzymes are not prematurely activated or that calcium
stones do not form. We propose that along the acini-duct axis ATP and other components of the purinergic
cascade mediate short-term regulation of secretion. The following ﬁndings lay the basis for these proposals. Acini
release ATP into the interstitium and most importantly into the lumen leading to pancreatic ducts [1]. The initial
ATP concentrations are in the high miromolar range, but since secretion also contains speciﬁc nucleotidases,
CD39 and CD73, these would regulate concentration of nucleotides/nucleosides along the ductal tree [2].
Acini themselves are relatively poor in functional P2 receptors. In contrast, pancreatic ducts, which secrete
HCO3
–rich ﬂuid, express several types of functional P2 receptors on the luminal and basolateral membranes [3].
On cellular level, P2X4 and P2X7 receptors stimulate Na
+ and Ca
2+ inﬂux, but seem to be without prominent
effects on Cl
- and H
+/H C O 3
j transport usually associated with ﬂuid secretion [3, 4]. However, possibly via
ERK1/ERK2 signalling pathways, they could be modulators of secretion. Initial studies on mice stimulated with
pilocarpine in vivo indicate that exocrine gland function is affected in P2X7 knockout animals.
Pancreatic ducts also express metabotrophic P2Y2 and P2Y4 receptors, which in many epithelia, including
human pancreatic duct cell lines, can stimulate Ca
2+ activated Cl
j channels [5]. In native rat pancreatic ducts,
patch-clamp experiments indicated inhibition of K
+ conductance [3]. In a recent study we found that pancreatic
ducts expresses Ca
2+ activated K
+ channels of a big conductance (BK, maxi-K
+ channels) and intermediate
conductance (IK). We used the oocytes expression and electophysiological recordings to study the interaction
between individual P2Y receptors and Ca
2+-activated K
+ channels. The most interesting result was that
stimulation of P2Y2 receptors inhibited BK [6]. Thus, as in the native epithelium, P2Y2 receptors inhibit BK,
which would down-regulate secretion, possibly preventing over-distension of the duct. In summary, elucidation of
66 Invited LecturesP2X and P2Y receptor regulated processes in pancreatic ducts will provide a better understanding of epithelial
secretion in health and disease, such as in cystic ﬁbrosis.
The projects were supported by the Danish Medical and Science Research Councils and the Lundbeck
Foundation.
1. Sørensen CE, Novak I. J Biol Chem 2001; 276: 329525–32.
2. Yegutkin GG, Jalkanen S, Novak I. this volume
3. Hede SE, Amstrup J, Christoffersen BC, Novak I, J Biol Chem 1999; 274: 31784–91.
4. Henriksen, K. L. and I. Novak. Cell.Physiol.Biochem. 2003;13: 93–102.
5. Lazarowski ER, Boucher RC, Harden TK, Mol Pharmacol 2003; 64: 785–95.
6. Hede SE, Amstrup J, Klaerke DA, Novak I. Pﬂu ¨gers Arch Eur J Physiol 2005; 450: 429–36.
Purinergic signalling triggers development of the eye
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Allosteric activators of glucokinase: The development of cyclopropane-derived
agents and their potential for use in the treatment of type two diabetes
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The glucose-sensing enzyme glucokinase (GK) plays a key role in glucose metabolism. A member of the
hexokinase family, it catalyzes the ﬁrst step in glycolysis, phosphorylation of glucose to glucose 6-phosphate. It is a
unique hexokinase in that it has a low afﬁnity for glucose, demonstrates non-Michaelis-Menten kinetics and
displays no inhibition by the product of the reaction [1]. These particular features make GK an ideal sensor of
physiological changes in blood glucose levels, translating them into changes in the metabolic status of the cell.We
report here the effects of a novel small molecule glucokinase activator, LY2121260, which enhances GK activity
via binding to an allosteric site located in the hinge region of the enzyme [2]. We discuss the affect of LY2121260
on the glucose afﬁnity of the enzyme and the velocity of the reaction, and present crystallographic data that
support its mechanism of action. We show that LY2121260 stimulates insulin secretion in pancreatic a ˆ-cells and
increases glucose use in rat hepatocytes in a glucose-dependent manner. Furthermore, animals treated with
LY2121260 show an improved glucose tolerance following an oral glucose challenge. We also describe some
structure-activity studies within this class of GK activators. Our results support the concept that GK activators
increase both insulin secretion and hepatic glucose use and in doing so may prove to be effective agents for the









1. Matschinsky FM. Diabetes 1996; 45(2): 223–41.
2. Efanov AM et al. Endocrinology 2005; 146(9): 3696–701.
Beyond purinergic receptors: Drugging the rest of the purine-binding proteome
S. Hall, A. Barabasz, T. Barta, J. Daw, L. Dubois, J. Eaves, P. Fadden, B. Foley, T. Freed, L. Geng, G.
Hanson, K. Hardemann, L. Hinkley, M. Jenks, M. Hu, K. Huang, M. Lewis, L. Liu, W. Ma, J. Otto, J.
Partridge, B. Pronk, J. Rice, A. Scott, M. Silinski, P. Steed, J. Veal, K. Verleysen, R. Ware, and T.
Wadkins
Serenex, Inc. 323 Foster Street, Durham, NC, 27701 USA
shall@serenex.com
Purinergic receptors represent an attractive class of druggable targets within the purine-binding proteome, yet
there are many other enzyme families of interest as therapeutic targets within this large superfamily. We estimate
that the purine-binding proteome contains at least 2000 members, with kinases composing the largest
fraction(25%) of this group. We report here a novel approach to screen hundreds of these targets in parallel,
thus providing an efﬁcient way to probe compound libraries as ligands to a broad variety of enzyme classes. We
constructed and screened a targeted library of 8000 compounds using a novel afﬁnity displacement assay (referred
to as proteome mining). Multiple tissues were used as the source of native purine-binding proteins to proﬁle this
library. Hits were obtained for nearly 100 targets, including well validated targets such as dihydrofolate reductase
and multiple kinases (e.g. CDK2, Her2, PDK1, AurA), and less well-validated targets such as the kinases Fer and
Nek9. Importantly, the method also provided afﬁnity information on potential toxicity targets (e.g. phosphorylase
kinase, pyruvate carboxylase, glucose-6-phosphate dehydrogenase). Thus, this approach provides primary target
afﬁnity information as well as selectivity data across the entire purine-binding proteome. In addition, afﬁnities of
compounds for their protein targets could be determined directly from the same assay and these measurements
were sufﬁciently quantitative and reproducible to drive the development of structure-activity relationships.
Unexpectedly, selectivity within a gene family was not predictive of selectivity between gene families across the
purine-binding proteome. The application of this screening approach to four diverse targets, dihydrofolate
reductase, Hsp90, quinone reductase 2, and PI3kinase will be described. In each case, the use of the afﬁnity
displacement assay enabled the identiﬁcation of novel, selective, orally active compounds. Taken together, these
results support the use of proteome mining as both an alternative to single target biochemical screens and as a
tool to drive SAR development.
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Challenges and Opportunities in the Identiﬁcation of Insulin-like Growth
Factor-I Receptor Kinase Inhibitors
C. Garcı ´a-Echeverrı ´a, M.A. Pearson, T. Meyer, J. Mestan, J. Zimmermann, J. Brueggen, H.-G.
Capraro, R. Cozens, D.B. Evans, D. Fabbro, P. Furet, D. Graus Porta, J. Liebetanz, G. Martiny-Baron,
S. Ruetz, S. Jacob, and F. Hofmann
Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
carlos.garcia-echeverria@novartis.com
The Insulin-like Growth Factor-I Receptor (IGF-IR) is a member of the insulin receptor family of tyrosine kinases.
Thistransmembrane-spanningproteiniscomposedoftwo!-andtwo"-subunitslinkedbydisulﬁdebonds.Whilethe
!-subunits are extracellular, the "-subunits span the plasma membrane and encompass an intracellular tyrosine
kinase domain devoted to the initiation of several signal transduction cascades. Signaling through IGF-IR is
initiated upon binding of the cognate ligand—Insulin-like growth factor-I (IGF-I) or II (IGF-II)—to the
extracellular domain of the receptor. It is thought that this peptide-protein interaction induces a conformational
change that results in auto-transphosphorylation of each "-subunit at speciﬁc tyrosine residues within the
intracellular kinase domain and outside the catalytic domain. Activation of the receptor triggers, through docking
and/or phosphorylation of several transduction molecules (e.g., IRS-1, IRS-2 or Shc), results in activation of
downstream signaling pathways, of which the Ras/Raf/MAPK pathway is primarily responsible for mitogenesis, and
the survival PI3K/PKB pathway appears to play a major role in mediating the IGF-IR biological functions.
A broad range of experimental studies have revealed that IGF-IR function is implicated in most of the
hallmarks of cancer, but it is probably the anti-apoptotic activity of this receptor that makes its kinase activity an
attractive therapeutic target in anti-cancer drug discovery. In this context, the identiﬁcation of speciﬁc low-
molecular mass inhibitors of IGF-IR has proven to be a major challenge for medicinal chemistry due to the high
sequence identity at the kinase domains of IGF-IR and InsR (around 84%) and, in particular, at the ATP-binding
pocket (100% sequence identity). Selectivity over the InsR is a critical requirement for any IGF-IR kinase
inhibitor to avoid disturbing glucose homeostasis. This presentation will cover the identiﬁcation and
characterization of a new series of IGF-IR kinase inhibitors. When used alone or in combination with cytotoxic
agents, the synthetic IGF-IR kinase inhibitors suppress tumor growth and prolongs survival of mice with diffuse
bone lesions of multiple myeloma. These preclinical ﬁndings and additional studies support the potential
application of targeted therapeutic strategies directed at IGF-IR in combination with established antitumor
modalities or for the treatment of IGFs-responsive neoplasias. Moreover, the selectivity achieved at the cellular
level with these IGF-IR inhibitors suggest conformation differences between the native forms of IGF-IR and InsR
-from the unactivated to the fully activated form—that can effectively be exploited for drug discovery.
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Protein kinases contribute to a diverse number of cellular processes and are the second most important group of
drug targets after G-protein-coupled receptors. Moreover, aberrant kinase activity is implicated in many human
diseases in particular those cancer and inﬂammatory diseases. Of the more than 500 kinases in the human kinome
very few are targeted by currently marked drugs, notably the anticancer agents Gleevec (BCR Abl kinase, c-Kit),
Tarceva (EGFR) Sorafenib (Raf, VEGFR) and Sutent (EGFR) Oriology remains the most fertile area for kinase
inhibitors followed by inﬂammatory diseases. One reason is that many kinase inhibitors are multi-targeted (Bdirty
drugs’’) and the lack of selectivity may be beneﬁcial in cancer to prevent resistance from occurring.
Several kinases including p38MAPK, JNK and IkB kinase-2 (IKK2) have been identiﬁed as key targets for a
plethora of inﬂammatory diseases and clinical trials are underway. A major advantage in directing anti-
inﬂammatory drug discovery programs against such targets is the ability to modulate multiple inﬂammatory gene
products including cytokines such as TNF and IL-1, cell adhesion molecules as well as enzymes such as Cox-2 and
MMPs that are pivotal in the pathology of inﬂammatory disease.
Many of the current kinase inhibitors were developed from Bfocused’’ small molecule kinase libraries that
target the ATP-binding site and the availability of crystal structures for several key kinases has greatly facilitated
lead optimization. Allosteric strategies have also been used successfully to identify kinase inhibitors notably p38.
The family of human protein kinases accounts for most cellular signal transduction and can provides an enormous
opportunity to develop new treatments for anti-inﬂammatory therapies.
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3H]Adenine_s High Filter Binding Precludes its Use as a Radioligand
for Adenine Receptors
Kai Ye, Thea Mulder-Krieger, Margot W. Beukers and Ad P. Ijzerman
Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden University, PO Box 9502,
2300 RA Leiden, The Netherlands
k.ye@lacdr.leidenuniv.nl
An orphan G protein-coupled receptor, rat MrgA10, one of the MAS-related G protein-coupled receptors, has
recently been characterized as an adenine receptor [1]. Among the methods used in the de-orphanization process
were binding studies with [
3H]adenine as a radioligand [1]. In subsequent studies from other research groups
saturation analysis, kinetic studies and displacement experiments were performed on native tissues such as rat
brain cortex with [
3H]adenine as a radioligand, demonstrating the presence of adenine binding sites in these
tissues [2, 3].
We initiated a program to address the medicinal chemistry aspects of the adenine receptor, with radioligand
binding studies as a primary screen. We prepared membranes from CHO cells stably transfected with the rat
adenine receptor (rAR) kindly donated by IriDM (Scherpenheuvel, Belgium), next to membranes of rat brain
cortex. Subsequently, radioligand binding assays with [
3H]adenine as the radioligand were developed.
In that process we observed a number of worrying phenomena. Firstly, we observed an unusually rapid association
of the radioligand in our kinetic studies, consistent with literature [2]. Secondly, in the displacement assays we
learned that decreasing the membrane protein concentration (see Figure for rat brain cortex membranes) led to
an increase in ‘‘speciﬁc’’ [
3H]adenine binding, such that in the absence of protein the highest binding was obse-
rved. Thirdly, the afﬁnities of adenine and a number of adenine derivatives to compete for [
3H]adenine ﬁlter
binding were in good agreement with the values in literature for the adenine receptor [1–3].
In conclusion, radioligand binding studies aimed at the adenine receptor with [
3H]adenine as the radioligand
should be performed with great care, if at all.
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A3 adenosine receptors are promising drug targets for a number of conditions like inﬂammatory diseases inclu-
ding asthma, ischemic injury or certain types of cancer. Consequently, intense efforts in many laboratories are
dedicated to the development of A3 selective agonists adn antagonists. A number of radioligands are in use for
screening of new compounds in binding assays. In agonist development it is advantageous to use an agonist as the
radioligand in order to avoid biphasic competition curves as a high afﬁnity radiolabeled agonist will bind to high
afﬁnity binding sites only. In the case of A3 adenosine receptors the two radioligands
125I-AB-MECA and [
3H]-
NECA are widely used. A tritiated ligand offers a number of advantages in routine applications. However,
[
3H]NECA is of limited value owing to the relatively low afﬁnity for human A3 receptors (Ki-value 6.2 nM), lack
of subtype selectivity and its tendency to bind to numerous proteins other than adenosine receptors.
Based on a recently characterized series of potent 2-substituted adenosine receptor agonists we developed a
tritiated A3 selective radioligand. The ligand of choice was HEMADO (2-hexyn-1-yl-N
6-methyladenosine) which
exhibits an Ki-value at the human A3 subtype of 1 nM. HEMADO is 300fold selective versus the A1 subtype and
1,100fold selective compared to the A2A receptor
[1]. Starting from the precursor 2-hexyn-1-yl-6-iodopurine-9-
riboside [
3H]HEMADO was generated by substitution of the 6-iodo with tritiated methylamine. The resulting









3H]HEMADO in radioligand binding studies revealed reversible binding to the human A3
adenosine receptor. In saturation binding studies for the A3 subtype a KD value of 1.3 nM was determined. The
nonspeciﬁc binding at a radioligand concentration of 0.5 nM amounted to 1–2% of total binding. Competition
binding with a panel of agonists and antagonists clearly conﬁrmed the correct A3 pharmacology of the binding site
labeled by [
3H]HEMADO. In concentrations up to 10 nM no speciﬁc binding was detectable at any of the other
adenosine receptor subtypes.
With [
3H]HEMADO we present a tritiated high afﬁnity agonist with Q300fold A3 selectivity and very low nons-
peciﬁc binding. [
3H]HEMADO is a useful tool for speciﬁc screening for A3 receptor agonists and antagonists in
radioligand binding assays.
1 Volpini R, Costanzi S, Lambertucci C, Tafﬁ S, Vittori S, Klotz K-N et al. J Med Chem 2002; 45: 3271–9.
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This work investigates the pharmacological and biochemical properties of A2B adenosine receptors in hA2BHE-




3H]-MRE 2029-F20), that shows high afﬁnity and selectivity for hA2B versus hA1,h A 2A and hA3
subtypes. In particular MRE 2029-F20 displays low afﬁnity for the human A1 receptor (Ki = 245 T 31 nM) and no
signiﬁcant afﬁnity for the human A2A and A3 subtypes (Ki >1,000 nM). [
3H]-MRE 2029-F20 bound speciﬁcally to
the hA2B receptor stably transfected in HEK293 cells with KD of 2.8 T 0.2 nM and Bmax of 450 T 42 fmol/mg
protein. Saturation experiments of [
3H]-MRE 2029-F20 binding in human neutrophils and lymphocytes detected a
single high afﬁnity binding site with KD of 2.4 T 0.5, 2.7 T 0.7 nM and Bmax of 79 T 10, 54 T 8 fmol/mg of protein,
respectively, in agreement with real-time RT-PCR studies showing the presence of A2B mRNA. The rank order of
potency of typical adenosine ligands with recombinant hA2B receptors was consistent with that typically found for
interactions with the A2B subtype and was also similar in peripheral blood cells. NECA stimulated cAMP accu-
mulation in both hA2BHEK293 and native cells whereas phospholipase C activation was observed in recombinant
receptors and endogenous subtypes expressed in neutrophils but not in lymphocytes. MRE 2029-F20 revealed to
be a potent antagonist in counteracting the agonist effect in both signal transduction pathways. In conclusion [
3H]-
MRE 2029-F20 is a selective and high afﬁnity radioligand for the hA2B adenosine subtype and in this work it has
been used to compare the presence and functional coupling of A2B receptor in a recombinant system and in
peripheral blood cells.
2,6,8-Trisubstituted-1-Deazapurines as Adenosine A1 Receptor Antagonists
Jacobien K. von Frijtag Drabbe Ku ¨nzel, Lisa C. W. Chang, Thea Mulder-Krieger, Joost Westerhout,
Thomas Spangenberg, Johannes Brussee and Adriaan P. IJzerman
Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, P.O. Box 9502, 2300 RA Leiden,
The Netherlands
ijzerman@lacdr.leidenuniv.nl
Exploration of two particular pyrimidine and purine series in previous publications [1, 2] led to a reﬁnement of a
pharmacophore deﬁned for antagonists of the adenosine A1 receptor. This contribution details the adoption of
these new criteria to produce a series of 1-deazapurines with consistently high afﬁnity for the adenosine A1
receptor. 1-Deazapurines (otherwise known as 3H-imidazo[4,5-b]pyridines) are structurally very similar to the
purines, however, in a synthetic sense they posed an array of challenges, mainly as a result of the reduced
reactivity about the 6-membered ring. The desired double aromatic substituents at the 2- and 6-positions were
amongst the most troublesome features to incorporate. An eventual adaptation of a known route resulted in a
series with ﬁve of the derivatives displaying Ki values in the sub-nanomolar range. Thus LUF5983 displayed an
afﬁnity of 0.87 nM at the human adenosine A1 receptor with >200-fold selectivity vs. human A2A and A3 rece-
ptors. The compound was shown to behave as a potent antagonist/inverse agonist in cAMP second messenger
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Adenosine mediates a wide variety of physiological effects by interacting with four receptor subtypes: A1,A 2A,
A2B and A3. All four adenosine receptor (AR) subtypes are coupled via G-protein to the adenylate cyclase in
either an inhibitory (A1 and A3) or stimolatory manner (A2A and A2B) [1]. AR antagonists have attracted great
attention for their potential therapeutic use, and the A3 AR antagonists are sought as potential anti-inﬂammatory
and anti-asthmatic agents [2]. In the last few years in our laboratory, much effort has been directed toward the
synthesis of tricyclic heteroaromatic systems rationally designed as antagonists of the hA3 AR subtype. In a recent
paper we reported the study on 2-arylpyrazolo[3,4-c]quinolin-4-amines which were endowed with nanomolar hA3
afﬁnity [3]. Onthisclassofderivatives,thepresenceofacylresiduesonthe4-aminogroupproducesproﬁtableeffects
both in terms of hA3 afﬁnity and selectivity [3, 4]. On this basis, we decided to synthesize a new set of 2-arylpy-









Afﬁnities of the new derivatives at hA1,h A 2A and hA3 AR and their inhibitory effects on NECA-stimulated
cAMP production in hA2B CHO cells were determined. The obtained results show that the 2-arylpyrazolo[3,4-
c]quinoline-4-heteroaroylamines are potent and selective hA3 antagonists, indeed they possess hA3 nanomolar
afﬁnities while they are completely inactive at the other three AR subtypes.
1. Fredholm, B.B.; Ijzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; Linden, J. Pharmacol. Rev. 2001, 53, 527-552.
2. Poulsen, S.A.; Quinn, R.J. Bioorg. Med. Chem. 1998, 6, 619-641.
3. Calotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; et al. J Med Chem, 2000, 43, 3118-3124.
4. Unpublished results reported in a Poster Presentation, 8th International Symposium on Adenosine and Adenine Nucleot-
ides, May 24-28, 2006, Ferrara.
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Adenosine is a ubiquitous neuromodulator eliciting many biological effects by activation of four different rece-
ptors subdivided into A1,A 2A,A 2B and A3 subtypes and belonging to the G protein-coupled receptor family [1].
In the last decade much research has been directed towards the study of adenosine receptor (AR) antagonists
which have proved to be attractive therapeutics in many pathophysiological conditions [2]. In particular, the A3
AR subtype antagonists are putative anti-inﬂammatory, anti-asthmatic or anti-ischemic agents [2]. A part of our
recent studies were aimed at ﬁnding new tricyclic A3 AR antagonists and among them the 2-arylpyrazolo[3,4-
c]quinolin-4-amino series was investigated [3]. In the preliminary study a single modiﬁcation at a time was app-
orted at the R1 or R4 position of 2-phenylpyrazolo[3,4-c]quinolin-4-amino scaffold and some of the mono-subst-
ituted derivatives resulted to be potent human (h) A3 AR antagonists. SAR studies pointed out that methyl and
methoxy groups at meta or para positions were the most proﬁtable R1 substituents for enhancing hA3 AR afﬁnity.
Advantageous effects were also elicited by introducing an acetyl or a benzoyl group at the R4 position. These
interesting results prompted us to continue investigating this class of hA3 AR antagonists with the purpose of
evaluating whether the contemporary functionalization of the key positions R1 and R4 with the above cited groups
could increase hA3 AR afﬁnity and selectivity. Also the bulkier diphenylacetyl substituent or two benzoyl residues















Preliminary binding data at the hA3 AR show that the simultaneous presence of the suitable substituents on the 2-
phenyl ring (R1) and the 4-amino group (R4) maintained the hA3 AR afﬁnity in the nanomolar range. Molecular
modeling studies are in progress in order to elucidate the binding mode of this series of derivatives to the hA3
receptor site and to rationalize the afﬁnity data.
1. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K-N, Linden J. Pharmacol Rev 2001; 53: 527–52.
2. Poulsen SA, Quinn RJ. Bioorg Med Chem 1998; 6: 619–41.
3. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G et al. J Med Chem 2000; 43: 3118–24.
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The biochemical pathways controlling cell death are often mutated and/or defective in cancer cells, contribu-
ting to the development of resistance to chemotherapy. Thus, for any given anti-cancer agent, it is important to
verify whether it can effectively induce cell death in cancerous cells carrying mutations of various apoptotic
pathways. We have previously demonstrated that human astrocytoma ADF cells are resistant to agents acti-
vating the intrinsic pathway of apoptosis due the presence of a mutated caspase-9 isoform (1). Nevertheless,
the anti-cancer agent 2-chloro-20-deoxyadenosine (Cladribine, 2CdA) induces cell cycle block and is still able
to effectively kill these cells by recruiting an atypical pathway of cell death, with caspase-2 acting as an
‘‘initiator’’ caspase, followed by caspase-3 (2). To better characterize 2CdA-activated apoptotic pathway in
ADF cells, in this study we have focussed our attention on the tumor suppressor protein p53 which is mutated
in more than 50% of human cancers. By cloning and sequencing the p53 isoform expressed by ADF cells, we
detected a single nucleotide mutation in position 797 which translated into a G-to-E substitution at position
266 which belongs to the DNA-binding domain of the p53 protein. Since phosphorylation of the Ser15 residue
of the p53 protein represents one of the most frequent post-translational modiﬁcation controlling its pro-
apoptotic activity, we have analyzed the importance of this phosphorylation reaction in cells exposed for
various time periods to 2CdA by means of a speciﬁc antibody directed against phosphorylated p53. A very
rapid apperance of the protein band corresponding to phospho-Ser15 p53 was observed, starting from a 30 min
and declining after 3 hours of incubation with the adenosine analog. P53 phosphorylation was completely
prevented by 2-deoxy-cytidine, which competes with 2CdA for its intracellular phosphorylation to the corres-
ponding chloro-deoxy nucleotides. Indeed, co-incubation with SP600125, a selective inhibitor of c-jun-terminal
kinases 1 and 2 (JNK1/2), completely blocked p53 phosphorylation, whereas inhibitors of other members of
the MAP kinase family of enzymes (e.g., ERK1/2 and p38) had no effect. SP600125 was also able to signiﬁ-
cantly reduce the percentage of apoptosis induced by 2CdA. However, p53 phosphorylation and 2CdA-induced
apoptosis are not correlated to each other, since !-piﬁthrin, which selectively inhibits p53 transcriptional act-
ivity downstream of post-translational modiﬁcations, was completely ineffective in preventing cell death. Taken
together, these results suggests that a JNK-dependent but p53-independent pathway of death is recruited by 2-
CdA. JNK1/2 were also involved in the 2CdA-induced cell cycle block at G0/G1 phases and enhanced expr-
ession of genes controlling cell cycle progression (e.g., p21, GADD45A) as demonstrated by microarray ana-
lysis. Despite the previously mentioned inability of the selective inhibitor PD098059 to prevent p53-
phosphorylation, we have also detected a pro-apoptotic role for ERK1/2, since PD098059 signiﬁcantly reduced
2CdA-mediated cell death. These results suggest that 2CdA treatment might represent an effective pharmac-
ological approach for cancer cells bearing mutations of different apoptotic pathways of death, by recruting
various members of the MAP kinases family.
(1) Ceruti S, Mazzola A, Abbracchio MP. J Pharmacol Exp Ther 2005; 314: 825–37
(2) Ceruti S, Beltrami E, Matarrese P et al. Mol Pharmacol 2003; 63: 1437–47
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Adenosine mediates its physiological effects through four G protein-coupled receptors (A1,A 2A,A 2B and A3). A
large number of agonists with high afﬁnity at A1,A 2A,A 3 adenosine receptors and moderate afﬁnity at A2B
receptor have been developed over the years. Many compounds originally thought to be selective for the A1 or
A2A subtypes later turned out to be also potent agonists at the more recently discovered A3 receptor. Owing to
the great interest in A1 agonists as neuroprotective, antilipolytic, anti-arrhythmic, and antinociceptive agents,
there is a need for novel agonists with high potency and selectivity at this receptor subtype to avoid side effects
due to the stimulation of the other subtypes. We discovered that the substitution of the hydrogen in 20-position of
the ribose moiety of the A1 selective agonist CCPA with a methyl group (20-Me-CCPA) reduces the afﬁnity at
human A2A and A3 receptors, thus increasing the selectivity for A1 subtype [1]. In this communication we report
on the afﬁnity at human adenosine receptors of 20-C-methyl derivatives of Tecadenoson (CVT510, N
6-3(R)-
tetrahydrofuranyl-adenosine), a potent and selective A1 agonist in clinical trials for treatment of supraventricular
tachyarrhythmias, and of its 2-chloro derivative (2-Cl-Tecadenoson). Tecadenoson, 2-Cl-Tecadenoson and their
20-C-methyl derivatives were evaluated for the afﬁnity at human A1,A 2A,A 2B, and A3 ARs expressed in CHO
cells in comparison with CPA, CCPA, 20-Me-CPA and 20-Me-CCPA. With the exception of Tecadenoson that
proved to be equipotent to CPA, N
6-3(R)-tetrahydrofuranyl substituted derivatives showed only 2.5- to 5-fold less
afﬁnity at human A1 AR in comparison with the corresponding N
6-cyclopentyl analogues. It was further conﬁr-
med that the introduction of a methyl group in the 20-position of the ribose moiety of adenosine analogues induces
a relevant decrease of afﬁnity at A2A and A3 receptors. Thus, 20-Me-Tecadenoson and 20-Me-2-Cl-Tecadenoson
turned out to be very selective compounds for human A1 AR (>4,762- to >6,452-fold vs human A2A, and 211- to
288-fold vs A3 receptor, respectively).
[1] Cappellacci L, Franchetti P, Pasqualini M, Petrelli R, Vita P, Lavecchia A, Novellino E, Costa B, Martini C, Klotz K-N and
Grifantini M. J Med Chem 2005; 48: 1550–62.
20-C-Methyl-2-Chloro-N
6-Cyclopentyladenosine, A Potent and Highly Selective
A1 Adenosine Receptor Agonist, Has Antinociceptive Activity and Modulates
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This study was undertaken to investigate the effect of 20-C-methyl-2-chloro-N
6-cyclopentyladenosine (20-Me-CCP-
A), a potent and highly selective A1 adenosine receptor agonist [1], on nociceptive responses and on spontaneous
activity of ON- and OFF- neurons of rostral ventromedial medulla (RVM). Moreover, we investigated whether the
intra-periaqueductal grey (PAG) microinjection of 20-Me-CCPA induced changes in the tail ﬂick latencies, as well as
tail ﬂick-related changes in RVM cell activities.
Systemic administrations of 20-Me-CCPA (2–5 mg/kg, i.p.), 10 min before formalin, reduced the late hyperalgesic
phase; in formalin test, these effects were prevented by DPCPX (3 mg/kg, i.p.), a A1 receptor antagonist, but not
by DPMX (3 mg/kg, i.p.), a A2 receptor antagonist.
Intra-PAG microinjections of 20-Me-CCPA (0.5–1 nmol/rat) increased the tail ﬂick latencies, delayed the tail ﬂick-
related onset to ON-cell burst and decreased the duration of OFF-cell pause in a dose dependent manner. Fur-
thermore, 20-Me-CCPA decreased RVM ON-cell and increased OFF-cell ongoing activities, in a dose dependent
manner. These electrophysiological effects were prevented by DPCPX (1 nmol/rat.).
In conclusion, this study conﬁrms the role of A1 receptors in the modulation of inﬂammatory pain and suggests a
critical role of PAG purinergic system for the control of acute and chronic pain.
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The ﬁrst allosteric enhancers (AEs) acting at the A1 adenosine receptor (A1AR) were reported by Bruns et al. in
1990 [1, 2]. PD81,723 (1) was one of the more potent and effective of the initial series of enhancers and has
subsequently been commonly used for benchmarking new AEs. Since this initial discovery, other researchers have
















1  AE Score = 28%
  ED50 = 13.6 µM
3  AE Score = 80%
  ED50 = 1.4 µM
However, relatively few 2-aminothiophenes with esters or amides in the 3-position have been tested as allosteric
enhancers. The initial study by Bruns and co-workers included two 2-amino-3-ethoxycarbonyl-4,5,6,7-tetrahy-
drothieno[2,3-c]pyridines [1, 2]. Whilst these compounds maintained some enhancing ability, they proved to be
less potent than the corresponding 3-benzoyl substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines. We
recently synthesised a series of substituted 2-amino-3-benzoyl-4,5-diphenylthiophene allosteric enhancers. En r-
oute to these target compounds we also prepared some novel 2-aminothiophene-3-carboxylates and carboxamides
to explore the effect of these substituents on AE activity [3]. Three of the ﬁve alkoxycarbonyl compounds proved
to be clearly more effective than PD81,723 (1), with 3-triﬂuoromethylbenzyl 2-amino-4-(4-methylphenyl)-5-phe-
nylthiophene-3-carboxylate (2) being the most effective compound in this group. We now report a more complete
structure-activity study of this class of compound as A1AR allosteric enhancers. A number of compounds, notably
3, proved to be more potent and efﬁcacious than PD81,723 (1). Conformationally restricted analogs have also
been prepared and evaluated.
1. Bruns RF, Fergus JH Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylth-
iophenes. Mol. Pharmacol. 1990, 38, 939–949.
2. Bruns RF, Fergus JH, Coughenour LL, Courtland GE, Pugsley TA, Dodd, JH, et al. Structure-activity relationships for
enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 1990, 38, 950–958.
3. Lu ¨tjens H, Zickgraf A, Figler H, Linden J, Olsson RA, Scammells PJ. 2-amino-3-benzoylthiophene allosteric enhancers of
A1 adenosine agonist binding: new 3, 4- and 5-modiﬁcations. J. Med. Chem. 2003, 46, 1870–1877.
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Receptor desensitization can determine the time course of transmitter action, and profoundly alter sensitivity to
drugs. Among P2X receptors, ion currents through homomeric P2X4 receptors exhibit intermediate desensitiza-
tion when compared to P2X1 and P2X3 (much faster) and P2X2 and P2X7 (slower) [1]. We recorded membrane
currents in HEK293 cells transfected to express the human P2X4 receptor. The decline in current during a 4 s
application of ATP (100 2M) was about 30%; this was not different during whole-cell or perforated patch reco-
rding. Alanine-scanning mutagenesis of the intracellular C-terminal identiﬁed two positions with much acceler-
ated desensitization kinetics (Lys
373:9 2T 3.2% and Tyr
374:7 4T 4.2%). At position 373, substitution of Arg or Cys
also strongly accelerated desensitization: however, in the case of K373C the wild-type phenotype was fully rest-
ored by adding ethylammonium methanethiosulfonate. At position 374, phenylalanine could replace tyrosine.
These results indicate that wild type desensitization properties requires an aromatic moiety at position 374, and an
amino rather than a guanidino group at position 373. These residues lie between previously identiﬁed motifs
involved in membrane trafﬁcking (YXXXK and YXXGL) [2, 3], and implicates the C terminal also in rearran-
gements leading to channel closing during the presence of agonist.
1. North RA (2002). Molecular physiology of P2X receptors. Physiol Rev. 82(4):1013–67.
2. Royle SJ et al. (2002). Identiﬁcation of a non-canonical tyrosine-based endocytic motif in an ionotropic receptor. J Biol Chem
2002; 277(38):35378–85.
3. Chaumont S et al. (2004). Identiﬁcation of a trafﬁcking motif involved in the stabilization and polarization of 2X receptors. J
Biol Chem 2004; 279(28): 29628–38.
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A new series of pyrazolotriazolopyrimidines bearing at the N5-position different heteroarylcarbamoylamino moie-
ties are described as an enlarged series of previously reported highly potent, selective and water soluble human A3

















hA1 Ki = 350 nM; hA2A Ki = 100 nM
hA2B Ki = 250 nM; hA3 Ki = 0.01 nM
hA1/hA3 = 35,000; hA2A/hA3 = 10,000
hA2B/hA3 = 25,000
The synthesized compounds showed A3 adenosine receptor afﬁnity in the nanomolar range and different levels of
selectivity evaluated in radioligand binding assays at human A1,A 2A, and A3 adenosine receptors. In particular,
the effect of the heteroaryl substituents at the N5 position has been analyzed and this study allows recognizing
that the presence of a pyridinium moiety in this position not only increases water solubility but also improves or
retains potency and selectivity at the human A3 adenosine receptors. In contrast, replacement of pyridine with
different heterocycles produces loss of afﬁnity and selectivity at the human A3 adenosine receptors. A molecular
modeling study has been carried out with the aim to explain these various binding proﬁles [2].
References
1. Maconi, A.; Pastorin G.; Da Ros T.; Spalluto G.; Gao, Z.G.; Jacobson, K.A. Baraldi, P.G.; Cacciari, B.; Varani, K.; Borea,
P.A. J. Med. Chem. 2002, 45, 3579–3582.
2. Pastorin, G.; Da Ros, T.; Bolcato, C.; Montopoli, C.; Moro, S.; Caccairi, B.; Baraldi, P.G.; Varani, K.; Borea, P.A; Spalluto,
G. J. Med. Chem. 2006, 49, 0000–0000.
A Cell-based Assay Suitable for HTS of Adenosine A1 Receptor Agonists
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Purinergic receptors are a family of seven ubiquitous transmembrane receptors comprising two classes, P1 and P2,
which are activated by adenosine and extracellular nucleotides, respectively. The P1 receptors signal through
multiple intracellular effectors in response to nucleoside activation. There are four subtypes of P1 receptors: A1,
A2A,A 2 B and A3.
In this study, we have focused our attention on the development of a cell-based system suitable for the identiﬁ-
cation of agonists of the adenosine A1 receptor, suitable for High Throughput Screening applications (HTS).
The A1 receptor is coupled to G!i, which inhibits adenylyl cyclase. Additionally, it mediates the activation of
several types of K
+-channels, the inactivation of N-, P- and Q-type Ca
2+ channels and the activation of phosph-
olipase C" (via "+ subunits).
Mainly through the A1 receptor, adenosine mediates potent effects on myocardium and conduction tissue, end-
othelium and vascular smooth muscle, inducing delayed tolerance to ischemia-reperfusion injury.
In particular, A1-receptor activation produces preconditioning to protect the heart and other tissues from subs-
equent ischemic injury. Therefore, the pharmaceutical industry is interested in producing selective A1-receptor
agonists as pharmacological treatment for cardiovascular diseases.
We have created a CHO cell line with stable expression of the reporter luciferase under the control of cAMP
response elements and a chimera of the human A1 receptor and G!s, which allows the switching of the receptor-
mediated signal towards adenylil cyclase stimulation. We have demonstrated for the ﬁrst time that activation of
the A1 receptor can be detected by the direct increase of luminescence.
This generated A1-G!s-expressing cell line is a sensitive and reliable functional cell-based assay suitable for the
HTS of speciﬁc receptor agonists.
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Adenosine has been reported to exert negative inotropic effects in isolated cardiac preparations of numerous
mammalian species, including man. The effects are assumed to be mediated via an A1 adenosine receptor. Inte-
restingly, derivatives of adenosine like diadenosine polyphosphates e.g. Ap4A exert similar effects via the A1
adenosine receptor in the human heart. Recently, uridine adenosine tetraphosphate (Up4A) was described as a
novel endothelian derived vasoconstrictive factor (Nat Med 11:223, 2005). Up4A was released under certain
conditions from endothelial cells and exerted potent vasocontrictory effects (EC50 ;1 nM) via P2-receptors. Here,
we studied the effect of Up4A on force of contraction in isolated electrically driven atrial preparations from
human hearts. The preparations were obtained from patients undergoing cardiac bypass surgery due to coronary
heart disease. Preparations were studied under isometrical conditions driven at 0.5 Hz.
Concentration response curves were obtained for the "-adrenoceptor agonist isoproterenol (1 nM–10 2M) and
Up4A (1 nM–0.3 2M). In the very same preparations, isoproterenol exerted a positive inotropic effect while Up4A
exerted a concentration dependent negative inotropic effect. The effect started at about 0.03 2M and amounted to
35% at 0.3 2M, the highest concentration of Up4A tested (n = 3). We assume that Up4A exerts the effect probably
via A1 adenosine receptors. In summary, the new endogenous vasoconstrictor Up4A can reduce force of contr-
action in the human heart.
Hence, it may play an autoregulatory function in the cardiovascular system.
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Completion of the Dictyostelium discoideum genome sequencing project has allowed a family of ﬁve putative P2X
receptor genes to be provisionally identiﬁed in this species of cellular slime mould. Functional characterisation of
a P2X or P2X-like receptor in this simple eukaryotic model organism could potentially contribute to our unde-
rstanding of this class of ligand-gated ion channel. Extracellular ATP release from Dictyostelium and ATP ind-
uced calcium inﬂux has previously been reported [1] supporting the presence of purinergic signalling pathways in
this species.
The ﬁve putative Dictyostelium P2X subunits possess 35–75.8% sequence identity between each other and 11.4–
16.1% sequence identity to human P2X1–7 subunits with conservation of key P2X receptor elements, such as an N-
terminal PKC motif, a C-terminal membrane stabilisation motif, two potential hydrophobic transmembrane do-
mains and a similar overall size (368–407 amino acids in length). The Dictyostelium gene showing most homology
to vertebrate P2X channels (dP2XE) was selected for further investigation.
Initially we attempted to express dP2XE protein in Xenopus laevis oocytes as this expression system has been
used successfully for the characterisation of vertebrate and Schistosoma mansoni [2] P2X receptors. Expression of
dP2XE protein in oocytes was achieved following introduction of a vertebrate Kozak sequence to the N-terminus.
However, cell surface biotinylation revealed that the protein was not trafﬁcked to the plasma membrane in these
cells and no ion channel currents could be detected by two-electrode voltage-clamp experiments.
In the presence of a food source Dictyostelium exist in a unicellular state. Upon starvation, cells aggregate and
develop into a spore containing fruiting body. Northern blot analysis of dP2XE expression demonstrated that the
dP2XE gene is transcribed at a constant level through all stages of development, potentially indicating a house-
keeping role. In order to determine the subcellular localisation of dP2XE in Dictyostelium, a C-terminal eGFP
fusion protein (dP2XE-eGFP) was expressed. This protein displayed a diffuse cytoplasmic distribution with dis-
tinct localisation to the membranes of an intracellular organelle but absence from the plasma membrane. Conf-
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membranes of contractile vacuoles, intracellular organelles involved in water expulsion/osmoregulation and po-
tentially calcium regulation. This intracellular localisation of dP2XE indicates a novel function compared to that
of the conventional cell surface membrane localised P2X receptors identiﬁed in vertebrates.
1. Parish, R.W.; Weibel, M., Extracellular ATP, ecto-ATPase and calcium inﬂux in Dictyostelium discoideum cells. FEBS Lett
1980, 118, (2), 263–6.
2. Agboh, K.C.; Webb, T.E.; Evans, R.J.; Ennion, S.J., Functional characterisation of a P2X receptor from schistosoma man-
soni. J Biol Chem 2004, 279, (40), 41650–41657.
3. Betapudi, V.; Mason, C.; Licate, L.; Egelhoff, T.T., Identiﬁcation and characterization of a novel alpha-kinase with a von
Willebrand factor A-like motif localized to the contractile vacuole and Golgi complex in Dictyostelium discoideum. Mol Biol
Cell 2005, 16, (5), 2248–62.
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The P2X7 receptor has a role in the host immune response to infection with the obligate intracellular pathogens,
Mycoplasma and Chlamydia. We describe three immunocompetent subjects with absent P2X7 function due to one
or a combination of inherited loss-of-function single nucleotide polymorphisms all of whom had a prolonged,
severe illness due to infection with the obligate intracellular protozoan parasite, Toxoplasma gondii. T gondii
usually causes an asymptomatic infection in immunocompetent humans but infection in immunocompromised
individuals can cause serious disease, including encephalitis while intrauterine infection can cause congenital
blindness, mental retardation and death. Our ﬁrst subject was a 20-year-old female who presented with subma-
ndibular lymphadenopathy. Serology was positive for recent Toxoplasma infection and a lymph node biopsy
showed features consistent with toxoplasmosis. The second subject was a 24-year-old female who had a foetal
ultrasound scan at 22 weeks gestation that showed gross cerebral ventriculomegaly consistent with congenital
Toxoplasmosis and conﬁrmed by PCR on amniotic ﬂuid. The third subject, a 14-year-old male, presented with a 2-
year history of tiredness, lethargy and generalized painless lymphadenopathy. Serology for T gondii was positive
for acute infection and an excision biopsy of an enlarged left axillary lymph node showed lymphadenitis consistent
with toxoplasmosis. Function of the P2X7 receptor, as measured by ethidium uptake using time resolved ﬂow
cytometry, was absent in two subjects and low in the third. Sequencing of the P2X7 gene conﬁrmed the presence
of one or a combination of loss-of-function single nucleotide polymorphisms previously described by our group.
All subjects were HIV negative and had normal T-cell subsets and normal serum immunoglobulins Therefore,
normal P2X7 function may be of importance in controlling Toxoplasma infection. Possible P2X7 dependent
mechanisms of the host immune response to Toxoplasma infection include P2X7 dependent phagosome-lysosome
fusion via phospholipase D activation and P2X7 triggered apoptosis of infected host cells, both of which have
been shown to play a role in the host response to Chlamydia and Mycobacteria infection.
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SpringerIn the adult rodent brain, active neurogenesis takes place in the subventricular zone of the lateral ventricles (SVZ)
and in the dentate gyrus of the hippocampus. In both neurogenic regions, astrocyte-like cells function as stem cells/
precursor cells. To date the cellular and molecular events driving a subpopulation of precursor cells into neurog-
enesis as well as the cellular transition states leading to mature neurons are poorly understood. We showed that
stem cells of the adult SVZ and progenitor cells in the dentate gyrus (residual radial glia) highly express the
extracellular nucleoside triphosphate-hydrolyzing enzyme NTPDase2 [1]. Patch-lamp analysis of cells in hippo-
campal slices derived from mice transgenic for GFP under the control of the nestin promotor suggest that proge-
nitor cells express P2X nucleotide receptors [2]. Progenitor cell-containing neurospheres cultured from the adult
mouse SVZ in the presence of epidermal growth factor (EGF) and basic ﬁbroblast growth factor (bFGF) express
the ecto-nucleotidases NTPDase2 and the tissue non-speciﬁc isoform of alkaline phosphatase, hydrolyzing extra-
cellular ATP to adenosine. ATP, ADP and to a smaller extent UTP evoke rapid Ca
2+ transients in neurospheres
that are exclusively mediated by the metabotropic P2Y1 and P2Y2 nucleotide receptors. In addition, agonists of
P2Y1 and P2Y2 receptors and low concentrations of adenosine augment cell proliferation in the presence of the
mitogenic growth factors EGF and bFGF. Neurosphere cell proliferation in the presence of growth factors is
attenuated after application of the P2Y1 receptor antagonist MRS2179 and in neurospheres from P2Y1 receptor
knockout mice. This suggests that constitutive P2 receptor activation via endogenously released nucleotide is
necessary for optimal cell proliferation [3]. Our results infer nucleotide receptor-mediated synergism that aug-
ments growth factor-mediated proliferation of adult neural progenitor cells. They support the notion that extra-
cellular nucleotides contribute to the control of adult neurogenesis in both, the SVZ and the dentate gyrus.
1. Braun, N., Se ´vigny, J., Mishra, S., Robson, S.C., Barth, S.W., Gerstberger, R., Hammer, K., and Zimmermann, H. 2003 Eur.
J. Neurosci. 17, 1355–1364.
2. Shukla, V., Zimmermann, H., Wang, L., Kettenmann, H., Raab, S., Hammer, K., Se ´vigny, J., Robson, S.C., and Braun, N. J.
Neurosci. Res 2005, 80, 600–610.
3. Mishra, S.K., Braun, N., Shukla, V., Fu ¨llgrabe, M., Schomerus, C., Korf, H.-W., Gachet, C., Ikehara, Y., Se ´vigny, J., Robson,
S.C., and Zimmermann, H. Development 2006, 133, 675–684.
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Background: Fibromyalgia (FM) is a chronic pain syndrome of unknown etiology characterized by widespread
chronic pain and tender points. Although the exact pathophysiology of FM is unknown, individuals with FM are
hyperalgesic to painful stimuli. Mice with targeted deletion of the adenosine A1 receptor (A1AR), like FM
patients, demonstrate increased sensitivity to painful stimuli, and are characteristically anxious and aggressive. We
therefore hypothesized that FM may be due to genetically-determined changes in A1AR.
Methods and Results: DNA was isolated and puriﬁed from peripheral blood from FM patients and age- and sex-
matched normal controls. Initially the gene (promoters, exons, UTR) was sequenced in 14 FM patients and 24
controls. A single nucleotide polymorphism in the 30UTR (C2526T) was observed in 3/14 FM patients and no
controls. For all subsequent genotyping assays a 241 bp region containing the SNP was ampliﬁed and sequenced
for all patients and controls. Patient samples and controls were obtained from two FM clinics and an increased
frequency in the C2526T SNP was observed in the FM patients as compared to controls (Table below). To
determine whether the C2526T SNP was in linkage equilibrium with other SNPs in the A1 gene the frequency of 3
known SNPs upstream and 3 SNPs downstream of the C2526T SNP was determined in patients and controls by
Taqman Assay and no differences were observed (data not shown). The overall frequency of the C2526T poly-
morphism in the FM patients was 17.3% as compared to 6.8% in the controls (p = 0.019)
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SpringerC/C C/T Frequency of C/T
Fibromyalgia
Michigan 31 7 18.4%
NYU 11 3 21.4%
Florida 73 14 16.1%
Total 115 24 17.3%*
Control
Michigan 35 3 7.9%
NYU 75 5 6.3%
Total 110 8 6.8%*
*p=0.019
Previous reports have suggested that subgroups of patients with FM have SNPs in the serotonin receptor gene
(5HT2AR) and COMT, an enzyme involved in metabolism of adrenergic agents but we observed no difference
between controls and FM patients with regard to the frequency of these SNPs (Data not shown)
Conclusion: A SNP in the A1AR (C2526T) is associated with FM suggesting that in some patients genetically
determined changes in adenosine receptor expression or function lead to ﬁbromyalgia.
A Truncated P2X7 Receptor Variant (P2X7–j) Endogenously Expressed
in Cervical Cancer Cells Antagonizes the Full-Length P2X7 Receptor
through Hetero-Oligomerization
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In human cervical epithelial cells the P2X7 receptor mediates ATP-induced apoptosis by a mechanism that inv-
olves pore formation, augmented calcium inﬂux, and calcium-dependent activation of the apoptotic mitochondrial
pathway. However, the degree of ATP- and BzATP-induced apoptosis is smaller in cancer than in normal cervical
cells [1]. A PCR product of a smaller size than the expected full-length P2X7 was identiﬁed in experiments trying
to amplify the full-length P2X7 gene. DNA sequencing and gene analysis of the smaller PCR product revealed an
identical P2X7 gene that lacks exon 8 except the A882, with a shift of coding frame to a new variant. The predicted
truncated naturally occurring variant (P2X7–j) (Genebank Accession Number DQ399293) is a polypeptide of 258
amino acids that lacks the entire intracellular carboxy terminus, the second transmembrane domain, and the distal
third of the extracellular loop of the full-length P2X7 receptor. The P2X7–j cDNA was subcloned into various
expression vectors and introduced into the host cells MDCK and HEK293 by transfection, and translation of a
speciﬁc product (a protein cluster of 45–42 KDa) was conﬁrmed. Expression of the P2X7–j as a naturally occurring
protein was also conﬁrmed in the human cancer cervical cell lines CaSki, HT3, SiHa, and Hela by Western blot
with anti-P2X7 antibody. The P2X7–j was expressed mainly in the plasma membrane but compared to the full
length receptor some of the P2X7–j also localized in nuclear/perinuclear regions. In host cells, inducible expression
of full length P2X7 alone, but not P2X7–j alone resulted in signiﬁcant decrease in cell number and increased
apoptosis. In contrast, P2X7–j expressing cells showed an increase in cell number and diminished baseline and
BzATP-induced apoptosis. Similarly P2X7–j expression showed diminished ligand-binding and channel function
capacities and failed to form pores in response to treatment with BzATP. Co-expression of the P2X7–j did not
signiﬁcantly affect expression of the full length P2X7–j, but it inhibited / blocked BzATP-induced P2X7 channel
activation, pore formation and apoptosis. The present results support the hypothesis that full length P2X7 mol-
ecules homo-oligomerize as oligo-trimers. Interestingly, the P2X7–j interacted with the P2X7–j in a manner sugg-
esting P2X7–j/P2X7–j homo-oligomerization, and with the full-length P2X7 suggesting P2X7–j/P2X7 hetero-
oligomerization. P2X7 immunoreactivities in HEK293 cells co-expressing the P2X7 plus the P2X7–j suggested
formation of inactive complexes of the P2X7 receptor in the order of [P2X7–j]3 \ [P2X7–j]2/[P2X7] > [P2X7]2/
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regulatory property for a truncated variant to antagonize its full-length counterpart through hetero-oligomeri-
zation. This may represent a general paradigm for regulation of a protein function by its variant. In cancer cells,
hetero-oligomerization of the P2X7–j with the P2X7 could result in inactive receptor, and abrogated P2X7-medi-
ated apoptosis could play a role in cervix neogenesis and enhance the growth of the cancer cells.
Support: AHA-SDG-0030019N, NHLBI-HL65492 (YHF); NIH HD29924, AG15955 (GIG).
1. Wang et al. Am J Physiol 287:C1349, 2004
A1 Adenosine Receptor Antagonist, L-97-1, Increases Survival in Rats
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Septicemia is a medical syndrome characterized by an overwhelming systemic response to infection that can
rapidly lead to shock, organ failure and death. Following its release from Gram-negative bacteria, elevated levels
of endotoxin in the plasma (endotoxemia) causes acute organ damage, including acute lung injury (ALI) and
death. Previously, it was reported that A1 adenosine receptor (AR) antagonists block endotoxin-induced ALI and
that endotoxin binds to and activates A1ARs on human pulmonary artery endothelial cells to induce the release
of IL-6 and TXA2 [1, 2]. L-97-1 is a water-soluble, small molecule A1 AR antagonist with high afﬁnity and high
selectivity for the human A1 AR [3]. In a rat cecal ligation perforation (CLP) model of Gram-negative septicemia
and endotoxemia, the effect of L-97-1 on mortality at 7 days (with and without antibiotics) following CLP was
investigated. Administration of L-97-1 as an intravenous (i.v.) therapy post-CLP improved 7 day mortality in a
dose-dependent manner (30–40% survival) as compared to untreated CLP control (17% survival) or antibiotics
alone (23% survival). In combination with antibiotics (gentamicin plus ampicillin), L-97-1 increased survival to
50–70% in a dose-dependent manner. In this animal model of Gram-negative septicemia and endotoxemia, L-97-1
as an adjuvant therapy to antibiotics is more effective than antibiotics alone to improve 7 day mortality. Despite
the introduction of an FDA approved adjuvant therapy, Xigrisi (drotrecogin alfa), the mortality rate remains
high for sepsis. As an adjuvant therapy to antibiotics, L-97-1 may improve the outcome for patients with Gram-
negative septicemia.
1. Neely, CF et al. Am J Physiol 272:L353–L361, 1997.
2. Wilson, CN and Batra, VK. J. Endotoxin Res 8:263–271, 2002.
3. Obiefuna, PC et al. J Pharmacol Exp Ther 315:329–336, 2005.
Supported by STTR Phase I Grant # AI056603
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Adenosine, an important signaling molecule in asthma, produces bronchoconstriction in allergic rabbits, primates,
and humans by activating A1 adenosine receptors (ARs) [1–3]. The effects of activation of A1 ARs on airway
inﬂammation in asthma are unknown. The effects of L-97-1, a water-soluble, small molecule A1 AR antagonist,
are compared to montelukast sodium (MK), a cysteinyl leukotriene-1 (CysLT1) receptor antagonist on early and
late phase allergic responses (EAR and LAR), bronchial hyper-responsiveness (BHR) to histamine, and airway
inﬂammation following House Dust Mite (HDM) administration in a hyper-responsive rabbit model of allergic
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Springerasthma. Rabbits were made allergic by intraperitoneal injections of HDM extract within 24 h of birth followed by
booster HDM injections. Hyper-responsive rabbits were subjected to aerosolized HDM (2500 AU), 1 h after
intragastric administration of L-97-1 (1 mg/kg) or MK (0.15 mg/kg) and, lung dynamic compliance (Cdyn) and
airway inﬂammation was assessed. Cdyn was signiﬁcantly higher following treatment with L-97-1 at all time points
and with MK at 60–300 min following HDM (p<0.05); thus, L-97-1 blocks both EAR and LAR, whereas MK
blocks only LAR. Both L-97-1 and MK signiﬁcantly blocked BHR at 24 h (p<0.05). Both L-97-1 and MK signi-
ﬁcantly reduced bronchoalverolar lavage (BAL) eosinophils at 6 h and neutrophils at 6 and 24 h (p<0.05). As
opposed to MK, L-97-1 signiﬁcantly reduced BAL lymphocytes at 6 and 24 h, while MK signiﬁcantly reduced
BAL macrophages at 6 and 24 h (p<0.05). By blocking both bronchoconstriction and airway inﬂammation, L-97-1
may be an effective oral anti-asthma treatment.
1. Ali S et al. J Pharmacol Exp Ther 1994; 268: 1328–1334.
2. Nyce JW, Metzger WJ. Nature 1997; 385: 721–725.
3. Bjorck T et al. Am Rev Respir Dis 1992; 145: 1087–1091.
Supported by North Carolina Biotechnology Center Kenan Award CFA #2000 CFG 8002 and STTR Phase I Grant #
HL070458.
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Four types of adenosine receptors have been implicated in adenosine-mediated physiological and pharmacolog-
ical responses in the lung. A2A receptor activation has been attributed to potent anti-inﬂammatory properties and
its deﬁciency may lead to activation of pro-inﬂammatory transcription factor NF-kappa B. The present study was
undertaken to investigate the role of adenosine A2A receptor on iNOS, Rel A (p65 subunit of NF-kappa B) and
A2A adenosine receptor gene expression along with the levels of pro-inﬂammatory cytokines in the lung in an
allergic asthma model [1–4] in adenosine A2A receptor knockout (KO) mice. A2A KO and wild-type (WT) mice
were sensitized with two i.p. injections of ragweed (200 2g) on days 1 and 6. Aerosolization challenge was perf-
ormed with 0.5% ragweed for 20 minutes both in the morning and afternoon on days 11, 12 and 13. Twenty-four
hrs after the last challenge, bronchoalveolar lavage ﬂuid (BALF) and lungs were collected from the mice for
cytokine and gene expression assays, respectively. Allergen challenge in sensitized mice increased gene expression
of both Rel A and i-NOS of WT and KO as compared to their respective controls (p<0.01), with KO having
greater expression of both of these genes than WT. A2A receptor expression was down-regulated by allergen
challenge in WT sensitized mice as compared to WT controls whereas no transcripts of this receptor were dete-
ctable in KO mice. On the other hand, levels of pro-inﬂammatory cytokines (IL-2 and IL-4) were found to be
higher in KO allergen challenged mice as compared to their respective WT sensitized and challenged mice (p<-
0.01). Moreover, total nitrates and nitrites as a measure of nitric oxide production in the lung were also found to
be higher in WT and KO allergen challenged mice as compared to their respective controls (p<0.01) with KO
sensitized and challenged mice having greater NO production than respective WT mice (p<0.05). These data
showed that A2A receptor down-regulation resulted in increased gene expression of Rel, A which is believed to be
involved in transcription of pro-inﬂammatory genes. The corresponding increased levels of pro-inﬂammatory
cytokines and expression of i-NOS along with increased NO generation in the lung may be a result of this Rel A
activation. These data suggest that A2A receptor deﬁciency might result in increased expression of pro-inﬂamm-
atory transcription factor Rel A leading to downstream expression of pro-inﬂammatory genes in this model of
asthma. (Supported by HL-027339).
1. Fan M, Mustafa SJ. Int Immunopharmacol 2006; 6:36–45.
2. Oldenburg PJ, Mustafa SJ. J Pharmacol Exp Ther 2005; 313:319–24.
3. Fan M, Qin W, Mustafa SJ. Am J Physiol Lung Cell Mol Physiol 2003; 284:L1012–9.
4. Fan M, Mustafa SJ. Pulm Pharmacol Ther 2000; 15:147–55.
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The research on adenosine receptors has resulted in considerable progress in identifying selective agonists and
antagonists and an increased understanding of the particular roles adenosine receptor subtypes play in physiol-
ogical processes [1]. In the last years, A2A adenosine receptor antagonists have been proposed as an attractive
pharmacological tool for the treatment of several diseases, such as motor dysfunctions, because of the interaction
between A2A and D2 dopamine receptors in the basal ganglia, and A2A antagonists could improve motor dysfu-
nction in a variety of models relevant to Parkinson_s disease. In addition, A2A adenosine receptor antagonists or
the absence of A2A receptors is associated to neuroprotection. In this work our attention has been directed toward
A2A adenosine receptor antagonists with adenine structure. In previous studies it was demonstrated that the
introduction in 2 position of 9-ethyladenine of alkylamine or alkoxy chains leads to compounds endowed with
afﬁnity for the human adenosine receptors in the 2M range [2, 3]. In particular 9-ethyl-2-phenylethoxyadenine (2)
and 9-ethyl-2-phenylethylaminoadenine (3) showing Ki A2A = 0.12 2M and 0.15 2M respectively, were slightly
A2A selective. In addition, the introduction of a bromine atom in 8 position of 9-ethyladenine (1) led to 8-bromo-
9-ethyladenine (4) endowed with improved afﬁnity for all receptor subtypes. Starting from these observations and
in the search for potent and selective adenosine receptor antagonists, a new series of 9-ethyladenine derivatives
bearing different chains in 2 and 8 position was undertaken. Binding studies at human adenosine receptors sho-
wed that the new compounds are endowed with high afﬁnity for the A2A receptor and are slightly selective for the
same subtype. In particular, 8-bromo-9-ethyl-2-phenylethoxyadenine (5;K i A2A = 0.002 2M) and 9-ethyl-8-furyl-
2-phenylethoxyadenine (6;K i A2A = 0.002 2M) resulted to be two of the most potent A2A antagonists with
adenine structure reported so far. Molecular modelling studies have been performed by docking analysis of the
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Absence of NTPDase1 Unmasks Vasoconstrictor Effects
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SpringerExtracellular nucleotides regulate vascular tone in different ways and can promote both vasodilation and vasoc-
onstriction. Activation of certain endothelial P2 receptors induces the release of endothelium derived vasodilating
agents (NO, PGI2, EDHF) leading to a vasorelaxation. In contrast, the direct effect of nucleotides on vascular
smooth muscle cells (SMC) P2 receptors induces the phosphorylation of myosin light chain, its association with
actin leading to SMC contraction and a vasoconstriction. Nucleoside triphosphate diphosphohydrolase-1 (NTP-
Dase1) is expressed on both vascular endothelium and smooth muscle. As NTPDase1 is the major ectonucleo-
tidase regulating nucleotide concentrations and platelet activation in the environment of blood vessels, we
propose that this enzyme may also regulate vasomotor tone. Despite normal adventitial expression of NTPDase2
in Entpd1 j/j mice vessels, the absence of NTPDase1 leads to a dramatic deﬁcit in global nucleotidase activity
(hydrolysis of ATP, ADP, UTP and UDP). Using ex vivo isometric contraction experiments we compared the
vascular reactivity of aortic ring of Entpd1 j/j and +/+ mice. We found that the effect of exogenous nucleotides
is enhanced in the absence of NTPDase1. While UDP and UTP (100 2M) induced a strong contraction (1.7 fold of
Phenylephrine-induced contraction) in Entpd1 j/j mice aorta rings, only a weak contraction could be measured
in Entpd1+/+ mice aorta rings (0.1fold of Phenylephrine-induced contraction). The pharmacological proﬁle of the
response suggests that a P2Y6 like receptor is involved in the uracil nucleotide-induced vasoconstriction. Our data
show that NTPDase1 regulates extracellular nucleotide signalling at the level of medial SMC.
Absence/Reduced Level of Diadenosine Triphosphatase (Fhit protein)
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Mammalian cells contain several intracellular diadenosine polyphosphates, ApnA, a family of dinucleotides with
intriguing biological functions. Among them, Ap3A and Ap4A receive most attention and appear to play antag-
onistic roles as intracellular signals in the control of cellular status. Cell proliferation and differentiation are
associated with increases in Ap3A/Ap4A ratio but apoptosis with decreases. Increased intracellular Ap4A conc-
entration may be involved in tumour cell growth suppression by inducing apoptosis. Diadenosine triphosphatase
(Ap3Aase) and asymmetrical diadenosine tetraphosphatase (Ap4Aase) are the most important regulators of in-
tracellular Ap3A and Ap4A levels. It has been reported that the novel tumour suppressor Fhit (fragil histidine
triad) protein displays dinucleotide hydrolase in vitro and that the ‘‘old’’ enzyme Ap3Aase and Fhit are identical
proteins. Re-expression of Fhit protein in Fhit deﬁcient cancer cells results in growth inhibition and restoration of
apoptosis.
We have determined the activities and expression of Fhit-Ap3Aase and Ap4Aase in soluble protein extracts from
the following tumoural cell lines: C6 (rat glioma) Daoy (human medulloblastoma) and PC12 (rat pheochromocy-
toma). Soluble protein extracts from brain areas (hypothalamus, hippocampus, temporal cortex, frontal cortex and
striatum), primary astrocytes from rat cerebellum and HCN-1A cells were used as controls. The ﬂuorogenic subs-
trates (-(Ap3A) and (-(Ap4A) were used for measurement of Ap3Aase and Ap4Aase activities and polyclonal Fhit
antibodies to detect Fhit-Ap3Aase expression by western blotting. Both Fhit-Ap3Aase and Ap4Ase were clearly
detected in all brain areas with activity levels around 4 and 22 mU/mg respectively and Ap4Aase/Ap3Aase activity
ratios ranging between 4 and 6. Similar values were obtained for whole brain extracts. These ratios seem to be organ
speciﬁc and limited between 4 and 10. Table I summarizes results obtained for cell cultures and whole brain.
Table 1. Fhit-Ap3Aase and Ap4Aase activity (mU/mg protein) in extracts of whole brain and cell cultures. Values
are means T SD. R means Ap4Aase/Ap3Aase ratio.
Ap3Aase Ap4Aase R Ap3Aase Ap4Aase R
Brain 4.22 T 0.43 22.10 T 2.21 5.23 T 0.43 PC12 0.10 T 0.03 5.46 T 0.72 53.63 T 8.19
Astrocytes 2.25 T 1.09 21.33 T 5.42 10.05 T 2.47 C6 0.33 T 0.53 15.98 T 2.32 140.7 T 163.8
HCN-1A 0.40 T 0.20 9.97 T 3.88 39.64 T 36.75 Daoy 0 14.76 T 3.76 V
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tumoural cell lines presented aberrant high Ap4Aase/Ap3Aase ratios at expense of low Ap3Aase activity. Lack of
Fhit-Ap3Aase activity correlated with lack of Fhit protein expression as detected by western-blotting. Results
suggest that alterations in metabolism of ApnA and their intracellular antitumour signalling pathways are invol-
ved in genesis/progression of neural tumours.
Acknowledgments: Work funded by grants TR5-02 and TR2003/06 (Gobierno de Canarias with participation of
Hospiten SA, NovoNordisk Ibe ´rica SA, Aventis Behring SA) and C03/06 (Red CIEN, FIS).
Activation of ecto-50-nucleotidase by phospholipids
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Backround: Ecto-50-nucleotidase is the major enzyme controlling extracellular adenosine production in endothe-
lial cells. Adenosine is a signal molecule involved in various hemodynamic and inﬂammatory processes. Activa-
tion of ecto-50-nucleotidase increases adenosine concentration on the cell surface, and therefore may provide a
tool to inﬂuence inﬂammatory processes. Furthermore, phospholipids are known modulators of various hemod-
ynamic and inﬂammatory processes. Therefore adenosine might act as part of a signal transduction pathway in
phospholipid signalling.
Methods: As experimental model we used human umbilical vein endothelial cells (HUVEC), pre-incubated with
5–10 2M of various phospholipids including +-acyl-"-lyso-!-phosphatidylcholine, "-arachidonyl-+-palmityl-!-pho-
sphatidylcholine, ",+-dipalmityl-!-phosphatidyl-choline, ",+-dipalmityl-!-phosphatidylethanolamine, ",+-dipalmi-
tyl-!-phosphatidylserine, +-acyl-"-lyso-!-phosphatidylethanolamine, +-acyl-"-lyso-!-phosphatidylic acid,
sphingosine-1-phosphate and sphingosylphosphorylcholine and "-acetyl-+-O-hexadecyl-!-phosphatidylcholine (k-
nown as platelet activating factor). In the cell supernatant the extracellular dephosphorylation rate of the ﬂuor-
escent AMP-analogue 1,N
6-etheno-50AMP to 1,N
6-etheno-adenosine was measured by HPLC.
Results: Out of these ten structurally related phospholipids only lysophosphatidylcholine (LPC), sphingosylphos-
phorylcholine (SPC) and platelet activating factor (PAF) increased the breakdown rate of AMP in a dose dep-
endent manner. Interestingly, the activation can only be observed in a narrow concentration range between 5 and
20 2M. At higher phospholipid-concentrations the effect is blunted. Pharmacological blocking experiments with
AOPCP, a speciﬁc inhibitor of ecto-50-nucleotidase, showed that this effect was due to an activation of ecto-50-
nucleotidase.
Although protein kinases A and C are known to activate ecto-50-nucleotidase, application of blockers of both
kinases did not diminish the effects of LPC, SPC and PAF. Furthermore, the effect does not seem to be mediated
by G-protein-coupled receptors, as suramine and pertussis toxin had no effect.
Conclusions: Using information on the known molecular structures of tested phospholipids, a phosphatidylcholine
residue in !-position and a short chain length fatty acid esteriﬁed in "-position seem essential for activation of
ecto-50-nucleotidase by phospholipids. The signal transduction/activation mechanism of ecto-5"-nucleotidase re-
mains unclear at present.
Lit.: Pexa A, Deussen A (2005) Modulation of ecto-50-nucleotidase by phospholipids in human umbilical vein endothelial cells
(HUVEC). Naunyn Schmiedebergs Arch Pharmacol 372:131–138
Activation of P2Y1 and P2X7 receptors induce calcium/calmodulin-dependent
protein kinase II phosphorylation in cerebellar granule neurons.
M
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The activation of nucleotide receptors -both ionotropic, P2X, and most of metabotropic, P2Y- increases intrac-
ellular calcium concentration, resulting in calcium-calmodulin-dependent protein kinase II (CaMKII) activation.
Stimulation of cerebellar granule neurons in culture -with different P2X and P2Y agonists and their effect on
CaMKII phosphorylation- was studied using immunocytochemical and microﬂuorimetrical techniques. P2X ag-
onist: 20-30-o-(4-benzoylbenzoyl)-adenosine 50-triphosphate (BzATP), !,"-methylene adenosine 50-triphosphate
(!,"-meATP) and diadenosine pentaphosphate (Ap5A), and P2Y agonists: 2-(methylthyo)-adenosine diphosphate
(2MeSADP) and uridine 50-bisphosphate (UDP), tested induced a CaMKII phosphorylation but with a different
immunostaining pattern in each group. Stimulation with 2MeSADP induced a Ca
2+ release from intracellular
stores and a signiﬁcant CaMKII phosphorylation in both cell somas and ﬁbres. This agrees with the subcellular
distribution of P2Y1. MRS 2179, a speciﬁc P2Y1 inhibitor, antagonized the 2MeSADP effect. On the other hand,
cerebellar granule neuron stimulation with BzATP, in Mg
2+ free conditions, produced extracellular calcium en-
trance and, as a result, a signiﬁcant increase in CaMKII phosphorylation mostly in ﬁbers, which correspond with
P2X7 subdistribution. Immunocytochemical and microﬂuorimetrical experiments, using Zn
2+ and Brilliant Blue G
(BBG), as an speciﬁc P2X7 antagonist, conﬁrmed that BzATP was acting through the P2X7 receptor. These
results, indicate that P2Y1 and P2X7, produce a signiﬁcant increase in CaMKII phosphorylation, but show imp-
ortant differences in subcellular distribution and in effect duration. The abundant presence of P2X7 at the syn-
aptic structures suggest the relevant role played by this receptor in synaptic plasticity.
Activation of the adenosine A2A receptor protects mice deﬁcient in CD8+
T-lymphocytes from liver ischemia-reperfusion injury.
McGreevy KS, Linden J.
Department of Medicine, University of Virginia, Charlottesville, VA 22908 USA
ksm3@hscmail.mcc.virginia.edu
BACKGROUND: The actions of T-lymphocyte subsets and their regulation through adenosine is of interest in
many disease models, including ischemia-reperfusion injury. This study explores the effect of the selective ade-
nosine A2A receptor agonist ATL-313 in animals depleted of CD4
+ or CD8
+ T-lymphocytes in a model of liver
ischemia-reperfusion. METHODS: Immune-competent B6 mice were depleted of CD4
+ or CD8
+ T-lymphocytes
in vivo by the introduction of an antibody to the respective cell type into the circulation. Rat monoclonal anti-
bodies were prepared by an intraperitoneal injection of the hybridoma cell lines GK1.5 or 2.43 into SCID mice.
Ascites ﬂuid was collected and puriﬁed, and the ﬁnal antibody concentration was adjusted to 1 mg/ml for storage.
Experimental animals were tested for appropriate depletion of CD4
+ or CD8
+ T-lymphocytes through FACS
analysis of the remaining T-lymphocyte population, labeled with commercially available antibodies. The antibo-
dies were titered to determine the optimal dose of each for producing effective and selective depletion, found to
be 0.05 mg per mouse delivered on two consecutive days. On the fourth day after the second injection animals
were subjected to liver ischemia/reperfusion, which was performed by application of a microaneurysm clamp to
the hepatic triad for seventy-ﬁve minutes. Drug-treated animals received a bolus injection of 3 2g/kg ATL-313
ﬁfteen minutes prior to reperfusion, and an Alzet pump delivering 1 ng/kg/min ATL-313 at reperfusion, while
control animals received vehicle. Blood was drawn 24 hours after the onset of ischemia, and a serum alanine
aminotransferase (ALT) assay was performed to assess the degree of liver injury. RESULTS: In vehicle treated
animals, the extent of injury in CD4
+ depleted mice (1846.2 T 440.8 IU/L) was signiﬁcantly less than that of wild-
type (5747.9 T 413.6 IU/L) or CD8
+ depleted mice (5809.4 T 1097.1 IU/L). ATL-313 provided signiﬁcant prote-
ction in wild-type (3472.0 T 666.0 IU/L) and CD8
+ depleted animals (3475.5 T 424.9 IU/L) but not in CD4
+
depleted animals (1768.9 T 735.2 IU/L). CONCLUSION: The loss of CD4
+ T-lymphocytes provides protection
from liver ischemia-reperfusion injury, while the loss of CD8
+ cells does not. A protective effect of the adenosine
A2A receptor agonist ATL-313 is seen in wild-type and CD8
+ depleted animals, but no further protection is
conferred upon CD4




1. Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L, Engelhardt JF. 1997. CD4+ T-Lymphocytes mediate isch-
emia/reperfusion-induced inﬂammatory responses in mouse liver. J. Clin. Invest. 100:279–289.
2. Day YJ, Li Y, Rieger JM, Ramos SI, Okusa MD, Linden J. 2005. A2A adenosine receptors on bone marrow-derived cells
protect liver from ischemia-reperfusion injury. J. Immunol. 174:5040–6.
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Membrane-bound NTPDase2 is a member of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase)
enzyme family involved in the regulation of P2 receptor signalling. NTPDase2 has broad substrate speciﬁcity for
extracellular nucleotides, but hydrolyses nucleoside 50-triphosphates with high preference over nucleoside 50-
diphosphates. In this study we have sought to determine how enzyme substrates acting on P2 receptors affect
intracellular NTPDase2 trafﬁcking. To achieve this, Chinese hamster ovary (CHO) cells expressing endogenous
P2X7 and P2Y2 receptor subunits were transiently transfected with rat-speciﬁc NTPDase2 cDNA (GenBank
accession no. NM_172030) tagged with a green ﬂuorescent protein (GFP) to allow direct visualisation of subce-
llular localisation and trafﬁcking of NTPDase2.
Methods: Cells were transfected with plasmid containing recombinant GFP-NTPDase2 cDNA using Lip-
ofectaminei 2000 reagent. Transiently transfected CHO cells were imaged using an inverted confocal microsc-
ope (Zeiss LSM410) with 488-nm excitation. Cells were perfused (1 ml/min) with NTPDase2 substrates (ATP,
UTP) and non-hydrolyzable ATP and ADP analogues ATP+S and ADP"S (0.5 mM) in phosphate-free saline
solution at room temperature. Z-stack image series were taken at 0, 5, 10, 20 and 30 minutes. P2 receptor inhi-
bitors (suramin, PPADS, brilliant blue) were pre-incubated with CHO cells for 60 minutes before adding extra-
cellular nucleotides. NTPDase2 incorporation into the cell membrane was determined at time intervals by
comparative analysis of pixel intensity of ﬂuorescence in the cytosolic and membrane compartments. To delineate
the plasma membrane, CHO cells were stained with a membrane dye Di 4 ANNEPS (Molecular Probes). For
calcium imaging, cells were loaded with 4 2M Fluo-4 (Molecular Probes) in cell culture medium for 60 minutes
before stimulation with ATP, UTP and ADP. This study conﬁrmed the functional expression of endogenous
ATP-preferring P2X receptors and ADP and UTP-preferring P2Y receptors. NTPDase2 activity was measured in
transiently transfected GFP-NTPDase2 CHO cells. Cells were perfused with NTPDase2 substrates ATP and UTP
(0.5 mM) individually to assess the hydrolysis rate. Perfusion was paused for 1 minute at time intervals used for
cell imaging and a sample aliquot was removed for HPLC analysis.
Results and conclusion: (1) The present study shows that NTPDase2 tagged with GFP is functional. (2) ATP and
its non-hydrolysable analogue ATP+S induce rapid membrane incorporation of NTPDase2 from putative intrac-
ellular stores in CHO cells transiently transfected with GFP-NTPDase2, whilst UTP and ADP"S are ineffective.
(3) NTPDase2 trafﬁcking requires extracellular Ca
2+. (4) Pharmacological studies show that activation of P2X
receptors involving Ca
2+ entry, rather than P2Y receptors releasing stored Ca
2+, may be linked to trafﬁcking of
NTPDase2 to the cell membrane. (5) Initial hydrolysis rate for ATP correlates with increased NTPDase2 expr-
ession on the plasma membrane, whilst the initial velocity of UTP hydrolysis remains steady. (6) Increased
trafﬁcking of NTPDase2 to the cell membrane may reﬂect a regulatory mechanism to limit excessive stimulation
and desensitisation of P2 receptors.
Supported by the Health Research Council of New Zealand and Auckland Medical Research Foundation.
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Background Characteristics of the metabolic syndrome are associated with a hyperdynamic circulation. In these
patients, a hyperdynamic circulation predicts future development of type 2 diabetes mellitus. Free fatty acids
(FFA) have been implicated as mediators of this hyperdynamic circulation in patients with the metabolic synd-
rome. Previous in vitro studies have shown that FFA can inhibit the mitochondrial adenine nucleotide transpo-
rter, thus increasing cytosolic adenosine concentration. We hypothesized that FFA-induced vasodilation is
mediated by adenosine receptor stimulation
1.
Methods Nine healthy subjects participated in a randomised cross-over trial. Intralipid was administered intrav-
enously for 2 hours with heparin to activate lipoprotein lipase to elevate plasma FFA. Glycerol/heparin was given
on the other occasion as Control treatment. Forearm blood ﬂow (FBF) was measured by venous occlusion plet-
hysmography. During the last 15 minutes of infusion, the adenosine receptor antagonist caffeine was administered
into the brachial artery of the non-dominant arm. In a validation study, adenosine was infused into the brachial
artery (5 2g/min per dl of forearm tissue) and subsequently caffeine was added (90 2g/min/dl) to conﬁrm effective
adenosine receptor antagonism (n = 6).
Results Administration of Intralipid increased plasma FFA from 334 T 108 2mol/l at baseline to 1269 T 234, whereas
Control infusion increased FFA from 338 T 114 2mol/l to only 432 T 175. Intralipid infusion induced a hyperdynamic
circulation: systolic blood pressure increased from 115 T 8 to 122 T 8 and from 116 T 10 to 120 T 9 mmHg, pulse
pressure increased from 53 T 6t o5 9T 6 and from 53 T 5t o5 5T 9 mmHg and FBF increased from 1.8 T 0.7 to 2.7 T 1.8
and from 2.3 T 0.7 to 2.7 T 1.8 ml/dl/min for Intralipid versus Control infusion, respectively. (P = 0.05, P < 0.05, and P
< 0.05). In the validation study, adenosine-induced vasodilation was effectively reduced by caffeine (P < 0.01).
However, the FFA-induced vasodilation could not be reduced by administration of caffeine (P = NS).
Conclusion Acute elevation of plasma FFA levels induces an increased skeletal muscle blood ﬂow, systolic blood
pressure, and pulse pressure (hyperdynamic circulation). The vasodilator response is not mediated by adenosine
receptor stimulation. Therefore, it is unlikely that adenosine mediates the association of a hyperdynamic circul-
ation and the metabolic syndrome.
1. Bakker, S. J.; Gans, R. O.; ter Maaten, J. C.; Teerlink, T.; Westerhoff, H. V.; Heine, R. J. The potential role of adenosine in
the pathophysiology of the insulin resistance syndrome. Atherosclerosis 2001, 155, 283–290.
Acyl derivatives of coenzyme A inhibit ADP-induced platelet function via
antagonism at P2Y1 and P2Y12 receptors.
Stan Heptinstall, Panagiotis Manolopoulos, Jacqueline R Glenn, Susan C Fox, Jane A May, Natalia
Dovlatova, Siau-Wei Tang, Nadine Bauer, Martin Hesse, Neil R Thomas
1 and Vera Ralevic.
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ADP plays a central role in platelet aggregation and is important in haemostasis and thrombosis. Individuals
whose platelets respond poorly to ADP often present with easy bruising or bleeding. Also a pharmaceutical agent
that inhibits ADP-induced platelet aggregation, clopidogrel, is in widespread use as an antithrombotic agent.
ADP induces platelet aggregation acting via P2Y1 and P2Y12 receptors and clopidogrel acts as an antagonist at
P2Y12 receptors. Interaction with P2Y1 induces rapid Ca
2+ mobilisation leading to a change in the shape of
platelets from smooth discs to spiny spheres and a transient aggregation response. Interaction with P2Y12 inhibits
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required for full aggregation induced by ADP. Antagonists acting at either P2Y1 or P2Y12 receptors (or both)
could be usefully employed as anti-thrombotic agents. Following an observation that derivatives of coenzyme A
(CoA) act as antagonists at P2Y1 receptors transfected into oocytes (1), we tested the effects of various acyl
derivatives of CoA on platelet aggregation. Measurements were performed in both whole blood and platelet-rich
plasma. CoAs containing a range of saturated and unsaturated acyl groups inhibited ADP-induced platelet agg-
regation. Those with saturated acyl groups containing 16–18 carbons were most effective and introduction of
unsaturation into the fatty acid chains reduced efﬁcacy. The effects of palmitoyl-CoA (16:0) were then tested on a
variety of aspects of platelet function. Speciﬁcity for effects on platelet aggregation induced by ADP was dem-
onstrated by showing that palmitoyl-CoA inhibited ADP-induced aggregation but not that induced by platelet
activating factor, thrombin receptor activating peptide (TRAP) or serotonin. ADP-induced aggregation and also
P-selectin expression (a marker of !-granule release) were inhibited in a competitive way. Measurements of shape
change were performed using the Biola laser aggregometer and also ﬂow cytometry. Complete inhibition of ADP-
induced shape change by palmitoyl-CoA indicated antagonism via P2Y1 receptors. Again there was no inhibition
when other agonists were used, including agonists that act at P2X1 receptors. Ca
2+ mobilisation was measured
using ﬂuo 3-labelled platelets and ﬂow cytometry. These studies also revealed complete inhibition by palmitoyl
CoA of the increase in [Ca
2+]i that occurred in response to ADP, again indicative of antagonism at P2Y1 rece-
ptors. Experiments were also performed to look for possible antagonistic effects of palmitoyl-CoA at P2Y12
receptors on platelets. This was done by examining platelet aggregation and/or Ca
2+ mobilisation in response to
collagen and to pairs of agonists: ADP and serotonin, and ADP and TRAP. Measurements of ADP-induced
changes in cAMP and vasodilator-stimulated phosphoprotein phosphorylation were also performed. Results ob-
tained with palmitoyl-CoA were compared with those for MRS 2179 (a P2Y1 antagonist), AR-C69931 (a P2Y12
antagonist) and combinations of these. The results were all consistent with palmitoyl-CoA inhibiting platelet
function via antagonism at P2Y12 receptors in addition to P2Y1 receptors. Acyl derivatives of CoA such as those
used in this investigation are natural agents that could be released into blood following cell and tissue activation
and/or damage and thereby be involved in endogenous control of platelet function. They might also form the basis
for a new class of antithrombotic drugs.
1. Coddou C et al. FEBS Lett. 2003;536:145–50
Adenine and adenosine salvage pathways in erythrocytes and the role
of S-adenosylhomocysteine hydrolase. A theoretical study using elementary
ﬂux modes
Dimitar Kenanov and Stefan Schuster
Department of Bioinformatics, Friedrich Schiller University, Ernst-Abbe-Platz 2, 07743 Jena, Germany
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This talk is devoted to the study of redundancy and yield of salvage pathways in human erythrocytes. These cells
are well known not to be able to synthesize ATP de novo. However, the salvage (recycling) of certain nucleosides
or bases to give nucleotide triphosphates is operative. As the salvage pathways use enzymes consuming ATP as
well as enzymes producing ATP, it is not easy to observe the net synthesis of ATP. As for pathways using
adenosine, a straightforward assumption is that these pathways start with adenosine kinase. However, a pathway
bypassing this enzyme and using S-adenosylhomocysteine hydrolase instead was reported. So far, this route has
not been analysed in detail.
For the analysis we use the concept of elementary ﬂux modes which can be described as a minimal set of enzymes
able to operate at steady state with all irreversible reactions running in the right direction. This method opens up
the possibility to study the various modes of behaviour of the biochemical system and it also allows detection of
possible bypasses otherwise not easily understood by just observing the metabolic pathway. This tool enables one
to simulate the interaction between several subsystems utilising substrates of interest or systems with enzyme
deﬁciencies which can be used in investigating diseases caused be these deﬁciencies.
Using the concept of elementary ﬂux modes, in the present study we investigate theoretically which salvage
pathways exist in erythrocytes, which enzymes belong to each of these and what relative ﬂuxes these enzymes
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that the network has considerable redundancy. For example, four different pathways of adenine salvage and 12
different pathways of adenosine salvage are obtained. They give different ATP/glucose yields, the highest being 3
: 10 for adenine salvage and 2: 3 for adenosine salvage provided that adenosine is not used as an energy source.
Implications for deﬁciencies of the enzymes ADA and PNPase are also discussed.
Reference:
S. Schuster and D. Kenanov. Adenine and adenosine salvage pathways in erythrocytes and the role of S-adenosylhomocysteine
hydrolase. A theoretical study using elementary ﬂux modes. FEBS J. (2005) 272: 5278–90.
Adenosine 50-triphosphate (ATP) in exhaled breath condensate of patients
with hypoxia
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ATP is released from many different cells in response to hypoxia activating purine receptors expressed by the
same or neighboring cells leading to bronchoconstriction in the airways. We hypothesized that in hypoxia ATP
concentration in the lungs is elevated compared to normal oxygenation. In our study we compared ATP conce-
ntrations in exhaled breath condensate (EBC) from patients with respiratory diseases causing hypoxia and healthy
subjects, we studied whether clinical improvement of patients resulted in a decrease in ATP concentrations and
investigated the correlation between ATP levels and partial arterial oxygen pressure. EBC was collected for 15
minutes from 15 patients with hypoxia and 8 healthy subjects. Simultaneously, blood gas of all participants was
analyzed. In 9 subjects, EBC collection and blood gas analysis were repeated following clinical improvement.
ATP was measured by a bioluminescence assay (ENLITEN ATP Assay System, Promega). Statistical analysis was
performed non-parametrically. Data are expressed as median [range]. Patients exhibited profound hypoxia co-
mpared to healthy subjects (7.51 [4.67–8.62] kPa vs. 10.23 [8.32–13.47] kPa, p < 0.01) but there was no signiﬁcant
difference in EBC ATP concentration between the two groups (40 [22–473] pM vs. 33 [26–257] pM). Although
clinical variables and pO2 demonstrate signiﬁcant improvement during hospitalization (n = 9, pO2 pretreated: 7.84
[5.07–8.62] kPa vs. pO2 at discharge: 8.85 [5.08–9.75] kPa, p < 0.01), ATP values did not change signiﬁcantly (n =
9, ATP pretreated: 26 [22–473] pM vs. ATP at discharge: 47 [18–77] pM) and there was no correlation between
changes in pO2 and ATP concentration in EBC. In summary, ATP is detectable in EBC; however, our results
suggest that hypoxia per se is not a major contributing factor to its level.
This study was supported by the Hungarian National Scientiﬁc Research Foundation (OTKA T-43396).
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Background: Schistosomiasis is a parasitic disease affecting more than 200 million people worldwide in which the
pathology, including hepatic ﬁbrosis and portal hypertension, results from host reactions to parasite. We have
documented that adenosine released endogenously ligates adenosine A2A receptors to promote ﬁbrosis but inhibit
inﬂammation. It also has been documented that A1 receptor activation may serve to regulate pulmonary and renal
inﬂammation in mice during chronic diseases. We therefore determined whether adenosine A1 and A2A receptors
contribute to the pathophysiology of schistosomal infection.
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SpringerMethods: 3–10 month old female A1 and A2A KO and WT littermate controls were infected with S. mansoni and
sacriﬁced 4 or 8 weeks post-infection (p.i.). Worms were perfused from the portal vein of infected mice and
measured. Fibrosis was digitally evaluated in 6 picrosirius red-stained sections/mouse. mRNA for IFN-+, IL-4, and
IL-10 from whole livers was analyzed by real time RT-PCR. Supernates of cultured mesenteric lymph node
(MLN) cells stimulated with soluble egg antigen were assayed for IFN-+, IL-4, IL-10 and IL-5 by ELISA.
Results: The worms from the A1KO mice were larger than their WT littermates 4 and 8 weeks p.i. There was also
an increase in the percentage of females in pairs in the A1KO in comparison to the WT (76 T 6 N = 8 vs. 36 T 19 N
= 3, p = 0.02) 4 weeks p.i. In the A2AKO mice there was a 5 and 20-fold increase in IFN-+ and IL-4 message,
respectively, 4 weeks p.i. This increase was accompanied by a striking 2-fold increase in hepatic ﬁbrosis in the
A2AKO compared to the WT mice (19 T 2 N = 8 vs. 8 T 1 N = 7, p < 0.0001). In addition, the levels of all cytokines
tested in supernates from cultured MLN cells showed at least a 2-fold increase in the A1KO and A2AKO mice as
compared to their WT controls. There were even more marked increases in IFN-+ and IL-4 levels in the KO mice















IFN-+ 170 T 7 N = 3 877 T 9 N = 3 <0.0001 5- fold 152 T 7 N = 3 1409 T 17 N = 3 0.0002 10-fold
IL-4 31 T 1 N = 3 140 T 3 N = 3 <0.0001 5-fold
Conclusion: Endogenous adenosine modulates immune responses to schistosomal infection via interaction with its
receptors. Increased hepatic ﬁbrosis in infected A2A KO mice most likely reﬂects enhanced immune reactions to
parasites observed in these animals. On the other hand, although A1 receptors modulate the immune response
they play no role in the development of hepatic ﬁbrosis in infected mice but appear to play a permissive role in
worm fecundity.
Adenosine A1 and A2A Receptors, CD39/CD73KO Inﬂuence Granulomatous
Responses to Mycobacterium Bovis BCG
Firas M. Kara
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Background: Granuloma formation around infected macrophage is a deﬁning cellular response to mycobacterium
infections. Granulomas eliminate bacteria and also protect surrounding host tissue from destructive inﬂammatory
responses. Without granuloma formation, mycobacterial infections can become widely disseminated and freque-
ntly lethal, as occurs in human AIDS-associated tuberculosis. Granuloma formation is characterized by a nodular
aggregation of mononuclear cells and multinucleated giant cells. Adenosine, formed extracellularly from adenine
nucleotides by nucleoside triphosphate dephosphorylase (CD39) and ecto-50nucleotidase (CD73), modulates m-
acrophage function by engaging cell surface adenosine receptors: A1 adenosine receptor activation promotes in
vitro giant cell formation and enhances phagocytosis, whereas A2A receptor activation inhibits in vitro giant cell
formation and phagocytosis. Therefore, we sought to study the formation of hepatic granulomas induced by BCG
in receptor (A1 and A2A) and adenosine-producing enzyme (CD39), (CD73) and (CD39/CD73) knockout mice.
Methods: 6 week old CD39KO, CD73KO and CD39/CD73KO, A2A KO and A1KO and appropriate WT female
mice were injected (IP) with BCG (10
7 CFU). After 4 weeks mice were sacriﬁced and hepatic granuloma number,
morphology and size analyzed digitally and expressed as granulomas/10  ﬁeld and pixels/granuloma, respectively.
Results: Granuloma size did not differ among CD39KO, CD73KO and WT mice (3445 T 796, N = 3, 2818 T 610, N
= 2 vs. 2767 T 205, N = 10) but were larger in CD39/73KO mice (8295 T 2681, N = 5, P < 0.0001 vs. WT mice).
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and 35 T 12 N = 5 vs. 53 T 5 N = 10, respectively). CD39KO mice showed increased number of signiﬁcantly
granulomas than wild type mice (63 T 26 N = 3 vs. 53 T 5 N = 10, P = 0.02).
A1KO mice formed more granulomas than WT mice (22 T 9 vs. 13 T 6, n = 5 for both, p = 0.004) although
granulomas were smaller in A1KO mice (1135 T 102 vs. 1611 T 136, n = 5 for both, p = 0.004). In contrast, there
were fewer granulomas in the A2AKO mice formed fewer granulomas (4 T 2 vs. 12 T 6, n = 5 for both, p = 0.00005)
of the same size as WTs (Data not shown).
Conclusion: Adenosine, produced extracellularly from adenine nucleotides, alters the response to mycobacterial
infections via interaction with A1 and A2A receptors on macrophages.
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Recent ﬁndings support the notion that adenosine and adenosine receptors play an important role in human sleep
regulation
1,2. Post-mortem studies demonstrated a high density of adenosine A1 receptors (A1AR) in brain regions
involved in sleep regulation, such as thalamus, hippocampus, striatum, basal ganglia and cerebral cortex. Moreover,
the non selective adenosine A1 and A2A receptor antagonist, caffeine, stimulates alertness and attenuates changes in
the waking and sleep EEG, which are typically found after sleep deprivation. Nevertheless, the distinct roles of A1
and A2A receptors for sleep regulation are still controversial. The recent development of the potent and selective
A1AR antagonist, 8-cyclopentyl-3-(3-
18F-ﬂuoropropyl)-1-propyl-xanthine (
18F-CPFPX), offers the opportunity to
directly visualize and quantify A1AR binding in the living human brain.
We established the radiosynthesis of
18F-CPFPX according to a recently reported two step reaction sequence
3.
We obtained the target compound
18F-CPFPX in a radiochemical yield of about 10% and a radiochemical purity
of >99%. Speciﬁc activity exceeded 100 GBq/2mol.
In a still ongoing study, we combine quantitative EEG recordings and positron emission tomography (PET) brain
imaging to determine whether A1AR occupancy is enhanced after 32 hours of prolonged wakefulness when comp-
ared to a baseline recording (after 8 hours of wakefulness). Moreover, we examine whether the sleep-deprivation
induced changes in subjective vigilance, neurobehavioral performance and the EEG are reduced after 300 mg slow-
release caffeine intake when compared to placebo. To date, two groups of 5 healthy young men completed the
study. The ﬁrst results support a high
18F-CPFPX accumulation in sleep regulatory areas such as thalamus and
cortex. In contrast, low ligand binding is found in cerebellum and brain stem.
We conclude that PET brain imaging with
18F-CPFPX is a promising new tool to gain new insights into adeno-
sinergic mechanisms of sleep regulation in humans. The effects of sleep deprivation and caffeine on cortical and
subcortical A1AR occupancy remain to be determined.
Research supported by a Center for Neuroscience Zu ¨rich PhD Grant and the Swiss National Science Foundation.
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Adenosine is a nucleoside widely distributed in nervous system where acts as a neuromodulator and neuroprotector
through speciﬁc receptors. Adenosine receptors have been classiﬁed into four types: A1,A 2A,A 2B and A3 receptors.
A1 and A3 receptors inhibit adenylyl cyclase activity through Gi/o proteins, while A2A and A2B receptors stimulate
adenylyl cyclase through Gs proteins. Adenosine acting through A1 receptors inhibits excitatory neurotransmitter
release, therefore acting as a neuroprotector. Pick"s disease (PiD) is a fronto-temporal dementia characterized by
severe atrophy of the frontal and temporal lobes that spares the pre-central gyrus and the posterior two-thirds of the
superior temporal gyrus. This is accompanied by marked neuron loss, mainly in the upper cortical layers, and the
appearance of typical phospho-tau-immunoreactive intraneuronal inclusions named Pick bodies, principally in the
dentate gyrus of the hippocampus, CA1 region of the hippocampus, amygdala, septal nuclei, and upper layers of the
entorhinal cortex and isocortex, together with phospho-tau-immunoreactive thorn-shaped and ramiﬁed astrocytes,
and tau-positive bodies in oligodendroglia. The aim of the present work was to study A1 receptors/adenylyl cyclase
(AC) pathway in post-mortem human cortex from Pick"s disease (PiD) as compared with age matched non-deme-
nted controls. Adenosine A1 receptors, determined by radioligand binding and Western-blotting assays were sign-
iﬁcantly increased in PiD samples, suggesting the up-regulation of this receptor. Real time PCR analysis revealed an
increase in mRNA coding A1 receptor in PiD cases. Adenylyl cyclase activity was determined in basal and stimu-
lated conditions via stimulatory guanine nucleotide binding proteins (Gs) using GTP, or directly with forskolin.
Basal AC activity was reduced in brains from PiD cases. This agrees with the decrease in AC I level detected by
Western-blotting. No signiﬁcant differences in GTP- or forskolin-stimulated adenylyl cyclase activity were observed
between PiD and control cases. However, inhibition of forskolin-stimulated AC activity by a selective A1Ra g o n i s t
was signiﬁcantly increased in brains from PiD. These results show that adenosine A1 receptors/adenylyl cyclase
transduction pathway is up-regulated and sensitized in cortex brain from Pick"s disease.
Adenosine A1 receptors in the phrenic motoneurons of adult rats: A biochemical
study
Saharan SR, Kizy T, and Nantwi, KD.
Department of Anatomy and Cell Biology, Wayne State University, School of Medicine, 540 E. Canﬁeld, Detroit,
MI 48202
knantwi@med.wayne.edu
Previous studies from our laboratory have demonstrated that in an animal model of spinal cord injury (SCI), a latent
respiratory motor pathway can be activated to restore respiratory activity to a hemidiaphragm paralyzed by an upper
cervical (C2) spinal cord hemisection. Activation of the motor pathway occurs during a reﬂex known as the ‘‘crossed
phrenic phenomenon’’, by asphyxia or systemically administered theophylline. Theophylline acts via blockade of
adenosineA1 receptors. Adenosine receptors are located in the phrenic motor neurons (PMN). The objective of the
present study is to characterize adenosine receptors in the PMN of adult rats by radioligand binding. Binding
Assays: The speciﬁc binding of the adenosine A1- receptor selective ligand [
3H]-DPCPX to spinal cord membranes
was determined using a rapid ﬁltration assay. Spinal cord membranes were ﬁrst incubated with adenosine deaminase
(ADA, 5 U/mg protein) in 50 mM Tris buffer, 2 mM MgCl2 at pH 7.4 to remove endogenous adenosine. Membrane
suspension (at 0.1 mg/ml protein in a ﬁnal volume of 500 2l) was incubated for 1 h at 4-Cw i t h[
3H]-DPCPX in the
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harvester GF/B ﬁlters 0.5% PEI). Each ﬁlter was washed four times with 4 ml of cold 50 mM Tris-HCl, pH7.4. Filter
discs were punched into vials using a Deposit/Dispenser. Three milliliter aliquots of FUltima Gold_ Scintillation
Cocktail were added into each vial prior to scintillation counting. Filter-bound radioactivity was determined by
liquid scintillation counting using a Tricarb-2800-TR Liquid Scintillation counter. [
3H]-DPCPX was used (at 8–12
concentrations) in saturation binding. Competition studies used theophylline as the competing ligand at ten conc-
entrations (20 mM–20 pM); against a standard concentration of [
3H]-DPCPX (1 nM). Binding data were analyzed
with (Graphpad software,). Results: In naı ¨ve animals, a single receptor binding site with Bmax and Kd values of
256.00 T 32.13 (fmol/mg protein) and 2.89 T 0.45 (nM), respectively, was detected. Theophylline induced detection of
a second binding site with a Bmax of 492.6 T 3.15 (fmol/mg) and Kd 14.09 T 2.06 (nM) respectively. Hemisection
induced an up-regulation of A1 receptors; a Bmax 316.6 T 25.10 fmol/mg protein without apparent change in afﬁnity
(Kd 2.72 T 0.72 nM). It is concluded that A1 receptors in the PMN of adult rats are altered signiﬁcantly by theop-
hylline administration and C2 hemisection. The changes may underlie respiratory effects of theophylline. Further-
more, the up-regulation of the receptors after hemisection may be involved in theophylline-induced functional
recovery.
Adenosine A1 Receptors Play a Critical Role in Osteoclast Formation
Firas M. Kara
1, Bertil Fredholm
2 and Bruce N. Cronstein
1
1Division of Clinical Pharmacology, Department of Medicine, NYU School of Medicine, New York, NY USA.
2Karolinska Institutet, Stockholm, Sweden
Firas.kara@med.nyu.edu
Background: Osteoclasts are bone-resorbing, multinucleated giant cells that are essential for bone remodeling
that are formed through the fusion of mononuclear precursor cells. Osteoclasts differentiate from hemopoietic
precursors of the monocyte/macrophage lineage in the presence of M-CSF and receptor activator of NF-.B ligand
(RANKL). Deﬁciency of osteoclasts leads to osteopetrosis, a condition characterized by increased bone density.
Nonetheless, most bone diseases are due to increased bone resorption by osteoclasts and inhibition of osteoclast-
mediated bone resorption is a primary therapeutic objective. Indeed, most current therapies for osteoporosis are
directed at inhibition of osteoclast function. Because we have previously reported that adenosine A1 receptor
occupancy is required for fusion of stimulated human monocytes to form giant cells in vitro we determined
whether there was a similar requirement for A1 receptor occupancy in osteoclast formation.
Methods: Spleens were harvested from female mice and, following isolation, splenocytes were resuspended in
!MEM containing 10% FBS. The cells were cultured in the presence of M-CSF (30 ng/ml) and RANKL (30 ng/
ml) with or without various concentrations of the A1 receptor antagonist DPCPX or the A1 receptor agonist N6-
CPA. The culture was fed every 3 days by replacing half of the media containing the M-SCF, RANKL and
adenosine receptor agonist/antagonist. After incubation for 7 days, cells were stained for tartrate-resistant acid
phosphatase (TRAP). Osteoclasts were identiﬁed as TRAP-positive cells with 3 or more nuclei; the number of
TRAP-positive multinucleated cells/well was then enumerated.
Results: We found that adenosine A1 receptor occupancy is critical for the formation of osteoclasts by murine
splenocytes incubated with M-CSF and RANKL in vitro. DPCPX inhibited osteoclast formation in a dose-dep-
endent fashion (P = 0.0033); DPCPX inhibits osteoclastogenesis by directly acting on osteoclast precursors on day
0 (95.00 T 2.309 vs. 24.00 T 4.509 N = 3, P = 0.0002) compared to day 3 and 6 (95.00 T 2.309 vs. 63.33 T 14.53 N = 3,
P = 0.0977) since removal of DPCPX by adding N6CPA after 3 and 6 days after the start of incubation did not
reverse the inhibition of osteoclastogenesis (24.00 T 4.509 N = 3 vs. 29.33 T 2.333 N = 3, P = 0.3528). In contrast to
their wild type controls splenocytes from A1 receptor KO mice formed almost no osteoclasts in response to M-
CSF and RANKL (120.4 T 23.93 N = 5 vs. 21.40 T 2.839 N = 5, P = 0.0034). The osteoclast number and function in
the A1 KO mice did not appear to be normal as, in contrast to WT controls, osteoclasts in the A1 KO mice are not
attached to bone and there is little bone resorption associated with these osteoclasts.
Conclusion: These results indicate that endogenously released adenosine, acting at adenosine A1 receptors, plays
a critical role in the formation of osteoclasts and bone remodeling. Study presented above will probably lead to
new therapeutic approaches in several diseases that are characterized by excessive bone resorption. These results
suggest that adenosine A1 receptor antagonists may be useful in the treatment of such conditions as osteoporosis,
prosthetic joint loosening and other conditions in which osteoclasts play a pathogenic role (eg Paget"s disease).
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OF FOCAL CEREBRAL ISCHEMIA IN THE RAT
Pedata F., Gianfriddo M., Vannucchi M.G.
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1Department
of Histology, University of Florence, 50139 Florence, Italy.
felicita.pedata@uniﬁ.it
Previous results indicate that the adenosine A2A antagonist SCH 58261 administered acutely immediately after
focal ischemia reduces glutamate outﬂow and acute motor disturbance in the ﬁrst hours after ischemia
1.
The effect of a subchronic treatment of the A2A receptor antagonist, SCH58261, was studied in the same model of
focal cerebral ischemia. Focal ischemia was induced by middle cerebral artery occlusion (MCAo)
2. SCH58261
(0.01 mg/kg, i.p.) was administered 5 min, 6 hours and 15 hours after MCAo. Soon after ischemia, contralateral
turning behavior was evaluated as the number of rotations per hour between 3 and 4 h after MCAo. In SC-
H58261-treated rats (n = 14), the number of rotations per hour was signiﬁcantly reduced with respect to vehicle-
treated rats (n = 13) (mean T S.E.: 116.9 T 34.6 vs 795.4 T 170.6, p < 0.0001). Twenty-four hour after MCAo,
neurological deﬁcit and ischemic brain damage were evaluated. SCH58261-treated rats (n = 14) showed signiﬁcant
improvement of the neurological score (mean T S.E: 10.8 T 0.4 vs 8.8 T 0.5, p < 0.001) and reduction in the extent
of the ischemic damage by 26% in the cortex (41.1 T 2.8 mm
3 vs 55.6 T 3.9 mm
3, p < 0.02) and by 45% in the
striatum (12.8 T 1.9 mm
3 vs 23.2 T 2.7 mm
3, p < 0.01) with respect to vehicle-treated rats. The rats were then
sacriﬁced for evaluation of phospho-p38 MAPK levels in the ischemic hemisphere. The phospho-p38 MAPK
levels in the ischemic striatum of vehicle-treated rats (n = 5) were increased by 500% compared to the contral-
ateral non ischemic striatum. In SCH58261-treated rats (n = 6), the phospho-p38 MAPK levels were signiﬁcantly
reduced by 70% in the ischemic striatum (p < 0.01) with respect to vehicle-treated rats. In the striatum and cortex
the phospho-p38 MAPK immunopositive cells showed swollen and hypertrophyc cell bodies, as well as processes,
and exhibited morphological features of activated microglia. Twenty-four hour after MCAo, astrocytes were
found only in the corpus callosum. Activated microglia immunostained by OX-42 or isolectin B4 was present in
the same cortical and striatal areas where phospho-p38 MAPK immunopositive cells were detected. SCH 58261
reduced phospho-p38 MAPK immunoreactivity in the striatum and cortex without changing the microglial cell
morphology.
Results indicate that the protective effect of the adenosine antagonist SCH 58261 24 hours after ischemia is not
due to reduced microglial activation but may involve inhibition of phospho-p38 MAPK and indicate that treat-
ment with the A2A antagonist from the ﬁrst to several hours after ischemia may be a useful therapeutic approach
in cerebral ischemia. (Grant from University of Florence and Ente Cassa di Risparmio Firenze, Italy).
(1) Melani, A.; Pantoni, L.; Bordoni, F.; Gianfriddo, M.; Bianchi, L.; Vannucchi, M.G.; Bertorelli, R.; Monopoli,
A.; Pedata, F. Brain Res. 2003, 959, 243–250.
(2) Melani,A.;Pantoni, L.;Corsi,C.;Bianchi,L.;Monopoli, A.;Bertorelli,R.;Pepeu,G.;Pedata,F.Stroke 1999, 30,
2448–2455
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Background: Adenosine isa potent endogenous regulator of inﬂammation and tissue repair. Since the adenosine A2A
receptor (A2AR) promotes dermal wound closure and increases dermal matrix deposition, we determined whether
adenosine may also play a role in ﬁbrosis in pathological conditions such as scleroderma. We therefore investigated
the effect of A2AR activation on ﬁbroblast collagen production and examined the role of A2AR in bleomycin-
induced dermal ﬁbrosis, a model of scleroderma.
Communications 99
SpringerMethods: Primaryhumandermal ﬁbroblasts (DFs) wereincubated withthe A2AR agonist CGS-21680 (1 nM–10 2M,
24 hrs) in the presence or absence of A2AR antagonist ZM241385 (1 2M). Collagen content in whole cell lysates and
supernates was analyzed by Western blot and Sircol assay respectively. Collagen I and collagen III mRNA (10 hrs)
were quantitated by real-time RT-PCR. Dermal ﬁbrosis was induced with bleomycin (0.1 U sc qod   18 days) in
A2AR-deﬁcient (A2AKO) versus wild-type (WT) littermate mice and in C57BL/6 mice treated with or without
ZM241385 (50 mg/kg/day ip) and compared to PBS-treated controls. Dermal morphometric measurements and
hydroxyproline content (reﬂecting collagen) were analyzed at sacriﬁce.
Results: CGS-21680 treatment increased type I collagen in dermal ﬁbroblast lysates by up to 151 T 21% in a dose-
dependent manner and this increase was reduced by coincubation with ZM241385 (1 2M, p < 0.04). Total collagen
content was increased in supernates of CGS-21680 stimulated DFs to 176 T 14% of control (n = 3, p < 0.01), and
this increase was completely abrogated by ZM241385 (10 2M, n = 3, p = NS vs. control). CGS-21680 increased
collagen I mRNA (146 T 15% control, n = 4, p < 0.05) as much as TGF-" (10 ng/ml), with a lesser increase in
collagen III mRNA (124 T 11% control, n = 4, p = NS). Following bleomycin treatment, WT mice had greater
punch biopsy thickness, skin-fold thickness and higher dermal tensile strength (p < 0.05 for all, data not shown)
than A2AKO mice. Furthermore, dermal hydroxyproline content was higher in WT than A2AKO mice (27.4 T 2.3
vs. 19.5 T 0.7 2g/mg tissue, WT vs. A2AKO, respectively, n = 5, p < 0.005). Compared to vehicle-treated mice,
ZM241385-treated mice were also protected from bleomycin-induced increases in morphometric measures as well
as in dermal hydroxyproline content (26.2 T 1.0 vs. 20.9 T 1.0 2g/mg tissue, control vs. ZM, n = 5, p < 0.005).
Conclusion: Adenosine, released in response to hypoxia or cell injury, promotes, collagen production by human
dermal ﬁbroblasts via A2AR occupancy. More importantly, deletion or blockade of adenosine A2AR protects mice
from bleomycin-induced dermal ﬁbrosis, a model of such ﬁbrosing conditions as scleroderma, and suggests a novel
therapeutic use for A2AR antagonists for the prevention of ﬁbrosis in the skin.
Adenosine A2A receptor activation and IgG-E. coli-immune complexes
synergistically up-regulate IL-10 production in mouse macrophages
Bala ´zs Cso ´ka, Zolta ´n H. Ne ´meth, Gyo ¨rgy Hasko ´
Department of Surgery, UMDNJ-New Jersey Medical School, Newark, NJ 07103
csokaba@umdnj.edu
IL-10 is produced by monocytes/macrophages, and it has important anti-inﬂammatory and immunomodulatory eff-
ects. This function of IL-10 is important for protecting the host from harmful effects of prolonged inﬂammatory
responses in the context of microbial infection. Adenosine, an endogenous purine nucleoside, is formed at sites of
metabolic stress associated with inﬂammation. Adenosine mediates its effects through four adenosine receptors (A1,
A2A,A 2B,A 3), all of which are expressed on macrophages. Stimulation of adenosine receptors results in increased
IL-10 production (~2-fold) in macrophages activated by endotoxin. However, the effect of adenosine on IL-10
production in IgG-E.coli immune complex-treated macrophages is not known. In this study we found that IgG-E.
coli-immune complexes increased IL-10 production approximately two-fold in peritoneal macrophages. Adenosine
dramatically (~8–10-fold) enhanced IgG-E. coli immune complex-activated IL-10 production, indicating a synergi-
stic effect. The A1 receptor agonist CCPA and the A3 adenosine agonist IB-MECA failed to mimic the stimulatory
effect of adenosine on immune complex-induced IL-10 production. However, both the selective A2A receptor ag-
onist CGS-21680 and the non-selective agonist NECA increased IL-10 production, and CGS-21680 was the most
potent. To further conﬁrm the role of A2A receptors in promoting immune complex-primed IL-10 production, the
abilities of selective adenosine receptor antagonists were examined in preventing the stimulatory effect of adenos-
ine. We found that only the selective A2A antagonist ZM241385 reversed the effect of adenosine on immune
complex-induced IL-10 production. In addition, we found that adenosine had no effect on immune complex-primed
IL-10 production in A2A KO mouse macrophages, which also emphasizes the importance of A2A receptor ligation in
IL-10 up-regulation. To investigate the intracellular mechanisms responsible for the augmented production of IL-10
by adenosine, we determined IL-10 mRNA levels using real-time PCR. We found that adenosine increased IL-10
mRNA levels in IgG-E. coli-immune complex-treated cells. We also examined the effect of adenosine on immune
complex-induced IL-10 promoter activity by transfecting RAW264.7 cells with a construct in which luciferase ex-
pression is driven by the IL-10 promoter. We found that adenosine enhanced immune complex-induced IL-10
promoter activity, and this effect was even more enhanced when RAW264.7 cells were co-transfected with an A2A
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immune complex-induced IL-10 production. This effect is mediated by A2A adenosine receptor activation, and is
associated with increased IL-10 mRNA accumulation and enhanced IL-10 promoter activation. Moreover the sy-
nergistic effect of adenosine was more robust on IgG-E. coli-activated IL-10 production than on LPS-induced IL-10
production.
Adenosine A2A receptor activation reduces lung injury in trauma/hemorrhagic
shock
Gyo ¨rgy Hasko ´, Bala ´zs Cso ´ka, DaZhong Xu, Qi Lu, Zolta ´n H. Ne ´meth, Edwin A. Deitch
Department of Surgery, UMDNJ-New Jersey Medical School, Newark, New Jersey, USA
haskoge@umdnj.edu
Hemorrhagic shock and resuscitation trigger a global ischemia/reperfusion phenomenon, in which various inﬂa-
mmatory processes critically contribute to the ensuing tissue damage. Adenosine is an endogenous nucleoside that
is released during shock. Activation of adenosine A2A receptors can broadly inactivate inﬂammatory cascades.
The current study was designed to evaluate the effect of A2A receptor activation on organ injury and inﬂamma-
tion in the setting of global ischemia/reperfusion elicited by trauma/hemorrhagic shock and resuscitation. Adult
male Sprague–Dawley rats were subjected to a laparotomy (trauma) and 90 minutes of hemorrhagic shock or
trauma/sham shock. The selective A2A receptor agonist CGS-21680 (2-p-(2-carboxyethyl) phenethylamino-50-N-
ethyl-carboxamidoadenosine; 0.5 mg/kg) or its vehicle was injected 30 min before shock or immediately after
resuscitation. At 3 hours following resuscitation, animals were killed and tissue harvested for analysis. Lung
permeability and pulmonary myeloperoxidase levels were used to quantitate lung injury. Intestinal injury was
determined by histologic analysis of terminal ileum. Red blood cell (RBC) deformability was measured by a laser-
assisted ektacytometer. Pretreatment with CGS-21680 protected the lung but not the gut against shock-induced
injury and prevented the shock-induced decrease in RBC deformability. Post-treatment with CGS-21680 ameli-
orated shock-induced lung injury but failed to prevent gut injury and preserve RBC deformability. A2A receptor
agonists may represent a novel therapeutic approach in preventing organ injury following trauma/hemorrhagic
shock.
Adenosine A2A Receptor Agonist Protects Mice from Compression-Induced
Spinal Cord Injury
Yuesheng Li and Joel Linden
Cardiovascular Research Center, University of Virginia Health System, Charlottesville, Virginia 22908
yjl4n@virginia.edu
The adenosine A2A receptor (A2AR) has been suggested as a predominant anti-inﬂammatory adenosine recept-
or1. In our previous studies, we have shown that activation of the A2AR inhibits the activity of various inﬂam-
matory cells in vitro
2–4 and in vivo
5,6. Although inﬂammation clearly exacerbates ischemia-reperfusion injury
(IRI) in heart, liver and kidney, it is not clear if this is also the case in spinal cord. We have developed a new
system for scoring hindlimb locomotor dysfunction in mice, the mBBB scoring system. This system has improved
our ability to evaluate compression-induced locomotor dysfunction following spinal cord injury (SCI) in mice
7.
We show that the A2AR selective agonist, ATL313, transiently applied during or after spinal cord IRI persistently
reduces mouse SCI based on the new mBBB locomotor score and a previously validated scoring system, tBBB
8.
Female mice were subjected to compression-induced SCI after laminectomy and periodically evaluated over 6
weeks. A 1   2 mm region of spinal cord was compressed for 5 min with a 15 g weight applied to the dorsal
surface of the cord at T12. ATL313 was administered IP for 5 minutes either before or just after injury, on the
evening after surgery, and twice daily for the next 3 days. Compared to vehicle controls ATL313-treatment
produced signiﬁcant locomotor improvement that reached a plateau within 7 days and was sustained until the end
of the experiment at 42 days. ATL313 did not inﬂuence SCI in A2AR knockout mice. Ongoing experiments with
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protection by ATL313 is due to receptors on bone marrow-derived cells and not due to receptors on neurons or
the vasculature. The results suggest that inﬂammation does exacerbate SCI following spinal cord IRI, and that
A2A agonists reduce injury by reducing inﬂammation. A2A agonist therapy may be useful for treating patients
subjected to spinal cord ischemia during the repair vascular tears or aneurisms.
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Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis
Gyo ¨rgy Hasko ´
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The mechanisms governing the impairment of bacterial clearance and immune function in sepsis are not known.
Adenosine levels are elevated during tissue hypoxia and damage associated with sepsis. Adenosine has strong
immunosuppressive effects, many of which are mediated by A2A receptors expressed on immune cells. We exa-
mined whether A2A receptors are involved in the regulation of immune function in cecal ligation and puncture-
induced murine polymicrobial sepsis by genetically or pharmacologically inactivating A2A receptors. A2A receptor
KO mice were protected from the lethal effect of sepsis and had improved bacterial clearance compared to WT
animals. cDNA microarray analysis and ﬂow cytometry revealed increased MHC II expression in A2A-inactivated
mice, suggesting improved antigen presentation as a mechanism of protection. Apoptosis was attenuated in the
spleen of A2A KO mice indicating preserved lymphocyte function. Levels of the immunosuppressive cytokines IL-
10 and IL-6 were markedly lower following A2A receptor blockade. Similar to observations with A2A receptor KO
mice, an A2A receptor antagonist increased survival even when administered in a delayed fashion. These studies
demonstrate that A2A receptor blockade may be useful in the treatment of infection and sepsis.
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Adenosine, released by cells and tissues, is an important endogenous purine neuromodulator which potently
regulates inﬂammation. Its physiological effects are transduced through four different receptor subtypes (A1,
A2A,A 2 B and A3) that are variably expressed on immune and inﬂammatory cells. All adenosine receptors are G-
protein coupled receptors (GPCR) of the type 1 variety which act by modulating adenylyl cyclase
(1). In particular
the A2A receptor subtype seems to be implicated in neuroprotective and anti-inﬂammatory mechanisms
(2); indeed
the accumulation of extracellular adenosine in inﬂammatory and damaged tissues and the immunosuppressive
properties of cAMP-elevating receptors indicate that signaling by A2A could be a possible natural mechanism of
inhibition and/or termination of inﬂammation
(3,4). The aim of this study is to investigate if an altered expression
and/or function of A2A receptors, could contribute to the inﬂammatory/neurodegenerative mechanisms involved
in Alzheimer"s disease (AD). We analysed the expression of this receptor in platelets and Peripheral Blood
Mononuclear Cells (PBMCs) from AD patients and sex- and age-matched healthy controls (HC); furthermore we
analysed a T/C single nucleotide polymorphism (SNP) at position 1083 of exon 2 of the A2A gene that seems to be
correlated with other neurodegenerative disorders. We found no statistical signiﬁcative differences in the distri-
bution of this SNP between AD and HC. By contrast the A2A mRNA levels in platelets were 25% higher in HC
than AD (1.09 and 0.82 respectively; p = 0.000). To conﬁrm these data we are analysing in a wider group of AD
and HC the mRNA and protein expression of A2a in PBMCs. The preliminary results match with those obtained
from platelets, suggesting a lower ability of AD subjects to terminate the inﬂammatory response and indicating a
possible role of the A2A receptor in the pathogenesis of AD.
1. Olah M.E., Stilles G.L. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev.
Pharmacol. Toxicol. 35, 1995; 581–606.
2. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inﬂammation and
protection from tissue damage. Nature 414, 2001; 916–919.
3. Cronstein B.N. Adenosine, an endogenous anti-inﬂammatory agent. J.Appl. Physiol. 76, 1994;5–13.
4. Huang S., Koshiba M., Apasov S., Sitkovsky M. Role of A2A adenosine receptor-mediated signaling in inhi-
bition of T cell activation and expansion. Blood 90, 1997; 1600–1610.
Adenosine A2A receptors modulate psychomotor activity and brain injury
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The adenosine A2A receptor (A2AR) has recently emerged as a leading non-dopaminergic therapeutic target for
Parkinson"s disease for its ability to regulate motor activity. Furthermore, A2ARs inﬂuence brain injury outcome
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neuronal-speciﬁc A2AR knockout (KO) mice, we here provide the ﬁrst direct evidence that A2AR-mediated
control of motor function and neuroprotection involve distinct cellular mechanisms. By crossing the ﬂoxed A2AR
mice with the CaMKII-Cre transgenic line, we selectively depleted A2AR mRNA and protein in forebrain neu-
rons to the background level of the global A2AR KO mice, as demonstrated by in situ hybridization, immunoc-
hemistry and receptor binding assays. This genetic deletion of A2ARs in forebrain neurons abolished the
psychomotor effect of the A2AR selective agonist CGS21680 and antagonist KW-6002 and of the non-selective
antagonist caffeine, and largely attenuated the pyschostimulant effect of cocaine. This demonstrates the key role
of forebrain neuronal A2ARs in the modulation of psychomotor activity. In contrast, genetic deletion of the A2AR
in forebrain neurons did not confer protection against ischemic brain injury by middle cerebral arterial occlusion
or against MPTP-induced dopaminergic neurotoxicity, despite abolishing CGS21680-mediated presynaptic facil-
itation of glutamate release in forebrain A2AR KO mice. Furthermore, intracerebral ventricular administration of
KW-6002 into forebrain A2AR KO mice reinstated neuroprotection against MPTP neurotoxicity. These results
provide the clearest data yet that A2AR activity in forebrain neurons is critical to control psychomotor activity,
but not for neuroprotection against brain injury, indicating that A2ARs modulate motor activity and brain damage
by distinct cellular mechanisms. This opens up the new possibility of selectively manipulating A2AR"s motor and
neuroprotective effects by targeting different cellular elements.
Adenosine A2A Receptors Stimulate Collagen Production in LX-2 Cells via
PKA, SRC and MAPK Cascade Signaling Pathway
Jiantu Che and Bruce N. Cronstein
Divisions of Clinical Pharmacology and Rheumatology, Department of Medicine, New York University School of
Medicine, New York, NY 10016
Background: We have previously reported that adenosine A2A receptor deletion protects mice from toxin-induced
hepatic ﬁbrosis and that adenosine A2A receptor occupancy promotes collagen production by hepatic stellate
cells. We therefore determined the signaling pathways involved in adenosine receptor-mediated stimulation of a
hepatic stellate cell line, LX-2 cells.
Methods: Soluble collagen was detected by Sircol assay according to the manufacturers directions. Type I and
type III collagen mRNA expression was measured by real-time PCR. In addition, collagen I and III levels were
detected semi-quantitatively by densitometric measurement of Western Blots. Phospho-Erk1/2 was detected by
Western Blot.
Results: Soluble collagen was stimulated both in supernatant and the cells by CGS21680, an adenosine A2A receptor
agonist, at concentrations ranging from 0.01–10 2M (P < 0.005 or P < 0.001). Starting at 6 hours after treatment and
reaching a peak at 24 hours. CGS21680 stimulated an increase in both mRNA and protein of collagens I and III (P <
0.001). ZM241385, an adenosine A2A receptor antagonist, completely blocked CGS21680-stimulated increases in
soluble collagen (by 100% at 24 hours after treatment, P < 0.001) as well as collagen I (by 100% at 24 hours after
treatment, P < 0.001) and III (by 100% at 24 hours after treatment, P < 0.001) with a relative potency proﬁle
consistent with blockade of an A2A receptor (maximal effect at 1 2M). Furthermore, the effect of CGS21680 on
stimulation of soluble collagen was attenuated by the addition of Peptide Inhibitor of protein kinase A (PKAI, by
30%, 1 2M, P < 0.005), Src inhibitor II (SRCI, by 28% P < 0.005), MEK-MAPK inhibitor U0126 (by 24%, P <
0.005), the ERK MAPK inhibitor PD98059 (by 37%, P < 0.001), and the p38 MAPK inhibitor SB202190 (by 35%, P
< 0.001). Real-time PCR and Western blot analysis demonstrated that PKAI, SRCI, U0126 and PD98059 inhibited
CGS21680-stimulated increases in both mRNA and protein of collagen I (by 50%, 48%, 44% and 42% respectively,
P < 0.001), whereas SB202190 did not. In contrast, SB202190 inhibited CGS21680-stimulated type III collagen
production (by 32%, P < 0.005), which was independent of PKA, Src and ERK MAPK signaling pathway. The
effect of PKAI, SRCI, U0123 and PD98059 on CGS21680-stimulated collagen production in LX-2 cells was asso-
ciated with signiﬁcantly decreased ERK1/2 phosphorylation.
Conclusions: These results further indicate that adenosine A2A receptors increase collagen production in LX-2
cells via a PKA-Src-MEK-ERK MAPK cascade or p38 MAPK signaling pathway. Moreover, these results pro-
vide further evidence that adenosine A2A receptor antagonists may be used to prevent hepatic ﬁbrosis. Finally,
prior studies indicate that coffee drinking prevents hepatic cirrhosis and our studies suggest that the mechanism
by which coffee drinking prevents hepatic cirrhosis is via blockade of adenosine A2A receptors in the liver.
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There is a continuing clinical need for an agent given after the onset of ischemia that will protect the heart. Herein
we present evidence that a speciﬁc agonist for the adenosine A2b receptor is cardioprotective when administered
just prior to termination of 30 min of regional ischemia in rabbit hearts. The role of A2b receptors has been
largely unexplored in adenosine-mediated cardioprotection because of the lack of speciﬁc A2b receptor agonists.
Bayer Healthcare was the ﬁrst to synthesize speciﬁc non-adenosine like A2b receptor agonists.
1 These A2b speciﬁc
agonists were characterized in CHO cells expressing human A1, A2a or A2b receptors. Here we report on BAY
A2b, a speciﬁc A2b agonist; EC50 values for receptor activation were >10.000 nM for A1, >10.000 nM for A2a and 3
nM for A2b receptors. Major aspects concerning synthesis and selectivity of non-adenosine like A2b receptor
agonists were also reproduced by other groups.
2
BAY A2b was given to open-chest rabbits experiencing 30 min of regional ischemia and 3 h of reperfusion. Rabbits were
anesthetized with sodium pentobarbital (30 mg/kg) and mechanically ventilated with 100% oxygen. The heart was
exposed through a left thoracotomy and a ligature was passed under a coronary branch to create ischemia. Drug was
g i v e ni n t r a v e n o u s l y1 0u g / k go v e r1m i ns t a r t i n g5m i np r i o rt o reperfusion and again 15 min after reperfusion. The heart
was removed after 3 h of reperfusion. The risk zone was stained with ﬂuorescent microspheres and the heart was cut into
2 mm slices and infarct size was determined by tetrazolium staining.
3
No adverse hemodynamic effects were seen with the agent. A better than 50% reduction of infarct size was seen
and was comparable to that in a third group receiving postconditioning
4, an established cardioprotective interv-
ention where the occluded artery is intermittently opened and closed for four 30-second cycles at the end of the
ischemic insult. The A2b agonist BAY A2b is equivalent to postconditioning in its potency. In conclusion we have
synthesized speciﬁc A2b receptor agonists and have shown that an A2b receptor agonist can reduce infarct size by






































in situ rabbit hearts
*
* p<0.05 vs. control
10µg/kg
(1) Bayer HealthCare AG. WO0125210, 2001; WO03008384, 2003
(2) Beukers, M. W.; Chang, L. C. W.; von Frijtag Drabbe Ku ¨nzel, J. K.; Mulder-Krieger, T.; Spanjersberg, R. F.;
Brussee, J.; Ijzerman A. P. J. Med. Chem. 2004, 47, 3707
(3) Ytrehus, K.; Liu, Y.; Tsuchida, A.; Miura, T.; Liu, G. S.; Yang, X. M.; Herbert, D.; Cohen, M.V.; Downey, J.
M. Am. J. Physiol. 1994, 267, H2383
(4) Zhao, Z.Q.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.:Wang, N.P.; Guyton, R.A.; Vinten-Johansen, J. Am. J.
Physiol. 2003, 285, H579–H588
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Background: Adenosine and heme oxygenase 1 (HO-1) are crucial regulatory molecules that participate in inﬂ-
ammation and immunity. HO-1 is a protective, inducible enzyme responsible for intracellular heme degradation
that exerts a wide range of anti-oxidative, anti-inﬂammatory and immunomodulatory actions. These are chieﬂy
mediated by the respective heme degradation products viz. carbon monoxide (CO), biliverdin/bilirubin and iron
with apo-ferritin induction. In a similar manner, CD39 and other ecto-nucleotidases catalyze the phosphohy-
drolysis of extracellular nucleotides to generate the respective nucleosides. Adenosine is an endogenous nucleo-
side that is usually present at low concentrations in the extracellular space. However, with stress or in several
patho-physiologic conditions, e.g. acute inﬂammatory responses, there may be dramatic increases in extracellular
levels of all purinergic mediators. Adenosine modulates the kinetics and magnitude of immune responses via four
different G protein-coupled receptors (A1, A2a, A2b and A3) that are differentially expressed on a variety of
cells. In spite of their apparent lack of connection to one other, there are striking similarities in the anti-inﬂam-
matory proﬁles of adenosine and HO-1 and its products (as detailed above).
Aim: To elucidate possible cross talk between these two highly conserved molecules and/or catalytic products in
the regulation of inﬂammatory and immune responses.
Results and Discussion: Adenosine exposure induces high level HO-1 expression in the macrophage cell line
RAW264.7. This effect, appears to be mediated via the A2A receptor. In a reciprocal manner, high HO-1 expr-
ession remarkably sensitizes the macrophages to adenosine and potentiates the anti-inﬂammatory effects of ad-
enosine and its analog 50-N-ethylcarboxamidoadenosine (NECA) in an in vitro model of LPS activation.
Adenosine mediated inhibition of LPS-induced TNF-! expression, is in part, HO-1 dependent as blockade of HO-
1 via siRNA abrogates the effects of adenosine on TNF-!. We demonstrate that HO-1 boosts the expression of
the anti-inﬂammatory A2a receptor and that CO can mimic and substitute for HO-1 in this response in RA-
W264.7 cells and mouse bone marrow derived macrophages which was not observed with biliverdin, one of its
other products. Moreover, CO exposure prevents NECA induced down regulation of A2A receptors supporting
the concept that HO-1 and adenosine are interrelated.
Conclusion: We demonstrate intimate cross talk between adenosine and HO-1/products. Based on these obser-
vations we can envision feedback loops, which may play a key role in the orchestration and resolution of inﬂa-
mmation.
Adenosine deaminase deﬁciency promotes dermal ﬁbrosis
Patricia Fernandez
1, Sean Trzaska
1, Janci L Chunn
2, Michael R Blackburn




1Department of Medicine, New York University School of Medicine, New York, NY;
2Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX
Patricia.Fernandez@med.nyu.edu
Background: Adenosine deaminase (ADA) catalyzes the deamination of adenosine to inosine. Recent studies
indicate that chronic adenosine elevations lead to pulmonary ﬁbrosis in ADA-deﬁcient mice, suggesting a proﬁ-
brotic role for adenosine in the lung [1]. We have also found that in a model of bleomycin-induced dermal ﬁbrosis
that mice lacking adenosine A2A receptors were protected from developing skin ﬁbrosis. We therefore tested the
hypothesis that chronic elevations of adenosine concentrations, due to either injury (as in the bleomycin-induced
model of dermal ﬁbrosis) or ADA deﬁciency, leads to dermal ﬁbrosis.
Methods: Male ADA deﬁcient mice (ADA KO) were supplemented with PEG-ADA enzyme therapy for the ﬁrst
three weeks after birth. After the last enzyme injection, animals were mantained without PEG-ADA for two
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Springerweeks and then sacriﬁced. Dermal morphometric measurements were assessed on freshly excised skin. In some
experiments mice were treated with the adenosine A2A receptor antagonist ZM241385 (50 mg/kg/day IP) for the
last 8 days prior to sacriﬁce when the mice were no longer treated with PEG-ADA.
Results: ADA KO mice showed signiﬁcant increases in dermal thickness (128.7 T 2.0%, n = 5, p < 0.001), skin-fold
thickness (140.6 T 2.8%, n = 5, p < 0.001) and breaking tension (136.8 T 5.3%, n = 5, p < 0.001) compared with
their wild type (WT) littermates. Dermal hydroxyproline content, a measure of collagen content, was also incr-
eased by 157.8 T 2.8% (n = 5, p < 0.001) in ADA KO compared to the WT mice. To determine whether the
adenosine A2A receptor was involved in the dermal ﬁbrosis observed in the ADA KO mice, we treated ADA KO
mice with the A2A receptor antagonist ZM241385. After ZM241385 treatment, the skin of treated mice was not as
thick (27.2 T 8.3% decrease, n = 4, p < 0.05), skin-fold thickness was 21.7 T 7.4% less (n = 4, p < 0.05), and dermal
tensile strength was reduced by 48.9 T 14.1% (n = 4, p < 0.05) compared with ADA KO mice treated with vehicle.
Furthermore, dermal hydroxyproline content was decreased (61.4 T 13.5%, n = 4, p < 0.001) in ZM treated ADA
KO mice compared with vehicle-treated ADA KO mice.
Conclusion: The marked increase in adenosine levels seen in other tissues in adenosine deaminase deﬁciency may
act similarly on skin to promote ﬁbrogenesis. Pharmacological protection of ADA deﬁcient mice with A2A rec-
eptor antagonist administration suggests a role for A2A receptors in the modulation of dermal ﬁbrogenesis.
[1] Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Blackburn MR. Adenosine-dependent pulmonary ﬁbrosis in
adenosine deaminase-deﬁcient mice. J Immunol. 2005; 175:1937–46.
Adenosine inhibits the release of arachidonic acid and its metabolites
(AAM) in activated human peripheral mononuclear cells
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The effects of adenosine (Ado) and subtype-speciﬁc activators of adenosine receptors (A1,A 2A,A 2B and A3)
were studied on the release of arachidonic acid and its metabolites (AAM) from human peripheral mononuclear
cells (monocytes). In the cells activated by protein kinase C- speciﬁc phorbol ester (phorbol 12-myristate 13–
acetate) and Ca
2+-ionophore (A-23187), adenosine and two subtype speciﬁc receptor agonists, CPA (A1)a n d
CGS-21680 (A2A) induced concentration dependent inhibitions in the release of AAM, whereas the stimulation of
A2B and A3 receptors were ineffective. The rank order of potency in the inhibition of AAM release was as
follows: CGS-21680 = CPA > adenosine > NECA (in the presence of ZM-24185 and DPCPX as A2A and A1
adenosine receptor antagonists) = IB-MECA. Adenosine inhibited the release of AAM only at and over the
concentration of 10
j4 M, whereas the inhibitory effect of A1 and A2A receptor speciﬁc agonists appeared at the
range of 10
j7 M. It can be concluded that adenosine physiologically may not have a signiﬁcant effect on the AAM
release of circulating monocytes, but in pathological conditions, where the local Ado concentrations increases, this
nucleoside by the activation of A2A and A1 receptors can exert its antiinﬂammatory action via the decrease in the
proinﬂammatory AAM production.
Adenosine is induced during peritonitis and downregulates cytokine
production and leukocyte recruitment
Sigal Nakav









Springer1Department of Clinical Biochemistry and
2Department of Nephrology, Soroka Medical Center, Ben–Gurion
University of the Negev, Beer–Sheva, Israel.
sigs@bgu.ac.il
Adenosine is an endogenous immunomodulator that has been shown to exhibit anti-inﬂammatory and immuno-
suppressive effects. These anti-inﬂammatory effects depend mainly on ligation with its cell-surface receptors
subtypes: A2A receptor (A2AR), A2B receptor (A2BR), A1 receptor (A1R) and A3 receptor (A3R) all of which are
G-protein coupled. The generation of extracellular adenosine involves phosphohydrolysis of adenine nucleotide
intermediates and is regulated by two enzymes, nucleotidase triphosphate dephosphorylase (CD39) which conv-
erts ATP to AMP, and 50 ectonucleotidase (CD73) which converts AMP to adenosine. Peritoneal mesothelial
cells (PMC) form a monolayer that covers the peritoneal membrane. Their location between the peritoneal cavity
and peritoneal blood vessels gives them a key role in intraperitoneal immune defense. Following stimulation with
inﬂammatory cytokines and bacterial products, mesothelial cells express adhesion molecules and produce various
cytokines and other pro-inﬂammatory mediators.
The aim of the present study was to elucidate the regulatory role of adenosine during peritonitis and to assess the
regulation of CD39, CD73 on PMC during the inﬂammatory processes.
In a mouse model of E. coli-induced peritonitis we found a gradual increase of adenosine levels which peaked at 24
hours then gradually declined up to 72 hours from inoculation. The intra-peritoneal inﬂux of leukocytes after
inoculation was blocked by the A2AR agonist CGS-21680. In inoculated mice, the A2AR agonist also caused a
signiﬁcant decrease in sera and peritoneal levels of TNF-! and IL-6 as compared to untreated mice. Analysis of
PMC mRNA and protein levels showed that both CD39 and CD73 levels increased ~3 fold higher than normal at
the initial phase of inﬂammation and decreased at the resolution phase.
These data suggest that adenosine is a potent regulator of peritoneal inﬂammation and the upregulation of both
CD73 and CD39 in the initial phase of peritonitis is responsible for the increase of peritoneal adenosine levels.
Adenosine modulates the release of catecholamines from rat carotid body
chemoreceptor cells through an interaction between D2 dopamine receptors
and A2B adenosine receptors
Conde SV, Obeso A and Gonzalez C
Department of Biochemistry, Molecular Biology and Physiology, IBGM, Faculty of Medicine, University of
Valladolid, CSIC, Valladolid, Spain.
svconde.farm@fcm.unl.pt
Carotid bodies (CB) are major peripheral chemoreceptor organs sensing changes in blood O2 responding by
generating action potentials at the carotid sinus nerve (CSN), which are integrated in the brainstem to induce a
hyperventilatory compensatory response. Hypoxia, the physiological CB stimulus increases the release of dopa-
mine
7 and adenosine
1,2 from rat CB. Adenosine is an excitatory neurotransmitter at the CB, increasing CSN
electrical activity and promoting hyperventilation through the activation of A2 adenosine receptors
4,5,6. Recently,
it has been described that caffeine inhibits the basal and evoked release of catecholamines (CA) from rat carotid
body chemoreceptor cells (CBCC) through an action on A2B adenosine receptors
3. The present work was perf-
ormed in order to investigate possible interactions between D2 dopamine and A2B adenosine receptors respon-
sible for the modulation of CA release in rat CBCC. Experiments were performed in CB removed from 3 months
old Wistar rats. The effect of adenosine A2B and dopamine D2 receptor agonists and antagonists applied alone or
conjunctly were studied on the basal and evoked release (10% O2) of CA from CBCC. Dose response curves for
these A2B and D2 receptor agonists and antagonists were performed. NECA, an A2 receptor agonist (0.1–100
2M), increase the basal and 10% O2-evoked release of CA from rat CB in a dose-dependent manner. Haloperidol
(0.01–10 2M) and sulpiride (0.1–10 2M), D2 dopamine antagonists, increase in a dose-dependent manner the
basal and/or evoked release CA from CBCC. Propylnorapomorphine, D2 dopamine agonist (0.2–200 nM), ind-
uced a dose-dependent decrease in the basal and evoked release of CA from rat CBCC. NECA (10 2M) when
applied in association with haloperidol (0.01–10 2M) potentiates the effect of this D2 antagonist, moving its dose-
response curve to the left. Sulpiride (1 2M), reversed the inhibitory effect of caffeine on basal and stimulus
induced release of CA from rat CBCC. Therefore, our results suggest that an interaction between A2B adenosine
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Springerand D2 dopamine receptors could exist in CBCC, contrarily to the described in the CNS between A2A and D2
receptors, modulating the release of CA.
Supported by MEC (Spain) Project BFU2004-06394/BFI, Red Respira (Iciii/RTIC C03/011) and by JCyL grant
VA 106A05. SV Conde is funded by a PhD grant from FCT (Portugal).
(1) Conde, S. V.; Monteiro, E. C. J. Neurochem. 2004, 89, 1148–1156.
(2) Conde S. V.; Monteiro, E. C. Adv. Exp. Med. Biol. 2006, 580, (in press).
(3) Gonzalez, C.; Conde, S. V.; Obeso, A. Rev. Neurol. 2005, 41 supl 2, 4.
(4) Monteiro, E. C.; Ribeiro, J. A. Naunyn-Schmiedeberg"s Arch Pharmacol. 1987, 335, 143–148.
(5) Monteiro, E. C.; Ribeiro, J. A. Naunyn–Schmiedeberg"s Arch Pharmacol. 1989, 340, 230–238.
(6) Runold, M.; Cherniak, N. S.; Prabhakar, N. R. Neurosci. Lett. 1990, 113, 111–114.
(7) Vicario, I.; Rigual, R.; Obeso, A.; Gonzalez, C. Am. J. Physiol Cell Physiol. 2000, 278, C490–C499.
Adenosine produced via the CD73/ecto-5-nucleotidase pathway has no impact
on erythropoietin production but is associated with reduced kidney weight
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CD73/ecto-5-nucleotidase which catalyzes the conversion of AMP to adenosine has been implicated in vascular
homeostasis. In kidneys, exogenous adenosine is known to dose-dependently act as a vasodilator and constrictor
and has been shown to enhance erythropoietin production. We therefore hypothesized that CD73-derived ade-
nosine promotes erythropoietin production and determines basal kidney perfusion.
CD73 knockout mutants recently generated in our laboratory were compared to wild type controls. CD73 local
expression was assessed by enzyme histochemistry and immunocytochemistry, CD73 activity determined by a
phosphate assay, adenosine determined by HPLC, erythropoietin expression by real-time quantitative PCR, er-
ythropoietin plasma concentration by an immunoassay, and renal plasma ﬂow and glomerular ﬁltration rate by
PAH and FITC-inulin, respectively.
Of all organs investigated, kidneys showed the most prominent CD73 activity that was preferentially located in
peritubular ﬁbroblasts of the renal cortex and the glomerular mesangium. In the absence of CD73, alkaline
phosphatase remained unchanged but tissue adenosine was reduced both under control conditions (by 76%) and
during normobaric hypoxia (by 72%). Despite the loss of CD73 activity and substantial reduction in adenosine,
EPO mRNA and plasma protein concentrations did not differ between WT and CD73
j/j under basal conditions
and following normobaric hypoxia (8% O2) and carbon monoxide (0.1% CO) inhalation (both for 4 h). Although
there was no difference in blood pressure and urine ﬂow volume, the average weight of the two kidneys was
reduced by 21% in the knockout (WT: 7.17 T 1.18 mg/g body wt; CD73
j/j: 5.70 T 1.91 mg/g body wt). Measur-
ement of renal plasma ﬂow (RPF) and glomerular ﬁltration (GFR) revealed no signiﬁcant difference when related
to the respective kidney weights.
Conclusion: The extracellular CD73 pathway is a major source of adenosine in the kidney. CD73 derived aden-
osine thas no impact on erythropoietin production under basal conditions and after hypoxic challenge but may
inﬂuence kidney growth.
Adenosine receptor activation protects against the development
of diabetes in mouse models of type 1 diabetes
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SpringerType 1 diabetes or insulin-dependent diabetes mellitus (IDDM) is a disease affecting 1.2 million patients in the
United States with 12,000 new cases diagnosed each year. The disease is characterized by the speciﬁc destruction
of insulin-producing "-cells in the pancreatic islets of Langerhans by the immune system. The islets are invaded by
immune cells, particularly by macrophages and T cells, and these cells are cytotoxic to islet "-cells, in part by
generating cytokines and free radicals. Currently there is no available treatment to prevent or cure type 1 diab-
etes. Based on evidence that adenosine receptor occupancy suppresses inﬂammatory cytokine production, we
hypothesized that selective stimulation of adenosine receptors using the potent and stable agonist 50-N-ethylcar-
boxamidoadenosine (NECA) would attenuate the course of diabetes in multiple-low-dose streptozotocin (MLDS)
treated and in non-obese-diabetic (NOD) mice. In the MLDS model, male CD-1 mice were treated with 40 mg/kg
streptozotocin (STZ) for 5 consecutive days simultaneously with NECA or its vehicle, and after the cessation of
STZ treatment NECA or vehicle treatment was continued for 21 additional days. We found that 0.03 mg/kg
NECA treatment prevented the MLDS-induced hyperglycemia (blood sugar levels on day 21 in mg/dl: control:
410.3 T 60, NECA: 222.8 T 50.9, mean T SEM, p < 0.05). The decrease in blood sugar levels was associated with
preservation of pancreatic insulin content. To assess the extent of inﬂammation in the pancreas, we measured the
pancreatic levels of tumor necrosis factor-alpha (TNF-!), macrophage inﬂammatory protein 1-alpha (MIP-1!),
interleukin-12 (IL-12), and interferon-gamma (IFN-+). Pancreatic contents of all four cytokines were signiﬁcantly
lower in mice treated with NECA than in vehicle-treated mice as shown in the table below.
Cytokine Level (pg/mg prot.) Vehicle NECA (0.03 mg/kg)
TNF-! 1.45 T 0.33 0.62 T 0.03**
MIP-1! 2.87 T 0.91 0.47 T 0.02**
IL-12 20.19 T 6.88 5.27 T 0.05*
IFN-+ 0.37 T 0.13 0.09 T 0.02*
Results are means T SEM (n = 10). *p < 0.05, **p < 0.01 versus vehicle-treated mice.
We next examined the effect of NECA in NOD mice, a genetic model of type 1 diabetes that has more in
common with human IDDM than the chemically induced MLDS model. NOD mice were given a single dose of
cyclophosphamide (200 mg/kg) and then daily injections of NECA (0.01 mg/kg). Even this low dose of NECA
signiﬁcantly decreased the blood glucose level in NOD mice (vehicle: 318.5 T 188 mg/dl, NECA: 155.8 T 76 mg/dl,
mean T SEM, p < 0.05). Taken together adenosine receptor stimulation might have great therapeutic potential in
the treatment of humans suffering from IDDM.
Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines:
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The present study was undertaken to investigate the presence of adenosine receptors on human colon cancer and
to evaluate the functional effect of these receptors on colon cancer cell biology. Therefore the expression of the
A1,A 2A,A 2B and A3 subtypes by means of quantitative real time RT-PCR and binding studies in both resected
colon cancer tissues from patients undergoing surgery and HT29, DLD1 and Caco2 colon carcinoma cell lines
have been analysed. Our results show that in human colon cancer tissues the density of A1 and A2A subtypes was
quite low in comparison with that of the A3 receptor. Analogous results were found in carcinoma cell lines.
[
3H]MRE 3008F20 reveals an afﬁnity and binding capacity very similar in all the cell lines investigated. Moreover
the effect of adenosine and of selective adenosine antagonists for A1,A 2A,A 2B and A3 subtypes on cell growth
have been investigated. The results of this work suggest that adenosine modulated cell proliferation through the
involvement of the A3 subtype.
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Pancreatic acini secrete ATP in response to cholinergic stimulation. Recent experiments show that pancreatic
juice also contains nucleotidases, CD39 and CD73. Thus apart from P2 receptors, also adenosine receptors could
be potential regulators of exocrine secretion. The aim of the present study was to determine whether pancreatic
ducts, which normally secrete HCO3
–rich ﬂuid, possess functional adenosine receptors.
Pancreatic ducts were obtained from collagense digests of rat pancreas. Electrical activity in single isolated ducts
was monitored using whole-cell nystatin patch-clamp method (1). The membrane voltage (Vm) was continuously
monitored during experiments in zero current-clamp mode. Periodically, voltage was clamped and the whole-cell
current and the total conductance (Gt) were measured. In another set of experiments, the Fura-2 method was used
to estimate [Ca
2+]i, in pancreatic ducts. In addition, RT-PCR analysis was carried out on isolated ducts and whole
pancreas.
In about half of the ducts studied, adenosine (1–100 2M) had no effect on resting Vm of about j55 mV. However,
in the other half of the ducts adenosine markedly and reversibly depolarized Vm by 10–40 mV, and also increased
whole cell membrane conductances (Gm) by about 30%. In such ducts lowering of the extracellular Cl- concen-
trations led to a further depolarization of Vm, indicating activation of a Cl- conductance. In another set of exp-
eriments, the effect of adenosine on intracellular Ca
2+ of isolated single ducts was monitored. However, adenosine
had no signiﬁcant effects in the Fura-2 ratio, indicating that intracellular signals were not mediated by Ca
2+
signalling. RT-PCR analysis showed that the isolated ducts have transcripts for the following adenosine receptors:
A1,A 2A,A 2B and A3.
In summary, the present study shows that some pancreatic ducts express functional adenosine receptors that lead
to opening of Cl- channels and possibly to the production of HCO3
–rich ﬂuid. Since Ca
2+ signals were not obs-
erved, it is likely that A2A or A2B receptors regulate CFTR Cl- channels in some pancreatic ducts.
The projects were supported by the Danish Medical and Science Research Councils, the Augustinus Foundation
and the Lundbeck Foundation.
1. Novak, I. and M. J. Hug. Cell.Physiol.Biochem. 1995; 5: 344–352.
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Background: Adenosine is a potent endogenous regulator of tissue repair released from injured cells and tissues.
Hepatic ﬁbrosis results from chronic and acute hepatic injury and we have previously reported that adenosine,
acting at A2A receptors, plays a role in hepatic ﬁbrosis. The enzymes involved in formation of adenosine following
hepatic injury have not been characterized.
Methods: Mice were treated with PBS, CCl4, thioacetamide or ethanol, sacriﬁced and their livers harvested. Liver
slices were incubated in medium for 24 hrs before adenosine concentration in the supernatant was measured by
HPLC. Hepatic ﬁbrosis was induced with thioacetamide in CD39 (nucleoside triphosphate phosphohydrolase)
knockout mice, CD73 (ecto-50nucleotidase) knockout mice, CD39/73 double knockout mice and C57BL/6 control
mice and was quantiﬁed by digital analysis of picrosirius red stained slides and hydroxyproline content.
Results: Thioacetamide, carbon tetrachloride and ethanol treatment led to a marked increase in adenosine in
supernates of hepatic slices (419.4 T 22.8 nM, 492.1 T 68.2 nM, 694.9 T 35.8 nM, respectively, vs 274.0 T 14.7 nM in
PBS-treated mice, n = 5 and P < 0.05 for all). Hepatic hydroxyproline content was signiﬁcant decreased in CD39/
73 knockout mice compared with C57BL/6 mice (0.31 T 0.06 2g/ml versus 0.40 T 0.08 2g/ml, P < 0.05). Hepatic
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0.21%, p = NS) and CD39/CD73KO mice (0.29 T 0.09%, p < 0.05) as compared to C57BL/6 (0.42 T 0.17%).
Conclusion: These results are consistent with the hypothesis that following hepatic injury adenosine is produced
extracellularly from adenine nucleotides and that the adenosine released promotes hepatic ﬁbrosis. We conclude
that inhibition of adenosine production or interaction with its receptor may help prevent hepatic ﬁbrosis.
Adenosinergic Mechanisms Contribute to Individual Differences in the Effects
of Sleep Deprivation on Psychomotor Performance and the EEG
Landolt HP
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Sleep deprivation impairs performance on neurobehavioral tasks and modulates the electro-encephalogram (E-
EG) in wakefulness and sleep. The changes in performance and the EEG are assumed to reﬂect a sleep-wake
dependent, homeostatic process of sleep regulation
1. Our observation that the adenosine receptor antagonist,
caffeine, attenuates the EEG correlates of sleep homeostasis in wakefulness and sleep is consistent with the
hypothesis that the adenosinergic system is prominently involved in sleep-wake regulation
2. Recent research
highlights the importance of studying individual differences in wakefulness and sleep as a novel approach to gain
insights into physiological mechanisms underlying human sleep-wake regulation
3. We recently found that genetic
variability in the adenosinergic system contributes to inter-individual differences in the waking and sleep EEG
4.
Here, we hypothesized that adenosinergic mechanisms also play a role for individual differences in neuro-
behavioral performance decline associated with prolonged wakefulness. We investigated psychomotor vigilance
task (PVT) performance and antero-posterior EEG power gradients during wakefulness and sleep following one
night of sleep deprivation. The PVT is a visual reaction time task that is sensitive to sleep-deprivation induced
impairments in sustained vigilant attention. Subjectively caffeine sensitive (n = 12) and insensitive (n = 10) young
men (age range: 20–30 years) underwent two 40-hour waking periods. After 11 and 23 hours waking they received
caffeine (200 mg per dose) and placebo in double-blind, cross-over fashion. The PVT and the EEG were assessed
in 14 sessions at 3-hour intervals. To quantify the effect of prolonged waking, the data from three test sessions that
occurred at analogous time of the day (at 11:00, 14:00 and 17:00 h) before and after the night without sleep were
averaged. The data were analyzed with repeated-measures analyses of variance (rANOVA) and Spearman_s rank
correlation analyses. In the placebo condition, optimal PVT performance (fastest 10th percentile of speed) was
more impaired by sleep deprivation in caffeine sensitive men than in caffeine insensitive men (p < 0.04). This
difference between the groups was not signiﬁcant in the caffeine condition (p > 0.05). In the placebo condition,
sleep deprivation enhanced a fronto-occipital EEG power gradient (fronto-central vs. parieto-occipital bipolar
EEG derivations) during waking (6.5–8.5 Hz range) and non-rapid-eye-movement (nonREM) sleep (<1 Hz ra-
nge) in caffeine sensitive subjects when compared to caffeine insensitive subjects (p < 0.01 and p < 0.001). After
caffeine these differences in the regional EEG power distribution between the groups were not signiﬁcant (p >
0.05). The sleep-deprivation and caffeine-induced changes in PVT performance, as well as in the EEG during
wakefulness and nonREM sleep were signiﬁcantly correlated on an individual basis. These results indicate that
adenosinergic mecha-nisms contribute to individual differences in the vulnerability to sleep-deprivation induced
changes in psychomotor function and in the EEG. Elucidation of these mechanisms will help in the identiﬁcation
of persons at risk for impaired performance following sleep deprivation and in the develop-ment of agents to
reduce the detrimental effects of prolonged waking on cognition and behavior. Research supported by the Swiss
National Science Foundation (Grant # 3100-067060.01).
(1) Finelli, L. A.; Baumann, H.; Borbe ´ly, A. A.; Achermann, P. Neurosci 2000, 101, 523–529.
(2) Landolt, H. P.; Re ´tey, J. V.; To ¨nz, K.; Gottselig, J. M.; Khatami, R.; Buckelmu ¨ller, J.; Achermann, P. Neur-
opsychopharmacol 2004, 29, 1933–1939.
(3) Van Dongen, H. P. A.; Vitellaro, K. M.; Dinges, D. F. Sleep 2005, 28, 479–496.
(4) Re ´tey, J. V.; Adam, M.; Honegger, E.; Khatami, R.; Luhmann, U. F.; Jung, H. H.; Berger, W.; Landolt, H. P.
Proc Natl Acad Sci U S A 2005, 102, 15676–15681.
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G-protein coupled receptors are responsible for transducing signals from a variety of extracellular hormones,
nucleotides and neurotransmitters to the intracellular machinery. Subsequent to agonist activation, GPCR sign-
aling can be terminated by desensitization followed by internalization into intracellular compartments. The occ-
urrence and mechanisms of agonist-induced internalization of the P2Y family of GPCRs are poorly understood,
primarily due to a lack of tools available for studying natively expressed receptors. Recently, we synthesized a
high afﬁnity, high speciﬁc radioactivity radioligand, [
32P]MRS2500, for the P2Y1 receptor (P2Y1-R) and establi-
shed its utility for detecting and quantifying P2Y1-R in a variety of mammalian tissues. An intact cell binding
assay was established using this ligand and applied to measure agonist-induced loss of [
32P]MRS2500 binding sites
in mammalian cell lines and intact platelets. Treatment of canine kidney (MDCK) cells with the P2Y1-R agonist
2MeSADP resulted in a 50% decrease in the number of surface [
32P]MRS2500 binding sites. This decrease
occurred with a t 1/2 of approximately 5–10 minutes and reached a steady-state within 30 minutes that was
maintained for up to one hour. The human P2Y1 receptor stably expressed in MDCK cells (P2Y1-MDCK) exh-
ibited similar kinetics for agonist-induced internalization. The extent of agonist-promoted loss of surface P2Y1-R
in P2Y1-MDCK cells was dependent on concentration of agonist, and internalization was inhibited almost com-
pletely by pretreatment of cells with 450 mM sucrose, an inhibitor of clathrin-mediated endocytosis. The initial
loss in surface P2Y1-R binding sites in P2Y1-MDCK cells was completely reversed within 15 minutes after rem-
oval of agonist from the medium. In human platelets, agonist-induced internalization occurred with much faster
kinetics, with the maximal extent of internalization occurring within ﬁve minutes. Taken together, these data
indicate that the P2Y1-R undergoes clathrin-mediated endocytosis in response to agonist stimulation.
Agonists of the Adenosine A2a Receptor Reduce Leukocyte Adhesion
and Platelet Aggregation in Sickle Cell Mice
Robert Figler PhD
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It has become increasingly appreciated that chronic inﬂammation plays an important role in the etiology of vaso-
occlusive crisis (VOC) and the long-term pathologic manifestations of sickle cell disease (SCD). Central to this
concept is evidence that VOC is not merely a result of the passive obstruction of the vasculature by deformed
erythrocytes, but an active process involving heterotypic interaction of erythrocytes, leukocytes, platelets and the
endothelium. In studies using a transgenic murine model of SCD (NY1DD) we have demonstrated the following:
1) increased adhesion of a monocytic cell line to primary aortic endothelial cells cultured from NY1DD mice; 2)
increased aggregation of platelets isolated from NY1DD mice; 3) increased formation of circulating leukocyte/
platelet aggregates in the blood of NY1DD mice; and 4) increased adhesion of leukocytes to the endothelium of
NY1DD mice in vivo.
This evidence of inﬂammation provides a rationale for the use of anti-inﬂammatory agents in the treatment of
SCD and vaso-occlusive crisis. Adenosine has been demonstrated to act through the adenosine A2A receptor
(A2AR) found on bone marrow-derived cells to inhibit inﬂammation. ATL146e is an A2A-selective agonist that
has already been shown to be safe in man and is currently in Phase III clinical trials. We investigated the effects of
ATL146e on indices of platelet and leukocyte activation in SCD.
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the effect of ATL146e on leukocyte interactions with the endothelium. At baseline, NY1DD mice have more than
three times the number of adherent leukocytes/ﬁeld when compared to congenic C57BL/6 mice. Treatment with
ATL146e caused a pronounced reduction in leukocyte adhesion to wild type baseline levels when administered by
either infusion (Alzet mini-pump, 10 ng/kg/min, overnight) or bolus injection (intraperitoneal, 5 2g/kg, 30 minutes
prior to cremaster exteriorization).
Single particle counting was used to study platelet aggregation in vitro. At baseline, platelets isolated from N-
Y1DD mice and subjected to sheer stress exhibit signiﬁcantly increased aggregation as compared to control
platelets. When NY1DD mice were pretreated in vivo with ATL146e (Alzet mini-pump, 10 ng/kg/min, O/N)
platelet activation in platelet rich plasma prepared from these animals and exposed to ADP added in vitro was
reduced to below control levels. Further, ﬂow cytometric analysis of whole blood indicates that NY1DD mice
exhibit an increased number of circulating leukocyte/platelet aggregates and that this number can be signiﬁcantly
reduced by pretreatment with ATL146e.
These data support the hypothesis that anti-inﬂammatory therapy will reduce the severity of vaso-occlusive crises
and indicate that adenosine A2A agonists may be clinically useful for the treatment of vaso-occlusive crisis in
SCD.
Allosteric enhancers of A1 Adenosine Receptors Catalyze Oxidation of Thiols
Mahendra D. Chordia,
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Adenosine an endogenous ligand for four subtypes of G protein coupled adenosine receptors. Important physi-
ological functions of Adenosine-A1 receptor activation have been described in many tissues including kidney,
heart, adipose tissue and brain. Adenosine or synthetic adenosine analogs that occupy the orthosteric A1 receptor
binding site have limited therapeutic potential due to cardiac and renal side effects and poor penetration into the
brain. Allosteric enhancers (AE) of adenosine receptors have been described.
1 These compounds decrease the
dissociation kinetics of agonist radioligands from A1 receptors and facilitate adenosine signaling. Due to their
lipophilic properties AEs may have clinical potential for producing analgesia, anti-seizure activity and sedation.
Allosteric agents have little activity in the absence of adenosine and may selectively amplify adenosine signaling
in hypoxic, ischemic or inﬂamed tissues that produce high levels of adenosine. Aminothiophenes, including PD
81,723 were the ﬁrst compounds reported to have AE.
2 We recently found that certain 2-aminothiazoles also have
AE activity.
3
We now report evidence suggesting that AEs act as thiol oxidants.. Reducing agents including DTT, N-acetylc-
ysteine, glutathione and TCEP all block the activity of AE_s to inﬂuence agonist radioligand binding. All com-
pounds that are active as AEs can catalyze the oxidization of thiols such as glutathione to disulﬁdes such as GSSH.
The oxidizing power of AEs is well correlated with the receptor activity. In addition we discovered that AE_s
render A1 receptors resistant to solubilization in digitonin; certain disulﬁdes have AE activity and H2O2 a strong
oxidant has AE-like activity. Based on these observations we hypothesize that AEs catalyze oxidation of one or
more Cys residues on the extracellular surface of A1 receptors to promote either intramolecular or intermolecular
disulﬁde bonds. Agonist binding to the A1 receptor may be stabilized by and facilitate this oxidation. We hypo-
thesize that formation of disulﬁdes is responsible for stabilization of the ternary complex between ligand, rece-
ptors and G-proteins. This paper will discuss the detailed progress made towards unraveling mechanistic aspect of
allosteric enhancer action on A1 adenosine receptors.
1. Gao, Z.; Kim, S.; IJzerman, A. P.; Jacobson, K. A. Mini-Rev.Med. Chem. 2005, 5, 545–553.
2. Bruns, R..F; Fergus, J.H.; Coughenour, L.L.; Courtland, G.G.; Pugsley, T.A.; Dodd, J.H.; Tinney, F.J. Mol.
Pharm., 1990, 38, 950–958.
3. Chordia, M. D.; Zigler, M.; Murphree, L. J.; Figler, H.; MacDonald, T. L.; Olsson, R. A.; Linden, J. J. Med.
Chem., 2005, 48, 5131–5139 and reference cited in there.
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Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality worldwide. Adenosine
acts through four distinct receptors to mediate pro- and anti-inﬂammatory effects. The primary aim of this study is
to investigate the expression in peripheral lung parenchyma, the major site of airﬂow obstruction in COPD, using
immunohistochemistry, radioligand binding and real time quantitative polymerase chain reaction. Adenosine
receptors were analyzed in age-matched smokers with COPD (n = 14) and smokers with normal lung function
(control group; n = 20). A1,A 2A,A 2B and A3 receptors were differentially expressed in peripheral lung parenc-
hyma. The afﬁnity of A1,A 2A and A3 receptors was signiﬁcantly decreased in COPD patients compared with
control group [KD(A1) = 3.15 T 0.19* versus 1.70 T 0.14 nM; KD(A2A) = 7.88 T 0.68* versus 1.87 T 0.09 nM; KD(A3)
= 9.34 T 0.27* versus 4.41 T 0.25 nM; *p < 0.01] whereas their density was increased [Bmax(A1)=5 3T 4* versus 32
T 3 fmol/mg protein; Bmax(A2A) = 852 T 50* versus 302 T 12 fmol/mg protein; Bmax(A3) = 2078 T 108* versus 770
T 34 fmol/mg protein; *p < 0.01]. The afﬁnity of A2B receptors was not altered but the density was signiﬁcantly
decreased in COPD patients compared with the control group (Bmax = 66 T 5* versus 189 T 16 fmol/mg protein;
*p < 0.01). A signiﬁcant correlation was found between the afﬁnity and density of the adenosine receptors and
forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio, an established index of airﬂow
obstruction. In conclusion, this is the ﬁrst report showing the presence of adenosine receptors differentially ex-
pressed in lung parenchyma in COPD compared with control smokers. These novel ﬁndings strengthen the hy-
pothesis of a potential role played by adenosine receptors in the pathogenesis of COPD.
ALTERED DISTRIBUTION, SIGNALLING AND FUNCTION OF A1 AND
A2a ADENOSINE RECEPTORS IN THE BRAIN OF WAG/RIJ RATS WITH
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Adenosine shows anticonvulsant properties in different types of epilepsy, but its role in absence seizures is still to
be deﬁned. Here, we investigated the distribution as well as the signalling pathways and function of A1 and A2A
adenosine receptors in genetically absence epileptic Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats compared with
August Copenhagen Irish (ACI) rats, not prone to develop this kind of epilepsy. In WAG/Rij rats, the disease
onset occurs after 2 months of age, due to generation of abnormal oscillatory rhythms within the thalamocortical
circuitry, including the reticular (nRT), ventroposterolateral and ventroposteromedial thalamic nuclei as well as
the frontoparietal somatosensory cortex. Our study, carried out in young (1,5 months) and adult (6 months)
animals, i.e. before and after seizure occurrence, focussed on cerebral areas above mentioned in comparison with
hippocampus, not involved in seizure triggering. Immunohistochemistry and Western Blot analyses showed a
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in adult epileptic animals as compared with ACI rats of the same age. In contrast, the distribution of A2A
receptors was uniformly decreased and increased in all brain areas of young and adult WAG/Rij rats, respectively,
as compared with matched control. Accordingly, the stimulation of A1 and A2A receptors was ineffective on the
modulation of cAMP formation and 50 mM K
+-evoked [C
14]-glutamate release in brain slices from young epil-
eptic in comparison with control. Moreover, the A2A receptor stimulation with 2-(4-(-2-carboxyethyl)-phenyl-
amino)-50-N-ethylcarboxamido- adenosine (CGS21680) increased either cAMP intracellular levels or K
+-evoked
labelled glutamate release to a greater extent in brain slices from adult WAG/Rij than ACI rats. On the contrary,
the A1 receptor activation with 2-chloro-N
6-cyclopentyladenosine (CCPA) inhibited forskolin-induced cAMP
formation, but not K
+-evoked labelled glutamate release, more remarkably in brain slices from adult WAG/Rij
rat brains than from matched control. We also examined the modulation of the mitogen-activated protein kinase
(MAPK) system, constituted by ERK1/2, p38 and JNK, because mostly p38 and JNK, when activated, are rega-
rded as promoters of tissue stress and injury. Either CGS21680 or CCPA activated the entire MAPK system
substantially in adult animals, more remarkably in brain slices from adult epileptic rats than from control. Thus,
the reduced number of A1 and A2A receptors in WAG/Rij rat brain during development as well as the greater
distribution of excitatory A2A receptors in adult epileptic rats, coupled to a signiﬁcant alteration in signalling
pathways and function linked to the activation of both receptors might deeply inﬂuence the pathogenesis of
absence seizures, conﬁrming some ﬁndings on the epileptogenic role of adenosine in such a disease
1,2.
1. Ilbay, G.; Sahin, D.; Karson, A.; Ates, N. Clin. Exp. Pharmacol. Physiol. 2001, 28, 643–646.
2. Ates, N; Sahin, D.; Ilbany, G. Epilepsy and Behaviour 2004, 5, 645–648.
AMP Deaminase and AMP-Regulated Protein Kinase Interaction in Heart Cells
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The C34T mutation of the AMP deaminase 1 gene (AMPD1) induces protective effect demonstrated clinically in
patients with dilated cardiomyopathy, ischemic heart disease and in donors of hearts for transplantation. Howe-
ver, the mechanism of this effect has not been established. The product of the gene, AMP deaminase (AMPDA) 1
is responsible for catabolism of AMP and decrease of this activity will lead to elevation of AMP concentration.
This in turn may activate dephosphorylation pathway of AMP degradation leading to formation of adenosine.
Alternatively, AMP could activate AMP regulated protein kinase (AMPK) and related signalling cascade that is
known to induce cytoprotective mechanisms. We have shown earlier that this mutation leads to about 50%
decrease in cardiac AMPDA activity and that increase in adenosine production is relatively small. The aim of this
study was to evaluate whether AMPDA could modulate the activity of AMPK.
AMPDA was isolated from human skeletal muscle using two step column chromatography on phosphocellulose.
A new assay system has been developed for measurement of AMPK activity using HPLC with UV and mass
detection that allows simultaneous monitoring of the substrate peptide (AMARA) phosphorylation and adenine
nucleotide concentration. This assay was used to study the effect of isolated AMPDA added to in vitro assay of
AMPK activity in human heart homogenates performed in the presence or absence of AMP.
Addition of AMPDA at 1 2g of protein reduced the activity of AMPK from 1.16 T 0.06 to 0.43 T 0.10 nmol/min/
mg prot (n = 7, p < 0.001). Surprisingly, AMPDA reduced the activity of AMPK even in the absence of AMP
from 0.72 T 0.10 to 0.33 T 0.09 nmol/min/mg prot (p < 0.05). This effect was dependent on the amoun of the
AMPDA added.
We conclude that AMPDA activity may affect the activity AMPK in the cell. This interaction has been observed
even without AMP added to the assay, possibly through competing with or deamination of AMP already bound to
AMPK. Interaction of AMP deaminase with AMP-regulated protein kinase may have important implications for
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inhibition in the heart.
An intracellular redox and mercury-sensitive site in a purinergic
P2X receptor.
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P2Xs are ionotropic receptors differentially modulated by transition trace metals that bind to speciﬁc allosteric-
sites. Extracellular histidines are essential for copper and zinc modulation in either P2X4 and P2X2 receptors,
however these residues are not relevant for mercury-induced modulation in either receptor. Mercury has oppo-
sitte effects on the P2X2 and P2X4 receptors, it potentiates the former but inhibits the latter. To identify the
mercury binding-site we used chimeric receptors containing the P2X4 ectodomain in the backbone of the P2X2
receptor. Chimeric P2X4/2 and native receptors were expressed in X.laevis oocytes, the ATP-induced currents
were analized by two electrode voltage-clamp. In the P2X4/2a chimera, 10 2MH g
2+ increased 3.7 T 0.8 fold the
ATP-responses and displaced leftward the ATP concentration-response curve lowering the EC50 from 4.8 T 0.6
2M to 2.4 T 0.8 2M. (n = 8, p < 0.05). In the P2X4/2b chimera (a splice variant of the P2X2 receptor, lacking a 68
amino acid sequence in the C-terminal region), mercury was inactive. Copper inhibited and zinc potentiated the
ATP-responses much alike the P2X4 receptor, conﬁrming the extracellular nature of the copper and zinc allosteric
sites. We mutated Cys-430 by alanine, one of the 68 amino acid sequence of the P2X2 receptor. In the C430A
mutant the mercury-induced potentiation was signiﬁcantly less than in the native P2X2 receptor, although a
smaller potentiation remained. The C430A mutant, of the P2X4/2a chimera was completely mercury-insensitive,
suggesting that Cys-430 is a target for mercury. We test the potential role of Cys-430 as a redox sensitive residue
with hydrogen peroxide (H2O2). As mercury H2O2 potentiated the activity of the P2X2 receptor by 2.8 T 0.3-fold
with 0.3 mM H2O2 (n = 5); the P2X4/2a chimera was also potentiated by H2O2 (1 mM, 1.9 T 0.2-fold). No
potentiation was observed in the P2X2 C430 mutant nor in the P2X4/2b chimera. Chemical alkylation of the P2X2
receptor with the membrane-soluble methyl methanethiosulphonate MMTS also abolished the H2O2-potentia-
tion. The P2X4 receptor was inhibited by 1 mM H2O2 by 50%, and this effect was prevented with the addition of 1
mM DTT, a reducing agent. In conclusion we identiﬁed intracellular Cys-430 as a key amino acid for the pote-
ntiation induced by mercury and hydrogen peroxide on the activity of the P2X2 receptor. This is the ﬁrst report
identifying an intracellular redox site in P2X receptor channels highlighting an additional role of P2X receptors as
sensors of the cellular redox potential. Funded by FONDAP 13980001 grant. The Millenium Institute MIFAB
contributed to fund the CRCP Center.
Analysis of the role of extracellular cysteine residues in the P2Y12-receptor
Irina Algaier, Ivar von Ku ¨gelgen
Department of Pharmacology, Universita ¨t of Bonn, Reuterstrasse 2b, 53113 Bonn, Germany
ialgaier@uni-bonn.de
ADP activates human platelets through two G-protein coupled receptors, the P2Y1- as well as the P2Y12-receptor.
Four extracellular cysteine residues of the P2Y12-receptor protein have been proposed to form disulﬁde bridges
between the extracellular receptor domains and to represent the sites of action of the active metabolites of
clopidogrel [1,2]. An important role of cysteine residues for receptor function has previously also been shown for
the human P2Y1-receptor [3]. In order to study the role of the extracellular cysteine residues of the human P2Y12-
receptor we replaced cysteine residues by alanine residues by site-directed mutagenesis of the respective DNA
sequence. Wild type P2Y12-receptor and mutant receptors were stably expressed in 1321N1-astrocytoma cells.
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ptor function were assessed by measuring 2-methylthio-ADP (0.01 pM to 1 2M) induced inhibition of cellular
cAMP levels. The addition of isoprenaline 10 nM elicited an increase in cellular cAMP levels (average increase by
55 T 4 pM cAMP per well). In cells expressing wild type receptors, 2-methylthio-ADP caused a concentration-
dependent inhibition of the cAMP production with an EC50 concentration of 0.9 nM and a maximal inhibition by
47%. In cells expressing recombinant receptors in which both the residue Cys17 in the N-terminus as well as the
residue Cys270 in the third extracellular loop were replaced by alanine residues (Cys17Ala/Cys270Ala), 2-met-
hylthio-ADP caused an inhibition in adenylate cyclase activity with a reduced maximal response (maximal inhi-
bition by about 10%). The same was true for cells expressing mutant receptors in which Cys97 (located near the
exofacial end of transmembrane region 3, TM3) as well as Cys175 (in the extracellular loop 2) were replaced by
alanine residues (Cys97Ala/Cys175Ala; maximal inhibition by about 10%). In contrast, in cells expressing Cy-
s17Ala/Cys97Ala-, Cys17Ala/Cys175Ala-, Cys97Ala/Cys270Ala- or Cys175Ala/Cys270Ala-mutant receptors any
inhibitory action of 2-methylthio-ADP was lost. Additional experiments were performed to study the action of
thiol agents at the P2Y12-receptor. These compounds have also been proposed to interact with extracellular
cysteine residues. p-Chloromercuribenzene sulfonic acid (pCMBS; 0.1 to 10 2M) and N-ethylmaleimide (NEM;
0.3 to 10 2M) abolished or markedly reduced the responses to receptor stimulation by 2-methylthio-ADP with
EC50 concentrations of 0.9 2M (pCMBS) and 10 2M (NEM), respectively. Furthermore, in experiments perfor-
med under reducing conditions (presence of ascorbic acid 40 2M) receptor-mediated inhibition of adenylate
cyclase activity was almost lost. In conclusion, our present results demonstrate that Cys17 (N-terminus) and
Cys270 (third extracellular loop) form one disulﬁde bridge and that Cys97 (exofacial end of transmembrane
region3, TM3) and Cys175 (second extracellular loop) the second bridge. Furthermore, the data indicate that the
presence of only one intact disulﬁde bridges reduces the maximal responses to activation by agonists and that thiol
reagents block the receptor. Hence, our ﬁndings are compatible with the view that the active metabolites of
clopidogrel or prasugrel interact with the extracellular cysteine residues of P2Y12-receptor.
[1] Ding, Z., et al., Blood 2003, 101, 3908–3914.
[2] Savi, P., et al., Biochem. Biophys. Res. Comm. 2001, 283, 379–383.
[3] Hoffmann, C., et al., J.Biol.Chem. 1999, 274, 14639–14647.
Application of adenosine 50-triphosphate (ATP) infusions in palliative home
care: a multiccentre randomized clinical trial
S. Beijer, P.C. Dagnelie, N.E.G. Wijckmans
Department of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
epid.unimaas.nl
Introduction: Palliative care in terminal cancer aims at alleviating suffering of patients. Complaints like progre-
ssive fatigue, deteriorating performance status, weight loss and decreasing functional abilities have a substantial
impact on the quality of life of the patient and his/her environment. So far, few if any therapies are available to
combat these devastating complaints. A randomized clinical trial in patients with advanced lung cancer showed
favourable effects of regular ATP infusions on body weight, fat and fat-free mass, muscle strength, fatigue and
quality of life, relative to untreated controls
[1]. However, so far, no evidence is available about the effectiveness of
ATP in other types of cancer, nor for the application of ATP infusions in a non-clinical setting. Based on this, we
have initiated a study 1. To reproduce the results, which were previously observed in lung cancer patients, in
patients with other types of advanced cancer, and 2. To test the feasibility and safety of regular ATP infusions at
the patient_s home.
Subjects and methods: The study is targeted on cancer patients with a life expectancy of less than 6 months, who
are (partly) mobile and suffer from at least one of the following three complaints: fatigue, weight loss, or anorexia
(lack of appetite). Only patients are included with a life expectancy of <6 months, and for whom no systemic
treatment is available: medical treatment options are restricted to palliative/supportive care. Patients are recruited
through oncology departments of ﬁve participating hospitals, and family doctors. After eligible patients have
signed informed consent, patients are stratiﬁed for tumour type and presence of weight loss (yes/no) and then
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Springerrandomly assigned to ATP or no ATP. The ﬁrst ATP infusion is given at the day care centre of the participating
hospitals, subsequent infusions are given at the patients_ home by an experienced and trained nurse of the infu-
sion team of regional community care organizations. Outcome parameters are assessed every two weeks, until
8 weeks.
Preliminary results: Preliminary results will be presented at the meeting. So far, we have enrolled and randomised
80 patients of a wide variety of tumour types. One of the problems encountered is a high rate of drop-out due to
rapid deterioration of patients_condition, which is difﬁcult to foresee at the time of inclusion: approximately 75%
of patients complete 4 weeks of follow-up, and 50% complete the full 8 week study period.
Reference
1. Agteresch HJ, Dagnelie PC, Gaast A van der, Stijnen T, Wilson JHP. Randomized clinical trial of adenosine 50-
triphosphate in patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute 2000;
92(4):321–328.






1, Paul A. Insel
2,3,a n dWolfgang G.
Junger
1





As a key cell of the innate immune system, polymorphonuclear neutrophils (PMN) play an important role in
inﬂammation and host defense. It is well known that PMN accumulate at sites of infection and inﬂammation
where they kill bacteria, but these cells can also damage host tissues by releasing cytotoxic mediators. PMN
possess complex mechanisms that allow them to travel to the source of chemotactic mediators released from
bacteria or inﬂamed tissues. Although many aspects of PMN chemotaxis have been identiﬁed in recent years, it
remains unclear how PMN amplify subtle differences in the concentration of chemoattractants within a gradient
ﬁeld.
Recent data from our laboratory indicate that chemoattractants such as the bacterial formyl peptide fMLP induce
the release of cellular ATP from PMN at the leading edge that is closest to the source of fMLP. HPLC analysis
revealed that PMN rapidly hydrolyze released ATP to adenosine. Using real-time RT-PCR analysis of all known
P1 adenosine and P2 nucleotide receptor subtypes, we found that PMN and PMN-like HL-60 cells predominantly
express the P2Y2 nucleotide and A2a and A3 adenosine receptor subtypes. Elimination of extracellular ATP or
adenosine with apyrase or adenosine deaminase (ADA), respectively, dose-dependently blocked PMN activation
and chemotaxis toward fMLP. Inhibition of P2 and A3 receptors signiﬁcantly reduced chemotaxis, while agonists
of these receptors, but not of A2a receptors, increased chemotaxis. Using ﬂuorescent antibodies and HL-60 cells
expressing P2Y2- and A3-EGFP fusion proteins, we found that cells migrating in a chemotactic gradient redist-
ribute stimulatory A3 receptors to the leading edge (Fig.), while P2Y2 and A2a receptors remain uniformly
distributed on the cell membrane. PMN of A3 knockout mice showed signiﬁcantly reduced PMN migration in
vitro and in a peritonitis model of inﬂammation.
Together these data imply that ATP release and positive feedback through P2Y2 receptors are essential steps
needed for the ampliﬁcation of initial chemotactic signals, while the accumulation of A3 receptors at the leading
edge and positive feedback through adenosine predominantly generated at the leading edge maintains the loco-
motion of cells in a chemotactic gradient ﬁeld. Based on these ﬁndings and conclusions, we propose a ‘‘pull-push’’
model of PMN chemotaxis whereby ATP release and adenosine formation together with stimulatory A3 receptors
that are enriched at the leading edge increase cell migration, while suppressive A2a receptors at the receding edge
facilitate membrane retraction.
This study was supported in part by grants from the National Institutes of Health (GM-51477, 60475, & 66232).
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SpringerFig. Confocal image of HL-60 cell expressing A3-EGFP receptor at the leading edge. The cell is migrating from
the top right to the bottom left corner of the image shown.
ATP as a neurotrasmitter of pain in migraine: a functional role for P2Y
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Migraine is a common episodic headache disorder affecting more than 10% of the population (1). Despite the
availability of adjuvant drugs, treatment of migraine remains unsuccessful in a signiﬁcant number of patients,
suggesting that yet-unidentiﬁed causative agents remain to be discovered. In analogy to its role in other chronic
pain states, ATP could represent a potential algogenic factor in trigeminal sensory terminals during migrainous
attacks (2). On this basis, the present study was undertaken to characterize, in primary cultured cells from mouse
trigeminal ganglia, the presence and function of ATP/P2 receptors, with special focus on P2Y receptors. As a ﬁrst
step, we have characterized the percentage of the various cell types in our culture (i.e. neurons, astrocytes, and
oligodendrocytes) by means of ﬂow cytometry. Data showed that about 50% of cells were positive for oligode-
ndrocyte markers, 20% for the astroglial marker GFAP, and 10% were neurons. Results were also conﬁrmed by
immunocytochemistry. Contaminating ﬁbroblasts probably represents the remaining population. As a second
step, we have characterized by RT-PCR the expression of all P2Y receptors cloned from rodent tissue (P2-
Y1,2,4,6,12,13,14) and of some ‘‘P2Y like’’ orphan G-protein-coupled receptors (oGPCRs). Results showed the pr-
esence of all P2Y receptors, together with four oGPCRs. Single-cell calcium imaging of Fura-2 loaded cells was
then used to dissect the functionality of speciﬁc receptor subtypes by measuring their coupling to intracellular
calcium ([Ca
2+]i) in the presence of subtype-selective P2 receptor agonist and antagonist ligands. We found that,
despite the presence, at the mRNA level, of all P2Y receptors, only some of them are functionally coupled to
increases of [Ca
2+]i. In particular, application of ADP or 2MeSADP, agonists at P2Y1,P 2 Y 12,P 2 Y 13, induced a
[Ca
2+]i increases in approximately 20% of a sub-population of small and medium-size neurons and in almost all
satellite-like glial cells. Treatment with the P2Y1 selective antagonist MRS2179 potently reduced [Ca
2+]i respo-
nses induced by ATP in both types of cells. Furthermore, in satellite-like glial cells, the ADP-induced [Ca
2+]i
responses were signiﬁcantly reduced by AR-C69931MX, an antagonist selective for P2Y12 and P2Y13 receptors,
suggesting that a component of the [Ca
2+]i responses evoked by ADP derives from activation of P2Y12 and P2Y13.
We also observed [Ca
2+]i increases in neurons and satellite-like glial cells stimulated with UTP, known to activate
P2Y2 and P2Y4 receptors, and with UDP, which activates P2Y6 receptors. Thus, in mouse trigeminal ganglia,
120 Communications
SpringerP2Y1, and, to a lesser extent, P2Y2,4,6,12,13 contribute to ATP-induced calcium-dependent signalling. The elucid-
ation of the interaction of these receptors with ionophoric P2X receptors (in particular, P2X3) after sensitization
of trigeminal neurons with algogenic stimuli (e.g., NGF, BDNF or bradykinin), may help identifying new potential
targets for the development of novel antimigraine drugs.
Sponsored by Comitato Telethon #GGP04037 to MPA. AR-C69931MX was a kind gift of The Medicines Com-
pany, Waltham, MA, USA.
(1) Pietrobon, D. Neuroscientist, 2005 11:373–386.
(2) Burnstock, G. The Lancet, 1996 347:1604–1605.
ATP inhibits the inﬂammatory response in stimulated whole blood, even under
conditions of severe oxidative stress
Els L.R. Swennen
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Over the past decades, evidence has accumulated which indicates that extracellular nucleotides and nucleosides
may be important regulators of inﬂammatory and immune responses. Many diseases in which inﬂammatory re-
actions are involved are associated with oxidative stress.
The purpose of the present study was to determine the effects of ATP on TNF-!, IL-10 and IL-6 release in
stimulated whole blood in the absence and presence of oxidative stress. Blood samples were drawn from healthy
volunteers and incubated with ATP and lipopolysaccharide + phytohemagglutinin for 24 h, without and with
H2O2 as an inductor of oxidative stress.
In the absence of H2O2, ATP at 100 2M and 300 2M induced a reduction in TNF-! secretion by 32 T 8% (mean T
SEM) and 65 T 4%, respectively. Furthermore, these ATP concentrations induced an increase in IL-10 secretion
by 93 T 5% and 166 T 7%
1. ATP-+-S and ADP also inhibited TNF-! release, but only ADP showed a stimulatory
effect on IL-10 release. Co-treatment with adenosine deaminase did not reverse the ATP effect on TNF-! and IL-
10. In the presence of 1, 5 and 10 mM H2O2, ATP at concentrations of 100 2M and 300 2M still inhibited TNF-!
release and stimulated IL-10 release in stimulated blood
2.
Our results demonstrate that even under circumstances of severe oxidative stress, ATP has marked anti-inﬂam-
matory properties in stimulated whole blood.
References
1. Swennen ELR, Bast A, and Dagnelie PC. Immunoregulatory effects of adenosine 5_-triphosphate on cytokine
release from stimulated whole blood. Eur J Immunol. 2005; 35(3): 852–858
2. Swennen ELR, Dagnelie PC and Bast A. ATP inhibits hydroxyl radical formation and the inﬂammatory
response of stimulated whole blood even under circumstances of severe oxidative stress. Free Radical research.
2006; 40(1): 53–58
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Background: Cells release ATP into the extracellular environment in order to retain homeostasis and in response
to mechanical and pathophysiological stimuli (e.g. ischemia, hypoxia). Plasma ATP measurement is complicated
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Springerby 1) degradation of ATP by circulating and cell-based ectonucleotidases and by 2) ATP release from erythro-
cytes and platelets. The aim of this study was to investigate the degradation proﬁle of ATP in plasma after
addition of ATP to blood in the absence or presence of LPS/PHA stimulation, because our group showed earlier
that ATP inhibits the inﬂammatory response induced by LPS and PHA in blood.
Methods: Fresh blood was aliquoted into 24-well plates and incubated with 300 2M ATP for 30 min at 37-Ca n d
5% CO2
1. Samples obtained 0, 0.25, 0.5, 1, 2, 4, 8 and 24 hours after incubation with LPS/PHA or medium
(control) were disposed of the cellular fraction and proteins by centrifugation. In a single run, ATP and metab-
olites were separated by methanol-gradient elution over a reversed-phase HPLC column, quantiﬁed by peak area
through UV-absorption and identiﬁed by comparison of peak retention times with standards.
Results: Results indicated continuous ATP degradation to ADP and AMP, which was complete by 4 hours. The
level of ADP initially remained constant, but started to decline after 30 min. AMP increased during the ﬁrst two
hours, but slowly declined between 2 and 8 hours. Relatively high levels of hypoxanthine were observed after 24
hours. By that time, ATP, ADP and AMP were totally depleted. Similar results were obtained after incubation in
the presence of LPS/PHA or medium.
Discussion: The simultaneous decline of ATP and ADP after 30 min possibly contributed to the strong increase of
AMP and hypoxanthine. The decline of AMP after 2 hours, which was probably caused by ongoing depletion of
its precursors ATP and ADP, did not lead to an increase in inosine or adenosine levels. This may have been
caused by uptake by erythrocytes and intracellular conversion to inosine and hypoxanthine, followed by secretion
from the erythrocytes
2. Finally, the increase in plasma hypoxanthine levels after 2 hours was not matched by its
degradation products xanthine and uric acid, which would suggest conversion to other products.
Conclusion: Our results so far indicate a slower ATP breakdown in blood than anticipated, which is accompanied
by a rise in hypoxanthine after 24 hours.
1. Swennen, E. L.; Bast, A.; Dagnelie, P. C., Immunoregulatory effects of adenosine 50-triphosphate on cytokine
release from stimulated whole blood. Eur J Immunol 2005, 35, (3), 852–8.
2. Grifﬁth, D. A.; Jarvis, S. M., Nucleoside and nucleobase transport systems of mammalian cells. Biochim
Biophys Acta 1996, 1286, (3), 153–81.
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Brain pericytes are cells that are located in ablumenal site of small blood vessels or capillaries with patchy
structure. Since capillaries lack smooth muscles and pericytes express !-smooth muscle actins, it is suggested that
pericytes may control microcirculation by regulating tonus of capillaries. However, contraction or relaxation of
brain pericytes is largely unknown. We previously reported that astrocytes release ATP that mediates glia-to-
neuron communications as well as glia-to-glia communications. In addition to this, astrocytes form endfeet to
surround the vascular wall, suggesting that astrocytic ATP may also control vascular functions. Exogenously
applied ATP and its analogues produced rises in [Ca
2+]i in cultured pericytes obtained from rat forebrain with
pharmacological proﬁle of P2Y2 and P2Y1 receptors. Interestingly, when stimulated, pericytes showed contractile
responses, which was inhibited by the P2 receptor antagonists. In addition, pericytes released ATP in response to
mechanical stimulation or even spontaneously, and produced elevations in [Ca
2+]i, suggesting that pericytes could
control function of capillaries by releasing endogenous ATP. We also demonstrate astrocytic control of pericytes
or vascular tonus, which is also mediated by ATP/P2 receptors.
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SpringerATP reduces lactate dehydrogenase (LDH) and triacylglycerol levels in lung
cancer patients– a potential explanation of ATP_s favourable clinical effects?
P.C. Dagnelie, T. Brouwer
Department of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
Dagnelie@epid.unimaas.nl
Background: Cancer-associated cachexia is a clinical syndrome of progressive weight loss associated with profo-
und changes in host metabolism, including elevated lipolysis, proteolysis, and liver gluconeogenesis, and causing
elevated plasma levels of lactate dehydrogenase (LDH) and triacylglycerols (TAG). At the same time, elevated
LDH levels are a well-known marker of tumour progression and reduced survival. We previously reported that
ATP infusions had marked beneﬁcial effects on weight and muscle mass in patients with advanced lung cancer,
1 as
well as on survival in a subgroup of cachectic patients.
2
Aim: To assess the effect of ATP infusion on plasma LDH and TAG levels in patients with advanced lung cancer.
Methods: Blood values from our previously published clinical trial in patients with non-small-cell lung cancer
(NSCLC, N = 58, stage IIIB/IV) were analysed. Patients were randomly assigned to either supportive care (co-
ntrol), or ATP infusions (total of 10 courses of 30 h, given at 2- to 4-week intervals over 24 weeks). Differences
over time were appraised by repeated-measures analysis.
Results: At baseline, ATP and control groups were similar with regard to prognostic variables, including weight,
tumour stage, and plasma values of LDH and TAG. Over the 24-wk study period, LDH and TAG increased in the
control group, indicating progression of tumour growth and deterioration of the cancer cachexia syndrome. In
contrast, LDH and TAG remained stable in the ATP group (between-group difference: P < 0.05 for both LDH
and TAG).
Discussion: The favourable effects of ATP on LDH and TAG levels in patients with advanced NSCLC may be
due to anti-inﬂammatory effects of ATP. Swennen et al.
3 recently showed that ATP inhibits the LPS-PHA inﬂ-
ammatory response in blood through inhibition of TNF-alpha release. TNF-alpha (a pro-inﬂammatory cytokine)
has been associated with 1. elevated glucose-lactate cycling and 2. decreased lipoprotein lipase activity. Suppre-
ssion of TNF by ATP could result in down-regulation of LDH production and increased clearance of plasma
TAG, explaining the observed metabolic effects of ATP.
Conclusion: Our study demonstrates that ATP infusion has favourable effects on both serum LDH and TAG
concentrations. These effects may partly explain the beneﬁcial effects of ATP on body weight and survival in
patients with NSCLC. Further investigations are needed for better understanding of the underlying mechanisms
of these effects.
References:
1. Dagnelie PC, Agteresch HJ. Drug Devel Res 2003; 59: 146–151 (7th Adenosine Meeting, Gold Coast,
Australia).
2. Agteresch HJ, Burgers SA, van der Gaast A, Wilson JHP, Dagnelie PC. Anti-Cancer Drugs 2003; 14: 639–644.
3. Swennen ELR, Bast A, Dagnelie PC. Eur J Immunol 2005; 35: 852–858.
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Usually, the controlled secretion of ATP occurs through the exocytosis of granules and vesicles. However, in some
cells, and under certain circumstances, other mechanisms control ATP release. In gap junctions, connexins (Cx)
link the cytoplasm of two adjacent cells by establishing an intercellular channel and control the passage of ions
and molecules up to 1 kDa. The channel is formed by two moieties called hemichannels or connexons. It has been
suggested that connexons may be an alternative pathway for ATP release. Connexins, like Connexin 38 (Xenopus
endogenous connexin) and Connexin 32 (Cx32) can, under certain circumstances, permeate for ATP (Bahima et
al., 2006). We have investigated ATP release through hemichannels formed by Cx32. This protein is expressed in
most of human organs, but, particulary, Cx32 mutations present in Schwann cells produce X-linked Charcot Marie
Tooth disease (CMTX). Expressing Cx32 in experimental model of Xenopus oocytes, we have combined the use
of two electrode voltage clamp to record the ionic current generated by the hemichannels and the bioluminscent
reaction of luciferin-luciferase. The hemichannels formed by Cx32 were estimulated by depolarizing pulses res-
ulting in an outward current. After this estimulation, during the repolarization period, there was an inward tail
current coincident with the release of ATP from the oocyte. The area of this tail current correlated with the
amount of ATP released. Moreover, when we treated the Cx32 injected oocytes with 5 2g/ml Brefeldin A, a
vesicular assembly blocker, there were no signiﬁcant changes in ATP release, indicating that there was no exo-
cytotic process implicated on it. On the other hand, in oocytes coexpressing Cx32 and P2X1 receptor, we found a
larger tail current because the autoactivation of the oocyte, due to the opening of P2X1 receptor by the ATP
released. Altogether these results strongly relate the release of ATP to the activation of Cx32 hemichannels in
Xenopus oocytes.
Acknowledgements: This work is supported by grants from the Spanish Government, MCYT (SAF2005-00736/
BFU2005-02202).
Bahima et al. 2006. Endogenous hemichannels play a role in the release of ATP from Xenopus oocytes. J. Cell
Physiol. Jan;206(1):95–102
ATP Stimulates Reactive Oxygen Species Generation by NADPH Oxidase via
P2X7 Receptors
Hewinson, J., Ward, S.G., & MacKenzie, A.
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Reactive oxygen species (ROS) play diverse roles in host defence and inﬂammation. They have important func-
tions in pathogen destruction, as highlighted in diseases such as chronic granulomatous disease, and have an
emerging role in the inﬂammatory process, especially in the regulation of cell adhesion molecule expression. A
few publications have shown that ROS generation in immune cells may be stimulated by ATP
1,2. However the
receptors and pathways involved have not be deﬁned in any detail, but are important in understanding the role of
ATP in inﬂammation and disease. In this work ATP-induced ROS generation in the human macrophage was
investigated.
All studies were performed using the human monocyte cell line THP-1 differentiated with phorbol 12-myristate
13-acetate and lipopolysaccahride, and real-time ROS generation was measured in cells pre-loaded with the ROS-
sensitive ﬂuorescent compound dichloroﬂuorescin diacetate. In these cells ATP induced ROS generation was
dose-dependent with a peak occurring at 3–5 mM (EC50 269 2M). ROS generation was not completely inhibited
using 1-[N,O-bis-(5-Isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62; 10 2M gave 52% in-
hibition with 3 mM ATP) which, taken with the dose response data, suggests P2 receptors other than P2X7 may
also signal ROS production. The detection of ATP (3 mM)-induced ROS generation was inhibited using N-
acetylcysteine (an antioxidant, concentrations Q1 mM gave complete inhibition) and diphenyleneiodonium (co-
ncentrations Q30 2M gave complete inhibition) but not with allopurinol (e30 2M) or N5-Nitro-L-arginine methyl
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Springerester (e100 2M). Therefore NADPH oxidase and not xanthine oxidoreductase (XOR) or nitric oxide synthase is
responsible for the generation of ROS, even though the cell lysates were shown to contain active XOR. None of
the effective compounds inhibited ATP-induced calcium inﬂux into Fluo-4 loaded cells therefore discounting the
possibility that direct inhibition of P2 receptors was occurring. In calcium-free medium ATP-induced ROS gen-
eration was completely inhibited and pre-treatment of cells with 10 2M LY294002, 100 nM wortmannin, and 10
2M PD98059 resulted in partial inhibition of this pathway (48, 29, and 29% inhibition, respectively), whereas
treatment with 10 2M Y-27632 (a ROCK inhibitor) and 0.3% butan-1-ol (a phosphatidic acid formation inhibitor)
had no effect. Therefore these results suggest the involvement of phosphatidyl inositol-3 kinase (PI3K) and
extracellular-signal regulated kinase (ERK) in the ATP-induced ROS generation signalling pathway. All effective
compounds were tested for cytotoxicity using a lactate dehydrogenase assay. At the concentrations tested none of
the compounds were cytotoxic.
These results suggest that ATP can signal the upregulation of ROS production in human macrophages. The
generation of ROS is ATP dose-dependent, occurs by NADPH activation, and involves a calcium-dependent
pathway that may rely on PI3K and constitutes a pathway that potentially has a role in host-defence and inﬂa-
mmation.
(1) Ferrari, D.; Idzko, M; Dichmann, S; Purlis, D.; Virchow, C.; Norgauer, J.; Chiozzi, P.; Di Virgilio, F.; Lutt-
mann, W. FEBS Letters 2000, 486, 217–224.
(2) Suh, B-C.; Kim, J-S.; Namgung, U.; Ha, H.; Kim, K-T. J Immunol 2001, 166, 6754–6763.
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In exocrine glands, ATP and other nucleotides/sides are thought to be important regulators of salt and ﬂuid
transport. In rat pancreas ATP is released from acini into the series of excurrent ducts that possess P2 receptors
and also adenosine receptors, as shown by the recent study (1). Close to acini the ATP concentrations are in the
high micromolar range. However, in ﬁnal pancreatic juice collected from the main duct of stimulated pancreas we
detected very low concentrations of ATP and high nucleotidase activity (2). Thus, in order to understand acino-
ductal paracrine regulation, it is important to determine which ecto-enzymes are present in pancreatic secretion.
For this purpose, in vivo experiments on rat pancreas were performed and the major purine-converting exchange
enzyme activities were determined in pancreatic juice.
Animals were stimulated with cholecystokinin (CCK-8) infusion (5.6 pmol/min/per 200 g animal) and pancreatic
juice was collected from the common pancreatic bile duct. Purine-converting activities and transfer of +-phosphate




with/without cold nucleotides as second substrates, followed by subsequent separation by TLC and autoradiog-
raphy (3). Pancreatic juice for enzymatic analysis was collected after 60 min of continuous CCK-8 stimulation
when secretion was about 3 2l/min. The time-courses of [
14C]ATP and [
3H]ADP hydrolyses show that pancreatic
juice contains enzymes that convert ATP to ADP, which is further rapidly converted to AMP. Data indicate that
the juice contain NTPDase that can hydrolyze both ATP and ADP about equally well, i.e. CD39. Reverse-phase
HPLC analysis additionally shows that this enzyme has broad substrate speciﬁcity towards other nucleotides, UTP
and ITP. In addition, secretion contains ecto-50nucleotidase, i.e. CD73, converting AMP to adenosine. Activities
of non-speciﬁc phosphatases, ecto-nucleotide pyrophosphatase/phosphodiesterases and adenosine deaminase w-
ere negligible. In addition to hydrolytic enzymes, there were also counteracting ATP-generating enzymes in
pancreatic juice, adenylate kinase and NDP kinase, capable of sequentially phosphorylating AMP via ADP to
ATP.
Taken together, following CCK-8 stimulation of pancreas, pancreatic juice contains signiﬁcant activities of enz-
ymes consistent with CD39 and CD73. There are also enzymes with lower activities that are able to regenerate
ATP from AMP and ADP, where other NTP can be used as donors of +-phosphoryl groups. This newly discov-
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eatic ducts lumen, and regulated release of ATP-hydrolyzing and ATP-generating enzymes.
The projects were supported by the Danish Medical and Science Research Councils
1. Novak, I., S.E. Hede, and M.R. Hansen (this volume)
2. Sørensen, C. E., J. Amstrup, H. N. Rasmussen, I. Ankorina-Stark, and I. Novak. J Physiol 2003; 551(3):
881–892.
3. Yegutkin, G. G., S. S. Samburski, and S. Jalkanen. FASEB J 2003; 17: 1328–1330.
Attenuation of Reperfusion Lung Injury and Apoptosis by A2A Adenosine
Receptor Activation is Associated with Modulation of Bcl-2 and Bax
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Background: Adenosine receptors (AR) and extracellular signal-regulated kinases (ERK) have been implicated
in tissue protection and apoptosis regulation during ischemia-reperfusion (IR) injury. This study tests the hypo-
thesis that reduction of reperfusion lung injury following A2AAR activation is associated with attenuation of
apoptosis, modulation of ERK activation, and alterations in anti- and pro-apoptotic protein expression (Bcl-2 and
Bax, respectively).
Methods: The arterial branch of the left lower lung lobe in intact-chest, spontaneously breathing cats was occl-
uded for 2 hr and reperfused for 3 hr (IR group). Animals were treated with the selective A2AAR agonist ATL313
given 5 min before reperfusion alone, or in combination with the selective A2AAR antagonist ZM241385.
Results: Western blot analysis showed signiﬁcant reduction in expression of Bcl-2 and increase in expression of
Bax after reperfusion compared with control lungs. Phosphorylated ERK1/2 levels were also increased following
reperfusion. Apoptosis was preferentially increased in alveolar epithelial cells. Compared to the IR group, AT-
L313 markedly (P < 0.01) attenuated indices of injury and apoptosis including the percentage of injured alveoli,
wet/dry weight ratio, myeloperoxidase activity, in situ terminal deoxynucleotidyl transferase-mediated deoxyur-
idine triphosphate nick end-labeling (TUNEL) positive cells, and caspase 3 activity and expression. Furthermore,
compared with reperfused lungs, in ATL313-pretreated lungs, Western blot analysis demonstrated substantial
ERK1/2 activation, increased expression of Bcl-2, and attenuated expression of Bax. The protective effects of
ATL313 were blocked by pretreatment with ZM241385.
Conclusions: In vivo activation of A2AAR confers protection against reperfusion lung injury. This protection is
associated with decreased apoptosis and involves ERK1/2 activation and alterations in anti-apoptotic Bcl-2 and
pro-apoptotic Bax proteins.
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SpringerWestern blot analysis of Bcl-2 and Bax protein levels in control, nonsichemic group (I), ischemia reperfusion (IR)
{II}. ATL313 continuous infusion of 1 ng I kg1 I min1 administered before IR (III), ATL313 continuous infusion of
10 ng I kg1 I min1 administered before IR (IV). ZM241385 (V). (a) Representative immunoblots (b) Densitom-
etric scan of Bcl-2 and Bax in lung tissue from the different groups. The intensities of bands in control treated
tissue samples (no ischemia or reperfusion, group I) were expressed as 100%. Data (mean ± SEM) were obtained
from Western blot assays performed at the end of reperfusion. Immunodetection of actin was performed as an
internal control. *p<0.05 compared with groups I, III, IV. **p<0.01 compared with groups II, V.
Augmentation of cutaneous hypersensitivity by perceived acute stress is mediated
by the adenosine A1 receptor.
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Adenosine is utilized by the body"s tissues for modulation of a diverse range of activities that include sleep,
cognitive function, immunity and pain perception. Acting through its speciﬁc receptors, adenosine modulates
neurotransmitter function and release, behavior, systemic immunity and cell metabolism. Adenosine is generated
extracellularly by degradation of released adenine nucleotides (ATP, ADP, AMP) and is constitutively present at
low levels in all tissues. However, extracellular adenosine levels can markedly increase under metabolically str-
essful conditions such as inﬂammation or hypoxia. Biological systems have evolved to utilize extracellular aden-
osine levels to activate protective responses against physiological stressors such as ischemia and infection. Acting
through the CNS, perceived psychological stress also affects biological functions within the body. In particular,
differential effects of acute and chronic stress on skin immunity have been demonstrated in the well-established
rodent model of non-painful restraint stress; with acute stress enhancing and chronic stress suppressing cutaneous
delayed-type hypersensitivity (DTH), an antigen-speciﬁc immune response known to be mediated by CD8+ T
cells
1, 2. In this study, we utilize the restraint stress model and the hapten dinitroﬂuorobezene (DNFB, 1% in 4:1
acetone/olive oil) to induce delayed type hypersensitivity in the skin. In WT mice undergoing restraint stress DTH
was augmented at 48 hrs (mean change in pinna thickness, non-stressed [NS] vs acute stressed [AS]: 0.08 mm vs
0.31 mm, respectively, p = 0.008). In contrast, stress does not enhance DTH responses in A1KO mice (mean
change NS vs AS, 0.18 mm vs 0.19 mm, respectively, p = 0.73). Further studies have failed to show any differences
in stress-augmented plasma corticosterone and urinary norepinephrine levels between A1 receptor knockout
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corticosterone-mediated deployment of monocytes and lymphocytes out of the blood vasculature into the surr-
ounding tissues. However, acute stress associated increases in circulating blood neutrophils, known to be mediated
by catecholamine release, were not seen in A1 KO mice (mean cell count, NS vs AS: 1.54   10
3 cells/2l vs 1.62  
10
3 cells/2l, p = 1.000), in contrast to their WT littermates (mean cell count, NS vs AS: 1.18   10
3 cells/2l vs 4.18  
10
3 cells/2l, p = 0.009). Others have suggested that the increased antigen speciﬁc T cell responses occurring with
acute stress are due to norepinephrine-driven dermal dendritic cell (DC) migration to draining lymph nodes
2.
Using FITC (1% in 1:1 acetone/dibutylphthalate) topically applied to shaved ventral skin, we show that the
enhanced rates of MHC class II
high CD11c+ DC migration to draining lymph nodes observed in acutely stressed
WT mice (DCs containing FITC, NS vs AS, at 6 hrs, 17% vs 26.8%; at 24 hrs, 29.1% vs 39.8%) do not occur in the
adenosine A1 receptor KO mice under similar conditions (NS vs AS, at 6 hrs, 27.4% vs 28.5%; at 24 hrs, 42.9% vs
38.1%). Thus, our results suggest that acute stress enhances cutaneous immunity and that adenosine receptor A1
signaling plays a critical role in acute stress-altered cutaneous DTH immunity, at least in part through its mod-
ulating effects on norepinephrine release and dermal DC migration rates.
1. Dhabhar, F. S.; McEwen, B. S., Acute stress enhances while chronic stress suppresses immune function in vivo:
a potential role for leukocyte trafﬁcking. Brain Behav Immun 1997, 11, 286–306.
2. Saint-Mezard, P.; Chavagnac, C.; Bosset, S.; Ionescu, M.; Peyron, E.; Kaiserlian, D.; Nicolas, J.-F.; Berard, F.,
Psychological stress exerts an adjuvant effect on skin dendritic cell functions in vivo. Journal of Immunology 2003,
171, 4073–4080.
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Ligand based 3D-structure-activity relationship (3D-QSAR) is an ensemble of strategies to study new compounds
starting from molecule structures and their corresponding chemical properties. Throughout the different appro-
aches, the combination of autocorrelation vectors
1 of molecular electrostatic potential
2,3 (MEP) surface properties
with the conventional partial least squares (PLS) analysis has been used for the prediction of the human A3
receptor antagonist activities. The autocorrelation allows in fact to compare molecules (and their properties) with
different chemical structures and with different spatial orientation without any previous alignment (which is often
not even possible).
A dataset of 358 structurally diverse human A3 receptor antagonists has been used to derive a novel ligand-based
3D-QSAR model. The molecular collection includes the most important chemical classes of human A3 antagonist
structure-activity relationship. A remarkable quantitative model was generated, with a cross-validated correlation
coefﬁcient of 0.81 and a test set correlation coefﬁcient of 0.82.
4
The aim of this analysis was to employ a rigorously validated QSAR model for a possible application of virtual
screening on available chemical databases to ﬁnd out new compounds with high predicted activity.
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BDNF-induced modulation of synaptic transmission requires functional
adenosine A2A receptors in the mouse hippocampus.
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Brain-derived neurotrophic factor (BDNF), a member of neurotrophin family, is able to enhance synaptic tran-
smission and to induce long-term potentiation (LTP) either in vitro or in vivo. BDNF and its tyrosine kinase
receptor (TrkB) are highly expressed in the hippocampus where an interaction with adenosine A2A receptors
(A2ARs) has been recently demonstrated (Diogenes et al, 2004). The aim of the present work was to evaluate
BDNF effects in the hippocampus of A2AR wild type (WT) and knock out (KO) mice (6 months of age). In
electrophysiological experiments in hippocampal slices (450 um) from WT mice, application of BDNF (10–20 ng/
ml, 30 min) increased the slope of excitatory post-synaptic ﬁeld potentials (fEPSPs) recorded in the stratum
pyramidale of CA1 region (113 T 6.7%, P < 0.05 vs basal, N = 11). The co-application of the selective A2A
antagonist ZM 241385 (50 nM) abolished the BDNF-induced potentiation of fEPSP slope (99.43 T 1.05%, N = 6).
Conversely, in slices from A2AR KO mice BDNF was no longer able to increase the fEPSP slope and it even
reduced it (88.83 T 3.29 P < 0.05 vs basal and vs WT, N = 12). Finally, enzyme immunoassay studies showed a
tendency to a reduction in hippocampal BDNF levels in A2AR KO vs WT mice. These results suggest that in the
hippocampus the presence and the tonic activation of A2ARs are necessary to allow BDNF-induced potentiation
of synaptic transmission. Given the key role exerted by hippocampal BDNF on both synaptic plasticity and
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BDNF effects under both physiological and pathological conditions.
Diogenes M. J.; Fernandes C. C.; Sebastiao A. M.; Ribeiro J. A. J. Neurosci. 2004; 24(12): 2905–2913.
Benzo [d]isothiazol-3-yl-benzamidines: a new class of protective agents on culture
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Several articular pathologies evolve from a local inﬂammatory disease to a chronic process with distinct inﬂam-
matory and destructive components. The progressive damage of the articular cartilaginous tissue represents a
central moment of the pathogenetic course, in which depletion of aggrecan, disregulated synthesis of matrix
components like proteoglycans and collagen play a fundamental role [1]. Moreover, the functional alteration of
cartilage results also from the interaction of different mediators, such as cytokines, e.g. interleukin-1" ?IL-1"),
that induces high levels of nitric oxide (NO), inhibits collagen and proteoglycans synthesis, increases susceptibility
to injury by other oxidants (e.g. superoxide anion and hydroxyl radicals, peroxides, and reactive oxygen species,
ROS).
The culture of human chondrocytes stimulate by IL-1" has been established, as a proﬁt experimental model, for
reproducing the mechanisms involved in the pathophysiology of arthritic diseases.
In the present study we determined the in vitro effects on human articular chondrocytes for a series of N-
benzo[d]isothiazol-3-yl-benzamidines hydrochlorides designed to improve the effectiveness of N-benzo[d]isothia-









R1= H, 2-Cl, 3-Cl, 4-Cl, 2-F,
   3-F, 4-F, 4-CH3, 4-CF3
We investigated the inﬂuence of the new amidines on the production of NO, MMP-3, ROS, GAGs, key molecules
involved in matrix destruction.
Our results clearly demonstrate that N-benzo[d]isothiazol-3-yl-benzamidines properly substituted can block mu-
ltiple cartilage destruction during the arthritic inﬂammatory process, as simulated in our experimental model.
[1] Flugge, L.A., Miller-Deist L.A., Petillo P.A., 1999. Towards a molecular understanding of arthritis. Chemistry
& Biology 6, 157–166.
[2] Panico, AM; Vicini, P; Massimo, G; Cardile, V; Gentile, B; Avondo, S; Vittorio, F; Ronsisvalle, G; 2004.
Protective effects of benzisothiazolylamidines on IL-1" induced alterations in human articular chondrocyte met-
abolism. Inﬂammation; 28 (4): 231–235.
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Purinergic receptors represent an attractive class of druggable targets within the purine-binding proteome, yet
there are many other enzyme families of interest as therapeutic targets within this large superfamily. We estimate
that the purine-binding proteome contains at least 2000 members, with kinases composing the largest fractio-
n(25%) of this group. We report here a novel approach to screen hundreds of these targets in parallel, thus
providing an efﬁcient way to probe compound libraries as ligands to a broad variety of enzyme classes. We
constructed and screened a targeted library of 8000 compounds using a novel afﬁnity displacement assay (referred
to as proteome mining). Multiple tissues were used as the source of native purine-binding proteins to proﬁle this
library. Hits were obtained for nearly 100 targets, including well validated targets such as dihydrofolate reductase
and multiple kinases (e.g. CDK2, Her2, PDK1, AurA), and less well-validated targets such as the kinases Fer and
Nek9. Importantly, the method also provided afﬁnity information on potential toxicity targets (e.g. phosphorylase
kinase, pyruvate carboxylase, glucose-6-phosphate dehydrogenase). Thus, this approach provides primary target
afﬁnity information as well as selectivity data across the entire purine-binding proteome. In addition, afﬁnities of
compounds for their protein targets could be determined directly from the same assay and these measurements
were sufﬁciently quantitative and reproducible to drive the development of structure-activity relationships. Un-
expectedly, selectivity within a gene family was not predictive of selectivity between gene families across the
purine-binding proteome. The application of this screening approach to four diverse targets, dihydrofolate red-
uctase, Hsp90, quinone reductase 2, and PI3kinase will be described. In each case, the use of the afﬁnity displa-
cement assay enabled the identiﬁcation of novel, selective, orally active compounds. Taken together, these results
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Bioinformatic analysis of the P2X receptor family
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P2X receptors for ATP are a family of ligand-gated ion channels consisting of seven receptor subunits that
associate most likely as homo- and heterotrimeric channels. They are expressed throughout the body and have a
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wide ranging therapeutic beneﬁts. For example, P2X1 receptors have been implicated in the regulation of thro-
mbosis and P2X3 receptor antagonists may act as analgesics and regulate bladder function. There are no crystal
structures available for the P2X receptor family, they have no obvious similarity to other ion channels or ATP
binding proteins and motifs such as the Walker motif are not present as in other ATP-sensitive proteins. For this
reason, mutagenesis studies have been relied upon to identify important residues involved in ATP action at the
receptors. However, the need for a structural model is imperative to functional studies aiding rational drug design
and the development of pharmacophores. A portion of the extracellular loop of P2X receptor proteins shares a
degree of homology with the catalytic domains of class II aminoacyl-tRNA synthetases and a homology model of
the rat P2X4 receptor has been published based on this similarity. However, existing models do not consider the
entire protein sequence of the receptor and the likely trimeric structure. Ihaveproducedpossible3Dmodelsforthe
structureofthehumanP2X1 receptor using ATP-binding proteins with known structures and similar ATP binding
environments to the P2X1 receptor as predicted by mutagenesis studies. The structural models attempt to rep-
resent the extracellular ligand-binding loop. The models are currently being tested by site-directed mutagenesis.
Supported by the Wellcome Trust
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The P2X7 system plays an important role in spontaneously occurring apoptosis and cell-number regulation in the
human cervix (1). Recent studies from our lab revealed the presence of naturally occurring truncated variant of
the human receptor P2X7 in human cancer cervical epithelial cells. The novel protein (P2X7jj), a polypeptide of
258 amino acids, lacks the entire intracellular carboxy terminus, the second transmembrane domain, and the distal
third of the extracellular loop of the full-length P2X7 receptor. Expression experiments in host cells that lack
endogenously the P2X7 receptor revealed diminished ligand-binding and channel function capacities, and failure
to form pores and mediate apoptosis in response to treatment with the P2X7 receptor agonist BzATP. The present
study extended those preliminary experiments to other epithelial tissues, including the ectocervix (EctoCx), en-
dometrium (EndoM), and skin. In the ﬁrst experiment primary-secondary cultures of normal and cancer epithelial
cells were generated on ﬁlters (2), and the degree of apoptosis was determined by the DNA solubilization assay
(3) following 9 hrs of treatment with 100 2M BzATP. The results in Fig. 1 show diminished apoptosis in all three
types of cancer cells compared to the corresponding normal cells. The second experiment determined mRNA
(Fig. 2) and protein levels (Fig. 3) of the P2X7jj and Full-Length P2X7 receptor in normal and cancer ectocervix,
endometrium, and skin tissues. mRNA levels were determined by Real-Time RT-PCR and normalized to GPDH;
protein levels were determined by densitometry of the P2X7jj – speciﬁc 45–42 KDa bands off Western blots using
Alomone-M0 anti P2X7 pAb (which recognizes the proximal extracellular loop of the P2X7 receptor) and nor-
malized to tubulin. The data show that in the three types of tissues the ratios of P2X7jj/P2X7 mRNA (Fig. 2) and
protein (Fig. 3) were greater in cancer than in normal cells. These results suggest a general pattern of upregulation
of the P2X7jj or downregulation of the Full-Length P2X7 in epithelial cancers. Because the P2X7jj variant
antagonizes the Full-Length P2X7 receptor (manuscript submitted), the present results suggest a novel pathop-
hysiological mechanism of apoptosis inhibition through regulation of P2X7 protein function by its variant the
P2X7jj. Dysregulated apoptosis could play a role in carcinogenesis.
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G-protein-coupled (heptaspanning) membrane receptors are target for a wide range variety of diseases. Recent
evidence shows that these receptors occur on the cell surface as homo and heterodimers. Therefore dimers but not
monomers are the actual targets for therapeutical useful drugs (already marketed or under development). The
heteromerization is oneof the molecular basis involved inthe negative cross-talkbetween adenosineanddopamine.
The anti-parkinsonian actions of A2AR antagonists in humans (already in phase 3 clinical trials) are to a substa-
ntital degree caused by blocking the action of endogenous adenosine on A2AR of the A2AR/D2R heteromer.
We have targeted A2AR/D2R heterodimers by the development of novel compounds that could potentially int-
eract simultaneously with dopamine D2 and A2A receptors. Dopamine-adenosine bivalent ligands have mixed
A2A receptor antagonist and D2 receptor agonist pharmacophores coupled by connecting spacers of variable
lengths. These spacers are polyamide-poly (ethylene) glycol type oligomers composed by a precise number of
monomer units [(NH-CH2CH2O-CH2CH2O-CH2CH2-NH-CO-CH2CH2-CO)] and were synthesized by a solid-
phase protocol. The potential of these bivalent ligands has already been conﬁrmed in cell models and subsequ-
ently patented. Bivalent liagnds of given lengths are more potent than monovalent compounds and can simulta-
neously bind to both D2 and A2A receptors in the heterodimer. Their efﬁcacy has been tested in cAMP level
determination assays in transfected cells. A lead compound has been selected that has D2 receptor agonist activity
and A2A receptor antagonists activity and higher relative efﬁcacy than monovalent counterparts. These bivalent
ligands prove that A2AR/D2R heteromers occur in striatum and they constitute novel therapeutical tools for PD.
It is expected that these compounds are more efﬁcacious than combined therapies using L-DOPA and adenosine
antagonists and have less side effects.
Blockade of adenosine A2A receptors differently alters convulsive behaviour and
prevents hippocampal damage in two models of temporal lobe epilepsy
Lisiane O. Porciu ´ncula, Paula M. Canas, Catarina R. Oliveira, Rodrigo A. Cunha
Ctr. Neuroscience Coimbra, Fac.Medicine, Univ.Coimbra, Portugal.
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Endogenous adenosine in the brain is thought to prevent the development and spread of seizures via tonic anti-
convulsant A1 receptor-mediated effects (Fredholm et al., 2005). However, adenosine modulation results from a
balanced activation of inhibitory A1 and facilitatory A2A receptors (A2ARs) and blockade of these A2ARs affords
neuroprotection against different brain insults (Cunha, 2005). Thus, we tested the role of A2ARs on the develo-
pment of behavioural seizures and hippocampal damage in the two models of epilepsy: kainic acid (KA) ip
administration and amygdala kindling.
Male Wistar rats injected ip with KA (10 mg/kg, ip) displayed rapid (within 30 min) and severe convulsions (stage
4–5 of Racine_s scale) and a pattern of neuronal damage (cresyl violet and FluoroJade staining) together with
astrogliosis (GFAP immunoreactivity) and microgliosis (tomato lectin or CD11b immunoreactivity) in the hipp-
ocampus at 24 h or 7 days after KA injection. SCH58261 (0.05 mg/kg, ip, 30 min before KA) caused an incons-
istent effect on convulsions (prevention, attenuation and no effect, 3 rats each) but abolished neuronal damage,
astrogliosis and microgliosis in all 9 rats.
To conﬁrm the role of A2ARs in the development of hippocampal damage resulting from behavioural seizures, we
compared the effect of KA in wild type and A2AR knockout male C57Bl6 mice. As occurred in rats, KA (35 mg/
kg, sc) injection in wild type mice triggered convulsions (stage 5–6 of modiﬁed Racine_s scale) as well as hippo-
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However, in A2AR knockout mice, KA injection caused a similar severity of convulsions but did not produce any
hippocampal damage (no FluoroJade staining and no modiﬁcation of GFAP- or CD11b-immunoreactivities co-
mpared to saline controls).
Finally, we investigated if A2AR blockade would interfere with epileptogenesis using a model of epilepsy (amy-
gdala kinding) that causes an onset of seizure activity slower (in the range of days) compared to kainate injection
(within 30 min). In vehicle injected control rats, tonic/clonic seizures were observed 8–10 days after starting the
kindling protocol (sub-maximal stimulation 500 2A, 1 msec pulses at 50 Hz for 1 sec, twice a day, 10 AM and 4
PM). In contrast, in 90% of kindled rats, the administration of SCH58261 (0.05 mg/kg, ip, 30 min before each
stimulation period) delayed and attenuated the severity of convulsions. Likewise, astrogliosis and microgliosis
observed after 15 days were prevented by SCH58261.
These results provide the ﬁrst evidence that endogenous adenosine participates in the development of epileptic-
induced damage through A2AR activation. These A2ARs might also aggravate epileptogenesis but this only evi-
dent in a chronic (kindling) rather than acute (KA) model of epilepsy. This questions the role of adenosine as an
anti-epileptic agent and suggests that A2AR antagonists may provide a novel strategy to control neuronal damage
occurring in temporal lobe epileptic conditions. (Supported by FCT)
Cunha, R.A. Purinergic Signal. 2005 1, 111–134.
Fredholm B.B. et al. Int. Rev. Neurobiol. 2005 63, 191–270.
Blockade of adenosine A2A receptors prevents "-amyloid (A"1j42)-induced




3, Catarina R. Oliveira
1, R.A. Cunha
1
1Ctr. Neuroscience Coimbra, Fac. Medicine, Univ. Coimbra, Portugal,
2Dept. Physiol. Pharmacol., Federal Univ.
Ceara, Fortaleza, Brazil,
3Dept. Neurology, Boston Univ. School Medicine, MA, USA
(canas.paula@gmail.com)
Alzheimer_s disease (AD) is the most common chronic neurodegenerative disease characterized clinically by an
atrophy of hippocampal regions and a progressive cognitive impairment (Hardy and Selkoe, 2002). The param-
eters that correlate better with memory dysfunction in AD are the levels of soluble A", mainly A"1–42, and a
decreased density of nerve terminals in cortical areas (Hardy and Selkoe, 2002). Thus, a major lead for the
development of novel therapeutic strategies for AD might be to explore mechanisms able to prevent this early
synaptotoxicity caused by A"1–42.
Adenosine plays a prominent role in controlling brain neurodegeneration. In particular adenosine A2A receptor
(A2AR) blockade confers a robust neuroprotection in chronic noxious brain conditions (Cunha, 2005). Accordi-
ngly, we showed that caffeine and selective A2AR antagonists prevent A"-induced toxicity in cultured neurons
(Dall_Igna et al., 2003). Thus, we tested if the A2AR antagonist SCH58261 (0.05 mg/kg, ip daily for 15 days)
prevented the synaptotoxicity and memory impairment observed in rats two weeks after administration of A"1–42
(2 nmol, icv). The rats displayed a mnemonic deﬁcit (Y maze) and a decrease of synaptophysin immunoreactivity
(evaluated by immunohistochemistry and Western blot analysis), but neither cell death (evaluated by cresyl violet
staining), nor microglia recruitment (evaluated by CD11b immunohistochemistry) was observed. In contrast, in
SCH58261-treated rats, A"1–42 failed to modify cognitive performance and there was no synaptotoxicity, i.e.
reduction of synaptophysin immunoreactivity compared to control.
We attempted to conﬁrm this key role of A2ARs in the development of the A"1–42-induced synaptotoxicity and
memory impairment using a genetic deletion rather than a pharmacological blockade of A2ARs, i.e. using A2AR
knockout mice. As occurred in rats, there was a mnemonic deﬁcit and a decrease of synaptophysin immunore-
activity, but neither cell death nor microglia recruitment in wild type C57Bl6 mice two weeks after administration
of A"1–42 (2 nmol, icv). In contrast, in preliminary experiments, none of these modiﬁcations were found two weeks
after administration of A"1–42 (2 nmol, icv) in A2AR knockout mice.
These results show that the blockade of A2ARs, which are enriched in hippocampal synapses (Rebola et al., 2005),
prevents A"-induced synaptotoxicity and consequent amnesia in rodents. This key role of A2ARs in the develo-
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suggestion that caffeine consumption (an adenosine receptor antagonist) might attenuate the incidence of AD
(Maia and de Mendonc ¸a, 2002). (Supported by CNPq Brazil, FCT, Pﬁzer award from SPN)
Dall"Igna, O.P. et al. Br. J. Pharmacol. 2003 138, 1207–1209.
Cunha, R.A. Purinergic Signal. 2005 1, 111–134.
Hardy, J.; Selkoe, D.J. (2002) Science 2002 297, 353–356.
Maia, L.; de Mendonc ¸a, A. Eur. J. Neurol. 2002 9: 377–382.
Rebola, N.; Canas, P.M.; Oliveira, C.R.; Cunha, R.A. Neuroscience 2005 132, 893–903.
Blockade of P2Y1 receptors prevents the synaptotoxicity and memory
impairment caused by A"1–42 administration.
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Amyloid beta-peptides (A") are accepted to be a major cause of neuronal death in Alzheimer_s disease (AD)
(Hardy and Selkoe, 2002) which is predated by a synaptic loss (Selkoe, 2002). Thus, a major lead for the devel-
opment of novel therapeutic strategies for AD might be to explore mechanisms able to prevent this early syna-
ptotoxicity caused by A"1–42. Upon cell damage there is an increase of the extracellular levels of ATP, which can
activate P2 receptors (P2Rs). Brain possesses both ionotropic P2XR and metabotropic P2YR which can control
neuronal damage (Volonte et al., 2003). Since we showed that P2X1–3Rs and P2Y1,2,4Rs are located in nerve
terminals (Rodrigues et al., 2005), we now investigated if P2 receptors could control damage in cultured hippo-
campal neurons and, in particular, the synaptotoxicity induced by the exposure to A"1–42.
A"1–42 (500 nM, 48 h) led to the death of 22 T 3% of neurons, which displayed apoptotic features (nuclear
condensation, cytochrome c release, caspase 3 activation). Blockade of P2Rs with 10 2M PPADS prevented A"1–
42-induced neurotoxicity, which was mimicked by the blockade of P2YRs with 10 2M reactive blue 2, but not
P2X1–3Rs using 10 2M NF023. The P2Y1R antagonist MRS2179 (10 2M) was also neuroprotective. This neuro-
toxicity was preceded (at 12 h) by a synaptotoxicity and dendritic atrophy (with no neuronal death yet), which was
abrogated upon blockade of P2Y1Rs in accordance with the synaptic localization of P2Y1Rs. Interestingly we
found an increased density of P2Y1Rs in hippocampal terminals of both rats (Wistar) and mice (C57-BL/6) two
weeks after administration of A"1–42 (2 nmol, icv) at a time where they displayed a mnemonic deﬁcit (Y maze)
and synaptotoxicity (reduced levels of immunoreactivity for synaptic markers such as SNAP-25 and synaptophy-
sin) but no neuronal death (Fluoro–Jade C staining). Finally, KO P2Y1R mice (C57-BL/6) did not display mne-
monic deﬁcit or synaptotoxicity two weeks after administration of A"1–42.
Altogether, these results show that pharmacological blockade or genetic inactivation of P2Y1 receptors is neur-
oprotective against synaptotoxicity/neurotoxicity and mnemonic impairment caused by A"1–42. This indicates that
extracelular ATP may be involved in the development of neurotoxicity caused by A"1–42, and prompts conside-
ring P2Y1R antagonists as potential candidates to interfere with the early events in AD. (Supported by FCT)
& Hardy J.; Selkoe D. J. Science 2002 297, 353–356.
& Rodrigues, R. J.; Almeida, T.; Richardson, P. J.; Oliveira, C. R.; Cunha, R. A. J. Neurosci. 2005 25, 6286–6295.
& Selkoe, J. Science 2002 298, 789–791.
& Volonte, C.; Amadio, S.; Cavaliere, F.; D"Ambrosi, N.; Vacca, F.; Bernardi, G. Curr. Drug Targets CNS Neurol.
Disord. 2003 2, 403–412.
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SpringerBlood leucocytes are mobile modulators of adenine nucleotide metabolism and
play an important role in determining the effects of adenine nucleotides on
platelet function.
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Endothelial cells display the ecto-enzyme NTPDase (CD39) which converts ATP into ADP and ADP into AMP
and it is believed that that these vascular cells play an important role in removing adenine nucleotides from blood
and preventing ADP causing widespread platelet activation with potential pro-thrombotic consequences. Rece-
ntly we have made several observations on the importance of leucocytes in adenine nucleotide metabolism and
their effects on platelet function. First we found that ATP added to blood induces platelet aggregation although
no such aggregation occurs in platelet-rich plasma (PRP). By adding autologous leucocytes back to the PRP we
showed that leucocytes are involved in the aggregation response and through the use of selective antagonists
showed that ADP is also involved (1). We then found that leucocytes (all neutrophils, all monocytes and a subset
of lymphocytes) test positive for CD39. In addition we found modiﬁed platelet aggregation responses to both ATP
and ADP in association with high leucocyte counts. Aggregation induced by ATP was more rapid while aggre-
gation induced by ADP was followed by rapid disaggregation. This was the case in blood from patients with
leucocytosis and also when leucocytosis was created experimentally in normal blood by adding autologous leuc-
ocytes (2). A systematic analysis of the role of blood cells and plasma enzymes in adenine nucleotide metabolism
by HPLC was then performed. Studies in normal blood conﬁrmed that leucocytes are the principle means through
which ATP and ADP added to blood are broken down to ADP and AMP respectively, and that platelets and
erythrocytes play virtually no part (3). Studies in leucocytosis demonstrated enhanced rates of conversion of ATP
to ADP and of ADP to AMP and explained the effects of leucocytosis on platelet aggregation to ATP and ADP
that we had demonstrated earlier (4). Recently we looked further at the role of CD39 on leucocytes in these
processes. Blood was obtained from patients with leucocytosis and normal controls, and analyses were performed
of platelet aggregation (measured in blood and PRP) and adenine nucleotide metabolism (measured by HPLC).
Levels of CD39 on leucocytes were determined by ﬂow cytometry. In all cases abnormalities in platelet aggreg-
ation in association with leucocytosis could be explained by enhanced adenine nucleotide metabolism brought
about by increased amounts of CD39 on either myeloid or lymphoid cells. In one case in which leucocyte count
returned to normal following successful chemotherapy, adenine nucleotide metabolism and CD39 also returned to
normal. In summary, leucocytes provide a means of metabolising adenine nucleotides that is additional to that
provided by vascular endothelial cells. Their mobility may enable modulation of platelet function throughout the
entire vasculature as well as at its periphery.
1. Stafford NP et al. Arterioscler Thromb Vasc Biol. 2003;23:1928–33. 2. Glenn JR et al. Platelets 2005;16:159–70.
3. Heptinstall S et al. J Thromb Haemost. 2005;3:2331–9. 4 Heptinstall S et al. Arterioscler Thromb Vasc Biol. in
press.
Boranophosphate Isosteres of Dinucleoside Polyphosphates are Highly Potent
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SpringerDinucleoside polyphosphates, NpnN0, exerting their physiological effects via P2-receptors, are attractive drug
targets as they offer better stability and speciﬁcity compared to nucleotides. To further improve the properties of
NpnN0, which are still pharmacologically unsatisfactory, we developed novel boranophosphate isosters of dinuc-
leoside polyphosphates, denoted as Npn(B)N. These analogues were obtained in a facile and efﬁcient synthesis as
the exclusive products in a concerted reaction of two nucleoside phosphorimidazolides and inorganic boranoph-
osphate. This unusual reaction is due to the pre-organization of three reactant molecules by the Mg
2+ ion. We
found that Ap3/5("+-B)A analogues were potent P2Y1-R agonists. Ap5(+-B)A, was equipotent to 2-MeS-ADP
(EC50 6.3   10
j8 M), thus making it one of the most potent P2Y1-R agonists currently known. Moreover, Ap5(+-
B)A did not activate P2Y2-R. In contrast, Up3/5("+-B)U analogues were extremely poor agonists of both P2Y1-R
and P2Y2-R. Npn(B)N analogues exhibited remarkable chemical stability under physiological conditions. Under
conditions mimicking gastric juice, Np3("-B)N analogues exhibited half-life (t1/2) of 1.3 h, whereas Np5(+-B)N
degraded at a much faster rate (t1/2 18 min). The hydrolysis of Ap3("-B)A by human nucleotide pyrophosphatase
phosphodiesterases (NPP1 and NPP3) was slowed by 40% and 59%, respectively, as compared to Ap3A. How-
ever, this effect of the boranophosphate was position-dependent, as Np5(+-B)N was degraded at a comparable rate
to that of Np5N. In summary, Ap5(+-B)A appears to be a highly potent and selective P2Y1-R agonist, as compared
to the parent compound.
1 A US patent application ﬁeld on June 15, 2005.
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Background The adenosine mono-phosphate deaminase (AMPD) enzyme converts AMP into IMP in muscle
cells. The common variant C34T encodes a severely truncated protein and is associated with improved cardiov-
ascular outcome in patients with coronary artery disease and heart failure, possibly due to increased levels of
interstitial adenosine during ischemia. We hypothesize that in subjects with this polymorphism increased adeno-
sine receptor stimulation during ischemia and reperfusion potentiates reactive hyperemia.
Methods In 100 healthy subjects the AMPD1 genotype was determined, as well as nucleoside uptake and aden-
osine kinase activity in erythrocytes. In 10 individuals heterozygous for the variant allele (C/T) and 10 matched
controls (C/C) forearm blood ﬂow (FBF) was assessed with venous occlusion plethysmography during 3, 5 and 5
minutes after 2, 5 and 13 minutes of forearm ischemia, with and without concomitant infusion of the nucleoside
uptake inhibitor dipyridamole into the brachial artery (7.4 nmol/min per dl of forearm tissue). Maximum FBF and
FBF averaged per consecutive minute were analysed. After washout, vasodilation induced by intrabrachial inf-
usion of sodium nitroprusside (SNP) and acetylcholine (ACh) was determined.
Results Both groups were similar in age, sex, weight, blood pressure, heart rate, baseline caffeine concentration,
and Vmax and Km values for the nucleoside transporter and adenosine kinase. Maximal FBF after 2, 5 and 13
minutes of ischemia was 25.4 T 2.5, 32.7 T 2.2, and 38.6 T 2.6 ml/min per dl of forearm tissue in the C/T group and
21.9 T 2.2, 28.5 T 2.4, and 41.0 T 3.3 ml/min/dl in the C/C group (mean T SE, P<0.05, repeated measures ANOVA).
One-minute averaged FBF was also higher in the C/T group after 2 minutes of ischemia (P<0.05), but not after 5
minutes (P = 0.09) and 13 minutes (P = 0.6). One-minute averaged FBF was potentiated by dipyridamole in both
groups for all periods of ischemia (P<0.05). However, the effect of dipyridamole on maximum FBF after 2, 5 and
13 minutes of ischemia was more pronounced in the C/C group than in the C/T group (P<0.05). Vasodilation
induced by SNP and ACh did not differ between both groups (P = 0.9 and P = 0.7, respectively).
Conclusions Dipyridamole potentiates reactive hyperemia, suggesting predominant extracellular formation of
adenosine during ischemia and early reperfusion. Heterozygous deﬁciency in AMPD1 augments reactive hyper-
emia but reduces the potentiating effect of dipyridamole during maximum vasodilation. These observations su-
pport the concept that the cellular uptake of adenosine is reduced in AMPD1 deﬁcient subjects during ischemia
and early reperfusion, resulting in increased adenosine receptor stimulation. This mechanism could well contri-
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Springerbute to the observed improved cardiovascular outcome in patients with the C34T polymorphism of the AMPD1
gene.
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Extracellular nucleotides play an important role in airway defense by controlling epithelial ion and ﬂuid transport
as well as ciliary beating. Nucleotide levels on airway surfaces, measured in vitro and ex vivo, show dynamic
changes due to the combination of basal and stimulated release and their rapid metabolism. The mechanism of
nucleotide release from epithelial cells is not well understood, and their hydrolysis at the airway surface makes it
difﬁcult to assess the magnitude and relative abundance of different nucleotide species released. In this study, to
minimize cell surface hydrolysis, we used a low-volume (300-2L) ﬂow-through chamber (1.3 ml/min perfusion
rate), and examined adenine and uridine nucleotide content in perfusates of human A549 cells prior to and during
50% hypotonic shock. Aliquots of the perfusates were collected at 15- to 60-s intervals. ATP, ADP, AMP, and
Ado were quantiﬁed by HPLC analysis of ﬂuorescent etheno derivatives, and UTP and UDP were measured
using HPLC-coupled radioenzymatic assays. After the onset of hypotonic shock, ATP, ADP, UTP, and UDP
content in the perfusates increased markedly and peaked at approximately 2 min, followed by a gradual decay
during the next 15–20 min; changes in Ado and AMP at peak were relatively minor. The peak concentrations and
fold increment (in brackets) were: 52 nM ATP [5], 16 nM ADP [5], 4 nM AMP [2], 27 nM Ado [1.3], 21 nM UTP
[>7], and 11 nM UDP [12]. Nucleotide release was almost completely abolished from cells loaded with the calcium
chelator BAPTA. Under isotonic conditions, elevation of intracellular calcium with the calcium ionophore ion-
omycin (5 2M, 3 min) also released nucleotides with kinetics and relative abundance as above, although less
robustly. ATP:ADP (3:1) and UTP:UDP (2:1) ratios in the perfusates from stimulated cells were markedly sm-
aller than the cytosolic ratios of these species, suggesting that an NDP-rich compartment, e.g., the secretory
pathway, contributed to nucleotide release. Laser confocal microscopy experiments illustrated increased uptake of
FM1-43 into the plasma membrane upon hypotonic shock or ionomycin treatment, consistent with enhanced
vesicle exocytosis under these conditions. In summary, our results strongly indicate that calcium-dependent ex-
ocytosis is responsible, at least in part, for adenine and uridine nucleotide release from A549 cells.
Supported by the Canadian Institutes of Health Research (to R.G.) and the National Institutes of Health USA (to
E.L.).
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Caffeine is the most widely used drug in the world and acts mainly through antagonism of the effects mediated by
the adenosine receptor subtypes A1,A 2A,A 2B and A3. Controversial results have been reported on the link
between caffeine and inﬂammation. Recently, caffeine has been found to have anti-inﬂammatory activity in dif-
ferent human substrates. From this background the present study was designed to evaluate the effect of repeated
caffeine administration at different doses and for different periods of time (400 or 600 mg/d for 1 week and 400
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concentrations after caffeine abstinence. Neutrophils were obtained from peripheral venous blood of 33 healthy
human volunteers at the end of 2 weeks of caffeine abstinence and at 1, 12, 24, 36, 48, 60 hours after the last dose
of caffeine. Saturation binding assays showed an increase of afﬁnity (KD) and density (Bmax) of A2A adenosine
receptors after caffeine intake at the doses of 400 mg/d for 14 days or 600 mg/d for 7 days. Interestingly, the
increase in density of A2A receptors found at 1 hour after caffeine withdrawal was similar to that observed at 12,
24 and 36 hour after the last dose of caffeine. On the other hand at 48 and 60 hour after the last dose of caffeine
the binding parameters were not different from control condition or from the control group. The upregulation of
A2A receptors does not appear to be ascribable to the synthesis of new receptors because were no changes in
mRNA levels at different times after the last dose of caffeine. The A2A receptor alteration was accompanied by
increases in cAMP accumulation and decreases in superoxide anion production after A2A stimulation by NECA.
Binding and functional changes of A2A receptors gradually return to baseline after 48 hours of caffeine withdr-
awal. In summary, caffeine intake and subsequent withdrawal mediates a temporary upregulation of A2A recep-
tors and as a consequence might represent the mechanism responsible for the observed anti-inﬂammatory effects.
Caffeine modulates P50 auditory sensory gating in healthy subjects.
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The P50 suppression paradigm is an index of sensory gating assumed to reﬂect an inhibitory process. Adenosine is
a neuromodulator with mostly inhibitory activity that is released by physiological stimuli and can be blocked by
non-selective adenosine receptor antagonists such as theophylline and caffeine. A previous study showed that a
single dose of theophylline decreased P50 suppression in healthy volunteers. Here we investigated the effect of
caffeine (0, 100, 200 and 400 mg p.o.) on P50 sensory gating in 24 healthy volunteers (15 habitual caffeine high-
users and 9 low-users). The 200 mg and 400 mg doses reduced P50 sensory gating (increase P50 ratio), whereas
100 mg produced a non-signiﬁcant effect. The effect of caffeine on P50 ration was independent of gender and
habitual caffeine intake. High caffeine users also showed baseline differences, with lower S2 amplitudes compared
to low-users. These results reinforce the participation of adenosine in the modulation of P50 sensory gating and
suggest that both chronic and acute caffeine ingestion should be controlled for in studies using the P50 sensory
gating paradigm.
Caffeine recognizes differently adenosine A2A receptors in homo or
heterodimers: A mechanism for caffeine tolerance.
Gemma Navarro, Francisco Ciruela, Sergi Ferre ´, Carmen Lluis, Rafael Franco Vicent Casado ´.
Molecular Neurobiology Unit. Institut d"Investigacions Biome `diques August Pi i Sunyer (IDIBAPS). University of
Barcelona. Diagonal 645. 08028 Barcelona.
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Caffeine is the most world-wide consumed psychoactive drug and its only known molecular targets at non-path-
ological doses are adenosine A1 and A2A receptors. Of the four known adenosine receptors (A1,A 2A,A 2B and
A3), adenosine A1 (A1Rs) and A2A (A2ARs) receptors are primarily responsible for the central effects of aden-
osine. The molecular mechanisms underlying the effects of caffeine are not fully elucidated. As indicated in
another session of this Conference (Franco R) and in Ciruela et al., (2006), A1 adenosine receptors form heter-
omers with adenosine A2A receptors. Functional studies showed that A1R-A2AR heteromers are responsible for a
strong A1R-A2AR antagonistic cross-talk. The strength of this cross-talk would depend on the concentration of
extracellular adenosine. To illustrate this, it can be expected that at adenosine concentrations high enough to
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in transfected cells or in samples from striatum, it was found that A1R showed the same KD for caffeine in A1R-
A2AR co-transfected than in A1R-transfected cells. Also, as previously shown using other transfected cell lines,
A2ARs displayed higher afﬁnity (lower KD value) for caffeine than A1Rs in single-transfected HEK cells. In
contrast, the afﬁnity of caffeine for A2ARs in A1R-A2AR co-transfected cells was 12-times higher (p<0.001) than
in A2AR-transfected cells. The afﬁnity of the A2AR for caffeine was not altered when co-transfected with the
dopamine D2 receptor (D2R), even though they form A2AR-D2R heterodimers. These results demonstrate the
existence of a selective reduction in the afﬁnity of A2AR for caffeine in the A1R-A2AR heteromer, i.e. the binding
of caffeine to A2ARs in the A1R-A2AR heteromer is qualitatively different from the binding to the non-hetero-
meric A2AR or other heteromeric A2ARs.
An unresolved issue about caffeine is the strong tolerance for many of its behavioural and biochemical effects that
develops after chronic treatment. It is generally assumed that tolerance to the behavioral effects of caffeine is
mostly related to pharmacodynamic factors involving adenosine receptors, but there is no consensus about which
are the signiﬁcant changes in either A1Ro rA 2AR function after chronic caffeine treatment. The most commonly
reported effect is the up-regulation of A1Rs. Nevertheless, there are reports indicating a lack of signiﬁcance in
these changes in receptor density and there are even studies showing down-regulation of either A1Ro rA 2AR
function. To test the role of A1R-A2AR heteromers in this phenomenon, competitive-inhibition experiments of
[
3H]R-PIA binding using CGS21680 were performed in striatal membrane preparations of caffeine-treated rats.
The displacement curve of [
3H]R-PIA binding by CGS21680 in striatal membranes from caffeine-treated rats was
signiﬁcantly (p<0.001) better ﬁtted by a two-site model than by a single-site model. The IC50 value corresponding
to the binding of CGS21680 to A1R (1.7 T 0.5 2M) was similar to that obtained in naı ¨ve rats (1.8 T 0.5 2M).
However, the inhibition of the [
3H]R-PIA binding to A1R when CGS21680 binds to the A2AR displays an EC50
value (8 T 3 nM) about three fold lower than the value obtained in naı ¨ve rats (22 T 6 nM). Interestingly, these
results indicate that caffeine pre-treatment alters the function of the A1R-A2AR heteromers, increasing signiﬁc-
antly (p<0.02) the sensitivity of A2AR to modulate (negatively) A1Rs.
Apart from the afﬁnity of the A1R, A2AR and A1R-A2AR for adenosine and caffeine and from the strength of the
A1R-A2AR intramembrane interaction, one more variable plays a substantial role when analyzing the effects
taking place after chronic caffeine administration. In fact chronic treatment with the methylxanthine leads to a
signiﬁcant increase in the plasma and extracellular levels of adenosine. Since at relatively low adenosine levels
there is little occupancy of A2ARs most of the behavioral and biochemical effects following an acute administr-
ation of caffeine are due to A1R blockade. Under chronic caffeine treatment (or other conditions leading to
increased adenosine levels), adenosine also binds and activate A2AR, which, in addition, has a reduced afﬁnity for
caffeine. This likely scenario would lead to a situation where the increased levels of adenosine acting on A2ARs to
inhibit A1R function by means of the potentiated A1R-A2AR intramembrane interaction. Under these conditions,
caffeine would have little effect on A1Rs, which would be already inhibited as a consequence of the A1R-A2AR
intra-membrane inter-molecular interaction.
Ciruela et al (2006) J Neuroscience In the Press
Can Acadesine increase adenosine level in rat cardiomyocytes?
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Acadesine (AICA-riboside) is thought to have a protective effect during cardiac ischemia via two mechanisms.
Acadesine can protect energy metabolism by elevating adenine nucleotides concentration, or it can elevates
adenosine (Ado) concentration, which acts via Ado receptors. In this study, we evaluated both of these mecha-
nisms in isolated, spontaneously beating rat cardiomyocytes and neonatal rat heart slices under normoxic and
various stress conditions.
In isolated rat cardiomyocytes and heart slices under normoxic conditions, 500 2M radiolabeled acadesine was
efﬁciently metabolized to the purine nucleotides ATP and GTP, although Hyp was the predominant product.
However, as acadesine rose to surpass 1 mM concnetration, radiolabeled ZMP accumulation increased and exc-
eeded the ATP concentration.
Communications 141
SpringerAfter 2 hrs incubation under anaerobic conditions in an argon atmosphere, ATP levels decreased three-fold in
isolated rat cardiomyocytes. In the same cells transferred to aerobic conditions in the presence of 500 2M acad-
esine, the ATP level appropriate for normoxic conditions was reconstituted after 2–3 hours incubation. Further
incubation in this condition caused a continuing increase in ATP levels.
While no Ado accumulation was observed under the conditions described above, we also evaluated Ado accu-
mulation in the presence of acadesine while chemically accelerating the cascade of ATP degradation. When
antimycin-A or iodoacetate chemically stressed cardiomyocytes or heart slices, Hyp and inosine increased several-
fold but not Ado accumulation was observed. However in the presence of 20-deoxycoformycin – inhibitor of ADA
activity, Ado accumulated but acadesine only slightly increased Ado concentration.
As opposed to Ado release and accumulation, we examined the effect of acadesine on Ado uptake in rat cardi-
omyocytes. Acadesine inhibited Ado uptake in these cells in a dose-dependent fashion under both normoxic and
anaerobic conditions. This effect required however a relatively high concentration of acadesine.
In conclusion, these data indicate that acadesine treatment effectively supports reconstitution of ATP levels
ischemic stress but it has no effect on Ado release and accumulation in rat cardiomyocytes. However, acadesine
may affect Ado uptake in the same cells.
Cardiac expression of NTPDase1 and caveolins are altered in human disease
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Pathological circumstances like inﬂammation or ischemic insult facilitate the release of adenine nucleotides am-
ong ATP, from several types of cells. Concentration of extracellular ATP is regulated by ectonucleotidases.
Endothelial and smooth muscle cells possess high ecto-ATPase activity and it has been demonstrated that this
enzyme activity is altered after LPS stimulus, ischemia, inﬂammation, viral infection and in multidrug resistance.
Upregulation of increased ecto-ATPase activity is associated with the appearance of higher number of caveolae,
specialized membrane invaginations, not only in endothelial and smooth muscle cells but, also in pericytes, astr-
ocytes and multidrug resistant cancer cells. Several molecules involved in signalling (e.g. eNOS, G-proteins,
receptors) are targeted to these membrane compartments; thus caveolae appear to integrate cellular activation
events. The ecto-ATPase enzyme within these signal-transducing microdomains has been identiﬁed as NTPDase1/
CD391. NTPDase1/CD39 can co-associate with scaffolding domain of caveolin1 or 3, or of RanBPM, and other
structural proteins of caveolae. The question has been arisen whether there is a link between higher NTPDase
expression and expression of caveolins during disease. We demonstrated the ecto-ATPase activity of healthy and
diseased human cardiac tissue by enzyme histochemistry, measured the concentration of the extracellular ATP
and metabolites by HPLC and identiﬁed NTPDase1/CD39 by immunohistochemistry and Western blotting2. The
presence of all the three types of caveolins were demonstrated in parallel ultracryo sections. We demonstrated the
presence of caveolin1 in human cardiac muscle cells. Double immunostaining conﬁrmed the co-localization of
NTPDase1/CD39 and caveolin1 in endothelial cells, whereas the CD39 signal was weak in the cell membrane of
cardiac muscle cells. Pathological samples from patients with ischemic heart disease exhibited signiﬁcant increases
in ecto-ATPase activity, as measured by HPLC and RT-PCR. Western blotting conﬁrmed higher CD39 expres-
sion in diseased as compared with control tissues. This higher activity and expression level of NTPDase1 unde-
rline a putative protective roles in the cardiovascular system and also support the administration of soluble
NTPDase1/CD39 in the treatment of ischemic complications. Caveolin3 expression was altered in pathological
samples. The lower expression level of caveolin3 may indicate lability in contrast to caveolin1.The high level
presence of caveolin1 in diseased cardiac muscle raises the possibility, that this caveolin isoform, at least in part,
may substitute for caveolin3.
Research was supported by Hungarian grants ETT 480/2003, OTKA M036314.
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CD73 is a GPI-anchored cell surface protein with ecto-50-nucleotidase enzyme activity which catalyzes the dep-
hosphorylation of 50-adenosine monophosphate to adenosine. As this molecule catalyzes the last step in the
generation of adenosine from extracellular adenine nucleotides, it has the capacity to regulate the activation of
adenosine receptors. For example, adenosine generated by CD73 can decrease endothelial cell permeability in
vitro
1). Moreover, Thompson et al.
2) demonstrated that cd73-deﬁcient mice have defects in endothelial barrier
function leading to neutrophil accumulation in tissues during hypoxia, a condition in which CD73 expression is up
regulated. In this study, we asked whether CD73 might also have a role in regulating lymphocyte migration into
lymph nodes during inﬂammation. Lymphocytes home from the blood stream to lymph nodes (LN) through a
process of tethering, rolling, adhesion and transmigration through the vasculature. High endothelial venules (H-
EV) are a key regulator of this process. The interaction of L-selectin on lymphocytes with peripheral-node ad-
dressins on HEV initiates tethering and rolling. Then, activation of "2 integrin (LFA-1) on lymphocytes by
chemokines induces ﬁrm adhesion with HEV. However little is known about the transmigration process and the
factors that control HEV permeability. Here we show preliminary evidence for a role of CD73 in regulating the
entrance of lymphocytes into draining LN under inﬂammatory conditions induced by LPS and poly (I:C). The
high expression of CD73 on HEV has been already reported
3). The size of secondary lymphoid organs is normal
in cd73-deﬁcient mice, making it likely that lymphocyte homing to peripheral LN is also normal under steady state
conditions. To examine the role of CD73 in lymphocyte migration during an inﬂammatory response, cd73-deﬁc-
ient mice and wild type controls were subjected to subcutaneous injection of LPS or poly(I:C) into the left hind
footpad, and lymphocyte migration into the draining popliteal lymph nodes was examined. PBS was injected into
contralateral site as a control. As expected, 24 hours after injection, the left draining lymph nodes were drama-
tically enlarged in both strains of mice (p<0.02); however, they were approximately twice as large in the cd73-
deﬁcient mice as in the controls (p<0.04). To more directly assess lymphocyte migration, ﬂuorescently labeled
wild type splenocytes were injected i.v. 24 hours after LPS or poly (I:C) injection and the accumulation of labeled
lymphocytes in the popliteal lymph nodes was measured after 1 hour. Although no difference was observed on the
control side, the number of lymphocytes that migrated into the draining LN of cd73-deﬁcient mice was 2.5-fold
increased compared with that of wild type mice (p<0.01). These results suggest that CD73 on HEV modulates
lymphocyte migration into peripheral draining lymph nodes during inﬂammation. Experiments are in progress to
identify the speciﬁc adenosine receptors involved.
References:
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CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med 1998, 188:1433–
1443.
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Chemotaxis, or directed cell migration, is a fundamental feature of eukaryotic cells and is important for many
physiological events, including embryonic development, inﬂammation and wound healing. The ability of a cell to
undergo chemotaxis requires the cell to assume a polarized morphology that is controlled by cell surface receptors
that activate the Rho family of small GTPases, including Cdc42, Rac and Rho [1,2]. Upon activation of a che-
moattractant receptor, Cdc42 and Rac localize at the leading edge of a cell and control directional cell movement
and lamellipodium formation, respectively [1]. Rho localizes at the rear and sides of a cell and controls the
formation of contractile actin-myosin stress ﬁbers [3]. Together, these GTPases promote cell migration towards a
chemoattractant by mediating extension of the actin cytoskeleton at the front edge of the cell and retraction of the
cytoskeleton at the rear. Recent studies have shown that G protein-coupled receptors activate Rac and Rac-
dependent lamellipodia formation through Gi/o, whereas the activity of Rho and Rho-dependent stress ﬁber
formation is controlled by G12/13 [3]. Previously, we reported that the G protein-coupled P2Y2 receptor (P2Y2R)
contains a consensus Arg-Gly-Asp (RGD) integrin-binding sequence that interacts with !V"3 and !V"5 integrins
[4]. Furthermore, we found that the RGD domain in the P2Y2R is required for Go- but not Gq-mediated calcium
signaling [4], leading us to speculate that !V integrin interaction with the P2Y2R is important for nucleotide-
induced chemotaxis. In this study, we show that mutation of the RGD sequence to RGE in the human P2Y2R
expressed in 1321N1 astrocytoma cells completely prevents UTP-induced chemotaxis and stress ﬁber formation as
well as activation of Go,G 12, Rac, Rho and Vav2, a guanine nucleotide exchange factor for both Rac and Rho. In
cells expressing the wild-type but not the RGE mutant P2Y2R, UTP also increases expression of vitronectin, an
extracellular matrix protein that is a ligand for !v"3/5 integrins. P2Y2R-mediated chemotaxis, Rac and Vav2
activation, and vitronectin upregulation were inhibited by pretreatment of the cells with anti-!v"5 integrin anti-
bodies, !v antisense oligonucleotides or the Gi/o inhibitor, pertussis toxin. P2Y2R-mediated stress ﬁber formation
and Rho activation were inhibited by anti-!v"5 integrin antibodies, !v antisense oligonucleotides or a dominant
negative G!12 construct. Collectively, these results suggest that the P2Y2R requires interaction with !V integrins
for coupling to Go and G12 proteins involved in chemotaxis.
This study was supported by the National Institutes of Health Grants 1 P01-AG-018357 and 1 R01-DE-07389.
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Small diameter arterioles play a signiﬁcant role in the maintenance of cerebral blood ﬂow (CBF). However, the
status of cerebral arteriolar reactivity and neurovascular coupling following SAH is unclear. The present study
tests the hypothesis that SAH results in alterations in cerebral arteriolar response to neuronal activation. An
endovascular ﬁlament model was used to induce SAH in halothane-anesthetized male Sprague-Dawley rats.
Then, at 24, 48, 72, 96, and 120 hours post-SAH, pial arteriolar responses to contralateral sciatic nerve stimulation
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(SEPs), CO2 reactivity, as well as dose-responses to topical application of adenosine (ADO) and sodium nitro-
prusside (SNP) were assessed. In sham-operated rats, SNS evoked a 23.6 T 1.8% increase in arteriolar diameter. In
rats subjected to SAH, pial arteriolar response to SNS was signiﬁcantly attenuated to 13.7 T 0.9%, 11.9 T 1.3% and
15.2 T 1.2% at 24, 48 and 72 hours post-SAH, respectively (p < 0.05; n Q 7). By 96 and 120 hours post-SAH, SNS-
induced dilations recovered and were similar to sham responses. In contrast, SEPs were unaffected, suggesting a
direct effect of SAH on cerebral arterioles that cannot be attributed to alterations in evoked neuronal or meta-
bolic activity. The effect of SAH on arteriolar reactivity to ADO or SNP paralleled our observations during SNS.
Pial vasodilatation to ADO (10 2M) and SNP (1 2M) were signiﬁcantly attenuated by 47% and 41%, respectively,
at 48 hours post-SAH (p < 0.05; n = 7), whereas responses at 96- and 120 hours post-SAH were similar to sham.
SAH also had no effect on CO2 reactivity suggesting that the attenuation of SNS-induced vasodilatation following
SAH is not the result of non-speciﬁc cerebral arteriolar paralysis. The present study demonstrates that SAH
signiﬁcantly attenuates cerebral arteriolar response to neuronal activation; the effects of SAH peak at 48 hours
and return to normal by 96 hours post insult. Moreover, vasodilatation to ADO and SNP (NO), purported
mediators of CBF regulation during increased neuronal activity, were similarly attenuated by SAH. The results of
the present study provide the ﬁrst evidence for alterations in arteriolar reactivity during increased neuronal
activity and underscore the importance of future investigations aimed at evaluating the status of cerebral arteri-
olar reactivity following SAH.
Acknowledgements: This study was supported by grants from the Research Foundation of the American Assoc-
iation of Neurological Surgeons (GWB), the American Heart Association (ACN) and the NIH (HRW, NS-21076)
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The Insulin-like Growth Factor-I Receptor (IGF-IR) is a member of the insulin receptor family of tyrosine
kinases. A broad range of experimental studies have revealed that IGF-IR function is implicated in most of the
hallmarks of cancer, but it is probably the anti-apoptotic activity of this receptor that makes its kinase activity an
attractive therapeutic target in anti-cancer drug discovery. In this context, the identiﬁcation of speciﬁc low-mol-
ecular mass inhibitors of IGF-IR has proven to be a major challenge for medicinal chemistry due to the high
sequence identity at the kinase domains of IGF-IR and InsR (around 84%) and, in particular, at the ATP-binding
pocket (100% sequence identity). This presentation will cover the identiﬁcation and characterization of a new
series of IGF-IR kinase inhibitors. The selectivity achieved at the cellular level with these compounds suggest
conformational differences between the native forms of IGF-IR and InsR from the unactivated to the fully
activated form, that can effectively be exploited for drug discovery.
Changes in levels of 30-AMP, an intracellular P-site inhibitor of adenylate
cyclase, and its forming enzyme activity in diabetic mice treated with
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Adenylate cyclase(AC) is regulated by a number of extracellular and intracellular signals. Intracellular adenosine
30-monophosphate (30-AMP), one of the degradation products of RNAs, is pharmacologically classiﬁed as a P-site
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and mice [1,2]. The forming enzyme activity is shown to be inhibited by divalent metal ions, especially zinc ion,
and activated by EDTA. However, the biological roles of 30-AMP and its forming enzyme still remains unclear.
Recently, Fujimori and Pan-Hou [3] reported that 2,5-dideoxyadenosine, a P-site inhibitor of AC, enhanced
cellular ATP levels in PC 12 cells. As cAMP released by AC modulates glycolysis and insulin secretion, 30-AMP
and its forming enzyme might be involved in glucose metabolism in various organs including pancreas and liver.
Streptozotocin (STZ) induces experimental diabetes in animals. Bis(picolinate)zinc (II) [Zn(pa)2] has been known
to possess potent insulinomimetic action of lowering blood glucose levels [4]. Zinc ion is not only an essential
trace element but also has inhibitory effect on 30-AMP forming enzyme activity. Therefore, it is of interest to
know whether 30-AMP levels and its forming enzyme activity in STZ-induced diabetic mice might be affected by
the treatment of Zn(pa)2. The objective of our reserch was to examine the effect of Zn(pa)2 on 30-AMP levels and
its forming enzyme activity in STZ-induced diabetic mice.
Male ICR mouse were treated with intraperitoneal injections of STZ (40 mg/kg body weight) during ﬁve conse-
cutive days, and then Zn(pa)2 (10 mg/kg body weight   2 days and 5 mg/kg body weight   9 days) was intrap-
eritoneally injected [4]. Determination of 30-AMP and its forming enzyme activity by HPLC were performed
according to the method described by Fujimori and Pan-Hou [1].
Zn(pa)2 effectively lowered the STZ-induced enhancement of blood glucose levels. Pancreatic 30-AMP levels in
the STZ-, Zn(pa)2- and STZ- Zn(pa)2 groups decreased, and hepatic levels in the Zn(pa)2 and STZ- Zn(pa)2
groups increased. Pancreatic 30-AMP forming enzyme activities in the Zn(pa)2 and STZ- Zn(pa)2 groups and
hepatic the activities in the Zn(pa)2 group increased. These results suggested that 30-AMP metabolism in pancreas
and liver in the STZ-induced diabetes at early stage might be affected by the treatment of Zn(pa)2.
1) H. Fujimori, R. Sato, M. Yasuda and H. Pan-Hou, Biol. Pharm. Bull., 21, 1348 (1998).
2) H. Fujimori, T. Fujita, and H. Pan-Hou, J. Health Sci., 43, 314 (2001).
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Subject: P2X7 receptor modulates a spectrum of cellular events in a variety of cells of the immune system.
Although the pharmacology and channel properties of the P2X7 receptors have been studied intensively, the
formation of the pore associated with the P2X7 remains an open question. Therefore, in the present study, we
have investigated the eletrophysiological characteristics of the M2 transmembrane domain portion from the P2X7
receptor. Methods and Results: Most of bioinformatics studies have shown that M2 transmembrane domain
(TM2) from the P2X7 receptor is conformed as an alpha helix. Using new algorithms of bioinformatics and
molecular dynamics, we veriﬁed that the consensus segment of TM2 might be conformed as a beta sheet conﬁ-
guration. To test this hypothesis, we veriﬁed experimentally in subsequent analyses whether this segment would
be able to form a channel in a planar lipid bilayer. The segment was synthetized with high degree of purity and its
activity onto the planar lipid bilayer was measured using voltage-clamp condition. We observed single-channel
currents which had conductance of 10pS in symmetric conditions with KCl, being cation selectivity. This peptide
forms also channels in a mammalian cell line (HEK) when analyzed by patch clamp in cell attach conﬁguration.
Conclusion: The consensus peptide segment from the TM2 forms a channel that has characteristics similar to
P2X7 channel but different from P2X7 associated pore. In addition, this study raises the possibility that some
regions of TM2 are not in alpha helix conﬁguration.
Financial Support: IOC, FAPERJ and CNPq
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The ATP-gated P2X7 receptor is an unusual ion channel that couples to multiple downstream signalling cascades.
Mouse P2X7, cloned from NTW8 microglial cells and heterologously expressed in HEK293 cells, is much less
sensitive to ATP than the human or rat homologs, although in vivo experiments indicate that the endogenous
mouse receptor is highly sensitive to ATP. We found single nucleotide variations in mouse cDNA sequences
cloned from NTW8 microglial cells [T33,G661,T848] and C57BL/6 mice [G33,A661,C848]. These nucleotide va-
riations result in three amino acid differences; [Phe
11,Ala
221,Met




283] from C57BL/6 mice. We expressed these receptors in HEK293 cells and compared membrane currents,
ethidium uptake and surface membrane expression. We found that the presence of Met
283 in the sequence derived
from NTW8 cells caused massive impairment of the ATP response. Maximum current densities at mouse P2X7
Met
283 were <5% of those at mouse P2X7 Thr
283, without change in the agonist concentration-response curve or
receptor trafﬁcking to the plasma membrane. Moreover, no ethidium uptake was observed for mouse P2X7
Met
283. The corresponding mutation in rat P2X7 (Thr
283-Met) also yielded currents that were <5% of wildtype
and no ethidium uptake was observed. Furthermore, characterization of the mouse P2X7 cytoplasmic domain
polymorphism Pro
451/Leu
451 surprisingly revealed similar maximum current densities and agonist EC50 values for
both alleles. However, both ethidium uptake and agonist-induced rise in intracellular calcium concentration were
signiﬁcantly reduced at the [Thr
283,Leu
451]P2X7 receptor. These results show that Thr
283 in the ectodomain is
critical for P2X7 receptor function and suggest that the intracellular residue at position 451 may affect downstr-
eam signalling independently of ion channel activity.
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Interleukin-1 (IL-1) is the prototypical pro-inﬂammatory cytokine, functioning at the apex of a cascade effecting
and co-ordinating a wide variety of inﬂammatory actions. Evidence from pathological specimens, animal models,
genetic and clinical studies implicates IL-1", particularly of endothelial cell origin, in the pathogenesis of the
atherosclerotic plaque and the arterial healing response to injury. The net effect of IL-1 signalling depends
primarily on the balance between IL-1" and its naturally occurring receptor antagonist (IL-1ra) acting on type I
IL-1 receptors (IL-1R1) at the target cell surface. IL-1" is a so-called leaderless secretory protein in that it lacks a
signal peptide sequence directing it to the endoplasmic reticulum and Golgi apparatus for classical exocytotic
release. In monocytes, release of leaderless IL-1" requires activation of the P2X7 receptor [1]. More recently,
release of the leaderless intracellular isoform of IL-1ra (icIL-1ra), the only isoform produced in endothelial cells,
was shown to occur via a P2X dependent process [2]. We therefore determined whether a similar mechanism
exists for the release of IL-1" from human endothelial cells.
Expression studies using RT-PCR and qRT-PCR showed that human umbilical vein endothelial cells (HUVECs)
predominantly express the P2X4 and P2X7 purinergic receptor subtypes and that their expression is inducible
under inﬂammatory conditions with IFN+ containing combinations having the most pronounced effect. Treatment
for 48 hr with IFN+ and TNF! resulted in a 100-fold and 65-fold increase in P2X4 and P2X7 mRNA levels
respectively, relative to an untreated control. These changes in mRNA expression were conﬁrmed at the protein
level using western blotting, immunoprecipitation and FACS.
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with an increase in the mean current density recorded from IFN+/TNF! treated cells (1.05 T 0.28 pA in control
and 2.63 T 0.39 pA in treated HUVECs).
Intracellular pro-IL-1" synthesis is negligible in untreated HUVECs, whereas signiﬁcant amounts are produced in
response to inﬂammatory stimulation (up to 4000 pg/ml following treatment with IFN+/TNF!, LPS and BzATP).
In contrast, caspase-1 is constitutively expressed in HUVECs but is similarly induced in response to inﬂammatory
stimulation. Low-level release of biologically active 17 kDa IL-1" was measured upon BzATP stimulation of
HUVECs by ELISA and Western blots and was in the absence of cell death as shown by an LDH release assay.
However, icIL-1ra was released under the same conditions, and at higher concentrations, so the net biological
effect is generally anti-inﬂammatory, when measured using an IL-1 sensitive bioassay.
We conclude therefore, that P2X receptors play an important role in regulating secretion of leaderless pro- and
anti-inﬂammatory cytokines in the endothelium; their expression and activation may determine the balance of IL-
1" and icIL-1ra released from endothelial cells, providing a target for altering the inﬂammatory state of the
arterial vessel wall.
(1) MacKenzie, A.; Wilson, H. L.; Kiss-Toth, E.; Dower, S. K.; North, R. A.; Surprenant, A. Immunity 2001, 15,
(5), 825–35.
(2) Wilson, H. L.; Francis, S. E.; Dower, S. K.; Crossman, D. C. J Immunol 2004, 173, (2), 1202–8.
Characterisation of a recombinant soluble apyrase from the blood-feeding
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Adenosine nucleotides such as ADP found in the blood as a consequence of vascular injury and granule release
from activated platelets are one of the most important physiological agonists of platelet recruitment, aggregation
and thrombus formation. As such, the blockade of platelet P2Y12 ADP receptors by thienopyridine derivatives
(e.g. clopidogrel) and the metabolic removal of ADP from the vascular milieu by ADP-hydrolyzing enzymes
(apyrases) offer great advantages for the prevention and treatment of cardio- and cerebrovascular vascular events
characterized by activated platelets.
We have previously reported the puriﬁcation and crystal structure of a novel soluble human apyrase (see Dai et
al., 2005. Cell. 116(5): 649–59). Based upon sequence homology to the apyrases identiﬁed in blood-feeding arth-
ropods, the human enzyme was ‘‘re-engineered’’ using site-directed mutagenesis to alter the calcium binding and
nucleotide substrate active site. As a result, the ADP hydrolyzing activity was enhanced more than 100 fold and
this engineered human apyrase was shown to be an effective inhibitor of ADP and collagen induced platelet
aggregation.
In spite of the enhanced ADPase activity of the engineered human apyrase however, the protein had lower Kcat
and anti-platelet activity compared to the soluble salivary apyrases of blood-feeding arthropods. As a result, we
expressed and puriﬁed the recombinant soluble apyrase from the blood-feeding sand ﬂy Phlebotomus papatasi.
The expressed Phlebotomus enzyme was a calcium-dependent ADP and ATPase, with a pH optimum of ~7, a low
KM for ADP and ATP (61 uM and 65 uM, respectively), and a very high substrate turnover rate (3.0   10
4 min
j1
and 2.9   10
4 min
j1 for ADP and ATP, respectively).
In in vitro platelet aggregometry assays of human platelet rich plasma and PFA-100\ analyses of human whole
blood under high shear conditions, the Phlebotomus apyrase was a potent inhibitor of ADP induced platelet
aggregation. The pharmacokinetics of the apyrase, administered intravenously at a single dose of 12.5 mg/kg, was
also investigated in rats. In vivo, the enzyme was distributed and eliminated rapidly, with a half-life of approxi-
mately 15 minutes. To examine the efﬁcacy of the apyrase as an anti-thrombotic agent, a rat vascular electrolytic
injury model was utilized. Intravenous administration of apyrase at a dose of 12.5 mg/kg showed a statistically
signiﬁcant ~35% inhibition in occlusive thrombus formation compared to control animals. A clear dose-response
relationship was observed, with approximately 22% and 15% inhibition seen at 1.0 and 0.3 mg/kg doses, respe-
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at 10 mg/kg in this model exhibited ~41% inhibition of thrombus formation.
Soluble apyrases act through the enzymatic ‘‘deletion’’ of the platelet pro-aggregant ADP, inhibiting platelet
aggregation and thrombus formation. Thus, the unique anti-platelet actions of the apyrase enzymes make them
particularly attractive in the context of therapeutic agents for the inhibition of platelet-mediated thrombotic
disorders.
Characterization of Adenosine Metabolism and Coronary Flow Control by
Adenosine in Mouse Heart
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The murine heart preparation has been increasingly used in recent years, because of the opportunity to employ
knockout or overexpression models. A further aspect relates to the use of expensive pharmacological tools, which
is more economical in this species due to the small organ size. Aims of the present study were the characterization
of adenosine metabolism and purine related coronary ﬂow regulation of mouse heart.
Methods. C57Bl6 mice weighing 19–25 g were anaesthetized and heparinized (urethane 2mg/g body mass, Liqu-
emin\ 500 I.U.). Hearts were isolated and retrogradely perfused via the ascending aorta according to the Lan-
gendorff-method providing 37-C warm Krebs-Henseleit-buffer equilibrated with carbogen gas (pO2 680 mm Hg,
pCO2 35 mm Hg) at a perfusion pressure of 85 T 3 mmHg. Heart rate was kept constant by pacing (505 T 5 bpm)
and coronary ﬂow was measured using an Ultrasonic\ ﬂow probe. A PVC-balloon was inserted into the left
ventricle via the left atrium to allow measurement of ventricular pressure development and dP/dt. A catheter
advanced into the right atrium was used for collecting venous efﬂuent perfusate for analysis of adenosine conc-
entration (HPLC technique) and gas partial pressures.
Results. Baseline parameters were (mean T S.E.M.): ﬂow 9.5 T 1 ml/min*g, dP/dtmax 4097 T 243 mmHg/s, coro-
nary venous pO2 160 T 7 mmHg, and adenosine concentration 18 T 3 nmol/l. The reactive ﬂow overshoot following
a 20 s ﬂow stop was 280 T 9% (n = 10) of baseline ﬂow. Elevation of the coronary arterial adenosine concentration
by 80 and 200 nM resulted in marked increases of coronary ﬂow (2.8-, 3.4-fold), an increased contractility (1.5-,
1.3-fold) and elevated venous pO2 (2.3-, 2.7-fold), respectively. Block of adenosine deamination and phosphor-
ylation by EHNA (5 2M) and ITU (10 2M), respectively, augmented adenosine release 8.9-fold. In parallel,
coronary ﬂow rose 3.2-fold. In presence of EHNA and ITU, NBTI (10 2M), a speciﬁc blocker of equilibrative
nucleoside transport, only moderately lowered adenosine release by 18%. Speciﬁc block of A1, (DPCPX 100 nM),
A2A (ZM-241385 100 nM, SCH-58261 100 nM) and A2B (Alloxazine 10 2M, MRS-1754 200 nM) adenosine
receptors did neither change adenosine release nor baseline coronary ﬂow signiﬁcantly. However, the effect of
exogenous adenosine (80 nM, 200 nM) on coronary ﬂow was almost completely blocked by A2A antagonism,
partly by A2B antagonism but not by blocking A1 adenosine receptors. During hypoxic perfusion, A2A antagonists
lowered coronary ﬂow by approximately 10%.
Conclusions. 1) The coronary ﬂow control of mouse heart exhibits a high sensitivity for adenosine. 2) Exogenous
adenosine acts mainly via activation of A2A-receptors. 3) Selective blockade of A2A-receptors does not largely
affect baseline coronary ﬂow and adenosine release. 4) During hypoxic perfusion endogenous adenosine contri-
butes to ﬂow control. 5) Block of membrane transport of adenosine is rather insensitive to NBTI (NBMPR) as
compared to other species.
Characterization of the platelet P2Y12 receptor with the new, selective radiogland
[
3H]PSB-0413
K.J. Griessmeier, A. El-Tayeb & C.E. Mu ¨ller
Pharmaceutical Sciences Bonn (PSB), Pharmaceutical Chemistry, Institute of Pharmacy, University of Bonn,
Kreuzbergweg 26, 53115 Bonn, Germany
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SpringerThe P2Y12 ADP receptor is one of the major regulators of hemostasis and thrombosis and the target of antithr-
ombotic thienopyridines and nucleotide analogs. It is a G protein-coupled receptor which upon activation inhibits
adenylate cyclase activity [1, 2]. The platelet P2Y12 receptor has been extensively characterized in functional
assays [1, 2]. However, characterization on the protein level has been hampered by the lacking of a selective
radioligand.
In the present study, we characterized the P2Y12 receptor in human platelet membrane preparations using the
newly synthesized enzymatically stable and P2Y12-selective radioligand [
3H]PSB-0413 (2-propylthioadenosine-50-
adenylic acid (1,1-dichloro-1-phosphonomethyl-1-phosphonyl) anhydride, AR-C67085MX) [3]. [
3H]PSB-0413 s-
howed a high afﬁnity for P2Y12 receptors natively expressed in human platelets (KD = 4.57 T 0.51 nM) as dete-
rmined in a saturation binding assay. The kinetically derived KD value was similar (3.69 T 1.58 nM at r.t. and 4.87
T 2.81 nM at 4-C, respectively). A membrane preparation of human platelets showed a high expression level of
P2Y12 receptors (Bmax = 7.66 T 0.69 pmol/mg of protein). It was much higher than than the density of P2Y1
receptors (170 fmol/mg protein). A competition assay for the screening of ligands was established and a series of
standard agonists and antagonists was evaluated. The rank order of potency for the inhibition of [
3H]PSB-0413
binding was (Ki values): 2-methylthio-ADP (4.88 nM) >> ADP"S (4.11 2M) > ATP+S (13.2 2M) = ATP (15.7 2M)
= ADP (17.6 2M). GTP shift experiments conﬁrmed that 2-methylthio-ADP and ADP were agonists and that
ATP and the precursor of [
3H]PSB-0413, PSB-0412 bearing a 2-propargyl instead of a 2-propyl substituent (Ki
value = 2.41 T 0.25 nM), were antagonists at human P2Y12 receptors of platelets. Radioligand binding was not
inhibited by 100 2M of the following P2 receptor ligands: pyridoxalphosphate-6-azophenyl-20,40-disulphonic acid
(PPADS), ",+-methylene-ATP, !,"-methylene-ATP, UDP-glucose, AMP, IDP, UMP, UDP or UTP. The radiol-
igand is selective versus the closely related P2Y receptor subtypes P2Y11 (EC50 = 1.5–8.9 2M) and P2Y13 (IC50 =
213–630 nM). These results indicate that [
3H]PSB-0413 speciﬁcally labels the P2Y12 receptor. In conclusion,
[
3H]PSB-0413 is the ﬁrst selective high-afﬁnity antagonist radioligand for the P2Y12 receptor.
[1] Zhang, F.L.; Luo, L.; Gustafson, E.; Lachowicz, J.; Smith, M.; Qiao, X.; Liu, Y.; Chen, G.; Pramanik, B.; Laz,
T.M.; Palmer, K.; Bayne, M.; Monsma, F.J. J. Biol. Chem., 2001, 276, 8608-8615.
[2] Hollopeter, G.; Jantzen, H.-M.; Vincent, D.; Li, G.; England, L.; Ramakrishan, V.; Yang, R.-B.; Nurden, P.;
Nurden, A.; Julius, D.; Conley, P. B. Nature, 2001, 409, 202-207.
[3] El-Tayeb, A.; Griessmeier, K.J., Mu ¨ller, C.E. Bioorg. Med. Chem. Lett., 2005, 15, 5450-5452.
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Cerebellar astrocyte cultures is one of the experimental models used to study nucleotide signaling in cerebellum.
In previous works, we showed that cerebellar astrocytes possess a great diversity of functional P2Y receptors,
ADP sensitive receptors, the P2Y1 and/or the P2Y13-like receptors, (see Poster of Carrasquero et al.) and ATP/
UTP sensitive receptors, the P2Y2/P2Y4 receptors, mainly coupled to PLC activation. These results contrast to
those reported for astrocytes from other brain areas, such as cortex or hippocampus, which also express some
ionotropic P2X receptors, including the P2X7 subtype. The P2X7 receptor is an ionotropic P2X receptor, only
activated at millimolar ATP concentrations in vivo, which exhibits very peculiar characteristics. It was thought to
be exclusive for cells of haematopoietic lineage, where its role in cellular toxicity and inﬂammatory process is well
established. Recently, it has been also detected at the nervous system, where has resulted to be an ‘‘intriguing’’
receptor and far from induce cellular lysis or apoptosis, could exert other actions, such as differentiation, gluta-
mate release, etc. Basing on these ﬁndings, we decided to explore their presence in cerebellar astrocytes using
BzATP, described as the most speciﬁc agonist for this receptor subtype. We have found that cerebellar astrocytes
displayed several BzATP responses, which are quite different to those elicited by other nucleotides, which would
be mediated by P2X7-like receptors: i) BzATP-induced calcium responses were sustained, and not transient, as
those obtained with the metabotropic agonists 2MeSADP and UTP, ii) Among the nucleotides BzATP produced
the maximal ERK activation, iii) BzATP also produced long-term effects, inducing morphological changes, that
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conﬁrmed. Although P2X4 subunits have been also detected, their functionality remains unclear.
The characterization of BzATP calcium responses was made by calcium imaging using fura-2. Most of tested cells
(80%) were sensitive to BzATP stimulations eliciting calcium responses, which are biphasic. They exhibited initial
transients with an EC50 value of 12.2 + 1.6 2M, followed by a sustained responses, that were not desensitized. But,
surprisingly, when BzATP challenges were applied in the absence of extracellular calcium, the initial transients
were maintained, whereas as expected the sustained responses were completely abolished, which clearly indicated
that the transients resulted from intracellular calcium mobilization. The same occurred by preincubation with 1
2M Brilliant Blue G, concentration at which this antagonist selectively acts on P2X7 receptors and stabilize the
inactive form of the receptor, the sustained responses were abolished, but the transient was also observed. BzATP
calcium responses were not affected by cross-desensitization with UTP or 2MeSADP, when were consecutively
applied, though each agonist was able to desensitize itself, indicating that they are acting on different receptors.
These data suggest that BzATP possess speciﬁc receptors, P2X7-like receptor type, in cerebellar astrocytes, which
are also coupled to PLC activation.
Chronic cyclosporine treatment increases total homocysteine levels and decreases
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Cyclosporine (CsA) is a potent immunosuppressant agent that has been extensively used in transplanted patients.
However, CsA administration is accompanied by a variety of adverse effects being allograft vasculopathy the
major cause of morbidity and mortality among renal and cardiac transplant recipients. The mechanisms involved
in the vascular injury and the putative participation of CsA are poorly understood. CsA administration might
affect homocysteine (Hcy) serum concentrations, a sulfur containing amino acid recognized as an independent
risk factor for atherosclerosis and venous thromboembolism. Excessive production of free radicals, increase on
platelet adhesiveness and decrease on tissue and plasmatic adenosine levels contribute to the vascular damage
caused by Hcy. Extracellular adenosine has important beneﬁc effects on the vascular system, avoiding thrombus
formation and circulatory problems through the regulation of platelet aggregation, vasodilatation, coronary blood
ﬂow and inﬂammation. Thus, control of the ratio of adenine nucleotide/adenosine in the extracellular space by
ecto-nucleotidases activities is one of the important steps for the maintenance of vascular homeostasis.
In this work, we examined the effects of chronic CsA administration on total serum Hcy levels, on the adenine-
nucleotides hydrolysis (ATP, ADP, AMP) through serum ecto-nucleotidases activities and its putative association
with vascular disturbance in adult male Wistar rats. Animals were daily administered with CsA 5 mg/kg, 15 mg/kg
or vehicle via gastric gavage during 8 weeks. Total Hcy concentrations in serum was measured using a commercial
MEIA kit (Abbott, USA) and ATP, ADP and AMP hydrolysis were evaluated through phosphate release, using
the method described by Oses et al. [1]. CsA induced a signiﬁcant increase on total Hcy concentration and a
decrease in ATP, ADP and AMP hydrolysis. The inhibition of nucleotides hydrolysis was negatively correlated
with total Hcy levels and positively with uric acid levels. Increased platelets number and ﬁbrinogen levels, invo-
lved in coagulation pathway, were also observed.
Altogether, these results indicate that chronic CsA treatment affects the homeostasis of vascular system by inc-
reasing platelets, ﬁbrinogen and serum levels of total Hcy. Moreover, we postulated that by inhibiting adenine
nucleotides hydrolysis, CsA might disrupt the equilibrium between adenine nucleotides/adenosine levels. Finally,
these alterations could be implicated in the vascular complications reported in patients under CsA therapy.
(Supported by CNPq Brazil, FAPERGS).
Oses et al. Life Sciences 2004;74(26):3275-3284.
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Background. Liver cells express various ecto-nucleotidases including CD39/ecto-nucleoside triphosphate diphos-
phohydrolase-1 (NTPDase1), CD39L1/NTPDase2 and CD73/ecto-50-nucleotidase to regulate nucleotide and nu-
cleoside levels at the cell surface. Since the these molecules control a number of critical cellular functions like cell
volume autoregulation and ionic secretion, the biological activity of ecto-nucleotidases appears essential for liver
homeostasis maintenance. Interestingly, the liver has one of the highest ecto-nucleotidase activity among tissues.
In the liver, NTPDase1 is expressed by Kupffer cells and vascular endothelial cells whereas NTPDase2 is prod-
uced by portal ﬁbroblasts and activated hepatic stellate cells. However, their combined activity appears much
lower than the total ecto-nucleotidase activity observed in liver tissue. Histochemical studies showed that the high
liver ecto-nucleotidase activity is mainly associated with the canalicular domain of hepatocytes and has the gen-
eral characteristics of an NTPDase activity. We have recently reported, in mouse, the cloning of a novel ecto-
nucleotidase, NTPDase8 whose cDNA is highly expressed in liver. The Aim of this study was to identify the main
ecto-nucleotidase(s) in the liver, particularly the one(s) expressed in the canalicular domain of hepatocytes.
Methods. NTPDase8 cDNA was cloned from human and rat liver tissues and inserted in pcDNA3 expression
vector. Constructs were used for transfection assays in COS-7 cell line. NTPDase8 was puriﬁed from rat liver by a
3-step chromatography. The biochemical characterization was performed with protein extracts from NTPDase8-
transfected cells or the puriﬁed protein. Antibodies against rat NTPDase8 and CD73 were generated and used to
examine the expression pattern of these proteins, by Western blot and immunoﬂuorescence. Results. Activity
assays on protein extracts (from COS-7 cells expressing rat or human NTPDase8) and puriﬁed rat NTPDase8
regarding substrate speciﬁcity, ion requirement and sodium azide inhibition showed that the enzyme displayed
similar biochemical properties as previously described for the puriﬁed porcine canalicular ecto-ATPase. The
analyses of the primary structures showed high resemblance between rat and human NTPDase8 when compared
to porcine ecto-ATPase. The speciﬁcity of polyclonal antibodies against rat NTPDase8 and CD73 was conﬁrmed
by immunoblot and immunocytochemistry, using transfected cells. By western blot, the anti-rat NTPDase8 det-
ected a protein with a molecular weight of 75 kDa with the highest expression in liver and also some expression in
kidney and jejunum. In liver sections, NTPDase8 was expressed in the canalicular membrane domain of hepat-
ocytes and co-localized with the canalicular marker MRP-2. Immunostaining for CD73 showed that this enzyme
was also present in the bile canaliculi. Conclusions. In this work, we report the cloning of NTPDase8 in human
and rat species, its identiﬁcation as the canalicular ecto-ATPase and demonstrate that it represents the major
ecto-nucleotidase activity of the liver. In addition, the canalicular localization of both NTPDase8 and CD73
suggest their potential involvement in biliary function.
Cloning, expression and characterization of the Torpedo marmorata
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Ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases) constitute a family of enzymes that hydrolyse
both ATP and ADP to AMP, differing in their substrate preferences and tissue distribution. They are broadly
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Springerexpressed enzymes, mainly membrane bound, playing a relevant role in several physiological processes. An E-
NTPDase activity in electric organ membranes of Torpedo ﬁshes was previously identiﬁed (1) and we have been
using these membranes as a source of E-NTPDase activity to study the effect of new possible inhibitors (2,3,4).
Enzymology studies pointed to the classiﬁcation of this enzyme into the class-1 E-NTPDases, since it shows nearly
equal preference for ATP and ADP (5). We report here the cloning of its full-length cDNA and its characteri-
zation.
The clone, obtained by means of RACE (Rapid Ampliﬁcation of cDNA Ends)-PCR technique, contains an open
reading frame of 1506 bp and codes for a 502 aminoacids-protein that exhibits high homology with other E-
NTPDases1 previously identiﬁed, including those of zebraﬁsh or Xenopus but also human, rat and mouse. Top-
ology analyses revealed the existence of two transmembrane regions, two short cytoplasmic tails and a long
extracellular domain containing the ﬁve highly conserved apyrase regions. Gene expression studies revealed that
this gene is expressed in all the Torpedo tissues analysed. We have also characterized the expression of the
recombinant protein expressed in COS and HeLa cells.
1. Grondal, EJM & Zimmermann, H; J. Neurochem., 47 : 871-881, 1986.
2. Martı ´, E. et al.; Br. J. Pharmacol., 118: 1232-1236, 1996.
3. Martı ´, E. et al.; Biochim. et Biophys. Acta, 1282: 17-24, 1996.
4. Escalada, A. et al.; Neurochem. Res., 29: 1711-1714, 2004.
5. Sarkis, JJ & Salto, C.; Brain Res. Bull., 26: 871-6, 1991.
This work was supported by grants of Ministerio de Educacio ´n y Ciencia from the Spanish Governement
(C.Solsona, project no. SAF2005-00736) and Comisio ´ de Recerca del Campus de Bellvitge (M. Martı ´n-Satue ´,
project no. ACESB/13) from the University of Barcelone, Spain.
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Adenosine and ATP are released from glia and neuron cells and are involved in a wide variety of both physiol-
ogical and pathological processes by their interaction with speciﬁc receptors classiﬁed as P1 and P2, respectively
(Abbracchio and Burnstock, 1998). Whereas the neuroprotective role of adenosine analogues active at the ade-
nosine A1 receptor subtype (A1AR) have been known for several years (Wardas, 2002), the role of purinergic
P2Y1 receptor (P2Y1R), enough if not fully characterized, indicate important pathological functions/involvements:
purine-mediated induction and maintenance of astrogliosis can be considered as a ﬁrst response to limit the loss of
neuronal tissue after insults (Franke and Illes, 2006). Recent data suggest the existence of a heteromeric complex
between A1ARs and P2Y1 purinergic receptors with novel pharmacological and functional properties (Yoshioka
and Nakata., 2004). As evidenced by G-protein coupled receptors heterodimerization studies, an important role in
the control of receptor signalling and regulation processes has been demonstrated (Maggio et al., 2005).
In the present work we investigated the co-localization of A1 and P2Y1 receptors on rat brain tissues and their
heterodimerization and functional cross-talk in astroglial cells (ADF).
Immunogold-electron microscopy quantiﬁcation was used to study the cellular localization of A1 and P2Y1 rec-
eptors on rat hippocampus which is considered as a damage sensitive brain area. The results demonstrated a
signiﬁcantly high expression of both receptors on synaptic and astroglia membranes. Since glial elements repre-
sented the cell population in which the higher A1/P2Y1 co-localization occurred, an astroglial cell line was used to
investigate the receptor functional cross-talk. A1AR and P2Y1R expression in ADF cells was demonstrated by
immunoblotting experiments; moreover, in co-immunoprecipitation assay we showed that these receptors const-
ituted an heteromeric complex in basal conditions.
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pathway induced by the P2Y1-agonist, 2-MeSADP.
In control ADF cells, A1AR agonist, CHA, was able to inhibit, in concentration dependent manner, the produ-
ction of cAMP (EC50 = 0,9 nM). ADF cell exposure to 2-MeSADP inhibited A1AR functional response in time
dependent manner with a maximal effect after 30 minutes. Moreover, a signiﬁcant right shift of CHA dose-
response curve occurred. These data demonstrated P2Y1R induced heterologus A1AR desensitisation in ADF
cells.
To clarify the cellular co-localization, the interaction and the function of heterodimerization of A1 and P2Y1
receptors and the possible alterations of P1–P2 receptor regulation processes during pathological conditions may
help to clarify the patho-physiological functions of ATP and adenosine in CNS.
Abbracchio MP and Burnstock G, 1998. Jpn J Pharmacol, 78: 113-145.
Franke H and Illes P, 2006. Pharmacol Ther, 109 (3): 297-324.
Maggio R, Novi F, Scarselli M, Corsini GU, 2005. FEBS J, 272 (12): 2939-2946.
Wardas J, 2002. Pol J Pharmacol, 54: 313-326.
Yoshioda K and Nakata H, 2004. J Pharmacol Sci, 94: 88-94.
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The ecto-Nucleoside triphosphate diphosphohydrolases or NTPDases are the enzymes responsible for signal te-
rmination and conversion in purinergic signalling. NTPDase1, 2 and 3 are localized on the cell surface, anchored
to the membrane by two transmembrane helices. They catalyze the sequential removal of +- and "- phosphate
from ATP, ADP and other nucleotides.
Due to their involvement in physiological processes like blood clotting and pain perception, but also in certain
types of cancer, they are now considered as potential new drug targets or drugs themselves. Soluble forms from
mammalian cell culture have been shown to inhibit platelet aggregation in vivo. However, mammalian production
of large amounts of therapeutic proteins is expensive and bears the risk of viral contamination. Therefore and for
structural characterization we established an E. coli expression system for insoluble production of the extracell-
ular domains of three NTPDases and optimized the in vitro refolding. The refolded proteins have been charact-
erized in several aspects: substrate speciﬁcity, KM values for ATP and ADP, pH dependance and metal cofactor
activation. Similarities and differences in the refolding behaviour and in enzymatic properties among the reco-
mbinant enzymes and in comparison to their wildtype counterparts will be discussed.
Our expression system allows for large scale production of active protein for further characterization and clinical
application. X-ray structure determination of the refolded proteins will provide valuable insights in the rational
design of medically relevant inhibitors.
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P2X receptors are ATP-gated ion channels permeable to small inorganic cations. The P2X7 receptor has several
peculiar characteristics compared to the other members of the P2X receptor family. The time course of activation
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Springerand deactivation is dependent on species, number and duration of ATP applications. The initial part of activation
is supposed to be so fast that it could not be investigated by conventional whole cell voltage clamp methods.
Therefore, we expressed human P2X7 receptors heterologously in Xenopus oocytes and investigated the kinetics
of activation and deactivation of P2X7-dependent single channel currents by means of the patch clamp method in
the outside-out conﬁguration. A combination of the U-tube technique and a piezo-driven liquid ﬁlament switch
technique enabled the application and withdrawal of different concentrations of the agonist ATP
4j within less
then 1 ms. Two different types of kinetics were observed and approximated by single exponential functions. A
low-noise patch current component activated and deactivated with time constants of about 300 ms. Its amplitude
was dependent on [ATP
4j] and the seal resistance but independent of the expression of human P2X7 receptors. It
was attributed to non-speciﬁc effects of ATP on the seal resistance. Extracellular application of ATP evoked
slightly inward rectifying single-channel currents with a conductance of about 10 pS and mean open times of about
5 ms at negative membrane potentials. The mean closed times but not the mean open times were dependent on
the activating ATP concentration. High ATP concentrations increase the probability of the additional opening of
channels with a conductance of about 14 pS and mean open times of about 20 ms. At positive membrane voltages,
the mean open time was increased to about 15 ms. The channels activated with activation and deactivation time
constants of about 15 ms. The channel activation was only little dependent on the agonist concentration. Activ-
ation and deactivation were not continuously dependent on the membrane voltage. We conclude that binding of
ATP
4j is not the only rate limiting step in the activation of P2X7 channels and that the ATP
4j binding site is not
located in the electrical ﬁeld of the membrane.
This work was supported by the Deutsche Forschungsgemeinschaft (Ma 1581/12-1) and the Roux-programme of
the ML university (FKZ 13/07).
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Purines such as adenosine (Ado) and ATP elicit conducted dilation and/or constriction in cerebral arterioles. In
this study, we evaluated the roles of the endothelium and smooth muscle in the conduction of vasomotor resp-
onses induced by purines along intracerebral arterioles. Penetrating intracerebral arterioles were isolated from
Sprague Dawley rats, and cannulated with a concentric micropipette system. Upon pressurization to 60 mm Hg,
the vessels developed spontaneous tone, contracting to 67 T 1% of passive diameter (77 T 4 2m, n = 9). The
experimental protocol consisted of pulse-application of vasoactive agents (Ado or ATP) via micropipettes, onto a
short segment of the arteriole. This induced both a direct local response, and a secondary conducted response that
spread longitudinally along the vessel. Ado is an endothelium-independent dilating agent, whereas ATP-induced
dilation is endothelium dependent. Pressure-pulse ejection of Ado (10 mM in pipette) elicited a local 14% dila-
tion, and a 4% dilation at a site 500 2m from the ejection site, whereas ATP (10 mM) microapplication evoked
biphasic local (18% constriction, 9% dilation) and conducted (11% constriction, 8% dilation) responses. Endot-
helial cells within an ~100 2m segment (positioned between the application and observation sites) were injured by
a luminal light-dye (L-D) technique using luminal Na Fluorescein. Alternatively, vascular smooth muscle (VSM)
cells were selectively damaged by adventitial L-D treatment. Endothelial injury did not signiﬁcantly affect the
conducted dilation responses to Ado, but virtually eliminated the conducted responses (both dilation and const-
riction) to ATP. VSM injury abolished conducted dilation responses to Ado, but did not affect ATP-dilation.
However, VSM injury attenuated the remote constriction responses to ATP microapplication. Our data suggest
that the endothelium is the predominant pathway for the conduction of ATP-induced dilation, whereas the sm-
ooth muscle layer primarily mediates the conduction of Ado-induced dilation. Both the endothelium and smooth
muscle appear to be involved in the propagation of ATP-induced constriction.
Funded by NIH Grant NS-21076 and AHA Grant 0255703N.
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The human adenosine A2B receptor belongs to class A G-protein-coupled receptors. In our previous work, con-
stitutively active mutant (CAM) human adenosine A2B receptors were identiﬁed from a random mutation bank
based on their ability to grow in histidine-deﬁcient medium [1]. In the current study, three known A2B receptor
antagonists, MRS1706, ZM241385 and DPCPX were tested on wild-type and 9 CAM A2B receptors with different
levels of constitutive activity in a yeast growth assay.
The compounds" ability to antagonize the agonist NECA on the wild-type receptor was assessed ﬁrst. The pA2
values of MRS1706, ZM241385 and DPCPX were derived from a Schild analysis, and found to be in good
agreement with available literature.
Since the wild-type receptor lacks constitutive activity, we employed CAM receptors to investigate whether these
antagonists could be reclassiﬁed as inverse agonists. All three compounds turned out to be inverse agonists for the
adenosine A2B receptor as they were able to fully reverse the basal activity of the 4 low-level CAM A2B receptors:
T42A, F84S, F84L and F84L/S95G. The basal activity of 3 medium-level CAM A2B receptors, N36S/T42A, T42A/

















Figure 1. Inverse agonism of ZM241385 on CAM receptors with varying levels of constitutive activity.
We also discovered 2 highly constitutively active or locked mutants, A18T/A23V/C83Y/A106V/R112S and Q21-
4L/I230N/V240M/V250M/N254Y/T257S/K269stop (a truncated receptor). Their basal activity could not be reve-
rsed by any of the three compounds. The inverse agonistic properties of ZM241385 on the T42A, N36S/T42A/
T66A and the truncated receptor are shown in ﬁgure 1 as a typical example.
The rank order of potency of the compounds matched the rank order obtained in the antagonist assay on the wild-
type receptor, that is ZM241385 = MRS1706 > DPCPX. However, ZM241385 was the strongest inverse agonist as
demonstrated by the rank order of intrinsic activities ZM241385 > MRS1706 = DPCPX.
In conclusion, this study is the ﬁrst to describe inverse agonism on the human adenosine A2B receptor. Moreover,
the use of receptor mutants with varying levels of constitutive activity enabled us to appreciate differences in
intrinsic activity of the inverse agonists.
1: Beukers et al. Mol Pharmacol (2004) 65: 702.
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SpringerContractile Effects of Adenosine, Coronary Flow and Perfusion Pressure in
Murine Myocardium
Laura Willems and John P. Headrick
Heart Foundation Research Centre, Grifﬁth University Southport, QLD 4217, Australia
j.headrick@grifﬁth.edu.au
There is mixed evidence adenosine receptors (ARs) may directly enhance myocardial contractility, though this
remains contentious. Identifying such effects is important in clarifying physiological and protective functions of
adenosine. We assessed inotropic actions of adenosine (50 2M) and selective AR activation with 100 nM N
6-
cyclohexyladenosine (CHA; A1AR agonist), 25 nM 2-[p-(2-carboxyethyl) phenethylamino]-50-N-ethylcarboxami-
doadenosine (CGS-21680; A2AAR agonist), and 100 nM 2-chloro-N
6-(3-iodobenzyl)-adenosine-50-N-methylur-
onamide (Cl-IB-MECA; A3AR agonist) in C57/BL/6J mouse hearts paced at 420 beats/min, and perfused at
constant-pressure, constant-ﬂow, or under conditions of stable ﬂow and pressure (achieved with nitroprusside-
mediated vasodilatation in constant-ﬂow hearts, prior to AR activation). Adenosine and CGS-21680 induced
signiﬁcant (albeit modest) positive inotropy in constant-pressure perfused hearts (up to 10 mmHg elevations in
systolic force). Inotropic effects of adenosine and CGS-21680 paralleled coronary vasodilatation (with up to 10 ml/
min/g elevations in ﬂow). Neither CHA or Cl-IB-MECA altered force or ﬂow. Under conditions of constant ﬂow,
adenosine and CGS-21680 reduced systolic pressure in parallel with coronary perfusion pressure. When changes
in coronary ﬂow and perfusion pressure were prevented (eliminating potential Gregg-related effects), CGS-21680
no longer modiﬁed contractile force. However, adenosine itself still signiﬁcantly enhanced systolic pressure by up
to 10vmmHg, independently of changes in coronary ﬂow, perfusion pressure, and heart rate. Relations between
ﬂow, perfusion pressure, and ventricular performance evidence signiﬁcant Gregg-related effects in murine myo-
cardium - ventricular systolic pressure increases transiently by ~1 mmHg per ml/min/g change in ﬂow during the
initial 1–2 min of hyperemia, and in a sustained manner by ~1 mmHg per mmHg change in coronary perfusion
pressure. These effects contribute to inotropic effects of AR agonists when coronary ﬂow or pressure are unco-
ntrolled. In summary, we ﬁnd no evidence of direct A1 or A3AR-mediated changes in contractility in intact
myocardium. Inotropic actions of A2AAR agonism are indirect, involving Gregg-related effects. Despite no A1,
A2A or A3AR-mediated effects, the endogenous agonist adenosine exerts a modest inotropic action indepen-
dently of ﬂow and perfusion pressure. The mechanistic basis of this response remains to be identiﬁed.
Contribution of PKC to the desensitisation of relaxation to luminally-perfused
purinoceptor agonists in rat small mesenteric arteries
Polly Winter & Kim. A. Dora
Department of Pharmacy & Pharmacology, University of Bath, Bath BA2 7AY, UK
pr9pw@bath.ac.uk
Protein kinase C (PKC) contributes to the desensitisation of the P2Y1 purinoceptor in response to prolonged
treatment with the non-hydrolyzable analogue of ADP, adenosine 50-["-thio]diphosphate (ADP"S) in isolated
blood platelets [1]. The aim of this study was to ascertain the extent of PKC modulation of the vasodilatation of
small rat mesenteric arteries in response to luminal perfusion of ATP, the non-hydrolysable analogue of ATP,
adenosine-50-(3-thiotriphosphate) ATP+S, and ADP"S.
Segments of third order mesenteric arteries were isolated from male Wistar rats (200–250 g), killed by schedule 1
methods of the Animals Scientiﬁc Procedures Act 1986 (UK). Arteries were cannulated, mounted in a pressure
myograph (Danish Myotechnology), pressurized to 50 mmHg and perfused with MOPS at 37-C. Following pre-
contraction with phenylephrine a multi-channel syringe pump was used to perfuse agonists through the lumen at
90 2l.min
j1. Once the peak relaxation response was established the time course of desensitisation of the relax-
ation response was assessed over a 2 min period. Values are means T s.e.mean of the percentage relaxation to
maximum diameter.
Luminal perfusion of ATP (3 2M) and ATP+S( 32M) resulted in peak vasodilatation responses of 91.3 T 1.5%
and 80.5 T 4.0% respectively. These levels of relaxation were maintained throughout the 2 min post-peak period
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with the selective inhibitor of PKC, bisindolylmaleimide 1 (BIS 1 2M) (3 2M ATP, 94.6 T 1.4%; 3 2M ATP+S, 88.8
T 1.5%). In contrast, luminal perfusion of ADP"S( 12M) and ATP (1 2M) resulted in relaxation responses of 70.0
T 6.6% and 40.5 T 8.2% respectively that decayed over the 2 min post-peak period (1 2MA D P "S, 41.5 T 6.1%; 1
2M ATP, 28.9 T 9.3%). Prior luminal incubation with BIS increased the peak relaxation response to ADP"S( 1
2M) (94.8 T 1.0%, P < 0.05; students paired t-test) and ATP (1 2M) (70.4 T 14.5%). The decay of the responses
observed in response to these two agonists was also signiﬁcantly reversed (1 2MA D P "S, 89.1 T 6.6%; 1 2M ATP,
67.9 T 13.8%, P < 0.01, students paired t-test).
PKC has been found to contribute to the desensitisation of the relaxation response to ADP"S( 12M) and ATP (1
2M) supporting a role for PKC in the desensitisation of P2Y1 receptors within the endothelium of isolated rat
mesenteric arteries. Activation of P2Y2 or P2Y4 receptors with ATP+S( 32M) did not evoke a response that
decayed over time. Variation in the downstream pathways beyond each P2Y purinoceptor subtype may therefore
exist.
This work was kindly supported by the British Heart Foundation
1) Hardy, A.R. et al., 2005. Blood., 105 (9); 3552-3560
Contributions of P2Y and P2X receptors to nucleotide-induced signaling in
macrophages revealed by single-cell Ca
2+ measurements and knockout mice
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Antigen-presenting cells express two families of nucleotide receptors: ATP-gated cation channels (P2X receptors)
and P2Y receptors, a subset of the G protein-coupled receptor superfamily. To identify the receptors mediating
the Ca
2+ responses of resident peritoneal macrophages to extracellular UTP, ATP and UDP, we performed Ca
2+
measurements on single cells isolated from various knockout mice. To obviate the confounding effects of extra-
cellular Ca
2+ sources, experiments were performed in Ca
2+-free buffer. Note that when ATP is applied to a
macrophage in the presence of Ca
2+, the observed increase in cytosolic [Ca
2+] ([Ca
2+]i) can be attributed to
endoplasmic reticular (ER) Ca
2+ release, Ca
2+ inﬂux through Ca
2+ release-activated Ca
2+ (CRAC) channels or
Ca
2+ inﬂux via P2X receptors (Figure 1). We found that application of UTP (or ATP), under Ca
2+-free conditions,
to macrophages isolated from wild-type mice induced a transient (lasting 1 min) increase in [Ca
2+]i with half-
maximal response at concentrations <1 2M. However, macrophages isolated from P2Y2/P2Y4 double knockout
mice did not respond to either UTP or ATP. Furthermore, the nucleotide-induced Ca
2+ response of macrophages
isolated from P2Y4j/j mice was normal whereas cells from P2Y2j/j mice were completely unresponsive. Thus,
P2Y2 is the sole receptor which couples extracellular UTP or ATP to phospholipase C-" (PLC-") activity and ER
Ca
2+ release. In contrast to UTP, UDP (puriﬁed with hexokinase) was an essentially ineffective agonist in both
P2Y2-deﬁcient and wild-type macrophages, suggesting that the P2Y6 receptor is weakly expressed. In P2Y2j/j
macrophages, though, the Ca
2+ responses to Fpure_ P2X receptor activation could be studied by applying ATP in
























Figure 1. Schematic diagram of Ca
2+ signaling in a mouse macrophage induced by extracellular nucleotides.
Conventional protein kinase C isoforms mediate human sperm capacitation
induced by A1 adenosine receptor agonist
Lavinia Liguori, Rossana Palazzo, Ilaria Bellezza & Alba Minelli
Dipartimento di Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Universita ` di Perugia,
via del Giochetto, 06123, Perugia, Italia.
albaminelli@virgilio.it
Mammalian ejaculated spermatozoa are infertile and the acquisition of the fertilizing capacity is obtained via a
sequential two-steps activation process, named capacitation and acrosome reaction. Capacitation, regarded as a
signal transduction receptor-mediated phenomenon, is an emerging concept (1,2) and our data, showing that the
stimulation of A1AR triggers a cascade of signalling events that leads to capacitation, support this concept. The
constant presence of A1AR on spermatozoa suggested a functional role (3), later identiﬁed either in human or in
murine species as capacitative (4,5). Murine spermatozoa, lacking the A1AR, showed a delayed capacitation
indicating that the A1AR modulates the velocity of the process without affecting the number of capacitated cells
(4). We have already shown that the signalling initiated by A1AR proceeds via PLC and IP3 release (5). The
comparative analysis of the effects of CCPA and FCSu during a 3.5 h incubation shows that CCPA is as effective
as FCSu, a known inducer of capacitation, although it does not stimulate O2
j& production and does not cause an
increase of the phosphorylation either of the tyrosine residues or of the Thr-Glu-Tyr-motif suggesting that when
the A1AR is activated, its signalling proceeds via kinase-induced events that target proteins different from those
obseved in the presence of FCSu. Treatment of human spermatozoa with different protein kinases inhibitors
shows that receptor type PTK, PKA, and PI3K are not involved in the CCPA-mediated response whereas PKC is
responsible for the capacitative effect. All the PKC inhibitors tested, acting with different mechanism and on
different PKC isoforms, caused a signiﬁcant decrease of CCPA-induced capacitation, indicating that all these
PKCs are activated via A1AR. This result was not unexpected after the reported involvement of PLC in the
A1AR signalling (5). Kinexus analysis of the phosphorylation levels of PKC isoforms after CCPA stimulation
shows the activation of the alpha isoform and disactivation of the gamma. PKC alpha isoform has been related to
alteration of cell permeability whereas PKCgamma isoform has been linked to G" phosphorylation thereby en-
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permeability occurring during the capacitative event and with the shift to G!i inhibitory signalling induced by
A1AR activation.
1 Mededovic, S., and Fraser, L.R. (2005) Mechanisms of action of angiotensin II on mammalian sperm function.
Reproduction, 129, 211-218.
2 Rossato, M., Ion Popa, F., Ferigo, M., Clari, G., and Foresta, C. (2005) Human sperm express cannabinoid
receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. J Clin
Endocrinol Metab, 90, 984-991.
3 Minelli, A., Allegrucci, C., Piomboni, P., Mannucci, R., Lluis, C., and Franco, R. (2000) Immunolocalization of
A1 adenosine receptors in mammalian spermatozoa. J. Histochem. Cytochem, 48, 1163-1171.
4 Minelli, A., Liguori, L., Bellezza. I., Mannucci, R., Jhoansson, B., and Fredholm, BB. (2004) Involvement of A1
adenosine receptors in the acquisition of fertilizing capacity. J. Androl, 25, 286-292.
5 Allegrucci, C., Liguori, L., and Minelli A. (2001) Stimulation by N
6-cyclopentyladenosine of A1 adenosine
receptors, coupled to G ! i2 protein subunit, has a capacitative effect on human spermatozoa. Biol. Reprod, 64,
1653-1659.
Conversion of Nucleoside-Based A3 Adenosine Receptor Agonists into Potent
and Selective Antagonists: Overcoming the Problem of Species Differences
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We have systematically probed the effects of base and ribose substitution of adenosine on both the afﬁnity and
intrinsic efﬁcacy at the A3 adenosine receptor (AR). The abilities of a nucleoside to bind to and to activate the
receptor are structurally distinct. Based on this observation we designed new nucleoside antagonists of the A3AR,
which bind potently and selectively, but do not activate the receptor. The goal is to convert agonists that are
A3AR-selective in both human and rat into species independent A3AR antagonists. Previously, the spirolactam
nucleoside derivative MRS1292 was designed as a cross-species A3AR antagonist, based on chemical constraint of
the ribose moiety [1]. This derivative was shown to lower intraocular pressure in the mouse, supporting the use of
A3 antagonists in the treatment of glaucoma [2]. The highly selective agonists of the A3AR, Cl-IB-MECA (2-
chloro-N
6-(3-iodobenzyl)-50-N-methylcarboxamidoadenosine) and its 40-thio analogue, were successfully conver-
ted into selective antagonists simply by appending a second N-methyl group on the 50-uronamide position [3]. The
2-chloro-50-(N,N-dimethyl)uronamido analogues bound to, but did not activate the human A3AR, with Ki values
of 29 nM (40-O, MRS3771) and 15 nM (40-S, LJ1256), showing >100-fold selectivity over A1,A 2A, and A2BARs.
Competitive antagonism was demonstrated by Schild analysis. We used rhodopsin-based, dynamic molecular
modeling of the A3AR and ligand docking to characterize the putative ligand-binding region and identiﬁed
distinct amino acid residues related to binding of ligands, such as agonist Cl-IB-MECA and antagonist MRS3771,
and activation. In general, removing H-bonding ability or introducing steric rigidity in the region of the ribose 50-
uronamide lowers efﬁcacy at the A3AR, consistent with predictions derived from modeling.
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Cooperation between Gq and Gs-linked signaling pathways in regulation of IL-4
by adenosine in mast cells
Sergey Ryzhov, Anna E. Goldstein, Italo Biaggioni and Igor Feoktistov
Vanderbilt University, Nashville, TN 37232, USA.
igor.feoktistov@vanderbilt.edu
Adenosine provokes bronchoconstriction in asthmatics through acute activation of mast cells and plays an imp-
ortant role in chronic inﬂammation by upregulating Th2 cytokines in mast cells, thus promoting IgE synthesis by
B-lymphocytes. This effect is mediated by A2B receptors because neither the selective A2A agonist CGS21680 nor
the selective A3 agonist IB-MECA reproduced it, and the selective A2B antagonist IPDX prevented it. To get
insight into molecular mechanisms underlying this unique role of A2B adenosine receptors in promoting Th2
inﬂammation, we studied intracellular pathways linking this receptor to upregulation of IL-4 in HMC-1 mast cells.
A2B receptors stimulate adenylate cyclase via coupling to Gs proteins, and stimulate phospholipase C" through
coupling to Gq proteins. Inhibition of phospholipase C" with U73122 completely blocked adenosine-induced IL-4
secretion. The protein kinase inhibitor Ro-32-0432 had no effect on A2B-mediated, but inhibited PMA-stimulated
IL-4 secretion. In contrast, chelation of intracellular Ca
2+ inhibited both adenosine and ionomycin-induced IL-4
secretion. This Ca
2+-sensitive pathway most likely includes calcineurin and NFAT, because adenosine-induced IL-
4 secretion was blocked with cyclosporine A or 11R-VIVIT peptide. Gs-linked pathways also play a role in the
A2B-dependent stimulation of IL-4 secretion; inhibition of adenylate cyclase with 20,50-dideoxyadenosine, or pr-
otein kinase A with Rp-cAMP or H-89, attenuated adenosine-dependent IL-4 secretion. Although stimulation of
adenylate cyclase with forskolin did not increase IL-4 secretion on its own, it potentiated the effect of Pasteurella
multocida toxin by 2-fold and ionomycin by 3-fold. Both forskolin and adenosine upregulated NFATc1 express-
ion. We conclude that A2B receptors upregulate IL-4 through Gq signaling that is potentiated via crosstalk with
Gs-coupled pathways. Thus, our data explain the necessity and underscore the importance of dual coupling of A2B
receptors to Gs/Gq proteins with concurrent stimulation of diverse intracellular pathways for adenosine-depen-
dent regulation of IL-4 production in human mast cells.
Cysteine scanning mutagenesis of the extracellular loop region 286-329 of the
Human P2X1 receptor.
Jonathan Roberts
* and Richard J. Evans
Department of Cell Physiology & Pharmacology, University of Leicester, Leicester, LE1 9HN, UK;
*jar20@le.ac.uk
As P2X receptors show little homology to other ATP binding proteins that have been crystallized models of
agonist binding to P2X receptors have been developed from analysis of site-directed mutagenesis studies. Alanine
Communications 161
Springermutagenesis of conserved amino acids has highlighted key residue K309, proposed to co-ordinate ATP phosphate
group binding, and the motif N290F291R292 co-ordinating binding of the adenine ring at P2X1 receptors. To
further develop the P2X receptor model and investigate the role of N290F291R292 and K309, adjacent non-
conserved amino acids and the contribution of the 20 amino acid linker to the second transmembrane domain, we
have undertaken substituted cysteine scanning mutagenesis (SCAM) of the region S286-I329 of the human P2X1
receptor. Analysis of the effects of these mutants on ATP potency, regulation by methanethiosulphonate comp-
ounds and determination of the accessibility of residues in a MTSEA-biotinylation assay has allowed us to identify
amino acids involved in ATP binding, channel properties and information on the secondary structure of this
section of the extracellular domain.
Cysteine substitution was well tolerated and functional responses were recorded from all of the mutant channels.
R295 and R305 however produced small currents of 16 and 94 nA respectively (10mM ATP). Substitution by
cysteine reduced ATP potency at N290C, F291C, R292C and K309C receptors (~125, 135, 20 and 240 fold res-
pectively) supporting previous alanine mutagenesis. At the majority of residues (27/44) MTSEA (+ve charge) had
no affect on ATP activation but caused a large inhibition of ATP responses for mutants N290C, R292C, G321C
and I328C (4%, 4%, 41% and 41% relative to control respectively). In contrast at mutants F291C and K309C
addition of MTSEA potentiated ATP evoked responses by 164% and 168% relative to control respectively.
MTSES (-ve charge) had no effect on ATP response at the majority of residues (34/44) but signiﬁcantly inhibited
ATP response at N290C, R292C, K309C, D316C and G321C (41%, 10%, 6%, 69% and 44% relative to control
respectively). F291C and A323C were both potentiated by 129% and 138% relative to control respectively. At
N290, F291, R292 and K309 modulation of ATP responses by MTS reagents were coupled to a change in ATP
potency indicating that these residues are involved in ATP binding. In contrast for mutants D316C, G321C,
A323C and I328C, located in the linker region near to the channel pore, MTS reagents had no effect on ATP
potency indicating involvement with gating or ionic ﬂow. MTSEA biotin labels accessible cysteine residues and
indicates possible local environment secondary structure around N290F291R292, K309 and the 20 amino acid
linker region. Western blotting with P2X1 Ab on MTSEA biotin treated samples immunoprecipitated with stre-
ptavidin agarose showed three areas of accessibility, ﬁrstly 286-294 which contains the ATP binding region (N2-
90F291R292), secondly 300-303 which contains a glycosylation motif (NGT) and thirdly the linker region close to
the channel pore (D327-I329C). Interestingly K309 was not accessible to MTSEA biotin possibly due to the
conformation of the binding pocket. These results provide a strong body of evidence supporting ATP binding at
N290, F291, R292 and K309 residues of the P2X1 receptor.
Supported by the Wellcome Trust
Co-release of ATP, NPY and NA from peripheral sympathetic nerves,
modulation by CGRP and bradykinin.
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To ascertain the extracellular role of purines in synaptic transmission and particularly adenosine 50 triphosphate
(ATP) as a sympathetic co-transmitter, we investigated whether ATP is co-released together with noradrenaline
(NA) and neuropeptide Y (NPY) from sympathetic nerve terminals. To examine the role of peptides as modul-
ators of sympathetic co-transmission, we investigated whether calcitonin gene related peptide (CGRP) or brad-
ykinin (BK) modulated the co-release of the sympathetic co-transmitters ATP, NA, and NPY. We used the
prostatic half of the rat vas deferens from adult Sprague Dawley rats, a preparation enriched in sympathetic nerve
endings. The tissues were mounted in superfusion baths and maintained with Tyrode buffer (37-C) supplemented
with 1 mM desipramine, gassed with 95% O2/5% CO2 and superfused at a ﬂow of 2 ml/min. Neurotransmitter
release was elicited by electrical ﬁeld stimulation (16 Hz, 60 V, 1ms during 1 min). All 3 sympathetic co-trans-
mittters were assayed in a same sample aliquot from the collecting ﬂuid. The overﬂow of ATP, NA and NPY were
analytically quantiﬁed from a same aliquot sample of the perfusion buffer. As controls, non-stimulated buffer
samples were also analyzed. Neurochemicals were determined by HPLC procedures: electrochemical detection
quantiﬁed NA, while ATP and metabolites were detected as ﬂuorescent derivatives. RIA quantiﬁed NPY. Ele-
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NA overﬂow was different; the release of NA was considerably delayed as compared to ATP. These differences in
the time course of overﬂow might indicate differential rates of diffusion from the tissues. The net outﬂow of ATP
was 4-10 times larger than the outﬂow of NA. The application of 10 nM CGRP, a concentration that reduced the
twitching of the electrically evoked muscle contraction, signiﬁcantly reduced the overﬂow of ATP, NA and ir-
NPY released by electrical stimulation. 30 nM BK, which increased 3-fold the electrically evoked smooth muscle
twitching, halved the overﬂow of ATP and the outﬂow of adenosine from 3421 T 526 to 1403 T 131 pmol (p<0.05,
n=4). The total NA and ir-NPY overﬂow was also reduced by BK, as shown in the following Table:
In conclusion, electrical nerve ending depolarization elicited the overﬂow of extracellular ATP and NA consonant
with their proposed co-transmitter role in sympathetic neuroeffector junctions. The much larger release of ATP
might be related to its afﬁnity for excitatory postjunctional P2X receptors, highlighting its role in sympathetic co-
transmission. CGRP is a presynaptic sympathetic modulator, while BK has a dual action on sympathetic neuro-
effector junctions highlighting the modulator role of neuropeptides in sympathetic co-transmission. The intrace-
llular signaling mechanisms triggered by CGRP and BK to control sympathetic co-transmission is under
investigation. Funded by FONDAP 13980001 and MIFAB.
CP-532,903 provides cardioprotection in two different mouse models of
ischemia/reperfusion injury via an A3 adenosine receptor-mediated
mechanism
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CP-532,903 is a 30-aminoadenosine-50-uronamide derivative shown previously to be a highly selective agonist for
the human and rabbit A3 adenosine receptor (AR). The goal of this study was to determine the selectivity of CP-
532,903 (CP) for the mouse A3AR and to characterize its cardioprotective proﬁle in an in vivo mouse model of
infarction and an isolated mouse heart model of global ischemia/reperfusion injury. In vitro binding assays con-
ducted with HEK 293 cells expressing recombinant mouse ARs and [
125I]I-AB-MECA determined that CP binds
to the mouse A3AR with high afﬁnity (9.6 T 2.5 nM) and ~100-fold selectivity versus the A1AR. In cAMP assays,
CP did not stimulate cAMP production in HEK 293 cells expressing either the recombinant mouse A2AAR or the
A2BAR at a concentration of 10 2M, demonstrating poor potency of the compound for mouse A2ARs. Infarct size
in control mice subjected to 30 min of coronary occlusion and 24 h of reperfusion was 57 T 2% of the area at risk.
In mice pretreated with 30 or 100 2g/kg of CP, infarct size was signiﬁcantly reduced to 43% and 39% of the area
at risk, respectively. Administration of CP produced a short-lived reduction in mean arterial blood pressure and
signiﬁcantly increased plasma histamine levels, responses likely due to A3AR-mediated degranulation of mast
cells. In the isolated mouse heart model, coronary infusion of 10, 30 or 100 nM CP for 10 minutes prior to 20 min
of global ischemia and 45 min of reperfusion produced a concentration-dependent improvement in recovery of
left ventricular developed pressure and +/-dP/dt (~30% at 30 and 100 nM) compared to vehicle-treated hearts. In
contrast to the in vivo studies, infusion of CP in isolated hearts produced no changes in hemodynamic parameters.
The selectivity of CP in the two mouse models for the A3AR was conﬁrmed by repeating the studies using A3AR
gene Fknock-out_ mice. We conclude that the A3AR agonist CP provides protection against ischemia/reperfusion
injury in mouse hearts by activating the A3AR.
Control BK CGRP
ATP (pmol) 95.79 T 23.54 (7) 45.56 T 35.36 (3) 37.74 T 10.65 (3)
NA (pmol) 46.92 T 9.22 (7) 19.24 T 8.40* (3) 11.75 T 4.98* (3)
Ir-NPY (fmol) 32.05 T 11.20 (4) 15.56 T 4.43 (2) 12.08 T 0.91 (2)
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Acute myocardial infarction (AMI) is among the leading causes of morbidity and mortality in the western cou-
ntries. Cardiac ischemic preconditioning (IP) has been described as the strongest form of in vivo protection during
AMI. Some evidence suggests that increased nucleotide phosphohydrolysis via CD73 [conversion of adenosine
monophosphate (AMP) to adenosine] and nucleoside signaling via adenosine receptors
1 contributes to the infarct
size limiting effects of IP
2. However, previous studies are limited to pharmacological approaches or indirect lines
of evidence. Therefore, we established a murine model of cardiac IP and studied cardioprotective effects using a
genetic approach.
Following cardiac IP, CD73 mRNA was induced in preconditioned myocardium (18,4 T 5,7- fold, n=6, p<0,05).
Immunhistochemistry and enzyme activity measurements conﬁrmed robust induction of CD73 protein and fun-
ction by IP in preconditioned hearts. Using our murine model of cardiac IP, infarct sizes were reduced following
IP by 69%, from 42.1 % to 13,5 % in wildtype mice. Alpha-beta-methylene-ADP (APCP, a highly selective CD73
inhibitor) treatment completely abolished the infarct size limiting effects of cardiac IP. Cd73
-/- mice had signiﬁ-
cantly bigger infarct sizes at baseline. Moreover, the infarct size limiting effects of IP were completely abolished in
these animals. Adenosine treatment of cd73
-/- mice resulted in a partial reconstitution of the cardioprotective
effects of IP (IP-Ado in cd73
-/-: 54% T 3,0 vs. IP+Ado in cd73
-/- 39,3% T 3,3 infarct size; p<0,05).
Taken together, our data reveal for the ﬁrst time direct in vivo evidence that CD73 is critical for the observed
cardioprotective effects of IP. Further studies will need to deﬁne the contribution of individual adenosine rece-
ptors to cardioprotection by IP with the goal to identify novel therapeutic targets in the treatment of medical
conditions associated with myocardial ischemia.
References:
(1) Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP. J Exp Med.
2003, 198, 783-796.
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The de novo pathways for purine and pyrimidine biosynthesis are cross-regulated, i.e., accumulation of a purine
nucleotide (ATP) activates pyrimidine synthesis and inhibits purine synthesis, and vice versa. In bacteria the
molecular mechanism relies on the modulation of a single enzyme, aspartate transcarbamylase (1). This enzyme is
activated by elevated ATP levels, which can be viewed as a signal of purine sufﬁciency, and inhibited by CTP and
UTP, a signal of pyrimidine sufﬁciency. In mammals the modulated enzyme is carbamoyl phosphate synthetase
(2). However, it is well established that several tissues and organs, including brain, rely more heavily on the
salvage synthesis of nucleotides from preformed bases and nucleosides, rather than on de novo synthesis from
simple precursors (3). This raises the following question: how do these districts maintain the right balance bet-
ween their purine and pyrimidine nucleotide pools?
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SpringerThe rationale of our experimental procedure is the following. Since the purine and pyrimidine salvage processes
occur at the base and nucleoside level, respectively (4, 5), rat brain cytosol is incubated in the presence of either
radioactive adenine and cold uridine, to follow the rate of purine salvage, or with cold adenine and radioactive
uridine, to follow the rate of pyrimidine salvage. We emphasize that this experimental procedure allows to me-
asure the rate of purine salvage when also pyrimidine salvage is operative, and vice versa. The time course of
radioactive purine and pyrimidine nucleotides formation is followed, in the presence of different concentrations of
effectors.
Our results show that in rat and human brain cytosol the two processes of purine and pyrimidine nucleotide
salvage respond in an opposite manner to the ﬂuctuation of intracellular [purine nucleoside triphosphates]/[pyr-
imidine nucleoside triphosphates] ratio (PUR/PYR ratio). The metabolic sensor is a two enzyme system which
maintains uridine homeostasis, composed of uridine phosphorylase (UPase) and uridine kinase (Uk). When the
activity of Uk is inhibited by relatively high UTP and CTP (6) concentration (low PUR/PYR ratio), uridine
accumulates and the equilibrium of the UPase reaction is shifted towards uridine phosphorolysis. The ribose-1-P
produced forms PRPP, an obligate substrate of adenine salvage (7). At a high ratio these effects are reversed.
Uridine kinase becomes fully active, and pyrimidine salvage is favoured over purine salvage.
1. Allewell, N.M. (1989) Escherichia coli aspartate transcarbamoylase: structure, energetics, and catalytic and
regulatory mechanisms, Annu. Rev. Biophys. Biophys. Chem. 18: 71-92.
2. Jones, M. E. (1980) Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP
biosynthesis, Annu. Rev. Biochem. 49: 253-279.
3. Stone, T.W., and Simmonds, H.A. (1991) Purine: Basic and Clinical Aspects, Kluwer, Dordrecht.
4. Kim, Y. A., King, M. T., Teague Jr, W.E., Rufo Jr, G. A., Veech, R. L., and Passonneau, J.V. (1992) Regulation
of the purine salvage pathway in rat liver, Am. J. Physiol. 26: E344-E352.
5. Lo ¨fﬂer, M., Fairbanks, L., D. Zameitat, E., Marinaki, A. M., and Simmonds, H. A (2005) Pyrimidine pathways
in health and disease, Trends Mol. Med. 11: 430-437.
6. Orengo, A. (1969) Regulation of enzymic activity by metabolites. I. Uridine-cytidine kinase of Novikoff ascites
rat tumor, J. Biol. Chem. 244: 2204-2209.
7. Barsotti, C., Tozzi, M.G., Ipata, P.L. (2002) Purine and pyrimidine salvage in whole rat brain. Utilization of
ATP-derived ribose-1-phosphate and 5-phosphoribosyl-1-pyrophosphate generated in experiments with dialyzed
cell-free extracts, J. Biol. Chem. 277: 9865-9869.
Cross-talk between human cysteinyl-leukotriene and extracellular nucleotide
receptors: implication in inﬂammation
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Cysteinyl-leukotrienes (cysteinyl-LTs) and extracellular nucleotides mediate inﬂammatory responses via speciﬁc
G protein-coupled receptors (GPCRs), the CysLTR and the P2YR, respectively. Evidence has begun to accum-
ulate for the existence of a multifaceted cross-talk between the cysteinyl-LT and the nucleotide systems, consi-
dering that these mediators accumulate at sites of inﬂammation and inﬂammatory cells express both classes of
receptors. For example, in rat microglia, activation of P2Y1R and CysLTR mediate co-release of both nucleotides
and cysteinyl-LTs. Furthermore, we recently demonstrated that two CysLT1R selective antagonists marketed for
asthma therapy functionally interact with P2YR signaling pathways by inhibiting nucleotide-induced calcium
mobilization. Herein, we investigated the molecular basis of desensitization and trafﬁcking of the human CysL-
T1R in response to LTD4 or nucleotides. Exposure of the CysLT1R endogenously expressed in monocyte-macr-
ophage like U937 cells to agonist induced a rapid homologous desensitization followed by receptor
internalization. Activation of P2YR with ATP or UDP induced CysLT1R heterologous desensitization. Conver-
sely, LTD4-induced CysLT1R activation had no effect on P2YR responses. Furthermore, ATP/UDP-induced
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SpringerCysLT1R desensitization was unable to cause receptor internalization and was dependent upon PKC, at variance
with homologous desensitization. Hence, CysLT1R desensitization and trafﬁcking are differentially regulated by
its cognate ligand or by extracellular nucleotides. This cross-talk may have a profound physiological implication in
the regulation of responses at the sites of inﬂammation, and may represent just an example of a feed-back
mechanism utilized by the cells to ﬁne tune their responses. Furthermore, it is also possible that other inﬂamm-
atory stimuli heterologously desensitize the CysLT1R in a similar way, as is the case for the chemoattractant
receptor system.
Partially supported by FIRB2001 to G.E.R. and by the Italian CARIPLO Foundation (2004 Projects ‘‘Promuo-
vere la ricerca scientiﬁca e tecnologica in tema di salute e scienze della vita’’ to G.E.R. and M.P.A., Project
coordinated by prof. Francesco Clementi, University of Milan, Italy).
CVT-3619, a novel partial A1 adenosine receptor agonist, lowers plasma free
fatty acids, triglycerides and improves insulin sensitivity without cardiovascular
effects.
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Elevated plasma free fatty acid (FFA) levels have been linked to the onset of insulin resistance. A1 adenosine
receptor (A1R) agonists are potent anti-lipolytic agents which inhibit adipose tissue lipolysis and lower circulating
FFA levels. Many A1R agonists have been developed in the past for the purpose of lowering FFA; however, their
concurrent effects on the cardiovascular system are major limitations for their therapeutic utility. In the present
study we report that CVT-3619, a novel partial A1R agonist, causes reduction in circulating FFA levels and
improves insulin sensitivity without any signiﬁcant effect on heart rate and blood pressure. Male Sprague Dawley
rats (250-300 gms) implanted with indwelling arterial and venous cannulas for blood sampling and drug admini-
stration were used in the study. CVT-3619 (1-10 mg/kg, PO dose) decreased both FFA and triglyceride (TG)
levels (15-57%) in a dose-dependent manner. CVT-3619 did not have any signiﬁcant effect on heart rate and
blood pressure up to 10 mg/kg, PO. At 25 and 50 mg/kg dose of CVT-3619 there was a small (10%) but signiﬁcant
decrease in heart rate. The FFA lowering effects of three consecutive single doses CVT-3619 were not signiﬁc-
antly different suggesting that there was no tachyphylaxis of the effect of CVT-3619. In addition, the anti-lipolytic
effect of CVT-3619 was not associated with a rebound increase in FFA levels as seen with Nicotinic acid. TG
secretion (mg/dl/min) by the liver was signiﬁcantly (p<0.001) reduced with CVT-3619 treatment (slope for control
5.5 T 0.12; CVT-3619 3.7 T 0.17). CVT-3619 also lowered FFA and TG levels in rats with impaired insulin
sensitivity caused by 2 weeks of high fat diet feeding. An oral glucose tolerance test (OGTT) in high fat diet fed
rats treated with CVT-3619 for 2 weeks showed improved insulin sensitivity as compared to untreated control rats
as indicated by the area under the curve for the time-course of the changes in glucose and insulin plasma levels
(AUCg x AUCi). In conclusion, CVT-3619 is a novel, partial, orally bioavailable A1R agonist that lowers circu-
lating FFA and TG levels resulting in improved insulin sensitivity in a diet-induced model of insulin resistance
with minimal cardiovascular effects.
Design and Synthesis of purine and pyrimidine nucleosides carrying phosphate
mimics groups at the 5_-position as potential P2 receptor ligands1
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Extracellular nucleotides regulate a wide variety of functional responses in many cell types by stimulation of both
G-protein coupled receptors (P2Y) and ATP-gated ion channel receptors (P2X). Selective ligands for purinergic
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Springerand pyrimidinergic P2 receptors are urgently needed in order to investigate their physiological role and the
pharmacological potential of such compounds
2. A useful approach to the discovery of novel P2 receptor ligands
may consists in the design of purine and pyrimidine nucleosides carrying phosphate mimics groups at the 50-
position. These compounds should be featured with structural changes compatible for the recognicition by the
receptors but stable to the enzymatic hydrolisys. Consequently, we have recently explored the possibility to obtain
a new class of stable nucleotide analogs endowed with isosteric substitution of the diphosphate group. The sub-
stitution of the diphosphate moiety of natural substrates with phosphonoacetic acid ester and amide moieties
should give a stronger interaction with the active site, thereby resulting in potent ligands. On these premises, on
the hand, we have prepared new nucleosides analogs designed in order to obtain bioisosters at the diphosphate
moiety. Taking into account our previous results have explored 50-phosphono acetic acid, amide and ester analogs
of inosine, adenosine, uridine, cytidine and ribofuranosiltimine. In this communication, the synthesis of these
compounds will be reported.
1This work was supported by FIRB, grant number RBNE03YA3L_008
2Ralevic and Bursntock G. Pharmacol. Reviews, 1998,50, 413-492
Design and synthesis of selective A2B adenosine receptor antagonists:
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Adenosine is an endogenous ligand that binds to four adenosine receptor subtypes – A1,A 2A,A 2B, and A3.
Activation of the A2B adenosine receprot (AdoR) on mast cells may play a putative role in asthma through mast
cell degranulation leading to the release of inﬂammatory cytokines (e.g. interleukin-8). Furthermore, activation of
A2B AdoRs on bronchial smooth muscle cells (BSMC) has been demonstrated to lead to the production of
interleukin-6 and monocytic chemotactic peptide-1, a process that can be blocked by selective A2B AdoR anta-
gonists. Therefore, potent and selective A2B adenosine receptor (AdoR) antagonists may play a beneﬁcial role in
understanding the role of A2B AdoRs in physiological and pathological conditions and as a potential treatment for
asthma. In our efforts to identify a slective high afﬁnity A2B AdoR antagonist, we explored 8-pyrazol-4-yl xant-
hine derivatives that represents a new class adenosine receptor antagonists.
1 Previously, we reported the SAR of
1,3-disubstituted 8-pyrazolyl xanthine derivatives that displayed high afﬁnity for the A2B AdoR and good selec-
tivity.
2,3 We have shown that substitution of the pyrazole nitrogen with a meta-substituted benzyl group (1)o r
with oxadiazoles (2) and isoxazoles increased the A2B AdoR selectivity. Herein, we describe our efforts to incr-
ease the A2B AdoR selectivity of 8-pyrazolyl xanthines by exploring the effects of mono-substitution at the N-1
and N-3 positions of the xanthine. The N-1 substituted 8-pyrazolyl xanthines 3 and 4 have displayed higher
selectivity compared to their corresponding disubstituted derivatives 1 and 2. The synthesis of mono substituted 8-






















2. R1 = n-propyl; h(A2B) - 39nM; h(A1) - 2900 nM
h(A2A) - >5000 nM; h(A3) - >6000 nM
4.R1 = H; h(A2B) - 14 nM; h(A1) - >6000 nM
h(A2A) - >5000 nM; h(A3) - >6000 nM
1. R1 = n-propyl; h(A2B) - 14 nM; h(A1) - 170 nM
h(A2A) - 400 nM; h(A3) - 56 nM
3. R1 = H; h(A2B) - 8 nM; h(A1) - >6000 nM
h(A2A) - >5000 nM; h(A3) - 700 nM
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SAH-hydrolase catalyzes the reversible hydrolysis of SAH to adenosine and homocysteine. One mol of the
enzyme contains 4 mol of NAD
+ which is the essential cofactor of the enzyme
1. As recently shown puriﬁed SAH-
hydrolase exhibits two adenosine binding sites one with a high and one with a low afﬁnity. These adenosine
binding sites are controlled by the enzyme-bound NAD
+/NADH ratio. The existance of the two sepatrate binding
sites were identiﬁed after covalent labeling with 8-azido-adenosine
2. Since adenosine competes with cAMP at the
high afﬁnity binding site of the enzyme
3, we examined in the present study the effect of cAMP on the enzyme
activity and its binding characteristics to SAH-hydrolase in its native, NAD
+ and NADH form.
Methods: SAH-hydrolase was puriﬁed to homogeneity from bovine kidney with chromatographical methods. The
activity of SAH-hydrolase was assayed in the direction of hydrolysis. With the spectrophotometric titration assay
we determined the ability of adenosine and cAMP to reduce the enzyme bound NAD
+ at 327 nm. To gain further
insight into the role of NAD
+ in cAMP binding we removed NAD
+ of the enzyme by dialysis and the apo-enzyme
was reconstituted either with 100% NAD
+ or with 100% NADH. For saturation binding experiments the enzyme
(10 2g/ml) was incubated with
3H-cAMP (0.01-5 2mol/l) two hours at room temperature in Tris/Hepes pH 7.4. To
identify the cAMP binding site, SAH-hydrolase was incubated with [2-
3H]-8-azido-cAMP. After irradiation the
reaction mixture was digested by Asp-N or trypsin and the peptides puriﬁed by HLPC were sequenced.
Results: cAMP enhanced the hydrolytic activity of SAH-hydrolase by 30% at 5 2mol/l. In contrast to adenosine,
cAMP did not reduces the tightly bound NAD
+ in the titration assay. In the presence of cAMP the conversion of
NAD
+ to NADH by adenosine is decreased in a concentration dependent manner. Saturation experiments per-
formed by increasing concentrations of
3H-cAMP and with the three differnt forms of SAH-hydrolase, native,
NAD
+ and NADH, indicated only one binding site with a high afﬁnity. This binding site was identiﬁed after
irradiation of the enzyme with [2-
3H]-8-azido-cAMP. One photolabeled peptide was isolated as Trp
310-Val
325
from the native SAH-hydrolase and one peptide as Asn
314-Gln
324 from both, NAD
+ and NADH forms.
Conclusion: Our data show that the cAMP binding site of the SAH-hydrolase is independent of the NAD
+/
NADH ratio of the enzyme. We conclude that the cAMP binding site is identical with the high afﬁnity binding site
of adenosine. This implies that the inhibitory effect of adenosine on the SAH-hydrolase can be antagonized by
cAMP. Whether this cAMP action may have physiological implications remains to be determined.
References
1. Palmer, J.L.; Abeles, R.H.; J. Biol. Chem. 1979, 254:1217-1226.
2. Kloor, D.; Lu ¨dtke, A.; Stoeva, S.; Osswald, H.; Biochem. Pharmacol. 2003, 66:2117-2123.
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Huntington disease (HD) is an autosomal, dominantly inherited neurodegenerative disorder characterized by
progressive motor and cognitive disturbances caused by an expansion in CAG repeats in the IT15 gene which
encodes the huntingtin protein. A pathogenetic role for excitotoxic cell death mediated by increased glutamate-
rgic excitoxicity in the striatum has been proposed. Drugs able to modulate striatal levels of glutamate are thus
candidates to protect striatal neurons from neurodegeneration. We have recently demonstrated that the extrac-
ellular concentration of adenosine increases in the striatum of HD transgenic (R6/2) mice and that the selective
antagonist of adenosine A2A receptors, SCH 58261, directly administered in the striatum, signiﬁcantly reduces
glutamate outﬂow
1. Furthermore we demonstrated that the p38 mitogen-activated protein kinase (MAPK) pat-
hway is activated in the neurons of the striatum of HD transgenic mice
1. The p38 MAPK is known to be a factor
activated and inducing the expression of pro- and inﬂammatory mediators and involved in the early gene c-Fos
phosphorylation. Products of Fos family are players in inducing inﬂammatory gene expression in glial cells. In HD
patient brain microglial activation in the striatum and in the cortex
2 and reactive astrogliosis in the striatum
during the late stage of pathology
3 were reported.
A ﬁrst aim was therefore to investigate glial cells and c-Fos activation in heterozygous transgenic R6/2 male and
wild-type mice at different ages, 10-11 (presymptomatic phase) and 14 week old (symptomatic phase), and to
evaluate the effect of selective adenosine A2A receptor antagonist SCH 58261. SCH 58261 was subchronically
administered (0.01 mg/kg i.p.) at time: -20, -17 and -2 h from sacriﬁced. Mice were transcardically perfused with
paraformaldheyde and brains were cut by cryostat into 30 2m thick slices. Microglial cells stained by isolectine-B4
and astrocytes immunostained by GFAP were not activated in the striatum of 10-11 (n=5) and 14 week old R6/2
mice (n=3). Astroglial cells were detected only in the cingolate cortex of 14 week old mice (n=3). In the brain of
10-11 week old R6/2 treated mice (n=5) speciﬁc c-Fos immunostaining was not changed in comparison to wild-
type mice (n=6). On the other hand, speciﬁc c-Fos immunostaining was increased in the piriform cortex, but not in
the striatum, of 14 week old mice (n=3) in comparison to wild-type mice (n=6). The selective antagonist of
adenosine A2A receptors decreased c-Fos immunoreactivity in the piriform cortex of 14 week old mice (n=3).
The results demonstrate that in transgenic R6/2 mice in the terminal phase, there is a modest activation of glial
cells and activation of c-Fos early gene in the cortex, and that adenosine A2A antagonism reduces c-Fos activation
in the cortex. (Grant by Italian Ministry of Health and Fondazione Monte dei Paschi di Siena, Italy).
(1) Gianfriddo, M., Melani, A., Turchi, D., Giovannini, M.G., Pedata, F.. Neurobiol. Dis. 2004, 17, 77-88.
(2) Sapp, E., Kegel, K.B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P.G., Vonsattel, J.P.,
DiFiglia, M. J Neuropathol. Exp. Neurol. 2001, 60, 161-172.
(3) Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D., Richardson, E.P., Jr. J. Neuropathol.
Exp. Neurol. 1985, 44, 559-577.
Developing an assay to probe the activity of the P2X1 receptor with
radio-labelled 2-azido ATP
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Mutagenesis of conserved residues at the P2X1 receptor has revealed reductions in the potency of ATP which
could be attributed to either binding or gating effects. To discriminate between them, we developed an assay to
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Springerprobe binding at the P2X1 receptor using 2-azido ATP. Whole cell patch clamp recordings show that 2-azido ATP
is a potent agonist at the P2X1 receptor. The ATP analogue contains a photo-active azido (-N3) group that is
chemically inert until activation by UV light. Upon irradiation, a covalent linkage between the compound and the
active site of the receptor is formed. Cross-linking should cause permanent P2X1 receptor occupation, therefore
subsequent ATP applications should produce responses that are greatly reduced from the control.
HEK293 cells stably expressing the P2X1 receptor were incubated in 302M 2-azido ATP and UV irradiated for 3
min, with the UV source positioned 7.5cm above the cells. Under these conditions and following a 10 min wash,
UV or ATP and UV had no effect on the amplitude of the P2X1 receptor response. However, UV irradiation with
2-azido ATP caused an 86% reduction in currents elicited by 12M ATP application (EC50 concentration). Control
responses were reduced from 3.47 T 0.28nA (n =15) to 0.49 T 0.09nA (n = 30). This reduction was maintained
throughout the recorded 45min time period. The effects of cross-linking were prevented by pre-treatment with
3002M ATP or 1002M suramin, this provided 29% and 73% receptor protection respectively.
To detect the binding of 2-azido ATP to the receptor, we used a
32P labelled version of the compound. HEK293
cells stably expressing the P2X1 receptor were treated with radio-labelled 2-azido ATP. To determine the level of
non-speciﬁc binding, non-transfected HEK293 cells were treated similarly. After lysis, the cross-linked P2X1
receptor was isolated by immunoprecipitation with the P2X1 antibody (Alomone) and the samples were run on a
10% SDS gel. Exposure of the dried gel to autoradiography ﬁlm directly provided evidence of 2-azido ATP
binding at the P2X1 receptor, no binding to non-transfected HEK293 cells and the reduced binding which occu-
rred at cells protected by excess ATP. Previously shown mutations of the NFR region (290-292) and the positive
lysine at the 309 position to either an alanine or cysteine residue revealed a signiﬁcantly reduced ATP potency
when compared to the wildtype. When expressed in Xenopus oocytes, binding of the radio-labelled 2-azido ATP
was signiﬁcantly decreased in these mutants when compared to the wildtype. This decrease is indicative of a
reduction in direct binding to the P2X1 receptor and provides further evidence that the NFR region and the lysine
residue at 309 contribute to the binding site of the P2X1 receptor.
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Development of a novel, automated method for the characterization and
screening of NTPDase inhibitors by in-capillary enzymatic microreaction
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The ecto-nucleoside triphosphate diphosphohydrolases (EC 3.6.1.5) represent a major and ubiquitous family of
ecto-nucleotidases. They catalyze the sequential hydrolysis of the +-a n d"-phosphate residues of nucleoside tri-
and diphosphates, producing the corresponding nucleoside monophosphate derivatives.1 The activation of P2
receptors is controlled by ecto-nucleotidases capable of hydrolyzing nucleoside tri- and diphosphates.1 Inhibition
of ecto-nucleotidases can thus result in a potentiation of purinergic signaling, supporting the notion that endog-
enous ecto-nucleotidases reduce the effective concentration of the released nucleotide.2 Inhibitors of ecto-nucl-
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Springereotidases could thus represent valuable tools for amplifying the biological effects induced by extracellularly rel-
eased nucleotides.
Several methods have been used for the determination of Michaelis-Menten constants (Km values), and inhibition
constants (Ki values for enzyme inhibitors) of NTPDases, including radioisotopic, HPLC and spectrophotometric
assays. All of these methods are time-consuming and suffer from further serious drawbacks. Capillary electrop-
horesis (CE) has recently emerged as a versatile technique for the quantitative analysis of nucleotides3 and for the
monitoring enzymatic reactions.
4 CE systems have been successfully applied for assaying enzyme activity, inclu-
ding the determination of Michaelis-Menten constants (Km values), and inhibition constants (Ki values for enz-
yme inhibitors), exhibiting a number of advantages over conventional methods. These include rapid separation of
substrate and product, ultra-low sample volume requirements, and high throughput by automation. CE is parti-
cularly useful for investigating enzymatic reactions involving charged substrates or products, e.g. for the monit-
oring of phosphorylation or dephosphorylation reactions.
In the present study we have developed an easy, rapid, nonradioactive at-capillary-inlet CE method for the
screening and characterization of NTPDases inhibitors.
5 The enzymes used in this study were expressed in CHO
cells. Different standard compounds were tested as NTPDase inhibitors by this new method and results were in
close agreement with data obtained from standard methods. The newly developed CE-based NTPDases inhibition
and characterization assay is suitable for automation using 96-well plates and can be used for the high throughput
screening of novel potential NTPDase inhibitors and substrates.
(1) Zimmermann, H. Naunyn Schmiedebergs Arch.Pharmacol. 2000, 362, 299-309.
(2) Bu ¨ltmann, R.; Driessen, B.; Goncalves, J.; Starke, K. Naunyn Schmiedebergs Arch.Pharmacol. 1995, 351, 555-
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Diadenosine polyphosphate analogue controls postsynaptic excitation in
CA3- CA1 synapses via a nitric oxide (NO)-dependent mechanism
Sergei Melnik,
1 Michael Wright,





2 and Natalia Lozovayaa
1
1Department of Cellular Membranology, Bogomoletz Institute of Physiology, Ukraine;
2Imperial College Imperial
College Genetic Therapies Centre, Imperial College London, UK.
a.miller@imperial.ac.uk
Previously, we have described the modulatory effect of diadenosine polyphosphates Ap4Aa n dA p 5A on synaptic
transmission in the rat hippocampal slices, mediated by presynaptic receptors (Klishin et al., 1994). We have re-
examined this phenomenon probing with a non-hydrolysable Ap4A analogue diadenosine-50,50-P
1,P
4-[","0-meth-
ylene]tetraphosphate (AppCH2ppA) of high purity and low salt content. In contrast to our previous report we
now describe how AppCH2ppA at low micromolar concentrations exerts a pure postsynaptic effect giving strong
non-desensitizing inhibition of orthodromically evoked ﬁeld potentials (OFPs), without affecting the amplitude of
excitatory postsynaptic currents (EPSCs) and antidromically evoked ﬁeld potentials (AFPs) recorded in the CA1
zone of hippocampus. The effects of AppCH2ppA on OFPs are eliminated by a P2 receptor antagonist PPADS
but not mimicked by purinoceptor agonists, !,"-methylene-ATP and ATP-+-S, indicating that a P2-like receptor is
involved but not one belonging to the conventional P2X/P2Y receptor classes. In contrast to AppCH2ppA, ATP
inhibits the EPSCs. Diadenosine polyphosphate receptor (P4) antagonist, Ip4I, was unable to modulate AppC-
H2ppA effects. Thus, the PPADS-sensitive P2-like receptor for AppCH2ppA appears to selectively control den-
dritic excitation of the CA1 neurons. The speciﬁc nitric oxide (NO)-scavenger 2-phenyl-4,4,5,5-tetramethyl-
imidazoline-1-oxyl-3-oxide (PTIO) is shown to attenuate signiﬁcantly AppCH2ppA mediated inhibitory effects,
indicating that NO is involved in the cascade of events initiated by the AppCH2ppA. Further downstream me-
diation by adenosine A1 receptors is also demonstrated. Such spatially selective postsynaptic dendritic inhibition
may inﬂuence dendritic electrogenesis in pyramidal neurons and consequently mediate control of neuronal net-
work activity.
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Nucleotides released by degranulating platelets are potential causative agents of post-operative contraction in
coronary artery bypass grafts. Diadenosine polyphosphates (ApnA) are released alongside mono-nucleotides and
have activity at several P2 receptors. Diadenosine polyphosphates are relatively long-lived vasoactive molecules,
as their stability is enhanced by the preferential metabolism of mono-nucleotides by ecto-nucleotidases. Therefore
diadenosine polyphosphates may be the cause of local nucleotide-mediated vasoconstriction at sites of tissue
injury and inﬂammation in coronary artery bypass grafts.
Following ethical committee approval, sections of human radial and internal mammary artery and saphenous vein
were obtained surplus to surgery with informed patient consent. Changes in tension were recorded upon applic-
ation of diadenosine polyphosphates or the P2X1 receptor agonist !"methyleneATP.
Radial artery and saphenous vein demonstrated robust concentration-dependent vasoconstriction to Ap4A, Ap5A
and Ap6A and !"methyleneATP. Cross-desensitisation revealed that diadenosine-mediated vasoconstriction ap-
parently occurred via the P2X1 receptor. In contrast, in the internal mammary artery !"methyleneATP-mediated
vasoconstriction was weak or absent in the majority of samples. Consistent with activity at the P2X1 receptor
diadenosine polyphosphate-mediated vasoconstriction was also absent. However in radial artery and saphenous
vein, responses to Ap5A could not be inhibited by PPADS but were inhibited by suramin or NF279 at high
concentrations. Indeed in the presence of PPADS, Ap5A-mediated vasoconstriction was enhanced suggesting that
ectonucleotidase activity was reducing the availability of Ap5A at the smooth muscle. Consistent with these
ﬁndings enhanced Ap5A-mediated vasoconstriction occurred when Ap5A-responses were repeated in the prese-
nce of excess ATP.
Our data would implicate diadenosine polyphosphates as a potential cause of post-operative vasoconstriction in
coronary artery bypass grafts. However this activity is limited to saphenous vein and radial artery grafts since in
comparison the internal mammary artery is relatively insensitive to the diadenosine polyphosphates.
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The P2Y1 and P2Y11 receptors are closest homologues among the family of G-protein-coupled P2 receptors and
are activated by adenine nucleotides exclusively 1, 2. We stably expressed the P2Y11 receptor in 1321N1 cells and
monitored the cells for the change in ﬂuorescence intensity of the calcium indicator Fura-2 after agonist stimul-
ation. By the use of this method we found a clear difference in potencies of several borano/sulfur-modiﬁed
diastereoisomers of ATP. The P2Y11 receptor clearly prefers the (B) isomers (ATP-!-B Sp isomers and ATP-!-S
Rp isomers) of the derivatives tested. The (B) isomers of all derivatives tested were more potent at the P2Y11
receptor than the corresponding (A) isomers (ATP-!-B Rp isomers and ATP-!-S Sp isomers) and the parent
compounds. In former studies we have shown that ATP-!-S and ATP-!-B diastereoisomers display a stereo-
selective activity at the P2Y1 receptor 3, 4. Here we report that the P2Y11 receptor exhibits exactly the opposite
chiral discrimination. Moreover, the (A) isomer of 2-MeS-ATP-!-B was found to be most selective at the P2Y1
receptor being 3000-fold more potent at this subtype than at the P2Y11 receptor. The 2-MeS-ATP-!-B diastere-
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Springeroisomers are ineffective at the P2Y2 receptor5. Thus, the 2-MeS-ATP-!-B (A) isomer can be used for subtype-
selective activation of the P2Y1 receptor in tissues expressing also the P2Y2 and P2Y11 receptors. The distinct
opposite diastereoselective activity of ATP derivatives at the P2Y11 and the P2Y1 receptor will allow deciphering
structural differences of the ligand recognition sites between these receptor subtypes. Presently, we are working
on the molecular basis of the diastereoselectivity. By means of mutagenesis and rhodopsin-based homology m-
odelling we aim to characterize the putative stereoselective nucleotide recognition site of the P2Y11 receptor. This
will aid in the development of subtype-selective agonists.
1. Communi, D.; Govaerts, C.; Parmentier, M.; Boeynaems, J. M., Cloning of a human purinergic P2Y receptor
coupled to phospholipase C and adenylyl cyclase. J Biol Chem 1997, 272, (51), 31969-73.
2. Burnstock, G., Purinergic signalling. Br J Pharmacol 2006, 147 Suppl 1, S172-81.
3. Nahum, V.; Zundorf, G.; Levesque, S. A.; Beaudoin, A. R.; Reiser, G.; Fischer, B., Adenosine 50-O-(1-bora-
notriphosphate) derivatives as novel P2Y(1) receptor agonists. J Med Chem 2002, 45, (24), 5384-96.
4. Major, D. T.; Nahum, V.; Wang, Y.; Reiser, G.; Fischer, B., Molecular recognition in purinergic receptors. 2.
Diastereoselectivity of the h-P2Y1-receptor. J Med Chem 2004, 47, (18), 4405-16.
5. Tulapurkar, M. E.; Laubinger, W.; Nahum, V.; Fischer, B.; Reiser, G., Subtype speciﬁc internalization of P2Y1
and P2Y2 receptors induced by novel adenosine 50-O-(1-boranotriphosphate) derivatives. Br J Pharmacol 2004,
142, (5), 869-78.
DIFFERENT BEHAVIOUR OF P2X7 RECEPTORS IN CORTICAL vs.
HIPPOCAMPAL ASTROCYTES
Bianco F., Colombo A, Mele R, Matteoli M. and Verderio C.
CNR-Institute of Neuroscience, Univ. of Milano Dept. of Medical Pharmacology,
Center of Excellence on Neurodegenerative Diseases, Milano Italy.
f.bianco@in.cnr.it
P2X7 is an ionotropic purinergic receptor with the characteristic to undergo transition from a selective channel to
an aspeciﬁc pore, permeable to molecules up to 900 kD. Prolonged activation of the P2X7 receptor and pore
transition can cause cell permeabilization and lysis.
The mechanisms leading to pore formation are just starting to be unravelled. One hypothesis suggests that pore
formation derives from dilatation of the channel through recruitment of additional receptor subunits (Wiley et al,
1998; Virginio et al, 1999; Smart et al, 2002) while another hypothesis suggests that activation of P2X7 determines
synthesis of a second messenger, which is responsible for pore opening. In this view, pore opening might occur
through a membrane protein distinct from the purinergic receptor (Persechini et al., 1998; Gu et al, 2001).
In line with the recent observation that MAPK may be involved in pore formation. (Faria et al, 2005), here we
show that the capability of P2X7 receptor to form an aspeciﬁc pore requires p38 MAPK activation, as pretreat-
ment with the MAPK inhibitor SB, strongly prevented pore transition, as assayed by Yo-Pro uptake. We also
provide evidence for different behaviour of the P2X7 receptor in primary astrocytes from two rat brain regions,
cortex and hippocampus. While P2X7 receptor in cortical astrocytes undergoes transition from selective ionotr-
opic channel to aspeciﬁc pore, P2X7 receptor in hippocampal astrocytes does not form a pore. The different
ability to undergo pore transition affects cytokine release. Following pore formation in cortical astrocytes exposed
to LPS, caspase-1 is activated, and the enzyme is able to process the pro-inﬂammatory cytokine IL1-beta which is
released in the extracellular medium in its active form. P2X7 activation in hippocampal astrocytes does not result
in IL1-beta secretion, although the pro-cytokine is present in the cytosol of astrocytes activated with LPS. The
different mechanisms involved in P2X7 receptor activation, by affecting the ability of cortical and hippocampal
astrocytes to release proinﬂammatory cytokines, might inﬂuence the onset on neuroinﬂammation during neuro-
degenerative processes in different brain areas.
& Faria RX, DeFarias FP, and Alves LA. Are second messengers crucial for opening the pore associated with
P2X7 receptor? Am J Physiol Cell Physiol 288: C194–C205, 2005.
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Differential Effect of Cyclic Stress and Constant Stress on ATP Release in
Human Airway Epithelial Cells
Brian Button and Richard C. Boucher
Cystic Fibrosis Research and Treatment Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Brian_Button@med.unc.edu
The airway surface liquid (ASL) layer lining the superﬁcial cells of the airways is crucial for regulating mucoci-
liary clearance and removal of noxious materials from the lungs. As a result of ion channel and ﬂuid regulation,
the height of the ASL is maintained at ~7 2m, where cilia are fully erect, capable of proper cilia beating. Our
overarching hypothesis is that the concentration of extracellular ATP and adenosine (ADO), via the activation of
P2Y2 and A2b purinoceptors located in the luminal membrane, modulate the activity of ion channels involved in
ﬂuid secretion and absorption, to maintain the ASL at this level. The signiﬁcance of ATP/ADO on ASL regul-
ation in airway epithelia is underscored by experiments that demonstrate: 1) addition ATP/ADO induces ASL
ﬂuid secretion and 2) Removal of extracellular ATP/ADO induces unregulated ASL ﬂuid absorption. We have
previously demonstrated that mechanical stimulation of airway epithelial cultures, using cyclic stress to emulate
the stresses experienced in the lung during normal tidal breathing, elicits ATP release, to levels that are sufﬁcient
to stimulate ASL secretion. In addition to cyclic stresses in the lung, constant (static) stress, such as those asso-
ciated with bronchoconstriction of the airways, can also be observed. However, the ability of such constant stress
to stimulate ATP release and ﬂuid secretion, like cyclic stress, is unknown. The goal of this study was to directly
compare ATP release and its subsequent effect on ﬂuid secretion, on airway cultures under physiological levels of
cyclic or static stress. In these studies, well-differentiated human airway cultures were exposed to 30 minutes of: 1)
constant transepithelial pressure of 20 cmH2O, 2) cyclic pressure, oscillating between atmospheric pressure and 20
cmH2O at 20 cycles/ min, or 3) atmospheric pressure only. To determine the rate of ATP release, a cocktail of
ATPase inhibitors (ebselen, "+MeATP and AP5A) were added to the luminal solution in order to prevent ATP
hydrolysis. The cumulative ATP present in the ASL at 30 minutes was assessed by microsampling the ASL and
quantiﬁed using a conventional luciferin-luciferase assay. In control cultures, the ATP release rate was 378 T 69
fmol/cm
2/min, similar to previously reported values. In cultures undergoing cyclic stress, ATP release was signi-
ﬁcantly stimulated, to 2514 T 823 fmol/cm
2/min. In contrast, the rate of ATP release during constant stress was 422
T 126 fmol/cm
2/min, signiﬁcantly less than cyclic stress at the same pressure (stress) magnitude. Further, exposures
of airway cultures to static pressure (20 cmH2O for 24h) failed to induce a signiﬁcant change in steady-state ASL
height, as measured by confocal microscopy (7.5 T 1.6 versus 7.8 T 0.9 2m for control). However, cyclic stress (20
cmH2O / 20 cycles/min for 24h) resulted in a doubling of ASL height (to 14.2 T 1.7 2m). The cyclic stress-induced
secretion was completely inhibited by the pre-treatment with apyrase/ADA to inhibit accumulation of ATP/ADO
(to 4.4 T 0.22m), demonstrating that ASL secretion requires the stimulation of ATP release, which was not
observed in cultures under constant stress. These results provide the ﬁrst evidence of differential effects of cyclic
and static stress on ATP release from airway epithelial cells. While the mechanism by which airway epithelial cells
differentiate between cyclic and constant stress remains to be elucidated, this model system is useful in delivering
the stimuli required to investigate this phenomenon. Supported by the Cystic Fibrosis Foundation.
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The A2A adenosine receptor (A2AAR) is a critical non-redundant suppressor of inﬂammatory responses in vivo.
One important mechanism by which this seems to occur is suppression of the NF-.B pathway, which controls the
induction of multiple genes encoding proteins that initiate and sustain pro-inﬂammatory responses. We have
previously demonstrated that A2AAR gene transfer in human umbilical vein endothelial cells (HUVECs) supp-
resses NF-.B activation in response to stimuli such as TNF! and LPS by reducing the nuclear accumulation of
p50/p65 heterodimers. To assess the functional sequelae of this phenomenon, we have compared the effects of
A2AAR gene transfer in HUVECs on the accumulation of three important gene products known to be controlled
at least in part by NF-.B; cyclooxygenase-2 (COX-2), E-selectin and vascular cell adhesion molecule-1 (VCAM-
1). Characterisation of COX-2 induction in response to TNF! revealed that while sustained induction (24 hr) was
solely dependent on activation of p38 MAP kinase, earlier time-points at which induction was ﬁrst detectable (8
hr) were also sensitive to inhibition of the NF-.B pathway. At this time–point, A2AAR gene transfer alone was
sufﬁcient to reduce TNF!-stimulated COX-2 induction compared with controls, while no effect of the A2AAR was
detectable at 24 hr. Surprisingly, addition of the A2AAR-selective agonist CGS21680 to A2AAR-expressing H-
UVECs actually reversed the effect seen with receptor alone. Time-course experiments in control cells using
elevated concentrations of the adenylyl cyclase activator forskolin demonstrated that cAMP elevation was sufﬁ-
cient to promote the transient induction of COX-2 even in the absence of TNF!. However, in the presence of
TNF!, exposure to different concentrations of forskolin exerted a biphasic effect, suppressing COX-2 induction at
low concentrations while enhancing it at higher concentrations. These data suggest that the effects of A2AAR
expression with or without agonist on TNF!-mediated COX-2 induction can be accounted for completely by
corresponding changes in cAMP. Comparative analysis with E-selectin revealed that induction of this gene was
more straightforward, being sensitive to NF-.B inhibition alone with no contribution of any other signalling
pathway being detectable. Moreover, while induction was suppressed by A2AAR gene transfer, the suppression
was more pronounced in the presence of CGS21680 and correlated with an ability of cAMP-elevating stimuli to
block TNF!-mediated E-selectin induction in control cells. Interestingly, TNF!-mediated induction of VCAM-1
was unaffected by either A2AAR gene transfer or pre-treatment of control cells with cAMP-elevating agents.
Taken as whole, these data argue that the ability of the A2AAR to modulate the expression patterns of deﬁned
.B-sensitive target genes in HUVECs can be explained completely by the ability of the receptor to couple
positively to adenylyl cyclase and elevate intracellular cAMP levels. They also suggest that the net effects of
A2AAR gene transfer on speciﬁc .B-regulated target genes will vary depending on the nature of their control by
cAMP elevation.
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SpringerExtracellular nucleotides and nucleosides modulate glial cell growth and are important factors involved in inﬂa-
mmation, stroke and progression of tumor cells. It is known that ATP and adenosine induce proliferation in
human astrocytoma cells and that ectonucleotidases play a key role in purinergic signaling regulation. We und-
ertook a comparative study of the degradation of extracellular nucleotides by primary astrocytes cultures and
glioma cell lines. We have previously observed that extracellular ATP and ADP degradation by glioma cell is
lower than by astrocyte cultures. In the present work, we have analyzed the pattern of phosphohydrolysis of
extracellular ATP by HPLC and have characterized the nature of E-NTPDases expression by RT-PCR, quanti-
tative real-time PCR, immunocytochemistry as well as Western blotting analysis in astrocytes and glioma cell
cultures. We noted that astrocytes generate AMP as 50% of the degradation product at 3 h, whereas this nucl-
eotide did not represent more than 5% of extracellular product in the glioma cell lines. Among the nuclosides and
the non-phosphorylated degradation products, normal astrocyte cultures generate twice as much inosine and
hypoxanthine (14 and 15%) when compared to adenosine (7%). Glioma cell lines had almost undetectable levels
of adenosine, generating inosine as the major non-phosphorylated degradation product. By quantitative real-time
PCR, we identiﬁed Entpd2 (CD39L1) as the dominant Entpd gene expressed by rat hippocampal, cortical and
cerebelar astrocytes, while C6 glioma cells exhibit low expression of all NTPDases investigated. The substantial
decreases in ATP and ADP hydrolysis observed in glioma cultures were substantiated by the absence of NTP-
Dase2. ATP is recognized as a mitogenic factor and potentiates the proliferation in human glioma cells. There-
fore, we suggest that reduction of the ATP hydrolysis in glioma cell lines may be part of a process to grant high
progression rates of these tumor cells. We propose that alterations in the ecto-nucleotidase expression may rep-
resent an important mechanism associated with malignant transformation of glioma cells.
Support: NIH grants HL-63972 (Dr. S.C. Robson) and CNPq, FAPERGS (Dr. A.M.O. Battastini)
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Nucleoside triphosphate diphosphohydrolases (NTPDases) are a family of ectonucleotidases that differentially
hydrolyze + and " phosphate groups of extracellular nucleotides. NTPDase1 is the major ecto-nucleotidase at the
luminal surface of blood vessels and hydrolyzes both triphospho- and diphosphonucleosides thereby terminating
platelet aggregation in response to ADP. In contrast, NTPDase2 is a preferential nucleoside triphosphatase in the
adventitia of blood vessels. By converting ATP to ADP, NTPDase2 activates platelet aggregation in the case of
vessel damage.
The enzymatic activity of NTPDase1 depends on cholesterol-rich domains of the membrane which points to a
NTPdase1-dependent protective role of cholesterol in thrombosis. If this is true, given the platelet-activating
action of NTPDase2, cholesterol should exert an opposite effect on this NTPDase. To address this question we
increased the cholesterol content of isolated heart membranes using cholesterol complexed with methyl-"-cycl-
odextrin and measured its effect on ecto-ATPase enzymatic activity. Interestingly, treatment of membranes with
increasing concentrations of cholesterol resulted in a corresponding inhibition of the enzymatic activity of NTP-
dase2.
To obtain further insights into this inhibition, we measured the endogenous cholesterol levels in the heart me-
mbranes. We were surprised by the ﬁnding that the cholesterol content in heart membranes (where NTPdase2 is
enriched) is 10 times lower than the cholesterol amount in placental membranes (where NTPdase1 is enriched). It
is therefore likely that NTPDase2 is localized in cholesterol-poor domains for maintaining a high enzymatic
activity.
A key function of NTPDase2 is to promote platelet plug formation in the case of vessel injury. To examine the
role of cholesterol on NTPDase2-dependent activation of platelet aggregation, we performed platelet aggregation
assays in the presence of heart membranes incubated with cholesterol. High levels of platelet aggregation were
obtained when heart membranes were added to platelets and ATP, which were signiﬁcantly reversed when heart
membranes had been incubated with cholesterol.
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SpringerThe above data raise the possibility that in pathological cases associated with high cholesterol levels, such as
hypercholesterolemia and atherosclerosis, a cholesterol-dependent protective effect against thrombosis is of cr-
ucial importance. Consistent with this view, we found that, similarly to cholesterol, oxysterols and oxidized LDL
exert an inhibitory effect on NTPdase2. Therefore, a concomitant differential control of NTPdase1 and NTPdase2
activities by cholesterol may result in a ﬁne tuning of extracellular nucleotide levels, providing a tight control of
purinergic receptor signaling. Such a regulatory mechanism is expected to apply not only in thromboregulation,
but also in other functions regulated by purinergic receptors where the ﬁne balance of ATP/ADP ratio is of major
importance.
Discovery of new potent, non-nucleotide ligands at human P2Y11-receptors
results in NF546, the ﬁrst non-nucleotide P2Y receptor agonist, and NF340,
the so far most potent and selective P2Y11 antagonist
Sabine Meis, Darunee Hongwiset, and Matthias U. Kassack
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sabine.meis@uni-bonn.de; kassack@uni-bonn.de
P2Y11 receptors are G protein-coupled receptors coupled to both, the phosphoinositide and the cAMP pathway 1.
Up to now, only suramin as a non-selective and low potency compound (pKi = 6.52) and NF157 recently intro-
duced by our group as a more selective and potent ligand (pKi = 7.35) have been described as P2Y11 antagonists 2.
Non-nucleotide agonists at P2Y receptors are not yet available. The aim of this study was to further improve the
potency and selectivity of NF157 and to search for non-nucleotide P2Y11 agonists. A large number of sulfonic and
phosphonic acid derivatives were screened at P2Y11 receptors recombinantly expressed in 1321N1 astrocytoma
cells. Compounds were ﬁrst studied with a previously described microplate-reader based Ca
2+-assay 3. Compo-
unds active in the Ca
2+-assay were then also examined in a cAMP luciferase reporter-gene assay at P2Y11 rece-
ptors and further tested for selectivity at other P2Y-receptors.
The tetrasulfonic acid derivative NF340 was identiﬁed as a competitive antagonist with nanomolar potency (pKi =
7.77) which is 2.6fold more potent than NF157. Concentrations up to 100 2M showed no effects at other P2Y
receptors (P2Y1, P2Y2, and P2Y6, recombinantly expressed in 1321N1 astrocytoma cells). Schild analysis with
ATP+S as agonist gave a slope not signiﬁcantly different from unity. The pA2 value was estimated as 8.07. The
screening also identiﬁed the ﬁrst non-nucleotide agonist at P2Y receptors. The tetraphosphonic acid derivative
NF546 showed almost the same intrinsic activity (95%) at P2Y11 receptors as the standard agonist ATP+S in both
assays, Ca
2+ and cAMP. An EC50 of 542 nM was obtained in the Ca
2+-assay. Schild analyses with NF546 as
agonist and NF157 or NF340 as antagonists were performed. The slopes of both Schild plots were not signiﬁcantly
different from unity, and the pA2 values of NF157 and NF340 using NF546 as agonist showed no difference from
the results using ATP+S as agonist: NF157 / NF546: pA2 = 7.66; NF157 / ATP+S: pA2 = 7.77; NF340 / NF546: pA2
= 8.00; NF340 / ATP+S: pA2 = 8.06. NF546 showed no effect at other P2Y receptors up to 10 2M.
In conclusion, NF340 was identiﬁed as a selective, non-nucleotide antagonist at P2Y11 receptors with improved
potency over the recently described NF157. NF546 is the ﬁrst non-nucleotide P2Y agonist and selective for P2Y11
receptors. Both compounds may serve as useful tools in studying the physiological role of P2Y11 receptors.
(1) Communi, D.; Govaerts, C.; Parmentier, M.; Boeynaems, J. M. J.Biol.Chem. 1997, 272, 31969-31973.
(2) Ullmann, H.; Meis, S.; Hongwiset, D.; Marzian, C.; Wiese, M.; Nickel, P.; Communi, D.; Boeynaems, J. M.;
Wolf, C.; Hausmann, R.; Schmalzing, G.; Kassack, M. U. J.Med.Chem. 2005, 48, 7040-7048.
(3) Kassack, M. U.; Hofgen, B.; Lehmann, J.; Eckstein, N.; Quillan, J. M.; Sadee, W. J.Biomol.Screening. 2002, 7,
233- 246.
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The P2X7 receptor is a ligand-gated ion channel that mediates a non–selective cation conductance in response to
extracellular ATP. Extended exposure to agonist leads to the formation of a pore permeable to large molecular
weight dyes. P2X7 is expressed in a fairly limited set of cell types, primarily the hematopoietic lineages and glia,
where it is thought to play a role in inﬂammatory process important in human disease states. In monocytes,
macrophages and microglia primed with an inﬂammatory signal P2X7 functions to initiate the post translational
processing and release of leaderless cytokines such as IL-1". Published work in P2X7 knockout mice shows that
the absence of P2X7 activity in vivo can modulate an inﬂammatory response and attenuate the severity of mAb
induced arthritis. In addition, absence of P2X7 attenuates mechanical and thermal hyperalgesia in the Seltzer
model of neuropathic pain and inﬂammatory hypersensitivity in FCA induced inﬂammation.
Our continued interest in the discovery and development of novel analgesic and anti-inﬂammatory therapeutics
has led to the identiﬁcation of multiple series of novel, selective and bioavailable P2X7 receptor antagonists.
Herein, we will disclose the in vitro and in vivo characterization of RN-6189, an early biological lead that inhibits
human P2X7 current in transfected HEK293 cells with an IC50 of 34 T 1.6 nM. In addition, RN-0276189 inhibits
both 20,30-O-(4-benzoylbenzoyl)-adenosine 50-triphosphate (BzATP) dependent pore formation and IL-1" release
in THP-1 cells in the same concentration range. Further property based drug design has led us to identify novel
compounds with improved potency and pharmacokinetic properties that are currently in preclinical evaluation.
Distinct effects of ticlopidine and clopidogrel on vascular ecto-nucleotidases




2 and Se ´vigny J.
1
1Centre de recherche en Rhumatologie et Immunologie, Universite ´ Laval, Ste-Foy, Que ´bec, Canada.
2Biocenter, J.W. Goethe-University, AK Neurochemistry, Frankfurt am Main, Germany.
e-mail: joanna.lecka@crchul.ulaval.ca
Ticlopidine (Tyklid) and clopidogrel (Plavix) are antiaggregatory drugs that irreversibly inhibit P2Y12 receptor
1.
The real active metabolites that reduce platelet activation are produced by the liver after daily administration of
the drugs
2. P2Y12 receptor is activated by extracellular ADP which leads to platelet aggregation. Adenosine, the
product of ADP dephosphorylation, inhibits platelet aggregation via activation of A2a receptors
3. Blood level of
both purine ligands is regulated by ectonucleotidases, mainly NTPDase1 and ecto-50-nucleotidase
4. As both of
these enzymes have an important implication in haemostasis, we examined in vitro whether ticlopidine and clo-
pidogrel could affect their biochemical activities. Concentrations of 30 2M ticlopidine and 10 2M clopidogrel have
been reported in the plasma of treated patients. At this concentration, ticlopidine reduced ATPase and ADPase
activity by 30% while 100 2M of both drugs inhibited 60% of ADP hydrolysis; they had no effect at 10 2M. Since
NTPDase1 is an important inhibitor of platelet aggregation, inhibiting this enzyme would be expected to generate
undesired effects in treated patients. Indeed, the antiagreggatory effect of human NTPDase1 was signiﬁcantly
weaker in the presence of ticlopidine, as seen in platelet aggregation assays. Additionally, ticlopidine (but not
clopidogrel) inhibited rat ecto-50-nucleotidase by 11% at 100 2M and 50% at 1 mM level. Interestingly, the human
ortholog of ecto-50-nucleotidase was insensitive to both drugs. We observed that the inhibition of the vascular
ectonucleotidases by ticlopidine is direct and did not require preincubation. Our data suggest that the action of
ticlopidine in haemostasis is complex and not exclusively antiaggregatory while its analog clopidogrel may be
more suitable for therapeutic use.
1. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.Pharmacol Ther.
2005 Nov;108(2):180-92. Epub 2005 Jun 13. Review.
2. Kam P.C., Nethery C.M. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists),
pharmacology and clinical developments.Anaesthesia. 2003 Jan;58(1):28-35. Review.
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4. Lecka J., Komoszynski M., The role of ecto-purines (e-purines) in regulation of blood pressure, haemostasis
and etiology of atherosclerosis. Progress in Medical Research (2003). Review.
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ENT1 is a well-characterized member of the equilibrative (SLC29) nucleoside transporter family that has an
important role in regulation of adenosine concentrations in the vicinity of extracellular purinergic receptors.
ENT1 has been designated as belonging to the es (equilibrative inhibitor-sensitive) subtype of nucleoside trans-
porters as it is potently inhibited by NBMPR (nitrobenzylmercaptopurine riboside) in the nanomolar range. It has
11 transmembrane helices with a large intracellular loop joining transmembrane domains 6 and 7, a cytoplasmic
N-terminus and and extracellular C-terminus.
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In this study we have used qualitative and quantitative immunological approaches to examine the relative distr-
ibution of rENT1 in the ventricles, atria and SA node of the rat heart. In parallel experiments using RT PCR and
tissue samples prepared from the same rats hENT1mRNA transcripts showed a similar distribution to the tran-
sporter protein. Although little is known about the mechanism of nucleoside transporter regulation, activity of the
transporter can be modulated by activators and inhibitors of protein kinase C and protein kinase A and by the
serine/threonine protein kinase, casein kinase II. Using a bioinformatic approach we have identiﬁed potential
phosphorylation sites in hENT1 that may be important in transporter regulation and expression constructs enc-
oding hENT1 mutants lacking the potential phosphorylation sites have been prepared.
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Purine nucleotides and nucleosides are responsible for modulating gastrointestinal function. Besides the direct
effect of ATP on neuronal P2X receptors, the nucleotide may indirectly control nerve excitability due to the
formation of metabolites. In the myenteric plexus, ATP actions are rapidly terminated by intense ecto-NTPDase 1
(ecto-diphosphohydrolase) activity generating AMP, which is then converted into adenosine by ecto-50-nucleot-
idase. Alternative formation of ADP by ecto-ATPase might be physiologically relevant to restrain acetylcholine
(ACh) release from myenteric motoneurons via P2Y1 purinoceptors activation. The co-existence of inhibitory
P2Y1 and adenosine A1 receptors in the rat myenteric plexus lead us to investigate their role to control [
3H]-ACh
release from stimulated (5 Hz, 200 pulses) cholinergic motoneurons.
The experiments were performed at 37-C on longitudinal muscle-myenteric plexus of rat ileum, superfused with
gased (95% O2 +5 %C O 2) Tyrode"s solution. The release of [
3H]-ACh from myenteric motoneurons loaded with
[
3H]-choline (2.5 2Ci/mL), was induced by electrical ﬁeld stimulation (5 Hz, 200 pulses, 0.5 ms, 60 V) (S1 and S2).
Test drugs were added 15 minutes before S2, and their effects in transmitter release were expressed by the S2/S1
ratios. When we evaluated changes in the effect of tested drugs induced by a modiﬁer, the latter compound was
applied 15 min before starting sample collection and hence it was present during S1 and S2.
Selective blockade of A1- and P2Y1-receptors respectively with 1,3-dipropyl-8-cyclopentyl xanthine (DPCPX, 10
nM) and MRS2179 (300 nM) increased [
3H]-ACh release by 43T12% (n=3) and 27T3% (n=4), respectively. A
reduction of tritium outﬂow was observed by activating adenosine A1 receptors, with R-N
6-phenylisopropyl ad-
enosine (R-PIA, 300 nM, j36T4%, n=4), or P2Y1 purinoceptors, with ADP"S (30 2M, j27T3%, n=4). The
inhibitory action of ADP"S (30 2M) was blocked by MRS2179 (300 nM), but the P2Y1-receptor antagonist was
devoid of effect on R-PIA (300 nM) inhibition. On the contrary, DPCPX (10 nM) attenuated inhibition by R-PIA
(300 nM), while signiﬁcantly enhancing (to 42T5%, n=4) ADP"S (30 2M)-induced depression. While ADP"S (30
2M) failed to modify the action of R-PIA (300 nM), activation of adenosine A1 receptors occluded the inhibitory
effect of ADP"S (30 2M).
We provided evidence showing that adenosine exerts a ﬁne-tuning control of tonic ACh release inhibition med-
iated by released adenine nucleotides at the myenteric synapse. The results indicate that over stimulation of
inhibitory P2Y1 purinoceptors is cut-short by sequential activation of inhibitory A1 receptors by endogenously
generated adenosine.
Work supported by FCT (POCTI/45549/FCB/2002, participation of FEDER funding).
EARLY AND TRANSIENT ALTERATION OF ADENOSINE A2A
RECEPTOR SIGNALLING IN A MOUSE MODEL OF HUNTINGTON
DISEASE
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Huntington Disease (HD) is a dominantly-inherited neurodegenerative disorder featuring progressive worsening
chorea, psychiatric disturbances and cognitive impairment due to brain cell loss. A2A receptors expressed on
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SpringerGABAergic striatal neurons have been suggested to play a pathogenetic role. Previous data demonstrated the
presence of an aberrant alteration of A2A receptor-dependent adenylyl cyclase in an in vitro model of the disease
(striatal cells expressing mutant huntingtin) and in peripheral circulating cells of HD patients, suggesting that the
aberrant A2A receptor phenotype may represent a novel potential biomarker of HD. Despite evidence suggesting
a facilitatory role of A2A receptors in neuronal death, a direct correlation between the peripheral A2A receptor
change in HD subjects and the status of this receptor in HD brain is still lacking. One of the best characterized
animal models of HD is represented by the R6/2 mice. We thus investigated in this model the presence, expre-
ssion and functionality of striatal A2A receptors at different developmental stages in comparison with age-matc-
hed wild type animals. A transient increase in A2A receptor density (Bmax) with no changes in afﬁnity (KD)a n d
A2A receptor-dependent cAMP production at early presymptomatic ages (7-14 postnatal days) was found. The
increase of A2A receptor-mediated adenylyl cyclase responsiveness in R6/2 mice was even more marked, as
demonstrated by an EC50 value of the A2A receptor agonist CGS 21680 ten fold lower with respect to corresp-
onding EC50 value in wild type mice (175T23 nM, with respect to 1922T197 nM). Both alterations normalized to
control values starting from postnatal day 21. In contrast, A2Areceptor mRNA, as detected by real time PCR,
dramatically decreased starting from PND21 until late symptomatic stages (12 weeks of age). The discrepancy
between A2A receptor expression and density suggests compensatory mechanisms. These data, reproducing ex
vivo the previous observations in vitro, support the hypothesis that an alteration of A2A receptor signalling is
present in HD and might represent an interesting target for neuroprotective therapies.
Sponsored by the Italian Ministry of Health (progetto ‘‘Ruolo del recettore A2A dell"adenosina e metabotropici
del glutammato nelle demenze da neurodegenerazione striatale’’, Alz4) and by the Hereditary Disease
Foundation.
Ecto-50nucleotidase (CD73) activity and expression in the rat ileum
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INTRODUCTION: Ecto-50nucleotidase (CD73) is a purine salvage enzyme located on the external surface of
plasma membrane in many cell types. CD73 is responsible for adenosine formation from AMP and has a regul-
atory role in neurotransmitter release, functions to control blood ﬂow and may play a role in antiinﬂammatory
responses
1-3. Concerning the intestinal tract, expression of CD73 has been demonstrated in human duodenal
mucosa, intestinal epithelial cells and in the longitudinal muscle strips of guinea pig ileum
1,4.
AIMS: The purpose of the present study was to evaluate the metabolism of exogenous AMP by rat ileum strips
(ISs) and the role of CD73 in the production of extracellular adenosine (ADO) in the intestine. Expression of
CD73 in ileum smooth muscle cells (ISMCs) was also examined.
METHODS: Rat ISs were incubated in vitro in 2 ml of Tyrode solution with exogenous AMP (50 2M) for 5 or 60
minutes and 1 ml of the medium was used for the determination of AMP, ADO, inosine and IMP by HPLC.
ISMCs were prepared according to the method of Khan
5 and the presence of CD73 was detected by confocal
ﬂuorescent microscopy using anti-CD73 antibody.
RESULTS: AMP added to the incubation medium was metabolised by 82% and 100% within 5 and 60 min,
respectively. Treatment with !," methylene-ADP (AOPCP, 200 2M), a CD73 inhibitor, allowed the recovery of
endogenous AMP and IMP (at 5 min 0.2T0.08 and 0.8T0.2 2M, respectively, and at 60 min 0.5T0.1 and 2.2T0.32M,
respectively). AOPCP also reduced the clearance of exogenous AMP, whose concentrations at 5 and 60 min rose
to 18.7T1.8 and 4.4T0.9 2M, respectively. The addition of AMP caused a marked increase in ADO concentration
in the medium. This increase was inhibited by AOPCP, indicating that the nucleoside is rapidly formed from
AMP. Inosine showed the same trend as ADO, in accordance with the high activity of intestinal ecto-ADA
6.
Addition of AMP in AOPCP-pretreated samples did not signiﬁcantly modify IMP levels, showing that the con-
tribution of AMP deaminase to exogenous AMP metabolism is irrelevant. Immunocytochemical analysis demo-
nstrated the high expression of CD73 on the surface of ISMCs.
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sine. Its expression on ISMCs, shown here for the ﬁrst time, points out the possible key role in the control of
intestinal motility. This is the ﬁrst step in the development of further studies aimed to understand how CD73
expression can be affected by drugs and by pathological conditions.
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Sites of inﬂammation are characterized by signiﬁcant shifts in metabolic activity1. Shifts in energy supply and
demand can result in diminished delivery and/or availability of oxygen, leading to inﬂammation-associated tissue
hypoxia and metabolic acidosis. These shifts in tissue metabolism, as indicated by previous studies, are frequently
associated with vasculitis and profound recruitment of inﬂammatory cell types, particularly myeloid cells such as
neutrophils (PMN) and monocytes. Under such conditions, we and others have observed activation of the global
hypoxia regulatory transcription factor hypoxia-inducible factor (HIF). A signiﬁcant HIF target gene during
mucosal inﬂammatory disease (e.g. inﬂammatory bowel disease, colitis) is CD732. Previous studies have deter-
mined that CD73 is regulated by HIF at the gene promoter level3. Since tissue proﬁling studies revealed highest
expression of CD73 in mucosal tissues, particularly the intestine4, we have addressed the role of CD73 in model
inﬂammatory disease in vitro and in vivo. Studies using intestinal epithelial cells have revealed that high expre-
ssion of CD73 is protective for a number of epithelial properties (e.g. barrier function, ion transport), likely
through generation of adenosine at the epithelial apical surface. Inﬂammatory studies in mice conditionally lac-
king the alpha subunit of HIF-1 in intestinal epithelial cells have shown that the loss of functional HIF-1 corre-
lates with decreased expression of CD73 and enhanced inﬂammatory disease in these mice. More recent studies
have addressed the role of CD73 colitic disease progression. These ongoing studies have revealed that the ind-
uction of colitis increases epithelial expression of CD73 mRNA and activity during the acute phase colitic disease.
Studies utilizing Cd73-null mice4 have revealed that relative that the loss of CD73 correlated with more severe
clinical symptoms of colitis (weight loss, colon length), and increased levels of inﬂammatory markers (neutrophil
numbers). Mechanisms of increased susceptibility with decreased CD73 will be discussed. Taken together, these
studies provide unique insight into tissue microenvironmental changes during model inﬂammatory disease and
identify CD73 as a critical control point during mucosal insult.
References:
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2005;4:256-258.
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The P2X7 receptor is expressed on most cells of the immune system including T lymphocytes. On these cells,
P2X7 expression can be modulated depending on cell activation. Allelic polymorphism of P2X7 such as the P451L
natural mutation in the mouse also affects its expression on the surface of naive T cells. In both wild type and
451L mutant





cells compared to naı ¨ve CD25
- T cells. Overexpression of P2RX7 may thus represent another marker of Tregs in
both mouse and man. Consistently, Tregs are more prone to apoptosis induced by exposure to ATP or the P2RX7
agonist bzATP. In the mouse, P2RX7 activation can also be induced by ART2 mediated ADP-ribosylation
2.I n
C57Bl/6 mice which harbour the 451L mutant but have a high density of ART2 on their surface, ART2 substrate,
NAD
+, induces the death of CD4
+ CD25
+ T cells but not that of CD4
+CD25
- cells. By contrast, Tregs from
BALB/c mice, which harbour the 451P wild type P2RX7 but a very low density of ART2, are resistant to NAD
induced cell death but not to ATP induced cell death. Results suggest that ATP also plays a new role as a danger
signal in the immune system. ATP released during inﬂammation and infection may contribute to the induction of
the adaptative immune response by inducing the death of suppressive regulatory T cells.
Supported by grants from the Ministe `re de la Recherche, Ligue Nationale contre le cancer, Association pour la
recherche sur le cancer.
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for nucleotide hydrolysis by platelets from rats: Kinetic characterization and
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Platelets are known to play a major role in the maintenance of endothelial integrity and hemostasis
1. ADP acts to
potentiate platelet aggregation
2. ATP has been considered as a competitive inhibitor or ADP-induced platelet
aggregation
3. The action of nucleotides is terminated by a surface-located enzyme cascade that sequentially de-
grades nucleoside 50-di and 50-triphosphates to their respective nucleosides
4. Since nucleotides exert different
responses in diverse tissues, it is norteworthy that cells can co-express two or more enzymes for nucleotide
hydrolysis. As earlier described
5, two enzymes are present on the ecto-surface of intact platelets: ecto-nucleoside
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Springertriphosphate diphosphohydrolase (E-NTPDase) and ecto-50-nucleotidase. In this study, we describe an ecto-nu-
cleotide pyrophosphatase/phosphodiesterase (E-NPP) activity in rat platelets. Using p-nitrophenyl 50-thymidine
monophosphate (p-Nph-50-TMP) as a substrate, we demonstrate an enzyme activity that shares the major bioc-
hemical properties described for E-NPPs: alkaline pH and divalent cation dependence, and blockade of activity by
metal ion chelator. KM and Vmax values for p-Nph-50-TMP hydrolysis were found to be 106 T 18 mM and 3.44 T
0.18 nmol p-nitrophenol/min/mg (meanTSD, n=5). We hypothesize that an E-NPP is co-localized with an E-
NTPDase and an ecto-50-nucleotidase on the platelet surface. Thus, 0.25mM suramin inhibited p-Nph-50-TMP,
ATP and ADP hydrolysis, while 0.5mM AMP decreased only p-Nph-50-TMP hydrolysis. Besides, 5.0, 10 and
20mM sodium azide just inhibited ATP and ADP hydrolysis. Angiotensin II (5.0 and 10nM) affected only ADP
hydrolysis. Gadolinium chloride (0.2 and 0.5mM) strongly inhibited the ATP and ADP hydrolysis. The set of
results presented here reinforces our hypothesis of the possible co-localization of E-NTPDase and E-NPP acti-
vities that, together with and ecto-50-nucleotidase could constitute a multienzymatic complex for the complete
nucleotide hydrolysis in the ecto-surface of intact rat platelets. The enormous tissue distribution of the members
of the E-NTPDase and E-NPP families make it difﬁcult to assign speciﬁc functions to these enzymes in individual
tissues
4. However, since these enzymes present different kinetic properties, they can act under distinct physiol-
ogical conditions and can be differently regulated. By converting ADP, released from aggregated platelets to
AMP, E-NTPDase may play an important role in the prevention of microthrombus formation
5. In addition,
phosphodiesterases may act as ‘‘guard dogs’’ to prevent subversion of the cell by destroying incoming DNA or
RNA
6. The E-NPP described here represents a novel insight into the control of platelet purinergic signaling.
1. Birk, A.V.; Bubman, D.; Broekman, M.J.; Robertson, H.D., Drosopoulos, J.H.; Marcus, A.J.; Szeto, H.H. J
Lab. Clin. Med. 2002,139, 116.
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Achondroplasia (dwarﬁsm) is a genetic pathology due to a mutation in the gene that encodes for the ﬁbroblast
growth factor type 3 receptor in cartilage cells, the chondrocytes. Studies carried out in different populations have
demonstrated that the most common mutation in achondroplasia is Gly380Arg position in the receptor transm-
embrane domain. This mutation produces a sustained activation of the receptor altering the normal equilibrium
between proliferation and maturation therefore inhibiting normal growth of the bone (L"Hote et Knowles., 2005).
Rat chondrocytes which have been transfected with the wild type form of human FGFR3 receptor and with the
mutated type form, were used to analyse in depth the intracellular signal transduction pathways triggered by over-
activated FGFR3. In this sense we have conﬁrmed the induction of mitogen-activated protein kinases (MAP
kinases) cascade. This pathway seems to be involved in alteration of chondrocyte differentiation process. Addi-
tionally this pathway elicits a lower synthesis of the extracellular matrix inhibiting bone growth (Yasoda et al.,
2004).
Therefore a good aproache for the treatment of achondroplasia could be focused to limit the activity of the MAP
kinase cascade, which is overstimulated by mutated FGFR3.
In order to modify the MAP kinase activity and taking into account that previously we have observed the pres-
ence of P2 receptors in achondroplasic chondrocytes, we have examined the effect of different dinucleotides and
nucleotides on MAP kinase activation.
Diadenosine triphosphate, Ap3A and diadenosine pentaphosphate Ap5A did not modify phosphorylation of MAP
kinase in achondroplasic chondrocytes. In contrast, diadenosine tetraphosphate, Ap4A reduced phosphorylation
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synthetic, increased or did not modify the levels of phosphorylated MAP kinase. This fact opens a new perspe-
ctive inviting to consider Ap4A as a new therapeutic target for the treatment of achondroplasia.
L"Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell
Res 2005; 304(2):417-31.
Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, et al. Overexpression of CNP in chondrocytes
rescues achondroplasia through a MAPK-dependent pathway. Nat Med 2004; 10(1):80-6.
This work has been supported by a research grant from la Comunidad de Madrid CAM GR/SAL/057372004,
Fundacio ´nLo ´pez Hidalgo and Fundacio ´n ICO.
EFFECT OF THE NEUROLEPTIC Chlorpromazine ON THE
NUCLEOTIDE AND PHOSPHOLIPID METABOLISM IN HUMAN
LYMPHOCYTES.
Gergely Keszler, Rita Su ¨meg, Tanjana Spasokoukotskaja, Lynette D. Fairbanks,+ Annamaria Stenger*,
H. Anne Simmonds+ and Maria Staub**
Semmelweis University, Medical Faculty, Department of Medical Chemistry, Molecular Biology and Pathobio-
chemistry 1444-Budapest, POB 260, Hungary
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Kingdom.
Chlorpromazine (CPZ) the amphiphilic amine, widely used as neuroleptic drug, decreased the ATP concentration
by 30% in human lymphocytes, at relatively low concentration (30 2M) and short incubation time (60 min)
without inﬂuencing the GTP, UTP and CTP concentrations. CPZ had the most pronounced effect on the nucle-
otide containing phospholipid precursors of the cells. At the same conditions, CDP-ethanolamine (CDP-EA)
decreased from 87 to 75 pmol/million cells, while CDP-choline (CDP-Ch) from 12 to 0 pmol/million cells during
incubation with 30 2M CPZ for 60 minutes. The effect of the anti-leukemic drug, arabinosyl-cytosine (araC) was
also measured on the phospholipid precursor concentration, as it has been shown, deoxycytidine (dCyt) and its
analogue araC can be also metabolized into the the phospholipids. AraC (50 nM) only slightly decreased the
CDP-EA (from 87 to 85 pmol) concentration, while it doubled the CDP-Ch concentration (12 to 25 pmol) of the
cells during 60 min incubation. The incorporation of labeled dCyt into dCDP-EA and dCDP-Ch were both
inhibited by CPZ, while araC increased the labeling of dCDP-EA and slightly enhanced it in dCDP-Ch.
The inositol-phospholipid pathway can only be labelled from extracellular dCyt, if its turnover was inhibited by
CPZ. Labelled dCyt appeared in dCDP-DAG only in the presence of CPZ, while its incorporation into DNA
decreased.
Similar effect of CPZ on the phospholipid biosynthesis were found in Y79 neuroblastoma cell lines to that,
measured in lymphocytes. Thus low concentrations of CPZ inhibited at many places the membrane phospholipid
synthesis, which might be its primary effect on neural functions.
Effect of adenosine receptor activation on lipopolysaccharide (LPS)-evoked
cytokine production in BV-2 microglia cells
Bala ´zs Koscso ´, Zsolt Selmeczy, E. Sylvester Vizi, Gyo ¨rgy Hasko ´
Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest,
Hungary
koscso@koki.hu
Microglia, the intrinsic macrophages of the central nervous system, are normally quiescent, but rapidly respond to
various kinds of noxious stimuli and these responses are relatively uniform irrespective of the noxius agent. One
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Springerof these noxious agents is bacterial LPS, which induces elaboration of a wide array of proinﬂammatory mediators
including cytokines and free radicals, as well as modulating the expression of cell surface markers. Although the
sequence of intracellular events during microglial activation in response to LPS has been well deﬁned, we have
relatively little knowledge about the extracellular signals which affect the inﬂammatory processes of microglia.
Adenosine is an endogenous purine nucleoside interacting with speciﬁc G protein-coupled receptors (A1,A 2A,
A2B, and A3), and is well recognized as an effective modulator of the immune system. In this study, we investi-
gated whether adenosine receptors regulate production of the proinﬂammatory cytokine TNF-! in the BV-2
murine microglial cell line. BV-2 cells were treated with increasing concentrations of different adenosine receptor
agonists (N
6-benzyl 50-N-ethylcarboxamidoadenosine (NECA), a non-selective adenosine receptor agonist; 2-ch-
loro-N6-cyclopentyl-adenosine (CCPA), an A1 receptor agonist; CGS-21680, an A2A receptor agonist; and N
6-(3-
iodobenzyl)-adenosine-50-N-methyluronamide (IB-MECA), an A3 receptor agonist) 30 minutes before addition
of 10 2g/ml LPS. 24 h later, the supernatants were collected and analyzed for TNF-! content using ELISA. Our
results showed that pretreatment with adenosine receptor agonists decreased LPS-induced TNF-! production in
BV-2 cells in the following order of potency: IB-MECAQCCPA>NECA>CGS-21680, indicating a primary role
for A3 receptors. Next, the cells were pretreated with various selective adenosine receptor antagonists (8-cyclo-
pentyl-1,3-dipropylxanthine (DPCPX), A1 antagonist; 4-(2-[7-amino-2-(2-furyl)[1,2,4] triazolo [2,3-a] [1,3,5] tria-
zin-5-ylamino]ethyl)phenol (ZM241385), an A2A antagonist; benzo[g]pteridine-2,4(1H,3H)-dione isoalloxazine
(alloxazine), an A2B receptor antagonist; and 5-propyl-2-ethyl-4-propyl-3-(ethylsulfanylcarbonyl)-6-phenylpyri-
dine-5-carboxylate (MRS-1523), an A3 receptor antagonist) before treatment with CCPA or IB-MECA. MRS-
1523, but not other antagonists, reversed the suppressive effects of both IB-MECA and CCPA on LPS-induced
TNF-! production. These results demonstrate that A3 receptor stimulation suppresses TNF-! production by BV-2
microglia. Thus, adenosine may be an important endogenous anti-inﬂammatory mediator in the brain.
Effect of low frequency electromagnetic ﬁelds on A2A and A3 adenosine
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The present study was designed to evaluate the binding and functional characterization of A2A and A3 adenosine
receptors in human neutrophils exposed to low frequency, low energy, pulsing electromagnetic ﬁelds (PEMFs).
Saturation binding experiments on A2A and A3 adenosine receptors revealed a single class of binding sites with
similar afﬁnity in control and in PEMF-treated human neutrophils (KD=1.05T0.10 and 1.08T0.12 nM for A2A
receptors and KD=2.36T0.16 and 2.45T0.15 nM for A3 receptors, respectively). PEMFs treatment revealed that the
A2A and A3 receptor density was statistically increased (Bmax=126T10 and 215T15* fmol/mg protein and Bma-
x=451T18 and 736T25* fmol/mg protein, respectively,*, P<0.01). In the adenylyl cyclase assays the A2A agonists,
HE-NECA and NECA increased cAMP accumulation in untreated human neutrophils with an EC50 value of 43
(40-47) and 255 (228-284) nM, respectively. The capability of the same compounds to stimulate cAMP levels in
PEMF treated human neutrophils was increased with an EC50 value of 10 (8-13)* and 61 (52-71)* nM, respecti-
vely, *, P<0.01. In the superoxide anion production assays examined agonists inhibited the generation of O2
- in
untreated human neutrophils with an EC50 value of 3.6 (3.1-4.2) and of 23 (20-27) nM, respectively. In PEMF
treated human neutrophils, the same compounds show an EC50 value of 1.6 (1.2-2.1)* and of 6.0 (4.7-7.5)* nM,
respectively, *, P<0.01. Similarly, typical A3 agonists such as Cl-IB-MECA and IB-MECA were able to inhibit
cyclic AMP accumulation and superoxide anion production. The potencies of Cl-IB-MECA and IB-MECA were
statistically increased after exposure to PEMFs. These data indicate in human neutrophils treated with PEMFs
the presence of signiﬁcant alterations in the A2A and A3 adenosine receptor density and functionality. In sum-
mary, these results should serve as an impetus for further investigation of the pharmacological changes in the
adenosine receptors and PEMF treatment. From a clinical point of view a clariﬁcation of the potential effects of
PEMFs facilitate the development of alternative treatments or the elaboration of novel promising therapeutic
tools.
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Background: Through the activation of P2-receptors, extracellular nucleotides regulate a variety of biological
functions. Concentrations of extracellular nucleotides are modulated by ectonucleotidases such as by members of
the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) and ecto-nucleotide pyrophosphatases/pho-
sphodiesterases (E-NPPs) families. These enzymes hydrolyze the terminal phosphate residue of tri- and/or dip-
hosphonucleosides, and, in concert with ecto-50-nucleotidase, facilitates the formation of adenosine
1. Four
different NTPDases, bound to plasma membrane, appears important in the control of nucleotide concentration,
namely NTPDase1 (CD39), NTPDase2, 3 and 8.
2 Also, NPP1 and NPP3 could be involved in the control of
extracellular nucleotides concentrations.
1 The lack of speciﬁc inhibitors for these enzymes impedes the research
on their functions. It has already been reported that several P2 receptor antagonists such as Reactive Blue-2 (RB-
2) and suramin also inhibit ecto-nucleotidases.
3 In this study, we investigated the effect of several P2-receptor
antagonists (suramin, NF279, NF449, RB-2 and MRS2179) on the activity of human NTPDases 1, 2, 3 and 8 and
human NPP1 and NPP3. Methods: Recombinant human NTPDases and NPPs were produced by transfecting
COS-7 or HEK 293T cells with an expression vector encoding each of these enzymes. The inhibition of NTPDase
activity (ATP and ADP hydrolysis) was measured by the quantiﬁcation of released phosphate (Pi). The inhibition
NPPs activity (pnp-TMP hydrolysis) was measured by the quantiﬁcation of para-nitrophenol produce using a
colorimetric assay. Results: Most NTPDases were inhibited by the P2-receptor antagonists tested. Broad range
antagonists RB-2 (100 2M) blocked all NTPDases activity by over 87% while suramin (100 2M) inhibited mainly
NTPDases 2 and 3 to 51T2% and 66T5% respectively. RB-2 completely inhibited human NPP1 and decreased
activity of human NPP3 by about 40% while suramin inhibited these enzymes by 70T2% and 8T3%, respectively.
More speciﬁc antagonists like suramin derivative NF279 (P2X1,P 2 X 7), NF449 (P2X1) blocked NTPDases 1 to 3
by over 70% at concentration of 100 2M while MRS2179 (P2Y1) only affected human NTPDase3 by about 50%.
Interestingly, NTPDase3 could be blocked by NF279 and NF449 at lower concentrations with EC50 of 0,1 and 5
2M respectively. All these speciﬁc antagonists blocked human NPP1 activity by over 75% while they had minimal
effect on human NPP3 (<15%). These data on P2-receptor antagonists are relevant for the interpretation of
pharmacological experiments with these molecules. Some of these P2 receptor antagonists may also be used as
inhibitors of ecto-nucleotidases and even discriminate between NTPDase3 activity and the other ecto-nucleoti-
dases.
(1) Zimmermann, H. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 362, 299-309.
(2) Kukulski, F.; Le ´vesque S.A.; Lavoie E.G.; Lecka, J.; Bigonnesse F.; Knowles, A.F.; Robson, S.C.; Kirley, T.L.;
Se ´vigny, J. Purinergic Signalling, 2005, 1, 193-204.
(3) Gendron, F-P; Benrezzak, O.; Krugh, B.W.; Kong Q.; Weisman, G.A.;Beaudoin, A.R. Current Drug Target,
2005, 3, 229-245.
Effect of Sulphate-Reducing Bacteria Infection on ATP-induced Apoptosis of
Human Intestinal Epithelial Cells.
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Sulphate-reducing bacteria (SRB) are a group of anaerobic organisms involved in the reduction of sulphate to
sulphide and are present in the majority of natural environments, plants, animals and humans. SRB were found
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Springercolonizing the human gut and have been associated with the development of ulcerative colitis, a kind of chronic
inﬂammatory bowel disease (IBD). Recently, it was shown that nucleoside-nucleotide free diet protects rat col-
onic mucosa from damage in a model of IBD. It was also shown that P2X and P2Y subtype receptors can be
positively modulated in smooth muscle and immune cells, respectively, on human IBD. Here, we evaluated if the
interaction of SRB with human intestinal epithelial cells can interfere with ATP-induced apoptosis on these cells.
Material and Methods: a subconﬂuent culture of HCT8 human intestinal epithelial cells (10
6 total cells) was
infected or not with pure SRB strain Desulfovibrio indonensiensis (ﬁnal concentration of 10
6 cells.ml
-1) and, after
24 h of infection, the cells were washed and treated with 2mM of ATP for 12 to 48 h. The attached cells were then
released from the wells with PBS/EDTA and recovered in Falcon tubes, washed and centrifuged for 7 min at 250g.
The cells were ﬁnally resuspended in apoptosis buffer containing 0.1% sodium citrate, 0.1% Triton X-100 and 5 g/
ml of propidium iodate. The DNA content of the acquired cells (10.000 cells per tube) was analyzed using a
FACScan Becton Dickinson ﬂow cytometry. SRB-infected and control epithelial cells were processed for scan-
ning electron microscopy analysis.
Results: we observed that both ATP and SRB induced speciﬁc apoptosis on 11 T 2 % and 6 T 1 % of HCT8 cells,
respectively. When SRB were led to infect the cells followed by ATP treatment, we observed stimulatory effect
on ATP-induced apoptosis growing up to 19 T2 % of cells. In addition, scanning electron microscopy analyses
showed that SBR were found attached to the surface of the epithelial cells. It was also observed signiﬁcant
differences on the morphological pattern of the infected epithelial cells, especially increased number of microvilla
projecting from their plasma membranes.
Conclusion: Our data suggest that SRB attach and cause apoptosis to intestinal epithelial cells and such bacterial
infection can interfere with P2 receptor signaling of these epithelial cells. We hypothesize that SRB together with
P2 receptor can have a role on the establishment of IBD.
Acknowledgments: CNPq, FAPERJ and PETROBRAS.
Effector-coupling of the A2A adenosine receptor is contingent on the action
of retinoic acid in neuroblastoma cells
Edin Ibrisimovic, Helmut Drobny, Stefan Boehm, Eduard Stefan, Christian Nanoff and
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The A2A-adenosine receptor has been implicated in the pathogenesis of movement disorders, as a drug target it
holds therapeutic potential. We have investigated if SH-SY5Y neuroblastoma cells (SH-cells) which endogenously
express an A2A-receptor and can be differentiated into a neuron-like phenotype may serve as a model for the
regulation of A2A-receptor signalling in nerve cells. We ﬁnd that receptor activation facilitated neurotransmitter
release and that the receptor molecule was targeted to cell extensions reﬂecting previous evidence obtained on
brain slices. An additional ﬁnding in SH-cells was that coupling of the receptor to its prototypical effector ade-
nylyl cyclase is contingent on pre-treatment of cells with all-trans retinoic acid (RA). We have investigated if
changes in the signal transduction complement accounted for the enhanced coupling. Productive receptor-effector
coupling correlated with an increase in catalyst activity but the treatment with RA had a stronger effect on
receptor- (~20-fold) than on forskolin-mediated cAMP formation (~4-fold). The maximum effect occurred one
day after pre-treatment of cells with RA. Both the time course and the regulation pattern consistent with the
presence of type I and V isoforms were suggestive of transcriptional regulation via the RA-receptor. However, we
did not detect alterations in the mRNA level speciﬁc for these and other adenylyl cyclase isoform transcripts in
SH-cells (type I, III, V, VII, IX) nor in the amount of membrane bound adenylyl cyclase type I and type V
protein. In G-protein levels we found a ~20% increase in G!s with no changes in G!i/o or G"+. Nevertheless, the
increase could hardly explain the increment in activity nor the altered regulatory pattern. The A2A-receptor level
was constantly low (~100 fmol/mg) even upon the phenotypic changes induced by treatment with RA. Our
current hypothesis is that RA fortiﬁes coupling by an indirect effect via an autocrine regulatory mechanism. This
is based on the following evidence. RA is known to induce the BDNF receptor trkB in SH-cells and we detected
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SpringerBDNF transcript in SH-cells treated with RA. Conversely, addition of a trkB inhibitor (K252a) during the RA-
dependent maturation interval impaired the effect, i.e. coupling of adenylyl cyclase to the A2A-receptor. This
raises the issue if RA might affect A2A-signalling in the adult brain.
Effects of adenosine receptor agonists and antagonists in WAG/Rij rats, a genetic
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Adenosine exerts anticonvulsant effects in convulsant epilepsies, mainly via inhibitory A1 receptors, whereas the
pharmacological blockade or genetic inactivation of the facilitatory A2A subtypes seems to attenuate convulsions
1.
However, the effects of A1 and A2A receptor activation were not yet evaluated in a particular type of epilepsy
such as absence seizures, characterised by brief interruption of consciousness associated with generalised, sync-
hronous spike-wave discharges (SWDs) in the EEG. Thus, we wanted to test whether the focal bilateral microi-
njection of A1 and A2A selective adenosine receptor agonists and antagonists into thalamic nuclei (nucleus
reticularis thalami, NRT; ventroposterolateral, VPL; ventroposteromedial, VPM) and the peri-oral region of the
somatosensory cortex (S1po), brain areas mainly involved in absence seizure triggering, modiﬁed the number and/
or duration of SWDs in a genetic animal model of absence epilepsy, the WAG/Rij rat. In animals equipped with
fronto-parietal cortical electrodes for EEGraphic recordings and two additional guide cannulae for bilateral focal
microinjection, drugs were focally administered in a volume of 0.5 2l/side
2. We evaluated the effects of drugs
selectively active on A1 (agonist= CCPA; antagonist= DPCPX) and A2A receptors (agonists= CGS21680 and
2HE-NECA; antagonist= SCH58261). Independently of the site of administration, CCPA dose-dependently re-
duced the number of SWDs, while affected their duration differently, i.e. CCPA increased or decreased SWD
duration when microinjected in VPM or VPL, respectively, whereas duration was not signiﬁcantly modiﬁed in the
other areas examined. The A2A agonists had no effects in the VPL, reduced the number and increased SWD
duration in the VPM and S1po, while, in the NRT, they increased SWD number without affecting the duration.
The A1 antagonist dose-dependently reduced the SWD number in all the examined areas, without affecting the
duration, except in NRT, where the duration was signiﬁcantly increased. Similarly, the A2A antagonist signiﬁca-
ntly reduced SWD number in all injected areas, modifying their duration only in NRT (increase) and VPL
(reduction). In conclusion, these results are mostly in agreement with a few previous ﬁndings indicating either a
protective activity by non selective adenosine receptor blockade with theophylline
3 or a pro-convulsive adenos-
ine
4 effect in the same animal model of absence epilepsy. Further studies need to better evaluate whether, in this
kind of epilepsy, is prevailing the pro-convulsant A1-mediated effect, probably related to an increased inhibitory
function in the brain, which plays a signiﬁcant role in the absence seizure pathogenesis, or the pro-convulsant
activity of the excitatory A2A receptors.
1. Ribeiro, J.A., Sebastiao, A.M., de Mendonca, A. Prog. Neurobiol. 2002, 68: 377–392.
2. Russo, E., Constanti, A., Ferreri, G., Citraro, R., De Sarro, G. Neuropharmacology 2004, 4: 865-78.
3. Ates, N, Sahin, D., Ilbany, G. Epilepsy & Behaviour 2004, 5: 645-648.
4. Ilbany, G., Sahin, D., Karson, A., Ates, N. Clin. Exp. Pharmacol. Physiol. 2001, 28: 643-646.
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SpringerObjective: In our previous study, we had demonstrated that adenosine A1 and A2a antagonists prevented hypo-
tension and QRS prolongation in an in-vivo model of rat amitriptyline toxicity
1. The aim of the study was to
investigate the effects of adenosine receptor antagonists on amitriptyline-induced cardiotoxicity in isolated rat
hearts. Methods: A randomized controlled experimental study was performed with hearts of adult male Wistar
rats mounted on a cannula of the Langendorff isolated perfused heart apparatus with constant ﬂow. Left Vent-
ricular Developed Pressure (LVDP), dp/dtmax, QRS duration and Heart Rate (HR) were measured. Two expe-
rimental protocols were performed. The amitriptyline concentration that prolongated the QRS duration more
than 150 % (10
-4 M) was accepted as the control group for the ﬁrst protocol and the concentration that prolon-
gated the QRS duration 50-75 % (10
-4.25 M) was accepted as the control group for the second protocol. In the ﬁrst
protocol, 10
-4 M amitriptyline was infused for 60 minutes following pretreatment with a selective adenosine A1
receptor antagonist, DPCPX (8-cyclopentyl-1,3-Dipropylxanthine,10
-4 to 10
-6 M) or a selective adenosine A2a
receptor antagonist, CSC (8-3-chlorostyryl -caffeine,10
-4 to 10
-6 M). At the second protocol, 10
-4.25 M amitriptyline
was infused for 60 minutes following pretreatment with DPCPX (10
-4 M) or CSC (10
-5 M). Statistical analyses
were performed by Student"s t test for paired data and ANOVA followed by Tukey-Kramer for multiple comp-
arison tests. Results: At the ﬁrst protocol, 10
-4 M amitriptyline infusion following pretreatment with 10
-4 M
DPCPX shortened QRS duration at 50 min. signiﬁcantly when compared to control group (146.7T13.3 % for
DPCPX pretreatment, 275.0T40.3 % for control, p<0.05). Amitriptyline infusion following pretreatment with 10
-4
to 10
-6 M DPCPX or 10
-5 or 10
-6 M CSC did not change LVDP, dp/dtmax and HR when compared to control
(p>0.05). At the second protocol, pretreatment with 10
-4 M DPCPX shortened the QRS duration (122.2T7.0 % at
40 min., p<0.05; 120.8T6.7 % at 50 min., p<0.01;120.8T6.7 % at 60 min., p<0.05). Pretreatment with 10
-5 M CSC
prolongated QRS duration (185.4T20.8 % at 20 min., p<0.05; 187.5T12.5 % at 30 min., p<0.05; 218.8T14.6 % at 60
min., p<0.05). Amitriptyline infusion (10
-4.25 M) following pretreatment with 10
-4 M DPCPX or 10
-5 M CSC did
not change LVDP, dp/dtmax and HR when compared to control (p>0.05). Conclusion: While 10
-4 M DPCPX
shortened QRS prolongation, 10
-5 M CSC prolongated QRS duration in the isolated rat hearts with prolonged
QRS by 50-75 % induced by 10
-4.25 M amitriptyline. However, 10
-4 M DPCPX was not sufﬁcient to shorten QRS
prolongation induced by the higher concentration of amitriptyline(10
-4 M). According to our results, adenosine A1
receptors might have a role in amitriptyline-induced QRS prolongation. Further studies with electrophysiological
effects of adenosine antagonists on action potential for amitriptyline cardiotoxicity is needed to explain the exact
mechanism.
(1) Kalkan, S.; Aygoren, O.; Akgun, A.; Gidener, S.; Guven, H.; Tuncok, Y. J Toxicol Clin Toxicol 2004, 42:945-
954.
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Selective antagonists of adenosine A1 but not A2 receptors produce diuresis and natriuresis (1,2). Non-selective
antagonism of adenosine receptors with 1,3-dipropyl-8-sulfophenylxanthine (DPSPX) induces hypertension (3)
and activation of the renin-angiotensin system (4,5). Angiotensin II induces tubular sodium reabsorption (6). This
study aimed at assessing renal function in DPSPX-hypertensive rats.
DPSPX (90 2g/kg/h; i.p.) was continuously infused from day 0 to day 7 to male Wistar rats (240-270g). Sham-
operated (S; n=6) and DPSPX (PX; n=5)-treated rats were housed in metabolic cages from day -2 to day 14 with
free access to water and rat chow. Intakes were monitored every day. Twenty-four hours urine was daily collected.
Plasma was collected on day 14. Sodium and potassium levels were quantiﬁed with ion-sensitive electrodes. Urea
was measured by an enzymatic test, creatinine by the Jaffe ´ method and total proteins by the biuret reaction.
Systolic blood pressure (SBP) was determined by tail-cuff. Statistical analysis was performed using Student"s t test.
DPSPX increased SBP (S=123.20T1.13 mmHg; PX=147.57T5.83 mmHg; p<0.05). Infusion of DPSPX decreased
food and water intake until day 7 and urinary excretion rate throughout the study (Table). Body weight gain was
similar between S and PX groups. DPSPX-induced hypertension was associated with reduced urinary sodium,
potassium and urea excretion rates (Table). No difference was found in urinary creatinine or protein excretion
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Springerbetween S and PX groups. On day 14, there was no difference in plasma sodium, potassium, urea, creatinine or
protein levels between S and PX groups. Creatinine clearance was similar between S and PX groups. Fraccional
excretion of potassium was lower in DPSPX-hypertensive rats (S=0.6T0.06 %; PX=0.4T0.02 %; p<0.05) while
fraccional excretion of sodium was similar to that of sham-operated rats.
We concluded that DPSPX-induced hypertension is associated with decreased excretion of ﬂuid, electrolyte and
urea. Future studies will clarify the net result of the concomitant antagonism of adenosine receptors with incre-
ased plasma angiotensin II levels on renal function.
(1) Collis, M.G.; Shaw, G.; Keddie, J.R. J. Pharm. Pharmacol. 1991, 43, 138-139.
(2) Suzuki, F.; Shimada, J.; Mizumoto, H.; Karasawa, A.; Kubo, K.; Nonaka, H.; Ishii, A.; Kawakita, T. J. Med.
Chem. 1992, 35, 3066-3075.
(3) Albino-Teixeira, A.; Matias, A.; Polonia, J.; Azevedo, I. J. Hypertens. 1991, 9, S196-S197.
(4) Sousa, T., Morato, M., Albino-Teixeira, A. Eur. J. Pharmacol. 2002, 441, 99-104.
(5) Morato, M., Sousa, T., Guimara ˜es, S., Moura, D., Albino-Teixeira, A. Eur. J. Pharmacol. 2002, 455, 135-141.
(6) Van der Mark, J.; Kline, R.L. Am. J. Physiol. 1994, 266, R739-R748.
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Effects of exogenous cAMP on rat intestinal motility
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INTRODUCTION: In these last few decades it has been proposed that cyclic AMP (cAMP) could be an extra-
cellular mediator, supported by the following facts: in several cell types cAMP was shown to be extruded into
interstitial ﬂuids and to bind to speciﬁc plasma membrane sites. Moreover extracellular cAMP can affect speciﬁc
functions in a variety of cells and tissues
1,2. AIMS: The purpose of the present investigation was to evaluate the
action of exogenous cAMP on the isolated rat ileum and to determine whether any such action is a) affected by
inhibition of tissue phosphodiesterase or ecto-phosphodiesterase or ecto-50nucleotidase activity, b) mediated by
P1 receptors and/or release of endogenous acetylcholine, c) possibly governed by the adrenergic activity.
METHODS: To measure the muscle tension, ileum segments (approximately 2 cm in length, 0.2T0.03 g wet tissue
weight) from Wistar rats (250T50 g b. w.) were mounted vertically in double-jacketed organ baths containing 10
mL of Tyrode solution (NaCl 136 mM, KCl 2.7 mM, CaCl2 1.4 mM, MgCl2 0.46 mM, NaH2PO4 0.32 mM,
NaHCO3 12 mM, glucose 5 mM), maintained at 37-C and continuously aerated with a mixture of 95% O2 and 5%
CO2. Changes in tension were recorded by isometric transducers coupled to a pen recorder, and they were
expressed as a percentage of the maximal response to carbachol (1 2M) measured at the beginning of each
experiment.
RESULTS: Addition of cAMP (0.1 2M to 1 mM) evoked a slight, transient relaxation which, in most cases (90%),
was followed by a marked, concentration-dependent contraction. Contractions began within 30 s after application
to the bath and the peak response was reached within 60 s. cAMP-induced contraction was sustained (over 15
min) and reversible with washing. Repeated administration of 0.5 mM cAMP, followed by washing at 15 min
intervals, did not induce tachyphylaxis. Pretreatments with 3-isobutyl-1-methylxanthine (IBMX, 10 2M), a PDE-
inhibitor, 1,3-dipropyl-8-p-sulfophenylxanthine (DPSPX, 0.1 mM), an ecto-PDE-inhibitor, and !," methylene-
Day 7 Day 13
SHAM DPSPX SHAM DPSPX
Food intake (g) 24.33T0.67 21.8T0.37* 24.0T1.10 20.8T2.75
Water intake (mL) 30.67T1.17 26.6T0.68* 29.3T3.39 29.6T1.36
Uexcretion rate (mL/min) 10.8T0.77 6.8T0.52* 13.0T1.11 7.0T0.65*
UNa
+ (mg/d/‘kg) 5.8T0.14 4.7T0.15* 6.1T.022 3.9T0.70*
UK
+ (mg/d/kg) 4.1T0.24 2.9T0.15* 5.8T0.34 3.3T0.30*
Uurea (g/d/kg) 1.91T0.04 1.52T0.04* 2.10T0.06 1.47T0.12*
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SpringerADP (AOPCP, 0.1 mM), an ecto-50NT-inhibitor, partially attenuated cAMP-induced contractions by 29%, 37%
and 50%, respectively. Pretreatment of the preparations with 8-phenyltheophylline (8-PT, 10 2M), a P1 antago-
nist, or with atropine (1 2M), a muscarinic antagonist, did not signiﬁcantly inﬂuence cAMP effect on ileum
tension. Concentration-dependent contractions induced by cAMP were signiﬁcantly reduced by in vivo treatment
of rats with reserpine, to deplete norepinephrine (NE) stores in nerve terminals.
CONCLUSIONS: These experimental observations suggest that extracellular cAMP may act directly on intestinal
smooth muscle by binding to speciﬁc cell membrane sites
1,3, but degradation products of the cyclic nucleotide are
also involved in its effects on rat ileum, that are controlled by the adrenergic system.
REFERENCES
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2. Ba ¨r, H.P. Adv. Cyclic Nucleotide Res. 1974, 4, 195-237.
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Effects of genetic deletion of adenosine deaminase and A1 receptors in
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Melissa Reichelt*1, Laura Willems*1, Jose G. Molina2, Chun-Xiao Sun2, Janci C. Noble2, Kevin J. Ashton1,
Jurgen Schnermann3, Michael R. Blackburn2, and John P. Headrick1.
*Equal ﬁrst authorship
1Heart Foundation Research Center, Grifﬁth University Southport, QLD 4217, Australia,
2Department of Biochemistry and Molecular Biology, University of Texas Health Science Center
at Houston, Medical School, Houston, TX 77030, USA, and
3National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health,
Bethesda, MD 20892, USA
m.reichelt@grifﬁth.edu.au
Adenosine deaminase (ADA) may be multifunctional,regulating adenosine levels and receptor (AR) agonism
and functionality. We assessed effects of ADA, A1AR, and dualADA/A1AR knockout (KO) on AR-mediated
responses and ischemic tolerance (20-25 min ischemia 45 min reperfusion) in murine hearts. Neither ADA or
A1AR KO modiﬁed basal contractility, though ADA KO reduced resting heart rate (an effect abrogated by
A1AR KO). AR mediated bradycardia and dilation with 2-chloroadenosine was unaltered by ADA KO, and
A1AR KO eliminated bradycardia. Adenosine efﬂux was increased 10- to 20-fold by ADA KO (at the expense of
inosine). Deletion of ADA improved outcome from 25 min ischemia, reducing diastolic pressure (21T4 vs. 38T3
mmHg) and LDH efﬂux (0.12T0.01 vs. 0.21T0.02 U/g/min ischemia), and enhancing pressure development (89T6
vs.6 6 T5 mmHg). Protection was also evident after 20 min ischemia, and mimicked by the ADA inhibitor EHNA
(5 2M). ADA KO enhanced tolerance in A1AR KO hearts, though effects on diastolic function were eliminated.
Absence of ADA does not alter functional sensitivities of cardiovascular A1 or A2ARs, despite enhanced ade-
nosine levels, but enhances ischemic tolerance. Conversely, A1AR KO impairs ischemic tolerance. Effects of
ADA KO on diastolic dysfunction are A1AR-speciﬁc while other ARs contribute to changes in contractile rec-
overy and cell death.
EFFECTS OF THE ADENOSINE RECEPTOR ANTAGONISTS ON
AMITRIPTYLINE-INDUCED VASODILATION IN RAT ISOLATED
AORTA
Kalkan S, Hocaoglu N, Akgun A, Gidener S, Tuncok Y.
Dokuz Eylul University, School of Medicine, Department of Pharmacology, Izmir, Turkey.
sule.kalkan@deu.edu.tr
Background: Although, we had demonstrated that adenosine receptor antagonists prevented hypotension in an in-
vivo rat model of amitriptyline toxicity
1, it was not clear that whether adenosine receptors in heart or in vascul-
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Springerature were dominant. The aim of the study was to investigate the role of adenosine A2a receptors on amitriptyline-
induced vasodilation in rat isolated aorta. Methods: After determining EC80 of noradrenalin (the concentration of
noradrenalin that produces 80% of maximal contractile response) as 10
-5M, IC50 value of amitriptyline was cal-
culated as the drug concentration causing a half-maximal inhibition of contractile responses to noradrenalin (NA)
in rat isolated aorta. In the experimental groups, tissues were ﬁrst contracted with EC80 of NA, then, DPCPX (8-
cyclopentyl-1,3-Dipropylxantine, a selective adenosine A1 antagonist, 10
-9-10
-5 M), CSC (8-(3-chlorostyryl), a
selective A2a antagonist, 10
-9-10
-5 M) or DMSO (dimethyl sulfoxide, a solvent for adenosine antagonists) were
incubated. Following the amitriptyline incubation, NA was administered again. IC50 of amitriptyline was comp-
ared in the presence of the DPCPX, CSC or DMSO. Statistical analysis was done by Student"s t test. Results:
Amitriptyline inhibited 49.9 T 3.7 % contractile response to NA on aorta segments at 1.8 x10
-5M (IC50). DPCPX
increased amitriptyline-induced inhibition on contractile response to NA dose dependently. CSC decreased am-
itriptyline-induced inhibition on contractile response to NA at 10
-5M. DMSO did not change amitriptyline- ind-
uced inhibition on contractile response to NA, signiﬁcantly. Conclusion: Adenosine A2a receptor stimulation
seems to be responsible for amitriptyline-induced vasodilation and hypotension since adenosine A1 antagonist,
DPCPX, increased amitriptyline-induced.
(1) Kalkan, S.; Aygoren, O.; Akgun, A.; Gidener, S.; Guven, H.; Tuncok, Y. J Toxicol Clin Toxicol 2004, 42:945-954.
Effects of the membrane lipid environment on adenosine A1 and A2A receptors
in rat brain striatum
A. Themann, A. C. Schiedel and C. E. Mu ¨ller
Pharmaceutical Sciences Bonn (PSB), Pharmaceutical Chemistry, Institute of Pharmacy, University of Bonn,
Kreuzbergweg 26, 53115 Bonn, Germany
andrea.themann@uni-bonn.de
Lipid rafts are plasma membrane microdomains rich in cholesterol and sphingolipids, which provide a particularly
ordered lipid environment. They play a central role in many cellular processes, including membrane sorting and
trafﬁcking, cell polarization, and signal transduction processes. Certain G protein-coupled receptors (GPCRs) and
associated molecules were shown to be enriched in cholesterol-rich microdomains which may act as signalling
platforms [1]. The family of adenosine receptors, which are GPCRs, consists of four subtypes designated A1,A 2A,
A2B and A3. Adenosine A1 and A2A receptors are expressed in high density in the striatum (caudate-putamen).
Striatal A2A receptors have been identiﬁed as novel targets for the treatment of Parkinson"s disease and related
motoric disorders (A2A antagonists) and for schizophrenia (A2A agonists) [2,3]. Lipid rafts were described as
detergent-insoluble membranes (DRMs) that can be isolated by sucrose-gradient centrifugation after treatment of
membranes with the detergent Triton X-100 at 4-C [4]. When striatal membranes were subjected to 0.4 % Triton
X-100 followed by sucrose-gradient centrifugation, we found that A1 and A2A receptors were highly enriched in
DRMs as shown by radioligand binding studies using the A1 agonist radioligand [
3H]CCPA, and the A2A agonist
radioligand [
3H]CGS21680, respectively. However, we could also demonstrate that DRMs are detergent-induced
artefacts, which are not representative of the structures in an intact cell membrane.
To examine the modulatory role of cholesterol on ligand binding and G-protein coupling of adenosine A1 and
A2A receptors, cholesterol was depleted from rat brain striatal membranes using methyl-"-cyclodextrin (M"CD)
[5]. Saturation binding experiments with the A1 agonist [
3H]CCPA, the A1 antagonist [
3H]DPCPX, the A2A
agonist [
3H]CGS21680 and the A2A antagonist [
3H]ZM241385 were performed at native and cholesterol-depleted
membranes. Cholesterol depletion signiﬁcantly altered the afﬁnity of A1 (increase) and A2A agonists (decrease)
without affecting antagonist afﬁnities. In addition, it reduced the number of receptors (Bmax values) recognized by
agonists and antagonists. Furthermore, [
35S]GTP+S binding assays were performed to assess receptor function.
Our data provide evidence that the cholesterol content inﬂuences the interaction of ligands with the highly
expressed adenosine A1 and A2A receptors in rat brain striatum. These results may have relevance for statin-
treated patients, and in Alzheimer"s disease where enhanced cholesterol levels have been observed.
[1] Ostrom, R.S.; Insel, P.A. Br. J. Pharmacol. 2004, 143, 235-245.
[2] Mu ¨ller, C.E. Drugs of the Future 2000, 25, 1043-1052.
[3] Yan, L.; Burbiel J.C.; Maass, A.; Mu ¨ller, C.E. Expert Opin. Emerg. Drugs 2003, 8, 537-576.
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Springer[4] Monastyrskaya, K.; Hostettler A.; Buergi, S.; Draeger A. J. Biol. Chem. 2005, 280, 7135-7146.
[5] Pucadyil, T.J.; Chattopadhyay A. Biochim. Biophys. Acta 2004, 1663, 188-200.
Electrophysiological characterization of aminoglycoside antibiotics effects on the
P2X2 receptor and a P2X2/P2X1 receptor chimera after heterologous expression
in Xenopus oocytes
Eva-Verena Bongartz and Ju ¨rgen Rettinger
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P2X receptors are cation-selective ligand-gated ion channels that open upon extracellular binding of ATP. Am-
inoglycoside antibiotics work by binding to the 30S ribosomal subunit of Gram-negative bacteria, causing inhib-
ition of protein synthesis. Their clinical use is limited by toxic side effects that include cochlear and vestibular
toxicity as well as nephrotoxicity. Micromolar concentrations of the aminoglycosides streptomycin or gentamycin
are commonly used in the culture medium of Xenopus laevis oocytes. It has previously been described that
neomycin causes voltage dependent inhibition of ATP-induced whole cell current of Guinea-pig outer hair cells
(OHC) (1) which have later been shown to express P2X2 receptors. To further characterize aminoglycoside
inhibition at deﬁned P2X receptors and determine their mode of action we investigated the inhibitory potency of
ﬁve different aminoglycoside antibiotics at homomeric rat P2X2 receptors and at a non-desensitizing P2X2/P2X1
receptor chimera which exhibits the ligand-binding properties of the P2X1 receptor (2). The respective subunits
were expressed in Xenopus laevis oocytes and the ATP induced membrane currents were analysed using the two-
electrode voltage-clamp technique. At -60 mV, all ﬁve aminoglycosides inhibited ATP induced inward currents
with varying potencies. The inhibition was dose dependent and displayed fast on-set and off-set. P2X2 receptor
currents were most potently blocked by streptomycin with an IC50 value of 35 2M, the weakest inhibition was
induced by paromomycin with half-maximum inhibition at 1.5 mM. The rank order of potency at P2X2 receptors
was streptomycin > neomycin > gentamycin > kanamycin > paromomycin. This rank order differs from the results
obtained from native P2X receptors on OHCs where neomycin was signiﬁcantly more effective than streptomycin
and gentamycin. Similar to what has been found on OHCs, the inhibition was voltage-dependent and greatly
reduced at more positive membrane potentials. Likewise, the ATP-current could not be reversed by increasing
the ATP concentration, indicating that the effect was non-competitive. To further analyze the blocking mecha-
nism we tested the aminoglycosides on a non-desensitizing P2X2/P2X1 receptor chimera in which the N-terminal
and ﬁrst transmembrane portion of the P2X1 were replaced by the corresponding regions of the P2X2 receptor
subunit and compared it to the properties of known P2X receptor antagonists. The onset rates of inhibition of
PPNDS, NF449 or TNP-ATP at this chimera were limited by the slow dissociation rate of ATP (C = 63 s). In
contrast, all tested aminoglycosides displayed a fast onset of inhibition at the chimera thus clearly indicating an
inhibitory action independent of ATP dissociation. Taken together, we show that aminoglycosides block the rat
P2X2 receptor with a rank order of potency different from that at native P2X receptors on guinea-pig outer hair
cells, and that the P2X2/P2X1 chimera provides a fast screening model to distinguish between competitive and
noncompetitive antagonism.
(1) Lin X.; Hume RI.; Nuttall AL. J. Neurophysiol. 1993, 70(4), 1593-1605.
(2) Rettinger J.; Schmalzing G. J. Biol. Chem. 2004 279(8), 6426-6433
Endothelial Catabolism of Extracellular Adenosine during Hypoxia: Role of
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Extracellular levels of adenosine signiﬁcantly increase during conditions of limited oxygen availability (hypoxia)
(1-3). Therefore, we reasoned that adenosine clearance mechanisms must exist to counter potentially deleterious
inﬂuences of adenosine (4). As guided by microarray results revealing a nearly ﬁfty-fold induction of endothelial
adenosine deaminase (ADA) mRNA in hypoxia, we pursued the hypothesis that hypoxia coordinates adaptive
catabolism of adenosine. Utilizing in vitro and in vivo models of adenosine signaling, we conﬁrmed induction of
ADA at the protein and functional levels. Further studies revealed that the ADA complexing protein CD26 is
coordinately induced by hypoxia, effectively localizing ADA activity at the endothelial cell surface. Functional
studies in murine hypoxia models revealed that inhibition of ADA with coformycin enhances protective physi-
ologic responses mediated by adenosine (e.g. vascular leak, neutrophil accumulation, pulmonary edema). Analysis
of plasma ADA activity in pediatric patients with chronic hypoxia (mean oxygen saturation of 81.9T6%) under-
going cardiac surgery (Bi-directional Glenn procedure) revealed a 4.1T0.6-fold increase in plasma ADA activity
compared to controls. Taken together, these results demonstrate induction of ADA as an innate metabolic ada-
ptation to elevated extracellular adenosine levels during hypoxia, and identify ADA inhibition as potential the-
rapeutic strategy for vascular leakage and excessive inﬂammation associated with acute hypoxia.
1. Eltzschig, H.K., P. Abdulla, E. Hoffman, K.E. Hamilton, D. Daniels, C. Schonfeld, M. Lofﬂer, G. Reyes, M.
Duszenko, J. Karhausen, A. Robinson, K.A. Westerman, I.R. Coe, and S.P. Colgan. 2005. HIF-1-dependent
repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med. 202:1493-1505.
2. Eltzschig, H.K., L.F. Thompson, J. Karhausen, R.J. Cotta, J.C. Ibla, S.C. Robson, and S.P. Colgan. 2004.
Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracel-
lular nucleotide metabolism. Blood 104:3986-3992.
3. Eltzschig, H.K., J.C. Ibla, G.T. Furuta, M.O. Leonard, K.A. Jacobson, K. Enjyoji, S.C. Robson, and S.P.
Colgan. 2003. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endo-
thelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198:783-796.
4. Blackburn, M.R. 2003. Too much of a good thing: adenosine overload in adenosine-deaminase-deﬁcient mice.
Trends Pharmacol Sci 24:66-70.
Endothelium-dependent adenosine A2B-receptor-mediated relaxation of
corpora cavernosa is impaired in men with vasculogenic impotence
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Purinergic transmission is important for initiation and maintenance of penile erection. Smooth muscle relaxation
to ATP may be mediated directly (via P2-purinoceptors) or indirectly, via adenosine generated by ectonucleo-
tidases (Mantelli et al., 1995, J. Androl., 16, 312-317). Due to its short half-life, adenosine has been used as an
agent for the diagnosis of vasculogenic impotence (Kilic et al., 1994, Int. J. Impot. Res., 6, 191-198). Therefore, we
aimed at characterizing the adenosine receptors regulating human corpus cavernosum (HCC) smooth muscle
tone. We also evaluated the pattern of extracellular catabolism of ATP in order to probe its contribution for
adenosine generation in HCC. HCC specimens were collected from organ donors (control subjects) and from
patients with vasculogenic erectile dysfunction (ED) according to the rules internationally accepted and approved
by the Ethics Committees of HGSA and ICBAS of the University of Porto. Longitudinal strips of corpus cave-
rnosum tissue were mounted in a 12-ml organ bath and superfused with oxygenated (95% O2 +5 %C O 2) Tyrode"s
solution at 37-C and connected to an isometric force transducer. To test tissue relaxant responsiveness, cumula-
tive concentration responses to adenosine and its stable analogues were evaluated in pre-contracted strips with 1
2M phenylephrine (PE). For the kinetic experiments of 30 2M ATP, AMP and adenosine catabolism in HCC
strips, samples (75 2l) were collected from the bath at different times up to 45 min for HPLC analysis of the
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Springervariation of substrate disappearance and product formation (Cunha & Sebastia ˜o, 1991, Eur. J. Pharmacol., 197,
83-92). We showed that HCC possesses a high ecto-NTPDase 1 activity converting ATP directly into AMP, which
is then dephosphorylated into adenosine by ecto-50-nucleotidase. Contrasting with most tissues, HCC strips slowly
inactivates adenosine. Adenosine and 50-N-ethyl-carboxamide adenosine (NECA) fully relaxed HCC (IC50 val-
ues of 30 2M and 3 2M, respectively) in control subjects. The selective A2A receptor agonist, CGS21680C,
produced only a partial relaxation (30-50%) of HCC (IC50~0.1 2M). MRS1706 (10 nM, a selective A2B receptor
antagonist) attenuated NECA-induced relaxation without affecting the effect of CGS 21680C. The relaxing eff-
ects of both agonists were attenuated by ZM241385 (50 nM, a selective A2A receptor antagonist). In contrast to
CGS21680C, NECA-induced relaxation was partially attenuated by NO synthase inhibition with N
G-nitro-L-
arginine (L-NOARG, 100 2M) and by the cyclooxygenase inhibitor, indomethacin (10 2M). Patients with endo-
thelial cell dysfunction (insensitivity to ACh) were partially resistant to NECA, but kept relaxation of HCC strips
to CGS 21680C. Data indicate that extracellular adenosine causes HCC relaxation via the activation of both
CGS21680C-sensitive (A2A) and –insensitive (A2B) receptors. Penile vessels from impotent men with severe
vascular diseases are partially resistant to relaxation by adenosine, probably due to endothelial A2B receptor
dysfunction.
Work supported by FCT (POCTI/45549/FCB/2002, participation of FEDER funding) and UP/Fundac ¸a ˜o Ilı ´dio
Pinho.
EPOXYEICOSATRIENOIC ACIDS (EETS) MEDIATE ADENOSINE-
INDUCED RENAL VASODILATION VIA A2A RECEPTORS
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Autocrine, endocrine and paracrine signals act on preglomerular microvessels (PGMV), where they generate a
variety of mediators/modulators of the renal circulation. Activation of renal adenosine1 receptors (A1R) and A2R
participate in the regulation of vascular tone and tubular function. A1R activation inhibits adenylyl cyclase (AC)
via Gi!, resulting in constriction of PGMV, whereas A2AR activation stimulates AC via Gs!, increasing renal
blood ﬂow. 1 The PGMV are endowed with high levels of cytochrome P450 (P450) which metabolize arachidonic
acid to EETs and 20-hydroxyeicosatetraenoic acid (HETE). A dynamic and antagonistic interaction between
EETs and 20-HETE is evident in their independent and opposing actions on autoregulation of blood ﬂow; 2 20-
HETE being a constrictor of PGMV and, in contrast, EETs dilate PGMV by activating calcium-dependent pot-
assium (K
+
Ca2+) channels of smooth muscle cells. 20-HETE has been shown to contribute to the ATP-induced
constriction of afferent arterioles via P2XR. Our study on vascular mechanisms served by EETs has uncovered a
close relationship between stimulation of the A2AR and increasing P450 epoxygenase activity; 11,12-EET was
identiﬁed as the likely candidate mediator of PGMV dilatation on activation of the A2AR. 3 EET levels in
PGMVs increased from 1.06 to 3.86 and 7.57 ng/mg protein/15 min in response to 10 and 100 2M CGS 21680, a
selective A2AR agonist, whereas, an A1R agonist failed to stimulate EET formation. Both A2AR antagonism and
inhibition of epoxygenase activity prevented elevation of EET levels produced by CGS 21680.
We have investigated the commonality of the signal transduction pathway - sequential inhibition of Gs!,A C ,
protein kinase A (PKA) and K
+
Ca2+ channel activity - to the vasoactive responses to A2AR activation by CGS
21680, and 11,12-EET. Rat microdissected arcuate arteries (ca 120 2m) were cannulated and pressurized to
80mmHg. Vessels were superfused with Krebs" solution and preconstricted with phenylephrine. 3-aminobenza-
mide (10 2M), an inhibitor of mono-ADP ribosyltranferases, reduced responses to 11,12-EET (3 nM) and CGS
21680 (10 2M) by 70% (p<0.05), without affecting the response to sodium nitroprusside (10 2M). Like cholera
toxin (100ng/ml), 11,12-EET (100nM) stimulated ADP ribose formation in homogenates of arcuate arteries.
Incubation of 11,12-EET (3nM to 32M) with PGMV resulted in an increased cAMP levels (p<0.05), suggesting
that A2AR coupled EET release is upstream of AC. An inhibitor of AC activity, SQ22536 (102M), decreased
responses to CGS 21680 and 11,12-EET, reducing the internal diameter from 22T2 2mt o1 T1 2m and from 24T5
2mt o9 T5 2m (p<0.05), respectively. Myristolated PKI (52M), an inhibitor of PKA, diminished the dilator res-
ponses to CGS 21680 and 11, 12-EET by 88% and 95%, respectively. The responses to both 11,12-EET and CGS




SpringerThus, in rat PGMV, EETs mediate A2AR-induced dilation. EETs stimulate mono-ADP ribosyltransferase resu-
lting in Gs! activation and sequential activation of AC, PKA and K
+
Ca2+ channel activity. We submit that EET
production by PGMVs mediate the renal protective effects of adenosine. In addition, activation of the A2AR
epoxygenase pathway in response to salt loading, greatly enlarges the scope of this pathway; namely, the assig-
nment of an antihypertensive function to adenosine via release of EETs. [4]
1. Fredholm BB, Arslan G, Halldner L, et al. Structure and function of adenosine receptors and their genes.
Naunyn Schmiedebergs Arch Pharmacol 2000;362:364-374.
2. Imig JD, Falck JR.Inscho EW. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to
afferent arteriolar autoregulatory responsiveness. Br J Pharmacol 1999;127:1399-1405.
3. Cheng MK, Doumad AB, Jiang H, et al. Epoxyeicosatrienoic acids mediate adenosine-induced vasodilation in
rat preglomerular microvessels (PGMV) via A2A receptors. Br J Pharmacol 2004;141:441-448.
4. Liclican EL, McGiff JC, Pedraza PL, et al. Exaggerated response to adenosine in kidneys from high salt-fed
rats: role of epoxyeicosatrienoic acids. Am J Physiol Renal Physiol 2005;289:F386-F392.
Evaluation of adenosine A2A receptor loss in a preclinical model of Huntington
disease using [
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Huntington"s disease (HD) is a neurological disorder characterized by progressive degeneration of striatal neur-
ons resulting in abnormal involuntary movements, psychiatric and cognitive abnormalities, and death. Adenosine
A2A receptor are mainly expressed in the striatum where they are functionally linked with D2 dopamine recep-
tors. Adenosine A2A receptor antagonists have been indicated as potential neuroprotective drugs, although the
mechanisms and efﬁcacy of these compounds remain to be elucidated. A loss of A2A receptors has been reported
at 8 days after the injection of quinolinic acid (QA) a neurotoxin that produces several neurochemical modiﬁc-
ation that approximate Huntington"s disease (1,2). Behavioral studies in rodents indicate that a single injection of
QA induces behavioral modiﬁcations that progress over time (3). However only few studies investigated the
neurochemical modiﬁcations, including the A2A receptors loss, present at later times after QA administration.
Aim of this study was to evaluate whether the loss of A2A receptors observed at 8 days progresses over time and if
this loss is correlated with other neurochemical modiﬁcations including dopaminergic D2 receptors loss and act-
ivation of microglial cells. For this purpose we measured ex-vivo the expression of A2A receptors until 60 days
after the monolateral intrastriatal injection of QA using [
11C]SCH442416 as a radioligand. Adenosine A2A rec-
eptor expression was correlated with that of D2 dopamine receptors and with the presence of activated microglial
cells using respectively [
11C]Raclopride and [
11C]PK11195 as radioligands associated with ex-vivo or in vivo
techniques. Results of the study showed a progressive decrease of [
11C]SCH442416 binding in the lesioned stri-
atum that reach a maximum reduction of approximately 58% of non lesioned striatum binding (p<0.05). A
progressive loss of D2 receptors was simultaneously observed by ex-vivo and in vivo techniques (YAP-(S)PET;
ISE, Italy); such a loss was maximal at 60 days after injection (60%; p<0.05). The different rate of reduction
between adenosine and dopamine receptors produced a progressive reduction in D2 over A2A ratios (approx-
imately 2.10 at 8 days until 0.8 at 60 days). Interestingly the decrease of A2A and D2 receptors was paralleled by a
four times increase of [
11C]PK11195 binding that was maximum at 8 days after injection (p<0.01). The results of
our study indicate a progressive degeneration of intrastriatal neurons as indicated by the simultaneous loss of
adenosine and dopamine receptors. Moreover, the different rate of loss of A2A and D2 receptors and the cons-
equent modiﬁcations in their binding ratios may indicate a different response of the two neurochemical system to
the neurotoxic insult. Interestingly, neuronal degeneration is followed by a constant activation of microglial cells
as indicated by the increase of [
11C]PK11195 binding that was maximum at 8 days and then remained stable.
Finally, the results of our study conﬁrm the feasibility of the use of molecular imaging techniques to follow disease
progression in selected preclinical models of neurodegeneration.
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Evidence for a patho-physiological and pharmacological role of guanine-based
purines as a new extracellular signalling system.
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In addition to the adenine-based purinergic intercellular signaling systems, involving adenine, adenosine and
adenosine phosphates, over the last 15 years analogous guanine-based systems have been discovered. Most of
these are involved in "trophic" effects, affecting the growth, differentiation and survival of various cells. Indeed,
guanine-based purines act synergistically with certain growth factors such as NGF, and also stimulate the prod-
uction and release from cells of several growth factors and cytokines. Guanine-based purinergic signaling has been
particularly investigated in cells of the nervous system and muscle. However, in addition other tissues, including
skin, respond to these compounds, indicating that, like adenine based purinergic signaling, guanine based signa-
ling may be widespread throughout many cell types and organs.
Guanine-based purines are released from cells, and when cells are damaged the release increases substantially.
Indeed, under conditions simulating ischemia, cells release more guanine-based purines than adenine based pu-
rines. Moreover, the extracellular concentration of the guanine-based purines is higher than that of the adenine-
based counterparts.
There is evidence that in some cases guanosine produces its effects through entering cells and interacting with an
NGF-inducible protein kinase. But there is also evidence that guanosine may interact with unique receptors on
the surface of cells. Similarly, there is evidence that GTP may also have cell-surface receptors that mediate some
of its effects. Moreover, guanosine is metabolized to guanine by the enzyme purine nucleoside phosphorylase
(PNP). Experimental studies have indicated that exogenous extracellular guanosine is relatively persistent com-
pared to adenosine, but a large proportion of guanosine is metabolized to guanine. Emerging evidence indicates
that guanine may also have its own extracellular signaling system that is distinct from guanosine. Certainly, this
would be of particular interest, since the enzyme that metabolizes guanine, guanine deaminase, shows 50 fold
regional variations in brain. This degree of regional variation is characteristically associated with enzymes that
degrade neurotransmitters.
It appears that the concept of intercellular signaling by guanine-based purines is now well substantiated. Since
GTP, guanosine and guanine have different biological effects, different receptive mechanisms and likely different
signal transduction mechanisms, it could be suggested the intriguing possibility that the extracellular intercon-
version of these guanine derivatives provides an extra layer of signal regulation by cells.
Evidence for Extracellualr ATP in Plants: Localization and Functional
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SpringerTransgenic Lotus japonicus plants expressing the soybean ectoapyrase (GS52), with a predicted extracellular
catalytic domain, showed increased root infection when inoculated with the nitrogen-ﬁxing symbiotic bacterium,
Mesorhizobium loti. These data suggest the presence of extracellular ATP (eATP) in plants and a role for this
molecule in symbiotic infection. A variety of recent publications have shown that exogenous addition of ATP can
affect plant processes. Indeed, a recent publication points to an essential role for eATP in plant cell viability.
What is missing from these investigations is clear demonstration of the presence of eATP under normal plant
growth conditions. We constructed a novel reporter protein where the cellulose binding domain was fused with
the ATP-requiring enzyme, luciferase. This construct, in the presence of the substrate luciferin, is expected to
produce luminescence only when eATP is present. Indeed, when added to legume plant roots, luminescence was
seen and localized to the interstitial spaces between cells of the root and the tips of growing root hair cells. The
secretion of eATP was dependent on Ca2
+, as indicated by reduced luminescence upon addition of GdCl, LaCl
(calcium channel blockers) or BAPTA (calcium chelator) and an increase in the intensity upon addition of CaCl2.
Treatment of roots with brefeldin A, an inhibitor of vesicular trafﬁcking, also blocked eATP release. In addition,
reactive oxygen species (ROS) production is also dependent on cytosolic calcium and its gradients are also closely
associated with root hair tip growth. Interestingly, addition of exogenous ATP signiﬁcantly increased the prod-
uction of ROS, but addition of adenosine, AMP, ADP, or non-hydrolyzable ATP ("+meATP) did not stimulate
ROS production. These data suggest that eATP is released from the root hair tip during vesicle exocytosis,
concomitant with polar growth. We postulate that eATP may act on polar growth through the production of ROS.
Taken together, our current work strongly suggests that eATP is present in plants and likely is an additional signal
involved in the earliest events of root hair infection by rhizobia.
Evidence for the involvement of basic amino acid residues in transmembrane
regions 6 and 7 of the human platelet P2Y12-receptor in ligand recognition
Kristina Hoffmann, Irina Algaier, Ivar von Ku ¨gelgen
Department of Pharmacology, University of Bonn, Reuterstrasse 2b, 53113 Bonn, Germany
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The P2Y12 receptor plays a crucial role in ADP-induced platelet aggregation. The ligand binding site of this
receptor has yet not been fully characterized. A patient with a congenital bleeding disorder has been shown to
carry a polymorphism with a change of R256 to glutamine in the upper third of transmembrane region 6 (TM6)
[1]. When expressed in cells, the R256Q mutant receptor had a defective receptor function. For the P2Y1-rece-
ptor, several amino acid residues in TM6 and TM7 are involved in ligand recognition [2]. We now studied whether
the corresponding amino acid residues are involved in ligand recognition of the P2Y12-receptor. Mutations were
introduced in the encoding DNA sequence by site directed mutagenesis. Wild type P2Y12-receptors and mutant
receptors were stably expressed in human 1321N1-astrocytoma cells. Immunoﬂuorescence staining revealed that
the expression levels of the mutant receptors were at least as high as those of wild type receptors. Receptor
function was then determined by measuring the 2-methylthio-ADP-induced inhibition of cellular cAMP levels.
For this purpose, cellular cAMP accumulation was increased by addition of isoprenaline 10 nM (increase of 52 T 2
pmol cAMP per well). In cells expressing wild type receptors, 2-methylthio-ADP caused a concentration-depe-
ndent inhibition of the cAMP production with an EC50 concentration of 0.9 nM and a maximal effect of 55 %
inhibition. In cells transfected with the S101A mutant receptor (TM3), the maximal response to stimulation by 2-
methylthio-ADP was decreased (maximal inhibition by 29%). Next we studied mutants with a change in TM6. 2-
Methylthio-ADP inhibited cellular cAMP production in cells expressing the R256K mutant receptor (change of a
basic residue to another basic residue) by a similar degree as observed for the wild type receptor (EC50 conce-
ntration of about 0.2 nM, inhibition by 39 %). When R256 was replaced by alanine (R256A), there was a clear
decrease in agonist potency with an EC50 concentration of about 10 nM (maximal inhibition by 23 %). In cells
expressing the R256D mutant (replacement of a basic residue by an acidic residue), the maximal effect was
decreased even more (only 18% inhibition left). Several mutations caused a total loss of receptor function. In cells
expressing Y259D mutant receptors, 2-methylthio-ADP (0.01nM to 1 2M) failed to elicit any inhibitory effect.
Similarly, 2-methylthio-ADP caused no effect in cells with the H253A/R256A double mutant receptor (TM 6). In




Springercts as a potent antagonist at the wild type P2Y12 receptors when used in nanomolar concentrations [3]. At the
R256A mutant receptor, AR-C69931MX 30 nM shifted the concentration-response curve to the right, excluding a
major change in the afﬁnity of the antagonist at this mutant receptor. In summary, our data indicate the involv-
ement of the residues H253, R256, Y259 (TM 6) and K280 (TM 7) in ligand recognition of the human P2Y12
receptor. S101 (TM3) may play an intermediate role.
[1] Cattaneo et al, 2003, PNAS, 100, 1978-1983
[2] Jacobson et al, 2002, J Med. Chem., 45, 4057-4093
[3] Takasaki et al, 2001, Mol. Pharmacol., 60, 432-439
Evidence for trophic effects of guanosine in SH-SY5Y neuroblastoma cells but
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It is known that after brain injury there is early proliferation of microglia, followed by astrogliosis and then, at a
later stage, proliferation of new capillary endothelial cells. The trophic effects of guanosine (GUO), which is
released at high levels by hypoxia, included: i) the stimulation of the synthesis and release of neurotrophic factors
which stimulate the proliferation of microglia and astrocytes and protect neurons against excitotoxic death, ii) the
stimulation of PI3-K and MAPK pathways, which protect astrocytes against apoptosis. Both actions appeared to
be mediated by putative GUO receptors. We questioned whether guanosine could also exert trophic effects both
in endothelial and neuronal cells.
The proliferation experiments with EA.hy926 human cell line were performed in: i) different FBS conditions,
starvation (0%), stand-by (1%) and proliferating (10%); ii) different exposure times (24-48 hrs) to different GUO
concentrations (12.5-3002M); iii) different times of starvation (24-48-72 hrs). GUO did not signiﬁcantly increase
the proliferation in any conditions tested. Similarly, it was unable to modify proliferation of HUVEC cells. Studies
to identify putative GUO binding sites were unsatisfactory. On the other hand, RT-PCR analysis to evaluate the
expression of a orphan GPCR (G3), hypothesised to be the putative receptor for GUO since RNAsi abolished the
GUO-induced phosphorylation of AKT or ERK1/2 in astrocytes, gave negative results in both cell lines. More-
over, GUO did not caused an increase in cAMP levels in the absence or presence of forskolin (32M).
In SH-SY5Y human neuroblastoma cells a treatment for 24 h with GUO (12.5-300 2M) induced a concentration-
dependent proliferative effect which was evident when the cultures were maintained in starvation (0% FBS),
whereas it was not detected when the cells were cultured in 2% serum. The proliferative effect was also maint-
ained in more severe conditions, prolonging the starvation up to 72 hrs. In this condition, when the 0% FBS
medium was replaced with 2% FBS medium the cells restarted to growth and once again the addition of GUO
was without effect. The cytoﬂuorimetric analysis showed that GUO induced a concentration-dependent shift of
cell cycle from G0-G1 phase towards S phase. The proliferative effects of GUO were not counteracted by the P1
receptor antagonists, DPCPX or DMPX, ruling out a role of endogenous adenosine in mediating GUO action.
Suramine, a non speciﬁc P2 receptor antagonist, per se induced an increase in cell growth that was not modiﬁed by
GUO. The proliferative effects of GUO were increased by the presence of 1mM propentophylline, a non speciﬁc
inhibitor of purine transporters, and was signiﬁcantly reduced by the pre-treatment of SH-SY5Y cells with 102M
PD098,059 and/or 302M LY-294,002 inhibitors of MAPKs and PI-3K pathways, respectively. GUO produced a
weak, but signiﬁcant, increase in cAMP levels and potentiated the forskolin action which were not changed by cell
treatments with ADA, DPCPX or DMPX. Preliminary experiments showed the presence of high afﬁnity binding
sites for GUO in SH-SY5Y cells that also express the G3 protein. In conclusion, these results show that guanosine
exert trophic effects also on neurons with mechanisms that could be similar to those involved in its trophic action
on glia, and reinforce the hypothesis of the existence of extracellular recognition binding sites for guanosine.
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FED RATS: ROLE OF EPOXYEICOSATRIENOIC ACIDS (EETs)
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Adenosine plays a critical role in the regulation of renal vascular tone and tubular function, thus modulating renal
blood ﬂow and glomerular ﬁltration rate. In the renal microcirculation, activation of the adenosine 1 receptor
(A1R) and A2AR subtypes has opposing effects: vasoconstriction in response to A1R activation enhances proximal
tubular NaCl reabsorption, whereas endothelium-dependent relaxation via A2AR promotes natriuresis1. Aden-
osine stimulation of A2AR in rat preglomerular microvessels is linked to production of EETs, cytochrome P-450
(CYP) epoxygenase metabolites of arachidonic acid2. EETs are important modulators of cardiovascular function
and their contribution to blood pressure regulation has been established in several different animal models. EETs
are thought to be natriuretic by virtue of their ability to dilate the renal vasculature as well as regulate Na
+
transport in proximal and distal tubules. An increase in natriuretic EETs is one of the signiﬁcant components of
the kidney"s adaptive response to prevent elevation of blood pressure in response to high salt (HS) intake. It is
also documented that renal ARs are affected by Na
+ intake3, and mice lacking A2AR exhibit elevated blood
pressure4. As adenosine levels are increased by dietary salt intake, we propose that adenosine is the stimulus for
increased renal epoxygenase activity in response to salt loading. More speciﬁcally, we hypothesize that HS intake
increases the renal response to adenosine, resulting in increased epoxygenase activity and EET levels.
Male Sprague-Dawley rats were fed HS (4.0% NaCl) or normal salt (NS; 0.4% NaCl) diet. On day 8, isolated
kidneys were perfused with Krebs" buffer and preconstricted to ca 150 mm Hg with phenylephrine (10
-7M). Renal
efﬂuent eicosanoids were analyzed by GC/MS. Bolus injections of the stable adenosine analog 2-chloroadenosine
(2-CA; 0.1-102g) resulted in dose-dependent dilation; at 102g, perfusion pressure (PP) was lowered to a greater
extent in the kidneys of HS rats compared to NS rats (-60 T 4 vs. -31 T 8 mm Hg; p<0.05) and the area of response
was increased (27 T 6 vs. 9 T 4m m
2; p<0.05), as was EET release (132 T 23 vs. 38 T 18 ng; p<0.05). HS treatment
increased A2AR and CYP2C23 epoxygenase protein expression. A selective epoxygenase inhibitor, N-methyl-
sulfonyl-6-(2-propargyloxyphenyl) hexanamide (MS-PPOH; 12 2M), signiﬁcantly reduced the response to 2-CA in
HS rats; PP, area of response, and EET release decreased by 40%, 70% and 81%, respectively, whereas lesser
changes were evident in NS kidneys. In addition to the increase in EET levels with HS intake, a ca 97% increase
of total purines (as an index of ﬂux through the adenosine pathway) was measured in renal efﬂuents obtained
from HS-fed rats compared to NS-fed rats (2357 T 268 vs. 1197 T 127 nmol/L; p<0.05). In vivo, infusion of MS-
PPOH (5mg/kg daily for 3 days) via osmotic pumps increased blood pressure and decreased UNaV in HS- com-
pared to NS-fed rats.
Thus, the greater vasodilator response to 2-CA seen in kidneys of HS-fed rats was mediated by increased EET
release, presumably via upregulation of A2AR and epoxygenase expression. As EETs have renal vasodilator and
natriuretic properties, A2AR activation may be a key link in a renal mechanism that contributes to the regulation
of blood pressure.
1. Jackson EK,Dubey RK. Role of the extracellular cAMP-adenosine pathway in renal physiology. Am J Physiol
Renal Physiol 2001;281:F597-F612.
2. Cheng MK, Doumad AB, Jiang H, et al. Epoxyeicosatrienoic acids mediate adenosine-induced vasodilation in
rat preglomerular microvessels (PGMV) via A2A receptors. Br J Pharmacol 2004;141:441-448.
3. Zou AP, Wu F, Li PL, et al. Effect of chronic salt loading on adenosine metabolism and receptor expression in
renal cortex and medulla in rats. Hypertension 1999;33:511-516.
4. Ledent C, Vaugeois JM, Schiffmann SN, et al. Aggressiveness, hypoalgesia and high blood pressure in mice
lacking the adenosine A2a receptor. Nature 1997;388:674-678.
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While the anti-inﬂammatory effects of the A2A adenosine receptor (A2AAR) are well-established, the molecular
mechanisms responsible for these effects remain unclear. Here we demonstrate that selective activation of end-
ogenous A2AARs by CGS21680 induces the expression of ‘‘suppressor of cytokine signalling-3’’ (SOCS-3) but not
the related protein SOCS-1 in human umbilical vein endothelial cells (HUVECs). The effect could be recapitu-
lated by elevation of intracellular cyclic AMP (cAMP) but was resistant to inhibition of PKA and was instead
mimicked by either selective activation of the cAMP-activated Rap GEF ‘‘Epac’’ or transient expression of
constitutively active Val12Rap1a. Importantly, SOCS-3 induction was associated with a PKA-independent ability
of cAMP to inhibit IL-6-mediated STAT1 and STAT3 activation by an interleukin-6 (IL-6) trans-signalling co-
mplex comprising IL-6 and soluble IL-6 receptor-! (hereafter termed IL-6/sIL-6R!) via gp130, a well-character-
ised target for inhibition by SOCS-3. Attenuation of SOCS-3 induction using either morpholino antisense-
mediated knockdown or employing SOCS-3-null murine embryonic ﬁbroblasts (MEFs) abolished the inhibitory
effect of cAMP on IL-6/sIL-6R!-activated STAT phosphorylation whereas inhibition of SHP-2, another key
negative regulator of gp130, was without effect. These data suggest that SOCS-3 is the dominant mediator of
cAMP"s effects. Interestingly, cAMP elevation activated the ERK pathway in HUVECs, and this was required to
observe SOCS-3 induction. Subsequent in silico analysis of the human SOCS-3 promoter identiﬁed several pot-
ential sites for ERK regulation, including consensus motifs for binding of the CAAT enhancer binding protein
(CEBP) transcription factor family. Chromatin immunoprecipitation assays conﬁrmed that either elevation of
cAMP or selective activation of Epac stimulated the rapid accumulation of CEBP" on the SOCS-3 promoter in
HUVECs. Together, these data argue for the existence of a novel cAMP/Epac/CEBP"/SOCS-3 pathway for
limiting pro-inﬂammatory signalling from Class I cytokine receptors in endothelial cells, and illuminate a new
mechanism by which the A2AAR may mediate its potent anti-inﬂammatory effects.
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Neurotransmission can be affected by exposure to heavy metals, such as mercury and lead. ATP is a signaling
molecule that can be inactivated by ecto-nucleotidases. Ecto-nucleotidases are ubiquitous enzymes with a broad
phylogenetic distribution, occurring in many vertebrate tissues. Zebraﬁsh is a consolidated model system in ne-
uroscience and toxicological studies. The zebraﬁsh genome project has demonstrated regions of syntenic relati-
onship with human genome. Purinoceptors were already identiﬁed in this teleost and, recently, we characterized
the presence of a NTPDase and an ecto-50-nucleotidase activities in brain membranes of zebraﬁsh. Considering
that mercury and lead are important environmental contaminants and the presence of purinergic receptors and
enzyme activities involved in extracellular catabolism of nucleotides in zebraﬁsh brain, the aim of present study
was to investigate the effect of mercury chloride (HgCl2) and lead acetate [Pb(CH3COO)2] on NTPDase and
ecto-50-nucleotidase activities and expression in central nervous system of zebraﬁsh. In vitro exposure to HgCl2
decreased ATP and ADP hydrolysis in an uncompetitive mechanism and AMP hydrolysis in a non-competitive
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but not ADP and AMP hydrolysis. In vivo exposure to HgCl2 or Pb(CH3COO)2 (20 2g/L, during 24h, 96h and 30
days) caused differential effects on ecto-nucleotidase activities. Exposure to HgCl2 during 96 h caused a signiﬁcant
inhibition of ATP (37%), ADP (42%) and AMP (39%) hydrolysis Interestingly, after 30 days of exposure to
HgCl2, ATP hydrolysis return to the control level and ADP hydrolysis was strongly increased (118%) when
compared to the control values. AMP hydrolysis at this time of exposure remaining inhibited (32%). However,
after 96 h of exposure to Pb(CH3COO)2, it is possible to observe a signiﬁcant decrease on ATP hydrolysis (17%),
but not on ADP and AMP hydrolysis. The chronic exposure to Pb(CH3COO)2 during 30 days also promoted a
signiﬁcant decrease of ATP (33%), ADP (37%) and AMP (40%) hydrolysis in brain membranes of zebraﬁsh. To
verify if the chronic exposure to mercury or lead during 30 days was able to modify ecto-nucleotidases expression,
RT-PCR experiments were performed. There were no changes in the expression of NTPDase1 and 50-nucleoti-
dase, following 30 days of exposure to both metals. The results indicate that the signiﬁcant alterations observed
probably are related to post-translational changes of the enzymes. Therefore, this study demonstrated that ecto-
nucleotidases can be a potential target related to neurotoxicity induced by mercury and lead and a possible
indicator of the biological impact of exposure to heavy metal contaminants.
Supported by: FAPERGS, CNPq, CAPES, TWAS.
Expression and function of A2A and A3 adenosine receptors in mouse neutrophils
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Adenosine is a potent anti-inﬂammatory agent, which partially explains its beneﬁcial effects when administered in
models of tissue injury and inﬂammation including ischemia/reperfusion injury. The aims of this study were to
comprehensively characterize the expression proﬁle of the four AR subtypes in mouse neutrophils and to dete-
rmine their roles in regulating neutrophil functions. Neutrophils were isolated from bone marrow by Percoll
density gradient centrifugation and immunomagnetic selection with an anti-Gr-1 antibody resulting in isolates that
were 99% pure based on cytospin images and FACS analysis. Real-time PCR analysis of puriﬁed neutrophil
populations revealed that mRNA expression levels of the A2A and A3AR were highest (3809.32 T 391.38 and
3524.19 T 685.17 copies of mRNA/50 ng of total RNA, respectively) followed by the A2BAR (162.89 T 32.87
copies of mRNA/ 50 ng of total RNA). mRNA expression of the A1AR was negligible. Radioligand binding
analysis using the A2AAR antagonist
125I-ZM-241385 and the A1/A3AR agonist [
125I]I-AB-MECA also suggested
that A2A and A3AR proteins are abundantly expressed in mouse neutrophils, conﬁrming the results of the quan-
titative PCR studies. We subsequently examined the role of A2A and A3ARs in regulating neutrophil superoxide
(O2
.-) production and chemotaxis. In O2
.- assays, Percoll gradient puriﬁed neutrophils were treated with AR
agonists for 30 minutes prior to stimulation with activating agents and O2
.- produced was measured using the
chemiluminescent probe 2-methyl-6-(p-methoxyphenyl)-3,7-dihydroimidazo [1,2-alpha]pyrazin-3-one (MCLA, 0.5
2M). The non-speciﬁc AR agonist NECA (300 nM), the A2AAR agonist CGS-21680 (100 nM) and the A3AR
agonist CP-532,903 (100 nM) inhibited O2
.- production by wild-type (WT) neutrophils activated with N-formyl
peptide fMLP (1 2M), complement C5a (3 nM) and platelet activating factor (PAF, 100 nM), but not with
phorbol myristate acetate (PMA, 800 nM). Subsequent concentration-response studies revealed that both CGS-
21680 and CP-532,903 inhibited O2
.- production by neutrophils with similar potencies (EC50 values of 16.43 T 2.07
nM and 38.10 T 1.60 nM respectively) and efﬁcacies (~45% and ~55% inhibition, respectively). In chemotaxis
assays, Percoll gradient puriﬁed WT neutrophils were treated with CGS-21680 or CP-532,903 (100 nM) for 30
minutes and directed migration towards fMLP (30 nM-10 2M) or C5a (300 pM to 100 nM) was measured using a
standard 48-well chemotaxis chamber with polycarbonate membranes (5 2m pore size). Activation of the A3AR
with 100 nM CP-532,903 (but not the A2AAR with CGS 21680) inhibited fMLP-induced chemotaxis of mouse
neutrophils producing ~25% inhibition elicited by 1 and 3 2M fMLP. Interestingly, CP-532,903 did not inhibit
C5a-induced neutrophil chemotaxis. In both the assays for O2
.- production and chemotaxis, the speciﬁcity of the
agonists for A2A and A3ARs was conﬁrmed by repeating the experiments with neutrophils obtained from A2AAR
or A3AR gene Fknock-out_ mice. In conclusion, while activation of the A2A or A3AR inhibits neutrophil O2
.-
production, activation of the A3AR may also lead to stimulant-speciﬁc inhibition of neutrophil chemotaxis.
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Type-B synoviocytes are actively involved in joint injury during chronic and acute rheumatic diseases producing
cytokines and inﬂammatory mediators.
The aim of this study was to investigate P2 receptors (P2R) expression and role in human B-type synoviocytes
obtained from articular biopsies.
mRNA levels of P2R were analysed by RT-PCR. Human primary synoviocytes were found to express mRNA for
the following P2X and P2Y receptors: P2X1, P2X2,P 2 X 4, P2X5, P2X6, P2X7, and P2Y1,P Y 4, P2Y11, P2Y12, P2Y13
and P2Y14. Moreover we observed P2X7 expression by Western Blotting.
We analyzed whether synovial cells have the ability to mobilize calcium when challenged with agonists that
interact with the purinergic receptors family.
ATP (1mM) induced an increase in intracellular free calcium concentration ([Ca
2+]i) in FURA-2 loaded synov-
iocytes in presence and in absence of extracellular calcium, suggesting that calcium rise depends either on inﬂux
across the plasma membrane or on release from intracellular stores and so both P2X and P2Y receptors appear to
be involved in calcium mobilization in synoviocytes.
To determine the speciﬁc role of P2X receptors we stimulated synoviocytes with a P2X7 receptor agonist, BzATP
(5002M),which was able to induce a rise in [Ca
2+]i in the presence of extracellular calcium; conversely, no changes
in [Ca
2+]i were observed when BzATP was tested in the absence of extracellular calcium.
Since BzATP was reported to activate also P2X1 and P2X3 receptors, we investigated the calcium mobilizing
activity of !,"MeATP, a speciﬁc agonist of these receptors. Indeed after !,"MeATP (100 2M) stimulation no
signiﬁcant [Ca
2+]i rise was observed, indicating the possible P2X7 receptor activation.
On the basis of the previous considerations we investigated the involvement of P2X7 receptor in the IL-6 release
in ELISA experiments through BzATP stimulation.
Synoviocytes spontaneously released low levels of the proinﬂammatory cytokine interleukin-6 (IL-6) as measured
in the supernatant by ELISA. Stimulation with IL-1" increased such secretion after 3-6-24h incubation. We
observed a time-dependency in the secretion of IL-6 after BzATP (100-5002M) treatment. In agrement with the
hypothesis about the P2X7 receptor involvement we used a P2X7-selective antagonist, oxidized ATP and we
observed that the increase in the cytokine release was inhibited.
This very preliminary study suggests that: i) human synoviocytes express mRNA for several P2X and P2Y rece-
ptors; ii) P2X7 activation is probably associated with cytokine release; iii) P2R antagonism may represent a
therapeutic target for the pharmacological manipulation of the proinﬂammatory activity of synoviocytes.
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Background and goal of the study: Adenosine is an endogenous neuromodulator that acts on 4 different subtypes
of G-coupled protein receptors (A1, A2a, A2b, A3). The presence of A2a receptor is well established in the
central nervous system, predominantly in the striatum where A2a receptor activation was described as a modu-
lator of the NMDA receptor (1,2). In contrast, the distribution and the role of A2a receptor in the spinal cord
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Springerremain unclear (3). The goal of this study is to explore the presence and the role of A2a receptor in the spinal
cord pain pathways.
Material and Methods: Total RT-PCR was ﬁrst performed to assess the expression of the adenosine A2a receptor
gene in the lumbar enlargement of the rat spinal cord. Second, single-cell RT-PCR was performed on acute slices
in order to identify cells expressing A2a receptor mRNA and to quantify the proportion of lumbar dorsal horn
neurons that express it. Third, we investigated whether the activation of A2a receptor has any modulatory effect
on the activity of NMDA receptor by using the whole cell patch clamp technique on projection neurons from
lamina II.
Results and Discussion: RT-PCR performed on the entire lumbar spinal cord revealed the presence of the ade-
nosine A2a receptor transcript. RT-PCR performed on single cell identiﬁed as projection neurons revealed the
presence of the adenosine A2a receptor transcript in 5 out of 32 cells. Electrophysiological recordings did not
show a signiﬁcant difference between the current induced in presence of 10 2M NMDA and the one induced in
presence of 102M NMDA plus 0.12M CGS 21680, the A2a receptor agonist (-107.32 T 16.93 pA vs –83.43 T 9.31
pA, n=7, student"s t-test, p>0.05).
Conclusion: Adenosine A2a receptor is present in the dorsal horn of the lumbar spinal cord. The receptor is
expressed on 15 % of the lamina II projection neurons. A2a receptor agonists seem not able to modulate the
NMDA receptor activity.
References: 1) Schiffmann SN, Neurosci Lett. 1991; 130(2):177-81. 2) Wirkner K, Br J Pharmacol. 2000;130(2):-
259-69. 3) Brooke R.E., J Neurosci. 2004; 24(1):127-37.
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In the adult murine brain, neurogenesis persists in two brain regions, the subgranular layer of the hippocampal
dentate gyrus and the subventricular zone (SVZ) of the lateral ventricles. In the SVZ, multipotential and self-
renewing astrocyte-like stem cells (type B cells) are the source of newly generated neuroblasts (type A cells). The
highly proliferating type C cells are thought to represent intermediates between type A and type B cells. The
neuroblasts migrate along the ventricular surface and the rostral migratory stream (RMS) towards the olfactory
bulb (OB). Forming a network of tightly associated cells, the migrating cells pass through tunnels formed by
processes of type B cells. In the OB, the type A cells move radially and differentiate into granular or periglom-
erular interneurons. We have previously shown that the ecto-nucleotidase NTPDase2 is selectively associated
with type B cells of the SVZ
1 and neural progenitors in the hippocampal dentate gyrus
2 and that neurosphere cells
cultured from SVZ stem cells express functional P2Y1, P2Y2 and P1 receptors whose activation synergistically
supports growth factor-mediated cell proliferation.
3
Using enzyme histochemistry and immunocytochemistry we demonstrate that an additional ecto-nucleotidase is
expressed by cells of the adult murine SVZ and RMS, the tissue non speciﬁc form of alkaline phosphatase
(TNAP). TNAP is capable of hydrolyzing nucleoside tri-, di- and monophosphates with an alkaline pH optimum.
In contrast to NTPDase2, TNAP can generate extracellular adenosine. Interestingly, TNAP is not expressed by
adult hippocampal progenitors. Using double immunohistochemistry and various cell markers, we demonstrate
that TNAP does not colocalize with the NTPDase2-expressing type B cells. It rather is associated with their
descendants, the Olig2-expressing type C cells and the doublecortin or PSA-NCAM-expressing type A cells. At
physilogical pH, the ATP-hydrolyzing activity of TNAP in the neurogenic zone is lower than that of NTPDase2.
During brain ontogeny, TNAP is already expressed within the mouse embryonic neurogenic zones at day 14
(E14), several days before NTPDase2. Taken together these results further support the notion that signaling via
extracellular nucleotides and presumably also nucleosides supports both embryonic and adult mammalian neur-
ogenesis. Ecto-nucleotidases would have the potential to control the availability of agonists at P2 and P1 receptors
whose cellular expression pattern in the neurogenic zones requires further investigation.
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EXPRESSION OF HUMAN ECTO 50-NUCLEOTIDASE IN PIG
ENDOTHELIUM AND ITS EFFECTS ON ADENOSINE PRODUCTION,
NK CELL-MEDIATED LYSIS AND PLATELET FUNCTION
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The use of xenogeneic cells, tissues and organs is one possible solution to circumvent the shortage of human
organs for allotransplantation. Pigs are considered as optimal candidates and major obstacle after transplantation
of pig organs into primates, hyperacute rejection has been partially resolved in transgenic pigs expressing human
complement regulatory proteins such as human decay accelerating factor (hDAF) or by knocking-out !1,3-gala-
ctosyltransferase. However, delayed xenograft rejection or acute vascular rejection that occurs within days to
weeks after pig-to-primate organ transplantation remains unresolved. This process is mediated by immune and
haemostatic mechanisms involving antibodies, natural killer (NK) cells and monocytes. Ecto-50-nucleotidase (E-
50N) is an endothelial surface enzyme that controls conversion of extracellular nucleotides that triggers thromb-
osis and immune response into into immunosuppressive and antithrombotic adenosine. We evaluated whether
expression of human E50N on pig endothelial cells (EC) attenuates human NK cell mediated cytotoxicity and
inhibit platelet aggreggation and adhesion.
A pig EC line was stably transfected with human E50N and human NK cell adhesion and cytotoxicity towards pig
EC cultures was measured by ﬂow cytometry and intracellular enzyme release. E50N activity in pig EC lysates
increased from 0.68 T 0.07 to 1013 T 293nmol/min/mg protein, whilst the rate of AMP to adenosine metabolism by
intact cells increased from 0.37 T 0.05 to >300nmol/min/mg protein in non-transfected and transfected cells, res-
pectively. The rate of adenosine production in transfected cells increased also with ATP as the extracellular
substrate. Cytotoxicity of human NK cells was reduced from 10.7 T 0.4% and 11.1 T 1.1% with non-transfected pig
EC to 5.2 T 0.2% and 5.0 T 0.2% in transfected cells with 502M and 2502M AMP respectively. Reduction of
cytotoxicity in E50N-transfected EC was abolished by the E50N inhibitor and was mimicked in non-transfected EC
by the addition of adenosine, demonstrating the key role of adenosine produced by E50N in inhibiting NK cell
cytotoxicity. Platelet aggregation measured using aggregometer was markedly reduced by supernatants of cells
transfected with E50N added to platelet reach plasma. Adhesion of ﬂuorescently labelled platelets to E50N tran-
sfected pig endothelial cells was reduced to 39 T 9% of the adhesion observed in non-transfected cells. Both
effects on platelet function were abolished by the E50N inhibitor. We suggest that over-expression of E50Ni nE C
of transgenic pigs is a possible strategy to ameliorate rejection after xenotransplantation.
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SpringerNucleotides such as ATP and UTP are emerging as a ubiquitous family of extracellular signaling molecules. They
have been shown to play a key role in transducing mitogenic, contractile, metabolic, and secretory signals in a
variety of cells through release and subsequent binding to the P2 (P2X and P2Y) family of purinergic receptors
1,2.
However, little is known regarding an autocrine role for ATP in hypoxia-induced vascular cell responses. In a
neonatal model of hypoxic pulmonary hypertension, we showed that Pulmonary Artery (PA) adventitial ﬁbro-
blasts proliferate both in vivo and in vitro in response to hypoxic conditions
3,4. We therefore examined the
hypothesis that hypoxia-induced adventitial ﬁbroblast proliferation would be mediated by hypoxia-induced
changes in ATP release and/or its extracellular degradation. We found that acute hypoxia (3%O2 10-60 min)
increased extracellular ATP concentrations in adventitial ﬁbroblasts and that chronic hypoxia (3%O2, 14-30 days)
markedly attenuated the rate of extracellular ATP hydrolysis by ectonucleotidase(s) suggesting that at least two
different cellular mechanisms may contribute to elevated extracellular ATP levels. Exogenous ATP (100 2M)
stimulated thymidine incorporation and increased the phosphorylation of Akt, Erk1/2, mTOR, and p70S6K in
ﬁbroblasts as did UTP, UDP, ADP, ADP"S, MeSATP, !"MeATP, BzATP and some other agonists, indicating
that both P2Y and P2X purinoceptors mediate mitogenic responses. PCR analysis revealed that adventitial ﬁbro-
blasts express P2Y1,2,6 as well as P2X2,4,6,7 receptor subtypes. The rank order of potency of various agonists to
activate each individual kinase pathway (ERK1/2, PI3K/Akt or mTOR/p70S6K) indicates that in these cells,
purinergic receptors are coupled to the proliferative responses in a pathway-speciﬁc manner. Importantly, in this
ATP-activated signaling network, a translational pathway, involving mTOR, p70S6K and S6 ribosomal protein,
plays a central role in integrating Erk1/2 and PI3K/Akt pathways. We also found that ATP (1002M) and hypoxia
(3%O2), induced expression and activation of the Egr-1 transcription factor, and both stimuli acted, in part,
through G!i-initiated ERK1/2 signaling pathway. Apyrase (2.5U/ml), as well as the non-selective P2 receptor
antagonists, suramin, cibacron blue 3GA, and PPADS (all used at 1002M) attenuated hypoxia- and ATP-induced
DNA synthesis, indicating an activation and a functional role of P2Y/P2X purinoceptors in hypoxia-induced
proliferative responses. In addition, suramin, cibacron blue 3GA and apyrase, markedly attenuated hypoxia-
induced ERK1/2 activation and Egr-1 expression. Collectively, our ﬁndings demonstrate that PA adventitial
ﬁbroblasts can be considered as endogenous source and a target of extracellular nucleotides within the vascular
wall and that a hypoxia-induced autocrine loop of ATP signaling plays a critical role in the regulation of ﬁbroblast
proliferation under hypoxic conditions.
1. Ralevic V, Burnstock G. Pharmacol Rev. 1998, 50:413-92.
2. Di Virgilio F, Solini A. Br J Pharmacol. 2002, 135(4):831-842.
3. Stenmark KR, Mecham RP. Annu Rev Physiol. 1997, 59:89-144.
4. Stenmark KR, Gerasimovskaya EV, Nemenoff RA, Das M 2002, Chest, 122:326-334.
Extracellular ATP: a potential regulator of vasa vasorum neovascularization
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Pathological vascular remodeling is a key component and frequently life-threatening consequence, of vascular
diseases in both the systemic and pulmonary circulation
1,2. In a neonatal model of hypoxic pulmonary hyperte-
nsion, we have demonstrated that hypoxia-induced pulmonary artery (PA) remodeling is associated with marked
increases in adventitial thickening and the expansion of vasa vasorum network
2. However, the precise cellular and
molecular mechanisms contributing to these changes remain unclear. Extracellular adenine nucleotides are inc-
reasingly recognized as important regulators of vascular function
3,4. Since hypoxia has been shown to stimulate
ATP release in endothelial cells and ﬁbroblasts
5,6, we hypothesized that the endothelium of newly forming adv-
entitial vasa vasorum may represent another, as yet unidentiﬁed, source of extracellular ATP and that ATP may
mediate or modulate angiogenic responses in vasa vasorum endothelial cells (VVEC). To test this hypothesis,
VVEC were isolated from PA adventitia of chronically hypoxic calves and characterized for the expression of
endothelial markers. We found that acute hypoxic exposure (1% and 3% O2, 10-60 min) induced an increase in
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Springerextracellular ATP in VVEC conditioned media from 0.02 to 2.12 nmol. Quinacrine staining revealed ATP con-
taining vesicles in the cytosol and around the nuclei. We showed that hypoxia-induced ATP release could be
attenuated by the PI3K inhibitors LY294002 (20 2M) and Wortmannin (12M); the Rho-kinase inhibitor Y27632
(10 2M); and by the inhibitor of exocytosis NEM (4 2M) suggesting that regulated exocytosis and PI3K/Rho
kinase pathways are involved in hypoxia-stimulated ATP release. We also found that exogenous ATP and hyp-
oxia stimulated growth and tube formation in VVEC and induced activation of PI3K/Akt, ERK1/2, and mTOR/
p70S6K, all of which are known to be associated with mitogenic and angiogenic signaling in endothelial cells.
Notably, the magnitude of ATP-induced mitogenic responses in VVEC reached 20 fold, suggesting that these cells
represent physiologically relevant sources and the targets of adenine nucleotides. Finally, we demonstrated that
hypoxia-induced mitogenic responses in VVEC were signiﬁcantly attenuated by the P2 receptor antagonists,
suramin (100 2M) and cibacron blue 3GA (100 2M). In summary, our data support the idea that ATP released by
VVEC into the local adventitial environment may serve as a potent autocrine/paracrine factor contributing to
vasa vasorum neovascularization in hypoxic pulmonary hypertension. The characterization of purinergic receptors
and coupled signaling pathways in VVEC will provide unique targets for therapeutic strategies aimed at inhibiting
pathologic angiogenesis in the blood vessel wall.
1.Rupnick MA, Panigrahy D, Zhang CY, et al. Proc Natl Acad Sci U S A. 2002; 99:10730-10735.
2.Davie NJ, Crossno JT Jr, Frid MG, et al. Am. J. Physiol. Lung Cell Mol. Physiol. 2004; 286:L668-678.
3.Burnstock G. Arterioscler Thromb Vasc Biol. 2002; 22:364-373.
4. Di Virgilio F, Solini A. Br J Pharmacol. 2002, 135(4):831-842.
5.Gerasimovskaya EV, Davie NJ, Ahmad S, Tucker DA, White CW, Stenmark KR, Chest. 2005, 128:608S-610S.
6.Gerasimovskaya EV, Ahmad S, White CW, Jones PL, Carpenter TC, Stenmark KR. J Biol Chem. 2002, 277(47):
44638-44650.
Extracellular ATP acting on murine RAW 246.7 macrophages enhances
thrombin generation in the absence of cell death.
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Extracellular adenosine 50triphosphate (ATP) acting at the P2X7 receptor (P2X7R) has been shown to be imp-
ortant for macrophage inﬂammatory responses including the release of pro-inﬂammatory cytokines and formation
of reactive oxygen species. Host inﬂammatory responses are closely linked to coagulation where macrophages can
participate in events leading to the formation of thrombin in atherosclerosis and inﬂammation
1. Cloned P2X7Rs
couple to the rapid externalization of phosphatidylserine (PS), a cofactor for the assembly of the prothrombinase
complex, in the absence of cell death
2. The objective of the present study was to characterize the pharmacological
properties of endogenous murine P2X receptors expressed by a RAW264.7 macrophage cell line and the potential
role in prothrominase activity.
Fluorescent measurements of intracellular Ca
2+ concentrations in Fluo-4-AM loaded cells or Ethidium Bromide
(EtBr, MW 390 Da) inﬂux have been used to evaluate functional P2X receptor expression. Unless stated, all
experiments were performed in saline containing 147 mM NaCl, 2 mM KCl, 2 mM CaCl2, 1 mM MgCl2,1 2m M
glucose and 10mM HEPES (pH 7.4) at 37 -C. ATP (0.1 2m - 3 mM) elicited a dose dependent increase in
intracellular Ca
2+ with a peak response at 3 mM. ATP-stimulated a dose-dependent increase in EtBr uptake with
an EC50 944 T 7.4 2M( n= 3) providing evidence for the expression of the P2X7R. Using 1mM ATP, EtBr uptake
was observed to increase 2-fold with the removal of extracellular divalent cations (n=3) but was unaffected by
replacement of extracellular Na
+ with 154 mM N-methyl D-glucamine (n=3) or isotonic KCl (n=3). Pre-appli-
cation of 3 2M Ivermectin did not alter ATP induced EtBr uptake (n=3). EtBr uptake evoked by 3mM ATP was
blocked by KN-62 with an IC50 1.25 T 0.001 2M( n=3).
Brief activation of P2X7Rs (<10 mins) is associated with PS externalization
3 and reversible membrane blebbing.
Exposure of PS on the outer leaﬂet of the plasma membrane is associated with a number of macrophage functions
such as the adhesion to endothelium
4 and the assembly of the procoagulant enzyme complexes
1. Prothrombin is
activated to thrombin by the enzyme complex termed ‘‘prothrombinase’’ consisting the enzyme factor Xa, cofac-
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2+ and negatively changed phospholipids most commonly PS. Assays performed in the presence
of factors Va and Xa demonstrate that exposure to 3 mM ATP (>2 mins) enhanced the prothrombinase activity (3
fold) on macrophages. By contrast, only prolonged stimulation with 3 mM ATP (>30 mins) triggered the release
of lactate dehydrogenase which was blocked by KN-62 (IC50 = 0.283 T 0.04 2M, n=3). This data indicates that
extracellular ATP can rapidly trigger an increase in prothrombinase activity in the absence of cell death.
(1) Ananyeva, N.M.; Kouiavskaia, D.V.; Shima, M. & Saenko, E.L. Blood. 2002. 99, 4475-4485
(2) MacKenzie, A.B.; Young, M.T.; Adinolﬁ, E. & Surprenant, A. J. Biol. Chem. 2005. 280, 33968-33976
(3) Wilson, H.L.; Francis, S.E.; Dower, S.K. J. Immunol. 2004. 173, 1202-1208
(4) Lesauskaite, V.; Ivanviene, L.; Valanciute, A. Medicina. 2003. (Kaunas). 39, 529-534
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Leukocyte-endothelial interactions involve both cell adhesion through speciﬁc receptor-ligand pairs and bidirec-
tional cell signaling, and are affected by soluble mediators, which modulate adhesive molecules and signaling
events in both cell types. Extracellular ATP and ADP are important signaling molecules mediating leukocytosis,
thrombosis and several inﬂammatory responses in the vasculature, whereas adenosine has a non-redundant cou-
nteracting role in the attenuation of inﬂammation and tissue damage in vivo. The duration and magnitude of
purinergic signaling is governed by a network of ectoenzymes and endothelial and lymphoid cells are generally
characterized by counteracting, ATP-inactivating and ATP-regenerating/adenosine-eliminating, phenotypes, res-
pectively. Here we have identiﬁed a link between the adhesion cascade and extracellular purine turnover. Upon
adhesion, lymphocytes prevent adenosine formation in the endothelial microenvironment that, as a consequence,
impairs the vascular barrier function and facilitates subsequent step of leukocyte transmigration into the tissue.
Together, these leukocyte adhesion-mediated shifts in the local nucleotide and nucleoside concentrations may
represent a previously unrecognised paracrine mechanism affecting the functional state of the targeted endoth-
elium and co-ordinately regulating lymphocyte trafﬁcking between the blood and tissues.
Extracellular ATP inhibits neutrophil apoptosis by increasing intracellular
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At sites of inﬂammation ATP is released from activated platelets and endothelial cells, and delays neutrophil
apoptosis in a concentration- and time-dependent manner, with signiﬁcant effects occurring within 10 minutes of
ATP exposure (% apoptosis at 5 hours: 23.0 T 4.9 (mean T SEM) control vs 9.9 T 1.2 102M ATP, p<0.05). Typical
P2X-receptor agonists BzATP and "+MeATP, the stable ATP analogue ATP-+-S, and the typical P2Y-receptor
agonist 2MeSATP, delayed neutrophil apoptosis to levels comparable to ATP, whereas the P2Y-agonist UTP was
without effect. We found highly-pure (i.e. PBMC depleted) populations of human neutrophils express P2X-1,
P2X-5, P2Y-1, P2Y-2, P2Y-4, P2Y-6 and P2Y-11 receptor mRNA. Increases in intracellular calcium [Ca
2+]i were
demonstrated by Ca
2+ ﬂuorimetry to be induced by UTP and thus independent of the delay of neutrophil apo-
ptosis. We then investigated other possible mechanisms by which ATP inhibits apoptosis. Inhibition of cAMP-
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46.2 T 5.0 control vs 27.5 T 3.9 1002M ATP, p<0.05, vs 56.4 T 6.3 0.7mM Rp-8-Br-cAMPS with 1002MA T P ,
p<0.01), whilst ATP increased intracellular cAMP [cAMP]i levels. These data suggest that ATP-mediated delays
in neutrophil apoptosis are likely P2Y-11 receptor mediated via increases in [cAMP]i, and that these effects are
not associated with increases in [Ca
2+]i.
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Muscle contraction consumes more than 50% of the ATP produced by the striated cells, moreover, the working
muscle also releases some of its precious nucleotide into the extracellular milieu. However, growing evidence
shows that this release is not a pure waste. It appears in fact that skeletal muscle cells utilize extracellular ATP to
stimulate relevant autocrine/paracrine signaling pathways, related, for example, to the differentiative program.
Present work was aimed at investigating the purinergic signaling of adult skeletal muscle. First, we conﬁrmed, at
the single ﬁber level, the release of ATP during contractile activity. The electrically stimulation (ﬁve 30-mV pulses
of 2 ms duration with 500 ms interval) of cultured rat ﬂexor digitorum brevis muscle ﬁbers, isolated by the
collagenase method, caused a substantial, rapid (seconds) release of ATP into the extracellular ﬂuid, whose level
returned to baseline with an estimated half-decay time of about 20 min. The decrease of the ATP concentration in
the extracellular milieu represents an indirect observation of the presence of an ATP-hydrolyzing activity at
muscle ﬁber surface, that we measured as high as 41 T 4 nmol Pi liberated per mg protein (n = 3). Consistently,
RT-PCR and WB analyses show the presence of NTPDase-1 and NTPDase-2, NPP1, and !-sarcoglycan in muscle
ﬁbers. Different purinergic receptors have been reported to be expressed in striated cells, a ﬁnding that we
conﬁrmed in adult muscle ﬁbers. Moreover, we demonstrated that P2X4 is localized mainly in the T-tubule
membranes, i.e., the critical site of excitation-contraction coupling of skeletal muscle.
Because all the elements of extracellular ATP signaling are present in skeletal muscle, we speculated that both the
enhanced Ca
2+ entry as well as the subsequent activation of Ca
2+-dependent intracellular processes could mod-
ulate muscle contraction, especially during sustained contractile activity. Therefore, we examined different in
vitro stimulation protocols on a typical slow-twitch muscle (soleus) in order to mimic such prolonged activity. We
found that stimulation of soleus muscle at low frequencies (between 0.016 and 0.05 pulses/s) produced a slow
progressive rise of twitch tension (potentiation) which, after 40 twitches, was about 20% higher than the initial
value. We then applied different protocols devoted either to prevent or stimulate any possible effect of extrace-
llular ATP in tension potentiation. The removal of extracellular ATP by speciﬁc enzymes (hexokinase/apyrase),
the inhibition of P2X receptors by a cocktail of P2 blockers (PPADS, suramin, and RB-2), or Ca
2+-free conditi-
ons, all abolished tension potentiation. The addition of Zn
+ or ivermectin, at levels known to stimulate P2X4, were
without effects, suggesting that the receptor is already fully activated. On the contrary, elevated doses of Zn
+,
ivermectin or 2meSATP reduced twitch tension potentiation.
Taking together, these data reveal that ATP-mediated Ca
2+ entry plays, by still unknown mechanism/s, an imp-
ortant role in modulating the contractile activity of skeletal muscle and add new hints regarding the extracellular
ATP signaling of this tissue.
The work was funded by MIUR (PRIN03), Telethon Italy and CNR.
Extracellular interconversion of nucleotides indicates the presence of an ecto-
adenylate kinase activity in the rat hippocampus
Bea ´ta Sperla ´gh and E. Sylvester Vizi




SpringerWhereas the enzymatic mechanisms, responsible for the inactivation of extracellular ATP and giving rise to the
formation of adenosine are well delineated in the nervous system, less is known about the reverse process i.e. the
rephosporylation of nucleotides and/or nucleosides to ATP. Although an early study indicated that there is a
catalytic activity in the extracellular space to convert 2 ADP to ATP and AMP in rat brain synaptosomes with Km
in the millimolar range (Nagy et al., 1989) and similar ecto-adenylate kinase (EC 2.7.4.3) activity has been re-
ported in non-neuronal cells (Yegutkin et al., 2002), the reaction products of such an enzymatic conversion has
not been directly demonstrated in intact brain preparations. To fulﬁll this objective, rat hippocampal slices and
synaptosomes were exposed to increasing concentrations of various nucleotides and nucleosides and their extra-
cellular interconversion were analysed by the HPLC-UV technique. If the slices were exposed to ATP (20-100-
500 2M), it converted to ADP, AMP, adenosine, inosine and hypoxanthine according to the enzymatic process
catalysed by the known families of ectonucleotidases. On the other hand, when the slices were challenged with
ADP, in addition to the generation of adenosine, inosine and hypoxanthine, a parallel formation of ATP and
AMP was also observed, which was strictly dependent on the initial concentration of ADP. A similar process was
also observed in puriﬁed synaptosomes; however AMP formation in this case prevailed, and ATP generation
could be only observed at higher initial ADP concentrations (100-500 2M). In the presence of the speciﬁc ade-
nylate kinase inhibitor diadenosine pentaphosphate (Ap5A, 200 2M), the decomposition of ADP and the parallel
formation of ATP in the slices was signiﬁcantly slowed down, although some additional ATP generation was also
detected, which was probably due to the breakdown of Ap5A to ATP, or to the release of ATP by P2 receptor
activation (Ballerini et al., 1996), homo- or heteroexchange (Sperla ´gh et al., 2003) or by other mechanism. Nev-
ertheless, no substantial change in the interconversion of ADP to ATP and AMP was found in the presence of the
nucleoside transport inhibitor dypiridamole (3 2M), the P2 receptor antagonist PPADS (30 2M) and the connexin
hemichannel inhibitor ﬂufenamic acid (50 2M). When slices were exposed to AMP or adenosine, ectokinase
activity was not detected, i.e. neither ATP nor ADP formation was observed.
In summary, here we demonstrate the parallel formation of ATP and AMP from ADP in the rat hippocampus,
indicating that there is an ecto adenylate kinase activity in this brain area. This activity, which functions in the
micromolar range, and is only partly associated to nerve terminals might represent the missing link of the nucl-
eotide utilizing enzyme chain present in the brain tissue.
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e) has been implicated in the regulation of intracellular calcium concentration
([Ca
2+]i) in many cell types and by means of different mechanisms (1-6). In human granulocytes, micromolar
NAD
+
e activates cell-speciﬁc functional responses, i.e. superoxide and NO generation and chemotaxis, by trigg-
ering the following signalling cascade: i) activation of adenylate cyclase (AC) and accumulation of cyclic AMP
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Springer(cAMP), ii) activation of protein kinase A, iii) stimulation of ADP-ribosyl cyclase activity with subsequent ove-
rproduction of cyclic ADP-ribose (cADPR), a universal Ca
2+ mobilizer through activation of ryanodine receptors,
and iv) inﬂux of extracellular Ca
2+ (7). Here we demonstrate that the addition of millimolar NAD
+
e to human
granulocytes promotes the intracellular production of both Inositol-1,4,5-trisphosphate (IP3) and cAMP, leading
to a two-step [Ca
2+]i elevation: an initial IP3-mediated Ca
2+ release from intracellular stores, followed by a second
cADPR-mediated sustained inﬂux of extracellular Ca
2+. The use of suramin, a broad inhibitor of the P2Y puri-
noceptors sub-family, abrogated the NAD
+-induced increases of [IP3]i, [cAMP]i, [cADPR]i and [Ca
2+]i, thus
indicating a role for a phospholipase C (PLC)- and AC-coupled P2Y receptor in initiating the signalling pathway
triggered by NAD
+
e. The P2Y11 receptor is the only known member of the P2Y receptor sub-family coupled to
both PLC and AC (8). Therefore, we investigated Ca
2+ responses to NAD
+
e in an hP2Y11-transfected 1321N1
astrocytoma cells (9), compared to native P2Y11-negative cells. Micromolar NAD
+
e induced a two-step elevation
of [Ca
2+]i in transfected cells, but not in the control cells, due to the enhanced intracellular production of IP3,
cAMP and cADPR. Thus, our results strongly suggest that "-NAD
+
e is an endogenous agonist of the P2Y11
purinoceptor.
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EXTRACELLULAR NUCLEOTIDES ENHANCE EGF-INDUCED C-FOS
EXPRESSION IN TWO BREAST CANCER CELL LINES, BY DRIVING
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There is increasing evidence that extracellular nucleotides play a pivotal role in cancer growth, metastasis, and
pain. We have previously shown that extracellular nucleotides synergise with growth factors to induce expression
of the proto-oncogene c-fos in various cell types. In this study, we have examined the effect of extracellular
nucleotides on growth factor-induced signalling in two breast cancer cell lines, HS578T and T47D. Using RT-PCR
we found expression of various P2Y and P2X receptor subtypes in both cell lines. Co-stimulation of these cells
with extracellular nucleotides and EGF lead to induction of endogenous c-fos above that observed with either
treatment alone. This effect was recapitulated using HS578T and T47D c-fos reporter cells and was more pron-
ounced with EN that predominantly act via P2Y receptors. EGF-induced phosphorylation of p44/p42 MAPK was
unaffected in either cell type following co-stimulation, although phosphorylation of AKT and ERK5 was effected.
EGFR phosphorylation appeared diminished upon co-stimulation, however the levels of total EGFR were also
diminished in cold 1% Triton lysates in both cell types. When lysates were prepared in denaturing hot SDS buffer
no reduction in EGFR levels was observed. This suggests that extracellular nucleotides may lead to inclusion of
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Springerthe EGFR into a Triton-insoluble membrane fraction, possibly lipid rafts, which may explain facilitated signalling
to the c-fos promoter. Synergy between extracellular nucleotides and growth factors may represent an important
mechanism promoting the growth and spread of tumours. This may be particularly relevant for breast cancer
metastasis to bone as bone cells constitutively release ATP, and in response to mechanical strain. This could play
a key role in creating an environment propitious for breast cancer cell growth after metastasis.
Extracellular nucleotides mediate LPS-induced IL-8 release from monocytes and
neutrophil migration.
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Increasing evidence suggests that extracellular nucleotides may mediate some of the proinﬂammatory effects of
gram negative bacteria lipopolysaccharides (LPS). For instance, P2Y6 receptor activation is required for the LPS–
induced secretion of interleukin-8 (IL-8) by THP-1 cells. Knowing that peripheral blood leukocytes (monocytes,
lymphocytes and neutrophils) and HUVEC also express P2Y6 mRNA and that they respond to LPS by the
secretion of IL-8, we have tested whether extracellular nucleotides mediate IL-8 release by these cells. As exp-
ected, all cells analyzed released IL-8 in response to LPS. However, this release was nucleotide-dependent only in
monocytes, as it was signiﬁcantly inhibited by a nucleotide scavenger (apyrase) and P2Y6 receptor antagonists
(MRS 2578 and reactive blue 2). Importantly, the former inhibition by apyrase was not due to the formation of
adenosine. In further support for a role of P2Y6 in IL-8 release by monocytes, these cells secreted important
amounts of IL-8 when stimulated with UDP.
IL-8 is a major human chemokine, so we next tested the chemotactic activity of conditioned media from treated
monocytes on neutrophil migration. Using modiﬁed Boyden chambers with an endothelial monolayer, we obse-
rved that the media of LPS-stimulated monocytes recruited signiﬁcantly more neutrophils than the corresponding
media to which LPS were added simultaneously with apyrase. Conditioned media of UDP-stimulated monocytes
were as effective to induce neutrophil migration as those of the cells treated with LPS. In addition, IL-8 neutral-
izing antibodies added to the media of LPS- or UDP-stimulated monocytes substantially decreased their chem-
otactic activity, demonstrating that IL-8 was the main chemokine responsible for cellular migration in these
assays.
In conclusion, extracellular nucleotides have the ability to regulate neutrophil recruitment to inﬂamed tissues by
mediating IL-8 release from human monocytes/macrophages.
Feed forward cycle of hypotonic stress-induced ATP release, purinergic receptor
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ATP is released in many cell types upon mechanical strain, the physiological function of extracellular ATP is
largely unknown, however. Here we report that ATP released upon hypotonic stress stimulated prostate cancer
cell proliferation, activated purinergic receptors, increased intracellular [Ca
2+]i and initiated downstream signal-
ling cascades that involved mitogen activated protein kinases (MAPKs) ERK1/2 and p38 as well as PI3-kinase.
MAPK activation, the calcium response as well as induction of cell proliferation upon hypotonic stress were
inhibited by preincubation with the ATP scavenger apyrase, indicating that hypotonic stress-induced signalling
pathways are elicited by released ATP. Hypotonic stress increased prostaglandin E2 (PGE2) synthesis. Conseq-
uently, ATP release was inhibited by antagonists of PI3-kinase (LY294002 and wortmannin), phospholipase A2
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Springer(MAFP), cyclooxygenase-2 (COX-2) (indomethacin, etodolac, NS398) and 5,8,11,14-eicosatetraynoic acid (ET-
YA), which are involved in arachidonic acid metabolism. Furthermore, ATP release was abolished in the pres-
ence of the adenylate cyclase (AC) inhibitor MDL-12,330A, indicating regulation of ATP-release by cAMP. The
hypotonic stress-induced ATP release was signiﬁcantly blunted when the ATP-mediated signal transduction ca-
scade was inhibited on different levels, i.e. purinergic receptors were blocked by suramin and PPADS, the Ca
2+
response was inhibited upon chelation of intracellular Ca
2+ by BAPTA, and ERK1,2 as well as p38 were inhibited
by UO126 and SB203580, respectively. In summary our data demonstrate that hypotonic stress initiates a feed
forward cycle of ATP release and purinergic receptor signalling resulting in proliferation of prostate cancer cells.
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The ﬁelds of P2Y-receptors and NTPDases lack analytical tools for the exploration of these proteins. Therefore,
we designed a novel probe: N
2,N3-etheno-adenosine-50-triphosphate, (N
2,N3-(-ATP) for improving the adenine
ﬂuorescence characteristics ( and 1max) while preserving its H-bonding pattern, required for molecular recognit-
ion. Here, we describe four novel syntheses of the target (-nucelotide, and related analogues. These methods are
short (3-4 step syntheses), facile, and provide the product regiospeciﬁcally and in a reasonable yield. In addition,
we report on the spectral properties of N
2,N3-(-ATP, including absorption and emission spectra, and dependence
of the spectral features on pH and polarity of the medium. Speciﬁcally, maximum emission of N
2,N3-(-ATP in
water is observed at 420 nm ( 0.03, excitation at 290 nm). The biochemical properties of N
2,N3-(-ATP were
evaluated with respect to P2Y1-receptor and NTPDase1 and 2. N
2,N3-(-ATP was found equipotent to ATP at the
P2Y1-receptor, and was hydrolysed by NTPDase1 and 2 at about the same rate as ATP. However, substitution at
the exocyclic amine of N
2,N3-(-ATP signiﬁcantly reduced afﬁnity to P2Y1-R and NTPDase1. These observations
emphasize the importance of free N1 and N
6 positions for the recognition of ATP-based probes by target proteins.
Furthermore, N
2,N3-(-ATP was ﬂuorescent also in the protein-bound state. Based on the unique ﬂuorescence and
full recognition by target proteins, we propose N
2,N3-(-ATP and related nucleotides as useful probes for studies
of these proteins.
1A US provisional patent application ﬁled on 24 January, 2005.
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P2Y2 receptors belong to the family of G protein-coupled nucleotide (P2) receptors. They are activated by the
physiological nucleotides UTP and ATP. There is a lack of potent and selective P2Y2 receptor ligands [1] which
are required as pharmacological tools. In addition, such compounds have potential as novel therapeutics, e.g. as
antiinﬂammatory agents, for the treatment of coronary vasospastic disorders, as analgesics, or as neuroprotective
drugs [1,2]. In order to design potent and speciﬁc agonists and antagonists for the P2Y2 receptor, information
about the structure, constitution, and conformation of the orthosteric binding site and of potential allosteric
binding sites will be highly useful.
The present study focuses on investigating the importance of single amino acids for ligand binding and activation
of the P2Y2 receptor. The amino acid residues His
262, Arg
265 and Arg
292 were previously shown to be part of the





found to be essential for apical targeting of the P2Y2 receptor but do not interfere with receptor activation [4].
We have designed several P2Y2 receptor mutants, including R177_180A, R194H and R272A. A retroviral tran-
sfection system was used to overexpress the wild-type and the mutated receptors in 1321N1 astrocytoma cells.
Characterization of the mutants was performed using a ﬂuorimetric calcium assay. A series of physiological
nucleotides, including the agonists ATP and UTP, as well as dinucleotide derivatives, have been tested at the
receptor mutants. Several non-competitive P2Y2 receptor antagonists previously developed in our group, in-
cluding ﬂavonoids [5], biﬂavonoids, and anthraquinone derivatives were also used to study the mutated P2Y2
receptors.
Furthermore, the role of the disulﬁde bonds was investigated. Under disulﬁde reducing conditions [6] (1–10 mM
dithiothreitol) activation of the P2Y2 receptor by UTP or ATP was strongly affected. Calcium release from the
endoplasmatic reticulum was reduced by up to 73 % while the muscarinic M3 receptor, endogenously expressed
on the cells, showed a very moderate decrease in activation of only 19 %. These results are consistent with a
computer-generated model of the P2Y2 receptor and indicate the existence of a disulﬁde bond in the extracellular
loops (Cys
25–Cys
278), which is essential for receptor activation.
[1] Brunschweiger; Mu ¨ller Curr. Med. Chem. 2006, 12, 763–771
[2] Moriyama et al., J. Neuroscience 2003, 23, 6058–6062
[3] Erb et al., J. Biol. Chem. 1995, 270, 4185–4188
[4] Qi et al., J. Biol. Chem. 2005, 280, 29169–29175
[5] Kaulich et al., Drug Dev. Res. 2003, 59, 72–81
[6] Heerding et al., Biochemistry 2001, 40, 8369–8377
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Chondrocytes are important cells in the development and growth of bones in mammals. Several molecules, hor-
mones, cytokines and growth factors drive the chondrocytes to a proper maturation and development. Among all
of them, transforming growth factors (TGF-"s), bone morphogenetic proteins (BMP), insulin-like growth factors,
(IGFs), ﬁbroblast growth factors (FGFs), interleukins (ILs) and others, interplay an organised sequence of events
that permit the normal development of bones. Alteration in any of these substances, or more commonly in any of
their receptors, will produce changes in ossiﬁcation that will lead to a group of pathologies termed as bone
displasias. One of these bone syndromes is achondroplasia, the most common type of dwarﬁsm. Achondroplasia
(dwarﬁsm) is a genetic pathology due to a mutation in the gene that encodes for the ﬁbroblast growth factor type
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Springer3 receptor (FGFR3, G380A). This mutation severely affects the chondrocytes, the consequence of such failure
being an acute reduction in the bone length.
We have investigated the presence of P2Y receptors in achondroplasic chondrocytes by means of immunocyto-
chemical techniques and intracellular Ca
2+ measurements. Also, we have explored the ability of these cells to
degrade extracellular nucleotides and dinucleotides by means of the HPLC technique.
Rat achondroplasic chondrocytes present P2Y1, P2Y2, P2Y6 and P2Y11 receptors as observed after immunocy-
tochemical analysis. At least some of the P2Y receptors were active since the perfusion of cells with various
nucleotides and dinucleotides produced signiﬁcant changes in the intracellular Ca
2+ concentration. Among them,
diadenosine polyphosphates (Ap3A, Ap4Aa n dA p 5A), ATP and UTP were the most effective compounds. At a
wide range of concentrations (10
j9 Mt o1 0
j3 M), ATP provided the highest increment of intracellular calcium,
followed by UTP, Ap4A, Ap5A and Ap3A. When analysed the pD2 values obtained from the concentration
response curves, it was possible to obtain the following potency order: Ap3A=A p 4A=A p 5A = ATP = UTP.
Four different antagonists were used to investigate P2Y receptors: MRS2179, suramin, PPADS and reactive blue
2 (RB-2). Among them the most effective on the Ca
2+ transient elicited by Ap4A was PPADS.
Diadenosine polyphosphates were weakly hydrolysed by extracellular ecto-nucleotidases, indicating that the eff-
ects observed were due to the dinucleotides rather than to their cleavage products.
This work has been supported by a research grant from la Comunidad de Madrid CAM GR/SAL/057372004,
Fundacion Lo ´pez Hidalgo and Fundacio ´n ICO.
G PROTEIN-COUPLED RECEPTORS TOPOLOGY: LIGAND-BASED
HOMOLOGY MODELING AS NEW APPROACH TO SIMULATE THE
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G protein-coupled receptors (GPCRs) constitute a very large family of heptahelical, integral membrane proteins
that mediate a wide variety of physiological processes, ranging from the transmission of the light and odorant
signals to the mediation of neurotransmission and hormonal actions. GPCRs are dysfunctional or dysregulated in
several human diseases and are estimated to be the targets of >40% of the drugs used in clinical medicine today
1.
The crystal structure of rhodopsin provides the ﬁrst information on the three-dimensional structure of GPCRs,
which now supports homology modeling studies and structure-based drug-design approaches
2.
In this work we review our recent work
3 on adenosine receptor, a family of GPCRs and, in particular, on Ade-
nosine A3 receptor subtype antagonists. We will focus on a different approach to computationally inspect the
reorganisation of the human A3 receptor induced by the antagonist-binding. Ligand-based homology modeling is
a new strategy to simulate the antagonist-like conformational states of the receptor induced by the ligand binding.
The success of this computational tool is due to the synergic interaction between theory and experiment.
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SpringerFlow chart of the ligand-based homology modeling technique considering an evolution of a conventional homo-
logy modeling algorithm implemented by Molecular Operating Environment modeling software.
1 Moro, S.; Bacilieri, M.; Deﬂorian, F.; Spalluto, G. New J. Chem. 2006, 30, 1–8.
2 Moro, S.; Deﬂorian, F.; Bacilieri, M.; Spalluto, G. Curr. Med. Chem. 2006, 13, 763–771.
3 Moro, S.; Deﬂorian, F.; Bacilieri, M.; Spalluto, G. Curr. Pharm. Des. 2006, 12, in press.
Gene expression proﬁling for the identiﬁcation of G-protein coupled receptors
in human platelets
Oscar O ¨ Braun
1, Stefan Amisten
1, Anders Bengtsson




2, Lund University Hospital, Lund, Sweden
oscar.braun@med.lu.se
G protein coupled receptors (GPCRs) play an important role in regulating platelet activation and thrombus
formation. Aberrant platelet activation may lead to thrombus formation and occlusion of blood vessels that may
result in myocardial infarction and stroke. It is of great clinical importance to further understand the mechanisms
inﬂuencing platelet activation. The aim of this study was to generate an expression proﬁle for G-protein coupled
receptors in circulating human platelets. Several studies have explored platelet gene expression based on large
amounts of blood, time consuming platelet puriﬁcation methods and samples of varying grade of contamination
by other cell types. In this study, a rapid platelet puriﬁcation process was used in combination with a very sensitive
leukocyte contamination detection system to generate a platelet gene expression proﬁle using the Affymetrix
Human HG-U133 Plus 2.0 GeneChip\. The generated gene expression proﬁle was used in combination with
quantitative real-time PCR (Q-RT-PCR) to characterize the G-protein coupled receptor gene expression in cir-
culating platelets. A platelet gene expression proﬁle with low levels of leukocyte contamination revealed expre-
ssion of 3,408 genes in circulating platelets. Gene expression of 24 G-protein coupled receptors was validated by
Q-RT-PCR. The thrombin receptor (1865 T 178%) was the most abundant GPCR expressed on platelets, follo-
wed by the ADP receptor P2Y12 (459 T 88%), succinate receptor 1 (257 T 48%), P2Y1 (100%), the orphan
receptor P2RY10 (68.2 T 3.3%), the LPA receptor GPR23 (48.2 T 11%), the orphan receptor GPR92 (26.1 T
3.3%), the alpha 2 adrenergic receptor (18.4 T 4.4%), the orphan receptor EBI2 (6.31 T 0.42), two adenosine
receptors A2A (2.94 T 0.24%) and A2B (2.88 T 0.16%) and the LPA receptor EDG2 (2.59 T 0.39%). In conclusion
we show for the ﬁrst time that the A2B receptor is expressed, in equal amount as the A2A receptor, in human
platelets. Interestingly enough we also conclude that eight among the 24 most abundant GPCRs expressed in
human platelets are or were thought to be purinergic receptors.
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Signalling through purinoreceptors is effectively controlled by nucleotide-metabolising enzymes, which regulate
the availability of extracellular nucleotides. Prominent roles are played by members of the ecto-nucleoside trip-
hosphate diphosphohydrolase (ENTPD, CD39-like) and ecto-nucleotide pyrophosphatase/phosphodiesterase (-
ENPP) families. Despite their importance for the control of purinergic signalling, investigation of these enzyme
families has been hampered by the lack of available antibodies, especially such ones that recognize the enzymes in
their native conformation. This is in part due to the structural complexity of these enzymes, which makes it
difﬁcult to produce sufﬁcient quantities of recombinant protein for immunization purposes.
Genetic immunization with cDNA expression vectors poses an attractive alternative to conventional immuniza-
tion strategies, since the protein of interest is produced in native conformation by cells of the immunized host (1).
We used this approach to raise antibodies against mouse ENTPDs 1, 2, 5, and 6, human ENTPDs 2 and 6, as well
as human ENPP-2 (Autotaxin). All antisera recognized their target antigens in immunoﬂuorescence analysis of
HEK cells transfected with the respective cDNAs, either on the surface of living cells or, in the case of the
secreted proteins ENTPD5 and ENPP2, in ﬁxed and permeablized cells. These studies show that genetic immu-
nization is a feasible method for raising antisera against ecto-enzymes in their native conformation, even in cases
where recombinant production/puriﬁcation of the antigen is difﬁcult.
supported by DFG grant No310/6-1 to FH and FKN
(1) Adriouch, S.; Dubberke, G.; Diessenbacher, P.; Rassendren, F.; Seman, M.; Haag, F.; Koch-Nolte, F., Probing
the expression and function of the P2X7 purinoceptor with antibodies raised by genetic immunization. Cell Im-
munol 2005, 236, (1–2), 72–77.
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P2X purinoceptors contain cytosolic N- and C- termini, two transmembrane domains and an extracellular ligand-
binding domain with ﬁve conserved intra-chain disulﬁde bridges. Peptide immunizations have generated antisera
that are useful for detecting P2X family members by immunoblot analyses. In general however, these antipeptide
antibodies do not recognize the native purinoceptors on the cell surface. Antibodies against native purinoceptors
are devoutly to be desired for monitoring purinoceptor expression on the cell surface. Production of soluble
recombinant purinoceptors in sufﬁcient quantities for immunizations is frought with inherent difﬁculties due to
the presence of cysteine residues and glycosylation sites. Genetic immunization with full length cDNA expression
vectors poses an attractive alternative immunization strategy since the protein of interest is produced in native
conformation by cells of the immunized host (1). Usind cDNA immunization technology we have successfully
raised antibodies that recognize human and mouse P2X1, P2X4, and P2X7 on the surface of living cells and on
paraformaldehyde-ﬁxed cells. We illustrate the utility of these antibodies for monitoring cell surface expression of
wild type and mutant P2X receptors by immunoﬂuorescence microscopy and ﬂow cytometry of transiently tran-
sfected HEK cells.
supported by DFG grant No310/6-1 to FH and FKN
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Glycolysis is important to ischaemic tolerance, and may be crucial to cardioprotection via adenosine and its
receptors. We assessed effects of glycolytic inhibition on functional tolerance to 25 min ischaemia and 60 min
reperfusion, and protection mediated by adenosine or A1 adenosine receptor (A1AR) overexpression in mouse
hearts. Control hearts (11 mM glucose as substrate) rapidly developed ischaemic contracture (time to onset or
TOC=272 T 22 s; peak contracture or PC=80 T 6 mmHg), and displayed signiﬁcant diastolic dysfunction (27 T 1
mmHg) with incomplete recovery of left ventricular developed pressure (LVDP) to only 58 T 3 mmHg (46 T 4%
of pre-ischaemia) after reperfusion. Glycolytic inhibition with 10 mM pyruvate+iodoacetic acid (IAA; 150
followed by 50 2M), which reduced GAPDH activity by ~98%, markedly delayed ischaemic contracture (TO-
C=779 T 72 s; PC=63 T 4 mmHg). This effect was duplicated by pyruvate alone, and by treatment with 5 mM 2,3
butanedione monoxime (uncoupling contractile function from [Ca
2+]) or 10 2M BIIB-513 (inhibiting Na
+-H
+
exchange). Despite delayed contracture, glycolytic inhibition worsened functional recovery (LVDP=26 T 3 mm-
Hg; 22 T 3%), due to exaggerated diastolic dysfunction (47 T 3 mmHg). In glucose-perfused hearts, adenosine (25
2M) and cardiac A1AR overexpression delayed ischaemic contracture and improved post-ischaemic recovery
(diastolic pressures=12–16 mmHg, LVDP=75–80 mmHg), as did inhibition of adenosine kinase with 5 2M iodo-
tubercidin to enhance endogenous [adenosine]. None of these strategies modiﬁed ischaemic contracture when
glycolysis was inhibited, whereas adenosinergic improvements in post-ischaemic outcome were still evident. These
data collectively reveal that: i) glycolysis improves post-ischaemic functional recovery in murine myocardium
despite accelerating contracture; ii) ischaemic contracture involves Ca
2+- or ion-dependent processes; iii) aden-
osine/A1AR-mediated inhibition of ischaemic contracture is glycolysis-dependent; whereas iv) adenosinergic
enhancement of post-ischaemic outcome involves glycolysis-independent mechanisms.
GSK-3 is involved in 2MeSADP signalling in cerebellar granule neurons
Raquel Pe ´rez-Sen, Felipe Ortega, and M
aTeresa Miras-Portugal.
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Cerebellar granule neurons express a great variety of nucleotidic receptors, both of ionotropic (P2X1,2,3,4,7)a n d
metabotropic type (P2Y1,4,12). These receptors are heterogeneously distributed along the granule cell cytoarch-
itecture between cell bodies and prolongations. Functional responses to nucleotides, measured as increases in the
intracellular calcium concentration, were dependent on the differentiation state of the culture, becoming signiﬁ-
cant in mature cultures (1). The intracellular nucleotide signalling beyond the calcium signal was investigated
beginning with MAPK kinases and GSK-3, proteins which play a key role in multiple processes of survival and
differentiation in granule neurons (2, 3).
We ﬁrst analyzed the effect of metabotropic nucleotidic agonists, among them, the highest levels of phosphor-
ylation of ERK-1,2 and GSK-3, were found for the ADP receptor agonist, 2MeSADP. The responses found for
the pyrimidine agonists UTP and UDP were much lower. These results agree well with the expression levels of
metabotropic nucleotidic receptors in granule neurons, as the major population of nucleotide responding cells was
sensitive to stimulation with 2MeSATP and 2MeSADP. Although the effect of 2MeSADP was clearly metabot-
ropic, it seemed to be mediated by other P2Y receptor different from P2Y1 and P2Y12, as it remained in the
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Springerpresence of the speciﬁc P2Y1 and P2Y12 antagonists MRS-2179 and 2MeSAMP, respectively. In addition, the
2MeSADP-mediated increases in ERK-1,2 and GSK-3 phosphorylation were both sensitive to treatment with
Pertussis toxin and wortmanin, suggesting the existence of a Gi coupled ADP receptor mediating these effects in
cultured granule neurons, and that PI3-kinase is a critical intermediate step. These data are relevant considering
that the PI3-kinase-Akt-GSK-3 cascade is an important survival signalling pathway in this cellular model (3, 4).
Taking into account that GSK-3 phosphorylation at Ser
9,21 involves the inactivation of this enzyme, one of the
main substrates of GSK-3 activity was examined, that is "-catenin. In the absence of GSK-3 activity, degradation
of "-catenin is abolished and this protein accumulates in the cytosol, and can reach the nucleus where it acts as a
transcriptional regulator (5). 2MeSADP was able to induce translocation of "-catenin to the nucleus of cerebellar
granule neurons, implying effects of this nucleotidic agonist at the transcriptional level.
1. Herva ´s et al., 2003. J. Neurosci. Res. 73:384–399.
2. Subramaniam et al., 2005. J. Neurosci. 25:2838–2852.
3. Chin et al., 2005. Mol. Brain Res. 137:193–2001.
4. Miller et al., J. Biol.. Chem. 272:9847–9853.
5. Nelson and Nusse 2004. Science 303:1483–1487.
Guanosine protects SY5Y neuroblastoma cells against MPP
+-induced apoptosis
K.M. Pettifer, C. Bau, S. Jiang, E.S. Werstiuk, M.P.Rathbone.
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Guanosine, an non-adenine based purine nucleoside exerts trophic and neuroprotective effects in the central
nervous system. Apoptosis (a morphological form of programmed cell death) has been inmplicated in the path-
ophysiology of Parkinson_s disease (PD), and thought to contribute to cell death of the dopaminergic neurons in
the substantia nigra and striatum. 1-Methyl-4-pheny-1,2,3,6- tetrahydropyridinium iodide (MPP
+) is a dopami-
nergic neurotoxin that mimics the intracellular characteristics of PD, such as apoptosis. We have shown recently,
that guanosine protects different types of cells from apoptosis induced by various stimuli (1, 2). We therefore
evaluated the effect of guanosine on MPP
+-induced apoptosis in human SH-SY5Y neuroblastoma cells. We added
guanosine to neuroblastoma cells prior to, or at the same time, or 24 h after the adminsitration of MPP
+ and
determined the extent of apoptosis by oligonucleosomal ELISA. We also measured caspase-3-activity by a spec-
torphotometric assay, and !-synuclein protein expression by an ELISA.
Exposure of neuroblastoma cells to MPP
+ (10 2M j 5 mM for 24 j 72 h) induced apoptosis in a concentration-,
and time-dependent manner (p < 0.01; 500 2M MPP
+ vs. vehicle at 48 h). Administration of guanosine (100 2M)
prior to, at the same time, or after the addition of MPP
+ abolished MPP
+-induced apoptosis (p < 0.05; vs. MPP
+ at
48h). Neither MPP
+ nor guanosine had any signiﬁcant effect on !-synuclein protein expression. Treatment of SH-
SY5Y cells with MPP
+ (500 2M) signiﬁcantly increased caspase-3 activity (p < 0.05 at 72 h vs. control at 0 time),
and this was abolished by pre-treatment, or co-treatment with guanosine. In contrast, administration of guanosine
24, or 48 h after MPP
+ addition had no signiﬁcant effect on the activity of this enzyme. Our data show that pre-
treatment, or co-treatment of SH-SY5Y neuroblastoma cells with guanosine prevents MPP
+-induced apoptosis,
and this is mediated by inhibiting caspase-3 activation. More importantly, guanosine can also reverse the pro-
apoptotic effect of MPP
+ when it is added after DNA fragmentation is already in progress. These ﬁndings reveal a
unique neuroprotective effect of guanosine, with a potential for effective pharmacological intervention in PD.
References:
1. DiIorio P, Ballerini P, Traversa U, Nicoletti F, D_Alimonte I, Kleywegt S, Werstiuk ES, Rathbone MP, Cacaigli
F, Ciccarelli R. 2004. The anti-apoptotic effect of guanoisne is mediated by the activation of the PI3-kiase/AKT/
PKB pathway in cultured rat astrocytes. Glia, 46: 356–368.
2. Pettifer KM, Kleywegt S, Bau C, Ramsbottom JD, Vertes E, Ciccarelli R, Caciagli F, Werstiuk ES, Rathbone
MP. 2004. Guanosine protects SH-SY5Y cells against "-amyloid-induced apoptosis. NeurReport, 15: 833–836.
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Osteoblasts are largely exposed to toxic and non-toxic doses of ROS due, for instance, to bone resorption proc-
esses by osteoclasts. High doses of ROS play an important role in controlling osteoblastic differentiation, by
acting at the transcriptional level through NF-kB and Egr-1 transcription factors. In this study we examined the
consequences of H2O2 administration on osteoblast calcium signalling. In the highly differentiated HOBIT cell
line, characterized by an elevated sensitivity to nanomolar extracellular ADP and UTP, addition of 1mM H2O2
induced oscillatory increases the cytosolic calcium concentration that were followed by a steady and sustained
calcium increase. Long lasting rhythmic calcium activity was induced by lower H2O2 doses (10–502M). These
calcium increases, due to both release from intracellular stores and inﬂux from the extracellular milieu, were
totally prevented by incubating the cells with suramin or apyrase. Similar results were obtained with the osteos-
arcoma cell line MG-63. At difference with HOBIT, these cells are totally unrensponsive to ADP and respond to
micromolar concentrations of UTP. In SAOS and in ROS17/2.8 osteosarcoma cells, 1mM H2O2 induced a slow,
moderated and sustained increase of calcium which was dependent on inﬂux from the extracellular medium and
could not be prevented by suramin and apyrase. SAOS cells responded to micromolar ADP but were largely
unresponsive to UTP, while ROS17/2.8 were totally insensitive to ATP, ADP and UTP in keeping with the
evidence that these cells lack functional purinergic receptors. In transfected ROS 17/2.8, permanently over-exp-
ressing the P2Y2 receptor (ROS/P2Y2), spontaneous calcium oscillations were observed in 60% of the population
and nanomolar concentration of extracellular ATP or UTP activated calcium oscillations in silent cells. Sponta-
neous activity was inhibited by suramin and apyrase. H2O2 (10–502M) mimicked ATP administration, inducing
oscillatory calcium activity that was blocked by suramin and apyrase. These results suggested that mild oxidation
activated purinergic signalling in osteoblast expressing P2Y2 receptors. The possibility that oxidative stress could
induce ATP release was evaluated by measuring the concentration of extracellular ATP with the highly sensitive
luciferin-luciferase luminescence method. Dose- and time-course experiments, however, failed to reveal an incr-
ease of extracellular ATP following H2O2 administration, indicating that the oxidative condition did not promote
ATP release.
The possibility that mild oxidation of P2Y2 receptor could lead its sensitization was explored in ROS/P2Y2 cells.
The sensitivity of these cells to nanomolar UTP concentrations was decreased by three orders of magnitude in the
presence of DTT, which was effective also in inhibiting spontaneous calcium oscillations. On the other hand, the
membrane-impermeant oxidant 5,5"-dithiobis (2-nitrobenzoic acid) (DTNB) induced calcium oscillations that w-
ere inhibited by incubating the cells with suramin or apyrase.
Taken together, these results indicate that mild oxidative stress could activate purinergic signalling in osteoblasts
through the sensitization of P2Y2 receptor.
Hepatic Adenosine Regulates Blood ﬂow and Sensory Reﬂex Control of
Renal Function
W. Wayne Lautt, Zhi Ming, and Dallas J. Legare
Department of Pharmacology & Therapeutics, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba,
Canada
Email: wlautt@cc.umanitoba.ca
This presentation represents an overview of studies that demonstrate a unique role for adenosine in regulation of
hepatic arterial blood ﬂow and as a sensory neurotransmitter that monitors hepatic regional blood ﬂow and results
in reﬂex control of renal function including accounting for renal ﬂuid retention in liver cirrhosis.
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SpringerThe hepatic arterial buffer response (HABR) is the inverse response of the hepatic artery to changes in portal
blood ﬂow. This material has been reviewed (1). Adenosine is produced, in an oxygen-independent manner, at a
constant rate and is secreted into the small extravascular space of Mall that surrounds the terminal branches of the
portal vein and hepatic artery. The concentration of adenosine is regulated by washout into the portal blood.
Reduction in portal blood ﬂow leads to accumulation of adenosine and dilation of the hepatic artery. This mec-
hanism is sufﬁciently powerful to regulate the hepatic artery from full constriction to full dilation.
We tested the hypothesis that the renal dysfunction seen in chronic liver disease was not related to a baroreceptor
reﬂex detecting portal hypertension but rather to a reﬂex dependent upon detection of reduced intrahepatic blood
ﬂow. By this hypothesis, reduction in portal ﬂow leads to accumulation of adenosine in the space of Mall where
sensory nerves exist. The sensory nerves are activated to produce a sympathetic reﬂex inhibition of renal urine
output thus tending to elevate circulating blood volume, increase cardiac output, and correct the reduction in
portal ﬂow. This mechanism is demonstrated in normal animals showing that intraportal adenosine inhibits uri-
nary output and the effect can be blocked by denervation of the liver, the kidney, or application of an adenosine
receptor antagonist directly to the liver (2). The same mechanism is shown to function in a chronic cirrhotic rat
model (3). The adenosine receptor subtype is shown to be A1 through the use of selective A1 and A2 antagonists
(unpublished). Intraportal caffeine, previously shown by us to have very weak in vivo A2 antagonistic actions was
also effective in blocking this hepatorenal reﬂex and suggests a potential therapeutic intervention through the use
of slow release caffeine to treat renal dysfunction at both an early and late stage of chronic liver disease.
1. Lautt WW. The 1995 Ciba-Geigy Award Lecture. Intrinsic regulation of hepatic blood ﬂow. Can J Physiol
Pharmacol 1996; 74: 223–33.
2. Ming Z, Smyth DD, Lautt WW. 2002. Decreases in hepatic portal ﬂow trigger a hepatorenal reﬂex to inhibit
renal sodium and water excretion in rats: role of adenosine. Hepatology 2002; 35: 167–75.
3. Ming Z, Lautt WW. Reﬂex regulation by portal blood ﬂow on renal function in healthy and cirrhotic rats: role
of adenosine – a conceptual review. Proc West Pharmacol Soc 2004; 47: 33–4.
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Purinergic P2X receptors are cationic channels activated by extra-cellular ATP. They are expressed throughout
the body and mediate a multitude of functions, including muscle contraction or neuronal excitability. To date,
seven subunits have been cloned, showing two transmembrane domains and a large extra-cellular loop. These
receptors assemble as trimeric association of homo- or heteromeric subunits. Based on co-immunoprecipitation
several potential heteromeric P2X receptors have been proposed (Torres et al., 1999), but these might represent
heteromeric assemblies that are not expressed at the plasma membrane. I addition, only few heteromeric P2X
receptors have been functionally characterized. We have previously characterized a stabilization motif (YXXXK)
located in the proximal C-terminal region of all P2X subunits (Chaumont et al., 2004). Mutation of this motif
induces a reduction of the surface expression of homomeric-mutated subunits due to their lack of stabilization at
the plasma membrane. However, co-expression of a mutated subunit with wild type homo- or heteromeric sub-
units, rescues normal trafﬁcking of mutated subunits.
In the present study, we used this property to systematically investigate all possible heteromeric P2X receptors
expressed at the cell surface. Our results show that only a subset of heteromeric receptors are expressed at the
plasma membrane; this includes 4 new combinations: P2X2/5, 4/3, 4/5 and 4/7, suggesting a speciﬁcity of interaction
between subunits.
Interestingly, in the case of the P2X5 subunit, we observed that wild type homomeric receptors are mostly intr-
acellularly expressed but that co-expression with either P2X2 or P2X4 subunits strongly enhance their surface
expression. This was further conﬁrmed by immuno-staining of tagged subunits and co-immunoprecipitation of the
subunits after surface protein biotynilation. Using brain extracts P2X2 and P2X5 were co-immunoprecipitated,
demonstrating that in vivo P2X5 is likely to be associated to other P2X subunits.
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SpringerCo-expression of P2X5 and a trafﬁcking-deﬁcient P2X2 subunit (P2X2[K366A]) also resulted in a normal P2X2
expression at the cell surface. Homomeric P2X2[K366A] subunits are not functional, but have quasi-normal
function when co-expressed with P2X3, we therefore used this mutant to investigate the functional properties of
heteromeric P2X2/5 receptors. However, no rescue of P2X2[K366A] currents by WT P2X5 could be obtained,
suggesting that P2X2/5 receptors are composed by two P2X2 subunits and a single P2X5, and that two functional
subunits are necessary for a receptor to be fully active.
Taken together, our results show that P2X5 subunit is expressed at the cell surface only in hetreomeric receptors
composed of either P2X1, 2 or 4 subunits. In addition, it is also suggested that only one P2X5 subunit is present in a
heterotrimeric receptor. The precise function of P2X5 subunit in heteromeric P2X receptors is currently being
investigated.
Torres GE, Egan TM, Voigt MM J. Biol. Chem. 274:6653–6659, 1999
Chaumont S, Jiang LH, Penna A, North RA, Rassendren F. J. Biol. Chem. 279:29628–29638, 2004
High glucose disturbs purinergic signalling system in rat retinal cell cultures
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Diabetic retinopathy (DR), the leading cause of blindness within the working-age group in western countries, has
been traditionally regarded as a vascular disorder. However, growing evidence indicates that this is also a neur-
odegenerative and inﬂammatory process. The underlying mechanisms are largely unknown and several intercel-
lular messengers, such as glutamate, VEGF, and insulin, have been suggested to play a role in this pathogenesis.
We propose, nonetheless, another extracellular signalling molecule as a possible relevant player in DR, ATP.
In the retina, ATP can be released by exocytosis, and can activate several P2 receptors, which have been shown to
be expressed in this tissue. ATP has been associated with several cellular functions, such as microglia activation,
modulation of glutamate release and cell death, which seem to be altered in DR. We also found, in previous work,
that the incubation of primary retinal cell cultures with a high concentration of glucose (HG) is associated with a
deregulation in ATP release and degradation. Therefore, ATP is a compelling candidate for a role in the path-
ogenesis of DR.
We have investigated the expression of several P2X receptors (1, 2, 3, 4 and 7), by immunoblotting and immu-
nocytochemistry, and found that all these receptors are expressed in our cell cultures. P2X4 is particularly exp-
ressed in microglia and its total expression is decreased when the retinal cells are incubated in HG.
We have also studied the effect of HG incubation on intracellular Ca
2+ ([Ca
2+]in) changes induced by P2 recep-
tors_ agonists and antagonists in these retinal cultures. We have found that there are clearly two distinct popul-
ations of retinal cells that are responsive to ATP and BzATP: neuronal and microglial. In both populations, ATP
and BzATP induce an increase in [Ca
2+]in, but the latter only does so in the presence of extracellular Ca
2+.
Furthermore, these [Ca
2+]in changes induced by BzATP are dependent on extracellular Na
+ in neurons, whereas
in microglia, they are not. Therefore, BzATP activates P2X receptors in both retinal neurons and microglia, and
this activation results in Ca
2+ inﬂux through P2X channels in microglia, and probably through VSCC in neurons.
We also found that basal [Ca
2+]in levels in neuronal cells incubated with HG are higher than in control conditions,
but [Ca
2+]in changes induced by BzATP are not signiﬁcantly different between control and HG cells. This implies
that HG incubated neurons are subjected to higher [Ca
2+]in both in basal and stimulated (BzATP) conditions.
We have also found that HG neurons are more susceptible to inhibition by PPADS. This suggests that: either
there is a modiﬁcation of the P2X expression proﬁle in HG neurons; a phenotypically selective neuronal death
associated with HG; or a post-translational modiﬁcation that changes P2X functional characteristics. The immu-
noblotting results are in agreement with the ﬁrst two hypotheses.
In conclusion, the incubation of primary retinal cell cultures with a high concentration of glucose induces changes
that indicate that the purinergic signalling system is altered in these cells, particularly in neurons. The extent and
implications of such changes are yet unclear, but if proven relevant in the context of DR, it would mean that
extracellular ATP dynamics and receptors could be aimed as new targets for the therapy or prevention of DR.
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Interaction of G protein-coupled receptors (GPCRs) with arrestins is an important step in receptor desensiti-
zation. GPCRs have been subdivided into class A and B receptors according to their interaction pattern with "-
arrestin-1, and -2. By means of confocal microscopy, we have investigated receptor internalization and interaction
of the human P2Y receptors 1, 2, 4, 6, 11, and 12 with different arrestins.
Human P2Y receptors were C-terminally fused with YFP and transiently expressed in HEK-293 cells. Upon
agonist stimulation receptor internalization was observed for P2Y1-YFP, P2Y2-YFP, and P2Y4-YFP receptor con-
structs, whereas no internalization was detectable for P2Y6-YFP, P2Y11-YFP, and P2Y12-YFP receptor constructs.
Next we measured "-arrestin translocation upon P2Y receptor stimulation. HEK-293 cells transfected only with
cDNA coding for "-arrestin-1-GFP, or "-arrestin-2-YFP showed no arrestin translocation upon stimulation with
ADP, ATP, UDP, or UTP. However, upon co-transfection of each individual wild-type P2Y receptor with "-
arrestin-1-GFP or "-arrestin-2-YFP and stimulation with the corresponding agonist, a differential translocation
pattern for individual P2Y-receptors was found. The P2Y1-receptor stimulated with ADP strongly translocated "-
arrestin-2-YFP, while only a slight translocation was observed for "-arrestin-1-GFP, classifying this receptor as
class A receptor. The P2Y4-recptor showed a strong translocation that was comparable for "-arrestin-1-GFP and "-
arrestin-2-YFP when stimulated with UTP, classifying this receptor as class B receptor. No arrestin translocation
was observed for the P2Y11-a n dP 2Y12-receptor, when stimulated with ATP and ADP respectively. The P2Y6-
receptor showed slight translocation for "-arrestin-2-YFP when stimulated with UDP, but only when GRK-2 was
transfected as well. The translocation was too weak to be quantiﬁed as a loss of cytoplasmic ﬂuorescence, but
nevertheless clearly visible at the plasma membrane. The most interesting observation was made in the case of the
P2Y2-receptor. The arrestin translocation pattern was dependent of the ligand used for stimulation. UTP transl-
ocated "-arrestin-1-GFP or "-arrestin-2-YFP equally strong, whereas ATP translocated "-arrestin-1-GFP to a
much lower extent than "-arrestin-2-YFP. Therefore the P2Y2 receptor can be classiﬁed as a class A receptor when
stimulated with ATP, or as a class B receptor when stimulated with UTP.
Hydrolytic Ectoenzymatic Activity on Diadenosine Polyphosphates in Synaptic
and Plasmatic Membranes Isolated from Rat Brain and Cerebellum
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Several diadenosine polyphosphates, mainly Ap4A and Ap5A, have been identiﬁed as releasable components of
storage granules in specialized neurosecretory cells and function as extracellular signals in nervous system. Acc-
ordingly, they bind to plasma membrane purinergic receptors (speciﬁc dinucleotide, P1 and P2), displaying phy-
siological actions as neurotransmitters/ neuromodulators. The inactivation of ApnA by hydrolytic ectoenzymes at
the cell surface provides a mechanism to regulate the receptor-mediated actions of ApnA. To date, a systematic
investigation of the ectoenzymatic system operating in brain and cerebellum for inactivation of exocytotically
released ApnA has been lacking.
We describe here the main biochemical characteristics of ectoenzymatic activity responsible for hydrolysis of
extracellular ApnA in rat brain and cerebellum. Highly puriﬁed plasma and plasma synaptic membranes and
synaptosomes obtained by sucrose gradient ultracentrifugation from several brain regions (hypothalamus, hippo-
campus, temporal cortex, frontal cortex and striatum) and cerebellum were used as ectoenzyme source, while the
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Springerdiethenoadenosine polyphosphates (-(ApnA) were used as ﬂuorogenic substrates. All (-(ApnA), n=2-5, were
broken down to (-adenosine as end-product by all membrane preparations. Partially puriﬁed ectoenzymatic act-
ivity by sequential ion-exchange and gel ﬁltration chromatography cleaved all substrates into mononucleotide
moieties: (-AMP and the corresponding (-adenosine (nj1) 5 ´phosphate. Ectoenzymatic hydrolysis reached max-
imal activity at pH 9.0 (range 6.5–9.0) and was activated by Ca
2+ and Mg
2+ ions with maximal effects around 2.0
mM cation. EDTA drastically reduced activity and Zn
2+ was required for enzyme reactivation. Hydrolysis of
substrates by membranes and synaptosomes followed hyperbolic kinetics with Km values in the 3–102M range and
similar Vmax values. ApnA (n=2–5) and heparin behaved as competitive inhibitors. AMP, ATP, !,"-methylene
ADP, ADP"S, ATP+S, ",+-methylene ATP and suramin were also inhibitors. Synaptic membranes from cerebe-
llum, hypothalamus and hippocampus presented the highest activity and no signiﬁcant changes were observed
between young and aged animals. Plasma membranes showed a more homogeneous distribution but a general
increase in activity was detected in aged animals, especially in hypothalamus and cerebellum, about 150%.
This ectoenzymatic activity shared characteristics typical of members of the E-NPP (ecto-nucleotide pyrophos-
phatase phosphodiesterase) family, which contains at least three isoenzymes: NPP1, NPP2 and NPP3, with very
similar catalytic properties. These results, together with previous data by others on cloning and expression of NPP
ectoenzymes, suggest that NPP2 could play a signiﬁcant role in extracellular inactivation of ApnA in brain and
cerebellum. Increased activity in plasma membranes of aged animals could play a deleterious role in aged brain by
limiting neuroprotective actions reported for extracellular Ap4A.
Acknowledgments: Work funded by grants TR5-02 and TR2003/06 (Gobierno de Canarias with participation of
Hospiten SA, NovoNordisk Ibe ´rica SA, Aventis Behring SA) and C03/06 (Red CIEN, FIS).
Hypoxia-induced pulmonary damage in transgenic sickle cell mice is reduced
after administration of adenosine A2A receptor agonists
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Sickle cell disease (SCD) is an inherited disorder arising from at least one mutant sickle hemoglobin (HbS) allele.
HbS is poorly soluble when deoxygenated and in hypoxic conditions polymerizes reversibly to form a gelatinous
network of ﬁbrous polymers. Although polymerization of deoxygenated HbS is the primary event in the molec-
ular pathogenesis of SCD, recent ﬁndings have revealed that chronic inﬂammation plays an important role in the
etiology of vaso-occlusive crisis (VOC) and the long-term pathologic manifestations of SCD.1 SCD patients and
transgenic mice (NY1DD) expressing human B
S-globin exhibit increased plasma levels of pro-inﬂammatory cy-
tokines, increased numbers of circulating endothelial cells, leukocytosis, and elevated expression of cell-surface
activation markers on leukocytes and endothelial cells.
2
Adenosine acts through the adensoine A2A receptor (A2AAR) found on bone marrow derived cells to inhibit
inﬂammation. We used hypoxia/reoxygenation to induce VOC in NY1DD mice and assessed plasma cytokine
levels, lung inﬂammation, and pulmonary function following the prophylactic administration of the A2AAR ag-
onist ATL146e (10ng/kg/min) or the acute administration of ATL313 (5ug/kg bolus, 1ug/kg booster) given im-
mediately at the start of reoxygenation. Compared to vehicle treated NY1DD mice, A2AAR agonist treated mice
displayed: 1) decreased plasma pro-inﬂammatory cytokine levels; 2) Improved pulmonary function as measured
by whole-body plethysmography. Pulmonary minute volume was markedly increased in NY1DD mice during and
after hypoxia, and this was improved to near normal levels by treatment with A2AR agonists; 3) Decreased
pulmonary vascular congestion as evidenced by histology; and 4) Reduced pulmonary hypoxia based on 2-ni-
troimidazole deposistion in hypoxic cells in lung tissue. Pulmonary hypoxia also was non-invasivley assessed in
living mice with whole body +-immaging following injection of animals with BRU59-21, a 99mTc-labeled 2-
nitroimidazole. The agent accumulated in the lungs of NY1DD mice after exposure to hypoxia and this was
reduced by A2AR agonsits treatment. These data suggest that A2AAR agonists may be clinically useful for the
treatment of VOC in SCD. NIH grant #PO1 HL073361.
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IB-MECA, an A3 Adenosine Receptor Agonist Prevents Bone Resorption
In Rats with Adjuvant Induced Arthritis
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Objectives: The anti-inﬂammatory effect of adenosine is partially mediated via the A3 adenosine receptor (A3-
AR), a Gi protein associated cell surface receptor. The highly selective A3AR agonist, IB-MECA was earlier
shown to prevent the clinical and pathological manifestations of arthritis in experimental animal models of coll-
agen and adjuvant induced arthritis (AIA). In this study we tested the effect of IB-MECA on the prevention of
bone resorption in AIA rats and looked at the molecular mechanism of action.
Methods: rats with AIA were treated orally twice daily with IB-MECA starting upon onset of disease and clinical
score was evaluated every other day. At study termination the foot, knee and hip region of both vehicle and IB-
MECA treated animals were subjected to histomorphometric analysis. Western blot analysis was carried out on
paw protein extracts.
Results: IB-MECA ameliorated the clinical manifestations of the disease and reduced pannus and ﬁbrosis for-
mation, attenuated cartilage and bone destruction, decreased the number of osteoclasts and reduced bone for-
mation. In cell protein extracts derived from paw of AIA rats, A3AR was highly expressed in comparison to naı ¨ve
animals. In paw extracts derived from IB-MECA treated AIA rats, down-regulation of the A3AR protein ex-
pression level was noted. PI3K, PKB/Akt, IKK, NF-.B, TNF-! and RANKL were down-regulated whereas ca-
spase 3 was up-regulated.
Conclusions: IB-MECA via A3AR activation, induces modulation of proteins which control survival and apopto-
sis resulting in the amelioration of the inﬂammatory process and the preservation of bone mass in AIA rats.
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The P2X7 receptor is found on different immune cells where it has been shown to be involved in interleukin
release, cytoskeletal rearrangements, L-selectin shedding and activation of phospho-lipase D and p38MAP kinase.
Its presence in neuronal cells is still under debate. It is distinguished from other P2X receptors by its very long
intracellular C-terminus, a low ATP sensitivity, and its ability to induce ‘‘cell permeabilization’’, meaning that
upon prolonged ATP application the opening of a permeation pathway for large cations is induced. Although the
C-terminus has been shown to be involved in this process, the mechanism of this ‘‘pore dilation’’ is still poorly
understood. Also, it is not clariﬁed to which extend this is an intrinsic property of the P2X7 protein or requires the
interaction with other proteins.
Here we describe the biochemical and functional properties of a P2X7 splice variant (P2X7(i)) which was cloned
from a rat lung cDNA library and compare it with the originally cloned P2X7 receptor. In the splice variant, the
N-terminus and 80% of the proposed ﬁrst transmembrane domain are replaced by an alternative sequence der-
ived from a yet unidentiﬁed exon in the P2X7 gene, which is highly lipophilic.
Upon heterologous expression in Xenopus oocytes, both the P2X7(i) and the P2X7(a) subunit are expressed as
complex glycosylated proteins of identical size. Analysis of the digitonin-solubilized receptor complexes by BN-
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plexes solubilized from various native tissues. Partial dissociation by SDS revealed two additional bands of higher
mobility demonstrating that both P2X7 isoforms assembled as trimers.
Two-electrode voltage-clamp analysis showed that the P2X7(i) receptor was functional and had a similar ATP
sensitivity as the P2X7(a) receptor. Current recordings and analysis of reversal potentials in N-methyl-D-gluca-
mine (NMDG) solution revealed a gradual permeability increase for NMDG upon prolonged activation by ATP.
However, the permeability shift was markedly less than the one observed for the P2X7(a) receptor. Unlike the
P2X7(a) receptor, the splice variant exhibited already a high permeability ratio (PNMDG/PNa) at the begining of the
ATP application suggesting that the channel is constitutively dilated upon opening.
Duplex RT-PCR with primer pairs selective for the P2X7(a) and P2X7(i) isoforms conﬁrmed the presence of the
P2X7(i) transcript in lung and showed a dominant expression in the spleen.
Taken together, we describe a novel P2X7 isoform with an alternative TM1 domain and a high propensity to form
NMDG permeable pores indicating that residues critically involved in pore dilation are located within the TM1
domain. This splice variant will help to elucidate the process of pore dilation and might provide an explanation for
the distinct properties described for P2X7 receptors in different tissues.
IDENTIFICATION OF A NOVEL NATURALLY OCCURING NUCLEO-
TIDE: 4-PYRIDONE-3-CARBOXAMIDE-1-" "-D-RIBONUCLEOSIDE TRI-
PHOSPHATE IN HUMAN ERYTHROCYTES AND ITS RELATION WITH
ATP CONCENTRATION
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We report the identiﬁcation of a hitherto unknown nucleotide that is present in micromolar concentrations in the
erythrocytes of healthy humans and massively accumulates in the erythrocytes of patients with renal failure. The
unknown nucleotide was isolated from the triphosphate fraction of erythrocyte extracts obtained from patients
with renal failure using anion-exchange high performance liquid chromatography (HPLC). Next, the isolated
nucleotide was degraded using alkaline phosphatase to obtain nucleoside and further processed by acid hydrolysis
to obtain the free base. The puriﬁed nucleotide, nucleoside and base were then characterized using HPLC with
UV and tandem mass detection, nuclear magnetic resonance (NMR), and infrared (IR) spectroscopy. This ana-
lysis revealed the molecular weight of the nucleotide (m=510), nucleoside (m=270) and base (m=138), the stru-
cture of the heterocyclic ring of the base as 4-pyridone-3-carboxamide (4PY) and hence the nucleoside as 4-
pyridone-3-carboxamide-1-"-D-ribonucleoside (4PYR). This base and the nucleoside were then chemically synt-
hesized and their identity with natural compounds conﬁrmed. The unknown nucleotide has therefore been ide-
ntiﬁed as 4-pyridone-3-carboxamide-1-"-D-ribonucleoside triphosphate (4PYTP). An erythrocyte concentreation
established in the normal human erythrocytes was established at 13.0T4.7 2M/L erythrocytes (range: 6–18) and its
concentration in the advanced chronic renal failure was 162T189 2M/L erythrocytes (range: 45–670). Subsequent-
ly, we demonstrated formation of the unknown nucleotide established here as 4PYTP in the intact human eryth-
rocytes during incubation with 4PYR accompanied by progressive depletion of cellular ATP and accumulation of
the IMP. Formation of 4PYTP and the effects on ATP concentration was abolished by inhibition of adenosine
kinase with 5_-iodotubercidin. No 4PYTP formation was noted with 4PY as the substrate. The base constituent
structure of this new nucleotide is related to oxidized nicotinamide nucleotides and this metabolite could be part
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related mechanism inside or outside the cell and its structural similarity with UTP, an agosnist for P2 receptors is
worth noting. However, physiological role of 4PYTP and the consequences of accumulation in renal failure
remain to be established.
Identiﬁcation of an inter-subunit cross-link between substituted cysteine residues
located in the putative ATP binding site
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P2X receptors are ATP-gated ion channels and are assembled as homo- or heterotrimers of homo-logous subunits
(1). Each subunit contains two transmembrane domains linked by a large extra-cellular loop containing the ATP
binding site. Although single residues that directly contribute to ATP binding have been identiﬁed, the location of
the binding site remains unclear. Mutagenesis data based on an ATP binding site model deduced from secondary
structure predictions, suggest an intra-subunit location (2). However, this model does not take into account three
conserved lysine residues (K68, K70, and K309 in P2X1) which are critical for high-afﬁnity ATP binding (3, 4).
The location of these residues on opposite ends of the extracellular loop opens the possibility of an inter-subunit
ATP-binding site, similar as in the nicotinic acetylcholine receptor.
Here we used a disulﬁde cross-linking approach to identify pairs of residues that are in close proximity within the
ATP binding site to determine whether this is formed within one or between two neighbouring subunits. Hexa-
histidyl-tagged P2X1 mutants in which single residues supposed to contribute to ATP binding were substituted by
cysteine residues were expressed in Xenopus laevis oocytes. Functional expression of these binding site mutants
was conﬁrmed by two-electrode-voltage clamp analysis of the respective mutations in a non-desensitzing
P2X2/1chimera. This chimera contains the N-terminus and the ﬁrst transmembrane domain of the P2X2 subunit
and the high-afﬁne ligand-binding domain of the fast desensitizing P2X1 receptor and has been shown to provide a
valid model for the ATP-binding site of the P2X1 receptor (5). Upon metabolic labelling, P2X receptor complexes
were puriﬁed under non-denaturing conditions. Blue native gel electrophoresis (BN-PAGE) analysis of these
mutants showed exclusively trimeric complexes thus excluding artiﬁcial disulﬁde formation due to aggregation of
receptor complexes. Non-reducing SDS-PAGE analysis of pairwise expressed mutants revealed a spontaneous
and speciﬁc dimer formation between the K68C and F291C mutants, suggesting an inter-subunit disulﬁde cross-
link. In support of this ﬁnding, the use of short cysteine reactive cross-linkers pointed to a close approximation of
residues R292C and K70C across the interface of two neighbouring subunits. An almost complete spontaneous
cross-link into trimers was achieved with the K68C/F291C double mutant. Deglycosylation analysis and BN-
PAGE analysis of the selectively labelled plasma membrane protein conﬁrmed that this double mutant was
correctly folded and inserted into the plasma membrane.
In summary, we provide ﬁrst evidence that loops from neighbouring P2X subunits contribute to the formation of
the ATP-binding site in P2X receptors.
(1) Nicke, A.; Ba ¨umert, H. G.; Rettinger, J.; Eichele, A.; Lambrecht, G.; Mutschler, E.; Schmalzing, G. EMBO J.
1998, 17, 3016–28.
(2) Yan, Z.; Liang, Z.; Tomic, M.; Obsil, T.; Stojilkovic, S. S. Mol. Pharmacol. 2005, 67, 1078–88.
(3) Jiang, L. H.; Rassendren, F.; Surprenant, A.; North, R. A. J. Biol. Chem. 2000, 275, 34190–6.
(4) Ennion, S.; Hagan, S.; Evans, R. J.; J. Biol. Chem. 2000, 275, 29361–7.
(5) Rettinger, J.; Schmalzing, G. J. Biol. Chem. 2004, 279, 6426–33.
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Hypoxic preconditioning (HPC) is a unique phenomenon of endogenous protection that renders cells tolerant to
more severe challenges of hypoxia. The molecular mechanism by which HPC confers such protection is currently
an area of intense investigation. Here, we sought to deﬁne the speciﬁc anti-inﬂammatory properties of HPC.
Using protocols of HPC, mice and cultured epithelial cells were proﬁled for known pathways common to pro and
anti-inﬂammatory responses. Guided by cDNA microarray analysis of lung tissue from preconditioned mice, we
identiﬁed signiﬁcant repression of NF.B regulated genes elicited by HPC. HPC evoked a 95T3% repression of the
NF.B–dependent gene IL-6, as was the case for other NF.B regulated genes. We conﬁrmed the functional down-
regulation of NF.B activation using a NF.B luciferase reporter assay. Transfected cells were exposed to an HPC
protocol (2% O2 for 45 minutes followed by re-oxygenation 21% O2 for 20 minutes for 3 cycles) followed by 24
hours of anoxia (0 % O2), and under such conditions, HPC cells showed a signiﬁcant down-regulation of NF.B
activity compared to control (p=0.01). Subsequent experiments revealed that the anti-inﬂammatory properties of
HPC could be conferred in soluble supernatants from HPC cells (p=0.05). An HPLC proﬁling of soluble super-
natants identiﬁed an active nucleotide fraction which carried signiﬁcant anti-inﬂammatory bioactivity. This active
fraction was identiﬁed as adenosine. Led by studies demonstrating the inhibition of NF.B activation occurs by
blockade of I.B-! ubiquitination, we proﬁled the mechanisms that regulate I.B-! stability. I.B-! ubiquitination is
mediated by the E3 ubiquitin ligase complex, which in turn is regulated by the modiﬁcation of the Cullin-1 subunit
by the ubiquititin-like protein NEDD-81. The state of Cullin-1 neddylation has been implicated in NF.B supp-
ression by bacteria2. Using the general adenosine receptor agonist NECA, we probed the state of neddylation of
Cullin-1. We found a dose dependent dennedylation of Cullin-1 in response to adenosine receptor stimulation
both in vitro and in vivo. Taken together these results demonstrate that HPC results in the extra-cellular accu-
mulation of adenosine responsible for the deneddylation of Cullin-1 and the subsequent suppression of NF.B
mediated pathways. These results deﬁne a novel molecular regulatory pathway by which adenosine provides
potent anti-inﬂammatory conditions.
References:
1. Maniatis T. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling
pathways. Genes Dev 1999;13:505–10.
2. Collier-Hyams LS, Sloane V, Batten BC, Neish AS. Cutting edge: bacterial modulation of epithelial signaling
via changes in neddylation of cullin-1. J Immunol 2005;175:4194–8.
Identiﬁcation of the Ecto Nucleoside Triphosphate Diphosphohydrolases
Regulating Bacterial Clearance in Human Airways
Maryse Picher, Lauranell H. Burch






1Cystic Fibrosis Center, University of North Carolina, NC, USA
2Laboratory of Respiratory Biology, NIEHS, Durham, NC, USA
3Centre de Recherche en Rhumatologie et Immunologie, CHUL, Ste-Foy, QC, CA
pichm@med.unc.edu
In human airways, extracellular nucleotides are among the most potent mediators of mucociliary clearance (M-
CC). Their interaction with P2Y2 receptors on epithelial surfaces stimulates mucus secretion, cilia beating activity
and maintains airway hydration. These mechanisms are impaired in chronic lung diseases including cystic ﬁbrosis
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their rapid metabolism. In the present study, we demonstrate that P2 receptor–mediated MCC is regulated by
ecto nucleoside triphosphate diphosphohydrolases (E-NTPDases; ATP ! ADP ! AMP). All experiments were
performed on polarized primary cultures of human nasal or bronchial epithelial cells maintained at air-liquid
interface. Cyclic compressive stress (CCS) mimicking normal breathing (20 cmH2O; 0.5 Hz) restored MCC in CF
cultures by a mechanism involving ATP release, P2 receptor activation and a 75% reduction in ectoATPase
activities. The E-NTPDase inhibitor, azide (20 mM), prevented CCS-mediated reduction in ATP metabolism. The
biochemical properties of airway E-NTPDases were investigated on static cultures. Azide reduced the metabolism
of 1 mM UTP and UDP by 45% and 55% on the mucosal surface compared to < 10% on the serosal surface.
Nucleotide speciﬁcity generated in the presence of azide was consistent with those of NTPDase 1 and 3 (ATP =
UTP < GTP < CTP), but not azide-insensitive NTPDase 2 or 8. While the azide-sensitive activity ratio for UTP/
UDP (6.2) obtained with 1 mM nucleotides was consistent with NTPDase 3, assays conducted with 0.01 mM
substrates generated a ratio (1.3) supporting NTPDase 1 expression. The co-expression of NTPDase 1 and NT-
PDase 3 in human airway epithelia was conﬁrmed by RT-PCR and RNAse protection assays. These two azide-
sensitive E-NTPDase activities were distinguished using ebselen (2-phenyl-1,2-benziso selenazol-3(2H)-one) and
Pseudomonas aeruginosa lipopolysaccharide (LPS). Biochemical assays performed on protein extracts from tra-
nsfected COS-7 cells indicated that acute exposures (15 min) to 30 2M ebselen signiﬁcantly inhibited NTPDase 3
(40%) while LPS inhibited NTPDase 1 (50%). Based on these compounds, both activities were detected on the
mucosal surface of nasal and bronchial cultures, while low (< 15%) NTPDase 1 activity was also detected on
serosal surfaces. On the mucosal surface, whereas NTPDase 3 was unaffected by cell type, NTPDase 1 activity
was 2-fold higher on bronchial than nasal epithelia, results were conﬁrmed at the mRNA level. Collectively, these
experiments demonstrate the functional co-expression of NTPDase 1 and NTPDase 3 on airway mucosa.
Furthermore, the fact that ebselen mimicked the effects of CCS on E-NTPDase activities suggest that NTPDase 3
plays a major role in the regulation of nucleotide-mediated MCC.
Work supported by the Cystic Fibrosis Foundation PICHER 05G0
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Sympathetic overactivity and increased neurotransmitter spillover are closely associated with progressive renal
failure. The present study investigates whether the alpha2A-adrenoceptor-subtype represents the presynaptic
autoinhibitory adrenoceptor that regulates noradrenaline (NA) and ATP release in mouse kidney. Moreover we
evaluated the renal phenotype of alpha2A adrenoceptor KO mice. This is of particular interest, since sympahtetic
neurotransmitters are able to mediate maladaptive changes within the kidney (Vonend 2004).
Wildtype and alpha2A-adrenoceptor-KO mice (C57/Bl6) were anaesthetized, renal arteries were cannulated and
kidneys isolated perfused with Krebs-Henseleit solution at a constant rate (7.25 ml/min g). Electrodes were placed
around the renal arteries to stimulate the renal nerves. The perfusion solution was collected and endogenously
released NA was measured by HPLC. The perfusion pressor was monitored continuously. To evaluate renal
phenotype blood pressure, puls, serum-creatinine, serum-BUN, urine-sodium and albumine excretion were
measured.
Renal nerve stimulation (RNS) induced a frequency (1, 2, 5, 7.5, 10, 15 Hz) dependant release of NA (1156+/
j223, 2509+/j332, 6728+/j584, 11542+/j1167, 19094+/j1241, 23846+/j2388 pg NA / g kidney +/j SE). In KO
mice RNS at 5 Hz increased NA release 2.7 fold. In wildtype animals the non selective alpha-adrenoceptor
blocker phentolamine increased RNS induced NA-release in a concentration dependent manner up to 350% of
control. No facilitation by phentolamine was observed in KO mice. Phentolamine decreased the RNS induced
pressor responses in WT mice at higher frequencies. NA does not seem to be responsible for pressor responses at
lower frequencies. Pressor reponses to 1 Hz and 2 Hz cannot be blocked by prazosin. Inhibition of presynaptic
alpha-receptors increased non-adrenergic (purinergic) pressor responses up to 300% in WT but not in KO mice.
Apart from a higher pulsrate in KO mice no signiﬁcant differences were detectable between both strains.
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knockout mice demonstrated that the alpha2A-adrenoceptor subtype is responsible for modulating NA and ATP
release in mouse kidney. ATP seems to be the predominant transmitter at physiological stimulation frequencies.
Even though the alpha2A-adrenoceptor KO mice is characterised by sympathetic overactivity no renal phenotype
was apparent. Compensatory mechanisms might play a role here. Another explanation could be the genetic
background. C57/Bl6 mice seem to be not susceptible for the development of glomerulosclerosis (Ma 2003).
Vonend, O., Turner, C. M., Chan, C. M., Loesch, A., et al., Kidney Int 2004, 66, 157–166. Ma, L. J. and Fogo, A.
B., Kidney Int 2003, 64, 350–355.
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Adenosine is a multi-faceted signaling molecule mediating key aspects of airway defenses, including bacterial
clearance. However, chronically-elevated lung adenosine initiates inﬂammatory responses in animal models. And
bronchoalveolar lavage from patients with chronic lung diseases exhibits high adenosine concentrations. The
source of this excess adenosine has not been identiﬁed. We recently showed that airway adenosine is generated by
sequential dephosphorylation of locally-released ATP on epithelial surfaces. The cell surface enzyme (ectonu-
cleotidase) responsible for the conversion of AMP to adenosine was identiﬁed as ecto 5_-nucleotidase (ecto 5_-
NT). In the present study, we identiﬁed the proteins regulating the elimination of airway adenosine. Experiments
conducted on polarized primary cultures of human nasal epithelial cells showed that 10 2M adenosine is elimi-
nated from mucosal surfaces by deamination (60%) and cellular uptake (40%). The cell surface conversion of
adenosine to inosine was completely inhibited by 10 2M erythro9-(2-hydroxy-3-nonyl)adenine (EHNA), selective
inhibitor of adenosine deaminase 1 (ADA1). This enzyme displayed Km and Vmax values of 24 2M and 0.14
nmole.min
j1.cm
j2. Adenosine transport was Na
+-dependent and inhibited by 2 mM phloridzin, inhibitor of the
concentrative nucleoside transporters (CNTs). Apparent Km and Vmax values for adenosine uptake were 17 2M
and 7.2 nmoles.min
j1.cm
j2. The permeability coefﬁcient ratio of adenosine/mannitol (18/1) indicated a minor
contribution of paracellular absorption. Competitive studies showed that adenosine uptake is not affected by
hypoxanthine but broadly inhibited by purines and pyrimidines (inosine = uridine > guanosine = cytidine >
thymidine). Messenger RNA for ecto 5_-NT, ADA1 and CNT3 was detected throughout airway epithelia, while
the expression of CNT2 was restricted to nasal epithelia. Cultured nasal epithelial cells from cystic ﬁbrosis pa-
tients exhibited a 5-fold increased rate in adenosine accumulation from exogenous 10 2M ATP. This ﬁnding was
correlated with a 4-fold increase in adenosine production by ecto 5_-NT and a 3-fold decrease in adenosine
elimination by ADA1. This study suggests that the excess airway adenosine detected in chronic lung diseases may
arise from an imbalance between the rates of adenosine production and elimination on airway epithelial surfaces.
The identiﬁcation of the proteins regulating airway adenosine, as well as pharmacological tools that regulate their
activities, may lead to a better understanding of the roles of chronically-elevated adenosine in lung diseases.
This study was supported by the Cystic Fibrosis Foundation (Picher 05G0)
Improved Syntheses of 2-(Aryl)alkoxyadenosine – Adenosine A2A Agonists for
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The development of chronic wounds, such as neuropathic foot ulcerations, is a major complication of diabetes.
Evidence suggests that a selective adenosine A2A agonist, when applied topically, can signiﬁcantly enhance the
rate of healing of these wounds. The mechanism of this enhanced capacity is thought to involve both an anti-
inﬂammatory component as well the down-regulation of the anti-angiogenic matrix protein thrombospondin 1.
Moreover, this enhanced capacity toward wound closure occurs in both normal animals, as well as those with an
impaired healing capacity, such as occurs in diabetes.
One class of adenosine A2A receptor agonists that has drawn attention, the 2-aralkoxy- and 2-alkoxyadenosines,
was described by Olsson and coworkers. Although these compounds are both potent and selective adenosine A2A
agonists with demonstrated in vivo efﬁcacy in models of wound healing, their development has been hampered by
the lack of a robust and scaleable synthesis. Previous reports indicate that protection of the 2_- and 3_-hydroxyls
with an ethoxymethylidene or isopropylidene moiety is important to prevent formation of a 2Y2_ polymeric
product and that the lability of the glycosidic bond to the acidic conditions required to remove these protecting
groups contributes to the low yields observed.
Here we describe two approaches to the synthesis of this class of molecules, in particular 2-[2-(4-chloropheny-
l)ethoxy]adenosine (MRE-0094, 1), a compound currently in clinical development for the treatment of diabetic
foot ulcers. In the ﬁrst approach, 2-amino-6-chloro-purine riboside triacetate (2) is hydrolytically diazotized and
then coupled with 2-(4-chlorophenyl)ethyl bromide. Concurrent displacement of the 6-chloro moiety and amm-
onolysis of the acetyl-protecting groups affords the desired MRE-0094. The second approach utilizes the tris(T-
ERT-butyldimethylsilyl)-protected 2-chloroadenosine (3) to condense with 2-(4-chlorophenyl)ethanol, followed
ﬂuoride ion deprotection to afford the target molecule. These approaches permit the preparation of kilogram quan-
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In rat hepatocytes, different adenosine receptor subtypes use different secondary
messengers to increase the rate of ureagenesis.
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In rat hepatocytes, the role of cAMP and Ca
2+ as secondary messengers in the ureagenic response to stimulation
of speciﬁc adenosine receptor (AR) subtypes was explored. Analyzed receptor subtypes were: A1,A 2A,A 2B and
A3. Each receptor subtype was stimulated with a speciﬁc agonist while blocking all other receptor subtypes with a
battery of speciﬁc antagonists. For the A1 and A3 AR subtypes, the secondary messenger was the cytoplasmic
Ca
2+ concentration ([Ca
2+]cyt). Accordingly, the A1 or A3-mediated increase in [Ca
2+]cyt and in ureagenic activity
were both inhibited by chelating Ca
2+ with either EGTA or BAPTA-AM. Also, Gd
3+ blocked both the increase
in [Ca
2+]cyt and ureagenesis, suggesting that a Ca
2+ channel may be involved in the response to both A1 and A3.A
partial effect was observed with the sarcoplasmic reticulum Ca
2+-ATPase inhibitor thapsigargin. The concentra-
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Springertion of cyclic AMP ([cAMP]) increased in response to stimulation of either the A2A or the A2B AR subtypes,
while it decreased slightly in response to stimulation of either A1 or A3. The stimulation of either the A2A or A2B
AR subtypes resulted in an increase in [cAMP] and an ureagenic response which were not sensitive to EGTA,
BAPTA-AM, Gd
3+ or to thapsigargin. In addition, the adenylyl cyclase inhibitor MDL12,330A blocked the ur-
eagenic response to A2A and A2B, but not the response to either A1 or A3. Our results indicate that in the
ureagenic liver response to adenosine, the secondary messenger for both, the A1 and A3 adenosine receptor
subtypes is [Ca
2+]cyt, while the message from the A2A and A2B AR subtypes is relayed by [cAMP]. Grants
IN211502-2, IN210401 from DGAPA, UNAM.
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3H]Adenosine 50-monophosphate, in vitro, cancer cells, nucleoside transporter
Mini-abstract: In vitro evaluation of the mechanism of intracellular uptake of adenosine generated from adeno-
sine monophosphate in various human tumor cell lines, and its potential as a metabolic tumor PET radiotracer
Abstract: Adenosine appears to play an important role in tumor growth and metastasis. Synthesis of [
11C]Ade-
nosine 50-monophosphate ([
11C]AMP) serves as a precursor for [
11C]Adenosine and has been recently reported as
a potential tumor imaging radiotracer. Methods: A variety of human tumor cell lines (SKOV-3, SCC-15, U251,







3H]Adenosine) in low physiologic glucose
serum free media. Selected cells were exposed to caffeine, dipyridamole, adenosine 50-(!,"-methylene)diphos-
phate (APCP), or cold adenosine prior to exposure to the radiotracer. R-Phycoerytherin conjugated mouse anti-
human monoclonal antibody to human CD73 was used for immunophenotyping. Results: There was signiﬁcant
intracellular uptake of [
3H]AMP on the order of 10 to 100 times the uptake of [
3H]FDG in corresponding cells,
depending on the particular tumor cell line. Pre-exposure of SKOV-3 cells to caffeine, a competitive inhibitor of
adenosine receptors, did not affect cellular uptake of [
3H]AMP. However, pre-exposure of SKOV-3 cells to
dipyridamole, an equilibrative nucleoside transporter inhibitor (ENT), APCP, a CD73 (ecto-50-nucleotidase) in-
hibitor, or cold adenosine signiﬁcantly inhibited cellular uptake of [
3H]AMP. SKOV-3 uptake of [
3H]Adenosine
was inhibited by dipyridamole but not APCP. U251 uptake of [
3H]AMP was signiﬁcantly inhibited by dipyrida-
mole and APCP. U87 uptake of [
3H]AMP was only partially inhibited by dipyridamole and APCP. However, Raji
and Daudi cells had signiﬁcantly lower uptake of [
3H]AMP compared to [
3H]FDG, but had signiﬁcantly increased
uptake of [
3H]Adenosine which was inhibited by dipyridamole. Raji and Daudi cells were negative, but the
SKOV-3 cells were positive for CD73 cell surface expression. Conclusions: Cancer cell lines evaluated in vitro had
signiﬁcantly elevated uptake of radiolabeled AMP generated adenosine, on the order of 10–100 fold, in compa-
rison to radiolabeled FDG. The mechanism of intracellular uptake is predominantly dependent on ENTs after
conversion of AMP to adenosine by CD73 in SKOV-3, SCC-15, and U251 cells. Raji and Daudi cells have low
uptake of radiolabeled AMP due to a lack of CD73 expression. This in vitro evaluation using [
3H]AMP with
tumor cell lines supports the potential for the use of [
11C]AMP to target the nucleoside transport pathway in PET
tumor imaging.
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The A1 adenosine receptor (A1AR) is widely distributed in the body and particularly prevalent in the central
nervous system. Activation of neuronal A1ARs results in decreased adenylate cyclase activity through activation
of pertussis toxin-sensitive Gi proteins and K
+ channels, respectively, as well as KATP channels. A1ARs are
involved in the regulaion of sleep and arousal, cognition and memory, neuronal damage and degeneration. Th-
erapeutic implications for epilepsy and multiple sclerosis as well as neurodegenerative diseases such as Parkins-
on"s and Alzheimer"s disease are currently under investigation. To investigate alterations of the A1AR in normal
and diseased states of the human brain we have recently developed a positron emission tomography (PET)
method to image and quantify the A1AR in the living human brain (Holschbach et al. 2002, Bauer et al. 2003,
Meyer et al. 2005).
Methods: Quantitative dynamic [
18F]CPFPX receptor PET was performed in healthy subjects and patients suff-
ering from brain tumor (glioma) or temporal lobe epilepsy. Regional cerebral ligand distribution was evaluated by
volume of interest and kinetic analyses, respectively, after co-registration of PET and individual magnetic reso-
nance data sets (Bauer et al. 2003, Meyer et al. 2004).
Results: [
18F]CPFPX PET displayed a high ligand accumulation throughout the brain with a region-speciﬁc bin-
ding pattern. Ligand distribution was in accordance with in vitro autoradiographic studies on the regional binding
pattern of A1ARs. Highest values of total distribution volume were found in temporal and occipital cortex,
striatum and thalamus, lowest values were detected in pons and cerebellum. The data point to signiﬁcant species
differences of the distribution of cerebral A1ARs in rodents and man. In ﬁrst clinical applications we observed a
belt of increased A1AR binding in the immediate tumor vicinity in patients suffering from high grade glioma
(Bauer et al. 2005). In vitro inspection of tumor specimens pointed to a primarily microglial and astrocytic source
of increased A1AR expression. In patients with unilateral temporal lobe epilepsy we found a reduction of A1AR
binding in the hippocampus and mesial parts of the temporal lobe which are in accordance with a reduced density
of A1ARs as described in in vitro studies.
Conclusion: [
18F]CPFPX PET is a promising tool for the investigation of the in vivo distribution of the cerebral
A1AR. It offers a unique opportunity to investigate the in vivo behaviour of the cerebral A1AR and permits the
investigation of human pathologies in the course of disease.
Bauer, A.; Holschbach, M.H.; Meyer, P.T.; Boy, C; Herzog, H.; Olsson, R.A.; Coenen, H.H.; Zilles, K. Neuroi-
mage. 2003, 19, 1760.
Bauer, A.; Langen, K.J.; Holschbach, M.H.; Olsson, R.A.; Cremer, M.; Weber, S.; Coenen, H.H.; Zilles, K. J.
Nucl. Med. 2005, 46, 450.
Holschbach, M.H.; Olsson, R.A.; Bier, D.; Wutz, W.; Sihver, W.; Schuller, M.; Palm, B.; Coenen, H.H. J. Med.
Chem. 2002, 45, 5150.
Meyer, P.T.; Bier, D.; Holschbach, M.H.; Boy, C.; Olsson, R.A.; Coenen, H.H.; Zilles, K.; Bauer, A. J. Cereb.
Blood Flow Metab. 2004, 24, 323.
Meyer, P.T.; Elmenhorst, D.; Bier, D.; Holschbach, M.H.; Matusch, A.; Coenen, H.H.; Zilles, K.; Bauer, A.
Neuroimage. 2005, 24, 1192.
Increased risk of acute myocardial infarction and elevated levels of C-reactive
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Extracellular ATP acting on the membrane receptor P2Y11 regulates inﬂammatory cells and has inotropic effects
on cardiac myocytes. We hypothesized that polymorphisms in the receptor could inﬂuence the risk of acute
myocardial infarction (AMI).
In a case-control study with 1244 AMI cases and 2488 paired controls, the common dimorphism Ala-87-Thr of the
P2Y11 gene (19.2% Thr-87 allele distribution in controls) was associated with acute myocardial infarction (odds
ratio 1.21, 95% C.I. 1.02 – 1.44, P = 0.03). Even stronger associations were found in the AMI subgroups containing
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Springerfamily history AMI cases (1.32, 1.02 – 1.69, P = 0.03), as well as early onset AMI (1.43, 1.13 – 1.82, P = 0.003). The
strongest association was seen in a third subgroup consisting of individuals with early onset AMI in combination
with a family history of AMI (1.56 95% C.I. 1.11 – 2.18, P = 0.01), supporting a genetic mechanism.
In the case-control study, as well as in the early onset AMI subgroup, homozygous carriers of the Thr-87 variant
of P2RY11 showed a stronger association with AMI than heterozygous carriers: Thr-87/Thr-87 (odds ratio 1.93,
1.02 – 3.66) vs. Thr-87/Ala-87 (1.18, 0.98 – 1.41, P = 0.08); early onset AMI subgroup: Thr-87/Thr-87 (2.48, 1.02 –
6.05, P = 0.046) vs. Thr-87/Ala-87 (1.39, 1.08 – 1.78, P = 0.009).
To determine a possible mechanism for the increased prevalence of AMI, we examined a cardiovascular group
population (n = 6101), with data of several cardiovascular risk factors. Interestingly, the inﬂammatory marker C-
reactive protein was signiﬁcantly elevated in carriers of the Thr-87 variant of P2RY11 (CRPThr-87 0.16 (0.07–0.30)
mg/ml, CRPAla-87 0.13 (0.07–0.28) mg/ml, P = 0.001). No difference was seen for blood pressure, lipids, body-mass
index or diabetes mellitus.
In conclusion, the common Ala-87-Thr polymorphism of the P2Y11 receptor is strongly associated with AMI
probably by stimulating inﬂammation. Our ﬁndings make the P2Y11 receptor a promising novel drug target in the
prevention of myocardial infarction and cardiovascular inﬂammatory disease.
Inﬂammatory role of adenosine in human lung cells
Dewan Zeng, Hongyan Zhong and Luiz Belardinelli
Department of Pharmacological Sciences, CV Therapeutics, Inc., Palo Alto, California 94304.
dewan.zeng@cvt.com
It has been suggested that adenosine might have both pro- and anti-inﬂammatory actions depending on the
pathophysiology of the diseases. In the lungs of asthmatics, inhaled adenosine or adenosine monophosphate
(AMP) increases the release of histamine, tryptase and leukotrienes, suggesting a pro-inﬂammatory role of ade-
nosine presumably due to the activation of adenosine receptors present in mast cells. The objective of our study
was to determine the potential role of adenosine and its receptors in the human lung cells such as bronchial
epithelial cells, airway smooth muscle cells and lung ﬁbroblasts. Among the four subtypes of adenosine receptors
(A1,A 2A,A 2B and A3), the A2B receptor is expressed at the highest level in all three types of lung cells. In airway
smooth muscle cells, activation of A2B receptors leads to the release of IL-6 and MCP-1. Similarly, in lung
ﬁbroblasts, activation of A2B receptors increases the release of IL-6, which in turn promotes the differentiations of
ﬁbroblasts into myoﬁbroblasts. In bronchial epithelial cells, activation of A2B receptors increases the release of IL-
19, which leads to the release of TNF-! from a monocytic cell line. Altogether, these results suggest that activation
of A2B receptors in the human lung cells increases the release of several pro-inﬂammatory cytokines and chem-
okines, which could lead to deleterious inﬂammatory responses in the lung.
Inﬂuence of A1 and P2 receptor-activation on angiotensin II mediated facilitation
of noradrenaline release in the rat mesenteric vessels
Talaia C., Hodan J., Morato M., Gonc ¸alves J., Queiroz G.
Laboratory of Pharmacology, CEQOFFUP, Faculty of Pharmacy, University of Porto, Rua Anı ´bal Cunha, 164,
4050-047 Porto, Portugal
Interactions between prejunctional inhibitory !2-autoreceptors and facilitatory angiotensin AT1 receptors have
been described in several sympathetic innervated tissues (1). However, the inﬂuence of other inhibitory receptors,
namely the purinoceptors, on the angiotensin II (ANG II) receptor-mediated facilitation of noradrenaline (NA)
release was never investigated in tissues where ATP is a sympathetic cotransmitter. Therefore, the inﬂuence of P2
and adenosine A1 receptors on modulation of NA release mediated by ANG II was studied in the rat mesenteric
artery and vein, tissues where ATP is an important cotransmitter (2) and where adenosine and ATP are neuro-
modulators (3).
Mesenteric arteries and veins from male Wistar rats (250–350 g) were isolated, incubated with 1 2M[
3H]-NA and
superfused with a physiological solution containing 0.4 2M desipramine. Tissues were stimulated with trains of 100
pulses at 2 Hz or 20 pulses at 50 Hz (50 mA, 1 ms). The effects of drugs on evoked NA release (estimated as
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Springertritium overﬂow) were calculated as % of change from the corresponding controls, expressed as mean T S.E.M,
and tested for signiﬁcance by one-way ANOVA followed by Dunnett_s test.
Stimulation with trains of 20 pulses at 50 Hz, elicited an overﬂow of tritium that was not changed by !2-adren-
oceptor-antagonist yohimbine (1 2M). However, tritium overﬂow elicited by trains of 100 pulses delivered at 2 Hz
was enhanced by yohimbine (1 2M) in the mesenteric artery and vein up to 489 T 31% (n = 4, P < 0.05). The
adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 0.1 2M) and the P2 receptor an-
tagonist reactive blue 2 (RB2, 30 2M) did not change tritium overﬂow evoked by stimulation at 2 Hz. When !2-
adrenoceptors were blocked with yohimbine (1 2M), DPCPX (0.1 2M), but not RB2 (30 2M), enhanced tritium
overﬂow elicited at 2 Hz (artery: 15 T 5%; n = 6, P < 0.05; vein: 28 T 4%; n = 5, P < 0.05). When tissues were
stimulated under marked ongoing !2-autoinhibition (100 pulses at 2 Hz), ANG II (0.01–100 nM) enhanced tritium
overﬂow up to 89 T 7% (n = 6, P < 0.05) and 69 T 7% (n = 6, P < 0.05) in the artery and vein, respectively. This
facilitatory effect was attenuated in the presence of yohimbine (1 2M) to 32 T 3% (n = 5, P < 0.05) and 24 T 6% (n
=6 ,P < 0.05) in the artery and vein, respectively, and abolished when tissues were stimulated with trains of 20
pulses at 50 Hz. In the presence of yohimbine, the enhancement of tritium overﬂow caused by ANG II (10 nM)
was not changed by DPCPX (0.1 2M) in the artery but was attenuated in the vein from 24 T 6% (n = 4) to 14 T 3%
(n = 8, P < 0.05).
In conclusion, in the mesenteric artery and vein facilitation of NA release by ANG II is ampliﬁed by tonic
activation of inhibitory receptors: the !2-autoreceptors in mesenteric artery, the !2-autoreceptors and adenosine
A1 receptores in the vein.
(1) Cox et al. (2000) Br J Pharmacol 129, 1095 –1102.
(2) Bobalova et al. (2001) Clin Exp Pharm Physiol 28, 397–401.
(3) Shinozuka et al. (2001) Jpn J Pharmacol 85, 41–46.
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Inhibition of Ischemic Contracture: A FSupraphysiological_ Response to




1, G. Paul Matherne




1Heart Foundation Research Center, Grifﬁth University, QLD, Australia,
2Department of Pediatrics, University of Virginia Health Sciences Center, Charlottesville, VA, USA, and
3Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston,
Medical School, Houston, TX 77030, USA
j.headrick@grifﬁth.edu.au
Inhibition of ischemic contracture development was one of the ﬁrst documented cardioprotective actions of ad-
enosine. However, whether this represents a normal protective function of endogenous adenosine is not known.
Moreover, the relevance of delayed contracture to adenosinergic improvements in post-ischemic outcome is un-
clear. We assessed effects of exogenous and endogenous adenosine on ischemic contracture, and relationships
between contracture and post-ischemic outcomes, in hearts from C57/Bl6 mice. Untreated wild-type hearts dev-
eloped a peak ischemic contracture (PC) of 75 T 5 mmHg at 8.5 T 0.8 min, with a time to reach 20 mmHg (termed
time to onset of contracture; TOC) of 4.4 T 0.3 min. Adenosine (50 2M) signiﬁcantly delayed TOC to 6.7 T 0.5.
This protection was mimicked by pre-treatment with the stable analogue 2-chloroadenosine (3 2M) and an A1
adenosine receptor (AR) agonist (50 nM CPA), but not by A3AR (150 nM Cl-IB-MECA) or A2AAR agonism (20
nM CGS-21680). A selective role for A1ARs was supported by abrogation of AR-mediated effects in A1AR gene
knockout (KO) hearts, and contracture inhibition with cardiac A1AR overexpression. Importantly, adenosine-
mediated inhibition of contracture was evident with prolonged (10 to 15 min) but not brief (3 min) pre-treatment.
Endogenously generated adenosine was also ineffective - A1AR KO and non-selective (50 2M 8-sulfophenylth-
eophylline) and A1AR selective (150 nM DPCPX) antagonism all failed to alter intrinsic contracture develop-
ment in the absence of AR agonists. Although inhibition of contracture does not, therefore, play any role in
cardioprotection via endogenous adenosine, delayed contracture with exogenous AR agonism and A1AR over-
expression was associated with improved coronary reﬂow (reﬂecting reduced vascular compression) and enhanced
functional recovery. In summary, our data conﬁrm that adenosinergic inhibition of ischemic contracture is solely
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SpringerA1AR-mediated, and represents a Fsupra-physiological_ response that is only evident with signiﬁcant pre-ischae-
mic AR agonism or enhanced A1AR density. Endogenous adenosine does not normally limit ischemic contract-
ure, potentially due to rapidity of contracture development vs. the time required for expression of AR-mediated
protection.
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Seven genes encode P2X subunits, which can form homo- and heteromeric ATP-gated cation channels. P2X3
homomeric and P2X2/3 heteromeric channels are predominantly found in a subset of primary sensory neurons.
Pharmacological inhibition of P2X3-containing receptors and studies of P2X3-knockout mice have highlighted the
importance of this receptor in animal models of chronic inﬂammatory and neuropathic pain.
Previous work has identiﬁed two conserved lysine residues in the P2X receptor ectodomain that may be involved
in ATP binding
1,2. In this study we have further investigated these residues (Lys
69, Lys
308; rat P2X2 numbering),
using heterologous expression of P2X receptor mutants in HEK293 cells. Currents evoked by ATP were then
measured using whole-cell patch clamp recording.
Both rat P2X2 and rat P2X3 receptors containing the single point mutations K69A or K308A (K63A or K299A in
P2X3) gave no current in response to up to 1 mM ATP. Co-expression of either of the P2X2 point mutants with
P2X3 wild type subunits produced currents with a distinct P2X2/3 phenotype (i.e. sustained currents to the ATP
analogue !"-metylene ATP) EC50 values were 27 T 3.3 2M (P2X2/3 wild type (n = 5)) 22 T 2.6 2M (P2X2[K69A] +
P2X3 (n = 5)) and 44 T 2.6 2M (P2X2[K308A] + P2X3 (n = 8)).
However, conversely co-expression of P2X3 subunits carrying equivalent point mutations with P2X2 wild type
subunits did not produce a functional heteromeric phenotype. Surprisingly the doubly mutated P2X2 receptor (K-
69A,K308A) could not be ‘‘rescued’’ into a functional heteromer by co-expression with wild type P2X3 subunits.
The P2X2/3 heteromeric channel activated by !"-meATP has been shown to contain a single P2X2 subunit and two
P2X3 subunits
3. Therefore, the simplest interpretation of the one-way rescue of ‘‘dead’’ P2X2 subunits by wild
type P2X3 subunits is that only two (P2X3) subunits are required to bind the agonist (!"-meATP) in order for the
channel to open. The ﬁnding that the doubly mutated P2X2[K69A,K308A] receptor cannot be rescued by P2X3
suggests that the agonist binding site is contributed to by lysines on two adjacent subunits. Therefore in this case,
mutating both lysines to alanine in the single P2X2 subunit would leave the heteromeric receptor with only one
binding site (i.e. carrying two lysines) located between the P2X3 subunits, which would insufﬁcient for the channel
to function.
This work was funded by the Medical Research Council and the Wellcome Trust.
1. Jinag L-H, Rassendren F, Surprenant A, North RA, J. Biol. Chem. 2000 275, 34190–6
2. Ennion S, Hagan S, Evans RJ, J Bio Chem 2000 275, 29361–67
3. Jiang L-H, Kim M, Spelta V, Bo X, Surprenant A, North RA, J. Neurosci. 2003 23, 8903–10
Interactions between stress-induced diadenosine polyphosphates and heat
shock proteins; how and why?
Michael Wright and Andrew D. Miller
Imperial College Genetic Therapies Centre, Imperial College London.
a.miller@imperial.ac.uk
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SpringerDiadenosine polyphosphates (ApnAs) were ﬁrst discovered in cells in the 1960s and in spite of the research of
many groups, their intracellular functions have remained elusive. Roles have been identiﬁed that are both positive
and negative to cell survival leading McLennan to ask the question famously, ‘‘Diadenosine polyphosphates;
friend of foe?’’ However, the reason for this lack of clear-cut progress in understanding has been the curiously
high metabolic lability of ApnAs in the face of batteries of ‘‘nudix’’ hydrolase enzymes that are found in different
cells of different organisms. Also, there have been few reliable chemical methodologies for the preparative syn-
thesis of ApnAs and useful ApnA analogues. Fortunately, reproducible preparative synthesis of ApnAs, analog-
ues, ﬂuorescent-labelled analogues and afﬁnity labels is now possible using a combination of Escherichia coli (E.
coli) stress-induced enzyme (LysU) catalyzed phosphate-phosphate bond formation, synthesis and powerful ani-
on-exchange chromatography.
The mechanism of LysU induced catalysis will be described in detail including the effect of phosphorylation. In
particular, we report that active LysU has a dual catalytic activity, initially producing diadenosine-50,50-P
1,P
4-
triphosphate (Ap4A) from ATP, before converting the tetraphosphate to a triphosphate. Therefore, LysU is also
an efﬁcient diadenosine-50,50-P
1,P
3-triphosphate (Ap3A) synthase. Mechanistic investigations reveal that Ap3A
formation requires reversal of Ap4A synthesis once complete, to regenerate ATP and a lysyl-adenylate interm-
ediate, of which the latter is attacked by inorganic phosphate so generating ADP in situ. This in situ ADP can then
attack further regenerated lysyl-adenylate giving rise to Ap3A. LysU may be a key control enzyme for recovery
from cellular stress responses that has the capacity to produce an accomodatory ‘‘spike’’ of [Ap4A] several mins
post stress-induction followed by a prolonged restoration of modulatory [Ap3A] levels with time leading to [A-
p3A]/[Ap4A] ratio 1.
The nature and properties of putative Ap4A interactions with E. coli molecular chaperone GroEL and cAMP
receptor protein (CRP) are also investigated. We show that GroEL is an Ap4A binding protein that binds Ap4A
at a set of binding sites (one per monomer) distinct from the GroEL ATP/ADP sites. Ap4A binding appears to
enhance ATPase rates at higher temperatures, encourages the release of bound ADP and may promote substrate
protein release through differential destabilization of the substrate protein-GroEL complex. We suggest that such
effects should result in enhanced GroEL/GroES chaperoning activities that could be a primary reason for the
improved yields of refolded substrate protein observed during GroEL/GroES-assisted folding/refolding at 30
oC
and above in the presence of Ap4A. We propose that Ap4A has a modulator or ‘‘repressor’’ function reducing the
tendency of GroEL to convert to its storage conformation from an active molecular chaperone conformational
state. Ap4A could contribute signiﬁcantly to E. coli ability to sustain a ‘‘skeleton’’ physiology and metabolism
during stress and aid the restoration to normality immediately post stress. In contrast, we are unable to obtain any
data to support a direct role for Ap4A interactions with CRP.
Interventions on neonatal adenosinergic system: evaluation of neurochemical and
nociceptive aspects.
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The activation of adenosinergic system exerts a modulator role since early phases of development. The expression
of adenosinergic receptors reaches the pattern of adult brain before the birth (1). Adenosine receptor activation in
embryonic and neonatal phases has been demonstrated to produce impairment of global animal development,
ventriculomegaly and loss of white brain matter (2;3). This information raises the question about the susceptibility
of immature brain towards some drugs, such as caffeine. Caffeine is a metylxanthine that exhibits stimulant
effects, which are based on unspeciﬁc blockade of adenosine receptors. In a work of our laboratory we verify that
chronic administration of caffeine (1g/L) in the drink water of rat dams during gestational and lactational phases
altered the pattern of MK-801-induced hyperlocomotion, in 21 days-old litters (4). These effects are persistent to
the deprivation of caffeine seven days before the experiment. In the present study, it has been evaluated the
effects of caffeine administration (1g/L) during gestational and lactational period on the pain threshold and
enzymes activities from cerebral preparation of the litters. Additionally, we veriﬁed the stress induced analgesia in
litters at 50 days of age. Young (14 days old) rats submitted to caffeine treatment have an enhancement of pain
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Springerthreshold, which is lost in adult life, probably by a reestablishment of the balance of adenosine receptor activation.
Young rats which were deprivated of caffeine 7 days before the experiment did not differ of control group. Stress
induced-analgesia is not altered by caffeine treatment, which may be related to an independent action between
the analgesia induced by adenosine or opioids. Caffeine treatment of dams promoted distinct alterations in act-
ivities of both nucleotidases and acetylcholinesterease activities from hippocampus preparations of neonates at 7,
14 and 21 days of age. Maternal caffeine intake altered nucleotidase and AChE activities from hippocampus of
neonate rats in a time- and treatment- dependent manner. However, the alterations occurs in different ways, since
that cholinesterase activity increased and nucleotidase decreased after caffeine treatment. Such alterations in the
immature brain could promote alterations in adult life, which must be further evaluated. This set of results
indicate that intervention on adenosinergic system during gestational and neonatal phases is able to promote
adaptations, probably related to up-regulation of adenosine receptors. These adaptations can reestablish the
normal neuromodulatory control of adenosine, considering the relevance of the adenosinergic control on the
systems evaluated to the organism maintenance.
(1). Ade ´n, U, Herlenius, E, Tang, L-Q, Fredholm, B B. Pediatr. Res. 2000, 48 (2), 177–183.
(2). Zimmerberg, B, Carr, K L, Scott, A, Lee, H H, Weider, J M. Pharmacol. Biochem. Behav. 1991, 39 (4), 883–
888.
(3). Turner C P, Yan H, Schwartz M, Othman T, Rivkees S A. NeuroReport. 2002, 13,1199–1204.
(4).DaSilva,RS,Hoffman,A,DeSouza,DO,Lara,DR,Bonan,CD.Eur. J. Pharmacol. 2005; 509 (2–3): 155–159.
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Resident microglia exhibit ramiﬁed shapes in the normal brain, however, in response to pathological stimuli, they
transform rapidly themselves into more motile amoeboid form called activated microglia and migrate toward the
lesioned sites, where the accumulating microglia secret a variety of substances
1) to repair the tissues. Thus, mic-
roglial cell migration is an important initial step of amelioration of the damaged nervous system.
Extracellular ATP is known to regulate physiological functions of microglia
2). Microglia possesses both ionotropic
P2X receptors (P2X4R and P2X7R) and G-protein-coupled P2Y receptors (P2Y2R, P2Y6R and P2Y12R). We
previously showed that ATP induced membrane rufﬂing and chemotaxis of microglia and suggested that the
membrane rufﬂing is mediated by Gi/o-protein-coupled P2Y12R
3, 4). We showed here that the ATP-induced
chemotaxis of microglia is also regulated by the ionotropic receptor, P2X4R in addition to the P2Y12R.
Stimulation of G-protein-coupled receptor lead to activation of phospholipase C (PLC) and phosphoinositide 3-
kinase (PI3K). We examined the effect of PLC and PI3K inhibitors on the formation of membrane rufﬂing and
the chemotaxis of microglia following the stimulation by ATP. A PLC inhibitor inhibited both membrane rufﬂing
and chemotaxis, while PI3K inhibitors suppressed only chemotaxis without inhibiting the membrane rufﬂing.
These observations indicate that PLC activation is essential for both of the membrane rufﬂing and the chemotaxis,
while the activation of PI3K is necessary only for the chemotaxis. Phosphorylation of Akt, which is known to be a
downstream target of PI3K pathway, was enhanced by ATP stimulation. The increase in Akt phosphorylation was
suppressed by chelating extracellular calcium. These results indicate that activation of PI3K pathway is modulated
by the extracellular calcium inﬂux suggesting a possibility that ionotropic P2XRs are involved in the PI3K acti-
vation. Therefore, we examined the effect of various P2XRs antagonists on the ATP-induced chemotaxis of
microglia. TNP-ATP signiﬁcantly inhibited the chemotaxis, but neither PPADS nor BBG were effective. Furth-
ermore, we constructed the lentivirus vector expressing short hairpin RNAi against P2X4R and introduced the
vector into microglia and showed that suppression of P2X4R reduced the ATP-induced chemotaxis of the cells.
These results clearly indicate that P2X4R in addition to P2Y12R are involved in the ATP-induced chemotaxis of
microglia.
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We summarize recent progress in the research of adenosine involved in sleep-wake regulation. Adenosine is
recognized as a major humoral sleep-inducing factor, accumulated in the brain during the prolongation of wak-
efulness. Because adenosine is rapidly metabolized in vivo; converted to AMP by adenosine kinase in the brain
parenchyma and to inosine by adenosine deaminase dominantly expressed in the leptomeninges (1), we ﬁrst used
stable analogs of adenosine to identify the adenosine receptor subtype involved in sleep regulation. The i.c.v.
infusion into wild-type (WT) mice of cyclopentyl adenosine, an agonist of A1 receptors (A1R), did not change the
sleep-wake cycle; whereas CGS21680, an agonist of A2A receptors (A2AR), induced potent non-REM sleep (2, 3).
The infusion of A2AR-agonist increased the expression of fos protein in the ventrolateral preoptic area (VLPO),
one of the sleep centers, in a non-REM sleep-dependent manner. The activation of VLPO neurons was associated
with a decrease in fos expression in the histaminergic tuberomammillary nucleus (TMN), one of the arousal
centers. The GABAergic inhibition of TMN was found to be involved in non-REM sleep induction by adenosine
A2AR-agonist (3). The neural network between VLPO and TMN is considered to play a key role in the regulation
of vigilance states. We then examined the sleep-wake cycles of WT, A1R-gene knockout (KO), and A2AR-KO
mice. Compared with WT mice, A1R-KO mice did not show any changes in non-REM and REM sleep regulation
under basal conditions and exhibited the same amount of rebound sleep after 6-hr sleep deprivation during the
light period. On the other hand, A2AR-KO mice showed a slight increase in non-REM and REM sleep during the
dark period under the basal conditions and exhibited almost no rebound of non-REM sleep after the 6-hr sleep
deprivation (4). Moreover, caffeine inhibited non-REM and REM sleep in WT and A1R-KO mice, but not at all
in A2AR-KO mice (5). These results, taken together, indicate that A2AR, but not A1R, is important for sleep
regulation and suggest that the genetic depletion of A2AR is compensated by other system(s) but is associated
with altered sleep-wake regulation1.
(1) Okada, T., Mochizuki, T., Huang, Z.-L., Eguchi, N., Sugita,Y., Urade, Y., Hayaishi, O. Biochem. Biophys.
Res. Commun. 2003, 312, 29–34.
(2) Urade,Y., Eguchi, N., Qu,W.-M., Sakata, M., Huang, Z.-L., Chen, J.-F., Schwarschild, M. A., Fink, J. S.,
Hayaishi, O. Neurology 2003, 61:S94–S96.
(3) Hong, Z.-Y., Huang, Z.-L., Qu, W.-M., Eguchi, N., Urade, Y., Hayaishi, O. J. Neurochem. 2005, 92, 1542–1549.
(4) Hayaishi, O., Urade, Y., Eguchi, N., Huang, Z.-L. Arch. Itali. Biol. 2004, 142, 533–539.
(5) Huang, Z.-L., Qu, W.-M., Eguchi, N., Chen, J.-F., Schwarschild, M. A., Fredholm, B. B., Urade, Y., Hayaishi,
O. Nat. Neurosci. 2005, 8, 858–859.
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ATP is an important signaling molecule on the peripheral and central nervous system (CNS). Nucleotides and
nucleosides induce proliferation in glioma cell lines and are hydrolyzed very slowly by gliomas when compared
with astrocytes. Gliomas growth can be involved with ATP liberation mechanism that occurs by the injury caused
by tumor resection. Glioma cells present a clear resistance to death induced by cytotoxic concentrations of ATP
when compared with normal brain tissue. To deplete the extracellular ATP, the enzyme apyrase was tested on the
treatment of gliomas implanted in the rats CNS. One million cells of gliomas in 32l of DMEM were injected in the
right striata of rats male Wistar, 250–270g. After 20 days, the rats were decapitated and the brain sectioning and
stained with hematoxylin and eosine (H&E). We performed immunohistochemical experiments with Ki67, CD31
and VEGF (vascular endothelial growth factor). Total RNA was isolated from cultured glioma C6 cells and the
cDNA was analyzed by Real Time-PCR with primers for the NTPDase family. Our results showed that C6 cells
effectively have a low expression of all NTPDases investigated, in comparison with normal astrocytes. The rats
with implanted glioma co-injected with apyrase had a signiﬁcant reduction in the tumor size (p < 0.05) in com-
parison with the rats injected only with gliomas or with gliomas plus inactivated apyrase (apyrase control). Ac-
cording to the pathological analysis, the malignant gliomas induced by C6 injection and co-injected with apyrase
presented a signiﬁcant reduction in the mitotic index and other histological characteristics that indicate a less
invasive/proliferative tumor. Reduction of proliferation induced by apyrase co-injection was conﬁrmed by coun-
ting the percentage of Ki67 positive glioma cell nuclei. According to counts with CD31, vessel density and neo-
formation was higher in the C6 group 20 days after implantation, in comparison with the group treated with
apyrase. Conﬁrming this observation, rats treated with apyrase presented less VEGF staining in comparison to the
control group (glioma alone). These results indicate the participation of ATP and the ecto-nucleotidases may be
associated with the development of this type of brain tumor in an in vivo glioma model.
Key words: Extracelular ATP, tumor growth, glioma, apyrase
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Involvement of P2Y6(like) receptor in UTP-evoked relaxation of the mouse aorta
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Objectives: Previously, we documented the presence of functional P2Y1, P2Y2 and P2Y6 receptors in murine aorta
endothelial cells. In general, endothelium-dependent relaxation evoked by ATP and UTP is mainly attributed to
P2Y2 receptors. In the mouse aorta, however, the antagonist suramin showed different apparent pKb-values for
ATP (4.53 T 0.07) and UTP (5.19 T 0.03). Particularly the pKb for UTP was different from values reported in rat
aorta, suggesting that other P2Y receptors might be involved in the action of UTP. Therefore this study was aimed
to identify the receptors for UTP.
Methods: In view of the lack of selective purinergic agonists and antagonists, we used P2Y2- and P2Y4-knockout
mice. Isometric force development of thoracic aorta segments of wild type (WT), P2Y2- and P2Y4-deﬁcient (CD1/
129SV) mice was measured in organ baths. Rings were contracted with phenylephrine and then exposed to
nucleotides.
Results: ATP and UTP evoked complete relaxation in P2Y4-deﬁcient aortas that did not differ in any aspect from
that of WT mice. Moreover, P2Y4 mRNA was not detected in whole aorta homogenates of WT mice, whereas
P2Y1, P2Y2 and P2Y6 mRNA was present. P2Y2-deﬁcient mice, however, showed impaired ATP- and ATP+S-
evoked relaxation, indicating that ATP and ATP+S activate predominantly P2Y2-receptors. In contrast, UTP-
evoked relaxation in P2Y2-knockout mice was indistinguishable from that of WT mice. Further, MRS2179, a
P2Y1-selective antagonist did not inhibit UTP-responses.
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P2Y4 receptors are not involved in UTP-induced relaxation of the murine aorta. Further, the results of the P2Y2-
knockout mice indicate that the P2Y2-subtype is not the main UTP-receptor. And MRS2179 excluded the invo-
lvement of the P2Y1 subtype. Therefore, UTP most likely acts on a P2Y6(like) receptor subtype. Furthermore, this
P2Y6(like) hypothesis is supported by identical pKb-values of suramin for UTP (5.19 T 0.03) and UDP(5.26 T 0.06)
and by indistinguishable dose response-curves of UTP and UDP. This was unexpected since UTP mainly activates
P2Y2 in human and rat arteries.
Is in vitro vasorelaxation by ticlopidine related to P2Y12 receptors?
G. Froldi, M. Montopoli, E. Ragazzi, RM Gaion, L. Caparrotta and P. Dorigo
Department of Pharmacology and Anesthesiology -Pharmacology Division- Largo E. Meneghetti 2, University of
Padova (Italy).
g.froldi@unipd.it
Ticlopidine is an antiplatelet agent also known as ADP receptor antagonist in vivo. The compound does not
inhibit ADP-induced platelet aggregation in vitro; hepatic biotrasformation into an active metabolite is required
for its action. The mechanism of antiplatelet action appears to be the irreversible alteration of the platelet surface
P2Y12 receptor, resulting in a reduction of ADP-induced platelet aggregation. Recently, P2Y12 receptor has been
identiﬁed in human blood vessels (1). The aim of our research was to study in vitro direct effects of ticlopidine on
resistance vessel. Rat-tail arterial rings were placed in a tissue bath containing Krebs–Ringer solution and their
viability was assessed by 10 2M phenylephrine and 10 2M acethylcholine. Ticlopidine from 0.01 2Mt o12M per se
did not signiﬁcantly change resting tension of arterial rings; only at 10 2M it slightly decreased the basal tone of
tissues. Ticlopidine per se evoked relaxation of arteries precontracted by 80 mM KCl, 0.5 2M phenylephrine (Phe)
and 0.5 2M 5-hydroxytryptamine (5-HT), as shown in the ﬁgure. The potency order was 5-HT Q Phe > KCl.
2-MethioADP (10 nM to 100 2M), a selective agonist of P2Y1 and P2Y12 receptors, induced a fast and transient
vasoconstriction. Preincubation with 1 2M ticlopidine did not change vasoconstriction by 10 2M 2-MethioADP,
whereas 300 2M suramine inhibited it. Also we studied the inﬂuence of suramine on concentration-related vas-
orelaxation by ticlopidine in tissues precontracted with 5-HT. Vasorelaxation induced by ticlopidine was never
inhibited, indicating that the effect is not related to P2 receptors.
Our experimental observations suggest that ticlopidine can directly induce vasorelaxation of rat resistance arte-
ries. Moreover, experimental data indicate that its effect is not linked to P2Y receptors and that other mechanisms
must be involved.
































1) Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D.
ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood
vessels. Arterioscler Thromb Vasc Biol. 2004, 24(10): 1810–5.
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The ﬁrst suggestions that purines acted in a cardioprotective role came with the demonstration that adenosine
mediated vasodilatation during hypoxia to increased blood ﬂow and thus maintain oxygen delivery to the heart
1,2.
Besides, adenosine is an important extracellular signalling molecule with aintithrombotic and antiinﬂamatory
properties. In heart, ATP is involved in positive ionotropic effects, may induce various forms of arrhythmia
besides hypertrophy and apoptosis
2,3. Traditionally, the inactivation of adenine nucleotides signaling is attributed
to its breakdown by cell-membrane bound enzymes, classiﬁed as ATPases, ecto-apyrases and ecto-50-nucleoti-
dases
4,5. The objective of the present study is to characterize the enzymes involved in ATP, ADP e AMP hydr-
olysis in cardiac synaptosomes of adult male rats. The crude synaptosomal-mitochondrial fraction was prepared as
previously described by Aloyo et al, 1991
6. The reaction was initiated by the addition of nucleotides (1.0 mM
ATP, ADP or AMP) after 10 minutes of pre-incubation at 37-C. The nucleotide hydrolysis was determined by the
Malachite Green method previously described by Chan et al, 1986
7. The protein concentration and the incubation
time were chosen in order to ensure the linearity of the reaction. Then, about 6 2g/tube of protein and 6 minutes
of incubation were used in enzymatic assays for ATP/ADP. The mitochondria ATPase inhibitors (olygomycin
22g/mL and sodium azide 100 2M) were used in all enzymatic ATP assays. For the study of AMP hydrolysis, 10
2g/tube of protein and 10 min were used. Both enzymes were cation-dependent: NTPDase showed a preference
for ion Ca
2+, while 50-nucleotidase showed a preference for ion Mg
2+. In addition, both activities were blockade by
metal ion chelator. KM and Vmax values for ATP, ADP and AMP hydrolysis were found to be 143 T 16 mM and
564 T 89 nmol Pi/min/mg protein (n = 3), 68 T 17 mM and 216 T 37 nmol Pi/min/mg protein (n = 4), 65 T 9m Ma n d
68 T 6 nmol nmol Pi/min/mg protein (n = 3), respectively. Extracellular nucleotides are known to regulate several
physiological responses, including vascular tone, cardiac funtion and haemostasis. There is evidence that purines
contribute to a number of processes involved in normal cardiovascular function, and that disturbances in purin-
ergic signaling are involved in some cardiovascular diseases
2. These results present ﬁrst evidences about the
kinetic characterization for nucleotide hydrolysis by crude synaptosomal-mitochondrial fraction obtained from
adult rats. Then these results may represent a new insight about the purines participation on the cardiovascular
system.
1. Berne, R.M. Am. J. Physiol. 1963, 204, 317.
2. Ralevic, V. and Burnstock, G. Drug News Perspect. 2003, 16, 133.
3. Vassort, G. Physiol. Rev. 2001, 81, 767.
4. Zimmermann, H. Biochem. J. 1992, 285, 345.
5. Plesner, L. Int. Rev. Cytol. 1995, 158, 141.
6. Aloyo, V.J.; McIlvain, H.B.; Bhavsar, V.H. and Roberts, J. Life Sci. 1991, 48, 1317.
7. Chan, K.; Delfert, D.; Junges, K.D. Anal. Biochem. 1986, 157, 375.
Lead optimization of a human A3 adenosine receptor antagonist: the application
of the 3D-QSAR (auto-MEP/PLS) approach as an efﬁcient pharmacodynamic-
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In recent work
1,2, we have reported that the combination of particular descriptors such as molecular electrostatic
potential (MEP) surface properties (autocorrelation vectors) with the conventional partial least squares (PLS)
analysis can be used to produce a robust ligand-based 3D structure-activity relationship (autoMEP/PLS) for the
prediction of the human A3 receptor antagonist activities. Following step of this project is the application of the
3D-QSAR (autoMEP/PLS) approach as efﬁcient and alternative pharmacodynamic ﬁltering method for small-size
virtual library. We have derived therefore a small sized combinatorial library (729 compounds) on one of the
scaffold known as potent human A3 antagonist, the pyrazolo-triazolo-pyrimidines
3. Once predictions have been
computed, the most interesting analogues were further prioritized for synthesis and pharmacological character-
ization. Remarkably, we found that all the new synthetized compounds are correctly predicted as potent human
A3 antagonists
4.
1. Moro, S.; Bacilieri, M.; Ferrari, C.; Spalluto, G. Curr. Drug. Disc. Techn. 2005, 2, 13–21.
2. Moro, S.; Bacilieri, M.; Cacciari, B.; Spalluto, G. J. Med. Chem. 2005, 48, 5698–5704.
3. Moro, S.; Braiuca, P.; Deﬂorian, F.; Ferrari, C.; Pastorin, G.; Cacciari, B.; Baraldi, P.G.; Varani, K.; Borea, P.A.;
Spalluto, G. J. Med. Chem. 2005, 48, 152–156.
4. Moro, S.; Bacilieri, M.; Cacciari, B.; Klotz, K.N.; Spalluto, G. Biorg. Med. Chem. submitted.
Local effect of adenosine 50-triphosphate on NSAID-induced permeability
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Introduction: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are among the most prescribed anti-inﬂammatory
and analgesic drugs worldwide. However, use of NSAIDs is associated with an elevated risk of mucosal damage in
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Springerthe gastrointestinal tract. Adenosine 50-triphosphate (ATP) signalling has been implicated in the control of epi-
thelial function and may play a protective role in the small intestine.
Objective: To determine the local effect of ATP on small intestinal permeability changes induced by short-term
challenge of the NSAID indomethacin in healthy humans.
Subjects and methods: Mucosal permeability of the small intestine was assessed by the lactulose/rhamnose (L/R)
permeability test, i.e. ingestion of a test drink containing 5 g lactulose and 0.5 g L-rhamnose followed by total
urine collection for ﬁve hours. Urinary excretion of lactulose and rhamnose was determined by ﬂuorescent det-
ection high-pressure liquid chromatography (HPLC). As a control condition, basal permeability of the small
intestine was assessed. As a model of increased small intestinal permeability two doses of indomethacin were
ingested prior to ingestion of the test drink (75 mg and 50 mg at j9 hrs and j1 hr, respectively). Placebo or 30
mg/kg ATP was administered concomitantly with indomethacin through a naso-intestinal tube.
Results: Median urinary L/R ratio (g/g) observed in the control condition was 0.030 (range: 0.015–0.051). In
comparison with the control condition, urinary L/R ratio after ingestion of indomethacin and administration of
placebo was signiﬁcantly increased (0.038 (0.016–0.131); P = 0.04). Urinary L/R ratio after ingestion of indome-
thacin and administration of ATP (0.027 (0.015–0.067)) was signiﬁcantly lower than the L/R ratio observed in the
placebo condition (P = 0.02).
Conclusions: Administration of ATP directly into the small intestine during short-term challenge of the NSAID
indomethacin completely prevents the NSAID-induced increase in small intestinal permeability in healthy hum-
ans. These ﬁndings would suggest that ATP could also be beneﬁcial in the treatment of intestinal disorders in
which intestinal permeability changes are involved such as Crohn_s disease.
Localization of nucleoside triphosphate diphosphohydrolyse-3 in mouse digestive
associated glands
Elise G. Lavoie and Jean Se ´vigny
Centre de recherche en Rhumatologie et Immunologie, CHUQ research center, Universite ´ Laval, Que ´bec, Canada
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Introduction: In the digestive system, extracellular nucleotide signalling, via the activation of P2 receptors, part-
icipates in the regulation of various functions including electrolyte and glandular secretion, smooth muscle con-
traction and the control of blood ﬂow. More speciﬁcally, in the associated organs, P2 receptors seem implicated in
the Sjo ¨gren_s syndrome (P2Y2) in the salivary glands [1], and, in pancreas, in insulin secretion (P2Y1)[2]. By the
hydrolysis of + and " phosphates of extracellular nucleotides, nucleoside triphosphate diphosphohydrolyses (N-
TPDases) may regulate some of these pathways. NTPDases 1–3 and 8 are the most important member of E-
NTPDase family that regulate nucleotides levels at the cell surface. In the digestive associated glands (pancreas
and salivary glands), a general localisation has ﬁrstly demonstrated the presence of NTPDases in the plasma
membrane of acinar cells, duct epithelial cells and blood vessels of pig pancreas and parotid glands. The parotid
myoepithelial cells were also stained. In mouse, NTPDase1 was located in the pancreatic acinar cells and NTP-
Dase2 in the duct epithelial cells of pancreas and in myoepithelial cells of sub-mandibular glands.
Aim: In this work, we determined the tissular localisation of the third member of the E-NTPDase family (NT-
PDase3) in the mouse salivary glands (parotid, sublingual and sub-mandibular glands) as well as in pancreas. We
also localised NTPDases 1 and 2 in parotid and sublingual glands to complete the previous studies.
Results: NTPDases were localised by immunological techniques with new antibodies and by enzyme histochem-
istry. In the pancreas, a strong level of NTPDase3 expression was detected in Langerhans islet cells. In parotid
and submandibular glands, NTPDase3 immunostaining was on the apical side of serous acinar cells. A weak signal
was detected in the sublingual glands. As expected, staining for NTPDases 1 and 2 was seen in blood vessels in
sublingual and parotid glands. NTPDase2 was principally localised on the cells surrounding the ducts. These
results suggest that NTPDase3 may play a role in the regulation of endocrine secretion in pancreas and in the
serous secretion of salivary glands by controlling the activation of nearly expressed P2 receptors.
1. Schrader, A.M., J.M. Camden, and G.A. Weisman, P2Y2 nucleotide receptor up-regulation in submandibular
gland cells from the NOD.B10 mouse model of Sjogren"s syndrome. Arch Oral Biol, 2005. 50(6): p. 533–40.
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Looking for the P2 receptor subtypes involved in the presynaptic inhibition
induced by ATP at the mouse neuromuscular junction
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At the neuromuscular junction, ATP is co-released with the neurotransmitter ACh and once in the synaptic space,
it is degraded to the presynaptically active metabolite adenosine. However, it was demonstrated that ATP is able
to modulate ACh release through a mechanism independent of the action of adenosine via its own P2 purinoc-
eptors. At mice diaphragms, we found that 100 2M ATP and 30 2M of the non hydrolysable ATP analogue "+-
imido ATP reduced MEPP frequency by 45.3% and 55.9% respectively, through the modulation of the voltage-
dependent Ca
2+ channels related to spontaneous secretion (L and N-type Ca
2+ channels). "+-imido ATP–induced
modulation on MEPP frequency was antagonized by the non-speciﬁc P2 receptor antagonist suramine (suramine
97.7 T 4.0% of control values; suramine + ATP 103.9 T 1.7%, n = 4). To investigate the type of P2 receptor
involved in the inhibition induced by ATP, the effect of "+-imido ATP on MEPP frequency was evaluated on
diaphragm muscles of CF1 mice in the presence of different P2 antagonists. We found that 10 2M PPADS
(antagonist of P2X receptors, although it was also described its action on the P2Y1, P2Y4, P2Y6 and P2Y13
receptors) did not modify the effect of "+-imido ATP (PPADS 95.9 T 2.7% of control values; PPADS + "+-imido
ATP 50.7 T 2.4%, n = 4), while the P2Y4,6,11,12,13 receptor antagonist reactive blue 2 (5 2M), prevented the effect
of the ATP analog (RB 98.8 T 2.8% of control values, RB + "+-imido ATP 100.3 T 4.7%, n = 8), suggesting that
the effect was mediated by P2Y receptors. On the other hand, pertussis toxin (2 2Mm l
j1 for 12–14 h) and NEM
(10 2M), which are blockers of Gi/o proteins, abolished the action of the nucleotide (PTX + "+-imido ATP 102.8 T
1.6%, n = 4; NEM + "+-imido ATP 122.9 T 5.6%, n = 4), indicating that the P2Y receptors involved are coupled to
Gi/o proteins. Amongst the P2Y receptors, P2Y12 and 13 are linked to Gi/o proteins; thus, we studied the effect of
"+-imido ATP in the presence of the P2Y12 and 13 antagonists 2MeSAMP (30 2M) and AR-C69931MX (1 2M).
Both antagonists prevented the effect of "+-imido ATP (2-MeSAMP 89.5 T 0.4% of control values, 2-MeSAMP +
"+-imido ATP 88.5 T 0.6%, n = 4; AR-C69931MX 97.0 T 4.9%, AR-C69931MX + "+-imido ATP 94.0 T 3.6%, n =
4). Moreover, AR-C69931MX also antagonized the presynaptic modulation exerted by 150 nM 2MeSADP (AR-
C69931MX 93.7 T 2.1% of control values, AR-C69931MX + 2MeSADP 94.6 T 2.0%, n = 4), which is the prefe-
rential agonist for these subtypes of receptors (2MeSADP 53.9 T 1.6%, n = 4).
The present results suggest that P2Y12 or 13 receptors mediate the inhibition of spontaneous ACh secretion
induced by adenine nucleotides at mammalian neuromuscular junctions.
Lowered activity of adenosine kinase leads to adenosine release and decrease of
diabetic T lymphocytes proliferation potential
Tadeusz Pawelczyk, Monika Sakowicz-Burkiewicz, Katarzyna Kocbuch, Marzena Grden
Department of Molecular Medicine, Medical University of Gdansk, 80-211 Gdansk, Poland
tkpaw@amg.gda.pl
Several aspects of immunity are altered in diabetic patients, which are generally more susceptible to some speciﬁc
infection and ultimate complications. The proliferative response of CD4+ T cells derived from type-1 diabetic
patients to the primary protein antigens was reported to be signiﬁcantly reduced [1], but the mechanisms respo-
nsible for impaired lymphocyte proliferation are largely unclear. Diabetic lymphocytes among functional altera-
tions display several metabolic changes including decreased rate of glucose and glutamine oxidation [2]. Our
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in diabetic lymphocytes [4, 5]. These changes may lead to impairment in energy provision especially under con-
ditions of increased energy consumption and elevation of nucleotides metabolites including adenosine. The pre-
sent study was undertaken to investigate the effect of insulin and changes in glucose concentration on adenosine
metabolism, transport and receptor-mediated action in rat T lymphocytes. Experiments were conducted on isol-
ated rat T lymphocytes cultured in medium containing various glucose and insulin concentrations. Proliferation of
T cells was induced with either the Con A or anti-CD3 plus anti CD28 mAbs.
Performed experiments showed that insulin and glucose differentially affected the activities of adenosine meta-
bolizing enzymes in resting and proliferating T cells. However, the vulnerability of T cells to metabolic stress
induced by 2-deoxyglucose was determined by insulin but not by glucose concentration. Irrespective of incubation
conditions the proliferation of T cells was not depended on expression level and functional state of nucleoside
transporters ENT1, ENT2, and CNT2. Inhibition of AK activity with 5-iodotubercidin lowered the proliferation
potential of T cells to the level observed in insulin-deprived cells. Moreover, insulin-deprived cells but not cells
cultured in the presence of insulin released signiﬁcant quantities of adenosine. Under resting conditions the level
of cAMP was ~6-fold higher in cells cultured at 20 mM glucose and the absence of insulin comparing to cells
grown at low glucose and the presence of insulin. T lymphocytes cultured at high glucose (20 mM) and the
absence of insulin displayed increased level of A2A adenosine receptor mRNA and decreased level of A3 receptor
mRNA. The expression level of A1 and A2B receptor was not affected by changes in insulin and glucose conce-
ntrations. Experiments with speciﬁc adenosine receptors agonists and antagonists showed that adenosine-induced
suppression of proliferation of T cells cultured at high glucose and the absence of insulin was mediated by A2A
adenosine receptor but not by A2B receptor. Treatment of T cells grown at high glucose and the absence of insulin
with H-89 (10 2M), a speciﬁc protein kinase A (PKA) inhibitor restored suppressed T cell proliferation.
Concluding, imparied proliferation of insulin-deprived T lymphocytes is evoked by decreased expression of AK
what in turn leads to outﬂow of adenosine from the cell. Released adenosine by acting on A2A receptor induces,
cAMP production leading to activation of PKA and suppression of T cell proliferation.
1. Eibl, N., Spatz, M., Fischer, G.F., Mayr, W.R., Samstag, A., Wolf, H.M., Schernthaner, G., & Eibl, M.M. (2002)
Clin. Immunol. 103, 249–259
2. Otton, R., Mendonca, J.R., & Curi, R. (2002) J. Endocrinol. 174, 55–61
3. Pawelczyk, T., Sakowicz, M., & Podgorska M. (2003) Exp. Cell Res. 286, 152–163
4. Sakowicz, M., Szutowicz, A., & Pawelczyk, T. (2004) Biochem. Pharmacol. 68, 1309–1320
5. Sakowicz, M., Szutowicz, A., & Pawelczyk, T. (2005) Int. Immunol. 17, 145–154
Lung shows a great content in inactive ecto-50-nucleotidase (CD73)
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Ecto-50-nucleotidase (eNT or CD73) converts extracellular AMP into adenosine. In lung, most of the eNT activity
is located in the epithelial surface covering the lumen of the respiratory ways
1. The importance of the eNT-
generated adenosine in this organ
1,2, and the ﬁnding of non-catalytic (inactive) eNT variants in muscle
3 and liver
4
of normal and dystrophic (merosin-negative) mice, prompted us to explore the presence of inactive eNT in lung,
as well as the effects of the merosin-deﬁcient muscular dystrophy on pulmonary eNT.
During the multi-step extraction protocol of eNT from lung, the addition of Triton X-100 + sodium deoxycholate
produces a 5-fold increase in eNT activity
5. Probably, the activity latency can be explained by the inﬂuence of the
lipidic environment upon the nucleotidase activity
6, and by the preferential location of the protein in caveolae and
lipid rafts
7, which are crucial for keeping the pulmonary air-blood barrier in optimal conditions
8.
Inactive eNT variants can be easily detected by comparing samples with the same units of activity in a Western
blot
3. Therefore, samples from tissues where inactive eNT has already been identiﬁed, such as muscle, liver and
kidney
3,4, were subjected to Western blotting together with samples from lung, all with the same units of eNT
activity. Theresultshowed:1)a4.4-foldincreaseintheintensityoflung-eNTbandsrespecttothatoftheotherorgans,
meaningthatthistissuecontainsahighamountofinactiveeNT
5; and 2) a smaller size of the eNT subunit in lung (66
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5. The great content of inactive eNT in lung might
represent a stock of enzyme susceptible of activation for facing pathological situations in which a high amount of
adenosine is required, as it happens in hypoxic episodes
9. On the other hand, digestion with peptide-N-glycosidase
F shows that the size difference of the lung-eNT subunit is due to its lower state of glycosylation. No differences
between normal and dystrophic lung exists in eNT activity, the immunolabeling intensity or size of the subunit.
At the transcriptional level, a single PCR product was identiﬁed, revealing that active and inactive eNT variants
differ in post-translational processing
5. Again, no differences between normal and dystrophic lung were detected
5.
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Mast cells secrete IL-15 by microvesicles shedding upon P2X7 receptor
stimulation
Elena Bulanova, Vadim Budagian, Zane Orinska and Silvia Bulfone-Paus
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Mast cells are recognized as the key cells of allergic inﬂammatory reactions. They express and secrete a number of
pro-inﬂamatory cytokines and chemokines. Interleukin-15 (IL-15) is a potent anti-apoptotic cytokine and a reg-
ulator of T, B and NK cells differentiation and proliferation. Bone marrow-derived mast cells (BMMCs) consti-
tutively express IL-15 mRNA and this expression is further upregulated by LPS stimulation. However, there is no
evidence for IL-15 cytokine secretion from activated mast cells. Recently, we have reported that ATP induces
apoptosis of BMMCs, as well as triggers pro-inﬂamatory cytokine secretion, presumably in the time period bet-
ween commitment to apoptosis and actual cell death.
1 Here we show that BMMCs release annexin-V-positive
microvesicles upon Bz-ATP stimulation. These vesicles contain biologically active IL-15, which later appears in
the vesicle-free supernatant and stimulates the proliferation of the IL-15-dependent CTLL cell line. The IL-15-
containing microvesicles were also found in the supernatants from THP-1 monocytic cell line upon agonistic P2X7
stimulation. Thus, the microvesicle shedding mechanism constitutes one of secretory pathways for a release of IL-
15 in mast cells and monocytes, which might play an important role in regulation by IL-15 of diverse physiological
processes or their pathological deviations.
1E. Bulanova, V. Budagian, Z. Orinska, M. Hein, F. Petersen, L. Thon, D. Adam, and S. Bulfone-Paus. Extrac-
ellular ATP induces cytokine expression and apoptosis through P2X7 receptor in murine mast cells. J. Immunol.
2005, 174, 3880–3890.
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Adenosine, a ubiquitous nucleoside, serves as a building block of nucleic acids and energy storage molecules, as a
substrate for multiple enzymes, and as an extracellular modulator of cellular activity. Extracellular adenosine can
be taken up by the cell and undergo a series of metabolic transformations or can bind to speciﬁc G-protein-
coupled receptors (1). Adenosine has been linked to a variety of physiological processes where its effects depend
either on extracellular adenosine concentration or on the expression of different adenosine receptor subtypes and
the signal transduction mechanism initiated by the binding of speciﬁc agonists. 2-chloroadenosine (2-CADO), a
non-selective adenosine receptors agonist as well as an hydrolysis- and deaminase-resistant adenosine analogue,
induces apoptosis in several cells with mechanisms still to be resolved (2). Prostate cancer (PCa), the second
leading cause of cancer deaths in men, is a complex disease whose etiology involves genetic changes, activated
oncogenes and growth factors, androgenic hormones, and dietary factors (3). In this study we have used the PC3
cell line that reﬂects molecular pathways of clinical androgen-independent PCa (4), to investigate the effects and
the mechanism of action of 2-CADO on cellular proliferation, cell cycle kinetic, and DNA synthesis.We have
shown that analogue uptake and its phosphorylations are fundamental pre-requisites for cellular response and that
the strong cytotoxic effect exerted by 2-CADO on PC3 cells derives from irreversible cytotoxic effect due to
permanent aberrant situations. 2-CADO elicits toxic actions by distributing cells into S-phase causing DNA
strand breaks, and interfering with DNA synthesis through enzymes that lead to a nucleotide pool imbalance. The
observed disappearance of all deoxy-ribonucleoside triphosphate suggests a strong inhibition of ribonucleotide
reductase, one of the rate-limiting enzyme in DNA biosynthesis whereas all ribonucleoside triphosphates, after a
marked initial reduction, showed a small re-synthesis, probably due to enzymes involved in de novo synthetic
purine and pyrimidine nucleotide pathways whose activities have not been inhibited by 2-CADO treatment. The
use of inhibitors of different key enzymes of nucleotides metabolism and DNA biosynthesis has shown that these
enzymes are also inhibited by 2-CADO. Only 5-azacytidine was capable of potentiating the cytotoxic effect of 2-
CADO suggesting that the two compounds target different enzymes and that 2-CADO does not inhibit DNA
methylation reactions.
1. Ralevic, V., and Burnstock, G. (1998) Receptors for purines and pyrimidines. Pharmacol Rev, 50, 413–92.
2. Bellezza, I., Agostini, M., Liguori, L., Minelli, A. (2005) Cytostatic effect of the nucleoside analogue 2-Chlo-
roadenosine on human prostate cancer cell line. Current Pharmaceutical Analysis, 1, 265–272
3. Routh, J.C., Leibovich, B.C. (2005) Adenocarcinoma of the prostate: epidemiological trends, screening,
diagnosis, and surgical management of localized disease. Mayo Clin Proc, 80, 899–907.
4. Culig, Z., Steiner, H., Bartsch, G., Hobisch, A. (2005) Mechanisms of endocrine therapy-responsive and -
unresponsive prostate tumours. Endocr Relat Cancer, 12, 229–244.
Mechanism of extracellular nucleotide-induced eNOS activation in human
endothelial cells.
Cleide Gonc ¸alves da Silva, Anke Specht, Elzbieta Kaczmarek
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
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Nitric oxide (NO) that is generated by endothelial NO synthase (eNOS), regulates vascular tone and leukocyte
adhesion to the endothelium, inhibits vascular smooth muscle cell proliferation and platelet aggregation, and
modulates cell apoptosis and angiogenesis. These diverse functions give endothelial-derived NO a signiﬁcant
inﬂuence on vascular function and integrity. The pathological effects of altered NO production and bioavailability
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Springerhave been linked to hypertension, hypercholesterolaemia, endothelial cell dysfunction, atherosclerosis, diabetes,
heart failure, and poor wound healing. In endothelial cells (EC), eNOS can be activated by various stimuli,
including vascular endothelial growth factor, bradykinin, tumor necrosis factor alpha, histamine, thrombin, end-
othelin-1, and angiotensin II. Multiple protein kinases, including phosphoinositide-3- kinase (PI3K), cAMP-de-
pendent protein kinase (PKA), extracellular signal-regulated kinase (ERK), protein kinase C (PKC), Ca
2+/
calmodulin-dependent kinase (CaMK) and AMP-activated protein kinase (AMPK) have been show to be invo-
lved in the activation of eNOS by phosphorylation of Ser-1177. ATP, which extracellular concentration can
rapidly increase in response to several stress events, also can induce generation of NO. However, a precise
mechanism of this observation has not been identiﬁed.
In this study we demonstrate that extracellular nucleotides, ATP, ADP and UTP (but not UDP or BzATP)
mediate eNOS phosphorylation on Ser-1177 in human umbilical vein EC (HUVEC). We conclude that P2Y1,
P2Y2 and/or P2Y4 receptors, while not P2Y6, P2Y11 and P2X receptors, are involved in eNOS activation in
HUVEC. We have also investigated a role of various kinases in extracellular nucleotide-initiated pathways of
eNOS activation. We excluded PI3K, ERK and CaMK II, since an inhibition of these kinases had no effect on
nucleotide-induced phosphorylation of Ser-1177 in eNOS. Recently, we revealed that in EC, extracellular nucl-
eotides induce AMPK activation in the Ca
2+- and CaMK kinase-dependent manner. In addition, our data indicate
that nucleotide-induced phosphorylation of eNOS depends on an increase in the concentration of intracellular
Ca
2+ since BAPTA-AM (a chelator of Ca
2+) totally inhibits eNOS activation. We presume that CaMK and
AMPK might be upstream components of purinergic activation of eNOS in EC. We hypothesize that P2 receptors
could be a target for the pharmacologic regulation of eNOS activity and its effects on EC function.
Methanol changes ectonucleotidase and acetylcholinesterase activities from
central nervous system of zebraﬁsh (Danio rerio)
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Methanol has been described as an environment contaminant that affects the aquatic biota. Furthermore, it is
also recognized as a neurotoxin capable of producing visual impairment or blindness, affecting optic nerve and-
retina. Studies have suggested that ATP and acetylcholine are co-released together in a Ca
+2-dependent manner.
After being released, the neurotransmitter acetylcholine is metabolized into choline and acetate by acetylcho-
linesterase (AChE), whereas ectonucleotidases controls the ATP and its metabolites levels. The zebraﬁsh genome
has demonstrated regions of syntenic relationship with human genes. In addition, this species has being useful
in biochemistry and toxicological studies, due to the presence of similar physiological response to apomorphic
animals when exposed to different drugs. Considering (i) the NTPDase and ecto-50-nucleotidase activities in
brain membranes of zebraﬁsh recently characterized; (ii) the co-release of ATP and acetylcholine at nerve end-
ings; (iii) the use of methanol in zebraﬁsh embryo cryoconservation protocols, the aim of this study is to test the in
vivo (acute) and in vitro effects of methanol on ectonucleotidase and acetylcholinesterase activities in zebraﬁsh
brain.
The in vitro experiments demonstrated that methanol promoted a signiﬁcant inhibition of ATP hydrolysis (19%
and 34%) at 1.5 and 3.0%, respectively, but ADP hydrolysis decreased only at 3.0% (29%). However, ecto-50-
nucleotidase was not affected by methanol treatment. After 1 hour of in vivo exposure at varying methanol
concentrations (0.25, 0.5 and 1.0%), there were signiﬁcant decrease of ATP (26.5% and 45.1%) and ADP (26.3%
and 30.0%) hydrolysis at 0.5 and 1.0%. The acute treatment with methanol was not able to promote any signif-
icant change on ecto-50-nucleotidase activity in zebraﬁsh brain membranes in all concentrations tested. The sig-
niﬁcant inhibition on NTPDase activity in zebraﬁsh brain membranes observed after in vivo methanol treatment
could be attributed to an indirect effect of this compound, because both methanol concentrations (0.5 and 1%)
did not promote any signiﬁcant change on ATP and ADP hydrolysis when added directly to the reaction medium.
The in vitro exposure of methanol did not present signiﬁcant effect on AChE activity when compared to control
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Springergroup. Nevertheless, zebraﬁsh exposed to methanol had a signiﬁcant inhibition of AChE activity in all concent-
rations tested (30–38%). Based on these ﬁndings, it is possible to suggest that methanol metabolites, such as
formaldehyde or formate could act on zebraﬁsh brain NTPDases and AChE, modulating ATP, ADP and ACh
hydrolysis.
Supported by: FAPERGS, CNPq, CAPES, TWAS
Microvesicle shedding as a mechanism of release of proinﬂammatory cytokines
in dendritic cells and macrophages
Cinzia Pizzirani, Sara Gulinelli, Davide Ferrari, Paola Chiozzi, and Francesco Di Virgilio
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The activation by extracelluar ATP of purinergic P2 receptors (P2R), in particular of P2X7R, has been shown to
be a potent stimulus for maturation and release of proinﬂammatory cytokines by immune cells
1,2. How cytokines
are externalized is still under investigation, even if in the last years there is evidence in human monocytes
3 and
microglia
4 of a mechanism of IL-1" release mediated by shedding of small microvesicles.
Here we demonstrate that monocyte-derived dendritic cells and macrophages release, respectively, IL-1" and IL-
18 by the same mechanism. Extracellular Ca
2+ chelation highly reduced the phenomenon, suggesting the release
of microvesicles to be a Ca
2+-dependent mechanism. The release of microvesicles is triggered by activation of
P2X7 receptor with millimolar concentrations of ATP and its other agonist BzATP. Moreover, pretreatment of
dendritic cells and macrophages with oxidized ATP, a covalent blocker of P2X7R, inhibits microvesicle shedding.
The microvesicles are clearly of plasma membrane origin as conﬁrmed from the presence of a series of proteins
that characterize antigen presenting cells such as MHC-II molecules, together with P2 receptors. The cytokines
stored in the microvesicles are released in the medium in the presence of cytotoxic extracellular ATP concentr-
ations. This suggests a dual role for the nucleotide: as a danger signal for the immune cells, triggering the exte-
rnalization of IL-1" and IL-18 and, after microvesicle shedding, as a stimulus able to induce microvesicles lysis
and cytokine delivery.
1. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, Di Virgilio F. Extracellular ATP
triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol. 159:
1451–8, 1997.
2. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L,
Gabel CA. Absence of the P2X7 receptor alters leukocyte function and attenuates an inﬂammatory response. J
Immunol 168: 6436–45, 2002
3. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid secretion of interleukin-
1beta by microvesicle shedding. Immunity 15: 825–35, 2001.
4. Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M, Verderio C. Astrocyte-derived ATP
induces vesicle shedding and IL-1 beta release from microglia. J Immunol 174: 7268–77, 2005.
Mitochondrial dysfunction induced by a cytotoxic adenine dinucleotide produced







1De Flora, A., and
1Zocchi, E.
1Dept. of Experimental Medicine, Section of Biochemistry, and Center of Excellence for Biomedical Research,
University of Genova, Viale Benedetto XV/1, Genova, Italy;
2Dept. of Biological Chemistry, University of Padova, Viale G. Colombo 3, Padova, Italy.
santina.bruzzone@unige.it
Communications 251
SpringerADP-ribosyl cyclases (ADPRCs) are a family of multifunctional enzymes, present from protists to mammals and
higher plants, that generate a number of products, i.e. cyclic ADP-ribose (cADPR), ADP-ribose, nicotinic acid
adenine dinucleotide and the ADP-ribose dimer, affecting the intracellular free calcium concentration ([Ca
2+]i).
Recently, ADPRCs from Porifera, molluscs and mammals have been shown to catalyse an additional reaction on
cADPR, introducing adenine into the C10-N1 bond of the cyclic nucleotide and generating three new adenine
homodinucleotides, called P18, P24 and P31 from their HPLC retention times (1). P31 proved to be diadenosine
50,5-P1P2-diphosphate (Ap2A). P18 and P24 are two isomers of Ap2A, each containing an unusual N-glycosidic
bond between the newly introduced adenine and one ribose: C10-N1 in P18 and C10-N3 in P24 (1). They are the
ﬁrst dinucleotides featuring a non-canonical N-glycosidic bond demonstrated in ADPRC
+ animal cells. P18 and
P24 both show a potent cytotoxic effect on cell lines and an even more severe growth-inhibitory effect on HP
colony growth (with IC50 values of 1.0 and 0.18 2M, respectively) (1).
These results prompted us to investigate the mechanisms underlying the cytotoxic effect of P18 and of P24, also in
view of their potential use in clinical hematology as antileukemic agents. Results obtained identify mitochondria
as a major target of P24 toxicity, with micromolar concentrations of the dinucleotide, i) dissipating the mitoch-
ondrial proton gradient in intact cells, ii) inhibiting the respiratory chain in isolated mitochondria, acting on
complex I, and, iii) inducing opening of the permeability transition pore (PTP). Conversely, P18 does not show
signiﬁcant effects on any of these functions, indicating the absolute requirement for a C10-N3 bond in the adenine
dinucleotide to exert its mitochondrial effects.
These results identify P24 as a novel endogenous regulator of mitochondrial function in mammalian cells, thus
extending the physiological functions of the ADPRC product family to include control of cell respiration. Inter-
estingly, cADPR and Ap2A partially antagonise P24-induced cytotoxicity and proton gradient dissipation, sugg-
esting that the relative intracellular concentrations of these ADPRC products may decide upon cell life and death.
References
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Modiﬁcation by kainate-induced convulsions of the density of presynaptic P2X
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Epilepsy is a common neurological condition, affecting 0.4–1% of the world_s population. Temporal lobe epilepsy
is a chronic neurologic disorder characterized by recurrent seizures that have a behavioral expression in the form
of convulsions accompanied by a modiﬁcation of limbic circuits and the frequent presence of neurodegenerative
features. Seizure activity results from a broken excitatory-inhibitory balance in the brain circuits and there is
evidence for a role of excitatory amino acids, mainly glutamate, in the neurotoxic effects of seizures, mostly
through activation of ionotropic glutamate receptors. Previous studies have shown that ATP is released upon
stimulation of hippocampal glutamatergic afferent (Wieraszko et al., 1989), in particular upon stimulation at
higher frequencies (Cunha et al., 1996) that are characteristic of seizure activity. Furthermore, we have recently
shown that ionotropic receptors for ATP (P2X1–3) are presynaptically located and control the release of glutamate
from hippocampal nerve terminals (Rodrigues et al., 2005). Thus, as a starting point to explore the potential role
of these P2X receptors in the control of seizure activity and consequent neurodegeneration, we now explored if
the density of these receptors was modiﬁed by a convulsive period triggered by the administration of kainate, a
validated animal model of temporal lobe epilepsy (Ben-Ari, 1985).
Male Wistar rats were divided into 2 groups, i.e. control (saline-injected) and kainate (10 mg/kg, intra-peritone-
ally). All kainate-injected rats displayed a rapid (within 30 min) period of severe convulsions, which reached stage
4–5 of the Racine_s scale. The animals were sacriﬁced 24 hours after kainate administration. Total membranes and
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Springernerve terminal membranes were prepared from the hippocampi of both kainate and saline-injected rats for We-
stern blot analysis of P2X1–3 receptor density, using previously validated antibodies (Rodrigues et al., 2005).
Our preliminary results indicate that the density of P2X1 receptors was not modiﬁed in total membranes, but was
selectively decreased in nerve terminal membranes of kainate-injected rats compared to saline controls. In con-
trast, the density of P2X2 receptors was decreased both in total membranes and in nerve terminal membranes,
whereas the density of P2X3 receptors was not modiﬁed in either total or nerve terminal membranes of kainate
compared to saline control rats.
These results suggest that there is a global tendency for a decrease of presynaptic P2X receptors in the hippoc-
ampus of rats that have suffered a convulsive period. However, the discrete decrease of particular P2X receptor
subtypes is consistent with the hypothesis that these receptors may contribute for the development of seizures
and/or of neurodegeneration during epilepsy, an issue that is currently being explored. (Supported by CNPq
Brazil and FCT).
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Adenosine is a neuromodulator that acts through activation of inhibitory A1 receptors (A1Rs) and facilitatory
A2ARs, which are mainly located in synapses (Fredholm et al., 2005). Upon ageing, adenosine modulation is
modiﬁed with increased levels of adenosine, increased density and effects of A2ARs and a decrease of A1Rs
(Lopes et al., 1999; Cunha et al., 2001). Notably, A2AR antagonists recover memory deﬁcits in aged animals
(Predinger et al., 2005). Since age-related memory deﬁcits are associated with a decreased a cholinergic function,
we now investigated how aging affects the density of adenosine receptors in cholinergic terminals and the tonic
adenosine modulation of acetylcholine (ACh) release in the rat hippocampus.
In young adult rats (2 months old), 64.4 T 3.1% of cholinergic terminals (immuno-positive for vesicular ACh
transporters) were endowed with A1Rs (n = 5) and 35.9 T 3.4% possessed A2ARs (n = 5). In aged rats (24 months
old), the percentage of cholinergic terminals with A1Rs was preserved (53.3 T 5.2%, n = 7, P > 0.05), whereas that
of A2ARs was larger (49.0 T 3.4%, n = 7, P<0.05) and A1Rs and A2ARs were co-located in 36.4 T 4.4% (n = 7) of
cholinergic terminals.
Electrical stimulation (40V, 3msec, 2Hz for 2min) of hippocampal slices triggered ACh release that was larger in
young than aged rats (Lopes et al., 1999). A1R blockade (50 nM DPCPX) enhanced (17.2 T 3.8%, n = 5) ACh
release in young rats and this tonic A1R-mediated inhibition was greater in aged rats (35.2 T 4.0%, n = 6, P < 0.05).
There was also a more pronounced role of adenosine tonically facilitating ACh release in aged rats since the
blockade of A2ARs with ZM241385 (20 nM) decreased ACh release by 11.5 T 1.3% (n = 7) in aged rats and was
devoid of effects (j4.0 T 1.4%, n = 6) in young adult rats. This indicates that lower levels of adenosine in young
adults are only tonically inhibiting ACh release through A1Rs, whereas the greater levels of adenosine in aged
rats (Cunha et al., 2001) cause a greater A1R-mediated inhibition and a simultaneous A2AR-mediated facilitation
of ACh release. Accordingly, removing endogenous extracellular adenosine with 2U/ml adenosine deaminase
(converts adenosine into its centrally inactive metabolite, inosine) caused a similar facilitation of ACh release in
young adult (15.3 T 2.8%, n = 6) and aged rats (19.3 T 1.1%, n = 7, P > 0.05).
These results indicate that there is an enhanced A2AR density and facilitation of ACh release to compensate for
the enhanced A1R density and presumably greater tonic A1R modulation of ACh release, preserving the global
adenosine modulation of ACh release in aged rats. Furthermore, since A2AR antagonists inhibit ACh release, it is
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lation of ACh release. (Supported by Portuguese Society of Neuroscience, Pﬁzer and FCT).
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LL-37 is a cationic peptide composed of 37 amino acids residues ﬁrst described as antimicrobial agent but which
possesses more potent immunomodulatory properties in physiological conditions. It is formed after the cleavage
of its inactive pro-form, the human cathelicidin hCAP-18 by proteinase-3. LL-37 is produced by neutrophils,
monocytes, epithelial cells,...Its structure in !-helix accounts for its destabilizing effect on microbial membranes
but LL-37 is also involved in apoptosis, chemokine production, angiogenesis, wound healing, anti-endotoxin ac-
tivity and chemotaxis (Bowdish et al., 2005). LL-37 was shown to induce interleukin-1" processing and release in
human LPS-primed monocytes after P2X7 receptor activation (Elssner et al, 2004).
The aim of the study was to examine the role of P2X7 receptor in LL-37 responses observed in mouse peritoneal
macrophages and to study its possible modulatory effects on purinergic responses. The experiments were cond-
ucted in peritoneal macrophages from normal mice and P2X7 receptor KO mice (Dr Gabel, Pﬁzer, Groton, Ct).
3 2M LL-37 increased the intracellular concentration of calcium ([Ca
2+]i) in normal and KO mice. Similarly, LL-
37, 1 2M, stimulated a phospholipase A2 (PLA2) activity in both mice. This shows that, in mouse peritoneal
macrophages, the effects of LL-37 are not mediated by P2X7 receptors. We then tested if this peptide could
modulate the cellular responses to purinergic agonists. The calcium response of macrophages to 1 mM ATP was
modiﬁed after a preincubation of the cells with 1 2M LL-37. Indeed, the P2X7 part of the response was completely
lost and the remaining ATP response was similar to that obtained in KO mice. This inhibitory effect was rever-
sible, elicited by low LL-37 concentrations (0.3 2M), also observed on the Bz-ATP response and reproduced by
polymyxin B, another cationic antibiotic. We then examined if this inhibitory effect was present on other P2X7-
mediated responses. Pore formation and phospholipase D activation induced by 1 mM ATP were not abolished
by 1 2M LL-37 while PLA2 activation was potentiated by the peptide.
In conclusion, LL-37 does not stimulate P2X7 receptors in mice peritoneal macrophages but modulates their
responses. The involved mechanisms will be discussed.
Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. (2005) Impact of LL-37 on anti-infective
immunity. J Leukoc Biol. 77,451–459.
Elssner A, Duncan M, Gavrilin M, Wewers MD. (2004) A novel P2X7 receptor activator, the human cathelicidin-
derived peptide LL37, induces IL-1 beta processing and release. J Immunol 172, 4987–4994.
S. Pochet is a postdoctoral researcher of the Fonds National de la Recherche Scientiﬁque of Belgium
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Adenosine is known to increase myocardial resistance to ischemia and reperfusion
1,2 but the mechanisms resp-
onsible for cardioprotection are not entirely understood. In rat heart, A3 adenosine receptor stimulation was
found to reduce [
3H]-ryanodine binding and sarcoplasmic reticulum (SR) Ca
2+ release, potentially leading to a
depletion of the SR Ca
2+ pool, and to the delay of the development of cytosolic Ca
2+ overload during ischemia
3.
In the present work we investigated the effect of the transduction pathway responsible for the anti-ischemic effect
in an isolated rat heart model.
Hearts were perfused for 20 min with control buffer or with 100 nM IB-MECA (N
6-(iodobenzyl)-adenosine-50-N-
methyluronamide), an A3 receptor agonist, 10 2M U-73122, a phospholipase C inhibitor, or 2 2M chelerythrine, a
protein kinase C inhibitor. At the end of each perfusion, the hearts were homogenized and used for one of the
following procedures: [
3H]-ryanodine binding assay, RT-PCR or western blotting experiments.
Perfusion with IB-MECA produced a signiﬁcant increase in coronary ﬂow while in the presence of chelerythrine
no signiﬁcant change was observed in hemodynamic variables. U-73122 determined a remarkable negative inot-
ropic action (75% reduction in cardiac output, P < 0.01; 35% reduction in systolic aortic pressure, P < 0.05). IB-
MECA perfusion caused a signiﬁcant decrease in ryanodine binding (Bmax: 379 T 15 vs. 434 T 15 fmol/mg of
protein, P < 0.05), which was abolished by chelerythrine (Bmax = 430 T 17 fmol/mg of protein, P = NS vs control),
but not by U-73122 (Bmax = 362 T 17 fmol/mg of protein, P < 0.05 vs. control). RT-PCR experiments showed that
ryanodine receptor gene expression was not affected by IB-MECA. In Western blot experiments, ryanodine
receptor phosphorylation on serine 2809 was not modiﬁed after perfusion with IB-MECA. In conclusion, the
modulation of SR Ca
2+ release by IB-MECA can be dependent on protein kinase C activation which, in our
model, is not due to phospholipase C activation. Changes in ryanodine receptor gene expression or direct phos-
phorylation of the ryanodine receptor on serine 2809 residue do not appear to be involved in the molecular
mechanisms of adenosine cardioprotection.
1. Berne, R.M., Cardiovasc. Res., 1993, 27(1), p. 2.
2. Ely, S.W. and. Berne, R.M, Circulation, 1992, 85(3), p. 893–904.
3. Zucchi R, Yu G, Ghelardoni S, Ronca F, Ronca-Testoni S. Cardiovasc. Res., 2001, 50, 56–64,
Modulation of Endothelial ATP- Signaling by Hypoxia: Functional
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Extracellular levels of adenine nucleotides (i.e. ATP, ADP, AMP) are elevated by various mechanisms during
hypoxia (1,2). Since vascular endothelial cells express multiple ATP receptors (2), we considered the possibility
that hypoxia might transcriptionally regulate the proﬁle of endothelial ATP receptors. An mRNA screen of
endothelial P2-receptors revealed that the P2Y2 isoform of ATP receptors was selectively upregulated by hypoxia.
Using an siRNA approach, functional examination of endothelia exposed to hypoxia showed robust increases in
P2Y2-dependent induction of vascular cell adhesion molecule-1 (VCAM-1) expression. Furthermore, using in
vitro models of ATP-signaling, we showed increased endothelial permeability following P2Y2– stimulation in
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P2Y2 receptor. Moreover, loss and gain of function studies in cell lines with genetically modiﬁed activity of the
transcription factor HIF-1 revealed that P2Y2 induction by hypoxia maps, at least in part, to HIF-1 dependent
gene regulation. Taken together, these results identify the selective induction of P2Y2 receptor by hypoxia. Such
results deﬁne a potential pro-inﬂammatory signaling pathway mediated by extracellular ATP during hypoxia.
1. Eltzschig, H.K., L.F. Thompson, J. Karhausen, R.J. Cotta, J.C. Ibla, S.C. Robson, and S.P. Colgan. Blood 2004.
2. Weissmuller, T., H.K. Eltzschig, and S.P. Colgan. Purinergic Signalling 2005.
This work was supported by a Fortune grant F1211250.1 to TW and HKE.
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Adenosine is a ubiquitous component of cells that act as a homeostatic regulator in the nervous system (Cunha,
2001). Its main role in the nervous system is to regulate neuronal activity modulating neurotransmitter release, the
postsynaptic component, and the nonsynaptic components. Besides the well-characterized inhibitory effect of
adenosine in the gastrointestinal tract operated by neuronal A1 receptors (e.g. Nitahara et al., 1995), the involv-
ement of A2 receptors mediating excitation of myenteric neurons was reported with conﬂicting results (Christoﬁ et
al., 1994). Recently, we demonstrated that endogenous adenosine plays a predominant facilitatory action on
[
3H]acetylcholine ([
3H]Ach) release from myenteric neurons of the rat ileum, via the activation of prejunctional
facilitatory A2A receptors (Duarte-Arau ´joet al., 2004). The co-existence of both receptor subtypes on cholinergic
neurons prompted the question of how does adenosine discriminate between these receptors to regulate synaptic
transmission in the longitudinal muscle-myenteric plexus (LM-MP) of the rat ileum. Electrical stimulation of the
LM-MP increased the outﬂow of adenosine, inosine and hypoxanthine. Myenteric neurons seem to be the main
source of endogenous adenosine, since blockade of action potentials with tetrodotoxin (1 2M) or omission of Ca
2+
(plus EGTA, 1 mM) in the buffer essentially abolished nucleosides release, while adenosine outﬂow remained
unchanged when smooth muscle contractions were prevented by nifedipine (1 2M). Inhibition of ecto-50-nucle-
otidase by concanavalin A (0.1 mg ml
j1) produced only a moderate decrease (~25%) on adenosine accumulation
in the LM-MP, indicating that the extracellular catabolism of released ATP might not be a major source of the
nucleoside. Data using the acetylcholinesterase inhibitor, physiostigmine (10 2M), and several subtype-speciﬁc
muscarinic receptor antagonists, 4-DAMP (100 nM), AF-DX 116 (10 2M) and muscarinic toxin-7 (1 nM), suggest
that cholinergic motoneurons are endowed with muscarinic M3 autoreceptors facilitating the outﬂow of adenos-
ine. Surprisingly, bath samples collected after stimulating the LM-MP exhibited a relatively high adenosine de-
aminase (ADA) activity (0.60 T 0.07 U ml
j1), which increased in parallel with the accumulation of adenosine and
its deamination products. Our ﬁndings are in keeping with the hypothesis that ADA secretion, along with a less-
efﬁcient dipyridamole-sensitive nucleoside transport system, may restrict endogenous adenosine actions to the
synaptic region channelling to facilitatory A2A receptors activation. Such a local environment may also limit
diffusion of exogenously added adenosine towards the active zones, as we showed that this constrain may be
overcome by inhibiting ADA activity with erythro-9(2-hydroxy-3-nonyl) adenine (50 2M).
Cunha, R.A., 2001. Neurochem. Int. 38, 107–125.
Nitahara, K., Kittel, A., Liang, S.D., Vizi, E.S., 1995. Neuroscience 67, 159–168.
Christoﬁ, F.L., Baidan, L.V., Fertel, R.H., Wood, J.D., 1994. Neurogastroenterol. Mot. 6, 67–78.
Duarte-Arau ´jo, M., Nascimento, C., Timo ´teo, M.A., Magalha ˜es-Cardoso, M.T., Correia-de-Sa ´, P., 2004. Br. J.
Pharmacol. 141, 925–934.
Research supported by FCT (POCTI/FCB/45549/2002, participation of FEDER funding). Determination of ADA
activity was performed by Ms. M.J. Carvalho and M.I. Garrido (Lab. Quı ´mica Clı ´nica – HGSA-SA, Porto).
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Under normal conditions, pain is associated with electrical activity in small-diameter ﬁbers of dorsal root ganglion
(DRG) of the spinal cord. In addition, numerous studies have shown that the descending noradrenergic pathway
from the locus coeruleus plays a crucial role in the modulation of sensory transmission in the spinal cord and
thereby attenuates pain sensation. Electrophysiological studies suggest that glutamatergic transmission in the
spinal cord is under the control of P2X receptors (Nakatsuka and Gu, 2001) and previous data (e.g. Sperla ´gh et
al., 2002, Papp et al., 2004) indicate that the release of both glutamate and noradrenaline are subject to modul-
ation by presynaptic facilitatory P2X and inhibitory P2Y receptors in the CNS, although there is a considerable
regional heterogeneity in the underlying receptors subtypes involved in these actions. In this study rat spinal cord
slices were stimulated electrically and the effect of different purinergic agonists and antagonists on [
3H]nor-
adrenaline and [
3H]glutamate release were examined.
Among agonists, ATP, ADP and 2-methylthioadenosine 50-disphosphate (2MeSADP) decreased concentration-
dependently the electrical stimulation-evoked tritiated NA efﬂux from superfused rat spinal cord slices with the
following rank order of agonist potency: 2MeSADP > ADP > ATP. The inhibitory effect of ATP could be
counteracted by reactive blue 2 (RB2 30 2M) and by the P2Y12/13 receptor antagonist 2-methylthioadenosine 50-
monophosphate (2-MeSAMP, 10 2M), and partly by the P2Y1 receptor antagonist MRS 2179 (10 2M), but not by
suramin (300 2M) and PPADS (30 2M). RB2 (30 2M) and 2MeSAMP (10 2M), per se, had no signiﬁcant effect.
On the other hand, 2-methylthioadenosine-50-triphosphate (2-MeSATP, 10–300 2M), and ADP at a lower conc-
entration range (100–600 2M) increased electrically evoked tritium overﬂow. The facilitatory effect of 2-MeSATP
was antagonized by PPADS (30 2M) and by the P2X1 receptor selective antagonist 4,40,4,40-[Carbonylbis[imino-
5,1,3-benzenetriyl bis (carbonyl-imino)]] tetrakis (benzene-1,3-disulfonic acid) octasodium salt (NF449, 100 nM),
but not by MRS 2179 (10 2M).
When the release of [
3H]glutamate measured, ATP, 2-MeSATP, and 2-MeSADP all decreased electrically evoked
tritium overﬂow, with the following rank order of agonist potency: 2MeSADP > ATP > 2-MeSATP. The effect of
ATP was fully antagonised by suramin (300 2M) and by 2-MeSAMP (10 2M), and partly by MRS 2179 (10 2M),
and PPADS (30 2M).
In conclusion nucleotides exert dual and opposite modulation on the release of noradrenaline in the spinal cord of
the rat. Whereas the inhibitory modulation is most likely mediated by P2Y12 and/or P2Y1 receptors, the facili-
tatory modulation is mediated by P2X1 receptors. In addition the release of glutamate is also subject to similar
inhibitory modulation; however, the identity of underlying P2 receptor subtype awaits further investigation.
References
Nakatsuka, T. and Gu, J. G. (2001) ATP P2X receptor-mediated enhancement of glutamate release and evoked
EPSCs in dorsal horn neurons of the rat spinal cord. J Neurosci 21, 6522–31.
Papp, L., Balazsa, T., Kofalvi, A., Erdelyi, F., Szabo, G., Vizi, E. S. and Sperlagh, B. (2004a) P2X receptor
activation elicits transporter-mediated noradrenaline release from rat hippocampal slices. J Pharmacol Exp Ther
310, 973–80.
Sperlagh, B., Kofalvi, A., Deuchars, J., Atkinson, L., Milligan, C. J., Buckley, N. J. and Vizi, E. S. (2002) Invol-
vement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. J Neurochem 81,
1196–211.
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Nucleotides in the extracellular ﬂuids serve as important signaling molecules which act via the P2 receptor family.
The P2Y2 receptor is a unique member of the P2Y receptor family which responds equipotently to ATP and UTP.
We have generated a stably transfected HEK 293 cell line overexpressing rat P2Y2 receptor with a GFP tag on the
C-terminus. We investigated the role of different proteins and factors that could be involved in the endocytosis of
the receptor. The localization of the expressed receptor was seen exclusively on the plasma membrane. This is in
accordance to the endogenous distribution of the P2Y2 receptor. To conﬁrm the functional expression of the
transfected receptor we stimulated the cells with ATP or UTP (100 2M) and monitoring the rise in [Ca
2+]i using
Fura-2. We could show that the endocytosis of the receptor proceeds via clathrin-dependent pathway (Tulapurkar
et. al., 2005). We further investigated the role of kinases (Tulapurkar et. al., 2006) and other proteins that could
modulate receptor trafﬁcking. The cells were pre-incubated with 0.75% v/v 1-butanol, an inhibitor of phosphol-
ipase-D2 (PLD2), and then stimulated with 100 2M UTP. It was observed that pre-incubation delayed the end-
ocytosis of the receptor and it delayed the reappearance of the receptor. To conﬁrm the role of PLD2 in
endocytosis of the receptor the cells were pre-treated with 0.75% v/V 2-butanol, before stimulation with UTP.
Then the kinetics of endocytosis was not affected. These results conﬁrmed that PLD2 modulates the endocytosis
of the P2Y2 receptor. Kinases are also known to modulate endocytosis of G-protein coupled receptors (GPCRs)
and the proliferation mediated via them. Pre-incubation of the cells with U0126, an inhibitor of MEK did not
affect the endocytotic kinetics of the receptor, but delayed the reappearance of the receptor. ATP and UTP,
equipotent agonists at the P2Y2 receptor in terms of the Ca
2+ responses, exhibited, however, an interesting
difference in terms of modulating reappearance of the endocytosed P2Y2 receptor. Endocytosis of the receptor
proceeded normally on stimulation of the cells with 100 2M of ATP or UTP for either 30 or 60 min. In case of
cells that were stimulated for 30 min with either agonist, the endocytosed receptor reappeared on the plasma
membrane 1 hour after withdrawal of the agonist. After 60 min of exposure of the cells to agonist and 60 min of
withdrawal for ATP treated cells the receptor completely reappeared on the plasma membrane, whereas in case
of UTP-treated cells there was a partial reappearance of the receptor on the plasma membrane. This indicates
that although ATP and UTP are equipotent at the P2Y2 receptor in terms of Ca
2+ response but not in terms of
reappearance of the receptor. The nucleotides speciﬁcally stimulated and modulated the proliferation of the HEK
293 cells. This stimulation in proliferation was not observed, when cells were treated with agonist for protease-
activated receptor or agonists of different growth factor receptors. This indicates that nucleotides could be used to
modulate speciﬁcally the growth of cells and trafﬁcking of the receptor is a ﬁnely modulated process.
Tulapurkar ME, Schafer R, Hanck T, Flores RV, Weisman GA, Gonzalez FA, Reiser G. Cell Mol Life Sci. 2005
62, 1388–99.
Tulapurkar ME, Zu ¨ndorf G, Reiser G J Neurochem.2006 96, 624–34.
MODULATION OF SYNAPTIC TRANSMISSION BY ADENOSINE A1
AND NPY RECEPTORS ON RAT CORTICAL NEURONS
Sichardt, K.; Beck-Sickinger, A.G.; Nieber, K.
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G-protein coupled receptors (GPCRs) have been extensively characterised with respect to both, ligand binding
and activation of various signalling pathways. There are considerable evidences that signalling via GPCRs can be
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for the pathophysiological consequences of receptor activation.
In the central nervous system (CNS) neuroprotection during hypoxia is based on the inhibition of glutamate
release from presynaptic terminals followed by inhibition of postsynaptic potentials. Two GPCR subtypes are
involved in this process on cortical neurons: the adenosine A1 receptor (A1R) and the neuropeptide Y Y1 receptor
(Y1R). Both are located presynaptical and inhibit the glutamate release. Therefore the aim of the present study
was to evaluate the effect of the two GPCRs on the synaptic transmission on pyramidal cells of the rat cingulate
cortex and to demonstrate a possible interaction between the two GPCRs. Intracellular recordings with glasmi-
croelectrodes were made on pyramidal cells in layer V of the cingulate cortex in rat brain slices. Postsynaptic
potentials (PSPs) were evoked by electrical stimulation with a concentric bipolar electrode in layer I. Previously
we found that activation of A1Rs by endogenous released adenosine or by the selective A1R agonist N6-cyclo-
pentyladenosine (CPA, 1nM–102M) depressed the PSPs [1,2]. Approximately 60% of the neurons responded to
NPY and the selective Y1 receptor agonist [F7, P34]pNPY suggesting a moderate distribution of Y1R in the
cingulate cortex. NPY and [F7, P34]pNPY inhibited the PSPs in a concentration dependent manner after a
superfusion about 5 minutes. The inhibition of NPY (1nM) and [F7, P34]pNPY (1nM) was nearly 40%. The effect
was antagonised by the Y1 selective antagonist BIBP3226 (50nM). In further experiments an interaction between
A1R and Y1R was tested. Two different types of experiments were conducted. Firstly, NPY and CPA were
superfused successively without washout, each in a concentration which induced maximum inhibition in individual
experiments. NPY (100nM) and CPA (102M) depressed the PSPs in the same range as in individual experiments.
Secondly the selective A1R antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) was superfused 5 minutes
before application of NPY. DPCPX (0.12M) decreased the NPY induced inhibition compared to the inhibition of
NPY alone. The current results suggest that the two GPCRs induce the inhibition of the PSPs independently from
each other. So far, an interaction cannot be excluded and it must be investigated whether a desensitization by
NPY exists.
[1] Brand, A, Vissiennon, Z, Eschke, D, Nieber, K: Adenosine A1 and A3 receptors mediate inhibition of synaptic
transmission in rat cortical neurons. Neuropharmacology 2001; 40: 85–95.
[2] Hentschel, S, Lewerenz, A, Nieber, K: Activation of A3 receptors by endogenous adenosine inhibits synaptic
transmission during hypoxia in rat cortical neurons. Rest. Neurol. Neurosci. 2003; 21: 55–63.
















T cell activation helps control the immune system. Here we examined the role of ATP, adenosine, P1/P2 rece-
ptors, and ecto-enzymes in regulating T cell function. Using Real-Time RT-PCR, we found that human CD4
+ T
cells and Jurkat T cells express similar patterns of multiple P1 and P2 receptor subtypes: T cells express high levels
of A2A adenosine receptors and the P2X4 and P2X5 nucleotide receptor subtypes, and moderate to low levels of
A1 (Jurkat only), A2B, and A3 adenosine receptors and P2X1,P 2 X 7,P 2 Y 1,P 2 Y 4,P 2 Y 6 (CD4
+ only), P2Y11, P2Y12
(Jurkat only), and P2Y14 nucleotide receptors. Cell stimulation with phytohemagglutinin (PHA; 50 ng/ml) and
phorbol ester (PMA; 5 ng/ml) altered these expression patterns in Jurkat cells. In particular, P2X1 and P2X5
receptor mRNA and protein expression increased in response to cell stimulation (see Fig.), suggesting a role for
these receptors in T cell activation.
T cell activation elicited a rapid release of ~0.1% of the total cellular ATP content (~36 pmol/cell) from Jurkat
cells. HPLC studies demonstrated that ATP released in response to PHA/PMA stimulation was rapidly hydrol-
yzed to ADP, AMP, adenosine, and inosine, most likely by ecto-enzymes. Resting Jurkat cells hydrolyze ATP,
reducing exogenously added ATP (5 2M) by 50% in <1 h to form ADP, AMP, and inosine; but little adenosine
was observed, suggesting a short half-life. Indeed, we found that Jurkat cells rapidly converted exogenously added
adenosine to inosine. Complete adenosine deamination occured in <1 min. Using the adenosine deaminase
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nucleoside transporters and rapid hydrolysis by ADA localized outside the cell likely account for low levels of
extracellular adenosine.
By measuring interleukin-2 (IL-2) mRNA induction and IL-2 expression with Real-Time RT-PCR and ELISA,
respectively, we found that ATP and adenosine elict opposing actions on T cell activation. Agonists of P2 rece-
ptors (ATP and ATP+S) enhanced IL-2 expression in Jurkat cells, while the P1 agonist adenosine and A2A
receptor-selective agonist (CGS 21680) suppressed IL-2 expression. Selective agonists for other P1 receptor
subtypes had little effect.
Together, these results suggest that T cell function is tightly controlled by the coordinated activation of compo-
nents involved in release of and response to ATP and adenosine. T cell stimulation may be supported by positive
feedback through ATP release and P2 receptor activation, while adenosine, formed from released ATP, may
terminate the T cell activation process through a negative feedback loop that involves A2A receptor activation.
Fine-tuning of the T cell response may occur through changes in the activity of ecto-enzymes that regulate
extracellular ATP and adenosine concentrations, and through changes in the expression patterns of speciﬁc P1
and P2 receptors.
Fig. Changes in P2X1 and P2X2 mRNA expression after stimulation with PHA and PMA for indicated times.
This study was funded in part by grants from the National Institutes of Health (GM-51477 & 60475).
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Cells release ATP during inﬂammatory processes or tissue damage. In our study we investigated the interaction of
the P2X7–receptor on the calcium signalling of B lymphocytes induced by B cell receptor (BCR) ligation. In B
cells ligation of BCR induces a biphasic Ca
2+ response. Activation of the P2X7 receptor raises a cationic ion
current which carries sodium, calcium and potassium. The extent of the accompanying increase in the global
intracellular calcium concentration is dependent on the degree of the depolarisation of the cell membrane, which
in turn is dependent on the activation and expression level of the P2X7 receptor. B lymphocytes were isolated
from human from tonsils and puriﬁed by means of the nylon wool method. The cells were loaded with Ca
2+-
sensitive and membrane potential-sensitive dyes. The ﬂuorescence signals were measured by ﬂow cytometry. The
cells were stimulated by the ligation of the B BCR by human F(ab0)2 anti-2 antibodies in combination with rising
concentrations of the P2X7 receptor agonist BzBzATP. We found a concentration dependent effect of BzBzATP
on the BCR-Ca
2+-response in P2X7-receptor expressing cells which was inhibiting at low concentrations (1 2M)
and additive at higher concentrations (50 2M) of BzBzATP. The interaction of these two receptors might be
signiﬁcant for the modulation of the innate immune response.
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The search of therapies alternative to L-DOPA or dopamine receptor agonists for the treatment of Parkinson_s
disease (PD) is very active and adenosine A2A receptors, for their interaction with the dopamine D2 receptor,
have became particularly attractive. Recent evidences obtained in rodent and primate models of PD and preli-
minary clinical trials, indicate that adenosine A2A receptor antagonists might represent a new valuable therapeutic
tool for the treatment of PD.
In this study we evaluated the effect of the A2A receptor antagonists SCH 58261 and ST 1535 in the unilateral 6-
hydroxydopamine (6-OHDA) rat model of PD.
In 6-OHDA lesioned rats, acute administration of SCH 58261 and ST 1535 counteracted the impairments in the
initiation of stepping movements and in the adjusting step induced by the lesion and increased the turning beh-
avior induced by L-DOPA. In chronic studies, SCH 58261 or ST 1535 + L-DOPA induce lower diskinetic mov-
ements than L-DOPA alone and did not induce long-term increase in GAD67 (the synthesizing enzyme of
GABA) and dynorphin mRNA in striatum.
The data indicate that A2A receptor antagonists ameliorate the motor impairment which characterize PD. Furt-
hermore the neuronal modiﬁcations observed in rat striatum after chronic treatment with SCH 58261 or ST 1535 +
L-DOPA, suggest that such treatments might not produce detrimental long-term changes as L-DOPA alone.
Molecular and functional evidence of a P2X7-like receptor in P2X7 knockout
mouse brain.
Patricia Marı ´n Garcı ´a, Jesu ´sSa ´nchez-Nogueiro, David Leo ´n, Miriam Leo ´n Otegui, Marı ´a Diez Zaera,
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P2X7 expression in mammalian central and peripheral nervous system is a matter of controversy because there are
not really speciﬁc agents for this receptor subtype. In this research, P2X7 expression and functionality was studied
in C57Bl6J wild type (WT) and P2X7 knockout (KO) mice from Dr. Gabel (Pﬁzer, Solle et al., 2001).
RT-PCR experiments using speciﬁc pairs of primers to amplify the disrupted region in P2X7 KO mice showed that
this DNA fragment is only present in WT mice. However, when the speciﬁc primers that codify for a region
before to the disrupted one or back to it were used, DNA fragments were ampliﬁed in WT and KO animals. In
western blotting and immunocytochemical experiments in brain, no differences from WT versus P2X7 KO were
found. However, western blotting assays in macrophages showed a P2X7 protein expression only in WT mouse.
Calcium imaging experiments were made to assess the P2X7 functionality. The physiological agonist, as ATP, and
pharmacological agonist as Benzoyl-ATP were tested in medium without magnesium; and so, inhibitors as zinc or
Brilliant Blue (BBG). A similar functional response in WT and KO mice was observed.
YO-PRO assays in a micro plate reader showed that no pore was formed in cerebellum granule neurons from WT
and KO.
These results indicate that in P2X7 KO mice brain may exist another protein very similar to P2X7 receptor, which
could assume its role in KO mice brain.
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IB-MECA in adjuvant induced arthritis
Avivit Ochaion, Sara Bar-Yehuda, Shira Cohen and Pnina Fishman
1
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Activation of the A3 adenosine receptor (A3AR) was found to mediate anti-inﬂammatory effects via the natural
ligand adenosine or synthetic A3AR agonists such as IB-MECA or Cl-IB-MECA. In this study we demonstrate
that the NF-kB signal transduction pathway is responsible for the ability of IB-MECA to prevent the clinical and
pathological manifestations of arthritis in an experimental animal model of adjuvant induced arthritis (AIA).
A3AR protein expression level was highly expressed in the paw, synovia, drain lymph nodes (DLN) and perip-
heral blood mononuclear cells (PBMNC) of rats with AIA in comparison to naı ¨ve animals. Upon treatment with
IB-MECA, down-regulation of A3AR expression was noted, both in the inﬂammatory tissues as well as in the
PBMNC. Analysis of synovia and DLN protein extracts revealed a decreased expression level of PI3K, PKB/Akt,
IKK, NF-kB and TNF-!, known to affect survival and apoptosis of inﬂammatory cells. Additionally, the level of
caspase-3, was up-regulated, demonstrating that apoptosis of inﬂammatory cells took place.
As a result of above events, AIA rats responded to IB-MECA treatment by a decrease in the clinical and
pathological score of the disease. The response to IB-MECA was neutralized by pre-treatment of the animals with
the antagonist MRS1220, conﬁrming that the efﬁcacy of the synthetic agonist was A3AR mediated. Taken tog-
ether, IB-MECA an orally bioavailable molecule activates A3AR, generating down-stream signaling pathway
which results in an anti-inﬂammatory effect. The ﬁnding that A3AR expression level in the PBMNC reﬂects
receptor status in the remote inﬂammatory sites suggests A3AR as a follow up bio-marker.
Taken together, high A3AR expression is found in the synovia and the immune cells in the DLN and PBMNC.
IB-MECA, an orally bioavailable molecule, activates A3AR inducing receptor down-regulation and the initiation
of a molecular mechanism which involves de-regulation of the PI3K – NF-.B signaling pathway. As a result, a
potent anti-inﬂammatory effect, manifested in the improvement of disease clinical and pathological score, takes
place. The ﬁnding that A3AR expression level in the PBMNC and DLN reﬂects receptor status in the remote
inﬂammatory site suggests A3AR as a follow up bio-marker.
MOLECULAR MODELLING OF A2B ADENOSINE RECEPTOR
Vladimir A. Palyulin
1, Andrei A. Ivanov
1, Pier Giovanni Baraldi
2, Nikolai S. Zeﬁrov
1
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The molecular model of A2B subtype of human adenosine receptor was built in homology with bovine rhodopsin.
The model includes a transmembrane domain, all extracellular and intracellular hydrophobic loops and terminal
domains. The molecular docking of adenosine as well as some known agonists and antagonists had been made and
their binding modes had been studied. The model of A2B receptor subtype had been compared with the models
obtained for other subtypes of adenosine receptors (A1,A 2A,A 3) and possible reasons of differences in ligand
activities with respect to different receptor subtypes were discussed.
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carried out. The conformational changes of the A2B receptor occurring during molecular dynamics simulations
were explored, and the stable binding modes of the studied ligands were analysed. According to the models
presented in this work, the residues involved in ligand recognition were determined for the A2B adenosine rec-
eptor. The binding modes of the A2B receptor ligands demonstrate good agreement with the site-directed mut-
agenesis data.
Ivanov, A.A.; Baskin, I.I.; Palyulin, V.A.; Piccagli, L.; Baraldi, P.G.; Zeﬁrov N.S. Molecular modeling and mol-
ecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the
A2B receptor antagonists. J. Med. Chem., 2005, 48, 6813–6820.
MOLECULAR SIGNALLING MEDIATING THE PROTECTIVE EFFECT
OF A1 ADENOSINE AND mGLU3 METABOTROPIC GLUTAMATE
RECEPTOR ACTIVATION AGAINST APOPTOSIS INDUCED BY
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Astrocyte apoptotic death occurs in acute and chronic neurodegenerative disorders. Since astrocytes are essential
for neuronal survival and synaptic function as well as for neurogenesis and neural repair, interventions aimed at
blocking or preventing astrocyte death may contribute to neuroprotection. Here, we investigated whether the
activation of A1 adenosine or mGlu3 metabotropic glutamate receptors was protective against apoptosis induced
in cultured rat brain astrocytes by 3-hour exposure to combined oxygen-glucose deprivation (OGD). Addition of
N
6-chlorocyclopentyladenosine (CCPA, 2.5–75 nM) or (j)2-oxa-4-aminocyclo-[3.1.0]hexane-4,6-dicarboxylic acid
(LY379268, 0.25–7.5 2M), selective A1 and mGlu3 receptor agonists, respectively, to the astrocyte medium for 4
h, starting from 1 h prior to cell exposure to OGD, reduced in dose-dependent fashion the apoptotic death rate
(maximal reduction by about 50%) caused by OGD. The combined addition of the two agents prior to OGD
produced less than additive effects. Protection was abrogated by cell pre-treatment with either the respective A1
[8-cyclopentyl-1,3-dipropylxanthine, DPCPX, 100nM] or mGlu3 [(2S,10S,20S)-2(9-xanthylmethyl)-2-(20-carboxy-
cyclopropyl)glycine, LY341495, 12M] receptor antagonists or pertussis toxin (200 ng/ml), an inhibitor of metab-
otropic receptor-coupled Gi protein activity. CCPA and LY379268 anti-apoptotic effects were also nulliﬁed by the
presence of U0126 and LY294002, inhibitors of extracellular signal-regulated kinase (ERK)1/2/mitogen-activated
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have been most implicated in maintaining cell survival. Immunoblot analysis of the molecular pathways involved
in either apoptotic or protective events showed that 3-h OGD promoted, yet after 30 min, the phosphorylation of
p38 and c-Jun N-terminal kinase (JNK) in the MAPK system, which are considered as promoters of cell stress and
injury. This event was abrogated by cell pretreatment with CCPA or LY379268. OGD also caused a transient and
delayed (at 2 h) phosphorylation of Akt, downstream target in the survival PI3K pathway, and of apoptosis signal-
regulating kinase 1 (ASK1) at Ser83, leading to its inactivation. However, this effect was obscured by cell pre-
treatment with CCPA or LY379268, which promoted Akt and ASK1 phosphorylation as early as 5 min and up to
3 h. CCPA and LY379268 also induced ERK1/2 phosphorylation and the expression of the antiapoptotic protein
Bcl-XL, both effects being abrogated by LY294002. Finally, CCPA and LY379268 inactivated the apoptotic factor
Bad causing its phosphorylation at Ser112 and Ser136, dependent on ERK1/2 and PI3K activity, respectively, as
these effects were counteracted by U0126 and LY294002, inhibitors of those pathways. Thus, the activation of A1
adenosine or mGlu3 receptors, which share common signalling pathways, protects astrocytes against OGD-ind-
uced apoptosis via the activation of intracellular pathways classically related to cell survival.
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As in other tissues, cell loss through apoptosis (Apo) participates in maintaining renal tissue homeostasis; mor-
eover, it has been considered as a major mechanism for either resolution of glomerular hypercellularity in glo-
merulonephritis or loss of cellularity and progression to glomerulosclerosis in chronic renal disease. Aims of this
study were to investigate the role of extracellular ATP (eATP) in mediating Apo in human mesangial cells
(HCM), and to identify the subtype(s) of P2 receptors (P2r) involved in this effect. HMC were probed with
different concentrations of nucleotides in the presence or absence of the P2X antagonist oxidized-ATP (oATP) or
the selective inhibitor of human P2X7, KN62. We assessed morphological changes by contrast-phase mycroscopy;
Apo rate by Annexin V/propidium iodide based ﬂow cytometry; activation (act) of caspase-3 by ﬂuorimetric
technique; plasma membrane potential alterations (PMDep) by bisoxonol uptake; calcium increase [(Ca
2+)i] by
Fura-2/AM uptake; P2Rs exp by RT-PCR, WB and immunoﬂuorescence (IF). eATP caused dose-dependent
shrinkage, emission of neurite-like protrusions, formation of small blebs in HMC; these varicosities were fully
prevented by oATP. BzATP induced alterations only at high concentrations and to a lower extent than ATP; its
effects were abolished by KN62. eATP 1 mM caused Apo in 14.6% of HMC (positive control:17.4% with TNF!);
oATP fully prevented ATP- or BzATP-triggered Apo (back to 6.5%). BzATP was less effective than ATP and
KN62 not only did not prevent BzATP effect but even potentiated it (from 11.7% to 26.7%). Caspase-3 act was
1376 T 324 AU with ATP and 1039 T 83 AU with 1 mM BzATP. eATP-stimulated Apo was a late event: 3 or 6 hrs
of incubation did not induce any cell death. To characterize either the mechanism of ATP-dependent Apo and
the level of P2X7 activity, we monitored (Ca
2+)i and PMDep. eATP triggered a fast, dose-dependent Ca
2+
release from intracellular stores (from 75 T 12 to 181 T 26 nM with 1 mM ATP), which was not followed by the
delayed plateau, suggesting that Ca
2+ inﬂux from the extracellular space is negligible. eATP also induced a
transmembrane ion ﬂux as shown by PMDep (46 T 13%). BzATP caused a smaller (Ca
2+)i as compared with ATP
(from 55 T 15 to 90 T 18 nM with 1 mM ATP), and was uneffective in inducing PMDep at all concentrations
tested. Irrespective of this relatively scarce functional activity, P2X7 was expressed in HMC, as shown by WB
and IF, with the typical ring-like structures localized at the periphery of the cells. Overall, these data suggest that
P2X7 have a negligible role in ATP-mediated Apo, and that P2Xr(s) others than it could participate in this
process. In addition to P2X7, HMC express P2X2,P2X3,P2X4,P2X6,P2Y2, P2Y5 and P2Y6 subtypes; given the
protective effect of oATP and the lack of effect of UTP, we focused our attention on others P2Xr, expecially
P2X4, already, even seldom, involved in Apo phenomena induced by eATP. We then tested the effect of the P2X4
blocker TNP-ATP, which, when co-incubated with BzATP and KN62, reduced Apo by 30–40%, thus conﬁrming
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upregulated either by ATP and BzATP. In conclusion, P2R stimulation or dysfunction, particularly distinct ch-
anges in P2X4 exp, accompany Apo in HMC, showing the relevance of the purinergic signaling in controlling the
fate of these cells.
Mutagenesis of Conserved Residues in Human Ecto-ATPase (E-NTPDase 2)
Reem Javed, KyokoYarimizu, Nicole Pelletier, and Aileen F. Knowles
Department of Chemistry and Biochemistry, San Diego State University, San Diego, California, U.S.A.
aknowles@chemistry.sdsu.edu
The human ecto-ATPase (E-NTPDase 2) contains conserved motifs (ﬁve ACR and four conserved regions) and
conserved lysine (K) and arginine (R) residues that are also present in other cell surface E-NTPDases. Some of
these are presumably involved in substrate binding and catalysis. In addition, the protein contains six potential N-
glycosylation sites. To determine the importance of these motifs and amino acid residues for the function and
expression of human ecto-ATPase, we have carried out site-directed mutagenesis using its cDNA that is inserted
in the expression vector pcDNA3. Activity of the mutants and protein expression are evaluated after transfection
of the mutant cDNA in HEK293 cells.
Results obtained with seven lysine mutants (K39A, K57A, K62A, K62R, K182A, K182R, K428A) and six arginine
mutants (R155A, R155K, R158A, R245A, R311A, R394A) indicate the following. (i) There is negligible protein
expression upon mutation of K62, which is located in conserved region 1 (CR1) immediately following ACR1,
and K182 which is downstream of ACR3. (ii) Protein expression is not restored in K62R but partial activity and
protein expression are obtained in the K182R mutant. (iii) R155, which is located in CR3, suffers loss of protein
expression and activity when mutated to alanine, but both are restored in the R155K mutant.
Conserved region 1 (CR1) of human ecto-ATPase with the sequence
58WPADKENDTGIV
69 is a critical region
for the function of the enzyme. It not only contains the invariable K62, but also contains the conserved N-
glycosylation site (
64NDT) as well as
65DTG
67, that is similar to the phosphate-binding motifs (DXG) in ACR1
and 4, which have been shown to be important for E-NTPDase 3 activity [1]. The D65A and G67A mutants of
human ecto-ATPase have only 10–30% activity of the wild type enzyme as well as a reduction in protein expr-
ession. Activity is partially restored in the D65E mutant indicating the importance of a negatively charged residue
at that site. Mutagenesis of other residues in this conserved region is in progress.
Mutation of asparagine at the six N-glycosylation sites (N64, N88, N129, N294, N378 and N443) individually to
glutamine indicated the importance of N64 (in CR1) and N443 (in ACR5), the two N-glycosylation sites that are
conserved in all cell-surface E-NTPDases [2,3]. N64Q and N443Q mutants have <20% ATPase activity of the
wild-type enzyme. The N378Q mutant is fully active even though N378 is glycosylated in the WT protein. N88Q,
N129Q, N294Q mutants suffer variable loss of activity. Double N (to Q) mutants other than N64 and N443 all
have reduced protein expression and activity, with N88Q/N294Q being the least active.
Our results indicate that, in addition to the ﬁve ACR, CR1 and possibly the other three CR are also important for
the function of cell surface E-NTPDases. (Supported by the California Metabolic Research Foundation. We also
wish to acknowledge the generous gift of the anti-C-terminus antibody of the human ecto-ATPase by Dr. Terence
L. Kirley.)
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phosphoribosyltransferase mRNA in mammalian leukaemia cells.
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Abstract Adenine phosphoribosyltransferase (APRT, EC 2.4.2.7) is a highly conserved purine salvage enzyme
that catalyzes the conversion of adenine and 5-phosphoribosyl-1-pyrophosphate to AMP. In mammals, APRT is
present in all tissues and provides the only known mechanism for the metabolic salvage of adenine (Simmonds et
al. 1995). In addition, APRT plays a crucial role in the activation of purine antimetabolites such as 2,6-diamin-
opurine (Turker and Martin 1985). APRT appears to be responsible also for toxic effects of N6-substituted
derivatives of adenine (cytokinins) in plants (Mlejnek et al. 2005). The role of APRT in the activation of N6-
substituted derivatives of adenine in mammalian cell is presumable but less clear as their toxicity is much lower
than those in plants (Mlejnek and Dolezel 2005).
We observed that N6-benzyladenine induced elevated expression of APRT gene in human leukaemia cells at least
at the mRNA level. Our results further supported the idea that the cytotoxic effects of N6-benzyladenine also
required the APRT enzymatic activity for its cytotoxicity to develop. The properties of N6-benzyladenine could
be of potential therapeutic value either for the treatment of APRT deﬁciency and/or for potentiation of cytotoxic
effects of other purines activation of which depends on APRT activity.
Acknowledgement This work was supported by grant #MSM 6198959216 (Ministry of Education, Youth and
Sports) and in part by the Czech Grant Agency, grant GA301/04/1239.
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Adenosine is an endogenous purine nucleoside that modulates a variety of physiological functions as a result of its
activation of speciﬁc G protein-coupled receptors deﬁned as A1,A 2A,A 2B and A3 adenosine receptors (AdoRs).
Physiological responses that are mediated by the A1-AdoR include cardiac (negative inotropic, negative chron-
otropic and negative dromotropic effects) and anti-lipolytic effects. Therefore, A1-AdoR agonists have received
much attention as anti-arrhythmic and anti-lipolytic agents. In general, selective A1-AdoR agonists were obtained
by monosubstitution of the N
6-position of adenosine (e.g. CPA, CHA), whereas substitution at the C-2 position of
adenosine yielded selective A2A-AdoR agonists (e.g. CVT-3146 (1), CGS21680). However, a wide range of N
6-
substituted adenosine derivatives have been reported to have high binding afﬁnity for both A1 and A3-AdoRs and
that represented a new challenge to discover selective A1-AdoR agonists.
1 Even though CCPA is considered to be
one of the most selective A1-AdoR agonists known to date, it displayed only 50 fold selectivity for the A1-AdoR
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Springerover the A3-AdoR. Hence, more selective A1-AdoR agonists are needed. Simultaneous substitution at the N
6 and
C-2 positions of adenosine have resulted in compounds with different activity and selectivity proﬁles and some of
these disubstituted compounds have high afﬁnity and selectivity for the A1-AdoR.
2,3 In previous communications
we have shown that introducing a methyl group into the N
6 position of compound 1 induces an increase in the
afﬁnity for the human A3-AdoR and simultaneously decreases the afﬁnity for the A1 and A2A-AdoRs, resulting in
signiﬁcant enhancement in A3-AdoR selectivity.
4 During that study, we have also observed that increasing the
size of the N
6 substituent from methyl to ethyl and propyl resulted in a decrease in the A3-AdoR afﬁnity and an
increase in the A1 and A2A-AdoRs afﬁnity and selectivity. This prompted us to explore the effect of introducing
substituents that are conducive to high A1-AdoR binding afﬁnity (e.g. cycloalkyls) into the N
6 position of our 2-
pyrazolyl adenosine derivatives with the idea of enhancing A1-AdoR binding afﬁnity and selectivity. This resulted
in analogs with very high afﬁnity and selectivity for the A1-AdoR (e.g. 2a & 2b). The synthesis and biological
activities of these new N












1. R1 = H, R2 =  CONHCH3(CVT-3146)
2a. R1 = norbornyl, R2 = H
Ki( l o w )hA1 = 0.4 nM, KihA2A = >5000 nM, KihA3= 1270 nM
2b. R1 = cyclopentyl, R2 = CONHCH3
Ki( l o w ) hA1 = 1.7 nM, Ki hA2A = >5000 nM, Ki hA3 = 1420 nM
(1) Gao et al., Biochem. Pharmacol., 2003, 65, 1675. (2) Beukers et al., J. Med. Chem., 2003, 46, 1492. (2) Jagtap et
al., Bioorg. Med. Chem. Lett., 2004,1 4 , 1495. (4) Elzein et al., J. Med. Chem., 2004, 47, 4766.
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The adenosine derivative N
6-cyclopentyladenosine (CPA) has been proposed as a potent antiischemic drug for
the central nervous system (CNS).
1 On the other hand, this compound has not yet entered in the clinical use being
(i) quickly degraded in blood; (ii) unable to reach the brain by the systemic way; (iii) able to induce relevant side
effects at other organs.
1 Recently, the nasal route has been proposed as a promising way to directly deliver into
the brain those drugs unable to overcome the physiologic barriers between blood and CNS.
2,3 Here, we report a
study regarding the preparation of powder formulations containing CPA for nasal delivery. The powders have
been obtained by spray-drying in the presence either of mannitol and lecithin, or chitosan as carriers. The drug
content was detected by UV-spectrophotometric analysis, morphology by scanning electronic spectroscopy and
particle size by laser diffraction. In vitro drug release studies from microspheres were carried out according to
USP 24. Ex vivo mucoadhesive tests were performed on sheep nasal mucosa blowing an air stream over the
microspheres spread onto the mucosa and calculating the detection of drug content by HPLC, upon dissolution in
water of microparticles still adhered onto the mucosa. The permeability of both free and microencapsulated drug
was studied across sheep nasal mucosa using phosphate buffer (pH 6.5) as receptor solution. Male Wistar rats
received an intravenous infusion of drug. Nasal administration was also performed using insufﬂators Monopowder
P\ (Valois Dispray, France). After the administration, blood and liquor samples, as well as the olfactory bulb and
ventricular sections of the brain were withdrawn and the respective drug amounts analysed by HPLC. According
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Springerto our results, the drug inﬂuenced the particle size and morphology in comparison with blank microparticles. The
drug dissolution rate increased or decreased after loading in mannitol or chitosan microparticles, respectively.
About 60% of chitosan microspheres was recovered from mucoadhesive tests. The permeation rate of free drug
was lower or higher than that of the encapsulated drug in mannitol or chitosan microspheres, respectively. The
drug was not found in the central nervous system (CNS) after intravenous administration, which led to blood
concentrations in the micromolar range. However, after nasal administration of the same dose, the drug was found
in the CNS (up to micromolar range in the liquor, up to 0.2 ng/mg tissue in the brain sections). The CPA amounts
detected in rat blood after nasal administration of the powders appeared negligible with respect to the amounts
detected after intravenous administration.
We can conclude that nasal administration of microparticles prepared by spray-drying appears a promising stra-
tegy to obtain the selective CNS targeting of antiischemic adenosine derivatives.
(1) Dalpiaz A., Manfredini S. Curr. Med. Chem. 2002, 9, 1923–1937.
(2) Illum L. Eur. J. Pharm. Sci. 2000, 11, 1–18.
(3) Illum L. J. Pharm. Pharmacol. 2004, 56, 3–17.
N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl
diphosphate synthase and protein prenylation.
C. Laezza*, M. Notarnicola., M. G. Caruso., M. Macchia-, G.Portella,` S Pisanti^, A Malﬁtano^, C.
Grimaldi ^, A. Santoro ^, P. Gazzerro^ and M. Bifulco^.
*Istituto di Endocrinologia e Oncologia Sperimentale. I.E.O.S., CNR, .I.R.C.C.S. "S. de Bellis" Castellana
G. (Bari), -Dipartimento di Scienze Farmaceutiche, Universita‘ di Pisa, `Dipartimento di Biologia e Patologia.
Cellulare e Molecolare ‘‘L.Califano,’’ Universita‘ di Napoli ‘‘Federico II’’, ^Dipartimento di Scienze
Farmaceutiche, Universita‘ di Salerno), Italy
The physiological effects of a variety of N6-substituted adenine and adenosine derivatives called cytokinins have
been documented in plants, but information on their occurrence and function in other biological system is limited.
Here we investigated the anti-proliferative effect of N6-isopentenyladenosine (i
6A), an adenosine and isoprenoid
derivative, in a thyroid cell system, FRTL-5 wild-type, and K-ras transformed KiMol cells. Addition of i
6At o
FRTL-5 cells caused a dose-dependent arrest of the G0-G1 cell phase transition associated with a reduction of
cells in the S phase that was much more evident in KiMol cells. I6A arrested tumor cell proliferation by inhibiting
farnesyl diphosphate synthase (FPPS) and protein prenylation. Indeed the addition of farnesol reversed these
effects and i6A affected protein prenylation, in particular lamin B processing. I
6A effect was not mediated by the
adenosine receptor but was due to a direct modulation of FPPS enzyme activity as a result of its uptake inside the
cells. I
6A inhibited FPPS activity more efﬁcaciously in KiMol cells than in normal FRTL-5. Moreover, the i6A
anti-proliferative effect was evaluated in vivo in a nude mouse xenograft model, where KiMol cells were impla-
nted subcutaneously. Mice treated with i6A showed a drastic reduction in tumor volume. Our ﬁndings indicate
that this isoprenoid end product might be used for antineoplastic therapy, an application emulating that of the
lovastatin and/or farnesyltransferase inhibitors.
chilaez@hotmail.com
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In search for new adenosine receptor antagonists our attention has been directed toward the synthesis of adenine
derivatives, since 8-bromo-9-ethyladenine resulted to be a compound endowed with good afﬁnity at human ad-
enosine receptors and slight selectivity toward the A2A subtype (8-bromo-9-ethyladenine, Ki A1 = 280 nM, Ki A2A
= 52 nM, Ki A2B = 840 nM, Ki A3 = 28,000 nM). Hence, in the search of potent and selective adenosine receptor







ANR 82,  R = Br
ANR 94,  R = O-Et
ANR 152,  R = 2-Furyl
In particular, 9-ethyladenine substituted in 8-position with halogens, alkyl, alkoxy groups and heteroaromatic
rings have been synthesized and tested in binding studies at adenosine receptors.
1 Among them, the three most
promising compounds in term of A2A binding afﬁnity and selectivity (see ﬁgure), have been tested in two in vivo
models of Parkinson_s disease: 1) the haloperidol catalepsy reversal and 2) the 6-OHDA (6-hydroxydopamine)
model of contralateral turning behviour.
2 The adenine derivatives, ANR 82, ANR 94 and ANR 152, reversed the
haloperidol induced catalepsy. In this model compounds ANR 82 and ANR 152 had maximum effect soon, after
administration, which lasted for about 80 minutes while ANR 94 showed slower but longer lasting effect than the
previous two. In the 2nd Parkinson model compounds ANR 94 and ANR 152 were able to potentiate L-DOPA
(L-dihydroxyphenylalanine) induced contralateral turning in L-DOPA sensitized rats, while ANR 82 was found
to be completely ineffective. Since these differences in efﬁcacies of the ANR compounds in the two models could
be explained in terms of different half-life, metabolic studies on rat liver microsomal cytochrome P450 (CYP)
activity are in progress and results will be presented.
1. Klotz, K. N., Kachler, S., Lambertucci, C., Vittori, S., Volpini, R., Cristalli, G. (2003) 9-Ethyladenine derivatives
as adenosine receptor antagonists: 2- and 8-substitution result in distinct selectivities, Naunyn-Schmiedeberg
1s
Arch. Pharmacol. 367, 629–634.
2. Pinna, A., Volpini, R., Cristalli G., Morelli, M. (2005) New adenosine A2A receptor antagonists: Actions on
Parkinson"s disease models, Eur. J. Pharm. 512, 157–164.
New messanger molecules of the adrenal glands
V. Jankowski, W. Zidek, M. van der Giet, J. Jankowski,
Vera.Jankowski@charite.de
Charite ´ – Campus Benjamin Franklin, Med. CliniC IV, Berlin Germany
Dinucleoside polyphosphates have been characterised as extracellular mediators controlling numerous physio-
logical functions like vascular tone or cell proliferation. Here we describe the isolation and identiﬁcation of
dinucleoside polyphosphates ApnA (with n=2–3), ApnG (with n=2–6) as well as GpnG (with n=2–6) from adrenal
glands. These dinucleoside polyphosphates are localized in granules of the adrenal glands.
The dinucleoside polyphosphates diadenosine diphosphate (Ap2A), diadenosine triphosphate (Ap3A), the
adenosine guanosine polyphosphates (ApnG) and diguanosine polyphosphates (GpnG), both with phosphate gr-
oup (p) numbers (n) ranging from 2 to 6, were identiﬁed by fractionating them to homogeneity by preparative
size-exclusion- and afﬁnity-chromatography as well as analytical anion-exchange and reversed-phase-chromatog-
raphy from deproteinized adrenal glands and by analysis of the homogenous dinucleoside polyphosphates cont-
aining fractions with post-source-decay (PSD) matrix-assisted laser desorption/ionisation mass spectrometry
(MALDI-MS).
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SpringerThe identity of the dinucleoside polyphosphates was conﬁrmed by retention time comparison with authentic
dinucleoside polyphosphates. Enzymatic analysis demonstrated an interconnection of the phosphate groups with
the adenosines in the 5 ´-positions of the riboses in all dinucleoside polyphosphates puriﬁed from adrenal glands.
In conclusion, the identiﬁcation of these dinucleoside polyphosphates in adrenal gland granules emphasizes that
these dinucleoside polyphosphates can be released from the adrenal glands upon stimulation into the circulation.
New Pyrrolo[2,1-f]purine-2,4-dione and Imidazo[2,1-f]purine-2,4-dione
Derivatives as Potent and Selective Human A3 Adenosine Receptor Antagonists
Pier Giovanni Baraldi,
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A3 adenosine receptors and their ability to regulate cell survival represent a promising therapeutic target in
diseases in which excessive cell death is either undesirable, such as neurodegeneration, or desirable, such as
cancer and inﬂammation.
1 The clariﬁcation of the role of adenosine and its receptors in cancer development may
hold great promise for the chemotherapeutic treatment of patients affected by malignancies.
Different classes of compounds with non-xanthine structures have been reported to be A3 adenosine receptor
antagonists.
2 In a recent work, compounds presenting an additional fused ring on the xanthine nucleus have been
reported to exhibit antagonistic activity with various levels of afﬁnity and selectivity towards the four adenosine
receptors subtypes A1,A 2A,A 2B and A3.
3 In particular, 1H,3H-pyrido[2,1-f]purine-2,4-diones
4 have been claimed
as potent A3 receptor antagonists. The report by Priego et al.
4 about the mentioned 1H,3H-pyrido[2,1-f]purine-
2,4-diones, highlighted the importance of a benzyl and a propyl moieties at the 1 and 3 positions, respectively. We
therefore evaluated the effect of the introduction of a benzyl and a propyl at the 1 and 3 positions respectively in a
new series of fused xanthine derivatives. In particular, we performed the synthesis of 1-benzyl-3-propyl-7-aryl/
alkyl-1H,6H-pyrrolo[2,1-f]purine-2,4-dione (general structure 1) and 1-benzyl-3-propyl-7-aryl/alkyl-1H,8H-imi-
dazo[2,1-f]purine-2,4-dione (general structure 2) derivatives
5 among which, very potent and selective A3
adenosine receptors antagonists have been identiﬁed. In particular, 1-benzyl-7-methyl-3-propyl-1H,8H-imi-
dazo[2,1-f]purine-2,4-dione shows a subnanomolar afﬁnity towards the desired receptor target with a noteworthy
selectivity versus the other adenosine receptors subtypes (Ki (hA3) = 0.8 nM, Ki (hA1/hA3) = 3163, Ki (hA2A/hA3)
> 6250, IC50 (hA2B)/Ki (hA3) = 2570). Interestingly, a notable concordance between binding and functional

















1. Merighi et al. Pharmacol. Ther. 2003, 100(1), 31–48.
2. Baraldi et al. Drug. Dev. Res. 2003, 58, 315–329.
3. Drabczyn ´ska et al. Eur. J. Med. Chem. 2003, 38, 397–402.
4. Priego et al. J. Med. Chem. 2002, 45, 3337–3344.
5. Baraldi et al. J. Med. Chem. 2005, 48, 4697–4701.
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Keratinocytes are the predominant cells of the skin. They express several purinergic receptors including P2Y2
(receptor for ATP and UTP). Purinergic receptor functions have been investigated and revealed their involve-
ment in keratinocyte differentiation, proliferation and apoptosis. After wound healing, keratinocytes stimulated
by numerous growth factors undergo profound morphological changes and migrate directionally to initiate re-
epithelialization. In the wound bed, ATP is released by damaged cells and platelets. The potential activity of
extracellular nucleotides on keratinocyte dynamic was never studied before. The aim of our study was to deter-
mine whether ATP or UTP may regulate keratinocyte shape and migration.
By wound healing assays, we surprisingly discovered that ATP (1002M) inhibited by 50% the serum-induced
migration of keratinocytes. Using video-microscopy, we observed that ATP and UTP destructed lamellipodia
(migrating structures) after 10 min of treatment. Due to a desentization of the cells, this effect was transiant and
lamellipodia started to regrow after 30 min of treatment. By kymography assays, we demonstrated that the
dynamic of the newly synthesized lamellipodia was dramaticaly decreased. Finally, we observed that these ATP-
mediated effects were accompanied by a profound reorganization of the actin network. In keratinocytes, lamel-
lipodia formation and cell migration are known to require activation of MAPK and PI3K/Akt pathways by growth
factors. Here, we further report that ATP and UTP unexpectedly inhibited the phosphorylation of Akt and Erk1,2
induced by serum factors. As described above for lamellipodia, this inhibition was transiant and preceded lame-
llipodia destruction. ATP and UTP were equipotent to alter keratinocyte shapes and to inhibit Akt and Erk1,2
activity. This observation suggests that the G!q-coupled P2Y2 receptor may be involved in these events. This
work evidences new crosstalks between purinergic P2Y receptors and growth factors receptors and shows that
ATP and UTP regulate keratinocyte migration and shape changes.
NMDA GLUTAMATE RECEPTOR BINDING IN SPINAL CORDS
OF MICE LACKING THE ADENOSINE A2A RECEPTOR
M.J. Hussey, G.D. Clarke, I. Kitchen and S.M.O. Hourani. University of Surrey, Guildford, UK
m.hussey@surrey.ac.uk
Adenosine is a neuromodulator with complex effects on pain pathways. Mice lacking the adenosine A2A receptor
are hypoalgesic (Ledent et al., 1997), and have altered analgesic responses to opioid agonists (Bailey et al., 2002).
The adenosine A2A receptor is absent from the spinal cord despite mRNA transcripts in dorsal root ganglion,
indicating transport of receptors to the peripheral terminal only (Kaelin-Lang et al., 1998), and the A2A agonist
CGS21680 causes hyperalgesia in the paw pressure test (Khasar et al., 1995). These ﬁndings suggest a role for the
A2A receptor in sensitizing afferent ﬁbres projecting to the spinal cord. As glutamate is a primary nociceptive
transmitter we have used spinal cord binding of [
3H]-MK801, an antagonist radioligand for the NMDA receptor,
as an indirect measure of spinal nociceptive processing in A2A receptor knockout mice, to investigate whether
peripheral A2A receptors inﬂuence pain transmission.
Adult male wildtype and A2A receptor knockout mice (CD1) were killed and the spinal cords removed. Sections
(202m) were cut from cervical, thoracic, lumbar and sacral regions. Total binding was determined by incubation
with 70nM [
3H]-MK801 for 1 hour. Adjacent sections were incubated in the additional presence of 1mM unlab-
elled MK801 to determine non-speciﬁc binding. Sections were apposed to [
3H] sensitive ﬁlm (Hyperﬁlm, Amer-
sham) with microscale standards and developed after 3 weeks. Quantitative analysis was carried out using an
MCID imaging system. Statistical analysis of [
3H]-MK801 binding to NMDA glutamate receptors was carried out
using 2-way ANOVA for the factors genotype and region.
There was a substantial reduction in binding of [
3H]-MK801 in all regions of the spinal cords of A2A knockout
mice (P<0.001). The mean overall decrease was 61.3% throughout the spinal cord with the highest decreases seen
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3H]-MK801 binding after
inﬂammatory challenge with PGE2. Initial results show a decreased level of binding in A2A receptor knockout
mice.
The decrease in NMDA glutamate receptor binding could reﬂect reduced peripheral sensory input to the spinal
cord and be related to the hypoalgesia in this genotype. These results support a key role for the adenosine A2A
receptor in peripheral pain pathways.
Bailey, A.; Ledent, C.; Kelly, M.; Hourani, S. M. O.; Kitchen, I., J Neurosci 2002, 22, (21), 9210–20.
Khasar,S.G.;Wang,J.F.;Taiwo,Y.O.;Heller,P.H.;Green,P.G.;Levine,J.D.,Neuroscience 1995, 67, (1), 189–95.
Kaelin-Lang, A.; Lauterburg, T.; Burgunder, J. M., Neurosci Lett 1998, 246, (1), 21–4.
Ledent, C.; Vaugeois, J. M.; Schiffmann, S. N.; Pedrazzini, T.; El Yacoubi, M.; Vanderhaeghen, J. J.; Costentin, J.;
Heath, J. K.; Vassart, G.; Parmentier, M., Nature 1997, 388, (6643), 674–8.
This work was supported by a BBSRC CASE studentship in collaboration with GlaxoSmithKline.
Non-phosphate analogues of adenine nucleotides
Erki Enkvist, Gerda Raidaru, Asko Uri
Institute of Organic and Bioorganic Chemistry, University of Tartu, Jakobi 2, Tartu, Estonia
Erki.Enkvist@ut.ee
Extra-cellular adenine nucleotides regulate cellular processes via activation of purinoceptors. Many agonists and
antagonists of nucleotide receptors are phosphate-containing analogues of native nucleotides with high negative
charge in small volume close to adenine moiety. We have replaced phosphate groups of nucleotides with nonh-
ydrolyzable carboxylate groups retaining high negative charge of the compounds. Flexible synthetic methods can
be used for the preparation of compounds with different positioning of carboxylate groups. Fragments of mole-
cules containing protected carboxylates were synthesised in solution or on solid-phase and connected to appro-
priate adenosine or adenine derivatives. Final deprotection and/or cleavage from the synthesis resin gave the
desired compounds. Adenosine-oligoaspartate conjugates revealed moderate antagonistic activity towards P2Y1
receptor
1. Analogues 2-thioalkyl derivatives inhibited P2Y12 receptors of rat brain and human platelets
2. Direct
connection of carboxylate-containing structures to the C9-position of adenine gave a class of compounds were the































1. Sak, K., Uri, A., Enkvist, E., Raidaru, G., Subbi, J., Kelve, M and Ja ¨rv, J. Biochem. Biophys. Res. Commun.,
2000, 272, 327–331.
2. Vasiljeva, K. S.; Uri, A.; Laitinen, J. Neuropharmacology, 2003, 45, 145–154.
3. Enkvist, E., Raidaru, G., Uri, A., Patel, R., Redick, C., Boyer, J. L., Subbi, J., Tammiste, I. Nucleosides,
Nucleotides Nucleic Acids, 2006, 25, 141–157.
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Adenosine is an endogenous nucleoside which exerts its physiological functions through activation of speciﬁc cell
membrane receptors, classiﬁed as A1,A 2A,A 2B and A3 receptors. Adenosine A3 receptor, cloned in the early
1990s, plays a key role in both stimulation and inhibition of cell growth, in the release of inﬂammatory mediators,
in the response to ischemia of the brain and heart and in glaucoma. Therefore, A3 selective antagonists represent
an attractive therapeutic tool with potential cerebroprotective, anti-inﬂammatory, anti-asmathic and anti-glauc-
oma activity.
A number of different heterocyclic compounds have been identiﬁed as promising leads for A3 receptor antago-
nists, either xanthines or non-xanthines, showing varying degrees of potency and receptor subtype selectivity. As
only few of them reach advanced clinical trials, the attention of the medicinal chemistry is still direct towards the
discovery of more speciﬁc and effective antagonists.
In this study we report the synthesis and the biological evaluation of novel pyrazolo[3,4-d]pyrimidines, substituted
at positions 2, 4 and 6 of the heterocyclic core, which proved to be potent and selective antagonists at the human








R1: NH2, NHCOAr, NHCONHAr
R2: H, C6H5
[1] P. G. Baraldi, B. Cacciari, R. Romagnoli, S. Merighi, K. Varani, P. A. Borea, G. Spalluto. Med. Res. Rev. 2000,
20, 103–128.
[2] C. E. Muller. Curr. Top. Med. Chem. 2003, 3, 445–462.
Novel Synthetic Stratergies Towards A1 Adenosine Receptor Full and Partial
Agonists
Trent D. Ashton
a, Peter J. Scammells
a, Stephen P. Baker
b
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Partial agonists of the A1 adenosine receptor are envisaged to act as therapeutic agents in the treatment of
arrhythmias. Their potential stems from less pronounced cardio vascular effects, less receptor down regulation
and tissue selectivity.
1–3 Our work has focused on the synthesis of a series of N
6-substituted-50-modiﬁed adenos-
ines of the general formula (2) through concise novel synthetic pathways
4 and their assessment as partial or full
Communications 273



















As the nature of the N
6-substituent has been shown to inﬂuence the potential for partial agonism,5 the develo-
pment of novel N
6-substituents has also been investigated. Structures such as 3 and similar analogues have been











(1) Dhalla, A. K.; Shryock, J. C.; Shreeniwas, R.; Belardinelli, L. Pharmacology and Therapeutic Applications of
A1 Adenosine Receptor Ligands. Current Topics in Medicinal Chemistry 2003, 3, 369–385.
(2) Zablocki, J. A.; Wu, L.; Shryock, J.; Belardinelli, L. Partial A1 Adenosine Receptor Agonists from a Molecular
Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation.
Current Topics in Medicinal Chemistry 2004, 4, 839–854.
(3) Hutchinson, S. A.; Scammells, P. J. A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic
Potential. Current Pharma. Design 2004, 10, 2021–2039.
(4) Ashton, T. D.; Scammells, P. J. An Improved Synthesis of 50-Deoxy-50-ﬂuoroadenosines. Bioorg. Med. Chem.
Lett. 2005, 15, 3361–3363.
(5) Morrison, C. F.; Elzein, E.; Jiang, B.; Ibrahim, P. N.; Marquart, T. et al. Structure-Afﬁnity Relationships of
50-Aromatic Ethers and 50-Aromatic Sulﬁdes as Partial A1 Adenosine Agonists, Potential Supraventricular Anti-
Arrhythmic Agents. Bioorg. Med. Chem. Lett. 2004, 14, 3793–3797.
NUCLEOTIDE RELEASE ASSOCIATED WITH MUCIN SECRETION IN
POLARIZED AIRWAY EPITHELIAL CELLS
Silvia M Kreda, Seiko Okada, Catharina van Heusden, Wanda O_Neal, Richard C Boucher,
and Eduardo R Lazarowski,
Cystic Fibrosis/Pulmonary Research and Treatment Center, The University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA.
Silvia_kreda@med.unc.edu
Nucleotides and nucleotide-sugars within the airway surface liquid play important roles in innate lung defense but
the mechanisms of airway epithelial nucleotide release are poorly understood. In this study, we report that pol-
arized monolayers of CalU-3 cells, a human airway-derived epithelial cell line known to express high levels of the
cystic ﬁbrosis transmebrane regulator (CFTR) Cl
j channel, produce and secrete mucins (e.g. MUC5AC) trough
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Springerthe apical surface. A fraction of cells (5–40%) displayed apically localized secretory mucin granules that resem-
bled those observed in native goblet cells, as revealed by electron microscopy and MUC5AC immunostaining/
confocal microscopy. Secreted MUC5AC was detected (by slot blotting) in the mucosal but not serosal bath of
unstimulated CalU-3 cells. Adenine nucleotides and UDP-glucose were present also in the apical (but not in the
basolateral) bath of resting cells. Elevation of intracellular Ca
2+ (1–10 2M ionomycin) promoted exocytosis trough
the apical membrane, as judged by increased (i) FM 1–43 membrane ﬂuorescence, (ii) secretion of MUC5AC into
the apical bath (slot blotting), and (iii) massive discharge of MUC5AC granules (immunostaining). Similarly,
intracellular granules that were pre-labeled with either FM1-43, quinacrine, or acridine orange were released
upon increase in intracellular Ca
2+. These exocytotic changes were paralleled by enhanced release of ATP and
UDP-glucose to the apical but not to the basal bath. Removal of Ca
2+ from bathing solutions or disruption of the
cytoskeleton (5 2M cytochalasin D) cancelled ionomycin-promoted both exocytosis and nucleotide release. In
contrast to Ca
2+-mediated changes, elevation of cyclic AMP levels and activation of CFTR (10 2M forskolin)
failed to promote exocytosis/mucin secretion or nucleotides release from CalU-3 cells. These studies indicate that
CalU-3 cultures can differentiate into cells that express mucin granules competent for regulated secretion. Secr-
etion of mucins may be accompanied by nucleotide release from mucous cells, suggesting that regulated exocyt-
osis of specialized glycoproteins may be an important mechanism to control the secretion of nucleotides and
nucleotide sugars in complex airway epithelia.
Opposing Effects of Extracellular ATP and Adenosine on Osteoblast
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Calciﬁc aortic valve disease is an active process ranging from aortic sclerosis to severe calciﬁcation with unknown
cellular mechanisms. Extracellular ATP is known to be an important molecule in bone remodelling, however, its
breakdown product, adenosine has been shown to exert anti-inﬂammatory properties. We hypothesise that both
extracellular ATP and adenosine will exert opposite effects on osteoblast differentiation in human valve cells. We
therefore, aim to asses the ability of extracellular ATP and adenosine to promote or inhibit the expression of
osteoblast-cell markers in human valve interstitial cells (VICs).
Primary cultures of human aortic VICs were treated for 21 days with ATP (1002M), ATP-+-S (102M), 2-Meth-
ylthio-ADP (102M); two stable agonists to the P2Y receptor. Alkaline phosphatase (ALP) (an osteoblast marker)
activity and expression were measured using a colorimetric assay and immunocytochemistry staining. Further-
more, cultures of VICs were also grown in osteogenic media in the presence and absence of adenosine (302M) for
21 days and ALP activity and expression were determined.
Extracellular ATP and the stable agonists to the P2Y receptor were able to mimic the effects of osteogenic media.
Valve ICs treated with osteogenic media signiﬁcantly increased ALP activity from 3.1T1.0 nmol/min/mg protein in
control cells to 14.4T1.4 nmol/min/mg protein. In addition, both ATP and ATP-+-S increased the ALP activity to
12.1T1.9 nmol/min/mg and 11.1T1.5 nmol/min/mg protein, respectively. This increase was reduced in valve ICs
treated with 2-Methylthio-ADP to 5.9T1.2 nmol/min/mg protein after 21 days of treatment (n=3). Adenosine
treatment inhibited the effect of osteogenic media by signiﬁcantly reducing the activity and expression of ALP
from 10.4T0.8 nmol/min/mg protein to 3.4T0.6 nmol/min/mg protein in human VICs (n=3).
In conclusion, extracellular ATP and stable agonists to P2Y receptor induced the transformation of VICs into
osteoblast-like cell phenotype, while adenosine was capable of inhibiting this transformation process. These op-
posite effects may have important implications in understanding the regulatory effect of extracellular nucleotides
on valve calciﬁcation and helps in identifying new therapeutic targets.
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Adenosine A2A receptors (A2ARs) have been proposed as possible targets to treat Huntington_s disease (HD).
However, the effects of A2AR ligands may become unpredictable in presence of HD mutation, since mutant
huntingtin was found to inﬂuence both the function and the expression of A2AR in cellular models of HD. The
aim of the present work was to investigate whether the HD mutation inﬂuenced A2AR-mediated effects on basal
synaptic transmission and on NMDA-dependent toxicity. Transgenic R6/2 mice in a frankly symptomatic phase
(12–13 weeks) and age-matched WT mice were used. The animals were decapitated, the brain removed and
corticostriatal slices (300 2m thick) cut with a vibratome. Extracellular ﬁeld potentials (FPs) were recorded in the
striatum; the mean basal FP amplitude was calculated, and the effects of the drugs expressed as percentage
variation with respect to basal values. Application of 75 2M NMDA to WT slices induced a transient disappea-
rance of the FP followed by a recovery of 67.9 T8.2 and 89.3T9 % of basal after 30 and 50 min of washout,
respectively (N=8). In slices from HD mice, the mean FP recovery was signiﬁcantly reduced (39.4T4 and 47.8T5%
of basal after 30 and 50 min of washout, respectively; N=9, P<0.05 vs WT in both cases). The co-application of
100 nM CGS 21680 (A2AR agonist) reduced the FP recovery in slices from WT mice (35.2 T10 and 46.7 T13.5%
after 30 and 50 min, respectively, N=6, P<0.05 vs NMDA alone). Interestingly, CGS 21680 exerted the opposite
effect (i.e. a signiﬁcant increase in FP recovery), in slices from R6/2 HD mice (59.7T8 % after 30 min, P<0.05, and
65.8 T9, NS, N=7). The A2AR antagonist ZM 241385 did not inﬂuence the FP recovery in WT or HD slices. These
results show that the pharmacology of A2ARs is altered by the HD mutation. In particular, A2ARs oppositely
modulate NMDA-induced toxicity in the striatum of HD vs WT mice. These results may have important impli-
cations for the neuroprotective potential of A2AR antagonists in HD.
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An integrated approach to the study of drug-receptor interactions, based on probing the receptor structure
through site-directed mutagenesis and molecular modeling, has been applied to adenosine receptors (ARs) and
other seven transmembrane-spanning receptors. Selective AR agonists are sought for therapeutic application,
1
however, because of the widespread distribution of native ARs, their activation is inherently nonselective. An
alternative approach to overcome the lack of speciﬁcity of conventional agonist therapy can be the reengineering
of the GPCRs and their agonists. A reengineered receptor (neoceptor) could be selectively activated by a mod-
iﬁed agonist, but not by the endogenous agonist.
2 Synthetic nucleoside agonists have been speciﬁcally tailored to
serve as neoligands, i.e. to activate only receptors in which the putative binding sites have been modiﬁed. This
orthogonal approach to receptor activation, intended for eventual gene therapy, has been explored for A3 and
A2AARs.
1–3 Assisted by rhodopsin-based molecular modeling, we pinpointed mutations of the A3AR for selective
afﬁnity enhancement following complementary modiﬁcations of adenosine. Ribose modiﬁcations examined incl-
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6 variations incl-
uded: 3-iodobenzyl, 5-chloro-2-methyloxybenzyl, and methyl. As predicted by the molecular modeling and ligand
docking, certain adenosine derivatives modiﬁed in the 30-position displayed selective afﬁnity enhancement at a
mutant (H272E), but not the wild-type, A3AR. An N
6-(3-iodobenzyl)-30-ureido adenosine derivative MRS3481
(LJ720) activated phospholipase C in COS-7 cells (EC50=0.18 2M) or phospholipase D in chick primary cardio-
myocytes mediated by the H272E neoceptor, but not wild-type, A3AR. The afﬁnity enhancements for MRS3481
and the corresponding 30-acetamidomethyl analogue MRS3174 were >100-fold and >20-fold, respectively. MR-
S3481 concentration-dependently protected cardiomyocytes transfected with the neoceptor against hypoxia. Un-
like MRS3481, adenosine activated the wild-type A3AR (EC50 of 1.0 2M), but had no effect on the H272E mutant
A3AR (100 2M). This truly orthogonal pair comprising an engineered receptor and a modiﬁed agonist should be
useful for elucidating signaling pathways and could be therapeutically applied to diseases following organ-targeted
delivery of the neoceptor gene.
1. Jacobson, K.A., et al. Chem. Biol. 2005, 30, 237–247.
2. Jacobson, K.A., et al. J. Med. Chem. 2001, 44, 4125–4136.
3. Kim, S.K., et al. J. Med. Chem. 2003, 46, 4847–4859.
Osmotic stress enhances neutrophil degranulation by the release of ATP and the
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Polymorphonuclear neutrophils (PMN) play a crucial role in the defense against invading bacteria, fungi, and
protozoa. However, excessive activation of PMN is involved in the pathology of various diseases, including major
post-traumatic complications. Hypertonic ﬂuids can be used to resuscitate trauma patients who have suffered
severe blood loss. Our previous work has shown that hypertonic resuscitation ﬂuids can reduce the risk of post-
traumatic complications by suppressing PMN function. We have found that hypertonic saline (HS) induces the
release of cellular ATP from PMN and that ATP is quickly hydrolyzed to adenosine, which in turn activates A2a
adenosine receptors expressed on the PMN cell surface. However, we and other researchers have found augm-
entation of the degranulation and enzyme release of PMN when the cells are activated before they are exposed to
HS. Here we studied if this enhancement of PMN degranulation also involves feedback mechanisms related to
ATP release and purinergic receptors.
We found that, like HS, exogenously added ATP and the non-hydrolyzable form ATP+S enhance enzyme (ela-
stase) release and the expression of the degranulation marker CD11b of PMN previously stimulated by the
peptide, fMLP. These effects were paralleled by corresponding increases in ERK and p38 MAPK activation
patterns. Removal of extracellular ATP with apyrase or inhibition of P2 receptors with suramin abolished the
enhancing effect of HS on elastase release. Agonists of A3, but not A2, adenosine receptors also enhanced
elastase release and p38 MAPK activation of fMLP-stimulated PMN, while A1 receptor agonists had the opposite
effect (Fig.). Studies with antagonists of these receptors showed that HS enhances degranulation via A3 receptors.
Communications 277
SpringerFig . Agonist of A3 receptors (IB-MECA) enhanced elastase release of fMLP-stimulated PMN, while A1 receptor
agonist (CPA) decreased PMN degranulation.
We conclude that pharmacological manipulation of the receptors that control the action of HS on PMN responses
could be a useful therapeutic approach to adjust the efﬁcacy of hypertonic ﬂuid resuscitation by reducing the risk
of exacerbated PMN activation and tissue damage in trauma patients.
This study was supported in part by grants from the U.S. National Institutes of Health (GM-51477 & 60475).
P2 RECEPTOR ANTAGONISM AND MAPK ACTIVATION IN A MODEL
OF FOCAL CEREBRAL ISCHEMIA
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Extracellular adenosine 50-triphosphate (ATP) levels increase under ischemic conditions in rat striatum in vivo
1.
Data in the literature support the idea that ATP exerts an excitotoxic role on P2 receptors in the brain. We
recently demonstrated that, in a model of focal cerebral ischemia, the non selective P2 receptor antagonist,
Reactive Blue 2 (RB2), reduced both the striatal and the cortical damage and improved the neurological deﬁcit,
24 h after ischemia
2. The aim of the present study was to evaluate if neuroprotective effect of RB2 involves
activation of mitogen-activated protein kinases (MAPKs) during cerebral ischemia.
Permanent focal cerebral ischemia was induced by right middle cerebral artery occlusion (MCAo) in the rat. RB2
(100 mg/kg, i.p.) was administered 5 min after MCAo. Between 3 and 4 h after MCAo an acute motor disturbance
was evaluated as number of rotations per hour. Twenty-four hour after ischemia, neurological deﬁcit was evalu-
ated by a battery of sensory-motor tests. Rats were then sacriﬁced by transcardiac perfusion with 4% paraform-
aldehyde solution. Brains were cut in 30-2m-thick coronal slices to evaluate ischemic brain damage by acetate
cresyl violet staining and activation of p38-, ERK1/2- and JNK-MAPK by speciﬁc antibodies. Neurons, microglia
and oligodendrocytes were also stained by NeuN, OX-42 and MAG speciﬁc antibodies, respectively.
Vehicle-treated rats, soon after ischemia, showed a deﬁnite turning behaviour contralateral to ischemic hemisp-
here. RB2 did not modify this acute motor disturbance. Twenty-four hours after ischemia, vehicle-treated rats
showed an extensive ischemic area in the vascular territories supplied by the MCA, the striatum and the sensory-
motor cortex, and a clear neurological deﬁcit. RB2 protected against ischemic striatal and cortical damage and
against the neurological deﬁcit. In vehicle-treated rats 24 h after MCAo, phospho-p38 MAPK, evaluated by
Western Blot, increased by 500% in the ischemic striatum. Phospho-p38 MAPK and OX-42 immunoreactive cells
were localized in the ventral striatum and frontoparietal cortex of the ischemic hemisphere. OX-42 and phospho-
p38 MAPK immunoreactive cells showed overlapping morphological features typical of reactive microglia. Pho-
spho-ERK1/2 immunopositive cells were localized in the cortex and in the striatum of the ischemic hemisphere
and showed morphological features of reactive microglia. Phospho-JNK immunopositive cells were present in the
corpus callosum and in the white matter of the striatal nuclei of the ischemic hemisphere. RB2 did not modify
activation of any of the MAPK investigated.
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involve modulation of MAPKs.
Grant by University of Florence and Ente Cassa di Risparmio di Firenze, Italy.
(1) Melani, A.; Turchi, D.; Vannucchi, M.G.; Cipriani, S.; Gianfriddo, M; Pedata, F. Neurochem. Int. 2005, 47,
442–448.
(2) Melani, A.; Amadio, S.; Gianfriddo, M.; Vannucchi, M.G.; Volonta `, C.; Pedata, F.; Sancesario, G. J. Cereb.
Blood Flow Metab. 2006 In Press.
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The present work seeks to offer a new perspective on a family of receptors, the P2 receptors, speciﬁc for nucle-
oside tri- and di-phosphates of both purines and pyrimidines. The prototype ligand is ATP, one of the most diffuse
extracellular signaling molecules in many organs and tissues, including the central nervous system. We emphasize
here that while decoding the inputs of various different, but closely related, extracellular ligands such as ATP,
ADP, UTP, UDP, UDP-glucose, P2 receptors are a clear example of the emergence of increasing biological
complexity. They are represented by ionotropic P2X and metabotropic P2Y proteins, by seven P2X and eight
distinct P2Y subunits; they couple to various ligands, own very heterogeneous ligand binding characteristics,
molecular properties, transduction mechanisms, cellular localization, and protein-protein interactions. While the
reason for this sophistication is currently unknown, a few compelling issues emerge in looking at such a rich
variety. We ask, for instance, why so many different receptor subtypes are necessary for triggering biological
properties and functions, and if these receptors are more than the sum of their single entities. A very ﬁrst poss-
ibility is that newly synthesized P2 proteins are casually located on the cell surface (stochastic hypothesis). Oth-
erwise, distinct P2 subunits could be engaged on the different cellular phenotypes by a strict genetic control
(genetic determinism) and/or selective recruitment under different physiopathological conditions and epigenetic
stimuli (epigenetic determinism). Nevertheless, the most proper way to dissect the vast biological scenario and
molecular diversities among P2 subunits and, at the same time, to integrate and upgrade this assortment into a
ﬁnal common outcome, is to regard these receptors as a ‘‘receptor web’’, that is, a dynamic architecture of P2
proteins legitimated by an energetic advantage. This condition is in turn sustained by a process of ‘‘ﬁne tuning’’, a
mechanism endorsing the dynamic nature of all biological reactions.
In the present analysis we would like to stimulate a scientiﬁc query on what contributes to the biological emer-
gence of such a vast P2 receptor sophistication.
The present work was supported by grants from MIUR 2004 and FIRB 2001. J.K.F. is a recipient of a post-
doctoral fellowship from the Brazilian funding agency CNPq.
P2-Receptor mediated immune-responses: a link to asthmatic airway
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SpringerExtracellular nucleotides has been shown to modulate in vitro the function of various cell types, including eosi-
nophils, lymphocytes, dendritc cells and airway epithelial cells, which are involved in the pathogenesis of asth-
matic airway inﬂammation. Therefore, the aim of the present study was investigate the role of P2-Receptors
mediated immune response in vivo an experimental asthma. Hereby we could show in a murine asthma model
(Balb/c mice) that local application of P2X and P2Y receptor antagonist (suramin, PPADS and oATP) suppresses
Th2-dependent eosinophilic airway inﬂammation and induction of bronchial hyperresponsiveness when given
during the allergen challenge phase (Figure 1A and B). Furthermore, local suramine treatment inhibited the
migration of lung DCs to the mediastinal lymph nodes and abolished the induction of a Th2 response to ovalb-
umin in these nodes. In contrast, intratracheal injection of ATP together with FITC-labelled OVA in naive Balb/c
induce a signiﬁcant recruitment of OVA-FITC
+-lung DC to the mediastinal lymph node, compared mice receiving
vehicle/FITC-labelled OVA. Finally, we could show here, that the levels of extracellular ATP are increased in the
airway of sensitized (‘‘asthmatic’’) mice compared to naive controls (Figure 2). These data demonstrate that
endogenous release of ATP occurs during asthmatic airway inﬂammation, and that application of P2-receptor
antagonists to the lung targets the key functions of airway DCs thus suppressing the cardinal features of asthma.
Future studies in asthma patients will demonstrate if this is a feasible strategy.
Figure 1 A   B 
Figure 2 


























































P2X4 receptor function in rat macrophage
Leanne Stokes & Annmarie Surprenant
Department of Biomedical Science, University of Shefﬁeld, Florey Building, Firth Court, Western Bank,
Shefﬁeld, S10 2TN. UK.
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Macrophages play a key role in inﬂammation due to the synthesis and release of pro-inﬂammatory cytokines, for
example one of the known functional roles of the ATP-gated ion channel P2X7 in macrophages is the release of
mature IL-1? following treatment with LPS and ATP. P2X4, another member of the ATP-gated ion channel
family, is often co-expressed with P2X7 in immune cells, but to date the physiological role of P2X4 is unclear. Our
group has shown functional expression of P2X4 but not P2X7 in the NR8383 rat alveolar macrophage cell line
(Bowler et al, 2003) making this cell line a useful model for the study of P2X4 function in isolation from P2X7.W e
are investigating whether activation of P2X4 can induce or inﬂuence cytokine secretion or affect key macrophage
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Springerfunctions. Classical activation of NR8383 macrophages with combinations of IFN-+, TNF-! and LPS has differing
effects on the macrophage P2X4 response. This appears to be correlated to regulation of cell surface expression of
P2X4 as determined by cell surface biotinylation experiments.
Bowler et al, 2003. P2X4, P2Y1 and P2Y2 receptors on rat alveolar macrophages Br. J. Pharmacol. 140, 567–575.
P2X7 purinergic receptor is involved in the process of renal inﬂammation and
ﬁbrosis of unilateral ureteral obstruction in mice
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Purinergic receptors have been involved in several cellular mechanisms including those related to inﬂammation
and immunological response. Receptors of the P2X7 type have been demonstrated in granulocytes, monocytes/
macrophages, B and T lymphocytes. The present study was designed to investigate the role of these receptors on
the inﬂammatory and ﬁbrogenic response of unilateral ureteral obstruction (UUO), by using P2X7 knockout mice.
C57Bl6 mice were submitted to surgical left ureteral obstruction and sacriﬁced after 14 days. Histopathology using
HE, PAS and Sirius red staining and immunohistochemistry with f4/80 for macrophages, !-SMA for myoﬁbro-
blasts and TGF-" were identiﬁed. Protocols were as follows: 1) UUO non-treated; 2) UUO P2X7 (j/j) mice;
3) Control; 4) Sham-operated. Mice were sacriﬁced 14 days after the surgery. Sirius red was signiﬁcantly higher in
group 1 (3917,1T 2416,8), compared to groups 2 (1416,8T1155,7 P<0.001), 3 (319,4T384,1 P<0.001) and 4 (349,
0T340,0 P<0.001). The pro-ﬁbrotic cytokine TGF-" was markedly high in group 1 (14,6T8,9) compared to groups 2
(7,1T5,7 P<0,001), 3 (2,0T2,4 P<0,001) and 4 (2,1T2,3 P<0,001). The percentage of myoﬁbroblasts cells was signi-
ﬁcantly higher in group 1 (22,1T13,1) compared to groups 2 (8,3T8,3 P<0,001), 3 (0,8T1,5 P<0,001) and 4 (1,3T2,5
P<0,001). The number of positive inﬂammatory cells was signiﬁcantly higher in group 1 (68,0T20,7), compared to
groups 2 (43,2T19,1 P<0.001), 3(1,1T1,2 P<0,001) and 4(1,4T1,3 P<0,001). Atrophic tubules measure by PAS was
7.8 T 3.6 per ﬁeld in group 1, whereas in UUO P2X7 (j/j) mice we observed a lower number of atrophic tubules
comprising aproximately 44% less atrophy than the ﬁndings in kidney tissue from group 1. Control and sham-
operated animals did not exhibit tubular atrophy. There was no statistical difference between groups 3 and 4 in all
analysis. In P2X7 knockout mice submitted to UUO, the inﬂammation and ﬁbrosis were of lower magnitude than
that observed in UUO wild type mice. These ﬁndings constitute the ﬁrst evidence that P2X7 receptors are imp-
licated in the mechanism of macrophage inﬁltration and collagen deposition in response to ureteral obstruction in
mice.
P2X7 receptor activation caused mitochondrial membrane depolarization









We investigated the effect of extracellular ATP on mitochondrial inner membrane depolarization in rat subma-
ndibular glands. High ATP concentrations caused a sustained depolarization of mitochondrial membrane. This
response was blocked in the presence of magnesium or apyrase and reproduced by low concentrations of 2 ´,3 ´-O-
(4-benzoylbenzoyl) adenosine 5 ´-triphosphate (BzATP), suggesting the implication of the P2X7 purinergic rece-
ptor. This fact was conﬁrmed comparing the response to ATP of wild-type and P2X7 knock-out (P2X7R
j/j) mice.
Blockade of calcium uptake by mitochondrial uncouplers (FCCP or rotenone) or a mitochondrial calcium unip-
orter inhibitor (ruthenium red) potentiated the cytosolic increase of calcium provoked by ATP, suggesting a
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drial membrane depolarization was not affected by extracellular calcium removal. Moreover, neither ruthenium
red nor ruthenium 360 (two blockers of the mitochondrial calcium uniporter) affected the mitochondrial mem-
brane depolarization by ATP. On the other hand, P2X7 activation is known to increase the permeability to
sodium. Extracellular sodium replacement with N-methyl-D-glucosamine almost completely blocked the mitoc-
hondrial depolarization. The effect of ATP was not reproduced by the sodium ionophore monensin but was
partially suppressed by the mitochondrial Na/Ca exchanger inhibitor 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-
benzothiazepin-2(3H)-one (CGP-37157). Interestingly, cyclosporine A had no effect on ATP-induced
mitochondrial depolarization, indicating that the mitochondrial permeability transition pore is not essential for
this phenomenon.
It is concluded that P2X7 receptor activation by ATP depolarizes the mitocondrial inner membrane. The uptake
of extracellular sodium plays a major role in this process, at least in part through the mitochondrial Na/Ca
exchanger. Sodium uptake seems to be necessary but not sufﬁcent, suggesting the implication of other P2X7
related responses in the mitochondrial membrane depolarization.
1 Departamento de Bioquı ´mica y Biologı ´a Molecular, Facultad de Ciencias, Universidad del Paı ´s Vasco, Barrio
Sarriena S/N Leioa, P.O. Box 644, 48080 Bilbao, Spain
2 Laboratoire de Biochimie et de Biologie Cellulaire, Institut de Pharmacie C.P. 205/3, Universite ´ Libre de
Bruxelles, B-1050 Brussels, Belgium
P2X7 receptor mediated proliferation: a mitochondrial-reticular explanation
Maria Giulia Callegari, Paolo Pinton, Rosario Rizzuto, Francesco Di Virgilio, Elena Adinolﬁ
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The P2X7 receptor is an ATP gated ion channel, that is endowed with a strong pro-apoptotic activity but also
promotes cell survival in the absence of serum. While the pro-apoptotic and pro-necrotic activity of the receptor
has been widely investigated, little is known about its growth promoting function. In the last years we focused our
attention on the organellar network, fundamental for both cell survival and death, studying the behavior of
mitochondria and endoplasmic reticulum (ER) in HEK cells expressing the P2X7 receptor. Thanks to targeted
calcium sensing probes we were able to measure increased mitochondrial calcium levels and enhanced reticular
calcium uptake in receptor transfected cells versus mock. Experiments with thapsigargin on cell populations
allowed us to estimate a total content of reticular calcium signiﬁcantly higher for P2X7 transfectants. P2X7 exp-
ressing clones also resulted more sensitive to carbachol stimulation that caused a burst in both reticular and
mitochondrial calcium levels.
This organellar calcium increase correlated with longer survival in the absence of serum and enhanced ATP
production. These data allow us to propose a model in which P2X7 expression will determine an increased cellular
calcium inﬂux that will be stored in both mitochondria ad ER causing on one hand an higher energy production
and on the other stimulating the proliferative pathways involving a release of calcium from the endoplasmic
reticulum.
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The ATP-gated P2X7 receptor is a plasma membrane receptor belonging to the family of P2X purinoceptors. Its
activation leads to multiple downstream events including inﬂux of ions, pore formation to allow the passage of
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of P2X7 receptor-mediated cell death is still unknown.The apoptotic cell death is thought to be correlated with the
pore formation, but does not directly result from the dilatation of pore [1]. The activities of intracellular Ca
2+
mobilization and pore formation by P2Z/P2X7 receptor are modulated during T cell differentiation in murine
thymus and spleen [2]. On the other hand, ERK1/2 phosphorylation is involved in P2X7 receptor-mediated nec-
rotic cell death in murine thymocytes [3]. Recently, we have reported the involvement of cell shrinkage following
pore formation in P2X7 receptor-mediated apoptotic cell death and the essential role of extracellular Cl
j in it
using a clone of chicken DT40 lymphocytes stably transfected with the rat P2X7 receptor [4]. In this study, to
assess the role of P2X7 receptor in cells endogenously expressing P2X7 receptors, we investigated P2X7 receptor-
mediated cell death during murine T cell differentiation and maturation.
P2X7 receptor expression and its activities (pore formation, ERK1/2 phosphorylation and cell shrinkage) were
higher in splenocytes than thymocytes. T cells of different developmental stages differed in sensitivity to P2X7
receptor-mediated cell shrinkage. Immature thymocytes (CD4-8- and CD4+8+), mature thymocytes (CD4+8- or
CD4-8+) and peripheral T cells (splenic CD4+ and CD8+) showed increasing reactivity. Decrease of extracellular
Cl
j suppressed the cell shrinkage without inhibition of ATP-induced ERK1/2 phosphorylation, whereas treatm-
ent with U0126 (a MEK inhibitor) suppressed the ERK1/2 phosphorylation but not the cell shrinkage. Decrease
of extracellular Cl
j and treatment with U0126 suppressed ATP-induced cell death, respectively. Moreover, tre-
atment with U0126 in a buffer containing low concentration of Cl
j inhibited ATP-induced cell death additively.
In conclusion, we demonstrate the presence of two independent pathways, one involving cell shrinkage and the
other involving phosphorylation of ERK1/2, in P2X7 receptor-mediated T cell death and the increase in P2X7
receptor activity during T cell maturation. Our ﬁndings could explain the so-called ‘‘P2X7 receptor-mediated
apoptotic and/or necrotic cell death’’and suggest the particular importance of peripheral T cell death in P2X7
receptor-regulated immune responses.
1. Virginio, C.; MacKenzie, A.; North, R. A.; Surprenant, A., Kinetics of cell lysis, dye uptake and permeability changes in cells
expressing the rat P2X7 receptor. J Physiol 1999, 519, 335–46.
2. Chused, T. M.; Apasov, S.; Sitkovsky, M., Murine T lymphocytes modulate activity of an ATP-activated P2Z-
type purinoceptor during differentiation. J Immunol 1996, 157, 1371–80.
3. Auger, R.; Motta, I.; Benihoud, K.; Ojcius, D. M.; Kanellopoulos, J. M., A role for mitogen-activated protein
kinase(Erk1/2) activation and non-selective pore formation in P2X7 receptor-mediated thymocyte death. J Biol
Chem 2005, 280, 28142–51.
4. Tsukimoto, M.; Harada, H.; Ikari, A.; Takagi, K., Involvement of chloride in apoptotic cell death induced by
activation of ATP-sensitive P2X7 purinoceptor. J Biol Chem 2005, 280, 2653–8.
P2Y RECEPTOR ACTIVATION BY URIDINE 50-TRIPHOSPHATE
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ABSTRACT
Effects of the P2Y receptor agonist, uridine 50-triphosphate (UTP) were investigated in isolated hearts in terms of
functional tolerance to ischemia-reperfusion. Langendorff perfused C57 mouse hearts were subjected to 20 min
global ischemia, followed by 45 min of reperfusion. Three experimental groups were studied with 250nM or 12M
UTP: i) 5 minutes pre-treatment prior to ischemia (Pre-ISCH), ii) 5 minutes treatment during reperfusion (Post-
ISCH), or iii) 5 minutes pre-ischemia and 5 minutes post-ischemia (Pre- & Post-ISCH). Post-ischemic functional
recoveries and tissue necrosis (LDH efﬂux) were assessed. Control (CTRL) hearts recovered 67T3 mmHg left
ventricular developed pressure (LVDP) (~50% of pre-ischemia) and exhibited sustained diastolic contracture
(31T2 mmHg) at the end of 45 min reperfusion. Pre-ischemic UTP treatment (250nM and 12M) did not modify
LVDP recovery, but end-diastolic contracture was signiﬁcantly reduced (17T1 and 21T4 mmHg respectively,
p<0.05). Pre-ischemic UTP treatment also resulted in a signiﬁcantly higher (~95% of pre-ischemia) coronary ﬂow
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by post-ischemic UTP treatment at either concentration. Interestingly, Pre- & Post-ISCH UTP at 250nM not only
signiﬁcantly reduced end-diastolic contracture (17T3 mmHg) but also resulted in a higher recovery of left ventr-
icular developed pressure (89T6 mmHg). However, Pre- & Post-ISCH UTP at the higher concentration (12M)
failed to change functional recovery. Whilst post-ischemic LDH efﬂux indicated a protective role of UTP in terms
of reducing tissue necrosis in treated hearts, the higher 12M UTP, although not signiﬁcant, appeared to worsen
tissue injury with Pre - & Post-ISCH UTP (CTRL, 23T1U/g vs 27T4 U/g). In summary, the P2Y agonist, UTP
when infused pre-ischemia enhances tolerance to ischemia, whilst post-ischemic treatment did not modify funct-
ional recovery. In addition, the cardioprotective role of UTP in reducing tissue necrosis is dose-dependent. A
recent study has shown release of UTP during cardiac ischemia and indicates that UTP may have a role in cardiac
regulation.
1 Current results suggest P2Y activation by UTP may exert a myocardial protective role in ischemia-
reperfusion. Given apparent dose-dependent effects of UTP, it is possible a combination of exogenous and en-
dogenous UTP may, under certain conditions, exert differing effects. High (12M) UTP may, together with local
UTP, enhance injury. Lower (250nM) UTP may act beneﬁcially.
1. Erlinge, D., Harnek, J., Van Heusden, C., Olivecrona, G., Jern, S., Lazarowski, E. Uridine triphosphate (UTP) is released
during cardiac ischemia. International Journal of Cardiology 2005; 100:427–433
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Ionotropic P2X (P2X1–7) and metabotrophic P2Y(1,2,4,6,11,12,13) receptors are expressed throughout the nervous
system, however their contribution to nucleotide signalling in spinal cord (SC) remains to be determined. RT-
PCR analysis indicated the presence of all P2 receptor transcripts in the SC, apart from P2Y4. In this study we
have used ﬂuorescent calcium imaging and western blotting to investigate the response of the SC to applied
nucleotides. SC cells from neonatal mice were dissociated and cultured for 3–5 days. Propidium iodide staining
and immunocytochemical analysis with glial fabrillary acidic protein (GFAP) indicated that the cultures consisted
of ~45% neurons, with the remainder glial in origin.
The contribution of deﬁned P2 receptors was determined using wild-type (WT) and P2Y1 receptor-deﬁcient (KO)
mice. In WT application of both ADP (102M) a P2Y1,P 2 Y 12, and P2Y13 receptor agonist and the pyrimidine
nucleotide UTP (1002M) a P2Y2 and P2Y4 agonist evoked a reproducible sustained response in ~100% and ~70%
of cells (F525 ratio 2.4,1.74) respectively, which remained largely unchanged in the absence of extracellular
calcium.
ADP (102M) did not evoke a calcium response in P2Y1 KO cells, whereas UTP (1002M) responses were unaf-
fected. ADP (1002M) responses were abolished in the presence of pyridoxalphosphate-6-azophenyl-20-50-disulf-
onate (PPADS) and Suramin, both broad-spectrum P2 receptor antagonists. MRS 2179 a P2Y1 selective
antagonist caused a concentration dependant inhibition to application of ADP.
Western Blot analysis on WT cells showed that application of ADP (102M) activated ERK phosphoryation in a
time dependant manner (10 mins optimal) and this was almost completely inhibited by the phospholipase C
inhibitor U73122. Application of BAPTA, a calcium-speciﬁc chelator, did not inhibit ADP evoked ERK phosp-
horylation, however pre-incubation of cultured cells with PPADS or suramin substantially reduced ERK phosp-
horylation. In contrast to ADP evoked calcium respones that were abolished ADP evoked ERK phosphorylation
was unaffected in P2Y1 KO SC.
Our results suggest that a range of functional P2 receptor subtypes are expressed by the SC which are coupled to
an increase in intracellular calcium demonstrating the presence of a functional ADP-sensitive P2Y1 receptors and
additionally UTP-sensitive P2Y2 receptors in mouse SC. However western blot analysis reveals that P2Y1 coupled
to PLC is not responsible for subsequent ERK activation seen in response to ADP and this activation is calcium
independent.
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Metabotropic P2Y1 receptors (P2Y1R) are G-protein coupled receptors (GPCRs) activated by extracellular nu-
cleotides that regulate a wide range of physiological events. Several GPCRs have been described as cell prolif-
eration inductors, by trans-activation of the epidermal growth factor receptor (EGFR). Considering that
nucleotides are continuously released from cells, we hypothesized that they might act as local trophic factors. We
assessed whether P2Y1R, like other GPCRs, could modulate cell proliferation via the EGFR. Epithelial FRT cells
and cancerous HeLa cells responded to the selective P2Y1R agonist 2-MeSADP by increasing [H
3]-thymidine
incorporation with EC50 values of 42T7 nM and 76T3 nM, respectively, an effect totally abolished by the P2Y1R
antagonist MRS2179. 2-MeSADP also increased the tyrosine phosphorylation of EGFR, by 3–4 fold in FRT cells
and more than 60 fold in HeLa cells, leading to activation of ERK1/2 proteins. Inhibitors of EGFR kinase
(AG1478), PKC (Ro318220), src (PP2) and metalloproteases (Ilomastat), and a negative dominant of G!q, all
reduced the rise in cell proliferation evoked by 2-MeSADP. Apyrase, used to degrade extracellular nucleotides,
reduced 15–25% the basal proliferation rate of FRT and HeLa cells, suggesting a trophic role of the nucleotides
endogenously released by each cell type. Nucleotides quantitation by high performance liquid cromatography
following derivatization of purines demonstrated that HeLa and FRT cells endogenously release near to 200nM
ATP after a mechanical stimuli such as the gently change of culture media; basal values of 20–50 nM ATP were
reached after 15–30 min. The released ATP was totally degaded to AMP using apyrase. On the other hand,
epithelial MDCK cells overexpressing P2Y1R increased their proliferation rate through a mechanism that depe-
nded on EGFR activation, as judged by AG1478 inhibition. Cells overexpressing the P2Y1R showed increased
levels of REGF expression and a basal activated form of ERK proteins, suggesting that regulation of REGF
through nucleotide receptors could involve other mechanisms, different than those involved in trans-activation.
These results revealed that P2Y1R activation trans-activates the EGFR leading to increased proliferation of both
epithelial and cancerous cells. While nucleotides permanently released to the media could be involved in the
maintenance of the basal proliferation rate, endogenous nucleotides widely released after cell damage and tissue
injury could also play a role in tissue repairing.
(Funded by FONDAP grant 13980001; Millennium MIDEPLAN project MIFAB also funded the CRCP Center)
P2Y1 receptors mediates release of tissue plasminogen activator (t-PA) in
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Background: The endothelial P2Y1 receptor is responsible for a large part of the reactive hyperemia following
cardiac ischemia. Tissue plasminogen activator (t-PA) increases during reactive hyperemia. We postulated that
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receptor.
Methods: t-PA was measured in peripheral arterial blood and locally in the venous blood from the coronary sinus
(CS) in a porcine model. 2-MeSADP (10
j5M), alone or as co-infusion with a selective P2Y1 receptor blocker,
MRS 2179 (10
j3M) was locally delivered in the left anterior descending artery (LAD) through the tip of a
coronary angioplasty balloon. In separate pigs the coronary artery was occluded with the balloon for ten min.
During the ﬁrst and tenth min of coronary ischemia, 2.5 ml of MRS 2179 (10
j3M) was delivered distal to the
occlusion in 8 pigs, 10 pigs were used as controls.
Results: 2-MeSADP increased levels of t-PA in the CS by 85% which could completely be inhibited by co-infusion
with MRS 2179. During cardiac ischemia and reperfusion t-PA increased signiﬁcantly, an effect that could be
signiﬁcantly inhibited by MRS 2179. Conclusion: Intra coronary administered MRS 2179, a selective P2Y1 rece-
ptor blocker, signiﬁcantly reduces the increased levels of t-PA caused by both 2-MeSADP and cardiac ischemia +
reperfusion in coronary arteries. Thus, ADP acting on the endothelial P2Y1receptor may play a major role in the
release of t-PA during post- ischemic hyperemia.
P2Y1 signalling in human monocyte derived dendritic cells
Blandine Maı ˆtre, Be ´atrice Hechler, Catherine Le ´on, Jean-Pierre Cazenave, Christian Gachet.
INSERM U311. Etablissement Franc ¸ais du Sang-Alsace, Strasbourg, France
blandine.maitre@efs-alsace.fr
Adenosine triphosphate (ATP) and adenosine diphosphate (ADP) have been reported to regulate human mon-
ocyte derived dendritic cells (DCs) by inhibiting IL-12 production and by modulating expression of costimulatory
molecules at their cell surface. ATP is thought to interact with DCs through the P2Y11 receptor [1] whereas the
receptors activated by ADP are not yet well characterized [2]. The aim of the present study was to investigate
whether ADP could stimulate the P2Y1 receptor in DCs and, if yes, the possible role of this receptor in matur-
ation of DCs and in regulation of the immune response. In human immature DCs, ADP (50 2M) induced an
increase in intracellular Ca
2+ both in the presence and absence of external calcium, which was absent in mature
dendritic cells. This intracellular Ca
2+ rise was totally inhibited by MRS2179 (250 2M), a potent and selective
antagonist of P2Y1. Moreover, ADP induced an increase in intracellular Ca
2+ in murine bone marrow derived
dendritic cells (BMDC), that was absent in BMDC derived from P2Y1 deﬁcient mice. To determine whether ADP
could inﬂuence maturation of human monocyte derived DCs, stimulation with 100 ng/mL lipopolysaccharide
(LPS) in the presence or the absence of 50 2M ADP for 24 hours was performed. ADP had a synergistic effect
with LPS on the increased cell surface expression of DCs maturation markers, CD83, HLA-DR, CD86 but not
CD80 and this effect was partially reversed by MRS2179 suggesting that, not only the P2Y1 receptor, but other
P2Y receptors are involved in this response. Finally, ADP inhibited Il-12p70 and Il-12p40 secretion by human
monocyte derived DCs induced by LPS (100 ng/mL). Increase of CD86 at the cell surface of DCs and inhibition of
IL-12 secretion suggest that ADP could potentiate a Th2 response. In conclusion, these results indicate that ADP
286 Communications
Springerinteracts with immature DCs through different P2Y receptors, of which P2Y1 and that ADP, like ATP, could
modulate the immune response by acting on immature DCs.
1. Wilkin, F., et al., The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells.
J Immunol, 2001. 166(12): p. 7172–7.
2. Marteau, F., et al., Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotides
diphosphates on human monocyte-derived dendritic cells. J Leukoc Biol, 2004. 76(4): p. 796–803.
Permeation properties of single human purinergic P2X7 receptors
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Purinergic P2X7 receptors belong to the family of receptor-operated ion channels. They are mainly expressed in
cells of the immune and inﬂammatory system and in epithelium. P2X7 receptors can induce a nonselective me-
mbrane permeability after prolonged or repeated stimulation by an unknown mechanism. To investigate this in
more detail, single channels currents of human P2X7 receptors heterologously expressed in Xenopus oocytes were
recorded using the patch clamp technique in the outside-out conﬁguration using Cs
+ as intracellular cation. Su-
bstitution of extracellular Na
+ ions by inorganic cations of increasing size successively decreased the single cha-
nnel conductance and shifted the reversal potential to more negative values. In extracellular solutions containing
the large cations tris
+ or choline
+, no single channel inward currents at negative membrane potentials up to
j160 mV but outward currents probably carried by Cs
+ at positive potentials were detected. Substitution of Na
+
by organic cations prolonged the mean open times and increased the open probability of single P2X7 channel
currents. Additionally, the deactivation time course was slowed. These single channel permeation properties did
not change during repeated or prolonged ATP applications. This was also found in single channel recordings in
the cell attached conﬁguration. We conclude that single P2X7 channels are only permeable to small cations
independent of the duration of agonist application. Substitution of Na
+ by large inorganic cations not only dec-
reases the single channel conductance but also has a pronounced inﬂuence of the hP2X7 channel kinetics.
This work was supported by the Deutsche Forschungsgemeinschaft (Ma 1581/12-1) and the Roux-programme of
the ML university (FKZ 13/07).
Pharmacological and safety evaluation of the platelet P2Y12 receptor antagonist
INS50589 in healthy human volunteers.
Jose ´ L. Boyer, Fred L. Johnson, Philip T. Leese, Todd Durham, Christopher S. Crean, Ramesh
Krishnamoorthy, Paul S. Watson and Donald J. Kellerman
Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 200, Durham, North Carolina, 27703. USA
JBoyer@inspirepharm.com
Platelets play a critical role in hemostasis and are involved in the pathogenesis of arterial thrombosis, where
platelet-rich thrombi are the hallmark of the disease. Platelet-speciﬁc cell-surface receptors as well as intracellular
signaling enzymes are the targets of current antiplatelet therapeutic agents. A number of antiplatelet drugs are
used in the management of cardiovascular and cerebrovascular thrombotic conditions. A key extracellular sign-
aling molecule involved in platelet activation is ADP, which binds to P2Y1 and P2Y12 surface receptors. A direct
and reversible antagonist of the platelet P2Y12 receptor, INS50589, is under development by Inspire for the acute
treatment of cardiovascular conditions where a strict control of platelet function is desired.
A phase 1 study involving 36 healthy volunteers was conducted to evaluate the pharmacological, pharmacokinetic
and safety properties of a continuous intravenous administration of INS50589 at doses of 0.1, 0.3, 1.0 and
3.0 mg/kg/h for four hours. Platelet function before, during and after the administration of the drug was assessed
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dependent inhibition of ADP-induced platelet aggregation following the administration of INS50589 was obser-
ved as early as 15 minutes, and the level of inhibition was maintained during the four-hour infusion period,
returning to predose levels following discontinuation of the infusion. The recovery rate of platelet function was
also proportional to the administered dose of INS50589 and can be associated with the systemic elimination of the
drug. At a dose rate of 0.1mg/kg/h, the extent of inhibition of platelet aggregation was 60% of the predose level
when stimulated with 5 2M ADP, and complete inhibition was observed at doses of 0.3, 1 and 3 mg/kg/h. The
plasma levels of the drug were proportional to the dose level and decreased rapidly upon discontinuation of the
drug. All subjects that initiated treatment completed the study and no serious adverse events were reported.
INS50589 was well tolerated and no clinically signiﬁcant changes in physical examination, serum chemistry, he-
matology, and electrocardiogram were observed during or after treatment.
Intravenous administration of INS50589 produces a rapid and reversible modulation of platelet function. The
results of this study support the advancement of this clinical candidate for acute use where a rapid and strict
control of platelet function is required.
Pharmacological characterization of novel adenosine ligands in recombinant and
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The present study was designed to evaluate the effects of novel and recognised compounds at human recombinant
A2B adenosine receptors expressed in Chinese hamster ovary (hA2BCHO), in human embryonic kidney 293
(hA2BHEK 293) and at endogenous A2B receptors in human mast cells (HMC-1). Saturation binding experiments




revealed a single class of binding sites in hA2BCHO, hA2BHEK 293 and HMC-1 cells with KD (nM) of 1.65T
0.18, 2.83T0.34, 2.62T0.27 and Bmax (fmol/mg protein) of 36T4, 475T50 and 128T15, respectively. The pharma-
cological proﬁle of new compounds, determined in inhibition binding experiments in hA2BHEK 293 cells using
[
3H]-MRE 2029F20, showed a rank order of potency typical of the A2B receptors with Ki values in the range
3.2–28 nM. In functional assays recognised and novel compounds were studied by evaluating their capability to
modulate the cAMP production in hA2BCHO and in HMC-1 cells. In particular, novel compounds showed an
high potency and MRE 2029F20 was the best compound with a KB of 23T3 nM and of 19T2 nM, respectively. New
compounds were also able to inhibit cAMP levels in the absence of NECA and in the presence of forskolin
stimulation in hA2BCHO and in HMC-1 cells. In each cell line examined all novel compounds at the 1 2M
concentration were able to decrease cAMP levels by 30–50%. Interestingly, in HEK293 cells MRE 2029F20
reduced cAMP basal levels with an IC50 value of 2.9 T 0.3 nM. These results suggest that novel compounds are
antagonists with an inverse agonist activity in recombinant and native human A2B receptors. As a consequence,
the development of potent and selective A2B compounds appears promising to increase the knowledge of the
potential role of A2B receptors in the pathogenesis of several disorders.
Pharmacological proﬁle of P2Y receptors involved in feed-back inhibition
of noradrenaline release in sympathetic innervated tissues
Queiroz G.
1, Talaia C., Gonc ¸alves J.
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In the sympathetic nervous system, ATP is co released with noradrenaline (NA) from postganglionic nerve
terminals and acts not only as a neurotransmitter but also as a neuromodulador (1). Adenine nucleotides, such as
ATP and its analogues, have been shown to inhibit NA release, by direct activation of presynaptic inhibitory P2Y-
receptors (2). However, the receptor subtype involved has not been identiﬁed. The aim of the present study was to
identify the subtype of P2Y-receptor involved on modulation of NA release in two sympathetically innervated
tissues, the epididymal portion of vas deferens and tail artery of rat, and if they are activated by the released ATP.
Epididymal portions of vasa deferentia and tail arteries from male Wistar rats (250–350 g) were incubated with 0.1
2M[
3H]-NA and superfused with a physiological solution containing 0.4 2M desipramine and antagonists of
adenosine A1 receptors (DPCPX, 0.1 2M) and !2-adrenoceptors (yohimbine, 1 2M). Tissues were stimulated with
trains of 100 pulses at 8 Hz or 5 Hz (50 mA, 1 ms). The effects of P2 agonists and antagonists on evoked NA
release (estimated as tritium overﬂow) were expressed in % of respective controls as mean T S.E.M, and were
tested for signiﬁcance by one-way ANOVA followed by Dunnett_s test.
The P2-receptor agonists 2MeSATP (1–100 2M), 2MeSADP (1–100 2M), ADP (1–300 2M) and ATP (1–300 2M),
decreased tritium overﬂow up to 53 T 7% (n = 6; P<0.01), in the epididymal portion and up to 61 T 6% (n = 6;
P<0.01), in tail artery. The order of potency was: 2MeSADP Q 2MeSATP > ADP Q ATP, in the epididymal
portion of vas deferens and ADP > 2MeSATP Q 2MeSADP in tail artery. The effects of 2MeSATP (1–100 2M)
were antagonized in both tissues by RB2 (10 2M), PPADS (10–30 2M) and by the selective P2Y1 antagonist MRS
2179 (10 2M) but were not changed by the selective P2Y12/P2Y13 antagonists, 2MeSAMP (30 2M) or MRS 2395
(30 2M). The P2Y-receptor antagonists, RB2 (1–30 2M), MRS 2179 (1–100 2M), 2MeSAMP (1–100 2M) and
MRS 2395 (30 2M) increased tritium overﬂow up to 142 T 5% (n = 4; P<0.01), in the epididymal portion of vas
deferens. The order of potency was: RB2 > MRS 2179 2MeSAMP Q MRS 2395. In the tail artery, they caused no
change on tritium overﬂow evoked at 5 Hz. In the epididymal portion of vas deferens, the effect of 2MeSADP
(30 2M; S2/S1 =6 2T 2%; n = 8) was abolished when tissues were pre-incubated with pertussis toxin (8 2g/ml; S2/S1
=9 6T 6%; n = 4, P<0.01) and was not changed by inhibition of phospholipase C or protein kinase C with U-73122
(S2/S1 =6 0T 3%; n = 4) and Ro 32-0432 (S2/S1 =5 8T 3%, n = 4), respectively.
It is concluded that, in the epididymal portion of vas deferens and tail artery of the rat adenine nucleotides
modulate NA release through activation of inhibitory P2 receptors coupled to Gi/o-proteins with a pharmaco-
logical proﬁle that resemble PY1 receptors.
(1) Burnstock G (2004) Curr Op Pharmacol 4:47–52.
(2) von Ku ¨gelgen I et al. (1999) Prog Brain Res 120:173–182.
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Pharmacology of AS-16; a novel and selective Adenosine A2B
receptor antagonist.
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There is considerable evidence to suggest that adenosine, through activation of A2B receptors on mast cells and
smooth muscle cells, is involved in the pathophysiology of asthma (Holgate, 2005). Here we describe the phar-
macology of a novel selective A2B receptor antagonist AS-16 (2-(4-benzyloxy-phenyl)-N-[5-(2,6-dioxo-1,3-dipro-
pyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl]-acetamide) which may have therapeutic utility in
asthma and respiratory disease. In radioligand binding studies utilizing the selective A2B receptor ligand [
3H]-
MRE-2029, AS-16 has an afﬁnity of 22 nM for the human recombinant A2B receptors expressed in HEK-293 cells.
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greater than 1,000 nM at these targets. In functional assays, using recombinant A2B receptors in CHO cells and
endogenous A2B receptors in the human mast cell line HMC-1, AS-16 demonstrates an afﬁnity (KB)o f7 5n Ma n d
87 nM respectively.,.
The in vivo efﬁcacy of AS-16 has been examined in sheep which are naturally sensitive to the allergen Ascaris
suum. In these animals antigen-induced bronchospasm has two phases similar to what occurs with allergen cha-
llenge studies in patients, an immediate increase in airﬂow resistance (early airway response), followed several
hours later by a second increase in airway resistance (late airway response). AS-16 (2 mg/kg) was dosed orally
twice-daily for 2 days prior to antigen challenge. This dosing regime gave a consistent plasma concentration (70–
100 ng/ml) during the experimental phase of the studies. AS-16 reduced the early airway response by approxi-
mately 20% and almost completely abolished the late airway response. A further feature of the sheep model,
which is also consistent with studies in patients, is that antigen challenge induces airway hyperresponsiveness
(AHR). AS-16 (2 mg/kg p.o.) completely prevented the AHR to inhaled carbachol, assessed 24 h after allergen
challenge. Finally, AS-16 (2 mg/kg p.o.) was able to completely block adenosine-induced bronchospasm, sugge-
sting that in sheep adenosine effects are mediated via the A2B receptor.
Thus, AS-16 is a novel, selective A2B receptor antagonist which will be a useful tool to further explore the
pathophysiology of asthma and respiratory disease.
References
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We investigated the effects of polydeoxyribonucleotide (PDRN) a compound holding a mixture of deoxyribo-
nucleotide polymers of different lengths, in an experimental model of burn wounds. This compound stimulates ‘‘in
vitro’’ ﬁbroblast proliferation and collagen production, likely stimulating the A2 purinergic receptor. In our ex-
periment C57BL/6 male mice of 25–30 g were immersed in 80 degrees C water for 10 seconds to achieve a partial-
thickness scald burn. Animals were treated daily for 14 days with PDRN (8 mg/kg/ip) or its vehicle (100 2l). On
day 14, burn areas were used for measuring malondialdehyde content, histological damage, neo-angiogenesis by
immunohistochemistry and expression (Western blot) of the speciﬁc endothelial marker CD31 as well as quant-
iﬁcation of micro-vessel density, endothelial and inducible nitric oxide synthase (eNOS and iNOS) expression and
wound nitrite content. PDRN decreased tissue oxidative stress index, increased epithelial proliferation, extrace-
llular matrix maturation, and augmented neoangiogenesis as suggested by the marked increase in micro-vessel
density and by the robust expression of the speciﬁc endothelial marker CD31. PDRN was also able to improve the
recruitment and differentiation of endothelial progenitor cells as conﬁrmed by the immuno-staining with VEGF-
R2 a speciﬁc surface marker of committed endothelial cells. Furthermore, PDRN caused a marked expression of
eNOS (vehicle 8.1 T 1.5 integrated intensity; PDRN 15.2 T 1.8 integrated intensity) and iNOS (vehicle 7.1 T 1.8
integrated intensity; PDRN 14.2 T 1.3 integrated intensity) and increased wound nitrite content. Our data suggest
that PDRN may be an effective therapeutic approach to improve clinical outcomes after thermal injury.
References
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P, Giugliano G, Scuderi N, Mioni C, Leone S, Squadrito F. Lipid peroxidation inhibition by raxofelast improves angiogenesis
and wound healing in experimental burn wounds. Shock. 2005 Jul;24(1):85–91.
290 Communications
Springer2: Galeano M, Deodato B, Altavilla D, Squadrito G, Seminara P, Marini H, Stagno d"Alcontres F, Colonna M, Calo M, Lo
Cascio P, Torre V, Giacca M, Venuti FS, Squadrito F. Effect of recombinant adeno-associated virus vector-mediated vascular
endothelial growth factor gene transfer on wound healing after burn injury. Crit Care Med. 2003 Apr;31(4):1017–25.
3: Thellung S, Florio T, Maragliano A, Cattarini G, Schettini G. Polydeoxyribonucleotides enhance the proliferation of human
skin ﬁbroblasts: involvement of A2 purinergic receptor subtypes. Life Sci. 1999;64(18):1661–74.
Potential role for neural adenosine A2A receptors in the dilations caused
by increases in tissue adenosine.
Richard J. Rivers, Naris Thengchaisri, Timothy M. Moore, and Larysa Voytenko
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We recently reported a distinct vascular network response initiated by elevated tissue concentrations of adenos-
ine, but the role of speciﬁc adenosine receptor subtypes has not been elucidated. To determine this, remote
arteriolar responses were tested in anesthetized hamster cheek pouch when adenosine (or its analogues) were
applied (32m tipped micropipette, 1psi, 10 seconds) into the tissue 500 2m away from the arteriole (n = 67,
baseline diameter 22.4T0.6 2m). Dilations did not decay along the arteriole when measured 1000 2m further away.
Control dilations caused by tissue adenosine (5T0.4 2m) were not altered by superfusion of the A1 receptor
antagonist DPCPX (1 2M; 4.6T0.3 2m), A2B receptor antagonist alloxazine (1 2M; 6T0.8 2m), A3 receptor anta-
gonist MRS1220 (5 nM; 5.6T0.8 2m) or intracellular P-site antagonist NBTI (1 2M), but were abolished by the
selective A2A receptor antagonist ZM241385 (0.1 2M; 0.8T0.2 2m), indicating that activation of A2A receptors
mediates these network responses. Direct arteriolar application of ZM241385 (0.1 2M; 4.9T0.4 2m) did not alter
the dilation caused by tissue adenosine, on the other hand, local application of ZM241385 into the tissue inhibited
adenosine induced network responses (1.9T0.3 2m) similar to superfusion. Furthermore, application of A2A rec-
eptor agonist CGS21680 (1 2M) but not A1 receptor agonist CPA (100 2M) in the tissue mimicked adenosine
network response.
The location of these tissue receptors is unknown. Using antibodies to the adenosine A2a subtype we found
numerous cells in the tissue that labeled during immunohistochemical studies. This includes capillary endothelium
and small neurons, with cell bodies, that co-labeled with calcitonin gene-related peptide (CGRP) and that inne-
rvated the arterioles. We tested for a role for endothelium damaging the endothelium in the dilating arterioles.
Despite loss of response to bradykinin and persistent dilation to nitroprusside, the response to increases in tissue
adenosine persisted. Thus, these data suggest a novel role of tissue A2A receptor in initiating the adenosine
vascular network response and that the A2a receptors on the endothelium are unlikely to be playing a role during
increases in tissue adenosine.
This research was supported by National Heart, Lung, and Blood Institute Grant R01 HL-072922 and American
Heart Association Grant-in-Aid 0455730U.
Priming of STAT1 and STAT3 for cytokine-triggered degradation by the prote-
asome upon A2A adenosine receptor (A2AAR) expression
Mohammed Safhi, William A Sands and Timothy M. Palmer
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Presenting author e-mail: 0410422s@student.gla.ac.uk
While the A2A adenosine receptor (A2AAR) is known to elevate cAMP, the molecular mechanisms underlying its
anti-inﬂammatory effects remain obscure, particularly with respect to its effects on cytokines that utilise the JAK-
STAT signalling pathway. Thus, since we had found that adenovirus-mediated A2AAR gene transfer into human
umbilical vein endothelial cells (HUVECs) profoundly suppresses NF-.B activation, the effect of A2AAR expr-
ession on cytokine activation of the JAK-STAT pathway was also tested in this system. Activation of the JAK-
STAT pathway was achieved by exposure of HUVECs to an interleukin-6 (IL-6) trans-signalling complex com-
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produced a time-dependent and sustained phosphorylation of STAT3 on Tyr705 and STAT1 on Tyr701 that
peaked between 15 and 30 min exposure and only began to diminish by 60 min. Expression of the A2AAR
resulted in a more transient phosphorylation of STAT1 and STAT3 that peaked at 15 min before diminishing to
basal levels by 30 and 60 min. Interestingly, detailed analysis of total STAT1 and STAT3 levels following IL-6/
sIL-6R! exposure revealed that both of these proteins were down-regulated in a cytokine-dependent manner in
A2AAR-expressing but not control cells, with maximal down-regulation occurring after 2 hr. This reﬂected a
cytokine-inducible degradation of STAT1 and STAT3, as down-regulation was abolished by pre-treatment with
the proteasome inhibitor MG132. Further experiments under conditions in which proteasomal degradation was
blocked revealed that the suppression of IL-6/sIL-6R! -stimulated STAT phosphorylation observed in A2AAR-
expressing cells could be completely accounted for by the down-regulation phenomenon. Moreover, the cytokine
inducibility of the effect reﬂected a requirement for JAK-mediated phosphorylation of STAT proteins, since pre-
treatment with a concentration of JAK inhibitor sufﬁcient to block IL-6/sIL-6R! -stimulated STAT phosphor-
ylation also abolished their down-regulation. Finally, the effect of A2AAR expression on cytokine regulation of
STAT degradation appeared not to be restricted to either IL-6 or vascular endothelial cells, since stable expre-
ssion of the A2AAR in rat C6 glioma cells suppressed the ability of interferon-+ (IFN+) to promote the tyrosine
phosphorylation of STAT1, and this was accompanied by an IFN+-induced time-dependent degradation of STAT1
protein. This was associated with an attenuation of the ability of IFN+ in conjunction with NF-.B mobilising
stimuli to mediate the induction of iNOS. Taken together, these data argue that expression of the A2AAR primes
STAT proteins for phosphorylation-triggered degradation by the proteasome, and thus leading to reduced target
gene transcription, by regulating the activity and/or expression of E3 ligases speciﬁc for JAK-phosphorylated
STATs.
PROMOTION OF RAT ALVEOLAR MACROPHAGE FUSION INTO
MULTINUCLEATED GIANT CELLS (MGC) BY GMCSF INVOLVES THE
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Multinucleated giant macrophages are a hallmark of many chronic inﬂammatory reactions but the mechanisms
regulating MA fusion and MGC formation remain unclear. In previous work, we have demonstrated that gran-
ulocyte-macrophage colony stimulating factor (GMCSF), a cytokine produced during inﬂammation, promotes the
fusion of rat alveolar macrophages (MA) into MGC, and such response was partly dependent on IL-6 production.
The purinergic P2X7 receptor has been implicated both in MGC formation and in the induction of the IL-1!IL-6
cytokine cascade. In the present study, we investigated the potential role of the P2X7 receptor in mediating
GMCSF effects on MA function and fusion into MGC. To this aim, parallel experiments were performed using
primary cultures of rat alveolar MA expressing the native receptor as well as HEK293 cells stably transfected with
the rat P2X7 receptor or a mock vector. Incubation of rat alveolar MA with GMCSF for 3 to 5 days increased in a
dose-dependent fashion T 2.5–10 ng/ml) MA fusion into multinucleated MA by up to 3-fold. Interestingly, pre-
treatment of MA with oxidized ATP (oATP)(100 2M), an irreversible blocker of P2X7, decreased signiﬁcantly
GMCSF-induced MGC formation (fusion index and MGC numbers) at all doses tested T 51% of control at
10 ng/ml GMCSF), suggesting the participation of P2X7. In support of this, GMCSF altered P2X7-dependent pore
forming activity, a hallmark of P2X7 function. Rapid (5 min) stimulation of MA with either GMCSF
(2.5–10 ng/ml) or ATP (5 mM) was performed under similar conditions and pore forming activity was measured
by ethidium bromide (EtBr) uptake. As observed with ATP, GMCSF increased the number of MA that became
permeabilized to EtBr (17%), albeit at a lower level than ATP (30%). Such effect was reduced by pre-treatment
of MA with oATP T down to 58% of control). In addition, GMCSF up-regulated the expression of P2X7 receptor
during MGC formation. Incubation with GMCSF (10 ng/ml) increased the percentage of P2X7 receptor immu-
292 Communications
Springernoreactive MA (55% compared to 27% for unstimulated MA). Enhanced P2X7 expression was seen at 24 h and
up to 72 h at which time it correlated with increased MGC formation. In agreement with this, stable expression of
rat P2X7 receptor in HEK293 transfected cells was associated with higher numbers of MGC compared to HEK293
cells transfected with a mock vector and that do not express P2X7. Quite interestingly, Polymyxin B (PMB) which
increases selectively P2X7 pore-forming activity in P2X7 transfected cells but not in mock transfectants, also
potentiated P2X7-dependent pore formation and IL-1 " release in rat alveolar MA as well as GMCSF-induced
MGC formation by rat MA (1.7-fold). All together, our data indicate that GMCSF promotion of MGC may result
from its ability to stimulate P2X7 function and expression and that its effect can be further increased by agents
that potentiate P2X7 receptor activity. Our study point to the P2X7 receptor as an important effector pathway in
the promotion of MGC formation by GMCSF, a cytokine produced during chronic inﬂammatory reactions.
(Supported by CIHR, NSERC,AIRC, IMESR and CNR Italy).
Protection from Bleomycin-Induced Pulmonary Injury by Activating A2A
or Inhibiting A2B Adenosine Receptors
Elaine Cagnina and Joel Linden
Cardiovascular Research Center, University of Virginia, Charlottesville, VA 22901
reb2w@virginia.edu
Pulmonary inﬂammation and ﬁbrosis are signiﬁcant side effects that complicate treatment with the anti-neoplastic
drug, bleomycin (BLM). BLM is also used in mice to model idiopathic pulmonary ﬁbrosis since it elicits mild
transient inﬂammation followed by progressive ﬁbrosis. Activation of the A2A adenosine receptor is known to
inhibit pulmonary macrophage activation and neutrophil chemotaxis, and activation of the A2B receptor stimul-
ates activation of pulmonary ﬁbroblasts. This study investigated the effects of the selective A2A receptor agonist,
ATL313 (1.44 2g/kg/day), or the selective A2B receptor antagonist, ATL851 (10 mg/kg/day), on BLM (0.075 U)-
induced inﬂammatory cell accumulation in the broncheoalveolar lavage (BAL) ﬂuid or pulmonary ﬁbrosis over a
2 week period. Drugs were administered continuously by subcutaneous Alzet minipumps implanted just prior to
BLM exposure. ATL313 reduced BLM-induced neutrophil and lymphocyte recruitment into the BAL at 3 days
post BLM treatment. ATL851 enhanced 2-week survival and reduced pulmonary collagen deposition and alveolar
damage at 2 weeks. ATL851 also blocked release of the pro-ﬁbrotic cytokine IL-6 from isolated murine pulmo-
nary ﬁbroblasts stimulated with the adenosine agonist N-ethylcarboxamidoadenosine. On the basis of these data
we speculate that pulmonary ﬁbrosis in response to BLM is triggered by an early inﬂammatory event that is
attenuated by activation of A2A receptors and progresses in part due to adenosine-mediated activation of A2B
receptors that stimulate mitogenic cytokine release from ﬁbroblasts and possibly other pulmonary cells.
Protective activity of guanosine in an in vitro model of Parkinson_s disease.
Buccella S., Romano S., D_Alimonte I., Nargi E., Ballerini P., Fischione G., Caciagli F., Di Iorio P.
Department of Biomedical Sciences. University of Chieti-Pescara. Chieti. Italy.
Email: silvana.buccella@unich.it
Parkinson_s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the
substantia nigra, where an inhibition of mitochondrial complex I activity has been reported [1]. 6-Hydroxydop-
amine (6-OHDA), which is widely used to generate in vitro and in vivo models of PD, induces both apoptotic and
necrotic cell death by inhibiting mitochondrial metabolic function and by inducing endoplasmic reticulum
stress [2].
This study aimed at verifying whether exogenous guanosine (eGUO), which exerts protective and anti-apoptotic
effects in different in vitro models of neurodegenerative disorders [3, 4], was able to protect against the toxic
effect of 6-OHDA.
Exposure of SH-SY5Y human neuroblastoma cells or cultured astrocytes of rat brain to 6-OHDA (12.5–200 2M)
for 12 h caused a dose-dependent decrease of cell viability, evaluated by MTT assay. The maximal effect (~75%
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50 2M 6-OHDA was evident after 3 h of cell treatment, whereas a longer time of exposure to lower concentra-
tions of 6-OHDA needed to cause a signiﬁcant effect. Within 3 h, 6-OHDA (50 2M) induced phosphorylation of
the stress-activated protein kinases (JNK and p38) and it also elicited a sustained ERK1/2 activation. These
effects were associated with an activation of caspase cascade and GSK3beta factor. A modest and delayed incr-
ease of AKT phosphorylation was also found (2–3 h after cell exposure to 6-OHDA for 3 h).
Pre-treatment of SH-SY5Y cells or astrocytes with 10–300 2M of eGUO, starting from 0.5 h before and carried on
the time of cell exposure (3 h) to 50 2M 6-OHDA, dose-dependently counteracted the toxin-induced cell death,
with a maximal reduction of the apoptotic cells by about 70%. A similar protective effect of eGUO was also
observed when it was either co-administered (3 h) with 50 2M 6-OHDA or administered (for 3 h at least)
immediately after cell exposure to the toxin.
As we previously found [4], eGUO induced an early and PI-3 kinase-mediated increase of ERK1/2 and Akt
phosphorylation. This effect was dose-dependent and reached the maximal degree after 10–15 min, lasting for the
following 30–40 min at least. Downstream these factors, eGUO caused an inhibition of pro-apoptotic factors, such
as GSK3beta, and a delayed activation (4 h) of anti-apoptotic proteins, such as Bcl-2.
Cell pre-treatment or co-treatment with eGUO reduced the 6-OHDA-induced phosphorylation of JNK and p38
as well as the activation of caspases and GSK3beta factor without affecting the increased levels of pERK1/2; these
effects were reduced by inhibiting the PI-3 kinase pathway. The protective effect of eGUO administered after cell
exposure to 6-OHDA seems to be linked to further molecular mechanisms, likely involving the Bcl-2 protein
activation downstream signals.
1. Bharath, S.; Hsu, M.; Kaur, D.; Rajagopalan, S.; Andersen, J.K. Biochem. Pharmacol. 2002, 64, 1037–1048.
2. Chen, G.; Bower, K.A.; Ma, C.; Fang, S.; Thiele, C.J.; Luo, J. Faseb J. 2004, 8, 1162–1164.
3. Rathbone, M.P.; Middlemiss, P.J.; Gysberg, J.W.; Andrew, C.; Herman M.A.R.; Reed, J.K.; Ciccarelli, R.; Di Iorio, P.;
Caciagli, F. Prog. Neurobiol. 1999, 59, 663–690.
4. Di Iorio, P.; Ballerini, P.; Traversa, U.; Nicoletti, F.; D_Alimonte, I.; Kleywegt, S.; Werstiuk, E.S.; Rathbone, M.P.; Caciagli,
F.; Ciccarelli, R. Glia. 2004, 46, 356–368.
Purine and pyrimidine nucleosides preserve human astrocytoma cell adenylate
energy charge in conditions of hypoxia
Francesco Balestri, Michela Giannecchini, Maria Grazia Tozzi, Marcella Camici
Dipartimento di Biologia, Unita ` di Biochimica, Via S. Zeno 51, 56100 Pisa
camici@dfb.unipi.it
The brain depends on both glycolysis and mitochondrial oxidative phosphorylation for maintainance of ATP
pools. Astrocytes play an integral role in brain functions providing trophic supports and energy substrates for
neurons. A number of papers have been published in which a neuroprotective effect of purine nucleosides in
conditions of hypoxia has been reported. Whether nucleosides exert their protective action by interacting with
speciﬁc receptors, or after their entry into the cell and metabolic conversion to energetic intermediates, is still
matter of debate. While in some cases the action of adenosine is receptor-mediated (1,2), to explain the effect of
its deamination product, inosine, the contribution of hitherto unknown speciﬁc receptors has been invoked (3).
On the other hand, several papers report a receptor-independent mechanism of nucleoside action, which ultim-
ately involves the phosphorolytic cleavage with generation of phosphorylated sugar which is used as energy source
(4–7). To address this question, we have used a human astrocytoma cell line (ADF) which has been subjected to
metabolic stress conditions by exclusion of glucose and pre-incubation with oligomycin (an inhibitor of oxidative
phosphorylation). This treatment brings about a depletion of the ATP pool, with a concomitant increase in the
AMP levels, which results in a signiﬁcant decrease of the adenylate energy charge (AEC) to a value of 0.7. A
further incubation of the oligomycin pre-treated cells in DMEM medium devoid of glucose brings about a dec-
rease in the AEC up to 0.4. The presence of glucose, inosine and guanosine in the DMEM medium preserves the
AEC. Besides purine nucleosides, also pyrimidine nucleosides, such as uridine and, to a lesser extent, cytidine, are
able to preserve the AEC. The determination of lactate in the incubation medium indicates that nucleosides can
preserve the ATP pool through anaerobic glycolysis, thus pointing to a relevant role of the phosphorolytic clea-
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tose, which through the pentose phosphate pathway and glycolysis can be converted to energetic intermediates.
1. Abbracchio, M.P., and Burnostock, G. (1998) Purinergic signalling: pathophysiological roles. Jpn. J. Pharmacol. 78, 113–145.
2. Tomaselli, B., Podhraski, V., Heftberger, V., Bo ¨ck, G., and Baier-Bitterlich, G. (2005) Purine nucleoside-mediated prote-
ction of chemical hypoxia-induced neuronal injuries involves p42/44 MAPK activation. Neurochem. Int. 46, 513–521.
3. Haun, S.E., Segeleon, J.E., Trapp, V.L., Clotz, M.A., and Horrocks, L.A. (1996) Inosine mediates the protective effect of
adenosine in rat astrocyte cultures subjected to combined glucose-oxygen deprivation. J. Neurochem. 67, 2051–2059.
4. Jurkowitz, M.S., Litsky, M.J., Browning, M.J., and Hohl, C.M. (1998) Adenosine, inosine and guanosine protect glial cells
during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation. J. Neurochem.
71, 535–548.
5. Litsky, M.L., Hohl, C.M, Lucas, J.H., and Jurkowitz, M.S. (1999) Inosine and guanosine preserve neuronal and glial cell
viability in mouse spinal cord cultures during chemical hypoxia. Brain Res. 821, 426–432.
6. Yoo, B-K., Choi, J.W., Yoon, S.Y., and Ko K.H. (2005) Protective effect of adenosine and purine nucleos(t)ides against the
death by hydrogen peroxide and glucose deprivation in rat primary astrocyres. Neurosci. Res. 51, 39–44.
7. Giannecchini, M., Matteucci, M., Pesi, R., Sgarrella, F., Tozzi, M.G., and Camici, M. (2005) Uptake and utilization of
nucleosides for energy repletion. Int. J. Biochem. Cell Biol. 37, 797–808.
Purinergic P2X2 receptor-channels as modulators of electrical excitability
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The anterior pituitary is composed of the ﬁve major hormone-secreting cell types, corticotrophs, lactotrophs,
thyrotrophs, somatotrophs and gonadotrophs, and their function is regulated by numerous hypothalamic and
intrapituitary factors. ATP may also contribute to the control of pituitary functions, since these cells release ATP
and express several subtypes of ion-conducting purinergic P2 receptor-channels (P2XRs), calcium-mobilizing P2Y
receptors, and ecto-nucleotidase eNTPDase 1–3 (1). However, the speciﬁcity in the expression of P2 receptors
among secretory cell types and their biophysical properties and roles in spontaneous and receptor-controlled
electrical activity, calcium signaling, and hormone secretion have been incompletely characterized. Our RT-PCR
analysis revealed that mRNA transcripts for P2X1, P2X2ab, P2X3,P 2 X 4 and P2X7 were expressed in pituitary cells
from embryonic, neonatal and adult rats. In further studies, we focused on functional identiﬁcation of P2XR
subtypes expressed in gonadotrophs from all three age groups. These cells ﬁre action potentials spontaneously and
respond to activation of gonadotropin-releasing hormone receptors with long-lasting membrane potential and
calcium oscillations, which are dependent on periodic calcium release from Ins(1,4,5)P3-sensitive store and ass-
ociated voltage-gated calcium inﬂux (2). Gonadotrophs from all three age groups also responded to ATP, but with
non-oscillatory, depolarizing, slowly desensitizing, and rapidly deactivating current, indicating that these cells
express P2XRs but not P2YRs. The amplitudes of P2X current responses and the rates of receptor desensitization,
but not the rates of receptor deactivation, were dependent on ATP concentration. The kinetics of receptor
activation, deactivation, desensitization, and resensitization in gonadotrophs were comparable with those obser-
ved in cells expressing recombinant P2X2R and/or P2X4R. The ATP-induced current was blocked by pyridoxal
5-phosphate 6-azophenyl-20,40-disulphonic acid, suramin, reactive blue-2 and elevated extracellular calcium con-
centrations, which is consistent with the expression of P2X2R subtypes in gonadotrophs. Activation of these
channels resulted in rapid plasma membrane depolarization, initiation of ﬁring of action potentials in quiescent
cells, increase in the frequency of spiking in spontaneously active cells and stimulation of gonadotropin release in
perifused pituitary cells. Effects of ATP on ﬁring of action potentials were also blocked with suramin and pyri-
doxal 5-phosphate 6-azophenyl-20,40-disulphonic acid, conﬁrming the relevance of P2X2R inward current in dep-
olarization of cells. ATP also inﬂuenced gonadotropin-releasing hormone-induced current and membrane
potential oscillations and hormone release in an extracellular calcium-dependent manner. These oscillations were
facilitated, slowed or stopped, depending of ATP concentration, the time of its application and the level of
calcium content in intracellular stores. These results indicate that in gonadotrophs P2X2Rs function as pacema-
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1. Stojilkovic SS, Koshimizu T. 2001. Signaling by extracellular nucleotides in anterior pituitary cells. Trends Endocrinol Met
12:218–225.
2. Stojilkovic SS, Reinhart J, Catt KJ. 1994. Gonadotropin-releasing hormone receptors: structure and signal transduction
pathways. Endocrine Rev 15:462–499.
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Purinergic (P2) receptors are expressed in many excitable and non-excitable cells where they mediate a great
number of physiological actions, including smooth muscle contractility, neuroendocrine secretion and synaptic
transmission. In addition, several data have provided evidence for a role of these receptors in physiopathological
events, such as platelet aggregation, chloride secretion by epithelia, hematopoiesis, and immunological reaction.
In the nervous system, P2 receptors mediate neurotransmission, release of proinﬂammatory cytokines, reactive
astrogliosis. Extracellular nucleotides activate multiple P2 receptors in neurons and glial cells, including P2X
receptors and G protein-coupled P2Y receptors (Abbracchio & Verderio 2006). Recent studies have demon-
strated the localization of some P2 receptors in lipid rafts. Given their ability to concentrate selected molecules
locally, lipid rafts are known to function in protein sorting, cytoskeleton regulation, signal transduction and
receptor/ion channel signaling or turnover. Therefore, we investigated whether P2Y receptors, known to be ex-
pressed in astrocytes, are recruited in lipid rafts. To this aim, primary astrocytic cultures from rat brain cortices
were treated with non-ionic detergent at 4-C and the so-called detergent resistant membranes (DRMs, believed to
represent lipid microdomains in intact cell membrane) were separated from the soluble proteins on sucrose
gradients by ﬂoatation. Analysis of the gradient fraction showed that the lipid microdomain markers, GM1 and
caveolin, were mainly localized in DRMs (Taverna et al. 2004) and ﬂoated in the low density region of the
gradients. In line with previous results, signiﬁcant amounts of the t-SNARE SNAP-23 and syntaxin3 were also
present in the low density fractions. When the distribution in the gradients of P2Y1 and P2Y6 was analyzed, we
found that a consistent amount of P2Y6 receptor localized in DRM containing fraction. Because several evidence
suggested that a number of non-physiological rearrangements may occur upon the addition of Triton X-100 to
membranes (Mukherjee and Maxﬁeld, 2004), to further demonstrate the localization of P2Y6 receptor in lipid
microdomains we used a morphological approach. To this aim ‘‘membrane sheets’’ were obtained from cultured
astrocytes by sonication and were immunolabeled for t-SNARE proteins or P2 receptors. As expected, SNAP-23
or syntaxin 3 showed a punctate staining on the inner membrane leaﬂet. Interestingly, P2Y6 showed a similar
clustered distribution. Irrelevant staining was observed when the membrane sheets were labeled with non-imm-
une mouse or rabbit IgG. Altogether these results are in line with the biochemical data and conﬁrm the presence
of P2Y6 in lipid microdomains. Studies are in progress to investigate the molecular organization of these domains
and their functional role in reactive astrocytes.
Abbracchio, M.P; Verderio, C. Novartis Found Symp 2006, in press.
Mukherjee, S.; Maxﬁeld, F.R. Annu. Rev. Cell Dev. Biol. 2004, 20, 839–866.
Taverna, E.; Saba, E.; Rowe, J.; Francolini, M.; Clementi, F.; Rosa, P., J. Biol. Chem. 2004, 279, 5127–5134.
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Matrix metalloproteinase-9 (MMP-9) activity is required for inﬂammatory response, leucocyte recruitment and
tumor invasion. There is increasing evidence to suggest the P2X7 receptor of mononuclear cells, which is activated
by extracellular ATP, is involved in inﬂammatory responses. In this study, ATP caused a rapid release of MMP-9
and a moderate decrease in TIMP-1 release from human peripheral blood mononuclear cells (PBMC) over a
30 min time course. The release was time and dose-dependent, and dissociated from ATP-induced cell death.
BzATP, which is the most potent agonist for the P2X7 receptor, also caused a similar effect at a lower dosage.
ATP-induced MMP-9 release was inhibited by the P2X7 receptor antagonists, periodate oxidized ATP and KN-
62, or by calcium chelators, as well as by a loss-of-function polymorphism in the P2X7 receptor, but not by
Brefeldin A, monensin or cycloheximide, or by anti-TNF-alpha or anti-IL-1beta monoclonal antibodies. Results
from puriﬁed subsets of PBMC showed monocytes were the major source for MMP-9 and TIMP-1 release and
ATP remained effective in puriﬁed monocyte and T cell populations. These observations suggest a novel role for
P2X7 as a pro-inﬂammatory receptor involved in rapid MMP-9 release and leucocyte recruitment.
Real-time detection of ATP release using a two enzyme assay system
Ross Corriden
1,2, Paul A. Insel
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Many different non-excitatory cell types release ATP in response to mechanical or biochemical stimulation. The
mechanisms responsible for this release, however, are not well understood. This is partly due to the difﬁculty of
studying the dynamics of ATP release immediately outside the cell membrane. Current methods for the measu-
rement of extracellular ATP do not allow for convenient visualization of release using a microscope. Here we
developed a method which allows us to both visualize and quantify localized ATP release. This method consists of
a two enzyme system which uses ATP and NADP as substrates that result in production of NADPH, a ﬂuoro-
phore, which can be easily detected by ﬂuorescence microscopy and hence serves as an indicator of extracellular
ATP.
The two enzymes, hexokinase and glucose 6-phosphate dehydrogenase (G6PD), are added together with NADP
to living cells (e.g., human neutrophils), and placed in a stage incubator of an inverted ﬂuorescence microscope
equipped with a 100 W mercury lamp. Images are acquired with an Orca II ER camera and analyzed with
Openlab imaging software. In the presence of glucose, ATP released from the cells is converted by hexokinase to
the product glucose 6-phosphate. G6PD in turn converts glucose 6-phosphate and NADP to the products
6-phosphogluconate and NADPH. We optimized a ﬁlter set that allows us to record in real-time the production of
NADPH. This ﬁlter set consists of a 340 nm band pass exciter, a 400 nm dichroic mirror, and a 434 nm band pass
emission ﬁlter. Figure 1 shows a sample image of a migrating human neutrophil. A ﬂuorescence signal outside the
moving cell in close proximity to the cell membrane indicates that migrating neutrophils release ATP in a pola-
rized fashion with greatest ATP release observed at the leading edge. We calibrated ﬂuorescence intensity values
using ATP solutions of known concentrations. Our new method allows the detection of ATP concentrations as
low as 1 2M, and it has a sufﬁciently wide dynamic range, being able to detected concentrations of up to 1 mM.
This assay may provide a valuable tool for researchers who are interested in visualizing and quantifying the
release of ATP in different cell systems.
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images was taken at the indicated intervals (0, 20, 45 s).
This study was supported in part by grants from the U.S. National Institutes of Health (GM-51477, 60475, &
66232).
Real-time measurements of ATP and adenosine release during oxygen/glucose
deprivation in area CA1 of rat hippocampal slices.
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The purines ATP and adenosine are released into the extracellular space during insults to the mammalian brain
such as head injury and cerebral ischemia. Under these conditions adenosine exerts a neuroprotective inﬂuence,
primarily via the adenosine A1 receptor, whereas activation of ATP P2X or P2Y receptors may contribute to
neuropathology. Although the release of ATP and adenosine is a pivotal event in the brain_s response to ische-
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for adenosine and ATP to measure in real-time their release from area CA1 during oxygen/glucose deprivation.
400 2m thick hippocampal slices were prepared using standard techniques from 11–26 day old rat pups. Extrac-
ellular or whole-cell patch-clamp recordings (33–34-C) were made from stratum radiatum and CA1 neurones,
respectively. Microelectrode (50 2m) biosensors for ATP and adenosine/inosine, along with a null (no-enzyme)
sensor to check for the presence of electroactive interferences, were inserted into stratum radiatum. The biose-
nsors possessed a selectivity screen that almost completely eliminated responses to potential electroactive inter-
ferences such as ascorbate, urate, dopamine and serotonin. The sensors were calibrated with exogenous adenosine
or ATP and the integrity of the screen assessed by applying serotonin at the end of each experiment. Biosensors
were purchased from Sarissa Biomedical Ltd www.sarissa-biomedical.com).
Omission of oxygen and glucose from the perfusion medium (ischemia; replaced by N2 and sucrose, respectively)
caused the rapid release of adenosine and the depression of the fEPSP. In the early stages of ischemia, no ATP
release was observed. However, during prolonged ischemia in older animals (22–26 days), ATP (1–2 2M) was
released around the time of the extra- or intracellularly-recorded anoxic depolarisation. Upon reoxygenation, a
second phase of adenosine, and, to a lesser extent ATP (2–3 2M), release was observed. Neither ATP nor
adenosine release was prevented by glutamate receptor antagonism (5 mM kynurenic acid), gap junction blockade
(100 2M carbenoxelone) or inhibition of glial cell metabolism (100 2M ﬂuorocitrate). ATP release was not a
harbinger of widespread cell death or lysis as ATP release occurred in the presence of kynurenic acid, which, once
washed from the slice, allowed recovery of the fEPSP. Omission of Ca
2+ in the aCSF did not prevent ATP release
and indeed increased adenosine release (~3-fold increase after 5 mins ischemia). However, combined omission of
extracellular Ca
2+ together with chelation of residual extracellular Ca
2+ with 1 mM EGTA greatly reduced ATP,
but not adenosine release. Inhibition of nucleoside transport with dipyrimadole (10 2M) and NBTI (5 2M),
sufﬁcient to depress the fEPSP by ~50%, did not prevent either ATP or adenosine release.
Our ﬁndings suggest complex and perhaps independent mechanisms underlying the release of adenosine and ATP
during in vitro ischemia. A better understanding of the release mechanisms might provide novel therapeutic
targets in acute human brain injury.
Reduced atherosclerotic lesions in P2Y1/ApoE double knockout mice
Be ´atrice Hechler, Catherine Le ´on, Monique Freund, Jean-Pierre Cazenave, Christian Gachet
INSERM U311, Etablissement Franc ¸ais du Sang-Alsace, Strasbourg, France
beatrice.hechler@efs-alsace.fr
Atherosclerosis is a multi-factorial disease of the arterial wall involving a complex interplay between circulating
blood cells (leukocytes and platelets), endothelial and smooth muscle cells of the vasculature. The P2Y1 receptor
is present on all those cell types, and plays a key role in platelet physiology. The aim of the present study was to
evaluate the potential involvement of P2Y1 in the development of atherosclerotic lesions in mice. Therefore, we
intercrossed atherosclerosis-prone apolipoprotein E deﬁcient mice (ApoE
j/j) with mice lacking the P2Y1 rece-
ptor (P2Y1
j/j) to generate P2Y1/ApoE double knockout mice (P2Y1
j/j/ApoE
j/j). Mice were maintained on
regular chow for 30 weeks before collection of the whole aortas and hearts for analysis of atherosclerotic lesion




j/j mice. In the entire aorta, atherosclerotic lesion areas, as quantiﬁed after staining with oil red O, tended
to be reduced in P2Y1
j/j/ApoE
j/j mice as compared to ApoE
j/j mice, although the difference did not reach
statistical signiﬁcance (P = 0.0981, Student_s test). In contrast, in the aortic roots, P2Y1
j/j/ApoE
j/j mice displ-
ayed a 24% reduction in atherosclerotic lesion areas as compared to ApoE
j/j mice (0.41 T 0.03 mm
2 vs 0.54 T 0.03
mm
2, n = 15, P = 0.003, Student_s test). This reduction in size was associated with a reduction in the percentage of
total plaque area occupied by macrophages, identiﬁed with Mac-3 staining (7.6 T 0.4% vs 9.6 T 0.8%, n = 15, P =
0.0372) and a slight reduction in the smooth muscle cell content, while the content in collagen ﬁbres remained
similar between the two genotypes. These results suggest that the P2Y1 receptor contributes to atherosclerotic
lesion development in ApoE
j/j mice. Whether this effect is entirely due to platelet inhibition or whether the
endothelial and/or leukocyte P2Y1 receptor are involved requires further studies.
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Extracellular ATP is recognized as a mediator of acute and chronic pain through its binding to several types of
P2X receptors. It has been recently shown that in the spinal cord, antisense-mediated P2X4 receptor knockdown
reduces neuropathic pain (Tsuda et al., 2004). It appeared that P2X4 receptors expressed by microglia were
involved in mediating neuropathic pain. Similarly, disruption of P2X7 gene impairs both neuropathic and inﬂa-
mmatory pain, the later being associated with a reduced secretion of the pro-inﬂammatory cytokine IL-1"
(Chessell et al., 2005).
In the present study, the involvement of P2X4 receptors in inﬂammatory and neuropathic pain was investigated
using P2X4 deﬁcient mice. Inﬂammatory pain was induced by a FCA injection in the hind paw of mice. 24h later,
P2X4 WT mice showed a signiﬁcant hyperalgesia, compared to baseline responses. P2X4 KO mice showed no
hyperalgesia. Cytometric analysis of cytokines of FCA injected paws demonstrated that the anti-inﬂammatory
cytokine IL-10 content was up-regulated in P2X4 KO mice whereas IL-1" release was unaffected. Quantitative
PCR from paw tissues, did not revealed major modiﬁcation of cytokine gene expression following FCA challenge
in KO animals compared to WT. Neither cytokine content nor expression was changed in spinal cord from P2X4
KO mice. Using LacZ staining, "-galactosidase and P2X4 immunostaining, only a slight up-regulation of P2X4
receptors in the spinal cord was observed up to 7 days after FCA injection. The absence of Cd11b staining, a
speciﬁc marker of microglial cells support the view that P2X4 receptors expressed by microglia are not involved in
short term FCA-induced inﬂammatory pain.
Following sciatic nerve ligation, P2X4 KO mice showed a signiﬁcant decrease in mechanical hyperalgesia up to 25
days compared to WT. Strong LacZ staining, "-galactosidase labelling and P2X4 expression was observed in the
dorsal horn of the spinal cord. Double immunostaining showed co-localization of "-galactosidase and CD11b
markers, indicating that up-regulation of P2X4 receptor is associated with microglial activation. In addition, in
neuropathic animals lacZ staining was also observed in supra-spinal centres such as in thalamic nuclei or discrete
cortical areas, suggesting an implication of P2X4 receptors along pain related pathways in the central nervous
system. Finally, results from western blotting, YO-PRO up-take and immunocytochemistry on microglial culture
showed that P2X7 receptors were still present and functional in P2X4 KO mice.
Our results indicate that P2X4 receptors are involved in both inﬂammatory and neuropathic pain through diffe-
rent mechanisms. In inﬂammatory pain, P2X4 receptors expressed by immune cells recruited at the injury site
certainly mediate pain processing through peripherally secreted cytokines whereas in neuropathic pain, P2X4
expressed by microglia are likely to be involved.
Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A et al. Nature 424:778–783, 2004
Chessell IP, Hatcher JP, Bountra C, Michel AD Hughes JP et al. Pain 114:386–396, 2005
Regulation of adenosine receptors on peritoneal mesothelial cells
during peritonitis
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Adenosine is an endogenous immunomodulator that has been shown to exhibit anti-inﬂammatory and immuno-
suppressive effects. These anti-inﬂammatory effects depend mainly on the ligation with its cell-surface receptors
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Springersubtypes: A2A receptor (A2AR), A2B receptor (A2BR) which interact with Gs to stimulate adenylyl cyclase activity
thereby elevating cAMP levels that have potent immunosuppressive effects. In contrast, the A1 receptor (A1R)
and A3 receptor (A3R), through interaction with members of the Gi/Go family, reduce levels of cAMP. We have
previously demonstrated that adenosine levels increase during peritonitis; furthermore, A2AR agonist of the ad-
enosine receptor strongly diminish leukocyte recruitment following E. coli inoculation.
Peritoneal mesothelial cells (PMC) form a monolayer that covers the peritoneal membrane. Their location bet-
ween the peritoneal cavity and peritoneal blood vessels gives them a key role in intraperitoneal immune defense.
Following stimulation with inﬂammatory cytokines and bacterial products, mesothelial cells express adhesion
molecules and produce various cytokines and other pro-inﬂammatory mediators.
The aim of this study was to assess the regulation of adenosine receptors on PMC during inﬂammatory processes.
Peritonitis was induced in CD1 mice by intraperitoneal injection of E. coli. Protein and mRNA were extracted
from the peritoneum at various time points and adenosine receptor levels were analyzed by western blot and real
time PCR analysis. Receptor mRNA and protein levels were evaluated in human PMC following inﬂammatory
stimulation.
In a mouse model of peritonitis, A1R protein levels on PMC peaked at 12 hours after inoculation and then
returned to baseline at 24 hours while the high afﬁnity A2AR protein level remained at its summit up to 24 hours
at which point adenosine concentration reached its highest level in the peritoneal ﬂuid. The low afﬁnity A2B
receptor maintained a slowly sustained elevation up to 48 hours. Treatment of isolated PMC with TNF!, and IL-1
up regulated of A2AR and A2BR mRNA and protein while IFN-+ decreased A2AR levels; however promote the
increase of A2BR levels.
The sequential increase of A1,A 2A and A2B receptors, as observed in our study, suggests that the complex
expression of adenosine receptors is probably part of the regulation of adenosine signaling during peritonitis. The
early increase of the A1R stimulates leukocyte inﬂux into the inﬂamed area, while the upregulation of the A2A
and A2B receptors that appear at a later stage moderates the number of leukocytes in the exudate thereby
reducing the potential damage to the peritoneal tissue caused by the cytotoxic molecules released by the
leukocytes.
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Among the vast array of regulatory functions attributed to adenosine it has been shown to mediate vasodilatation
of blood vessels and to exert negative chronotrophic and ionotrophic upon the myocardium. These regulatory
effects depend mainly on the ligation with its cell-surface receptors subtypes: A2A receptor (A2AR), and the A1
receptor (A1R) (and possibly A3 receptor (A3R)) respectively.
Major trauma often represents a state of severe hemodynamic shock caracterized by fatal dysfunction of the
cardiovascular system and impaired metabolism. It has been established that in such stressfull conditions, resulting
in tissue ischemia, the concentration of adenosine in the extracellular ﬂuid rises dramatically.
The aim of this study was to assess the role of adenosine in the acute phase of major trauma. To test our
hypothesis we chose thermal injury as our model. In order to asses the presence of adenosine following thermal
injury, blister ﬂuids from burn patients were collected in the Emergency Room. Adenosine levels were determ-
ined using high performance liquid chromatography (HPLC). In a murine thermal injury model, full thickness
40% of total body surface area (TBSA) dorsal burn was inﬂicted upon female CD1 mice with (immediately post-
burn and every 12 hours for 3 days) or without A1 and A3 receptors antagonists. Survival, Blood glucose, and
major organs architecture by histology were evaluated. All experiments were approved by the local institutional
Helsinki committee.
We found adenosine concentration in blister ﬂuids sampled during the ﬁrst 12 hours post burn to be signiﬁcantly
elevated. In a mouse model of thermal injury, survival of burned mice treated with A1R antagonist and A3R
antagonist simultaneously (N = 12), improved dramatically demonstrating survival of 62% in comparison with
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Springer12% in the burned untreated group (N = 12). There was no signiﬁcant difference in survival of burned mice
treated solely with either A1R antagonist or A3R antagonist. 24 hours post burn, blood glucose levels of burned
mice treated with A1R antagonist and A3R antagonist simultaneously (N = 6) were not signiﬁcantly different in
comparison with untreated mice. Liver histology demonstrated central lobular ischemia of burned mice which was
not present in mice treated with A1R antagonist and A3R antagonist simultaneously (N = 6).
Tissue adenosine is present in higher concentrations in burn patients. The increased survival of burned mice
treated with A1Ra n dA 3R antagonists is suggestive for improved cardiovascular response to severe trauma. The
unchanged survival of burned mice treated solely with either A1Ro rA 3R antagonists implies of their synergistic
affect in this process. The conserved liver tissue may imply of an additional positive effect by maintaining the
blood ﬂow to major organs during the acute phase of trauma. This data not only, strongly suggests of adenosine_s
involvement in the morbidity from major trauma but also opens a new path for the development of new efﬁcient
therapeutics.
Regulation of ATP release from naive and inﬂamed airway epithelia
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In airway epithelia, extracellular ATP and its metabolite adenosine (ADO) facilitate mucociliary clearance ess-
ential for pulmonary host defense. Thus, elucidating the ATP and ADO concentrations in the thin (~7 2m) ﬁlm of
airway surface liquid and linking these to regulation of epithelial function is important, but doing so has been
difﬁcult to achieve. Here we measured ATP concentrations ([ATP]s) at the apical surface of well-differentiated
primary human bronchial epithelial (HBE) cells with luciferase fused to the IgG-binding domain of Staphylo-
coccus protein A (SPA-luc)
1. Real-time measurements of [ATP] by SPA-luc attached to the apical HBE culture
surface via an antibody against endogenously expressed keratan sulfate were compared with those determined
with soluble luciferase dissolved in bulk mucosal liquid. [ATP] on resting HBE surfaces were in the low nM range
as measured by both methods. Inhibition of extracellular ATPases by the addition of ", +-methylene-ATP, leva-
misole and ebselen resulted in ATP accumulation at a rate of ~250 fmol/cm
2/min, which reﬂected basal ATP
release. Following 33% hypotonic challenge, HBE cells swelled and [ATP] transiently reached ~1 2M as meas-
ured by cell-attached SPA-luc, reﬂecting an increase in ATP release rate to 200–900 pmol/cm
2/min. The peak
[ATP] in mucosal liquid following hypotonic challenge as measured by soluble luciferase was volume dependent,
with measurements in a small volume (25 2l/cm
2) approximating those of cell-attached SPA-luc.
These techniques were applied to address whether inﬂammation augments ATP release from airway epithelia,
similar to what has been reported in other systems. A challenge with supernatant of mucopurulent material
(SMM) collected from cystic ﬁbrosis airways was utilized to induce inﬂammation in HBE cells
2. Mucosal exposure
to SMM for 48 h augmented hypotonicity-induced ATP release from HBE cultures (peak [ATP] = 1130 T 200 and
2050 T 150 nM in vehicle- and SMM-treated cultures, respectively), which paralleled the increased secretion of
inﬂammatory markers such as IL-8. No difference was observed in resting state ATP concentrations and release
rates between vehicle- and SMM-treated cultures. Because SMM treatment increased Ca
2+
i stores and augmented
agonist-induced Ca
2+
i mobilization in HBE cells2, we examined the effect of Ca
2+
i chelation on ATP release.
BAPTA treatment did not signiﬁcantly alter the peak [ATP] following hypotonic challenge in vehicle-treated
cultures; however, it reduced peak [ATP] of SMM-treated cultures to the range of vehicle-treated (840 T 40 and
1330 T 250 nM in vehicle- and SMM-treated cultures, respectively). Fourteen days after the cessation of SMM- or
vehicle-exposure, both IL-8 secretion and ATP release from SMM-treated cultures returned to the range of those
of vehicle-treated. These ﬁndings suggest that inﬂammation in HBE cells augmented hypotonicity-induced ATP
release in a reversible fashion. In contrast to the hypotonicity-induced ATP release from naive HBE cells having
observed to be largely Ca
2+
i-independent, the $[ATP] gained by inﬂammation was mostly Ca
2+
i-dependent, su-
ggesting that inﬂammation conferred Ca
2+
i-dependent pathways of ATP release to HBE cells, which were not
major players in non-inﬂamed epithelia.
(Supported by National Institute of Health and Cystic Fibrosis Foundation.)
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2: Ribeiro, C. M.; Paradiso, A. M.; Schwab, U.; Perez-Vilar, J.; Jones, L.; O"Neal, W.; Boucher, R. C., Chronic airway infection/
inﬂammation induces a Ca2+i-dependent hyperinﬂammatory response in human cystic ﬁbrosis airway epithelia. J Biol Chem
2005, 280, (18), 17798–806.
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The cell surface E-NTPDases (E-NTPDase 1, 2, 3, 8) are anchored to the membrane by two transmembranous
domains (TMD), one each at the N- and C-termini. Of the three E-NTPDases that we cloned, expressed and
characterized, the chicken E-NTPDase 8 is unusual in that it remains active in the presence of high concentrations
of certain detergents, e.g., NP-40 [1]. In contrast, human E-NTPDase 2 and 8 are inhibited by low concentrations
of NP-40 which can be prevented by prior treatment of the enzymes by a cross-linking agent, glutaraldehyde [2,3].
Furthermore, the human E-NTPDase 2 is susceptible to substrate inactivation [2] whereas the chicken and human
E-NTPDase 8 are not [1, 3].
The TMD of the chicken E-NTPDase 8 and human E-NTPDase 2 have different amino acid sequences. In order
to elucidate the roles of the TMD in the two E-NTPDases in their different responses to detergents and substrate
inactivation, we generated the following constructs: (i) chimeras (ck-hu ACR1, ACR5, and ACR1,5) in which the
N- or C-terminal regions of chicken E-NTPDase 8 or both are exchanged for the corresponding regions of the
human E-NTPDase2, (ii) chimeras (hu-ck ACR1, ACR5 and ACR1,5) in which the N- and C-terminal regions or
both of the human E-NTPDase 2 are exchanged for the corresponding regions of the chicken E-NTPDase 8, and
(iii) soluble extracellular domains (ECD) of the three E-NTPDases. Except for hu-ck ACR1, all are expressed in
HEK293 cells upon transfection with the cDNA constructs.
Chimeras containing one or both of the N- or C-terminal TMD of the human E-NTPDase 2, regardless of the
parent molecule, are all susceptible to inhibition by NP-40 and substrate inactivation. Interestingly, substrate
inactivation is more pronounced in ck-hu ACR1 than in ck-hu ACR1,5. However, the chimera of human E-
NTPDase 2 with both chicken TMD (hu-ck ACR1,5) is now insensitive to NP-40 inhibition nor substrate inact-
ivation. These results suggest that catalysis at the active site in the ECD is affected by the interhelical interaction
of the respective pairs of TMD, which is affected differently by NP-40 in the two enzymes.
As expected, none of the soluble enzymes of the three E-NTPDases are affected by NP-40. However, their enzy-
matic characteristics are signiﬁcantly altered from the membrane-bound enzymes. Both soluble human E-NTPD-
ase 2 and 8, in contrast to the membrane-bound enzymes, show a preference for CaATP, and the soluble human
E-NTPDase 2 is no longer inactivated by substrates. Unexpectedly, soluble chicken E-NTPDase 8 shows marked
substrate inactivation in a temperature dependent manner. Thus the presence of TMD in the chicken E-NTPDase
8 abrogates substrate inactivation of its ECD, which is exactly the opposite of that observed with the soluble and
membrane-bound human E-NTPDase 2. (Supported by the California Metabolic Research Foundation.)
References:
1. Mukasa, T., Lee, Y. and Knowles, A. F. Biochemistry 2005, 44, 11660–11170
2. Knowles, A. F. and Chiang, W-C. Arch. Biochem. Biophys. 2003, 418, 217–227
3. Knowles, A. F. and Li, C. (submitted) Biochemistry
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SpringerSecretion in epithelia of airways, pancreas, small intestine and sweat glands is initiated by opening of Cl- channels
(e.g. CFTR), and K
+ channels that keep the driving force for the secretory process. In our previous studies on
native rat pancreatic ducts we have shown that activation of P2Y2 and P2Y4 receptors causes increased intrac-
ellular Ca
2+, and surprisingly inhibition of K
+ channels that would decrease the secretion (1). However, the
identity of the K
+ channels associated with the epithelia of pancreatic ducts was not known. Therefore the aim of
the project was to determine the molecular identities of the K
+ channels expressed in the native pancreatic duct
and to elucidate at a cellular level how the purinergic receptors P2Y2 and P2Y4 regulate epithelial K
+ channels.
To resolve which K
+ channels are present in pancreatic ducts, we performed RT-PCR experiments and identiﬁed
transcripts for BK (Slo-1), IK and KCNQ1 but not SK. We also tested whether the recently discovered BK
subtypes Slo-2 and Slo-3 were expressed, but they could not be detected.
To elucidate at a cellular level how the pancreatic purinergic receptors P2Y2 and P2Y4 regulate the epithelial IK
and BK and KCNQ1 channels, we co-expressed the channels with one of the receptors in Xenopus oocytes and
measured currents by two-electrode voltage clamp. The purinergic receptors were stimulated by UTP (10
j4 M).
When human BK and IK were expressed in oocytes together with human P2Y2 and P2Y4 receptors, these
channels could be activated or inhibited, depending on the combination of channel and receptor. The most
notable ﬁnding was that P2Y2 receptors inhibited BK (20%) similar to what we have found in native rat ducts.
Co-expression of P2Y4 receptors stimulated the BK-channel (30%). IK stimulated both P2Y2 (5 fold) and P2Y4
receptors (10 fold)(2). The KCNQ-1 channel was expressed with its "-subunits (KCNE1 or KCNE3), but none of
these constellations were affected by stimulation of the purinergic receptors. Taken together, the combination of
P2Y2 and BK channels in the oocytes give similar data as in the native pancreatic ducts and indicates that this
constellation is dominant. Traditionally, the P2Y2 receptors have been assumed to couple to Gq and its downs-
tream effectors, including PKC. We tested if PKC could be the link between activation of P2Y2 and inhibition of
BK channels. In these experiments the PKC activator PMA (n = 4) failed to inhibit the BK currents in P2Y2 and
BK expressing oocytes. Also pre-incubation of the oocyte with the PKC inhibitor staurosporine (n = 4) could not
prevent inhibition of BK. Based on these studies we expect that the P2Y2 induced inhibition of BK current is
independent of PKC and other intracellular signalling partners have to be considered.
This work was supported by The Lundbeck Foundation, The Augustinus Foundation and the Danish Medical and
Science Research Council.
1. Hede SE, Amstrup J, Christoffersen BC, Novak I (1999) J.Biol.Chem. 274:31784–31791
2. Hede SE, Amstrup J, Klaerke DA, Novak I (2005) Pﬂugers Arch. 450 (6):429–36.
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The human P2Y receptor subtypes are activated by different physiological nucleotides, including the purines ATP
and ADP, and the pyrimidines UTP, UDP and UDPglucose, depending on the receptor subtype. Four P2Y
receptor subtypes are sensitive to uracil nucleotides, the P2Y2 (UTP, also ATP), the P2Y4 (UTP), the P2Y6
(UDP), and the P2Y14 (UDPglucose).
1 There is a lacking of potent, selective and enzymatically stable agonists
and antagonists for uracil nucleotide-activated P2Y receptors. Such compounds are required as pharmacological
tools and have considerable potential as novel drugs.
1 Only limited information on structure-activity relationships
of uracil nucleotide derivatives and analogs is available so far.
In the present study, we synthesized a series of base-modiﬁed UTP, UDP and UMP derivatives as well as UTP
analogs in which the triphosphate group was replaced by an enzymatically more stable residue. Base-modiﬁed
uracil nucleotides were obtained starting from the uracil derivatives, which were silylated and subsequently rea-
cted with benzoyl- or acetyl-protected ribose in the presence of a Friedel-Crafts catalyst according to a modiﬁed
Hilbert–Johnson method, to afford the protected nucleosides. After deprotection
2 an N3-substituent could be
introduced by alkylation with alkyl halogenides in the presence of K2CO3 in acetone/DMF.
3 The obtained nuc-
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Springerleosides were susceptible to phosphorylation in the 50-position according to a procedure described by Ludwig
4 to
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The synthesized nucleotides were investigated for their potency to increase P2Y2-, P2Y4-, and P2Y6-receptor-
mediated inositol phosphate accumulation in recombinant astrocytoma 1321N cells expressing the respective
receptor subtype. Several of the synthesized nucleotides showed high activity at certain receptor subtypes. N3-
phenacyl-UDP was a potent and selective P2Y6 agonist (EC50 = 70 nM), and 2-thio-UTP was a potent P2Y2
agonist (EC50 = 50 nM). A 5-Bromo-UTP analog stabilized by a P"P+-dichloromethylene bridge to enhance the
enzymatic stability was synthesized and showed relatively high activity at P2Y2 and P2Y6 receptors with EC50
values of 354, and 120 nM, respectively.
1. Brunschweiger, A.; Mu ¨ller, C. E. Curr. Med. Chem. 2006, 12, 763–771.
2. Hamamura, H.; Sato and K.; Moffatt, G. J. J. Med. Chem. 1972, 15, 1061–1065.
3. Yamamoto, I; Kimura, T.; Tateoka, Y.; Watanabe, K.; Ho, K. I. J. Med. Chem. 1987, 30, 2227–2231.
4. Ludwig, L. Acta Biochim. Biophys. Acad. Sci. Hung. 1981, 16, 131–133.
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A1 adenosine receptors (A1ARs) are widely distributed, ubiquitously expressed in the central nervous system and
in internal organs such as heart, kidneys, liver and bladder. Adenosine causes via A1ARs locomotor depression,
anxiolysis and sedation in the CNS, while in the heart has negative chronotropic, dromotropic and inotropic
effects. Moreover A1ARs stimulation provokes in the kidney vasoconstriction and a decrease in the glomerular
ﬁltration rate.
A1AR antagonists have therapeutic potential in the treatment of various forms of dementia, depression and as
cognition enhancers in geriatric therapy. Moreover A1AR antagonists are currently studied as potassium saving
diuretics and for the treatment of acute renal failure.
Among the non xanthine derivatives A1AR antagonists, only few examples of pyrazolo[3,4-b]pyridine derivatives
are reported in literature, the most active of them showing afﬁnity of 0.3 2M, but scarce selectivity.
A few years ago, in this context we have synthesized a series of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazol-
o[3,4-b]pyridine-5-carboxylic acid ethyl esters, possessing an interesting antagonistic proﬁle, the most active co-
mpound showing a 50 nM afﬁnity toward A1ARs.
1 Very recently, on the basis of our pseudoreceptor model, we
have synthesized new compounds bearing different amino groups on C4 and different esters on C5, obtaining











We reported here the synthesis and the afﬁnity data of other pyrazolo[3,4-b]pyridine derivatives 1, following SAR
studies on all the inhibitors previously reported, bearing differently substituted phenylethylamino groups on C4
and an activated phenyl ring on the N1 side chain.
(1.) Bondavalli, F.; Botta, M.; Bruno, O.; Ciacci, A.; Corelli, F. et al. Synthesis, molecular modeling studies, and pharmacol-
ogical activity of selective A1 receptor antagonists. J. Med. Chem. 2002, 45, 4875–87.
(2.) Manetti, F.; Schenone, S.; Bondavalli, F.; Brullo, C. at al. Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent
and selective inhibitors of A1 adenosine receptors. J. Med. Chem. 2005, 48, 7172–85.
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The importance of chirality to the biological activity of drug molecules is well precedented. In certain cases, the
stereochemical integrity of a raw material can be compromised during chemical processing steps used to manu-
facture starting material or drug substance. The development of pharmaceutical agents based upon adenosine
introduces four stereogenic centers in the ribosyl-moiety that may be impacted. Because 2-chloroadenosine serves
as an important starting material for a number of 2-modiﬁed adenosine analogues, we undertook the synthesis of
the four single-inversion epimers (1, 2, 3, and 4, respectively) of this key starting material. The syntheses of the 10-,
30-a n d4 0-epimers were accomplished by coupling an appropriately protected sugar molecule with 2,6-dichloro-
adenine, promoted by tin tetrachloride, followed by regioselective displacement of the 6-chloro group with am-
monia, and deprotection. The 20-epimer (2) was synthesized from commercially available 2-chloroadenosine by
inversion of the hydroxyl group at the 20-position. This poster will describe the synthesis and characterization of
these epimers, as well as a chromatographic method for the quantitation of their relative content in 2-chloroad-
enosine. These epimeric materials also serve as starting materials for the synthesis of the corresponding epimers
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There is now strong evidence that ATP induces a semi-maturation state of human monocyte-derived dendritic
cells via the activation of the P2Y11 receptor. In the same cells, ADP exerts partially similar effects via the
activation of Gi-coupled receptors, which have not been identiﬁed. Whereas the mouse is largely used for in vivo
studies of immunity and inﬂammation, very few data are available on the modulation of murine dendritic cells by
purines. We have shown that ADP"S increases cytosolic Ca
2+ in Flt-3 ligand-expanded splenic dendritic cells.
That response was abolished by AR-C69931MX and AR-C67085MX. It was also abolished in P2Y12
-/- but not in
P2Y13
-/- mice. ADP"S reduced the production of IL-12p70 by splenic dendritic cells stimulated by cell-bound
CD40 ligand. This inhibition was relieved by AR-C69931MX, which by itself increased the production of IL-12.
However the reduction by ADP"S was maintained in P2Y12
-/- and P2Y13
-/- mice. This might suggest that both
P2Y12 (via Ca
2+) and P2Y13 (via another signal) decrease IL-12. In bone marrow derived dendritic cells, ADP"S
inhibited the production of IL-12 induced by lipopolysaccharide. However that inhibition was resistant to AR-
C69931MX and MRS 2179, but it was abolished by 8-(p-sulfophenyl)theophylline. These studies show that mul-
tiple receptors play a role in the regulation of dendritic cells by purines, depending on species and subpopulation:
& in human monocyte-derived dendritic cells, ATP induces a semi-maturation state via activation of the P2Y11
receptor;
& in murine bone marrow derived dendritic cells, it is adenosine that plays a dominant role;
& in murine splenic dendritic cells, the P2Y12 receptor is functionally expressed, but another AR-C69931MX-
sensitive receptor, probably P2Y13, seems to be involved also in the action of ADP.
Targeted knockdown of cytosolic 50-nucleotidase (cN-II) with siRNA.
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Cytosolic 50-nucleotidase (cN-II) belongs to a family of proteins involved in the hydrolysis of intracellular nucl-
eotides. Members of this family differ widely in cellular location, substrate speciﬁcity, regulation and aminoacid
sequence (1). cN-II has been described as a bifunctional enzyme since catalyzes both the hydrolysis of IMP and
GMP and the transfer of phosphate from a mononucleotide donor to a nucleoside acceptor such as inosine,
guanosine, deoxyinosine and several nucleoside analogs in use as antiviral or antineoplastic purine prodrugs (2,3).
Furthermore, cN-II seems to be responsible for the resistance to several purine derivative drugs. Therefore, it
would seem that cN-II plays a fundamental role in the effectiveness of several purine drugs and its activity has
been indicated as predictive of patient survival in acute myeloid leukaemia (4,5). cN-II is ubiquitously present in
cells and organs and its involvement in the intracellular production of adenosine from AMP has been hypothe-
sized at least where cN-I (nucleotidase speciﬁc for AMP) is absent. We puriﬁed and characterized this enzyme
from different sources and obtained the bovine recombinant enzyme which presents a 99% homology with human
cN-II (6). We demonstrated that the enzyme catalyze the hydrolase/phosphotransferase reaction through the
formation of a covalent enzyme-phosphate intermediate and described its complex regulation depending on int-
racellular energy charge (7). Furthermore, on the bases of site directed mutagenesis we identiﬁed aminoacid
residues involved in catalysis (8, 9). In order to study the metabolic pathways in which this enzyme plays a
fundamental role and to unequivocally assess its involvement in adenosine production, we decided to utilize the
siRNA technique to obtain the cN-II knockdown. Here we report our more recent results on the silencing of cN-
II both in mouse and in human cells with the small interfering RNA technique, utilizing different viral vectors. We
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silencing proved to be lethal for cells we are now developing a viral vector harboring an inducible promotor.
1-Bianchi V., and Spychala J. (2003) Mammalian 50-nucleotidase. J.B.C. 278, 46196–46198
2-Banditelli S., Baiocchi C., Pesi R., Allegroni S., Turriani M., Ipata P.L. Camici M., Tozzi M.G. The phosphotransferase
activity of cytosolic 50-nucleotidase: a purine analogs phosphorylating enzyme. (1996) Int,J,Biochem.Cell Biol., 28, 711–720
3-Johnson M.A. and Fridland A. (1969) Phosphorylation of 20-30-dideoxyinosine by cytosolic 50-nucleotidase of human lymp-
hoid cells. Med. Pharmacol. 36, 291–205
4-Galmarini C.M., Mackey J.R., and Dumontet C. (2001) Nucleoside analogues: mechanisms of drug resistence and reversdal
strategies. Leukemia, 15, 875–890
5-Mackey J.R., Galmarini C., Graham K.A., Joy A.A., Delmer A., Dabbagh L., Giubrecht D., Jewel L.D., Lai R., Lang T.,
Hanson J., Young J.D., Merie-Beral H., Binet J., Cass C.E., and Dumontet C. (2005) Quantitative analysis of nucleoside
trasporter and metabolism gene expression in chronic lymphocytic leukaemia (CLL) identiﬁcation of fuldarabine sensitive
populations. Blood, 105, 767–774
6- Pesi R, Turriani M., Allegrini S., Scolozzi C., Camici M., Ipata P.L. and Tozzi M.G. (1994) The bifunctional cytosolic
50-nucleotidase:regulation of phosphotransferase and nucleotidase activities. Arch. Biochem. Biophys., 312, 75–80
7- Allegrini S., Pesi R., Tozzi M.G., Fiol C., Johnson B., and Eriksson S. (1997) Bovine cytosolic IMP/GMP speciﬁc
50-nucleotidase: cloning and expression of active enzyme in Eescherichia coli. Biochem.J 328, 483–487
8 Allegrini S., Scaloni A. Careddu M.G., Cuccu G., D_Ambrosio C., Pesi R., Camici M., Ferrara L., and Tozzi M.G.. (2004)
Mechanistic studies on bovine cytosolic 50-nucleotidase II Eur.J.Biochem 271, 4881–4691
The adenosine A2A receptor agonist CGS-21680 fails to ameliorate the course
of dextran sulphate-induced colitis in mice
Zsolt Selmeczy, E. Sylvester Vizi, Gyo ¨rgy Hasko ´
Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest,
Hungary
e-mail: selmeczy@koki.hu
Crohn_s disease and ulcerative colitis, collectively referred to as inﬂammatory bowel disease, are chronic spont-
aneously relapsing disorders of unknown cause. Several murine models of intestinal inﬂammation have an imp-
ortant role in the research of these disorders. One of the murine models of inﬂammatory bowel disease is colitis
induced by oral administration of dextran sulphate sodium (DSS). Some of the symptoms and pathophysiologic
features of DSS-induced colitis are similar to those found in human inﬂammatory bowel disease. Meanwhile, it is
well recognised that certain naturally occurring purines, mainly adenosine and its analogues, are effective mod-
ulators of the immune system. Physiological actions of adenosine result from its occupancy of cell surface aden-
osine receptors (A1,A 2A,A 2B,A 3), which are expressed on immune cells. As A2A receptors dominate in
mediating the anti-inﬂammatory effects of adenosine, in this study we investigated the effect of CGS-21680 (2-p-
(2-Carboxyethyl)phenethylamino-50-N-ethylcarboxamidoadenosine hydrochloride), an adenosine A2A receptor
agonist, in a model of DSS-induced colitis in NMRI mice. Mice were fed 5 (w/v) % DSS, and were treated
intraperitoneally with 0.5 mg/kg CGS-21680 or appropriate control (10 (v/v) % DMSO) for 10 days. Parameters
recorded in these experiments were body weight, colon length, and bleeding from rectum. Furthermore, levels of
two chemokines, macrophage inﬂammatory protein (MIP)-1! and MIP-2, as well as four proinﬂammatory cyto-
kines, interferon gamma (IFN+), interleukin (IL)-1", IL-12 and tumor necrosis factor-alpha (TNF-!) were dete-
rmined from homogenates of colon biopsies. DSS-induced colitis signiﬁcantly decreased body weight (control:
110.9 T 10.3% vs. DSS: 81.3 T 10.2%, P < 0.001) and colon length (control: 5.96 T 0.56 cm vs. DSS: 3.62 T 0.51 cm, P
< 0.001), and it increased the incidence of rectal bleeding compared to DSS-untreated animals. Treatment of DSS-
induced animals with CGS-21680 failed to affect these parameters (bodyweight, DSS: 81.3 T 10.2% vs. CGS+DSS:
76.2 T 8.3%; colon length, DSS: 3.62 T 0.51 cm vs. CGS+DSS: 3.69 T 0.47 cm). Among investigated chemokines
and cytokines, levels of MIP-1!, MIP-2 and IL-1" were elevated during DSS-induced colitis by 25-, 65- and 15-fold
compared with controls, respectively, while the concentrations of IFN+, IL-12 and TNF-! did not change following
CGS-21680 administration. CGS-21680 had no effect on the production of MIP-1!, MIP-2 and IL-1". According
to our results, CGS-21680 is ineffective in ameliorating DSS-induced colitis in mice.
Research was supported by a grant from Hungarian National R&D Programme 1A/036/2004.
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IMMMUNO-SUPPRESSION FOLLOWING TRAUMA
Charles C. Caldwell, Andre Martignoni, Maria Reid, Holly Goetzmann and Lisa Choi
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In ancient Greece, the treatment of trauma consisted of bandaging, immobilization of fractures, amputations, and
removal of foreign objects. Between this time and the present, exponential advances in treatment and understa-
nding the pathophysiology of trauma have resulted in historical increases in trauma patient outcome. However,
the trauma patient subsequently committed into the ICU faces a signiﬁcant possibility of multi-organ dysfunction
(MODS). Further, following trauma, the patient is susceptible to infections that would normally be cleared.
Hypoxic conditions are known to exist following trauma and during sepsis. Hypoxia leads to an increase of
extracellular adenosine. In leukocytes, activation of the adenosine A2a receptor (A2aR) increases intracellular
cAMP, which, in turn, inhibits inﬂammatory cytokine secretion and enhances anti-inﬂammatory cytokine release.
In our studies, we have induced trauma injury by inﬂicting mice with an 18% total body surface area dorsal scald
burn. Here, we show that this trauma results in a systemic inﬂammatory response that peaks at 12–24 hours as
measured by a 200-fold increase in serum IL-6. Following injury, splenic T cells show marked immunosuppression
as determined by ex vivo stimulation of T cells and measurement of the T cell-secreted cytokines IFN-gamma and
IL-4. As compared to T cells from sham animals, IFN-gamma secretion taken from traumatized animals decre-
ased by as much as 75%. In contrast, T cells taken from A2aR-deﬁcient animals showed some decreased interf-
eron-gamma production, but still 2-fold higher than T cells from sham animals. A common observation in the ICU
is that there is lymphocyte depletion following trauma injury. This is considered signiﬁcant in that it has been
recently demonstrated that the adoptive transfer of apoptotic lymphocytes worsens survival during sepsis due to
increased immunosuppression. Here, we show similar reduction of IFN-gamma production in T cells from mice
one day after only being injected with apoptotic lymphocytes. Thus, we conclude that adenosine, acting through
the A2aR, plays a role in increasing immunosuppression following trauma, possibly by exacerbating a bystander
effect driven by apoptotic lymphocytes through an undetermined mechanism. We expect that pharmacological
treatment with A2aR antagonists will result in less immunosuppression coupled with less susceptibility to subs-
equent infections. Support: SHC Project 8560
The adenosine A2a receptor is pro-apoptotic in lymphoyctes following trauma
Andre Martignoni, Maria Reid, Holly Goetzmann, Lisa Choi and Charles C. Caldwell
Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267; and Department of
Research, Shriner_s Hospital for Children, Cincinnati, Ohio 45229. E-mail: Andre.Martignoni@med.uni-muen-
chen.de
Trauma leads to a number of systemic physiological changes associated with alterations in the immune system. In
injuries, the systemic inﬂammatory response syndrome (SIRS) is ﬁrst observed, followed by the compensatory
anti-inﬂammation response syndrome (CARS). These systemic effects include tissue damage, inﬂammation, ly-
mphocyte apoptosis, and subsequently, immunosuppression. Of the leukocytes that are involved in SIRS and
CARS, the macrophage and the lymphocyte play important roles. It is known that the adenosine A2a receptor
(A2aR) is expressed on these cells. The A2aR mediates leukocyte functions by increasing the intracellular con-
centration of cAMP. It has been reported that corticosteroids and increased intracellular cAMP cooperate syn-
ergistically to cause the loss of lymphocyte viability
1. Further, it has been shown that the pro-apoptotic molecule
Bim was upregulated using a cAMP agonist in dexamethasone-treated lymphomas
2. This is considered signiﬁcant
in that it has been recently demonstrated that the adoptive transfer of apoptotic lymphocytes worsens survival
following trauma due to increased immunosuppression
3. In our studies, we have induced trauma injury by inﬂi-
cting mice with an 18% total body surface area dorsal scald burn. Here, we show that this trauma results in a 90%
depletion of the total number of splenic naive T and follicular B lymphocytes within one day of the trauma.
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strands with exposed 30-hydroxyl ends, a hallmark of late stage apoptosis. However, in this model, there was a
signiﬁcant reduction of lymphocyte depletion in mice either genetically or pharmacologically devoid of the A2aR.
This is signiﬁcant in that we and others have shown that lymphocytes are protective against a subsequent infection
following injury. Thus, adenosine, acting through the A2aR, plays a role in increased lymphocyte depletion
following trauma. Altogether, we expect that antagonism of the A2aR, either genetically or pharmacologically,
will decrease the anti-inﬂammatory phenotype following thermal injury, at least partially by decreasing lympho-
cyte apoptosis. We expect that this antagonism will then enhance survival during the subsequent infection.
Support: SHC Project 8560.
1. Gruol, D. J.; Altschmied, J., Synergistic induction of apoptosis with glucocorticoids and 30,50-cyclic adenosine mono-
phosphate reveals agonist activity by RU 486. Mol Endocrinol 1993, 7, (1), 104–13.
2. Zhang, L.; Insel, P. A., The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocort-
icoid-promoted apoptosis of lymphoid cells. J Biol Chem 2004, 279, (20), 20858–65.
3. Hotchkiss, R. S.; Chang, K. C.; Grayson, M. H.; Tinsley, K. W.; Dunne, B. S.; Davis, C. G.; Osborne, D. F.; Karl, I. E.,
Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves sur-
vival in sepsis. Proc Natl Acad Sci U S A 2003, 100, (11), 6724–9.
The carboxyl terminus of the A2A-adenosine receptor is a docking site
for several interaction partners
I. Gsandtner, V. Reiterer, T. Kirpenko, E. Stefan, C. Charalambous, M. Freissmuth, J. Zezula, C.
Nanoff, O. Kudlacek
Institute of Pharmacology, Center for Biomolecular Medicine and Pharmacology, Wa ¨hringer Straße 13a; A-1090
Vienna, Austria
E-mail: ingrid.gsandtner@meduniwien.ac.at
The A2A adenosine receptor is a prototypical Gs-coupled receptor and has an extended carboxyl terminus. Tru-
ncation of the C-terminus by 100 amino acids has only very modest effects on the signalling pathways controlled
by the receptor (i.e. the Gs-induced cAMP accumulation and stimulation of mitogen-activated protein (MAP)
kinase, which is independent of heterotrimeric G proteins). In order to understand the biological function of the
long C-terminus, we screened a human library for proteins that bind to the last 120 amino acids of the A2A
receptor. Using the appropriate LexA-fusion protein, we identiﬁed several potential binding partners, including
ARNO/cytohesin-2, (a nucleotide exchange factor for the small G protein Arf6), the deubiquitinating enzyme
USP4 and SAP102, a protein that belongs to the MAGUK (membrane associated guanylat kinase-like domain)
proteins. The interaction site was mapped by employing baits comprising C-termini of varying length: USP4
required the distal portion of the carboxyl terminus, because it failed to bind to truncated LexA fusion proteins
which lacked the last 50 or 100 amino acids. In contrast, ARNO/cytohesin-2 bound to the proximal segment, i.e.
the ﬁrst 20 amino acids adjacent to the 7th transmembrane domain of the receptor. All interactions were conﬁ-
rmed by pull-down assays and by co-immunoprecipitation. The following functional effects were assigned to the
interactors: USP4 greatly enhanced cell surface expression of the receptor by relaxing overprotective quality
control in the ER; this was associated with an increased accumulation of cAMP after agonist stimulation. ARNO/
cytohesin-2 or its catalytic inactive mutant did not alter the level of A2A receptor expression, and did not affect
Gs-dependent stimulation of adenylyl cyclase. This was also true for agonist induced receptor desensitisation.
However, the presence of ARNO/cytohesin-2 was required for alternative (i.e. Gs-independent) signalling to
mitogen activated kinase (MAP kinase). This conclusion was based on the following observations: (i) dominant
negative ARNO and (ii) dominant negative Arf6 efﬁciently suppressed sustained phosphorylation of MAP kinase,
while (iii) brefeldin A (an inhibitor of other sec7-containg ARF-GEFs) did not affect the time course of MAP
kinase stimulation. SAP102 interacted with the A2A-receptor via its (catalytically inactive) GUK domain and
colocalized with A2A-adenosine receptor in dendritic spines of hippocampal neurons.
These results demonstrate that the extended carboxyl terminus of the A2A-adenosine receptor subserves a role
that is irrelevant to G protein coupling. It is however a docking site of several proteins that are relevant to sorting,
targeting and prolonged signalling.
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The nucleoside, adenosine, plays multiple roles in the efﬁcient functioning of the heart by regulating coronary
blood ﬂow, cardiac pacemaking and the contractility of the heart. It is produced by the cardiac myocardium under
stress and acts as a major local autocrine and paracrine regulator of tissue function in situations of reduced oxygen
supply relative to demand. In the mammalian heart the release and uptake of nucleosides such as adenosine is
mediated by members of the equilibrative nucleoside transporter (ENT) or SLC8 family. The results of probing a
multiple tissue expression RNA array with an oligonucleotide corresponding to a portion of the hENT4cDNA
demonstrated that ENT4, a recently identiﬁed member of the equilibrative nucleoside transporter family is widely
distributed in human tissues, but is particularly abundant in the heart, brain and skeletal muscle. A quantitative
survey of the distribution of rENT4 in distinct regions of the rat heart was conducted using densitometry of
Western blots of whole tissue lysates probed with afﬁnity puriﬁed anti-peptide antibodies raised against residues
301–319 of hENT4: the transporter was more abundant in the ventricular than the atrial tissue and virtually absent
from the SA and AV nodes. Using the speciﬁc antibodies to hENT4301–319 and immunoﬂuorescence microscopy of
endothelial and cardiac cells, it was revealed that in contrast to ENT3, but like ENT1 and ENT2, the human-,
mouse- and rat- ENT4 proteins, hENT4, mENT4 and rENT4 respectively, all have a predominantly plasma
membrane location. Characterization of the transporter activity in Xenopus oocytes and in mammalian cells
revealed the protein to be a low afﬁnity adenosine transporter. It was partially sensitive to the nucleoside trans-
porter inhibitors dipyridamole and dilazep, insensitive to nitrobenzylthioinosine (nitrobenzylmercaptopurine ri-
boside; NBMPR), and strongly dependent upon pH, the optimum pH value of mENT4 and hENT4 activity being
5.5 and 6.0, respectively.The presence in the heart of a purine nucleoside transporter able to function optimally at
acidic pH might aid restoration of normoxia following, for example, an ischaemic attack when the blood pH may
fall as low as 6.6 or below. In contrast, ENT4-mediated serotonin inﬂux was not proton-dependent, similar activity
being recorded at both acidic and physiological pH. We propose that ENT4 is a cell surface protein that in
addition to its published role as an organic cation transporter is a genuine nucleoside transporter.
THE EFFECT OF ANOXIA AND ADENINE NUCLEOTIDE POOL
ON NUCLEOTIDE RELEASE FROM ERYTHROCYTES
Ewa M Slominska
1), Magdi H Yacoub
2), Ryszard T Smolenski
1,2)
1) Department of Biochemistry, Medical University of Gdansk, Poland.
2) Heart Science Centre, Imperial College at Hareﬁeld Hospital, U.K.
eslom@amg.gda.pl.
ATP release from the erythrocytes has recently been found to be linked to haemoglobin oxygenation status and
suggested as the mechanism that controls vascular tone and other P2 receptor dependent processes such as
platelet aggregation or cell migration and proliferation. However, little is known about the metabolic factors that
affect erythrocyte ATP release. One of the crucial elements could be adenine nucleotide pool in the erythrocytes.
This is particularly relevant to pathological conditions such as chronic renal failure or erythrocyte AMP deami-
nase deﬁciency where elevation of erythrocyte ATP concentration has been observed or Tarui_s disease and 50-
nucleotidase superactivity where depletion of erythrocyte ATP was noted. We aimed therefore to evaluate wh-
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and anoxic conditions.
Fresh washed human erythrocytes were ﬁrst preincubated for 120 min in Hepes buffered, 2% albumin supple-
mented Krebs solution containing 5 mM adenosine and 5 mM ortophosphate to increase ATP pool (A) while 5
mM ortophosphate was used in controls (C). At the end of preincubation erythrocytes were washed and both A
and C cells were incubated for a further 90 min under air oxygen tension (OA, OC) or in CO2 supplemented
anoxic environment induced with BD Gaspak system (DA, DC). At the end of incubation, erythrocytes and
incubation medium were rapidly separated and analysed for ATP and its metabolites content by HPLC.
Preincubation with adenosine and orthophosphate in A resulted in elevation of the ATP concentration to 2370 T
40 2mol/l erythrocytes as compared to 1170 T 18 2mol/l erythrocytes in controls (C) (n = 5, T SEM, p<0.001. No
differences in GTP or NAD concentrations were observed. This was accompanied by increased in extracellular
ATP concentration from 0.50 T 0.05 to 0.68 T 0.08 2mol/erythrocytes l (p<0.05) under normoxic conditions and
from 3.42 T 0.59 to 7.10 T 1.90 2mol/l erythrocytes (P<0.05) during anoxia after 90 min incubation. No GTP, NAD,
haemoglobin or lactate dehydrogenase release has been observed.
We conﬁrmed that hypoxia induces ATP rerlease from the erythrocytes. Furthermore, we have demonstrated
here that erythrocyte ATP pool is additional factor that controls the extracellular ATP concentration. Changes in
the disease conditions that affect erythrocyte nucleotide pool such as renal failure could affect signaling mediated
by erythrocyte ATP release. On the other hand the effect we demonstrated here provides opportunity to control
ATP mediated signaling by regulation of erythrocyte nucleotide pool.
The Effects of Metabolic Stimulators and Inhibitors on Histamine-Induced
ATP Release in HaCaT Cells.
H.E.Burrell, J.A. Gallagher & A.W.M. Simpson.
Department of Human Anatomy & Cell Biology, School of Biomedical Sciences, The Sherrington Buildings,
Ashton Street, Liverpool, L69 3GE, U.K.
Email: H.E.Burrell@liv.ac.uk
Extracellular nucleotides, acting via P2 receptors, are regulators of important cellular functions such as prolifer-
ation, differentiation and apoptosis. In the epidermis, activation of the P2Y2 receptor results in an increase in
proliferation in the basal layer, while the P2X5 receptor is involved in differentiation in the granular layer, and the
P2X7 receptor is conﬁned to the apoptotic corniﬁed layer. Extracellular nucleotides are also released from cells
via a variety of postulated mechanisms. These principally fall into two groups: anion channels and exocytosis.
While the production of ATP by mitochondria and its subsequent release into the cytoplasm has previously been
studied [1], the effect of changes in cytosolic ATP on ATP release have not been investigated. In this study, we
have investigated the effects of different metabolic stimulators and inhibitors on ATP release from the HaCaT
keratinocyte cell line. HaCaT cells were seeded into 12 well plates at a density of 1   10
5 cells per well and
allowed to adhere and grow overnight until conﬂuence. Cells were then washed with warm PBS and serum-
starved in 0.5 ml HEPES-buffered saline for 1 hour prior to treatment. The medium bathing the cells was then
sampled (200 2l) in duplicate and the ATP content analysed using luciferin-luciferase luminometry in a Berthold
tube luminometer [2]. We have previously reported that HaCaT cells release ATP under static, unstimulated
conditions [2]. We now show that release can be concentration-dependently stimulated by addition of histamine
(100–10,000 nM). The time-course of ATP release (0–5 minutes) also differs depending on the concentration of
histamine. While low concentrations of histamine (100 nM) induce a spike of ATP release lasting for a period of
seconds, high histamine concentrations (10,000 nM) induce a longer release of ATP, which lasts for a period of
minutes. We postulate that these differences reﬂect previously published changes in [Ca
2+]i signalling [1]. Hista-
mine-induced ATP release is concentration-dependently stimulated by addition of glucose (5–15 mM, when
added for 1 hour prior to addition of histamine) or 1 mM sodium succinate (added for 2 minutes prior to hista-
mine) in comparison with glucose or sodium succinate alone. Conversely, histamine-induced ATP release is
inhibited by addition of 1 mM extracellular calcium in the presence or absence of glucose (added for 1 hour prior
to addition of histamine), indicating that ATP release from HaCaT cells is unlikely to occur via exocytosis and
may occur through hemichannels [3]. Addition of oligomycin (6 2M) for 5 minutes prior to addition of histamine
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ulation or inhibition of mitochondrial ATP production directly affects ATP release by the cells.
1) Jouaville, L.S., Pinton, P., Bastianutto, C., Rutter, G.A. & Rizzuto, R. (1999). Proc. Natl. Acad. Sci. USA 96: 13807–13812.
2) Burrell, H.E., Wlodarski, B., Foster, B.J., Buckley, K.A., G. R. Sharpe, Quayle, J.M., Simpson, A.W.M. & Gallagher, J.A.
(2005). J. Biol. Chem. 280: 29667–29676.
3) Bahima, L., Aleu, J., Elias, M., Martin-Satue, M., Muhaisen, A., Blasi, J., Marsal, J. & Solsona, C. (2006). J. Cell Physiol.
206: 95–102.
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Ecto-nucleotidase triphosphate diphosphohydrolase (E-NTPDase) is a family of enzymes that catalyse the dep-
hosphorylation of extracellular nucleotides and thus regulate the signalling function of P2 receptors (1). In the
cochlea, P2X and P2Y receptors are associated with regulation of sound transduction, electrochemical homeos-
tasis, blood ﬂow and auditory neurotransmission (2). There is also evidence that changes in purinergic and pyri-
midinergic signalling may be associated with cochlear pathology and hearing loss (3). The distribution of
membrane-bound NTPDase1 and NTPDase2 in cochlear tissues has been established and is consistent with
regulation of extracellular nucleotide concentrations and a putative otoprotective role (4). In contrast to other
E-NTPDase family members that contain two transmembrane regions, NTPDase5 and NTPDase6 lack the
C-terminus and can be cleaved to produce a soluble protein. Both enzymes are located intracellularly, but have
intra- and extracellular functionality as they can be released from cells. NTPDase5 and 6 have high preference for
nucleoside 50-diphosphates, such as UDP and GDP (5,6).
Methods: This study investigates the expression of NTPDase5 and NTPDase6 mRNAs (RT-PCR) in the rat
cochlea, and their distribution in cochlear tissues (Western blotting, immunohistochemistry). Enzyme localisation
was determined using polyclonal antibodies raised in rabbits by the injection of the encoding cDNA or the
enzyme-speciﬁc peptide.
Results and conclusion: Immunoperoxidase histochemistry and confocal immunoﬂuorescence demonstrated NT-
PDase5-speciﬁc immunolabelling in the perikarya of the primary auditory neurones in the spiral ganglion and
their central neural processes. NTPDase5 may be required for termination of extracellular UDP signalling via
P2Y6, and possibly P2Y14 receptor subunits associated with auditory neurotransmission. In the organ of Corti,
NTPDase5 is localised to the supporting Deiters_ cells, inner border cells and inner phalangeal cells surrounding
the sensory hair cells. These cells are known to express UTP/UDP-preferring P2Y receptor subunits, suggesting
the involvement in regulation of UDP signalling associated with sensory transduction and cochlear ampliﬁcation.
By contrast, NTPDase6 expression is conﬁned to the cytoplasm of the inner hair cells. Intracellular distribution of
NTPDase6 resembles the localisation of the glycogen stores in the inner hair cells, suggesting a role for this
soluble enzyme in the glycosylation of proteins and lipids that may be required for sensory transduction. Funct-
ional studies characterising the respective roles of NTPDase5 and NTPDase6 in cochlear function are underway.
Supported by the Auckland Medical Research Foundation and Health Research Council of New Zealand.
1. Zimmermann, H. (2001) Drug Development Research, 52, 44–56.
2. Housley GD et al. (2002) Audiology & Neuro-Otology, 7, 55–61.
3. Thorne PR et al (2002) Audiology & Neuro-Otology, 7, 180–184.
4. Vlajkovic SM et al. (2004) Neuroscience, 126, 763–773.
5. Mulero, JJ et al. (1999) Journal of Biological Chemistry, 274 (29), 20064–20067.
6. Braun, N. et al. (2000) Biochemical Journal, 351, 639–647.
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Glutamate is the main excitatory neurotransmitter in mammalian CNS, essential for brain activities, as those
involved in development, aging, memory, and adaptation to the environment. However, hyper-activation of the
glutamatergic system may be potentially neurotoxic, involved in the pathogenesis of various acute and chronic
brain injuries.
Our group has given strong evidence that the guanine-based purinergic system is effectively neuroprotective
against glutamate toxicity, in acute and chronic animal models, both in vitro and in vivo studies. Although the
administration of guanine derivatives (GD) exerts neuroprotection, our results strongly indicate that the active
compound is the nucleoside guanosine (GUO).
In in vivo studies carried out in rat and mouse, GD protect against brain damage caused by hyper-activation of the
glutamatergic system. Indeed: i) chronically, GMP administration in rat striatum protects cells against death
caused by quinolinic acid (QA); ii) acutely, GMP or GUO i.c.v., i.p. or orally administered protect against
seizures induced by QA (or !-dendrotoxin). In in vitro studies carried out in brain slices, GUO protects cell
against death caused by in vitro ischemia.
Searching for mechanisms implicated in this neuroprotection, we demonstrated that: i) GUO stimulates the ast-
rocytic glutamate uptake (in astrocyte cultures and brain slices), the main process involved in endogenous neu-
ronal protection; ii) QA induced-seizures decrease glutamate uptake by cortical brain slices and this decrease is
reversed by GUO when it acts as anticonvulsant; iii) Brain ischemia decreases glutamate uptake by hippocampal
slices and i.p. GUO administration prevents this decrease. Thus we propose that the stimulatory effect on glut-
amate uptake is involved in the neuroprotective actions of GUO.
These results encourage further studies aiming at the therapeutic use in humans of GUO in acute (hypoxia,
ischemia, brain traumatism) and chronic (neurodegenerative diseases) brain injuries involving glutamate excito-
toxicity.
The immune-response modiﬁer imiquimod is an adenosine receptor antagonist
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Imiquimod is an imidazoquinoline derivative which is in use for topical treatment of skin diseases. It acts as an
immune-response modiﬁer and has shown antiviral and antitumoral activity both in vitro and in clinical applica-
tions. A number of studies have shown that imiquimod and related compounds mediate their effects on immune
responses through activation of toll-like receptors TLR7 and/or TLR8. Activation of the NF-.B pathway ultim-
ately leads to an increased production of cytokines like TNF!, IL-2, IL-6, IL-12, GM-CSF, TNF!, and chemok-






SpringerThe structure of imiquimod resembles the large family of adenosine receptor antagonists that is derived form the
nonselective triazoloquinazoline compound CGS 15943. Therefore, we determined binding afﬁnity of imiquimod
at adenosine receptors in CHO cells stably transfected with the human subtypes. In addition, their effect on
adenylyl cyclase activity was tested in order to establish their potential functional role in adenosine receptor-
mediated signal transduction.
In competition binding experiments we found that imiquimod binds to A1 receptors with a Ki of 2.9 2M, to A2A
receptors with a Ki of 2.2 2M, and to the A3 subtype with a Ki-value of 14.6 2M. A potential interaction with the
A2B adenosine receptors was investigated in adenylyl cyclase studies. In concentrations up to 100 2M no effect of
imiquimod on cyclase activity was detected. However, 100 2M imiquimod caused an about 30–50% inhibition of
NECA-stimulated cyclase activity suggesting that it acts as a weak A2B antagonist. Likewise, we could not detect
activation of adenylyl cyclase in CHO cells transfected with A2A adenosine receptors, again suggesting that
imiquimod is a receptor antagonist. In CHO cells stably transfected with A1 or A3 adenosine receptors a small but
reproducible inhibition of forskolin-stimulated cyclase activity was observed. Although this observation may su-
ggest that imiquimod exhibits some partial agonistic activity at these subtypes, experimental evidence argues
against such a notion: Imiquimod inhibits forskolin-stimulated cyclase activity in untransfected CHO cells or in
A2A-CHO cells to the same degree as in A1-CHO or A3-CHO cells. These results suggest that imiquimod is a
nonselective adenosine receptor antagonist which, in addition to the adenosine receptor-mediated effects, shows
an inhibitory effect on adenylyl cyclase activity downstream from the G protein-coupled adenosine receptors.
We have characterized the immune-response modiﬁer imiquimod as a nonselective adenosine receptor antagonist
with afﬁnity to the receptor subtypes comparable to the prototypical xanthine antagonist theophylline. The blo-
ckade of A2A adenosine receptors may contribute to the pro-inﬂammatory response which is induced by imiqu-
imod. The additonal receptor-independent effect on cAMP levels may add a further complementary mechanism
resulting in the intense inﬂammatory response that is observed in clinical treatment with imiquimod.
The mobility of the A2A receptor is not restricted by the actin cytoskeleton
C. Charalambous, L. Milan-Lobo, I. Gsandtner, O. Kudlacek, H. Farhan,
J. Zezula, H.H. Sitte, M. Freissmuth
Institute of Pharmacology, Center of Biomlecular Medicine & Pharmacology. Medical University of Vienna
Wa ¨hringer Str. 13a; A-1090 Vienna, Austria
Christoforos.charalambous@meduniwien.ac.at
The A2A-adenosine receptor is a prototypical Gs-protein coupled receptor. The A2A-adenosine receptor has long
been known to activate adenylyl cyclase in a manner inconsistent with collision coupling (1). In contrast, many
other Gs-coupled receptors such as the "2-adrenergic receptor activate cAMP formation with kinetics consistent
with a random walk and collision coupling (2). We have investigated the basis of this phenomenon by determining
the diffusion rate of the A2A-receptor tagged with the yellow ﬂuorescent protein (YFP) and heterologously
expressed in HEK293 cells. The YFP-moiety was bleached and ﬂuorescence recovery after photobleaching (F-
RAP) was measured by confocal laser microscopy. As a control, we employed the YFP-tagged CRF-receptor-2,
which is similar in size as the A2A-receptor. We also veriﬁed that both, the A2A-receptor and the CRF-receptor-2
form homodimers (assessed by ﬂuorescence resonance energy transfer, =FRET-microscopy, using YFP and CFP-
tagged versions of the receptors). Under basal conditions, i.e. in the absence of agonist, ﬂuorescence recovered
with comparable half-lives (t/2 = ~10 s) for the two receptors. Upon agonist activation, the mobility of the CRF-
receptor increased; this effect was however absent in the A2A-receptor. It has been proposed that the C-terminus
of the A2A-receptor is linked to the actin cytoskeleton via binding of !-actinin (3). In addition, the C-terminus of
the A2A-receptor binds to ARNO/cytohesin-2, which is an exchange factor for Arf6 (which regulates the actin
cytoskeleton, ref 4). We have therefore tested whether manipulations of the actin cytoskeleton affected the
mobility of the receptor: (i) treatment of cells with latrunculin A to disrupt the cortical actin, (ii) expression of the
receptor in the absence and presence of wild type and dominant negative ARNO to manipulate the ability of the
receptor to signal to cortical actin, (iii) truncation of the C-terminus of the receptor to affect its ability to bind to
!-actinin. None of these manipulations had a detectable effect on the FRAP lifetime of the wild type receptor and
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Springerits mutated versions. We therefore conclude that the restricted collision coupling mode is a property speciﬁed by
the core of the receptor and unrelated to the actin cytoskeleton.
References:
1. Braun S, Levitzki A. (1979) Adenosine receptor permanently coupled to turkey erythrocyte adenylate cyclase. Biochemistry
18:2134–2138
2. Rimon G, Hanski E, Braun S, Levitzki A. (1978) Mode of coupling between hormone receptors and adenylate cyclase
elucidated by modulation of membrane ﬂuidity. Nature 276:394–396
3. Burgueno J, Blake DJ, Benson MA, Tinsley CL, Esapa CT, Canela EI, Penela P, Mallol J, Mayor F Jr, Lluis C, Franco R,
Ciruela F (2003) The adenosine A2A receptor interacts with the actin-binding protein !-actinin. J Biol Chem 278:37545–37552
4. Gsandtner I, Charalambous C, Stefan E, Ogris E, Freissmuth M, Zezula J (2005) Heterotrimeric G protein-independent
signaling of a G protein-coupled receptor. Direct binding of ARNO/cytohesin-2 to the carboxyl terminus of the A2A aden-
osine receptor is necessary for sustained activation of the ERK/MAP kinase pathway. J Biol Chem. 280:31898–31905
The N-terminal fatty amino acid 6-methylheptanoic/octanoic-DAB is crucial
for polymyxin B-mediated modulation of P2X7 receptor functions in immune
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We previously showed
1 that the antibiotic polymyxin B (PMB), which binds to and neutralizes the toxic residue of
bacterial lypopolysaccharide (LPS), greatly ampliﬁes cellular responses mediated by the P2X7 receptor (P2X7R).
However, the molecular mechanism involved was not elucidated. In the present study we show that PMB effects
depend on the presence of its N-terminal fatty amino acid 6-methylheptanoic/octanoic-diaminobenzoic residue as
deletion of this residue abolished PMB-dependent modulation of ATP triggered responses in HEK293 stably
expressing the P2X7 receptor (HEK293-hP2X7). In contrast to PMB, the polymyxin B nonapeptide (PMBN),
which is the deacylated amino derivative of PMB lacking the N-terminal fatty amino acid 6-methylheptanoic/
octanoic-diaminobenzoic residue, was unable to potentiate a) the ATP-induced Ca
2+ increase, b) pore formation
and consequently ATP-mediated plasma membrane permeabilization, and c) ATP-dependent cytotoxicity also in
natively expressing P2X7 cells such as human macrophages. In addition, PMBN was unable to revert the effect of
the P2X7 reversible blocker KN-62 and did not induce cell fusion. However, PMBN was partially active when the
more potent P2X7R agonist benzoylbenzoyl-ATP (BzATP) was used in place of ATP. In summary, our data show
that interaction of PMB with P2X7R depends on the presence of the highly hydrophobic N-terminal region of this
antibiotic.
1. Ferrari, D., C. Pizzirani, E. Adinolﬁ, S. Forchap, B. Sitta, L. Turchet, S. Falzoni, M. Minelli, R. Baricordi, and F. Di Virgilio.
2004. The antibiotic polymyxin B modulates P2X7 receptor function. J. Immunol. 173:4652.
THE ROLE OF PHOSPHORYLATED P38 MAPK IN THE PROTECTIVE
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SpringerActivation of either A1 adenosine receptor (A1R) or A3 adenosine receptor (A3R) elicits protection against
infarction, ischemia or hypoxia. The mechanism of this protection is not fully understood. Recently it was also
shown that ischemic preconditioning attenuated ischemia/reperfusion (I/R)-induced cardiac dysfunction through
modulation of p38 MAPK. The purpose of this study is to investigate the involvement of p38 MAPK in the
mechanism of adenosine receptor activation in cardioprotection in cardiomyocyte cultures as well as in the whole
heart.
Cultured cardiomyocytes were incubated with SB203580 (a speciﬁc inhibitor for phosphorylated p38) for 15 min,
then treated with CCPA or Cl-IB-MECA (the agonists of A1 and A3 adenosine receptors, respectively) before
being subjected to 90 min hypoxia. Levels of LDH released from the cells, and ATP content were measured.
Phosphorylated p38 MAPK was examined using Western blot analysis on both cell culture and isolated rat hearts
that were injected with CCPA or Cl-IB-MECA (10 nM) 24 hours before I/R.
Results: Both A1R and A3R agonists reduced hypoxia-induced injury both in vivo and in-vitro. How-
ever, when SB203580 was given together with these agonists, the protection was prevented as revealed
by LDH release, ATP content and mitochondrial membrane potential. It was also shown that phosp-
horylated p38 appeared only in heart pretreated with adenosine receptor agonists.
Conclusions: CCPA and Cl-IB-MECA protect both cell culture and isolated hearts against ischemia.
This protection was partially related to the increased phosphorylation of p38 MAPK before and during
ischemia. It is known that phosphorylation of p38 MAPK activates intracellular signaling which protects
the cytoskeleton against degradation.
Ticlopidine and clopidogrel affect vascular smooth muscle cell proliferation
in culture
M. Montopoli, E. Ragazzi, L. Caparrotta and G. Froldi
Department of Pharmacology and Anesthesiology - Pharmacology Division- Largo E. Meneghetti 2, University of
Padova. E-mail: monica.montopoli@unipd.it
Extracellular nucleotides have been shown to mediate the proliferation and migration of vascular smooth muscle
cells (VSMC) involved in intimal lesions following vascular injury. Ticlopidine and clopidogrel are prodrugs that
are converted in the liver into irreversible antagonists of P2Y12 receptors, having the highest expression among
the P2 receptors in platelets. The aim of our research was to study direct effects of thienopyridines on VSMC
proliferation. We carried out experiments in VSMC derived from rat aorta and cell vitality was measured by MTT
test. 1 2M Ticlopidine per se decreased cell proliferation, whereas at 100 2M it signiﬁcantly stimulated VSMC
proliferation (Figure). Incubation of VSMC with ticlopidine (1–100 2M) and 50 2M ADP, a well known activator
of VSMC proliferation, added up effects of single substances. 2-MethioADP (0.1–1 2M), a stable analogue of
ADP with high afﬁnity to P2Y1 and P2Y12 receptors, only slightly increased VSMC proliferation. 0.1 2M
2-MethioADP did not modify effects of ticlopidine (1–100 2M) on VSMC proliferation. 1 and 10 2M Clopidogrel
slightly decreased SMC proliferation, whereas at 100 2M an increased proliferation was evidenced (+140% T 7).
The effects induced by clopidogrel were not affected by the presence of 50 2M ADP or 0.1 2M 2-MethioADP; as
for ticlopidine, no inhibition between adenine nucleotides and clopidogrel on the VSMC proliferation was evid-
enced. It has been shown that clopidogrel signiﬁcantly inhibits intimal proliferation after arterial injury in rabbit
by unknown mechanisms (1) and it has been suggested that ticlopidine enhances the interleukin 1"-stimulated NO
release in cultured rat smooth muscle cells via cAMP- and pKA-dependent mechanism (2). Our experimental
data indicate that thienopyridines, without hepatic biotrasformation, can directly inﬂuence vascular cell growth in
culture, since both ticlopidine and clopidogrel at micromolar concentrations inhibit VSMC proliferation, whereas
at higher concentrations stimulate it. Also our results indicate that thienopyridines action is independent from
P2Y1 and P2Y12 receptors. Further researches on the proliferative effects of the two antiplatelet drugs are under
evaluation.
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Toll-Like Receptors (TLRs) Synergistically Enhance Adenosine A2A Receptor
(A2AR)-Mediated Induction of a Switch in Macrophages from an Inﬂammatory
to an Anti-Inﬂammatory, Angiogenic Phenotype.
S. Joseph Leibovich, Ph.D.
*, Thomas W. Lysz, Genie Elson, Grace Pinhal-Enﬁeld, Ph.D., Joseph
Quispe, and Stan Grinberg
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TLR2, 4, 7 and 9 agonists synergize with A2AR agonists to induce a phenotypic switch of macrophages from an
inﬂammatory to an anti-inﬂammatory, angiogenic phenotype
1, 2. This switch strongly up-regulates expression of
VEGF, IL-10 and sphingosine kinase-1 (SK-1), while strongly down-regulating expression of TNF!, IL-12, MIP1!
and matrix metalloproteinase-9 (MMP9). Up-regulation of VEGF expression is mediated at both the transcrip-
tional and mRNA stability levels, and involves the induction of expression of Hypoxia-Inducible Factor-1! (HIF1-
!) mRNA and stabilization of HIF1-! protein. The Hypoxia Response Element (HRE) in the promoter of the
VEGF gene is critically required for the A2AR-depenent induction of VEGF transcription, while putative NF-.B
sites in this promoter are not. In contrast, the down-regulation of TNF! expression by A2AR agonists is mediated
at the translational level rather than transcriptionally, and is also independent of NF-.B activation. As reported
by Murphree et al
3, TLRs up-regulate expression of A2ARs, as well as of A2BRs on macrophages, and this up-
regulation may play an important role in the angiogenic switch. The TLR and A2AR-dependent induction of
VEGF expression is not blocked by adenylyl cyclase inhibitors (SQ22536, 20,50-dideoxyadenosine), by Protein
Kinase-A (PK-A) inhibitors, or by MAP-kinase inhibitors, suggesting a cAMP/PK-A independent signaling
pathway. Also, speciﬁc inhibitors of Gs! signaling such as NF449, do not block the up-regulation of VEGF or
down-regulation of TNF! expression. In contrast, inhibition of myo-inositol speciﬁc phospholipase-C (PL-C) with
selective inhibitors suggests that PL-C signaling is speciﬁcally involved in both the up-regulation of VEGF tran-
scription and the down-regulation of TNF! expression. Speciﬁc ablation of PL-C" isoforms using siRNA in
LPS-treated macrophages suggests a key role for the PL-C"2 isoform in this pathway. Ablation of PL-C"2
strongly up-regulates expression of VEGF in LPS-treated macrophages, while simultaneously down-regulating
TNF!-expression, thus mimicking the effects of A2AR agonists. This suggests an important role for PL-C"2
signaling in the regulation of the switch of macrophages from an inﬂammatory to an anti-inﬂammatory, angio-
genic phenotype.
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Two new pathways of AMP-activated protein kinase (AMPK) activation
in endothelial cells. Involvement of P2 receptors and adenosine transporters.
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AMPK plays a key role in the regulation of energy homeostasis and is activated in response to cellular stress,
including hypoxia/ischemia and hyperglycemia. AMPK is a heterotrimeric Ser/Thr kinase consisting of a catalytic
alpha subunit and regulatory beta and gamma subunits. Depletion of ATP followed by an increase in the AMP
level and AMP:ATP ratio lead to activation of AMPK. However, AMPK can also be phosphorylated and acti-
vated by the mechanism independent of changes in the AMP:ATP ratio. AMPK is activated allosterically by
AMP and by phosphorylation of Thr-172 on the alpha subunit, which is catalyzed by upstream kinases, including
LKB1 and Ca
2+/calmodulin-dependent kinase kinase (CaMKK). Activated AMPK turns on catabolic pathways
that generate ATP and turns off pathways that consume ATP by phosphorylation of multiple targets. Since
AMPK is essential in controlling the metabolism of glucose and fatty acids, its role in obesity and type 2 diabetes
is of major importance. AMPK is expressed in skeletal muscle, brain, liver, adipocyte and pancreas. AMPK has
been also localized in endothelial cells (EC), however pathways of its activation, as well as the functions of this
kinase in the endothelium are still not well understood.
The stress events are accompanied by rapid release of extracellular nucleotides from damaged tissues or activated
EC and platelets. We demonstrate that extracellular nucleotides (ATP, ADP and UTP, but not UDP) and ade-
nosine, independently induce phosphorylation and activation of AMPK in human umbilical vein EC (HUVEC)
by the mechanism that is not linked to changes in the AMP:ATP ratio. HUVEC express NTPDases, as well as
50-nucleotidase, hence nucleotides can be metabolized to adenosine. However, inhibition of 50-nucleotidase had
no effect on ATP/ADP/UTPinduced phosphorylation of AMPK, indicating that AMPK activation occurred as a
direct response to nucleotides. Pharmacological evaluation of nucleotide-evoked phosphorylation of AMPK in
HUVEC led to the conclusion that AMPK activation was mediated by P2Y1, P2Y2 and/or P2Y4 receptors, while
P2Y6, P2Y11 and P2X receptors were not involved. The nucleotide-induced phosphorylation of AMPK was
affected by changes in the concentration of intracellular Ca
2+ and by CaMKK, while most likely it was not
dependent on LKB1 kinase. Adenosine-induced phosphorylation of AMPK was not mediated by P1 receptors but
required adenosine uptake by equilibrative nucleoside transporters followed by its (intracellular) metabolism to
AMP. Moreover, adenosine effect was Ca
2+- and CaMKK-independent while probably associated with upstream
LKB1. We hypothesize that P2 receptors and adenosine transporters could be novel targets for the pharmacologic
regulation of AMPK activity and its downstream effects on EC function.
Typical neuroleptics regulated A2A adenosine receptors in human platelets
of patients affected by bipolar disorder.
M. Letizia Trincavelli, M. Montali, S. Cuboni, E. Cerrai, A. Ciapparelli, A. Lucacchini, GB Cassano, L.
Dell_Osso, C. Martini.
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Neuroleptic drugs, potent dopamine receptor antagonists, are commonly used in the treatment of psychotic and
affective illness. An antagonistic functional interactions between A2A adenosine receptors (ARs) and D2 dopa-
mine receptors (DRs) has been demonstrated in the central nervous system suggesting that the adenosine system
may be involved in the pathogenesis of basal ganglia disorders. In a previous work we have demonstrated that
chronic treatment with typical antipsychotics induced a signiﬁcant modulation on A2A AR binding parameters
and receptor responsiveness in platelets from psychotic patients with respect to healthy volunteers, pointing to
A2A ARs as a possible target to test the efﬁcacy of typical antipsychotic therapy.
In this work we evaluated the effect of typical neuroleptics on A2A AR binding parameters in human platelets of
patients affected by bipolar disorder (BD) under chronic treatment with these drugs, in particular evaluating the
correlation between D2 DR occupancy and the A2A AR alterations. A cohort of 28 patients affected by BD with
or without psychotic symptoms were consecutively recruited from the Department of Psychiatry at the University
of Pisa (Pisa, Italy). All patients were naturalistically treated with antipsychotic drugs for at least one month.
Control group included 32 healthy volunteers with no history of mental disorder, alcoholism, or drug abuse and
with no medical illness, as determined by clinical interview. The study was approved by the local Ethical Com-
mittee in accordance with the Declaration of Helsinki (1996) and with the Guidelines of the Good clinical
Practice (1995).
A2A AR equilibrium binding parameters were determined on platelet membranes obtained from healthy volun-
teers and from patients, by saturation binding studies using the selective A2A AR antagonist, [
3H] ZM241385. For
correlation studies, the mean dosage of drugs was reported as equivalent of chlorpromazine.
The obtained results demonstrated that in BD patients, typical neuroleptics induced a signiﬁcant decrease in A2A
AR ligand afﬁnity values with respect to healthy volunteers demonstrating a signiﬁcant alteration in receptor
comphormational state. On the contrary, no signiﬁcant alterations in maximum density of A2A AR binding sites
was detected. By the means of ANOVA statistical test a signiﬁcative correlation between A2A AR afﬁnity values
and the mean drug dosage was detected in relation to severity illness.
These results suggest A2A AR are selectively regulated by D2 DR antagonists in relation to dopamine receptor
occupancy and to the individual responsiveness to the drugs.
Sundram et al. (2003) Current Mol. Med. 3: 393–407.
Martini C. et al. (2006) J. Psych. Res. 40: 81–88.
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Retinoids, general term of vitamin A derivatives, play critical regulatory roles in growth and differentiation in
epidermis. They are often used clinically to the cure of some skin troubles or disorders, such as pigmentation and
wrinkles. So far, however, molecular mechanisms by which retinoids reveal their therapeutic effects have only
limited attention, let alone their effects on P2 receptors, receptors that regulate various skin functions. In this
study, we used normal human epidermal keratinocytes (NHEKs) and assessed the effect of retinoids on P2
receptors. DNA array analysis showed that among P2 receptors in NHEKs, mRNAs for P2Y2 receptors are
selectively upregulated by the treatment with all-trans retinoic acid (ATRA), an agonist to RAR (retinoic acid
receptor). ATRA increased the mRNA for the P2Y2 receptor in a concentration- (1 nM to 1 2M) and an
exposure time- (2 to 24 hr) dependent manner. Am80, a synthesized agonist to RAR, showed a similar increment,
whereas 9-cis retinoic acid (9-cis RA), an agonist to RXR (retinoid   receptor), induced a lesser enhancement of
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SpringerP2Y2 genes. These results indicate that retinoids upregulate P2Y2 mRNAs mainly via RAR. Moreover, fura-2
based Ca
2+ imaging analysis revealed that ATRA also increased function of P2Y2 receptors in NHEKs. P2Y2
receptors are important for proliferation in basal layer of skin (ref 1,2), and our present results indicated that
retinoids selectively upregulated P2Y2 receptor-mediated responses in NHEKs. All these ﬁndings suggest that
retinoids would, at least in part, achieve their growth effects via upregulation of P2Y2 receptors, thereby leading
to therapeutic gain of retinoids against ailments and aging events in skin.
1. Greig AV et al., J Invest Dermatol 120: 1007–1015, 2003
2. Burrell HE et al., J Invest Dermatol 120: 440–447, 2003
Uracil nucleotides protect murine HL-1 cardiomyocytes from cell-cycle changes
and apoptotic/necrotic death induced by adenine nucleotides and tumor necrosis
factor-alpha
Alessia Mazzola*, Emanuela Amoruso*, Elena Tremoli, Maria P. Abbracchio
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Despite available therapies, chronic heart failure (CHF) remains a major cause of morbidity and mortality in
western countries, suggesting that key pathogenic mechanisms still have to be uncovered. Pyrimidine and purine
nucleotides are released from heart sympathetic terminals and hypoxic cardiomyocytes. In addition to their int-
racellular functions in signalling and genetic coding, nucleotides have an important role as extracellular signalling
molecules. P2 receptors activated by nucleotides consist of two families: seven ligand-gated ion channels (the
P2X1–7 receptors) and eight G-protein-coupled receptors (the P2Y1,2,4,6,11,13,14 receptors) (1). At variance from
P2X receptors, some P2Y receptors can also or exclusively respond to uracil nucleotides. We recently demonst-
rated the presence of four P2Y receptors (P2Y2,4,6,13 receptors) in an in vitro model of murine cardiomyocytes
(HL-1 cells) (see: Amoruso et al., accompanying abstract), the only cell line that continuously divide, spontane-
ously contract and maintain a differentiated adult cardiac phenotype in culture (2). In the present study, we have
focused our attention on the differential role of adenine (ATP and ADP) and uracil nucleotides (UTP, UDP,
UDP-glucose) in regulating the viability of HL-1 cells. Exposure of HL-1 cells to ATP or ADP (5002M) for
24 hours induced signiﬁcant apoptosis and necrosis. The effect induced by ATP was concentration-dependent. In
line with previous data (Banﬁ et al., 3, and Amoruso et al., accompanying abstract), these effects were increased
by pretreatment of cells with the cytokine tumor necrosis factor alpha (TNF-!, 10ng/ml) for 16 hours. On the
contrary, uracil nucleotides (UTP, UDP and UDP-glucose, 5002M), utilized either alone or with TNF-!, did not
induce apoptosis or necrosis ‘‘per se’’, but signiﬁcantly reduced cardiomyocyte death induced by adenine nucle-
otides. Flow-cytometry analysis showed that ATP and ADP-induced cell death was also associated to altered cell-
cycle progression; in particular, a reduction of the number of HL-1 cells in S and G2/M phase was observed.
Uracil nucleotides also effectively prevented the alterations of cell-cycle progression induced by adenine nucle-
otides in the presence of the proinﬂammatory cytokine. Globally, these data suggest that, in cardiomyocytes,
activation of speciﬁc P2Y receptor subtypes by uracil nucleotides can counteract induction of cell death by ATP
and ADP. We are currently evaluating the role of mitochondria and the involvement of caspase cascades in our
experimental model. The present results suggest an important role for some P2Y receptor subtypes (P2Y2, P2Y4
and/or P2Y6) in cardiomyocyte survival and cardioprotection and may lead to the identiﬁcation of new therape-
utic strategies for heart disease.
The authors warmly thank Professor William Claycomb, LSU Health Sciences Center, New Orleans, LA, USA,
for the kind gift to HL-1 cells
(1) Abbracchio, M.P.; Boeynaems, J.M.; Barnard, E.A.; Boyer, J.L.; Kennedy, C.; Mira-Portugal, M.T.; King, B.F.; Gachet, C.;
Jacobson, K.A.; Weisman, G.A.; Burnstock, G. Trends Pharmacol Sci, 24, 52–55.
(2) White, S.M.; Costantin, P.E.; Claycomb, W.C. Am. J. Physiol. Heart Circ.Physiol. 2004, 286 (3), H823–829.
(3) Banﬁ, C; Ferrario, S; De Vincenti, O; Ceruti, S; Fumagalli, M; Mazzola, A; D" Ambrosi, N; Volonte, C; Fratto, P; Vitali, E;
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Considerable effort has been devoted towards improving functional recovery and reducing the extent of infarction
after ischemic episodes since coronary heart disease remains a major worldwide threat. It was found that the heart
was signiﬁcantly protected against ischemic injury, if it was ﬁrst preconditioned (PC) by a brief ischemia. Accu-
mulating evidence suggests that adenosine, adrenoceptors, bradykinin, opioid and ATP receptors contribute to
PC.
Massive amounts of nucleotides are released during ischemia and hypoxia in the cardiovascular system. Whereas
the effect of purine nucleotides (ATP) in myocardial infarction was intensively studied, the role of pyrimidine
nucleotides (UTP) under hypoxic condition has not been demonstrated. The principal aim of our study is to
elucidate the protective effects of UTP and pyrimidinergic receptor activation against detrimental factors of
ischemia/hypoxia as well as to investigate the mechanism by which the relevant pyrimidine receptor is coupled to
its respective intermediate effectors, such as IP3 receptors, and the downstream cascade, which exerts distinctive
cardioprotective responses.
Results: We found that UTP signiﬁcantly reduced cardiomyocyte death induced by hypoxia [1]. This effect of
UTP was not observed with its derivative, UDP. Even incubation (1 hour) with UTP, 24 hours before exposing
the cells to hypoxic conditions, protected the cells. The cardioprotective effect of UTP was reduced in the pres-
ence of the non-selective P2 antagonist - suramin. In addition, UTP caused a transient increase of [Ca
2+]i level in
cardiomyocytes. PPADS or RB2, other antagonists of P2 receptors, abolished [Ca
2+]i elevation caused by UTP.
Using various inhibitors of the Ca
2+ signaling pathway, we have shown that UTP originating from intracellular
sources, elevated the [Ca
2+]i level via PLC and the IP3 receptor. Interestingly, BAPTA-AM, a [Ca
2+]i chelator,
and other inhibitors of the Ca
2+ signaling pathway, did not prevent the protective effect caused by UTP. Preli-
minary studies in an in vivo model of myocardial infarction showed the same protective effects.
Conclusion: This study describes the cellular protective role of UTP nucleotide on cardiomyocytes against hypoxic
damage, which is mediated via nucleotide receptor(s).
1. Yitzhaki, S., Shneyvays, V., Jacobson, K.A. and Shainberg, A. Involvement of uracil nucleotides in protection of cardiom-
yocytes from hypoxic stress. Biochem. Pharmacol. 69, 1215–1223, 2005.
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Hypoxia-inducible factor-1 (HIF-1) is a key regulator of genes crucial to many aspects of cancer biology. Here we
show that in the human A172 and U87MG glioblastoma cell lines under hypoxic conditions (1% O2) adenosine
up-regulates HIF-1! protein expression in a dose- and time- dependent manner, exclusively via the A3 receptor
subtype. The response to adenosine was generated at the cell surface since the inhibition of A3 receptor
expression, by using small interfering RNA, abolished the nucleoside effects. We investigated the effect of A3
receptor antagonists on HIF-1 and vascular endothelial growth factor (VEGF) expression. We found that A3
antagonists inhibit adenosine-induced HIF-1! and VEGF protein accumulation in the hypoxic cells. Investigations
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Springerof the molecular mechanism showed that A3 receptor stimulation activates p44/p42 and p38 MAPKs that are
required for A3-induced increase of HIF-1! and VEGF. Further studies are required to demonstrate the in vivo
relevance of these observations with regard to the proposed role for adenosine as a key element in situations of
hypoxia and tumors.
Which is the receptor mediating ADP signaling in rat cerebellar astrocytes?
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During the last years it has been demonstrated that nucleotides are important signaling molecules in the SNC,
some of the actions previously attributed to ATP appear to be mediated by other nucleotides, such as ADP. ADP
possesses speciﬁc metabotropic receptors, the P2Y1, P2Y12 and P2Y13 subtypes. The characterization was made in
heterologous system expression, but going to native tissues is quite difﬁcult, with the exception of platelets, which
are an excellent model for ADP receptor signaling studies. Although the three receptors exhibit high afﬁnity for
ADP and 2MeSADP, they differ in the relative potency of the two agonists; P2Y1 is coupled to PLC activation,
whereas P2Y12 and P213 receptors are negatively coupled to adenylate cyclase. With respect to antagonists, MRS-
2179 is selective for P2Y1, but, to date, there are no antagonists able to discriminate between P2Y12 and P2Y13
receptors. The unique selective antagonist for P2Y12 receptor is a metabolite originated from clopidogrel meta-
bolism, which limits its use to animal models.
Several studies suggested the existence of ADP Gi-coupled receptors in rat cerebellum, by which we decided to
investigate their presence in cultured cerebellar astrocytes. In previous studies we found that all cerebellar astr-
ocytes responded to ADP and ATP stimulations with metabotropic calcium responses, which were mediated by
P2Y1 and P2Y2/P2Y4 receptors, respectively. However, additional studies carried out using the new available
agonist 2MeSADP, have demonstrated that calcium responses and other intracellular cascades triggered by ADP
and/or 2MeSADP could be mediated mainly by a P2Y13-like receptor. This was supported by the following data:
1.- ADP and 2MeSADP inhibited adenylate cyclase activation induced by isoproterenol, with similar IC50 values,
which suggested the involvement of a P2Y13 receptor. These experiments were carried out in the presence of
MRS-2179.
2.- Microﬂuorimetric experiments using fura-2 showed that 2MeSADP induces intracellular calcium mobilization.
These responses were comparable to those elicited by UTP. However, when the effect of MRS-2179 was checked,
cells exhibited heterogeneous responses: there were cells in which 2MeSADP responses were abolished or dim-
inished in different extents, and there was also a subpopulation, whose responses were not affected, indicating that
another receptor different from P2Y1 is being activated.
3.-Finally, we studied the effect of 2MeSADP in ERK activation. We observed that the stimulation of the cells
with this compound induced an increased in phosphorylated ERK levels. This effect was dosis-dependent with a
EC50 of 4.85 T 1.5 nM and insensitive to MRS-2179. ERK activation was sensitive to Pertussis Toxin, src protein
inhibitors and long-term treatment with phorbol esters.
All these ﬁndings would indicate that P2Y13-like receptor present in cerebellar astrocytes triggered several intr-
acellular cascades, that at ﬁrst were supposed to be mediated by P2Y1, such as PLC activation and the parallel
MAP kinase cascade activation, and which have not been described for the cloned P2Y13 receptor. The question
that arises is what it is role of P2Y1 receptor?
Xanthines foster up-regulation of export-deﬁcient variants of the A1-adenosine
receptor
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SpringerCaffeine consumption fails to up-regulate the A1 adenosine receptor in the CNS in vivo. However, we ﬁnd that
the lipophilic xanthines 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) and isobutyl-methylxanthine (IBMX) can
act as efﬁcient pharmacochaperones for the A1-receptor in cultivated cell lines. Using A1-receptor variants with
wild-type sequence or with sequence mutations in the receptor carboxyl-(c-)terminus we have assessed the
mechanism by which xanthines up-regulate the receptor. (i) Both the low- and high-afﬁnity antagonist ligands
DPCPX and IBMX caused an increase in receptor density; agonists, by contrast, had no effect. When an export-
deﬁcient receptor was tested the pharmacochaperones raised the level of surface expressed receptors to the range
of wild-type receptors. For the mutants the drug-induced increase was marked as assessed by radioligand binding
(~15-fold with 1 2M DPCPX; ~6-fold with 50 2M IBMX). FACS (ﬂuorescence activated cell sorting) using an
antibody against an extracellular epitope indicated that the plasma membrane was the site where receptor density
increased. On the wild-type receptor, however, the effect was more modest (1.6-fold). (ii) By contrast, the reco-
mbinant A1-receptor expressed in bacteria was completely refractory to pharmacochaperoning suggesting that the
ligand does not act as a scaffold during co-translational membrane insertion and folding. Rather, we believe that
the effect of the pharmacochaperone set in once the receptor was mature enough to pass the endoplasmic reti-
culum (ER) quality control since our previous ﬁndings had indicated that A1-receptor retained in the ER fails to
bind ligand. (iii) Pharmacochaperoning was critically controlled by an ER-associated cytosolic heat-shock protein,
DRiP78 (dopamine receptor interacting protein, member of the hsc40 family), that was found to directly bind to
the A1-receptor c-terminus. Overexpression of DRiP78 reduced receptor surface expression and, in addition,
blunted the pharmaco-chaperone effect. This inhibition was reverted by sequence speciﬁc RNA-interference. The
ﬁndings point to the ER-exit gate as the bottle neck in the export pathway where DRiP78 acts as a guardian. (iv)
The export deﬁcient receptor variants had been created by mutating single amino acid residues present in the
conserved NPXXY(X)6F motif within the junction between helices 7 and 8. Exchanging either Y or F to alanine
resulted in receptors that gave very low surface expression levels. Nevertheless, the F/A mutant receptor was
perfectly capable of inhibiting cAMP formation. As opposed to the wild-type receptor, however, the surface level
of the F/A variant was not augmented by DRiP78 RNAi. Thus, antagonist ligands can up-regulate the A1-
adenosine receptor provided that the receptor is functional but retained intracellularly; we speculate that phar-
macochaperoning is effective unless retention is critically controlled by the components of the ER-quality control
machinery.
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